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Lita Annenberg Hazen (1909-1995)
Lita liked me for my brains and also because as a successful scientist I was optimistic
and never worried her about what I should do next. But she did not like to see me becom-
ing almost fat after I took on leading the Human Genome Project and had one job more
than I could handle. I then would sense her displeasure when I sat down opposite her at
her Pierre Hotel apartment and she would look at my belt not adequate for its job. So
when I again became trim, like a long thin DNA molecule, we would not have that
awkward start to our conversations where she expressed sharp, clear thoughts and never
exuded unreasonable goodliness when the facts were awful.
We had first met when I was badly in need of big money to move the Cold Spring Har-
bor Laboratory beyond the gene and onto the ultimate challenge of biology, the human
mind. I had long known of her philanthropy to biology and medicine, but despite urgings
from a colleague who said that our souls were made for each other, I was initially scared
to approach her. At a gala several years earlier, I had already gazed upon the firm
regality that had emerged out of her Annenberg intellect and money. Yet she could be
the friend and patroness who would let me have aspirations beyond common sense.
So I got up my courage and began to let her know me, often in the California beauty
of her Homby Hills home overlooking the Los Angeles Country Club. At first I assumed
that her penchant toward biology brains arose out of the tragedy of her eldest daughter
Gwynne's premature death from leukemia and her subsequent endowing of a cancer re-
search laboratory at the nearby UCLA Medical Center. In fact, she had to live with the
knowledge that it had been her early interest in medical research that had led her to a
specialist who used X-rays to treat her daughter's intractable eczema in the days before
the cancer-causing attributes of ionizing radiation were firmly established.
vii
Turning away from rationality was not, however, Lita's thing and much happiness in
her later life came from bringing together the scientific elite in groups small enough to let
her know whom she was helping. For several years, she also provided a major prize in
clinical research, but felt almost betrayed when the recipients of her generosity seemed
to vanish from her life almost as quickly as they entered her world at the prize ceremony
dinners. The receipt of even a holiday card would have made matters different, but I re-
member that when I was still hot on the trail of scientific discovery, I was so obsessed
with the future that the time never came to think backward toward those who had helped
propel me forward.
Lita's heart thus increasingly focused on her prestigious several-day-long gatherings
of the best minds in biology and medicine whom, with Martin Meyerson's help, she
brought together, in charismatic locations like Aspen, Stockholm, Venice, and San Fran-
cisco. There one could linger and talk free from the small details of our usual lives that
never seemed to transform into any form of the big picture. Of course, Lita could not un-
derstand the fast-flowing scientific ideas that came whizzing past her head during formal
discussion, but at meal times, she loved replying to the unexpected words and ideas that
intellectuals must feed upon to stay alive.
Lita's first visit to the Cold Spring Harbor Laboratory came about in a most un-
expected way. Knowing that her friend David Eisenberg was out on Long Island at one of
our big symposia, she arrived on an unbearably hot June day at our kitchen door telling
my wife Liz that she was a philanthropist in need of cab fare. Liz rose to the financial
emergency and soon she and Lita found David below our house in the picnic line for hot
dogs. Famished without any lunch, Lita uncharacteristically ate a hot dog and then to
everyone's horror collapsed onto the ground. In panic we feared that our philanthropist
might not be long for this world. Quickly, however, Lita recovered sufficiently to drink
some cold water and within a few minutes Lita and Liz were in the shade of our front
porch getting to know each other. Early the next week, the cab fare came in the form of a
$25,000 check.
The following year, we began preparing plans for a Neuroscience Center that could
enable the Cold Spring Harbor Laboratory someday to become a major force in brain re-
search. In building the complex, we wanted to emphasize our evolution from our past role
as a high-powered summer camp for scientists into a major year-round academic center.
The architectural trick used to make this point was to be a powerful bell tower that would
let us know when the next hour had arrived. Although the tower was bound initially to an-
noy those who would like every last dollar spent to have a scientific mission, I felt that no
one who saw it could ever more doubt that we had a future. And they would see us
moving ahead with the architectural flair that most leading academic institutions like to
display.
To make this possible, we asked Lita to join our board of trustees. Knowing exactly
what I meant Lita accepted, and the next week the big check arrived that let us go for-
ward. Today, the now four-year-old Hazen Tower projects majestically upward outside my
office, and when its bell tolls the hour, we remember Lita's great generosity and faith that
through scientific research the human condition will improve.
In her last several years, age began to be cruel to Lita's mind, and Liz and I in-
creasingly felt dreadful when her memories of the immediate past no longer held. But al-
most to the very end, she was still a force to be reckoned with. On her last visit to Lita's
29th floor Pierre apartment, Liz made reference to an acquaintance as one of Lita's close
friends. Immediately Lita replied that this individual was a good friend and not a close
friend. After coming back to Cold Spring Harbor and relating this incident, Liz burst into
tears. We believe that Lita saw us as her close friends.
October 5, 1995 James D. Watson
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PRESIDENT'S
REPORT
Ten years have now passed since serious consideration was first given to start-
ing the Human Genome Project, the task of determining the order (sequence) of
the four base pairs (AT, TA, GC, and CG) along the 24 very long DNA molecules
that collectively comprise the human genome. Contained within these DNA se-
quences are the genetic instructions of our 24 different human chromosomes (22
autosomes and two sex chromosomes X, Y), each of which contains a single
DNA molecule. These DNA molecules are the most important molecules underly-
ing human life since each contains on the average some 4000-5000 of our hu-
man genes, each gene representing a long linear collection of base pairs posi-
tioned at a precise site along one of our chromosomes. In proposing to sequence
the some 3 x 109 base pairs (bp) of the human genome, our primary aim was to
identify the location and structure of all our genes along their respective chromo-
somes. With this information in hand, the genetic code lets us automatically know
the precise amino acid sequences of the protein products of each gene.
Knowing the location and structure of each of our human genes would pro-
vide an enormous resource to the worlds of biology and medicine. To start with,
the amino acid sequences of many human proteins by themselves would give us
strong clues as to their primary functions. So through the possession of the hu-
man genome, we would have our first overview of the totality of the molecular
functions underlying the development of a fertilized human egg into a functioning
adult human being. Equally important, the establishment of the location and
structure of all the human genes would immeasurably speed up the identification
of those normal human genes whose mutant forms are the cause of the countless
genetic diseases that diminish the lives of so many human beings and their
respective families.
When first proposed, however, the Human Genome Project generated deep
controversy within the community of molecular biologists, the very scientists
whose expertise in manipulating and analyzing DNA would lie at the heart of its
successful completion. Among many younger scientists, deeper anxieties devel-
oped that first were publicly expressed at our June 1986 Symposium on the
Molecular Biology of Homo sapiens. Toward its conclusion, a late-afternoon dis-
cussion on the pros and cons was chaired by Wally Gilbert and Paul Berg, whose
past research on DNA sequencing and recombinant DNA technologies had
helped make the Human Genome Project an attainable goal. They both wanted
the project to start soon, but a number of younger scientists in the audience
worried that its costs might be so high that it would be completed only by con-
taining the momentum of their own research projects. Here in the United States,
many of us were initially troubled that the American component of the project
might be largely directed by administrators in the Department of Energy (DOE)
who oversee the biology programs of the national laboratories at Los Alamos and
Livermore. They were far from the heart of the recombinant DNA world, yet they
were saying, starting in 1986, that they should lead this effort since it would re-
quire the technological and logistical bases that only the super-sized national
laboratories possessed.
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Much of the scientific opposition to the Human Genome Project thus
evaporated when the National Institutes of Health (NIH) came into the act, early in
1988, proposing that the project be scientist-led as opposed to bureaucrat-led.
Moreover, unlike the DOE administrators, who obstinately insisted that they would
only support human DNA sequencing, the scientist-led NIH endeavor, of which I
became the first director, proposed that the much smaller genomes of biological-
ly well-studied model organisms, such as the bacterium Escherichia coli (4.5 x
106 bp), the budding yeast Saccharomyces cerevisiae (1.5 x 107 bp), the worm
Caenorhabditis elegans (108 bp), and the fly Drosophila melanogaster (1.5 x 108
bp), should be sequenced prior to the large-scale sequencing of human DNA.
There has been much conservation of gene structure during the evolution of life
on the earth, and the amino acid sequences of, say, many bacterial proteins
show strong similarities (homology) to those human proteins that carry out similar
functions. From the start of the Human Genome Project, we perceived that the
establishment of most human gene structures would proceed much faster if the
structures of their less complex bacterial, yeast, worm, and fly equivalents had al-
ready been established.
Not only do these model organisms have smaller genomes, they also have
much higher gene densities along their respective chromosomes. In humans,
probably less than 5% of the base pairs code for amino acid sequences,
whereas in bacteria and yeast, virtually all of their base pairs specify amino acid
sequences. As a result, identifying the genes of bacteria and yeast is almost a
routine endeavor. In contrast, identifying the human genes from human DNA se-
quences is much trickier since their coding (exon) sequences are interrupted by
much larger amounts of noncoding (intronic) sequences. Initially unclear was
whether spotting the genes within C. elegans and Drosophila would be a
noticeably simpler task than for their human equivalents. Although their introns
would be much smaller, their numbers might be almost as large.
Several other factors led to the NIH proposal that genomic sequencing
should start with model organisms. To begin with, the effective cost of DNA se-
quencing in 1988 was at least five dollars per base pair. Before extensive human
DNA sequencing commenced, the cost per base pair had to be reduced by a
factor of ten to fifty cents or less per base pair. This would allow the Human
Genome Project to be completed at a cost of no more than three billion dollars.
Given that this project was likely to require 15 years from inception to completion,
its annual cost when in full gear need be no more than 200 million dollars a year,
a figure that amounted to less than 2% of the total worldwide project for nonclini-
cally directed biomedical research.
Happily from the start of serious discussion, much lower sequencing costs
seemed a realistically attainable objective since the first DNA sequencing ma-
chines were just becoming commercially available. Although they initially had
teething difficulties and even the first labs possessing them were more often
using manual sequencing, the best guess was that machine-based production-
line procedures would become increasingly more effective over the next several
years.
Cost was not the only reason why human DNA genome sequencing was ini-
tially put on the back burner. Unlike with the smaller model organisms where the
ordered cloned DNA segments were available for sequencing, only very
restricted parts of human DNA had been cloned and sited relative to known
markers on the human genetic map. In fact, the human genetic map of 1988 was
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of much too low a resolution to specify closely the relative chromosomal location
of most genetic disease genes. So the first major objective of the Human
Genome Project had to be the mapping of a very large number of new genetic
markers. Here the correct decision was made to abandon the use of polymorphic
markings that reflected differences in restriction enzyme cutting sites. In their
place were to be generated markers based on frequent polymorphisms in the
length of the CACA-repetitive segments present in very large numbers through-
out the human genome. Such segments are easily displayable on gels using
polymerase chain reaction (PCR) amplification and are suitable for analysis on
the same machines used for DNA sequence analysis. Already this first goal of the
Human Genome Project is essentially complete largely due to the very effective
generation of very large numbers of CA repeat markers by Jean Weissenbach at
Genethon, the large genome center established near Paris in 1990 by the AFM
(Association Francaise contre les Myopathies). By late 1995, they had created
polymorphic CA repeat markers on the average for every 500,000 bp.
The existence of these ordered genetic markers greatly simplified the second
main goal of the Human Genome Project-the making of a physical map of
cloned segments of human DNA running from one end to the other of each of the
24 human chromosomes. Key to the success of making such physical maps has
been the development of methods for the cloning of DNA fragments large
enough so that their ordering into increasingly larger sets of overlapping frag-
ments (contids) was a practical objective. Here a major breakthrough occurred in
1987 at Washington University, where in Maynard Olson's laboratory, procedures
were developed to clone 3 x 105 to 5 x 105-bp-sized fragments of human DNA
in yeast artificial chromosomes (YAC5). Such inserts were far larger than the big-
gest human DNA segments previously cloned. Later at Genethon, Daniel
Cohen's use of megabase-sized (105) fragments allowed the 1993 construction
of the first physical maps, albeit with many gaps, for all of the human
chromosomes. This task has now been brought close to completion through the
development of highly automated production-line mapping procedures at the
Genome Center directed by Eric Lander at the Massachusetts Institute of Tech-
nology. The physical mapping phase of the human genome is thus almost over,
leaving now the more mundane task of generating the sets of overlapping smaller
DNA segments now used to generate actual DNA sequence data.
Completion of the genetic and physical maps should not be seen as merely
the prelude for the final goals-sequencing and gene identification-of the Human
Genome Project. These maps are now very useful in their own right as today's
tools for speeding up the discovery of more human disease genes. Ten years
ago, with the resources then available, the cloning of many important human dis-
ease genes was at best very difficult and more often effectively an unattainable
objective. Not enough genetic markers then existed to accurately pinpoint the
cloned chromosomal regions containing their disease genes. For example, even
though the gene for Huntington's disease had been located in 1984 to near the
end of the small arm of chromosome 4, its eventual cloning took ten years, well
into the period when the Human Genome Project began to speed up the pace of
finding disease genes. And although it took four years from the 1990 mapping of
the breast cancer gene BRCA1 to the long arm of chromosome 17 to its eventual
cloning in 1994, the ever-increasing resources provided by the Human Genome
Project led to cloning of a second breast cancer gene, BRCA2, in only a little
more than a year after its mapping to chromosome 13. Likewise greatly speeded
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up by the new genetic resources has been the identification of all the major
genes responsible for predisposition to Alzheimer's disease. As with Huntington's
disease and breast cancer, only through the finding of genes that lead to its
predisposition have we been able to begin to think rationally at the molecular
level about how the generation of Alzheimer's disease is initiated. The monies
thus spent so far on the Human Genome Project already may have been returned
to the public through better ways to approach the eventual control of these hor-
rific diseases.
Clearly, disease gene hunting will proceed even faster once all of the human
genome has been sequenced and all of the human genes have been identified.
Then, once we suspect that a disease gene resides along a specific section of a
human chromosome, we can look to see whether any genes in that location with
already known functions might be good candidates for the respective disease.
We know such an approach can greatly shorten the time associated with disease
gene hunting. For example, when there was suggestive evidence that a gene
leading to late-onset Alzheimer's disease mapped to a specific region of
chromosome 19, the known genes within this region were examined, particularly
the one coding for apoliprotein E, a protein associated with the amyloid-
containing plaques characteristic of diseased brain portions of Alzheimer victims.
Quickly it was found that Alzheimer patients preferentially carried the D polymor-
phism that only rarely is found in unaffected individuals. In this way, the important
role of apoliprotein E in the etiology of Alzheimer's disease became established.
Strong medical reasons thus dictate the complete sequencing of the human
genome as soon as possible.
The third major goal of the Human Genome Project, using the sequencing of
model organisms to develop production-line procedures for low-cost sequenc-
ing, is also close to completion. The first available DNA sequencing machine,
jointly developed between 1982 and 1986 in Lee Hood's Caltech lab by Lloyd
Smith and at Applied Biosystems (ABI) by Mike Hunkapiller, has lived up to the
task. That the ABI sequences could be the workhorse of the Human Genome Pro-
ject has been convincingly demonstrated through the project to sequence the
100-Mb genome of C. elegans through the collaborative efforts led by John Sul-
ston at the Sanger Centre just outside Cambridge, England, and by Robert
Waterston at Washington University. Funded by both the National Center for Hu-
man Genome Research and the British Medical Research Council, the C.
elegans genome project started in 1990. By 1995, both labs were up to sequenc-
ing some 10 million C. elegans base pairs per year with the cost falling to fifty
cents per base pair, the figure that had been set for the start of large-scale hu-
man DNA sequencing.
Initially unclear, however, was whether human genome sequencing (because
of its much larger repetitive DNA component) would prove more expensive.
Fortunately, this is not the case since both the Sanger Centre and the Washing-
ton University groups have found that it is at least as easy to sequence human
DNA as worm DNA. Although it was initially feared that the computerized DNA
assembly programs might not improve at the same rate as the sequencing ma-
chine technologies, this has not been the case. Particularly invaluable have been
the new sequence assembly programs created by Phil Green, first at Washington
University and more recently in Seattle at the University of Washington. Thus,
there is a realistic chance for the cost of sequencing to fall by another factor of
two over the next year or two. If so, only 750 million dollars need be spent to total-
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ly sequence the Human Genome by 2005, the target date set in 1990 when the
Human Genome Project funds first began really to flow. The Human Genome Pro-
ject may thus be completed not only on time, but also below its original target
price of three billion 1988 dollars.
Initially we believed that most human genes would not be revealed until the
last several years of the Human Genome Project when the production-line se-
quencing was in full swing. Today, however, the partial structures of possibly
more than one half of all human genes have already been found through the
large-scale examination of their expressed gene products, the messenger RNA
(mRNA) molecules, which function as the actual templates for protein synthesis.
Through knowing their structures, we automatically know the sequences of the
genes on which they are made. More importantly, the molecular processes that
produce functional mRNA molecules splice (cut) out the intron sequences, effec-
tively leaving only base pairs that code for the amino acid of their gene protein
products. To learn the sequence of these mRNA products, which often are
tissue-specific, the enzyme reverse transcriptase is used to make com-
plementary DNA (cDNA) copies of the mRNA molecules. It is these cDNA
polynucleotide chains that are then sequenced.
This expressed sequence tag (EST) approach was first effectively explored in
the laboratory of Craig Venter when he was at NIH. By examining ESTs from
many different cell types, Venter's lab was able quickly to catalog the sequence
of several tens of thousands of different ESTs. How many different genes gave
rise to the ESTs, however, was unclear since most EST sequences are only
several hundred bases long. Moreover, through differential splicing, single genes
are capable of generating several distinct EST products. To help promote his
EST approach, Venter created a privately funded institute, The Institute for
Genome Research (TIGR), located near NIH in Bethesda. Within a year, sufficient
additional ESTs had been sequenced to generate overlaps between many of the
ESTs and so generate more complete versions of the functional mRNA trans-
cripts revealed by EST analysis. Venter currently believes that his some 175,000
different ESTs arise from at least 30,000 (and possibly as many as 60,000) dif-
ferent genes, possibly more than half of the total human gene number, which has
been estimated to lie between 60,000 and 120,000.
The EST methodology, however, will never totally characterize the human
complement. It will always be strongly biased against rarely expressed genes.
Moreover, it can never expose the nature of the upstream and downstream
regulatory regions that are seldom transcribed into mRNA products. It has, how-
ever, already revealed the existence of many human genes that otherwise we
would only have later known when their respective DNA genomic fragments had
been sequenced. It was the thought that many such EST sequences might be
commercially valuable that, in fact, led to the multimillion dollar funding of TIGR
by its parent biotechnology company, Human Genome Sciences. But this TIGR
funding came with the price that the ESTs so obtained would remain secret until
Human Genome Sciences had been given not only a first look, but also control
over their future commercial exploitation. All of the sequenced TIGR human ESTs
are still kept out of public databases, although in September 1995, the functions
of many ESTs that are similar to already known genes (proteins) were released.
But before a given laboratory can obtain real sequence information about these
ESTs, it must sign an agreement limiting their commercial use, a requirement that
many scientists and companies find difficult to accept. To circumvent the restric-
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tion governing the use of Venter's EST database, a second massive EST se-
quencing effort began some 18 months ago at Washington University, with the
funds provided by the pharmaceutical giant Merck. As soon as these Merck-
funded ESTs are sequenced, they are placed in the Genbank public database
and analyzed for sequence overlaps to identify those coming from the same
gene transcripts. By now the number of ESTs in the public database is beginning
to approximate those held privately. More data as to the tissues where these
ESTs are expressed remain privately held.
The value of many EST sequences will improve when the chromosomal DNA
segments from which they are expressed become known. Unless, however, there
is reason to believe that an EST comes from a gene important for either biological
or commercial reasons, the cost of finding its location on the human physical
map will keep most such sequences unassigned until their respective genomic
segments are sequenced as part of the Human Genome Project. Over the near-
term, most subsequent EST studies will likely be driven by commercial consider-
ations.
The EST approach to gene finding never made sense for the smaller model
organisms such as bacteria and fungi since the total sequencing of their
genomes always seemed to be realistic objectives once the cost of sequencing
became no more than fifty cents per base pair. The first bacterial genome so se-
quenced has been that of Hemophilus influenzae (2 x 106 bp) done at TIGR
using DNA provided by Hamilton Smith of Johns Hopkins Medical School.
Revealing the genome underlying the existence of a single cell was clearly a
milestone in the history of biology. Most important, more than two thirds of its
1800 genes were assigned precise metabolic functions. Equally exciting was the
subsequent sequencing at TIGR of a much smaller Mycoplasma genitalium, a
tiny bacterial type cell that exists as a parasite inside its much larger vertebrate
host cell. Because this tiny cell obtains so many of its essential building blocks
from its host cell, it does not need the proteins (genes) involved in their respec-
tive synthesis. As a result, its functioning and replication require only some 450
different genes. Here again, precise functions have been assigned to some 60%
of their genes. Genome analysis gives us the reassuring conclusion that we al-
ready have identified more than half of the molecular components essential for
the function and multiplication of single-celled organisms.
The same message now comes from the virtually complete sequencing of the
budding yeast Saccharomyces cerevisiae. This success results from a very large
international collaborative effort involving laboratories in Europe, the United
States, Canada, and Japan. Already the public databases contain the sequences
of virtually all of its some 6000 genes. Happily we already know the function of
about half, with more having homology with genes in other organisms. Most excit-
ing to cell biologists is the fact that some 30% of the genes code for proteins
whose structures suggest that they are membrane components, reinforcing the
importance that membranes play in intracellular metabolism of even the smallest
eukaryotic cells.
Although more than half of the yeast genes were sequenced through a cot-
tage industry approach involving about 100 different laboratories, costs dictate
that most future genome sequencing successes be the products of highly auto-
mated large laboratories such as the Sanger Centre, the Washington University
Genome Center, and TIGR. Only they will prove capable of reducing sequencing
costs much below the fifty cents per base pair milestone. In such large centers, a
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single ABI sequencing machine can generate over a year 106 by of highly ac-
curate final sequence. Only through the creation of several more such large-
production sequencing facilities will the human genome be sequenced by the
year 2005. The Sanger Centre and the Washington University facility have al-
ready reached sizes where we can be confident that the 108-bp C. elegans
genome will be finished at high accuracy by the turn of this century. They have
tackled first the more gene-rich internal chromosomal regions, leaving the repeti-
tive sequence-rich chromosomal ends to be sequenced as the project draws to
its conclusion. Here the decision must be made whether the same accuracy
should accompany the sequencing of uninformative DNA segments that goes
into sequencing genetically important regions. Clearly, no one wants to miss the
presence of real genes interspersed within much larger lengths of biologically ir-
relevant DNA. The job will not be well done if say 5% of the some 16,000 C.
elegans genes are missed. On the other hand, if only 16 out of 16,000 were to be
missed, the study of C. elegans development and functioning might proceed ef-
fectively unimpeded.
The question of how accurate we want the final sequence to be may prove far
more difficult to settle for the human genome. We must remember that the true
objective of the Human Genome Project is gene identification and mapping, not
the accurate sequencing of a particular human genome. Many polymorphic dif-
ferences exist within most repetitive DNA segments as well as within the unique
segments coding for intron DNA sequences. Once we have identified a particular
DNA signal as repetitive or intronic, should we sequence it to the same accuracy
as those segments coding for obvious biological functions? Common sense tells
us we should not, and already there are proposals to first do a relatively low-
resolution genome sequencing effort over the entire human genome. Although
such a scan would miss a few percent of the human genes, it would nonetheless
largely establish the general nature of the human genome. How this dilemma is
finally answered is likely to depend on whether the current cost of sequencing
can be reduced over the next several years to say ten cents per base pair. If so,
there is no reason not to go for the same accuracy that we want to achieve from
the larger-model organisms such as C. elegans or D. melanogaster. But if further
cost reductions prove hard to achieve, the argument to concentrate our accurate
sequencing efforts on biologically relevant sequences may come to the fore. In
any case, there is enough money in current fiscally strained genome budgets to
give confidence that at least 95% of our genes will be identified by 2005.
Our job will then be to much more deeply understand how the human body
develops and functions, using the information provided within the human
genome. Effectively, this century will be perceived biologically as that of the
gene. In this coming century, we will have the opportunity to see in detail how the
controlled expression in space and time of our some 100,000 genes gives rise to
our human bodies with brains so powerful that we finally have the means to
define the molecular essence of what it means to be human.
At the same time, the sequencing momentum generated by the Human
Genome objective will positively spill over into virtually all aspects of biological
research. Most pleasing will be the ever-growing ability to see how genomes
have evolved and expanded during the three billion years of biological evolution
on earth. As the cost of sequencing moves down to the level of cents per base
pair, the genomes of a large variety of evolutionarily diverse species will be open
to analysis. Here at Cold Spring Harbor, we are involved in the international effort
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to sequence the smallest known plant genome, that of Arabidopsis thaliana
(around 108 bp). Just as the complete genome sequence for a yeast has trans-
formed how we comprehend the nature of the yeast cell, the possession of the
complete genome of this small member of the mustard family will radically push
forward research on all forms of higher plants, including trees.
We need not fear that biology will slow down in the foreseeable future.
April 25, 1996 James D. Watson
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DIRECTOR'S
REPORT
History will almost certainly judge the current era of biology as one of the most
productive periods of scientific endeavor, comparable to the dramatic dis-
coveries in quantum physics in the early half of this century. The discoveries in
physics led to a fundamental understanding about the nature of the atom and the
beginnings of time. The understanding was so deep that it drove some to philos-
ophy to "explain" the unexplainable, whereas others pursued more practical
endeavors that prepared the way for a major technological revolution. On the
other hand, the dramatic increase in our ability to study life means that experi-
mental biologists will be kept busy for at least the next 100 years and thus may
not have time for more philosophical pursuits. Moreover, because advances in
biology are so intimately linked to human health, the biologists will always have
important practical problems to unravel. How this might be done best should be
a topic of constant conversation.
Advances in the basic biomedical sciences are coming at a very rapid pace,
and from all directions. The current efforts to sequence the genomes of many
organisms, the daily identification of interesting new proteins and discovery of
their functions, and the remarkable ability to investigate gene function using pow-
erful genetic manipulations offer unparalleled opportunities for medicine. The
amount of biological information that is emerging from this revolution is stagger-
ing, and there is an urgent need for more efficient ways to keep track.
Luckily, within the last year or so, there has surfaced a potential solution to
the information storage and retrieval problem. A number of journals are now com-
pletely available in electronic form on the Internet (for example, the Journal of
Biological Chemistry is a particularly useful online resource). In the best cases,
the full text of the journal can be rapidly searched for information. Key words and
references in the research articles are electronically linked to information data-
bases, such as databases containing genome and protein sequences, genetic
and disease databases, and even other scientific literature. This makes it relative-
ly easy to seek out relevant information that is connected to the original research.
I suspect that in the very near future, a substantial amount of biology can be
"done" by computer informatics experts who seek connections between pub-
lished experimental results. It may well be that a new field of biology, "virtual
physiology," will emerge as an essential contributor to progress in the biological
sciences. Ideally, these virtual physiologists will link up with the experimental
scientists so that biology does not become completely theoretical. For example,
even today there are those who make claims about the function of proteins based
on DNA sequence similarities when they have no intention of following up on
these claims.
At the same time, scientific meetings such as those held here at the
Laboratory will be ever more important as the amount of information increases.
Such conferences provide to a scientist an overview of a field in a matter of a few
days which probably would take weeks or even months to comprehend by read-
ing the literature.
As exciting as the advances in modern biology are, there is a pressing need
for institutions such as our own to better facilitate connections in biology, particu-
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larly the transfer of the exciting advances in basic science to clinical research. In-
teraction between basic and clinical research groups is now cast by the National
Institutes of Health (NIH) as "translational" research, but more often this term is
used by scientists to secure grant funds than it is for advancing real transfer of
information between the sciences.
There are often long lag times between basic research discoveries and clini-
cal applications. It is common for the brightest minds that contribute to the spec-
tacular advances in basic research to be unaware of the day-to-day problems
faced by the clinician. It is equally common for the clinician to be unapprised
about new discoveries in basic research. As the advances in basic science be-
come more extensive and complicated, it will be increasingly necessary to bring
those interested in transferring basic discoveries to the clinic together with the
clinical researchers. This will be particularly necessary for the critical design of
patient-based research because of the complexities in planning good clinical
studies and the enormous costs that are often associated with this type of inquiry.
How clinical research might be best done and how basic scientists might contrib-
ute are problems that need attention.
With these thoughts in mind, a meeting was organized at the Banbury Confer-
ence Center in October, 1995, that focused on neurofibromatosis type 1 (von
Recklinghausen disease, NF1), a devastating disease that affects about 1 in
4000 people throughout the world. This dominantly inherited trait causes learning
disabilities in young children, and children and adults are affected with a variety
of deformities, such as café-au-lait spots, neurofibromas, optical and bone prob-
lems, and malignancies. The NF1 mutations were mapped to chromosome 17 in
1987, and the altered gene that causes these severe abnormalities was cloned in
1990 through a cooperative research effort, spearheaded by Francis Collins, now
head of the National Center for Human Genome Research at the NIH.
The protein product from this gene is large and its full functions are not
known, but the protein displays similarities to a known regulator of the human
RAS protein. As shown by Michael Wig ler and his colleagues at Cold Spring Har-
bor, as well as others, when mutated, the human RAS oncogene contributes to
cancer progression in a large fraction of human tumors. This provides an interest-
ing, but still speculative, link between tumor formation and the NF1 protein. Be-
cause of the links with human cancer, a great deal has been done on the
biochemistry of the RAS protein. This information has come from basic research
on the RAS protein in species as diverse as yeasts, the fruit fly Drosophila, and
mammals such as mice, and there are very interesting potential anti-cancer
drugs that have been developed by the pharmaceutical industry based on this
basic research.
There is thus an enormous amount of information known about the biochem-
istry and genetics related to NF1 disease. The gene that causes the primary
problems is in hand and a great deal of information is known about the possible
biochemical pathways the NF1 protein controls. Yet there are significant prob-
lems that clinicians have in diagnosing and treating the disease. Despite the ap-
parent genetic simplicity, there is extreme clinical variability in the outcome of the
disease; diagnosis, particularly of the cognitive deficits, is a major problem for
the clinician and a detailed description of the nature of some of the clinical
defects is lacking. Because these clinical problems still exist, but also because
there is a strong interest by scientists in the biology of the NF1 protein, it seemed
that a meeting that brought together clinicians, scientists interested in clinical
and basic research, and investigators from the pharmaceutical industry to dis-
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cuss the disease would be valuable. Although there have been other meetings
on NF1, the charge at the Banbury meeting was to discuss how clinical science
and medicine would be best advanced by the better design of clinical research
and better coordinated basic research. Another goal was to explore progress in
both clinical research and therapeutic strategies targeted at all aspects of the
disease. Because so much is known about the underlying mechanisms that lead
to NF1, our agenda was to assess critically how this understanding was being
exploited for further treatment and what might be done to speed clinical prog-
ress. Our intention was to use NF1 as a model disease to determine some of the
problems that arise in moving basic research into the clinic and how best to facil-
itate good clinical research. In this respect, the meeting was an outstanding suc-
cess.
It was apparent during the meeting that while basic research on this disease
was progressing well, clinical research lagged sadly behind and many transla-
tional opportunities were missed. There appeared to be too many cases where
there was insufficient clinical information available to enable therapeutic
strategies to be assessed. For example, it was clear that there was a dearth of
systematic, longitudinal studies on the development and growth of
neurofibromas. Even the origin of the cells in the neurofibromas remains an
enigma. In another case, it was very clear that although the vast majority of hu-
man cancers containing mutations in the RAS protein affected one of the three
RAS proteins in humans (K-RAS), the best animal model available for assessing
drugs that target the RAS pathway is a transgenic mouse expressing an ac-
tivated form of a different human RAS protein (H-RAS). Thus, the relevance of this
animal model to human disease and for testing existing drugs that target the RAS
pathway is questionable. The latter deficiency has implications far beyond NF1
research.
As a result of lengthy discussions at the meeting and conversations since
then with many investigators, a series of recommendations emerged that I be-
lieve may greatly enhance clinical studies on NF1. More importantly, however,
this type of approach could become a paradigm for facilitation of needed clinical
research generally.
The NF1 community of basic scientists and clinicians present at the meeting,
including representatives from large pharmaceutical houses, decided to estab-
lish small working groups whose charge is to solicit consensus opinions on the
deficiencies in translational and clinical research. The groups chosen for NF1
covered five areas: orthopedics, cognition, neurofibromas, malignancies, and op-
tic glioma. Each of these areas was selected because they represent distinct
clinical problems. Each group has a Chair to coordinate the agenda, which is to
identify deficiencies in the clinical knowledge base, initiate new ideas for clinical
research, coordinate multicenter clinical proposals, and maintain limited data-
bases of information. These groups in turn will report to a parent steering com-
mittee (headed by Dr. Bruce Korf at the Children's Hospital in Boston) that will
oversee the progress of the individual groups, coordinate research between the
groups, and set any recommendations that might be forwarded to the NIH. These
recommendations could be then sent to the office of the Director at an ap-
propriate Institute within the NIH where they could decide, in consultation with the
working group Chair, a suitable method of approach. In many situations, this
could be a very effective mechanism for the NIH to identify high priority areas for
program announcements for future peer-reviewed research. This mechanism
would then ensure that the research was investigator-initiated, was deemed by
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the scientific community to be of high value, and that any research funded did
not bypass the normal stringent NIH standards for reviewing and funding
science.
As a result of the Cold Spring Harbor meeting on NF1, the mechanism has
been established, and already the groups are working to discuss how clinical re-
search in this area might be enhanced. There is every reason to believe that this
experience with NF1 could be copied for many other areas of clinical research
that are tied to specific diseases or groups of disease. The NF1 meeting held
here, and importantly, the mechanism for generating subsequent recommenda-
tions, could become a model for future meetings on other equally pressing medi-
cal research. It should be the responsibility of research institutions to facilitate
such meetings, to host the initial meetings where the problems that exist are dis-
cussed, and then to facilitate the establishment of working groups. Ideally, institu-
tions should coordinate these meetings with the NIH by inviting Institute Directors
or appropriate program staff, as well as with research foundations and academic
or research societies. Certainly, the ability to access and exchange information
on the Internet will also help in such endeavors and may ultimately provide a
vehicle for providing information about the disease to the public. In many ways,
the search for the affected gene and a possible cure for Huntington's disease
that was coordinated by Nancy Wexler from Columbia University is a shining ex-
ample of how clinically relevant research might be advanced by discussion
groups. Unfortunately, not every important problem in medicine has someone like
Nancy Wexler to keep the momentum going. Perhaps the example set at the
Banbury Center will become a valuable precedent, and it is hoped that this
mechanism for facilitating clinical research will spread throughout the biomedical
research community.
The NIH would need to be receptive to such proposals, but clearly if highly
relevant and important science, particularly in the clinical arena, were to derive
from such meetings, then I believe they would be more than welcome. At pres-
ent, in many Institutes at the NIH, it has become the role of program staff to in-
itiate and solicit new research via the "Request for Application" (RFA) mechanism.
It is my experience that many of these RFAs happen to be in obvious well-funded
areas and that they shy away from the "not-so-obvious" basic research and clini-
cal research. The NF1 model will allow clinicians, scientists, and the pharmaceu-
tical experts to provide important advice and suggestions to the Institute Direc-
tors and program staff at the NIH prior to decisions they make on the general
directions for extramural research. I believe the mechanisms discussed above
will not only further progress in clinical research, but also provide a valuable me-
chanism to collect scientist- and clinician-driven rationales for convincing the
public and Congress to continue to support biomedical research.
April 26, 1996 Bruce Stillman
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HIGHLIGHTS OF THE YEAR
Research Highlights
Cold Spring Harbor Laboratory research focuses on three major areas: cancer,
neurobiology, and plant genetics. In 1995, all three areas saw exciting progress.
Our neurobiology program had a banner year with tremendous breakthroughs in
understanding the genetic basis of learning and memory. Senior Staff Scientist
Tim Tully came to Cold Spring Harbor in 1991 concurrent with the dedication of
the Beckman neuroscience building. He brought with him fruit flies and the train-
ing apparatus he had developed for them.
Tully is a behavioral geneticist and performs behavioral experiments on the
fruit fly Drosophila. Using a Pavlovian approach, he and his colleagues train the
fruit flies to avoid a particular odor by associating it with an electrical shock. With
the help of an outstanding research technician, Maria Del Vecchio, Tully found
that normal wild-type fruit flies require ten training sessions with rest intervals in
order to learn an associative learning task and to produce maximum long-term
memory. Additional training sessions provide no additional benefit to long-term
memory. In contrast, repeated sessions without rest intervals (massed training)
produced no long-term memory. Thus, like humans, Drosophila remembers best
when a task is learned over a period of time as opposed to learning a task
crammed into one intense training session, which produces little, if any, long-
term memory. By comparing the results of experiments using genetically altered
fruit flies with those done using normal wild-type flies, Tully and his colleagues
have associated differences in learning patterns with genetic mutations, tracking
down the genes and proteins critical to the learning process.
While Tully is training fruit flies, Senior Staff Investigator Alcino Silva is one
floor below in Beckman doing similar studies with mice. Silva began by studying
the effects of mutations in mice on learning and memory. His work focuses on the
function of the hippocampus, a region of the brain that is critical to the formation
of new memories in mice and humans. He first studied how removal of the gene
that produces an enzyme called CaMKII affects learning and memory in mice. Al-
cino uses a standardized test known as the Morris Water Maze to test learning in
mice.
In the Morris Water Maze, the mice are placed in a tank of cloudy water,
where a platform is hidden somewhere just below the surface. Initially, the mice
do not know where the platform is, but eventually they learn with the help of a flag
on the platform and large geometric shapes on the walls that serve as orientation
markers, or landmarks. Both normal mice and mice lacking the CaMKII gene
soon learn to find the platform easily by swimming to the flag. When the flag is
removed, however, the normal mice continue to swim directly to the platform fol-
lowing clues from the orientation markers, whereas the mice with the CaMKII
gene deleted swim aimlessly about, having failed to retain the spatial orientation
necessary to remember where the platform is located. Subsequent experiments
to test visual impairment, decreased motivation, and other possible effects of the
CaMKII deletion proved that in every other way these mutant mice are
normal-only their ability to learn how to follow the orientation markers is appar-
ently severely impaired.
These parallel studies on flies and mice have converged on the importance of
Tim Tully
Alcino Silva
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a protein called CREB, which regulates gene transcription. Tully, his associate
Jerry Yin, and Silva have discovered that the CREB gene has a critical role in the
formation of long-term memory in both flies and mice.
Jerry Yin, a Senior Staff Investigator, studies the genetic components of learn-
ing and memory. In collaboration with Jonathan Wallach, a graduate student in
the lab of Chip Quinn at the Massachusetts Institute of Technology, Jerry dis-
covered that the CREB gene produces two proteins, an activator and repressor.
Tully and Yin blocked the activity of the CREB protein in the fruit flies by stimulat-
ing the repressor form using a genetic tool known as a heat shock promoter. By
attaching the heat shock promoter to the CREB repressor, and then raising the
flies' body temperature by warming the chamber in which they are trained, they
were able to block the activity of CREB in the fly. To study CREB in mice, Silva
obtained mice from Gunther Schutz in Heidelberg that lacked the CREB gene.
Experiments by both Cold Spring Harbor groups-using flies and mice-yielded
Jerry Lin the same results: CREB-impaired organisms have short-term memory intact,
whereas the formation of long-term memory is impeded.
In 1995, a series of experiments by Tully and Yin produced an unprece-
dented result. Although in the earlier experiments they along with Alcino Silva
were able to prevent learning by inhibiting the activity of the CREB protein, last
year they asked whether increasing the activity of CREB would improve memory,
a much more difficult experimental result to achieve. Again, using the heat shock
promoter, Tully and Yin hyperstimulated the activator form of CREB. In doing so,
they were able to produce instant long-term memory in fruit flies after only one
exposure to a given task!
The generation of such "photographic" memory has not yet been ac-
complished in mammals-Silva does not have the luxury of using a heat shock
promoter in his mice. Mice do have such a genetic switch, as do humans, but as
warm-blooded creatures, they are only mildly susceptible to changes in body
temperature based on changes in the atmosphere. However, as the research
progresses and scientists look for other genetic tricks that might be utilized in
mammals, we look forward to achieving even greater understanding of learning
and memory-knowledge that may lay the groundwork for treatment of learning
disabilities, Alzheimer's disease, trauma, and other disorders.
As exciting as the Cold Spring Harbor neurobiology program is, there
remains an unfaltering dedication here to basic cancer research. David Beach's
lab continues to make progress in studies of cell cycle control. Recent work in his
lab further elucidated the role of three genes that encode related regulatory
proteins that are similar to the yeast CDC25 protein, two of which-CDC25A and
CDC25B-have been implicated in breast cancer. Overexpression of one or both
is seen in 70% of breast cancer tumors. Work on this very promising area of can-
cer research is ongoing and promises to bring new light to the search for effec-
tive breast cancer treatment.
Carol Greider studies telomerase, an enzyme that she discovered 10 years
ago, while a graduate student with Elizabeth Blackburn at the University of Cali-
fornia, Berkeley. Since that time, continued research has shown that telomeres,
the ends of chromosomes, are normally shortened with each replication cycle in
cells that ultimately die. Telomerase maintains the length of the chromosome's
ends and when absent in unicellular organisms causes them to senesce. Inter-
estingly, telomerase is found in approximately 90% of tumor cells but not in most
normal cells. 1995 was a year of extraordinary progress in the search for greater
understanding of this immortalizing and potentially oncogenic enzyme.
David Beach
Carol Greider
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Early in the year, Greider along with Kathleen Collins and Ryuji Kobayashi
purified essential protein components of the telomerase enzyme and cloned their
corresponding genes. Months later, Greider, in collaboration with researchers at
Geron Corporation in Menlo Park, California, cloned the RNA component of hu-
man telomerase, termed hTR. Maria Blasco of Greider's lab cloned the
telomerase RNA component found in mice, an accomplishment that will allow
direct experimental testing of the role of telomerase in normal mammalian devel-
opment and cancer. Greider and associates also succeeded in expressing a
complementary RNA strand, which latches on to the active telomerase RNA,
thereby inhibiting the telomerase activity and allowing the shortening of telomeres
and ultimate cell death. We hope to know soon whether telomerase might
represent an ideal target for anti-cancer drugs.
Michael Wig ler and Nikolai Lisitsyn recently developed a technique for gene-
finding that has led not only to significant discoveries in their own lab, but also to
discoveries nationwide by assorted researchers in various fields. Representa-
tional Difference Analysis, or RDA, is a high-tech method of comparing the DNA
of healthy tissue with that of diseased tissue. RDA has been used in the Wig ler
lab and elsewhere to locate mutations in cancer cells from the breast, kidney,
bladder, lung, colon, skin (melanomas), and brain (neuroblastomas). RDA has
also enabled researchers at Columbia University to identify a virus suspected of
causing Kaposi's sarcoma in AIDS patients, scientists at Abbott Laboratories to
identify three previously unknown hepatitis viruses, and researchers at
Pathogenesis to identify a form of human herpesvirus that may be associated
with multiple sclerosis. RDA was also successfully employed by researchers at
Johns Hopkins to screen for mutations in pancreatic cancer. The technique was
granted a patent by year end and is considered to be a most promising tool in
the fight against cancer and infectious disease.
Our plant genetics program, which carries on the Nobel prize-winning work of
the late Barbara McClintock, made great strides as well in 1995. Plant geneticists
Rob Martienssen and Venkatesan Sundaresan and their colleagues developed a
powerful new system for identifying genes involved in plant growth and develop-
ment. The system utilizes McClintock's maize transposable elements and is
being used to generate a large collection of Arabidopsis plants, each carrying a
transposon tag integrated into or near a different plant gene. This system facili-
tated identification of the prolifera gene, a homolog of yeast and mammalian
genes that regulate DNA replication.
With strong progress in neurobiology, cancer, and plant genetics, we now
look forward to an equally exciting 1996.
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Symposium LX: Protein Kinesis
This year's annual CSH Symposium on Quantitative Biology marked the event's
60th anniversary. The topic of discussion for 7 days in early June was Protein
Kinesis: The Dynamics of Protein Trafficking and Stability. Gunter Blobel, of the
Howard Hughes Medical Institute and Rockefeller University and a CSHL trustee,
delivered the annual Dorcas Cummings lecture entitled "How Proteins Find Their
Addresses in Cells." Dr. Blobel presented a clear overview of the complex system
of traffic and transit of proteins within cells, drawing analogies including
molecules as cars and microtubules as tracks and describing the types of in-
formation encoded in the amino acid sequence of each protein. Dr. Blobel's talk
was followed by the traditional Symposium dinner parties in the homes of local
Laboratory supporters. At the close of the Symposium, George E. Pa lade, Nobel
prize winner in 1974 for his work on the structural organization of the cell,
delivered the summary.
At this year's Symposium, we inaugurated the Reginald G. Harris Lecture in
honor of the former director of the Laboratory who initiated the Cold Spring Har-
bor Symposium in 1933. Harris recognized the need to bring biologists together
to discuss their science and to provide a forum for making biology more rigorous;
hence, the name "Cold Spring Harbor Symposia on Quantitative Biology." We
were pleased to have Dr. Randy Schekman, University of California at Berkeley,
present the first Reginald Harris Lecture.
Banbury Conference Center
The J.P. Morgan Executives' Meeting. It is hard to believe that 1995 marked the
tenth year of our program designed for the senior executives of pharmaceutical
and biotechnology companies. Initiated in 1986, these meetings have achieved a
remarkable reputation for combining the best in modern research with the best
from the business world. That this has been so is due in large part to our succes-
sion of sponsors-first Shearson-Lehman Brothers, then Baring Brothers, and now
J.P. Morgan Co. This year's meeting was entitled Infectious Diseases: Ancient
Plagues, New Epidemics and covered topics ranging from a history of epidemics
to the ways in which X-ray crystallography is being used to understand im-
munological responses to viruses. A highlight of the meeting was the presenta-
tion by Ham Smith on the rapid sequencing of the complete genomes of
Hemophilus influenzae (1.6 million base pairs) and Mycoplasma genitalium (0.6
million bases pairs). This served to show how far we have come since the first
meeting on "The Genetic Knowledge of Man" in 1986. At that meeting, Lee Hood
talked of his work on sequencing the whole of the HLA region, a project that was
at the outer limits of what was then possible. Since we have come so far in ten
years, who can tell what might be the subject of our twentieth meeting?
Meetings on Breast Cancer. Two meetings at Banbury Center exemplified our
commitment to understanding and using our knowledge of the genetic causes of
breast cancer. The first meeting was a joint venture of the Banbury and DNA
Learning Centers to provide a forum for members of Long Island's 1 in 9 Breast
Cancer Action Coalition to learn in more depth about molecular genetics and
cancer. In addition to talks on the fundamentals of genetics from Mark Bloom,
Dave Micklos, and Jan Witkowski, there were talks by invited speakers such as
Elizabeth Claus of Yale University School of Medicine and experiments at the
DNA Learning Center. The second meeting, Molecular Diagnostics of Breast
Cancer, brought together the world's leading breast cancer epidemiologists and
molecular geneticists to examine the implications of the cloning of the BRCA1
breast cancer gene (an event that was followed, some two months after the meet-
ing, by the isolation of the BRCA2 gene).
Duchenne Muscular Dystrophy. In 1980, we held a meeting at Banbury Center to
examine how the then new advances in molecular human genetics could be ap-
plied to what was perceived at that time as the most intractable of the human in-
herited disorders. Six years later, the gene was cloned, and 15 years later, we
were able to hold an open meeting in Grace Auditorium to discuss the various
approaches to therapy.
The meeting was intended to provide an opportunity for parents of affected
children to hear from key researchers, including Gordon Foulkes, Chief Scientific
Officer of Oncogene Science, Inc. The Laboratory has been working with On-
cogene Science in utilizing a new strategy in the search for compounds that will
turn on a gene that may replace the one damaged in Duchenne muscular
dystrophy. We cannot tell how likely success will be, but all avenues must be ex-
plored to find a treatment for this terrible disease.
50 Years of Phage
This year marked the fiftieth anniversary of phage research at Cold Spring Har-
bor. It was in the summer of 1945 that the first course on bacteriophage research
was introduced here by Max DelbrUck. An annual phage meeting ensued, com-
mencing in 1947 in Nashville, Tennessee, and moving to Cold Spring Harbor in
1950, where it was wisely scheduled to dovetail with the phage course, en-
couraging course participants to stay on and attend the meeting. The course ran
through 1970, after which it evolved into what is today called the ABG course, for
advanced bacterial genetics, and the meeting has been at the Laboratory every
year since 1950, with the exception of one. The meeting in August was both a
celebration of the rich history of phage research and a forum for the presentation
of new advances building upon the foundation of knowledge laid here so many
years ago. Participants shared memories and data and many younger attendees
Francois Jacob, Gunther Stent, Marilyn Zinder
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were excited to become acquainted with people whose names they knew from
the classic papers.
Notable participants included Waclaw Szybalski, Evelyn Witkin, Gunther
Stent, Francois Jacob, Franklin Stahl, Takashi Yura, Rollin Hotchkiss, Norton
Zinder, Charles Yanofsky, Dale Kaiser, Boris Magasanik, and Gisela Mosig; it
was especially delightful to welcome back the witty and charming Manny Del-
bruck. The meeting was enriched by historic displays of abstracts dating back to
the 1950s, photographs, and memorabilia. As the days passed, a sign-in book
for reminiscences was filled with insights from phage participants old and new,
creating a wonderful new artifact for the Cold Spring Harbor phage collection. By
all accounts, the event was a great scientific, historic, and social success.
Fifth Anniversary of the Human Genome Project
In November, 1995, the Human Genome Project celebrated its fifth anniversary.
In honor of this milestone, a group known as The Genome Action Coalition
(TGAC) sponsored the First Annual James Watson Lecture and Awards
Ceremony at the National Academy of Sciences in Washington D.C.
TGAC is a voluntary association of more than 70 patient advocacy groups,
professional organizations, and biotechnology and pharmaceutical companies
who have pledged their support to this important project through its completion.
In recognition of my role (J.D.W.) as the first director of the National Center for
Human Genome Research at the National Institutes of Health, I delivered the in-
troduction and opening remarks. Dr. Francis Collins, its current director, then
gave an update on the status of the progress of genome mapping and sequenc-
ing. The featured speaker for the afternoon was Senator Mark Hatfield of Oregon,
the Chairman of the Senate Appropriations Committee and one of the leading
congressional advocates of biomedical research. Senator Hatfield spoke about
the relationship between groundbreaking genetics research and public policy.
The event was also honored by the attendance of Secretary Donna Shalala of
the Department of Health and Human Services, who was awarded the TGAC Na-
tional Policy Leadership Award, and Senator Pete Domenici of New Mexico,
Senator Tom Harkin of Iowa, and Congressman John Edward Porter of Illinois,
who received TGAC Congressional Awards for their support of basic research.
Board of Trustees
In 1995 the Board of Trustees nominated and elected three new members: Wil-
liam E. Murray, Whitney D. Pidot, and Lola N. Grace.
Mr. Murray is an attorney in private practice specializing in estates and trust.
Bill has been a friend to the Laboratory for many years-he assisted in establish-
ing the Samuel Freeman Computer Laboratory (1985), the Neuroscience Center
(1988), and the Samuel Freeman Laboratory of Cancer Cell Biology (1989).
Mr. Pidot is an attorney in corporate law, currently a partner at the firm
Shearman & Sterling in New York City. Mr. Pidot is a long-time neighbor of the
Laboratory residing in nearby Locust Valley.
Mrs. Grace is a managing director of Sterling Grace Capital Management in
New York and is a director of the Society of Memorial Sloan-Kettering. Lola and
her husband John are part of an outstanding family of Laboratory supporters. The
late Oliver Grace, John's father, and his wife Lorraine have been true friends of
the Laboratory for many years; in 1984, they gave funds toward the construction
of Grace Auditorium, allowing the Laboratory to create an exceptional forum for
world-renowned scientific meetings, and in 1987, they established the Oliver
Grace Chair for Cancer Research which I (J.D.W.) am privileged to hold.
Thomas Jessell completed his six-year term on the Board this year. Dr. Jes-
sell, a former instructor of Cold Spring Harbor neuroscience courses, continues
his studies on developmental neurobiology at Columbia University and was
recently elected a Fellow of the Royal Society. We wish him the best in his future
endeavors.
Townsend J. Knight, Esq., completed his most recent term on the Board and
has been named an Honorary Trustee. Townie is a descendant of John D. Jones,
founder of the Biological Laboratory at Cold Spring Harbor in 1890 and of the
Wawepex Society, an organization established to administer the family's
philanthropic interests. Among the family's charitable ventures were the donation
of land and monies that were used to establish the first research laboratory at
Cold Spring Harbor (known now as Jones Laboratory) built in 1893 and the es-
tablishment of the Knight Trust. Townie has served on the Board for many years
(1971-1975, 1982-1995), and his continuing presence as an honorary trustee
will provide us with invaluable advice and counseling.
Trustee Receives Lasker Award
Scientific trustee Don Wiley, Ph.D., of Harvard University, received the 1995 Al-
bert Lasker Medical Research Award for distinguished contributions to biomedi-
cal research. Dr. Wiley, professor of biochemistry and biophysics at Harvard Uni-
versity, was recognized for his revolutionizing work in immunology.
Robertson Research Fund
A tradition of giving was established by the Robertson family of Lloyd Harbbr
back in 1973, when Charles Robertson gifted nearly $8 million to the Laboratory
to create the Robertson Research Fund. At that time, he also initiated the transfer
of the Robertson property on Banbury Lane, now the site of our Banbury Confer-
ence Center, and a fund for its maintenance. Then, two years later in 1975, the
Banbury Fund-the Robertson family's private foundation-established the Marie
H. Robertson Memorial Fund to support neuroscience research at Cold Spring
Harbor. Its availability soon after allowed the establishment of year-round re-
search in leech neurobiology by Birgit Zipser in the newly renovated Jones
Laboratory.
In 1995, the Robertson Research Fund-its value now up to $56 mil-
lion-distributed $1.6 million to basic research at Cold Spring Harbor, supporting
16 staff scientists; CSH fellow Scott Lowe, who works in James Laboratory on
apoptosis and cancer therapy; postdoctoral fellow Chantal Autexier, who studies
telomeres (the ends of chromosomes) in Carol Greider's lab; and graduate stu-
dent Shirley Pinto, who is studying the latheo gene, implicated in learning and
memory in Drosophila, in Tim Tully's lab. The Marie Robertson Memorial Fund
also supported research into the genetic basis of learning and memory in
Drosophila in the Tully lab, including support for postdoctoral researcher Michael
Regulski, and in mice in Alcino Silva's lab, including support for postdoctoral re-
searcher Yoon H. Cho.
Townsend J. Knight, Esq.
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Major Gifts
We are again grateful for the strong support of our Trustees, interested individu-
als, foundations, corporations, arid other charitable organizations. A major priority
this year was the proposed acquisition of the beautiful Friends World College
property in Lloyd Harbor. Through the generosity of our trustees, the Dolan Fam-
ily Foundation, Thomas Saunders, David Luke, Edwin Marks, John Reese, an
anonymous donor, and the William Stamps Farish Foundation, we received
pledges in excess of $3 million toward the purchase. In consideration of con-
cerns voiced by a group of community members, we have withdrawn our ap-
plication for the use of the Friends World College campus from the Village of
Lloyd Harbor and, with our Board of Trustees, are discussing alternative projects
to meet the needs for administrative and editorial space and additional scientist
housing. We deeply appreciate the support of our friends at a time when we
hoped to preserve the lovely 30-acre estate while fulfilling pressing needs of the
Laboratory.
Our Undergraduate Research Program (URP) received important additions to
its endowment with gifts of $100,000 from The Garfield Foundation; $100,000
from the estate of Joan Redmond Read; $60,000 from our friend and colleague
Bentley Glass; $40,620 from the Burroughs Wellcome Fund, proceeds of $51,000
from the wonderfully warm and well-received concert given by Flicka von Stade
and Friends in the spring, and $7,500 from Jephson Educational Trust.
The Laboratory science programs were well supported during the year with a
gift of $290,000 from Westvaco for the plant genetics program; $150,000 from the
McKnight Endowment for Science and one of $120,000 from the John Merck
Fund, both for Dr. Alcino Silva's lab; $150,000 from the Prichard Trust for
scientific equipment; $100,000 from the Glaxo Research Institute and $75,000
from Alan and Edith Seligson, each toward postdoctoral research fellowships;
$45,000 from 1 in 9: Long Island Breast Cancer Coalition for Dr. Mike Wigler's lab
for cancer research, especially breast cancer; $30,000 from the Goldring Family
Foundation for postdoctoral support in Dr. Bruce Stillman's lab; $20,000 from the
Irving A. Hansen Memorial Fund; $20,000 from Arrow Electronics for equipment;
$15,000 from the Lauri Strauss Leukemia Foundation for Dr. Nick Tonks; $15,000
from Mrs. Oliver R. Grace for equipment; $10,000 from the Dextra Baldwin
McGonagle Foundation and $10,000 from the Edward S. Moore Foundation for
scientific equipment.
A most gracious gift was made by the Olin family in the form of three mag-
nificent sculptures. Gerry and Sue Lin have been generous supporters of the
Laboratory and recently, after the death of Sue's father, William Cohen, the Olins
had to handle the distribution of his estate. Located on Mr. Cohen's property in
Sands Point were original works of art ranging in height from 6 feet to 12 feet tall.
The Olins were interested in placing these large sculptures in an appropriate en-
vironment and chose to offer them to the Laboratory to be placed on our beautiful
grounds.
A cor-ten steel sculpture called Profile /Canto #1, by Ernest Trova-an impos-
ing 8 feet high and 12 feet across-was relocated to the field on Bungtown Road
across from the Yellow House. Draco, a gray Vermont marble piece by Kenneth
Campbell now stands on the lawn of Ballybung while a second Campbell piece,
twice the height at 12 feet and crafted of white marble, named Pyramus and
Thisbe, stands just outside the north door of the Beckman Neuroscience Center.
The campus has been both enriched and beautified with the addition of these
one-of-a-kind heirlooms.
Our endowment funds fared well, led by a gift of $150,000 from Bill and Mar-
jorie Matheson for the Matheson Fund; $50,000 from the Banbury Fund for the
Robertson Chair; and an addition of $74,000 to the Harrison Chair.
Support for research into the causes of Duchenne muscular dystrophy con-
tinued, with a contribution of $52,000 from John Cleary. The DNA Learning Cen-
ter received a grant of $50,000 from Genentech to help in the construction of the
new Cellarium exhibit and the Barker Welfare Foundation provided $15,000 for
program support.
The companies contributing to the Cold Spring Harbor Corporate Sponsor
Program continue to provide a very substantial underpinning of the meetings pro-
gram in Grace Auditorium and at the Banbury Center. Full acknowledgment of
their generosity can be found in the Finance Section.
DNA Learning Center
Story of a Gene opened in May. The first exhibition to be developed in-house at
the DNA Learning Center (DNALC), it traces the story of human growth hormone
(HGH), an ideal case study in modern human genetics. HGH affects an obvious
physical trait (height), its physiology and cell biology are well understood, and it
was one of the first human therapeutics produced by recombinant DNA. The
backdrop for the exhibit is the remarkable Cellarium, a room-size mural depicting
the expression of the hormone within a single pituitary cell. Interactive exhibits
challenge visitors to consider the parameters of human growth and the physical
effects of growth hormone, as well as the controversial use of growth hormone to
improve lifestyle for humans and milk production in dairy cows. November saw
the publication of Laboratory DNA Science, a college-level course in recom-
binant DNA techniques developed by Learning Center staff members Mark
Bloom and Dave Mick los, in collaboration with Cold Spring Harbor alumnus Greg
Freyer of Columbia University.
The DNALC continues to play a unique part in promoting genetics education.
In 1995, no fewer than 8,000 students and teachers came to the DNALC for
hands-on DNA workshops and an additional 10,000 visitors saw the exhibits
Story of a Gene and Long Island Discovery.
Scientists Recognized
Our reputation as an institution staffed by the best and the brightest is frequently
reinforced by recognition in the form of awards to our scientists. This year, two
Cold Spring Harbor scientists received major prizes: Michael Hengartner
received the first annual Pharmacia Biotech & Science Prize for Young Scientists.
Sponsored by Science, the journal of the American Association for the Advance-
ment of Science, the award recognizes outstanding molecular biologists early in
their careers. The grant of $20,000 was formally presented at a ceremony in
Sweden and recognized the excellence of Michael's Ph.D. thesis on apoptosis,
or programmed cell death, which was completed while he was a graduate stu-
dent at the Massachusetts Institute of Technology.
Carol Greider was honored by the American Society for Cell Biology, with the
presentation of the first annual Glenn Foundation Award at the ASCB's 35th an-
nual Symposium in December. The $5,000 grant is in recognition of Greider's
work on telomerase, a protein implicated in extending the lives of cancer cells in-
definitely. Michael Hengartner
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CSHL Press
Twenty new books were published, plus a new videotape set and an audio
tape/CD. The total titles in print now number more than 220. The most successful
new title was PCR Primer, a laboratory manual on amplification techniques, which
sold more than 2,500 copies when released in the last quarter of the year. Also
notable were four other lab manuals developed from practical courses taught at
the Laboratory and two scholarly monographs edited with colleagues by two of
the Laboratory's senior scientists: Telomeres, assembled by Carol Greider and
Elizabeth Blackburn, and Translational Control, edited by Michael Mathews with
John Hershey and Nahum Sonnenberg. A special reprint of Francois Jacob's
autobiography The Statue Within was published to coincide with the fiftieth an-
niversary of the Laboratory's bacteriophage course.
The journal program continued to expand in scope and frequency. The suc-
cessful five-year old bimonthly methods journal PCR Methods and Applications
evolved into the monthly research journal Genome Research. The print issues
were supplemented with information such as video clips made available through
the journal's World Wide Web site, the first use of the Internet in this way by a
science journal. Genes & Development consolidated its position in the top ten of
the world's biology journals with another successful year editorially, increased
circulation, and an increasingly important contribution to the financial per-
formance of the Press.
The first issue of the annual directory, The Lab Manual Source Book, con-
tained information from more than 600 suppliers about 15,000 products used in
laboratory work with genes, cells, and proteins. It was distributed to 40,000
scientists worldwide. In addition, an interactive database, BioSupplyNet, was cre-
ated on the World Wide Web to allow scientists rapid access to more detailed in-
formation about available products and their sources of supply.
CSHL Association
The annual meeting of the CSHL Association began with lunch at Ballybung on
February 5 and was followed by a special lecture by Rich Roberts, the
Laboratory's most recent Nobel Laureate. Roberts, who won the highest award
of science in 1993, spoke to the audience of directors and friends of the
Laboratory about his work on RNA splicing and about the extraordinary festivities
associated with the Nobel prize ceremony in Stockholm, Sweden.
Joan Pesek, Associate Director for the annual fund, left the Association after
nearly nine years; we will miss her enthusiastic participation. Jean Schwind, for-
mer grants assistant here at the Laboratory, has stepped into the position and is
effectively handling the many facets of Association fund-raising.
One of the goals of the Association is to reach out to a new generation of sup-
porters for basic research. Toward this end, the Association has initiated the Next
Generation Outreach Program, a lecture series designed to stimulate the interest
of a generation of 30-40-year-old community members and to bring the impor-
tance of basic research home to the audience. In the first lecture, Tim Tully dis-
cussed breakthrough discoveries in learning and memory and their implications
for humans. The second lecture included Carol Greider, who discussed the im-
portance of fellowships on the path to independent research, and Winship Herr,
who discussed educational programs at the Laboratory. In the third lecture,
Michael Wig ler addressed what is probably the most prevalent question about
basic research today: What kind of progress are we making in cancer research?
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The final lecture featured David Mick los of the DNA Learning Center, who dis-
cussed personal and social implications of reading DNA.
The Association has an outstanding history of support of science and educa-
tion here at the Laboratory, support that has played a crucial part in fostering our
research, especially that of our young scientists. We are sure that through this
outreach we will inspire participation by the next generation.
President's Council
The President's Council was formed in an effort to bring together a small group of
individuals with a keen interest in science and the work of Cold Spring Harbor
Laboratory. Through their annual commitment of $25,000, the members provide
support for the Cold Spring Harbor Fellows program. The funding is critical in at-
tracting top young scientists fresh from their Ph.D. studies. It allows them the op-
portunity to pursue their own research, rather than assisting in the laboratory of
an established scientist.
A major feature of the Council is an annual meeting to bring together this
select group of leaders from business, finance, and science to discuss the latest
developments in genetic research and biotechnology. The Council's first meet-
ing, held May 12-13, began with lunch at Ballybung for Council members and
their guests. Senior Scientist Adrian Krainer and CSH fellow Ueli Grossniklaus
spoke to the group about the importance of the Cold Spring Harbor Fellows pro-
gram in allowing scientists to do unrestricted independent research. The discus-
sion at the meeting focused on the Societal Implications of Modern Human
Genetics. The mix of minds of leaders in the business world and scientific com-
munity evoked provocative discussion as to the implications and issues that are
coming to the forefront as our knowledge of the genetics of human behavior in-
creases. The keynote speaker, Dr. Nancy Wexler, Columbia University College of
Physicians & Surgeons, opened the meeting on Friday evening with her talk on
The Promise and Perils of Human Genetics. A panel discussion was held on Sat-
urday morning to discuss the ethical, legal, and social issues arising from our in-
creasing genetic knowledge. Leading the discussion were Dr. Tom Bouchard,
University of Minnesota; Dr. Tom Caskey, Merck & Co. Inc.; Dr. Tom Murray,
Case Western Reserve University School of Medicine; and Dr. Norton Zinder,
President's Council
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Rockefeller University. The day and the meeting ended with the guests gathering
once again at Ballybung for a parting luncheon.
Founding members of the President's Council include Abraham Appel, Appel
Consultants; Michel David-Weill, Lazard Freres & Co.; Frederick Frank, Lehman
Brothers, Inc.; Leo A. Guthart, ADEMCO; Charles E. Harris, Harris & Harris
Group, Inc.; Walter B. Kissenger, Long Island Research Institute; David
Mahoney, The Charles A. Dana Foundation; Donald A. Pels, Pelsco, Inc.; George
B. Rathmann, ICOS Corporation; Frank E. Richardson, Wesray Capital Corpora-
tion; Hubert J.P. Schoemaker, Centocor, Inc.; James H. Simons, Renaissance
Technologies Corp.; George Soros, The Soros Foundations; Margo Walker,
Citivilla Properties; and Sigi Ziering, Diagnostic Products Corporation.
Special Events/Fundraisers
On March 25, Flicka von Stade and Friends charmed and entertained a packed
house in Grace Auditorium for a second time. The very talented and equally
beautiful diva strayed from her operatic style, performing a spectacular blend of
ethnic folk songs, bluesy jazz, a little ragtime, and several rearrangements of
classics by Bach and Shubert. Accompanied by Bill Crofut on banjo and vocals,
Chris Brubeck on bass and trombone, and Joel Brown on guitar, Flicka raised
additional funds for the Frederica von Stade Endowment, a fund that will provide
an annual fellowship for our Undergraduate Research Program.
In June, 1 in 9: The Long Island Breast Cancer Action Coalition held their sec-
ond annual Michael Scott Barish Sand Soccer Tournament in Long Beach. In Oc-
tober, several Lab members were invited to participate in 1 in 9's first annual
Governor's Dinner Dance at the Seawane Club in Hewlett Harbor. Proceeds of
the outdoor sporting event and the black-tie gala attended by Governor George
and Libby Pataki were donated to the Laboratory in support of Michael Wigler's
lab and the Human Cancer Fund. In a public ceremony in November, 1 in 9 pre-
sented the Laboratory with a check for $45,000, more than doubling their initial
grant to us in 1994 in support of Dr. Wigler's cancer research.
In September, CSHL Association director Carol Large coordinated a new
event at Cold Spring Harbor: the Old Westbury Gardens Tree Symposium.
Sponsored by the Westvaco Corporation, the event was conceived by Carol and
organized in cooperation with Old Westbury Gardens and the Cornell Coopera-
tive Extension of Nassau County. Horticulturists, gardeners, and other lovers of
things green were drawn to Grace Auditorium to hear a day-long forum where
horticulturists, landscape designers, and plantsmen presented, discussed, and
debated their views on the present and future use of trees in the landscape.
Participants included noted author Professor Michael Dirr of the University of
Georgia and Robert Halpern of the Wildlife Conservation Society. The benefit
raised nearly $8,000 for the CSHL Association which supports scientific research
by supporting research fellows.
A most rewarding cultural event is our Young Artist Concert series. Young
classical musicians, many of whom have played to audiences around the world,
perform in Grace Auditorium during our scientific meetings. Melvin Chen and
Alexis Pia Gerlach performed in April at the Cytoskeleton meeting, on piano and
cello, respectively. In May, Todd Palmer played clarinet and Margaret Kamp-
meier played piano before an audience of scientists interested in RNA process-
ing. Respite from transcription factor studies in September was provided by
Catherine Cho and Benjamin Loeb on violin and piano. Violinist Dmitri Berlinsky
and pianist Elena Baksht, both natives of Russia, provided melodic entertainment
for the DNA replication crowd gathered at the Laboratory later in September with
pieces from Ravel, Tchaikovsky, and Franck.
Some of the Young Artists performances are organized through Young Con-
cert Artists, Inc. (YCA), a management company; others are privately sponsored.
All are conducted free of charge for the scientists working at and visiting Cold
Spring Harbor Laboratory. The Laboratory's long-time friend Roger H. Samet gra-
ciously sponsored the Chen/Gerlach performance, and Dr. Mark Ptashne, moved
by an earlier YCA performance, donated $5,000 through the D'Egville Foundation
to provide support for the promotion of young artists and was the sponsor for the
Cho/Loeb concert.
Family Spirit
The events that contribute to the Laboratory's family atmosphere spanned the
year. The Easter Egg Hunt returned to Airs lie lawn this past spring, sending chil-
dren with baskets scampering about in search of brightly colored eggs. The sum-
mer brought the annual July Staff Picnic, which took place on one of the
notoriously hot, over-100° days. Well-attended by staff, family, and friends, the
harbor beach was the most popular place to be, second only to the shade
beneath the trees along the shore.
Laurie Landeau, our long-time friend and former trustee, held her annual Au-
gust beach party for the scientific staff at her still wonderfully undeveloped Eaton
Neck property. In the cold of winter, children of Laboratory staff attended the an-
nual Christmas party replete with gifts for every child, and food and drink for
everyone. Afterward, the crowd gathered around the Christmas tree on Bungtown
Road for caroling and the tree lighting. Carolers were distracted from the cold by
the smooth sounds of the American Concert Band, a five-piece brass ensemble
well-versed in the traditional songs of the season.
The Lab Makes History
In a satisfying culmination of 25 years of historic preservation here at Cold Spring
Harbor, the Laboratory was honored in June with a certificate proclaiming its his-
toric significance at both the state and national levels. Thanks to the tireless ef-
forts of Liz Watson and her dedication to the architectural and historical integrity
of each building on the grounds of the Laboratory, we have succeeded in earn-
ing a place on the New York State and National Registers of Historic Places
(NRHP).
The nomination to the Register of Historic Places was initially inspired by the
magnificent and historically true restoration in 1980 of Davenport House-the
pumpkin-colored Victorian house built in 1884 that faces Route 25A at the
entrance to the Laboratory. As Liz assembled the NRHP proposal, it became
clear that virtually all of our buildings were historically significant: Airs lie House,
built in 1806 for Major William Jones; Davenport Laboratory (now Delbruck
Laboratory), built in 1926 and subsequently named for Nobel prize winner Max
Delbruck who established the famous "phage course" at Cold Spring Harbor; our
grants and development building, Wawepex, built in ca. 1825 during the whaling
era and named for the Indian word for "at the good little watering place." Indeed,
the land itself, including the field on which Barbara McClintock grew the corn
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used in her Nobel prize-winning work, earned a place on the National Register,
as did the Cold Spring Harbor Fish Hatchery, established in 1887.
The designation celebrates not only the historic scientific and cultural sig-
nificance of the Laboratory, its grounds, and the Fish Hatchery, but also the dedi-
cated efforts of Liz and of Jack Richards of our Buildings & Grounds Department,
who supervised much of the restorative construction. Bernadette Castro, Com-
missioner of New York State Department of Parks, Recreation, and Historic
Preservation, presented a beautifully framed certificate to Liz at a breakfast
ceremony in Blackford Hall on June 2. Among those in attendance from the
Laboratory were Dr. Bruce Stillman, Director; Morgan Browne, Administrative
Director; Dr. Winship Herr, Assistant Director; Arthur Brings, Director of Facilities;
Susan Cooper, Director of Public Affairs and Development; Nathaniel Comfort,
Science Writer who supplied the written documentation necessary for the
nomination; and Jack Richards. Representing the CSH Fish Hatchery were
Norman Soule, Director, and his wife Mary Ann and board members Mary Jo
Hossfeld, Richard Cohen, George Dennis, Carol Dubois, Chris Nuccio, Muffy
Osterhus, Mark Trotter, and Charles Holcomb. In addition, Allison Hain of School
District 2 and Laurie Hempton, Historic Preservation Field Representative for the
New York State Office of Parks, Recreation, and Historic Preservation (who
worked so diligently with Liz to bring the project to fruition), were on hand to
celebrate the designation.
Gavin Borden Lecture
Our graduate students are a vital part of Cold Spring Harbor Laboratory, both for
their research and for the vitality they bring. This year, the Laboratory instituted a
new event to honor a friend to science and the Laboratory and to acknowledge
the role of the graduate students. The Gavin Borden graduate student seminar
and lecture was named for the energetic and charismatic publisher of The
Molecular Biology of the Cell (MBC) who died in 1994 of cancer.
Bruce Stillman (Left) and Bruce Alberts (center) at the Gavin Borden Lecture
The program opened on March 9 with a lecture by one of the six authors of
Molecular Biology, Bruce Alberts, President of the National Academy of Sciences
and Professor of Biochemistry and Biophysics at the University of California. The
lecture, geared toward graduate students-Borden's target audience as a
writer-was entitled "Avoiding a Train Wreck: What Happens When RNA
Polymerase and DNA Polymerase Collide." After the lecture, there was a recep-
tion for Dr. Alberts, and then he and the graduate students had dinner together.
The following day, Dr. Alberts met individually with me (B.S.) and Assistant
Director Winship Herr, and senior scientists Carol Greider, Michael Wig ler, Nick
Tonks, and Tim Tully. After a lunch with members of the scientific staff, Dr. Al-
berts met with all of the graduate students for an informal discussion. Topics dis-
cussed included the varied careers that young scientists can consider. Dr. Al-
berts' visit ended with supper at Ballybung with the Watsons. The education of
graduate students was a mission dear to Gavin Borden's heart and the
Laboratory proudly and enthusiastically supports that important charge.
Funding for the creation of the Gavin Borden Lecture series was provided by
Gavin's widow Elizabeth Borden, myself (J.D.W.) and Liz, Dr. Bruce Alberts, and
Robert Winthrop.
Undergraduate Research Program (URP)
The Undergraduate Research Program at Cold Spring Harbor Laboratory pro-
vides an opportunity for college undergraduate students to participate in active
research projects under the supervision of Laboratory staff scientists. Since the
inception of the URP program in 1959, 440 students have participated in the
course and many have gone on to productive careers in biological science.
The URP seeks to provide not only a greater understanding of the fundamen-
tal principles of biology, but also an increased awareness of experimental ap-
proaches to science and a deeper understanding of the major issues in the fields
of genetics and molecular and cell biology. The participants also garner a per-
sonal acquaintance with research, research workers, and centers for study.
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This year, 22 students were selected from more than 280 applicants. Support
for the URP was provided by Bio-Rad Laboratories, Burroughs-Wellcome Fund,
C. Bliss Memorial Fund, The Garfield Internship, Hanson Industries, Jephson Ed-
ucational Trust, Libby Internship, National Science Foundation, Phillips Petroleum
Foundation., Inc., Powers Foundation, William Shakespeare Internship, and the
Frederica von Stade Internship. (For a list of these students by name and univer-
sity, see the URP Section in this Annual Report.)
Partners for the Future
In a mission to open Laboratory doors to an ever younger audience, the
Laboratory has solicited nominations from all Long Island high schools each year
since 1990. The Partners for the Future program is now in its sixth year, and once
again, we have five talented high school students doing original research in the
laboratories of staff scientists. The five students chosen to participate in the pro-
gram come to the Laboratory each day after school, October through March, and
do original experiments under the guidance of a scientist mentor. The culmina-
tion of the program is an oral presentation by the students in which they present
the results of their months of study to an audience of proud parents, teachers,
and mentors.
The 1995-1996 Partners, their schools, and mentors are Hay ley Solomon of
Plainedge High School with Dr. James Dezazzo; Danielle Cain of Sachem High
School in Lake Ronkonkoma with Dr. Michael Regulski; liana Kurshan of Hunting-
ton High School with Dr. Venkatesan Sundaresan; Dominik Rosa of Commack
High School with Dr. Hong Ma; and Elizabeth Tegins of St. Anthony's High School
in South Huntington with Dr. Kim Arndt.
Project WISE
In an effort to encourage bright young women to enter into the fascinating world
of science and technology, the Laboratory has entered into a program with the
State University of New York, Stony Brook, called Project WISE (Women in
Science and Engineering). Stony Brook recruited our participation, as well as that
of Brookhaven National Laboratory and the American Association of University
Women, in this program designed to expose high school girls to the sciences.
Mary Horton of our Grants Department orchestrated our involvement, which in-
cluded sponsoring two trips to the DNA Learning Center. On the first trip, the stu-
dents used restriction enzymes to cut DNA from bacteriophage A, and then ana-
lyzed the fragments, all under the guidance of Laboratory scientist Diane
Esposito.
On the second trip to the Learning Center, each young woman isolated a
sample of her own DNA and fingerprinted it using the automated polymerase
chain reaction (PCR). In addition to the DNA Learning Center workshops, the
participants had dinner with and visited the laboratories of six Laboratory
scientist mentors: Hollis Cline, Carol Greider, Ann Sutton, Roberto Malinow, Luis
Pena, and John Horton. Each student participates for four years-9th through
12th grade. The Laboratory will, each year, instruct the 10th graders in molecular
biology and genetics, offering a foundation upon which they can build a future in
technology and the sciences.
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Long-term Service
Nine Laboratory employees celebrated long-term service anniversaries this year.
Madeline Wisnewski, scientific secretary, celebrated her 25th year with us.
Madeline joined us in 1970 and has worked in various offices throughout the
Laboratory, including as secretary to Dr. Watson, before landing in Demerec
Laboratory where she works with Drs. Helfman, Greider, and Spector. Vincent
Carey, grounds foreman, and Robert McGuirk, senior laboratory technician, both
celebrated their 20-year milestones. Fifteen-year honorees included Michael
Riggs, laboratory technician, and Linda Rodgers, research associate, members
of Michael Wigler's lab; Bruce Fahlbusch, buyer for the Buildings & Grounds De-
partment; Georgia Binns, research associate in Ryuji Kobayashi's lab; Marlene
Rubino, administrative assistant in Environmental Health & Safety; and Andrea
Stephenson, now meetings administrator.
Changes in Administrative Staff
This was a year of transition for the Laboratory's computer department. Fred Stel-
labotte, former Computer Systems Manager, left us to take a position with the
Avis Corporation. Jerry Latter, former manager of the Quest Protein Database,
was appointed Director of the Information Services Department (ISD) and
charged with improving and restructuring the Laboratory's use and support of
computers. Latter is orchestrating improvements in the staffing, networking, and
approach to troubleshooting for the extensive network of hardware and software
of some 560 employees who use a variety of computing systems.
The Buildings & Grounds (B&G) Department has undergone administrative
changes as well. Jack Richards retired from his position as Director of B&G, but
he remains active in architectural and construction projects. Jack was convinced
to join the Laboratory in 1969 after bidding on the renovation of the James
Laboratory Annex. Over the years, he has played a valuable part in consulting
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with architects and supervising construction and renovation; his attention to detail
and quality workmanship during the preservation of many Laboratory buildings
was without question a factor in the Laboratory's successful nomination to the
State and National Registers of Historic Places. As Jack would tell it, however, it
was the construction of the wastewater treatment plant in the 1970s that present-
ed the greatest challenge. That facility, planned and constructed under his direc-
tion, maintained a perfect record for meeting health department standards during
its years of operation and is among the most attractive settings on the harbor. It is
with great pleasure that we acknowledge Jack's extraordinary contributions by
naming the future B&G building in his honor.
Art Brings has stepped into the Director's position, managing the staff of 80
who comprise B&G, Environmental Health and Safety, Security, and the Harris
Animal Facility. It is a credit to Jack and Art that we have maintained and beauti-
fied the grounds and buildings, continually striving to provide not only a pleasant,
but also a healthy and safe working environment for all members of the
Laboratory staff.
Changes in Scientific Staff
Each year, the Laboratory is infused with fresh new intellect ranging from bright
and enthusiastic graduate students and postdoctoral researchers to experienced
senior staff scientists. At the same time, we inevitably see the departure of others.
Dan Marshak, a protein chemist who was a part of the Laboratory for 10
years, went on to a position with Osiris Therapeutics, Inc. in Baltimore, Maryland,
where we wish him all the best. Nikolai Lisitsyn, Senior Staff Investigator and
codeveloper of a powerful new technique for genetic research known as Repre-
sentation Difference Analysis (RDA) with Michael Wig ler, has accepted a position
as assistant professor at the University of Pennsylvania, School of Medicine in
Philadelphia and Hiroyuki Nawa, Senior Staff Investigator interested in mechan-
isms of neuronal communication, accepted a professorship at Niigata University
in Japan. Harriet Feilotter, Staff Investigator with us since 1990, was an integral
part of the Dana Consortium-the Laboratory's collaboration with researchers at
Johns Hopkins and Stanford University established to identify genetic com-
ponents of manic depressive disorder. Harriet has moved to Queen's University
in Ontario as a research associate.
Several staff associates have accepted positions elsewhere and have
departed Cold Spring Harbor: William I. Chang left the Marr lab to accept a posi-
tion as Senior Software Engineer at Infoseek Corporation in Mountainview, Cali-
fornia; Mi Sha left the Roberts lab to a position as staff scientist at the Genetic In-
stitute in Cambridge, Massachusetts; Ann Sutton departed from the Arndt lab to
accept a visiting professorship at SUNY, Stony Brook; Xu Duffy from the Wig ler
lab went to a research scientist position at North Shore University Hospital here
on Long Island; and Michael White moved to the University of Texas South-
western Medical Center in Dallas, as an assistant professor. Computer scientist
Marty Hiller left the Marr lab this year to fill the same position with Millenium
Pharmaceuticals in Cambridge, Massachusetts, and Howard Hughes Medical In-
stitute associate Hui Zhang left the Beach lab to become a lecturer at Yale Uni-
versity School of Medicine.
Five visiting scientists completed their stays at the Laboratory in 1995. Young-
Seuk Bae returned to Kyungpook National University in South Korea from the
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Marshak lab; Doug Demetrick returned to Foothills Medical Center at University
of Calgary in Canada from the Beach lab; Carina Dennis left the Helfman lab to
return to the Ph.D. program at Oxford University in the United Kingdom; Boris
Kuzin returned to the Russian Academy of Science in Moscow from the lab of
Grigori Enikolopov; and Peter Barker departed from the Wig ler lab.
Two special visitors to the Laboratory, Jonathan Montague and Greg Jeffries,
have returned to the United Kingdom. Both graduates of Eton College in Windsor
came to Cold Spring Harbor to study with our scientists for one year before pro-
ceeding on to university life. Jonathan studied plant genetics in Rob Martiens-
sen's lab and has gone on to begin his studies at Oxford University. Greg worked
with Michael Hengartner on studies of programmed cell death in C. elegans and
is now attending Cambridge University. It was our pleasure to host Jonathan and
Greg, and we wish them well in their studies.
New Staff Members
More than 30 new postdoctoral researchers and 20 graduate students joined the
Laboratory this year. Tatsuya Hirano joined us as a Senior Staff Investigator, after
6 years at the University of California, San Francisco, studying chromosomal
dynamics. Leemor Joshua-Tor also signed on as a Senior Staff Investigator; she
arrived from Caltech in Pasadena to join our Keck Structural Biology Laboratory.
Peter Nest ler made the short trip from Columbia University in New York to join us
as a Staff Investigator. Peter will be working on combinatorial chemistry.
We have several new visiting scientists this year: Benjamin Horwitz came from
Israel to work on plant genetics in the lab of Hong Ma; Isabelle Jupin arrived from
the Institut Jacques Monod University in France to work with Linda Van Aelst on
viral/host interactions in viral RNA replication; Leslie Kerrigan came up from
Osiris Therapeutics in Baltimore to work in Dan Marshak's lab with Timothy Con-
nolly, who was here on sabbatical; Boris Kuzin from the Russian Academy of
Science in Moscow is studying the role of nitric oxide in Drosophila development
in Grigori Enikolopov's lab; Roberta Maestro has come to the lab of David Beach
from CRO Avino in Italy to study the p53 gene and apoptosis; R. Sanders Wil-
liams came on sabbatical leave from University of Texas, Southwestern Medical
Center to work in the Stillman lab on regulation of DNA replication; and De Ye
from the Biotechnology Institute in University Park, Pennsylvania, joined
Venkatesan Sundaresan's lab and is working on embryogenesis in Arabidopsis.
Promotions
Several staff members were recognized this year with promotions. Two scientists,
Tim Tully, Cold Spring Harbor Laboratory's Drosophila learning and memory ex-
pert, and plant geneticist Rob Martienssen were promoted from Senior Staff In-
vestigator to Senior Scientist. Staff Investigators Michael Hengartner and Yi
Zhong-both having arrived fresh out of graduate school-were promoted to
Senior Staff Investigator positions. Michael will continue to study apoptosis, and
Yi will focus on neural development and learning and memory. Joseph Colasanti,
a postdoctoral researcher in Venkatesan Sundaresan's lab, and Michael White, a
postdoc in the Wig ler lab, were both appointed Staff Associates. Shou Waga, a
postdoc in the Stillman lab who studies mechanisms and regulation of eukaryotic
DNA replication, was promoted to Staff Investigator.
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Postdoctoral Departures
Masahiro Akiyama left Bruce Stillman's lab for an associate professor position at
the Nara Institute of Science and Technology in Japan; Zoltan Asztalos went from
Tim Tully's lab to a scientist position with ERATO, the Yamamoto Behavioral
Genes Project in Tokyo; Wei Guo left David Helfman's lab to continue postdoc-
toral research at the Scripps Research Institute in San Diego; Chang-Deok Han
went from a postdoctoral position with Rob Martienssen to a position as a re-
search scientist at the Gysong-Song National University in Korea; Keiko Mizuno
left Hiruyuki Nawa's lab; Piruz Nahreini went from Mike Mathews' lab to a
Scientist II position at Ribozyme Pharmaceuticals Inc., in Colorado; and
Catherine Weiss left Hong Ma's lab to be a research biologist at American
Cyanamid, Agriculture Research Division. David Beach's lab saw the departure
of three postdoctoral researchers: Scott Davey to an assistant professorship at
Queen's University, Cancer Treatment and Research Foundation in Ontario;
Taekook Kim to a research associate position at Harvard University, Molecular
and Cellular Biology Department; and Brad Nefsky to continue his postdoctoral
research elsewhere. Ariel Avilion and Kathleen Collins both left Carol Greider's
lab-Avilion to do her postdoctoral research in Robin Lovell-Badge's laboratory at
the MRC in London and Collins to an assistant professorship at the University of
California, Berkeley, Department of Molecular and Cell Biology. Nick Tonks said
good-bye to Susann Brady-Kalnay, who left to become an assistant professor at
Case Western Reserve University in Cleveland, and to Hong Sun, who is now as-
sistant professor at Yale University, Department of Genetics. Yoon Cho left Alcino
Silva's lab to do additional postdoctoral research at the Center for Behavioral
Neuroscience at SUNY Stony Brook and Bruno Frenguelli left the Malinow lab to
continue his postdoctoral research at the University of Bristol, Anatomy Depart-
ment in the United Kingdom. Kim Arndt bade farewell to Cecilia Devlin, who is
continuing her postdoctoral research in Akron, Ohio, and to Fong C. Lin, who is
doing the same at New England Biolabs in Beverly, Massachusetts. Doris
Germain from Bruce Futcher's lab is continuing her postdoctoral research at the
Peter Mac Callum Cancer Institute in Melbourne, Australia. Dorre Grueneberg fol-
lowed Michael Gilman to Ariad Pharmaceuticals in Cambridge, Massachusetts,
and Henry Sadowski accepted a position as assistant professor at Mt. Sinai
School of Medicine, Biochemistry Department, in New York. Louis A. Pena and
Christian van den Bos left Dan Marshak's lab-Pena to become a research asso-
ciate professor at Memorial Sloan-Kettering Cancer Center, Rockefeller Research
Laboratory in New York, and van den Bos to accept a staff scientist position at
Osiris Therapeutics, Inc. in Baltimore.
Graduate Students
Ann Ryan and Ken Simon left the Gilman lab to continue their graduate studies at
Ariad Pharmaceuticals, and Terrance Vale left the Beach lab and Yaolin Wang
left the Zhong lab each to do the same-Vale at the University of Texas Southwest
Medical Center and Wang at University of Kansas.
Many of our researchers obtained their degrees and made the transition from
graduate student to postdoc. David Casso, of David Beach's lab, went on to do
postdoctoral research at the University of California, San Francisco, and Sonja
Witte went from the Cline lab to do the same at Massachusetts College of
Pharmacology at Quincy College. Michele Cleary, of Winship Herr's lab, will be
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going on to postdoctoral work at Shirley Tilghman's lab at Princeton University,
but for the time being has remained at Cold Spring Harbor, working for the jour-
nal Genes & Development in an editorial capacity, assisting Dr. Watson with revi-
sions of his book Molecular Biology of the Gene, and continuing to do research in
the Herr lab. Cynthia Sadowski of Nouria Hernandez's lab earned her degree and
will be leaving to do postdoctoral research at New York University in February
1996. Nick Chester, from the Marshak lab will be doing his postdoctoral research
at the Howard Hughes Medical Research Institute, Department of Genetics at
Harvard University; Yuliang Ma from Mike Mathews' lab went on to the University
of California at San Diego; Robert Mihalek from Tim Tully's lab is doing postdoc-
toral research at University of Pittsburgh; and Tao Zhong of Kim Arndt's lab went
on to Massachusetts General Hospital. Maureen Barr left the Wig ler lab to do her
postdoctoral research at the California Institute of Technology and George
Tokiwa left Bruce Futcher's lab to do postdoctoral research at New York Univer-
sity Medical Center. Patricia (Beth) Elliott has entered into the plant breeding
business here on Long Island.
Planning our Entry into the 21st Century
In this report, we see the research made possible by the great burst of building
activities that were planned in the last decade (1980-1989) of the Laboratory's
first century. It was the creation of the Walter Page Laboratory (1987) and the ac-
quisition of our Uplands Farm Experimental Station (1984) that allow us an inter-
national role in plant genomics and developmental biology. And only through the
1991 completion of our Beckman Laboratory did we have the capability of being
a world leader in how genes control the acquisition of memory. By our imagina-
tive expansion (1993) of McClintock Laboratory, we have remained at the center
of cell cycle research with its vast potential for the eventual control of cancers.
The new space so provided let us also create the Lita Annenberg Hazen
Genome Center.
Now we must initiate a new set of planning initiatives to ensure that we enter
the 21st century with the facilities needed for continued innovation. At this year's
annual November meeting of our Board of Trustees, we set up four new com-
mittees to make recommendations during 1996 as to how best to ensure our con-
tinued leadership roles. One, headed by me (B.S.), is looking into the future of
neurobiology, in particular, how we should exploit further our research on learn-
ing and memory in flies and mice to encompass the problem of human memory
and learning. The second committee, headed by Winship Herr, will look into the
Laboratory's future role in graduate education. We now have 51 graduate stu-
dents doing their Ph.D. thesis requirements here, almost all enrolled in graduate
programs at SUNY, Stony Brook. The question we need to ask is whether the
ever-increasing size of our graduate training program might demand our becom-
ing a degree-granting institute. Our third committee is looking into the question of
whether the Laboratory should be more pro-active in the commercial exploitation
of research done here at Cold Spring Harbor. During the past decade, some ten
biotechnology companies have been developed using ideas and technologies
generated here. Only two, however, Protein Databases and Oncogene Science,
are located here on Long Island. Now a committee, headed by John Maroney, is
asking whether future laboratory inventions would more likely stay on Long Island
if we help bring into existence a nearby biotechnology-oriented industrial park.
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Lastly, we have set up a committee to look into how we should house our growing
numbers of graduate students and postdoctoral fellows. Neither of these categor-
ies of younger scientists receives salaries commensurate with the relatively high
cost of housing on the north shore of Long Island. To plan how to respond,
Morgan Browne heads a committee that is looking into ways to generate nearby
housing units. All of these groups are to report to the Board of Trustees at our
1996 annual November meeting.
During 1996, we will thus be very future-oriented. In this way, we will continue
to promote the world of biology that still has so much to offer to human society.
April 30, 1996 Bruce Stillman, Director
James D. Watson, President
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ADMINISTRATION
The past year was a very satisfactory one here at Cold Spring Harbor Laboratory.
The scientific staff continued to make important and surprising discoveries about
cancer, neuroscience, and plants, which are the Laboratory's major areas of re-
search, and there was much well-deserved recognition in the national media.
Equally pleasing was the growing impact of the Laboratory's broad range of edu-
cation programs, which sometimes are overshadowed by the greater visibility of
research.
During 1995, approximately 6000 scientists from all over the world came here
to present and discuss their latest results at Grace Auditorium symposia, to
define and focus on new issues in science at Banbury Center seminars, and to
learn new scientific techniques at the unique postgraduate level courses held in
our teaching labs in Beckman and DelbrOck, as well as at Banbury. In addition,
there were more than 100 postdoctoral fellows in training on our campus and
more than 50 graduate students fulfilling thesis requirements for their Ph.Ds.
Twenty-two university students gained admission to our highly competitive
Undergraduate Research Program and worked side by side for the summer with
senior scientists at the laboratory bench. At our DNA Learning Center, the excite-
ment and implications of molecular biology and genetics were conveyed both to
science teachers and to the next generation of young scientists through hands-
on laboratories, lectures, exhibits, and multimedia curricula. Our academic press
published 3 science journals and 20 new books.
Financial results for 1995 were very much better than expected at the begin-
ning of the year. Revenues reached a new high of $43.8 million, and there was a
surplus from operations of $92,000 after provision of $2.8 million for depreciation.
There was no need to utilize reserves of $1.15 million established in prior years to
cover start-up expenses of the neuroscience program or shortfalls in research
funding. Contributing to the good results were the success of Laboratory
scientists in competing for Federal grants, strong meetings attendance, increas-
ing royalties from technology transfer, and higher investment income. The
Laboratory's budget has been balanced in each of the past seven years, and op-
erations over that period have produced $17.2 million of positive cash flow that
has been invested in maintaining and renewing infrastructure, building new
facilities, and replacing and acquiring scientific equipment.
A lean and unbureaucratic administrative structure at the Laboratory has an
important role in keeping costs in check and greatly facilitates rapid decision
making. Government pressure to reduce indirect costs continues and now seems
focused on separating such costs into administrative and facility categories and
most likely imposing a cap on one or both. Recent initiatives at the Laboratory to
address indirect costs have included reduction of staff through attrition and
lowering overtime costs through improved scheduling and outsourcing of ser-
vices such as housekeeping for off-site facilities. Waste disposal costs have been
reduced through improved management of hazardous materials and a recycling
program for paper and bulk products. This July we will switch over from
secondary to primary metering of electricity, permitting the purchase of power at
wholesale rates. We have plans for more efficient lighting systems and a major
capital investment to replace the HVAC system of Demerec Laboratory-all
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designed to reduce substantially our staggering energy bill of over $1.7 million
per year.
Very important to the Laboratory's good financial results have been the addi-
tional revenues generated by the Meetings and Courses Department, headed by
David Stewart, and Commercial Relations, led by John Maroney. The traditional
science meetings held in Grace Auditorium have for many years been character-
ized by well chosen subjects, a focus toward younger scientists who are given
ample opportunity to present their work, and an ambiance unique to Cold Spring
Harbor Laboratory which keeps many of the scientific groups returning year after
year. New in recent years are additional meetings, apart from the traditional
scientific symposia but still scientifically interesting and appropriate to the
Laboratory, that enable corporations and other organizations to make use of our
extensive facilities during the quiet portions of the year.
The success of technology transfer under John Maroney's leadership has
been remarkable. Royalty income continues to expand and the Laboratory has
become an equity participant in seven new biotechnology companies that have
been founded, to a greater or lesser extent, on technology developed here. The
Laboratory has led the way in committing the proceeds from technology transfer
exclusively to the support of future science. This was done by establishing the
Science Fund, a special category of endowment, where are placed the royalty
and equity proceeds from all such activities. In recent months, several of the
Laboratory holdings have become publicly traded at substantial valuations, lend-
ing credence to our dream that one day the Science Fund may represent a major
new endowment for science.
The Laboratory's current endowment, which collectively includes the Robert-
son Funds and the Cold Spring Harbor Fund, reached an all time high of nearly
$109 million at year end, ahead 20% from the previous year. The investments in-
clude a balanced mix of domestic and foreign equity, fixed income securities,
and short-term liquid instruments. During the year, the funds benefited from out-
standing market returns in both equity and fixed-income markets, an addition of
$500,000 from Laboratory operations, and a $50,000 gift from the Banbury Fund
directed toward further building the Charles S. Robertson Neuroscience Chair.
Over the years, the Laboratory has positioned the annual drawdown from endow-
ment at a very conservative average of less than 3.5% of market value, and this
has been a major factor in the growth of the Funds. Endowment is our primary
source of internal funding for science and provides important support for $30 mil-
lion of tax-exempt bonds issued in recent years to finance construction of
science and infrastructure facilities. Almost since inception, the firm of Miller
Anderson & Sherrerd has provided outstanding investment management for the
equity and fixed-income portions of the endowment. During the past two years,
U.S. Trust has managed short-term liquid investments. Now, due to the very sub-
stantial growth of the funds, our Finance and Investment Committee has initiated
a search to add one or more managers to provide further diversity and assist in
continuing the high level of past market performance.
Very disappointing during the year was the unexpected and unfortunate out-
come of the Laboratory's effort to acquire the campus of Friends World College in
Lloyd Harbor. In 1992, the College, for financial reasons, had transferred its pro-
grams to Long Island University and offered the property for sale. The Village
then approached the Laboratory to find a compatible use that would preserve
public access and the historic buildings, the activities of the Sagamore Rowing
Club, and the remarkably beautiful open land and waterfront views of the 28-acre
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site. After extended fund-raising and negotiations, the Laboratory proposed to
the Village a plan to use the campus for the editorial and administrative activities
of our academic press and for housing needs of our meetings visitors and
scientific staff.
Much misinformation and exaggeration about the proposed use of the prop-
erty were circulated around the Village, and there was vehement opposition from
some residents. There was Concern over traffic, misunderstanding that our aca-
demic press was a commercial venture, and fear of a precedent set for large-
scale multifamily housing. There was mistrust of the Laboratory's intentions
despite our more than 15-year exemplary management of the much larger
Robertson (Banbury Center) property, where many Village residents enjoy the
freedom to walk its woodland and open areas.
The Laboratory tried to address concerns through discussion with Village offi-
cials and small groups of residents. We proposed a new access route to resolve
traffic problems permanently. We dropped the proposed use by our academic
press. We offered to purchase the site as is, using existing buildings for existing
uses with only the future right to build a small amount of additional housing. We
also proposed protective covenants for the open land.
Although the Laboratory received broad support from a large segment of the
Village residents, there remained a well-organized group of residents adamantly
opposed to the project. Village officials instructed the College to evict all current
residents from the site and then notified the Laboratory that the educational use
permit was canceled and would not be renewed.
Having hoped to go forward in partnership with the Village, we had no wish to
polarize the residents. The College was under intense financial pressure and time
was of the essence. Therefore, with much regret, we decided not to pursue the
matter further.
We especially thank those individuals and Foundations who pledged financial
support for the project. We have offered each the return of all funding with inter-
est, and we are much encouraged by their expressed intent to participate in-
stead in other high-priority projects in science and infrastructure.
The Buildings & Grounds Department, under the very capable leadership of
Art Brings, had a busy year in 1995 despite the village-wide moratorium which
stopped all nonresidential construction throughout the year. Most obvious from
an appearance standpoint, Bungtown Road (from Route 25A to Nichols), which is
a Village street, and the south section of the Grace parking lot were repaved at
our expense. New curbing was installed in front of Blackford Hall and on portions
of Bungtown Road. A new berm was constructed and landscaped at theWater-
side parking lot to screen cars from across the harbor. The Bonn House, Fire
House, Nichols, Williams, Osterhaut, Hooper, and the BanburyConference Cen-
ter were all painted, and Richards, Wawepex, the Library, and Hershey received
new roofs. Further landscaping and a lawn sprinkler system were installed at
Ballybung and Jones.
Less visible but no less important, the HVAC system of Sambrook Laboratory
was replaced to improve temperature and humidity control. The Hooper
Dormitory was completely renovated with new carpet, furniture, ceiling fans, light-
ing, photographs, and paint, which were warmly welcomed at the fall meetings
by many of our visiting women scientists. At Uplands Farm, two new state-of-the-
art greenhouses were built to replace dilapidated structures. At the DNA Learn-
ing Center, a new exhibit, "Story of the Gene,' was constructed as was office
space for a computer design facility. On October 6, Doubleday House was
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severely damaged by fire. Fortunately, no one was injured and the house was
back in use by year end.
Under the watchful and seasoned eye of Jack Richards, now Director of Spe-
cial Projects, planning moved forward on future projects temporarily stymied by
the moratorium. These include the Child Care Center, the aptly named Richards
Building and Grounds Facility, and additional cabins for our meetings visitors.
Earlier in the planning stage are a new imaging building, additional offices for our
neuroscientists, new space for software design, and a long awaited athletic facil-
ity. There is much to do, and we are counting on Jack not to become too
enamored of his new home in Florida.
Public Affairs and Development, ably led by Susan Cooper, portrays the
Laboratory to the outside world, schedules and manages the many community
and other events held at the Laboratory, and is responsible for the fund-raising
activities that have grown enormously in number and diversity in recent years.
During 1995, much attention was directed toward relations with our local vil-
lages. Communication with residents on Long Island's North Shore is difficult in
the absence of frequently published local newspapers. It depends primarily on
personal contact achieved at small group meetings and mailings to individuals of
fact sheets, newsletters, and personal correspondence. Much was accomplished
by these in countering misinformation and portraying accurately the Laboratory's
activities and intentions. In addition, the Laboratory's program of lectures, semi-
nars, and special events for the community was continued and expanded.
Fund-raising focused on a number of priorities, foremost of which were
Friends World College, the Child Care Center, and program and equipment sup-
port for science. Much effort was also directed toward supporting the very impor-
tant annual funds of the CSHL Association and of the DNA Learning Center Cor-
porate Advisory Board. The Association Fund, under the leadership of John
Cleary, supported by Jean Schwind, raised a record $650,000. The Corporate
Advisory Board Fund, led by Rick Clark, supported by Laura Hundt, raised
$130,000. Laura deserves special recognition for organizing and managing the
2nd Annual CSHL Golf Tournament which raised nearly half of this latter total.
Probably the high point of the year was the gala "Flicka von Stade and
Friends' concert held on March 25 which raised $55,000 for the Undergraduate
Research Program's von Stade Endowment.
In December, much to our regret, Jill Clark departed for Boulder, Colorado,
where her husband, Rick became chief operating officer of Insession Inc., a
promising young computer software company. Jill had proved herself an invalu-
able member of the staff who always could be counted on to convey with great
style the essence of a project to a foundation or major donor. In April of this year,
the Burroughs Wellcome Foundation announced a $1,000,000 grant, initiated and
shepherded by Jill, for our Undergraduate Research Program. We miss her and
she will be difficult to replace.
In the Library, Margaret Henderson and her staff continued to provide us with
invaluable resources despite a creeping encroachment upon available space by
other departments. After much analysis, the water leakage problem in the base-
ment was finally resolved, but already these offices are being spoken for by more
voices than can possibly reside there. During the year, much use was made of
an additional online reference service: Med line Grateful Med, Current Contents
Life Sciences for Mac. Thanks to funding from the previous year by the Gladys
Brooks Foundation, a microfilm reader/printer was purchased and back volumes
of Biochemica et Biophysics Acta were made available. A new Library com-
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mittee, consisting of Yuri Lazebnik (Chair), Tracy Calhoun, Grisha Enikolopov,
Ueli Grossniklaus, and Margaret Henderson, was formed to make helpful sug-
gestions.
Other very important administrative departments such as Grants, headed by
Susan Schultz; Human Resources, led by Cheryl Sinclair; and Purchasing,
headed by Phil Lembo are indispensable to the smooth functioning of the
Laboratory. In particular, the very sizable cost savings uncovered through the
quiet and extremely thorough professionalism of Phil and his staff have been eye
openers to us all. Phil's first year at the Laboratory clearly demonstrates that he
was the perfect choice to head the Purchasing Department.
Bill Keen, our Controller, and Barbara Wang, Assistant Controller, as always
have succeeded in managing our finances and budget to ensure that any sur-
prises turn out to be good ones. In 1995, in close conjunction with Jerry Latter
and his newly organized and smoothly functioning Information Service Depart-
ment, Bill and Barbara successfully met the very major challenge of overseeing
the conversion to updated software and new computer hardware in all adminis-
trative departments. By year end, the task was nearly complete and improved ef-
ficiency for all was becoming obvious.
Sadly it must be reported that on October 21st, Roberta Sa lant lost her
beloved and devoted husband, Jack, to a sudden and completely unexpected
death. Her courage in carrying on so valiantly through the months since her ter-
rible loss has impressed upon all of us the remarkable quality of this grand lady,
who each year takes such good care of the needs of myself, John Maroney, and
the Laboratory's Board of Trustees.
Now half-way into 1996, it is pleasing to report further improvement in the
Laboratory's relations with the Village of Laurel Hollow. The effort to establish bet-
ter communication with residents has made many aware that the Laboratory
voluntarily provides substantial financial support to the Village for use of services
and also assists the school district with both cash payments and extensive in-
kind services for the education received by the Laboratory children living in tax-
exempt housing. Last fall, the Village approved the environmental impact state-
ment prepared by the Laboratory for the Village Board of Zoning Appeals, which
concludes that there would be no significant environmental impact from the Child
Care Center or from any of the other seven projects covered by the study. At year
end, the Village provided a draft of its proposed new zoning ordinance and be-
gan discussions with Laboratory representatives concerning its provisions. The
Laboratory has serious objections and reservations about the ordinance and has
registered them clearly for the record. Nevertheless, we are moving forward with
the Village in a new sense of cooperation that has characterized recent relations.
In April, the Village Board passed the new ordinance and lifted the almost two-
year moratorium on nonresidential construction. The Board then approved the
use of the de Forest Stables for the Child Care Center and has since also ap-
proved its site plan. Shortly, a building permit should be issued that will allow the
Child Care Center to proceed in time for a spring 1997 opening.
G. Morgan Browne
May 16, 1996 Administrative Director
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Yakov Gluzman 1948-1996
Cold Spring Harbor Laboratory lost a dear colleague on April 6, 1996, with the untimely death of
Yakov Gluzman. Even after he left Cold Spring Harbor in 1987, he remained loyal, coming back just
this year to help us prepare our application for continued funding of the Tumor Virus program pro-
ject, now in its 25th year. This important program project has been indelibly changed with his loss.
Yasha, as he was known, was always different. He was not even born on his official birthday of
January 2, 1948. He was born at home on December 22, 1947, but following a practice not un-
common at that time, his parents delayed reporting his birth until after the new year, thereby delay-
ing by a year his induction into the Soviet military.
He was born and grew up in Chernovski, a predominantly Jewish city in Ukraine. In 1965, he
was admitted to Moscow State University where he studied biology. Shortly after his marriage in
1969, his wife, along with members of her family, emigrated to Israel, but he was not allowed to
leave. To increase his chances of obtaining an exit visa, Yasha left the university just prior to com-
pleting his Diploma studies and became a carpenter, because carpentry was viewed by the Soviet
regime to be less important to the country's welfare than scientific professions. Despite this move,
however, it was only after extensive political appeals, including an appeal by the U.S. Congress,
that he was granted an exit visa by the Soviet government in 1971.
When Yasha arrived in Israel, he met his 14-month-old son, Ilan, for the first time. Shortly there-
after, on the basis of an interview, he was admitted to the prestigious Weizmann Institute without
the requisite degree. Under the guidance of Ernest Winocour, he performed his doctoral studies on
the transformation and replication properties of the simian DNA tumor virus SV40. Although he had
devised several ruses to avoid the military while in the Soviet Union, in Israel he served in the army
and saw combat in an artillery unit during the 1973 Yom Kippur war. After obtaining his Ph.D. de-
gree in 1977, he came to Cold Spring Harbor Laboratory as a postdoctoral fellow with Joe Sam-
brook to continue his studies on tumor viruses.
Even as a graduate student, Yasha had had the vision to use viruses as tools to help mankind.
At that time, he studied how SV40 can mutate such that its ability to replicate and kill cells is
destroyed while its ability to induce cells to proliferate remains intact. At Cold Spring Harbor, he
elegantly engineered mutations into SV40 to produce a debilitated virus that, although unable to
replicate itself, could allow the replication of other engineered DNA molecules carrying the SV40
origin of replication. He generated cells carrying this disabled virus and called them COS cells.
COS cells could be made to produce large amounts of biomedically important proteins. The impor-
tance of these cells was recognized immediately, and, to this day, they are used worldwide in
biomedical research and in the fight against human disease.
Yasha remained at Cold Spring Harbor until 1987 and made important contributions to the
fields of SV40 DNA replication and control of gene expression. In 1987, he decided to become
directly involved in the development of pharmaceuticals and moved to Leder le Laboratories in
Pearl River, New York. This move afforded him the opportunity to apply his efforts directly to the
discovery of treatments for human disease. There, he helped develop drugs to treat viral infections,
including respiratory syncytial virus infection, the cause of a potentially serious respiratory disease
in children.
Yasha was a true virologist, who appreciated that, if one listened carefully, viruses had much to
tell about themselves. He was highly regarded for his ability to examine experimental problems with
clarity and from unique perspectives; often, he inspired his colleagues to re-evaluate their scientific
assumptions and interpretations. As a colleague, Yasha had a special sense of humor. Friends
remember him for his famous bear hugs, which once accidentally broke the ribs of a colleague. He
was also known for turning upside down and dangling by the ankles a student who was not think-
ing clearly.
In the recent months preceding his death, he was making plans to return to Israel and start his
own biotechnology company, where he could continue to develop anti-viral drugs.
His life was too short. We will sorely miss him, not only for his friendship, but also for the dis-
coveries he never had a chance to make.
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TUMOR VIRUSES
The Tumor Virus section continues to use viruses to probe the mechanisms of cell function and to
identify the changes a cell undergoes when it becomes transformed. Although much of the re-
search has diversified as new methods to isolate cellular genes and to dissect their structure and
function have developed, the guiding principles and questions remain remarkably similar. We con-
tinue to probe the mechanisms and regulation of DNA replication, transcription, mRNA processing,
and translation. Our studies of the cellular responses to viruses are teaching us about the control of
signal transduction in human immunodeficiency virus-infected cells and the mechanisms of apop-
tosis or programmed cell death, a natural cellular defense to virus infection. This year, Scott Lowe,
who trained with our former colleague Earl Ruley while at MIT, joined our program as a Cold Spring
Harbor Fellow. He and Yuri Lazebnik have joined forces to understand the regulation of apoptosis
in cancer cells: Scott Lowe is using a genetic approach and Yuri Lazebnik is dissecting the pro-
cess biochemically. The combining of such complementary approaches is characteristic of the re-
search process at Cold Spring Harbor and is one of the important elements that keeps the Tumor
Virus program vital.
DNA SYNTHESIS
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During the past 12 months, we have continued to
focus our efforts on understanding many aspects of
the mechanism and control of DNA replication in
eukaryotic cells. As in the past, these studies have
relied on a multidisciplinary approach by drawing
upon the advantages offered by different experimen-
tal systems. Biochemical studies on the small DNA
tumor virus, simian virus 40 (SV40), during the past
11 years have led to the identification of the human
cell proteins that cooperate with SV40 T antigen to
replicate the viral genome. The functions of many of
these proteins have been discovered, and similar
proteins have been identified in the yeast Sac-
charomyces cerevisiae, where we have been able to
demonstrate a role for these proteins in replication of
the cell genome. We have also continued to study the
mechanism of chromatin assembly during SV40
DNA replication and the function of chromatin as-
sembly factors from human cells. Furthermore, dur-
ing this year, similar chromatin assembly activities
have been identified in Drosophila and yeast cells.
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Studies on the mechanism and control of the initia-
tion of replication of cell chromosomal DNA have
continued by focusing on the origin recognition com-
plex (ORC), a multisubunit protein that binds to cel-
lular origins of DNA replication and determines
where replication will begin. These studies include
the identification of proteins that interact with ORC
either to establish a prereplication complex at origins
of replication or to activate these prereplicative com-
plexes following commitment to cell division and
entry into S phase. Just as we have studied in parallel
the mechanism of DNA replication at the fork in both
human and yeast cells, we have now found similari-
ties between the proteins that are required for the in-
itiation of DNA replication in yeast with proteins
present in mammalian cells. This important develop-
ment should eventually enable identification of the
DNA elements in mammalian chromosomes that
determine the location of origins of DNA replication
and how they might be controlled through the cell
cycle and during tissue development.
Mechanism and Control of DNA
Synthesis at the Replication Fork
G. Cullmann, V. Ellison, R. Li, S. Waga
SV40 LARGE TUMOR ANTIGEN
SV40 encodes a protein, the large tumor (T) antigen,
that performs multiple functions during the initiation
of DNA replication. These include binding to the
specific DNA sequences that determine the location
of the origin of DNA replication, a DNA helicase
function that facilitates unwinding of the DNA begin-
ning at the origin and an additional function that
directs loading of the DNA polymerase a/primase
complex on to the template DNA. A continued col-
laboration with Dr. Daniel Simmons (University of
Delaware) has generated data suggesting that T
antigen also has an additional function in DNA
replication via interaction with topoisomerase I, an
enzyme that untwists the double helix as the helicase
unwinds DNA at the replication fork.
REPLICATION FACTOR C
As part of a continuing effort to understand the func-
tions of the eukaryotic cell DNA replication proteins,
we have systematically isolated the genes encoding
the proteins that function at the replication fork. This
year, the five genes encoding the replication factor C
(RFC) protein subunits have been isolated from the
yeast S. cerevisiae and they were all shown to be es-
sential. This was somewhat surprising because all of
the proteins have extensive sequence similarity, par-
ticularly the four small subunits. Also of interest was
the sequence comparison of the RFC proteins with
the functionally related proteins present in prokary-
otes and bacteriophages. Unlike other replication
proteins such as the proliferating cell nuclear antigen
(PCNA), where there exist functionally related
proteins in eukaryotes and prokaryotes that do not
have obvious amino acid sequence similarities, the
RFC family of proteins are quite conserved in se-
quence, even in organisms as diverse as bac-
teriophage T4, Escherichia coli, S. cerevisiae, and
humans (Fig. 1). One of the RFC genes in S.
cerevisiae, encoding the largest subunit of the five-
subunit protein complex, proved to be identical to the
CDC44 gene. Mutations in cdc44 result in a pheno-
type consistent with a defect in chromosomal DNA
replication, and studies in Dr. Connie Holms'
laboratory (University of California, San Diego) have
shown that mutations in the gene encoding PCNA
suppress cdc44 mutations. These observations pro-
vide strong genetic evidence in support of our pre-
vious biochemical evidence for an interaction be-
tween RFC and PCNA during SV40 DNA replication
in vitro.
INTERACTIONS BETWEEN p21 AND PCNA
The p53 tumor suppressor protein has been shown to
function in a cell cycle checkpoint control pathway in
mammalian cells. For instance, in response to DNA
damage caused by genotoxic stimuli such as UV or y-
irradiation, the level of p53 protein increases and ar-
rests cell cycle progression in the GI or G2 phase so
that replication of damaged DNA or segregation of
damaged chromosomes can be prevented. p53 is a
transcription factor that activates the expression of a
set of unrelated genes. Among them, the gene encod-
ing p21 (Wafl, Cipl, Sdil) appears to encode a criti-
cal component of p53-mediated G1 arrest in response
to DNA damage. The p21 protein is capable of bind-
ing directly to cyclin/CDK complexes, and when
present in excess, it inhibits the activity of the kinase
necessary for GI to S phase progression in the normal
cell cycle.
Of particular interest to us was the finding in
David Beach's laboratory at Cold Spring Harbor that
in normal human diploid cells, but not in many trans-
formed cells or p53-deficient cells, p21 formed a
quaternary complex with a cyclin, a CDK, and
B. subtilis dnaH
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FIGURE 1 RFC and related proteins. A tree comparing the
sequences of RFC and related proteins. The horizontal dis-
tance is a measure of relatedness.
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PCNA. We thought it likely that this quaternary com-
plex functions in normal cells to regulate coordinate-
ly cell cycle controls, DNA replication, and DNA
repair and therefore collaborated with David Beach
and Greg Hannon (CSHL) to test this idea.
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Results reported in the previous Annual Report
demonstrated that p21 differentially regulated DNA
replication and repair in response to DNA damage.
p21 inhibited PCNA-dependent DNA replication and
did not require the presence of CDK cyclin proteins.
FIGURE 2 Immunofluorescence of the localization of PCNA and p21 in human diploid
fibroblasts. (Left panels) Incorporation of bromodeoxyuridine (BrdU) into DNA either in S
phase DNA replication (a and c) or DNA repair in Gt phase (e). The BrdU staining was
detected by immunofluorescence using anti-BrdU-antibodies. (Right panels) Immunofluores-
cence directed against either PCNA (6) or p21 (d and f). The cells in a were extracted with
Triton X-100 prior to cell staining to show PCNA associated with DNA replication sites. (a and
b) PCNA is present in a Triton-insoluble form only in cells actively replicating DNA in S phase,
but is extracted in cells in and G2. (c and d) p21 is absent in the cells replicating DNA, but
is present in the cells that are not replicating DNA. In contrast, e and f show that p21 is pres-
ent in all cells that are repairing UV-induced DNA repair.
In contrast, DNA repair was completely refractory to
p21, even though this repair was dependent on
PCNA. We then proposed that the interaction be-
tween p21, PCNA, and the CDK-cyclins served to
coordinate DNA replication and repair with cell cycle
progression, both in normal cycling cells and in cells
that had suffered DNA damage.
We first tested this model by examining the levels
of p21 in human diploid fibroblasts during the normal
cell cycle and in cells irradiated with UV. During the
normal cell cycle, p21 levels were high in G1 phase,
but the protein disappeared as cells entered into S
phase (Fig. 2). These observations were consistent
with our in vitro data demonstrating that p21 in-
hibited PCNA-dependent DNA replication.
Next, to determine whether DNA repair in vivo ac-
tually takes place in the presence of elevated levels of
p21, we examined the cellular distribution of p21 and
PCNA following UV irradiation of normal human
diploid cells that were in the G1 phase of the cell
cycle. Immunostaining experiments with anti-p21
and anti-PCNA antibodies have shown that the ma-
jority of cells actively repairing DNA contained high
levels of p21 in the nucleus, indicating that DNA
repair can occur in the presence of p21 induced by
DNA damage (Fig. 2). The p21 levels in the cells
corresponded well with the levels of p53 induced by
the DNA damage. Therefore, this in vivo observation
is also consistent with the in vitro data described
above.
The cellular distributions of p21 and PCNA fol-
lowing UV irradiation were examined further as fol-
lows. In this series of experiments, normal human
diploid cells synchronized by serum deprivation were
irradiated with UV and released into G1 by the addi-
tion of serum. Either 0, 4, or 16 hours later, the cells
were fixed and double stained with anti-p21 and anti-
PCNA antibodies. Consistent with the previous data
showing the p53-independent induction of p21 by
serum, a transient induction of p21 was seen upon ad-
dition of serum without UV irradiation, but the level
of p21 diminished as the cells progressed into S
phase. In contrast, in the UV-irradiated G1 cells, high
levels of p21 were induced by DNA damage and
were sustained in nuclei for at least 48 hours after
release into G1. The levels of PCNA seen in nuclei
appeared to be constant throughout the time course,
whether cells were irradiated with UV or not. Inter-
estingly, although both PCNA and p21 in nuclei of
the untreated cells could be extracted with Triton X-
100 prior to fixation of the cells, in the UV-irradiated
cells, a large fraction of p21 as well as PCNA in the
nuclei became resistant to extraction with detergent.
These results suggest that upon DNA damage, p21
and PCNA redistribute in nuclei and become more
tightly associated with the nuclear structure, most
probably sites of DNA repair.
To further assess the involvement of p21 and
PCNA in DNA repair in vivo, we examined the cel-
lular localization of these proteins following UV ir-
radiation in the cells derived from patients with the
cancer-prone disease, xeroderma pigmentosum, ei-
ther complementation group A (XPA) or group G
(XPG). These two cell lines are deficient in global
nucleotide-excision repair. Immunostaining revealed
a distinct and punctate pattern of p21 that colocalized
with PCNA in these cells, whereas in normal cells,
staining with anti-p21 or anti-PCNA antibodies was
more homogeneous. In contrast, in Cockayne's
syndrome and XPC cells that are deficient in
transcription-coupled DNA repair, but not in global
nucleotide-excision repair, the p21 and PCNA stain-
ing patterns were the same as those in the wild-type
cells. We argued from these data that p21 and PCNA
play a part in the sensing of genome-wide DNA
damage following UV irradiation, a hypothesis we
propose to pursue in the future.
Taken together, we assume that p21 plays a part in
coordinating cell cycle control, DNA replication, and
DNA repair to maintain the integrity of the genome.
It is possible that in normal cells, a quaternary com-
plex consisting of cyclin, CDK, PCNA, and p21
might be responsible for such a regulatory function.
Therefore, the rearrangement of the quaternary com-
plex that is observed in many tumor cells might cause
genomic instability due to the uncoupling of cell
cycle controls with the replication and repair ma-
chineries.
Chromatin Assembly
P. Kaufman, A. Verreault
CAF1
Our previous work on DNA replication-dependent
chromatin assembly has identified a multisubunit
chromatin assembly factor called CAF1 that pro-
moted the assembly of nucleosomes during DNA
replication in vitro. The cloning and characterization
of cDNAs from human cells encoding the two largest
subunits of CAF1 have been reported previously. In
47
collaboration with Ryuji Kobayashi here at the
Laboratory, the p50 subunit of CAF was sequenced
and cDNAs encoding the protein were isolated. The
amino acid sequence of this subunit (now called p48)
is 95% identical to another protein called p46 that is
encoded by a separate gene. There are also two re-
lated genes in the yeast S. cerevisiae. All of these
proteins contain a repeated sequence motif called the
WD40 (or (3-transducin) repeat, a motif that is also
present multiple times in the p60 subunit of CAF1.
Notwithstanding the similarity of the p46 and p48
proteins, only the p48 protein appears to be a part of
CAF1 in vivo.
Sequence database searches revealed that the p46
and p48 proteins had been identified by Dr. Eva Lee
(University of Texas, Austin) as proteins that bind to
the retinoblastoma tumor suppressor protein. It is in-
triguing that these proteins were identified as Rb-
binding proteins, although many proteins are known
to bind to Rb. We have confirmed that the p46 and
p48 proteins bind Rb in vitro, but we as yet do not
have evidence that they bind Rb in vivo in a physio-
logically significant manner.
IDENTIFICATION OF A LARGE CHROMATIN
ASSEMBLY COMPLEX
CAF1 appears to function as a molecular chaperone
for an acetylated-H3/H4 multiprotein complex to fa-
cilitate assembly of chromatin during DNA replica-
tion. We have continued to search for other proteins
that are required for replication-dependent chromatin
assembly by fractionating cell extracts and reconsti-
tuting DNA replication and replication-coupled
chromatin assembly with purified proteins. To this
end, we have reconstituted DNA replication with
fractions containing all the known human-cell DNA
replication proteins, purified CAF1, purified histones
H2A and H2B from chromatin, and other fractions
from human-cell extracts. Using this reconstituted
system, we have discovered a large, multiprotein
complex that has been purified to near homogeneity
which will assemble chromatin under conditions
where pure CAF1 will not. This chromatin assembly
complex (CAC) contains the three CAF1 subunits,
acetylated forms of histones H3 and H4 (but not H2A
and H2B), and other as yet unidentified proteins. The
histone H4 is acetylated on lysine residues 5, 8, and
12 near the amino terminus of the protein, but not on
lysine 16, an acetylation commonly associated with
gene transcription. Histone acetylation on lysine
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residues 5 and 12 has long been known to be associa-
ted with the assembly of chromatin during the S
phase of the cell cycle.
DROSOPHILA CAF1
The analysis of the human-cell CAF1 using the SV40
system has provided great insight into the mechanism
of chromatin assembly during DNA replication, but it
does not afford the ability to take a genetic approach
to determine the function of the proteins in vivo. We
have therefore searched for CAF1 activity in
Drosophila and yeast and have found promising ac-
tivities in both. The Drosophila studies have been
done in collaboration with Jim Kadonaga'a labora-
tory at the University of California, San Diego. The
first surprise was that extracts from Drosophila early
embryos (prior to cellularization of the syncytial
nuclei) are able to support SV40 DNA replication in
an origin- and T-antigen-dependent manner. Impor-
tantly, we found that the Drosophila extracts super-
coiled the DNA in a replication preferential manner
and a CAF activity was purified from the extract. In
collaboration with Ryuji Kobayashi, some of the
proteins present in the Drosophila CAF1 (dCAF1)
have been sequenced and were found to be very high-
ly similar to the human CAF1 subunits.
Cell Chromosome
Replication
M. Akiyama, K. Gavin, M. Hidaka, M. lizuka,
C. Liang, C. Mirzayan, H. Rao, M. Weinreich,
R.S. Williams, L. Zou
INITIATION IN YEAST CELLS
Studies on the replication of cell chromosomes now
focus almost entirely on the mechanism and control
of the initiation of DNA replication in both human
and yeast cells. These studies were greatly advanced
a few years ago by the discovery of the origin recog-
nition complex (ORC) in S. cerevisiae. This initiator
protein functions in the initiation of DNA replication
by binding to the replicator sequences in the genome
which determine the location of an origin of DNA
replication. In the last year, we have reported the iso-
lation of all of the genes encoding the ORC subunits
and have shown them to be essential for progression
through S phase. Temperature-sensitive mutations in
the genes encoding the ORC subunits affect the fre-
quency of initiation at individual replicators. If the
function of ORC is reduced to very low levels in the
cell, the frequency along the chromosome of initia-
tion of DNA replication becomes so low that the cells
die.
The only sequence similarity to other proteins
present in the protein sequence databases was found
with the Orc I p. This protein is related as sequence to
two proteins: the Sir 3p that controls silencing of tran-
scription of the yeast mating-type genes and the
Cdc6p, a protein that controls the initiation of DNA
replication. We have demonstrated that the Orcl p has
a specialized domain that is dispensable for its func-
tion in DNA replication but is essential for transcrip-
tional silencing. This further strengthens the link be-
tween control of gene expression by silencing and the
initiation of DNA replication.
In last year's Annual Report, we reported that the
Cdc6 protein (Cdc6p) binds to ORC and cooperates
to determine the frequency of initiation of DNA
replication at individual origins. This protein is par-
ticularly interesting because others have shown that it
is expressed in a cell-cycle-dependent manner prior
to establishment of a prereplicative complex at each
origin and that the protein is very unstable. We be-
came interested in Cdc6p because genetic studies
suggested an interaction with ORC. In the past year,
other genetic studies have indicated an interaction be-
tween the MCM family of proteins and ORC. Inter-
estingly, there was no genetic interaction between
CDC6 and any of the MCM genes. The MCM pro-
teins, of which there are five in S. cerevisiae, have
been shown by others to be required for the initiation
of DNA replication in yeast and other organisms.
They are part of a regulatory factor called the replica-
tion licensing factor that plays some part in limiting
DNA replication to once per cell cycle. Physical
mapping of the initiation of DNA replication at
several origins has shown that mutations in the gene
encoding Cdc6p and each of the five genes encoding
the MCM family of proteins reduce the frequency of
initiation of DNA replication at each origin (Fig. 3).
Thus, the ORC proteins, the MCM proteins, and
Cdc6p all cooperate to establish prereplicative com-
plexes at origins of DNA replication.
In contrast, temperature-sensitive mutations in
genes encoding other proteins that control the initia-
tion of DNA replication, such as Cdc7p and Cdc28p,
eliminate initiation at the nonpermissive temperature
but show normal initiation at the permissive tempera-
ture. Thus, these proteins seem to function as on-off
switches for initiation (see Fig. 3). We are now exam-
ining the physical interaction between all these
proteins.
INITIATION IN HUMAN CELLS
During the last year, we have expanded our studies to
include the important problem of the mechanism and
control of the initiation of DNA replication in mam-
malian cells, particularly in human cells. We posited
that the initiation of DNA replication in mammalian
cells occurs in a sequence-specific manner as it does
in yeast. This was not an obvious conclusion because
a number of observations suggested that vertebrate
DNA replication was different from that of yeast,
particularly the studies with Xenopus eggs and trans-
fection of plasmids containing human DNA se-
quences into mammalian cells. We further hypothe-
sized that the process of initiation was conserved and
that ORC would have a similar role in yeast and in
mammalian cells. It was therefore logical for us to
search for the human ORC proteins. This approach
has been successful with the demonstration that both
Orclp and Orc2p are found in human cells, as well as
in other species such as other yeasts, plants, and in-
vertebrates. Parallel research in Dr. Michael Botch-
an's laboratory at the University of California,
Frequency of Initiation in the Genome
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FIGURE 3 Frequency of initiation of DNA replication in the
genome for various temperature-sensitive mutants in genes
encoding proteins that control progression from G1 into the
S phase during the cell cycle. Shown is a representative
chromosome from a single cell in a population of cells. The
shaded ellipse represents an active origin at a particular
locus. The frequency of active origins along a chromosome
is determined by the Cdc6p, ORC, and MCM family of pro-
teins, and this frequency is affected by temperature. In con-
trast, Cdc28p and Cdc7p act as on-off switches, either fully
on at the permissive temperature or off at the nonpermissive
temperature.
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Berkeley, has identified ORC in Drosophila. We are
now searching for other ORC proteins from human
cells.
The discovery that the ORC complex is conserved
strongly suggests that the mechanism of initiation of
DNA replication is also similar in yeast and mam-
malian cells. In particular, we are interested in
whether or not the sites for initiation along a
chromosome are determined by specific DNA se-
quences and how these might be linked to other
nuclear processes during cell growth and differentia-
tion.
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MOLECULAR BIOLOGY OF PAPILLOMAVIRUSES
A. Stenlund M. Berg J. Sedman
E. Gillitzer G. Chen
T. Sedman M. DaCosta
The papillomaviruses infect and transform the basal
epithelium in their hosts, inducing proliferation of the
cells at the site of infection. The resulting tumors are
in most cases benign and will usually regress after
some time, but certain types of human papilloma-
viruses (HPVs) give rise to tumors that are prone to
progress toward malignancy, especially frequently
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cervical carcinoma. In total, HPV DNA can now be
found in biopsies from approximately 80% of all cer-
vical carcinomas.
A key impediment to the study of papilloma-
viruses has been the inability to define a simple in
vitro cell culture system for HPVs, largely due to the
fact that these viruses normally require specialized
differentiating cells that only with great difficulty can
be generated in cell culture. Therefore, a bovine
papillomavirus (BPV-1) has become the prototype
virus for the papillomavirus group largely because a
convenient cell culture system exists for this virus. In
this cell culture system, viral gene expression, on-
cogenic transformation, and viral DNA replication
can be studied. The DNA replication properties of
papillomaviruses show some unique and interesting
characteristics. As part of their normal life cycle,
these viruses can exist in a state of latency which is
characterized by maintenance of the viral DNA as a
multicopy plasmid in the infected cells. The copy
number of the viral DNA appears to be tightly con-
trolled, and the viral DNA is stably inherited under
these conditions. This system therefore provides a
unique opportunity to study plasmid replication in
mammalian cells.
In previous years, we have reported the develop-
ment of a short-term replication assay that has
enabled us to define the viral components that are re-
quired for viral DNA replication. More recently, we
have directed our attention toward detailed biochemi-
cal analysis of the replication process. We are study-
ing the biochemical properties of the two viral
proteins (El and E2) that are required for viral DNA
replication. We are also studying how these two
proteins interact with the ori and with each other to
generate initiation complexes.
We have also adapted and modified a cell-free
replication system that was originally developed in
M. Botchan's laboratory. From these studies, we now
have a detailed picture of the relative roles of the El
and E2 proteins in replication. El has all the charac-
teristics of an initiator protein, including ori recogni-
tion, DNA-dependent ATPase activity, and DNA
helicase activity. El can also function to unwind a
supercoiled plasmid that contains the ori sequence.
The E2 polypeptide, whose function has remained
more elusive, appears to serve simply as a specificity
factor for El. Through an interaction with both El
and the ori, E2 can provide sequence specificity in
the formation of the initiation complex. We have also
completed some work (in collaboration with T.
Melendy in B. Stillman's laboratory) to identify the
cellular factors that are required for viral DNA
replication. The results from this study indicate that a
number of the replication factors that have been iden-
tified as being required for replication of SV40 are
also required for BPV replication; however, one or
more additional factors appear to be required for
BPV replication.
Role of the Transcription
Factor E2 in BPV DNA
Replication
J. Sedman, T. Sedman, A. Stenlund
The smallest sequence element from BPV that can
direct initiation of replication in vivo (ori) is approxi-
mately 60 nucleotides long. This sequence contains
three different, separable, elements. Two of these ele-
ments have known functions and constitute the bind-
ing sites for the viral El and E2 proteins, respective-
ly. The third element has been termed the A+T-rich
region and its function is unknown. We have devel-
oped a series of assays to study the binding of El and
E2 to the ori sequence to determine the requirements
for binding and for formation of productive replica-
tion complexes. By a combination of DNase protec-
tion, gel retardation, and interference assays, we have
established that El is capable of binding to the ori in
at least two different forms, either together with E2 to
form an El-E2-ori complex or by itself to form a
multimeric El-ori complex. The El-E2-ori complex
is formed by cooperative binding of El and E2 to ori
and requires low concentrations of El. Formation of
the El -ori complex requires higher concentrations of
El and forms on the same ori sequence but does not
require E2 or E2-binding sites for its formation. To
determine which of these complexes are important
for replication in vivo, we have generated a large
number of point mutations in the ori. These mutants
have been tested for their ability to form the two dif-
ferent complexes and for replication. The sum of
these results indicates that the ability to form the El-
E2-ori complex is important for replication activity in
vivo.
For replication in vitro under standard conditions,
El alone is sufficient to initiate replication in an ori-
specific manner. This result presents an apparent
paradox: In the absence of E2 and an E2-binding site,
the El -E2 -ori complex obviously cannot form. Con-
sequently, replication can clearly be initiated in vitro
without the formation of the El-E2-ori complex. A
possible resolution to this paradox could be that as-
sembly of a replication complex is a multistep pro-
cess where formation of the El-E2-ori complex is a
required early intermediate which can be bypassed
under the conditions used for in vitro replication. A
clear difference between in vitro and in vivo condi-
tions for replication is the presence of vast quantities
of competing cellular DNA sequences under in vivo
conditions. Since El appears to have a relatively
modest sequence specificity, E2 might function to in-
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crease the selectivity of binding. By challenging
binding of El with nonspecific competitor DNA, in
the absence or presence of E2, we have demonstrated
that the sequence specificity of El is greatly in-
creased in the presence of E2. Consequently, we have
modified the conditions used for replication in vitro
by including competitor DNA. This modification
results in a complete dependence on E2 protein for
replication, resulting in a cell-free replication system
that in all important aspects reflects the requirements
observed for replication in vivo. These results also
establish that E2 is likely to function as a specificity
factor for El.
Binding of El and E2
to the BPV ori
J. Sedman, T. Sedman, A. Stenlund
An important factor in elucidating the function of the
two different El-containing complexes that can form
on the ori is the specific composition of the com-
plexes and the stoichiometry of binding. This in-
formation is also important to determine if a
precursor-product relationship exists between the two
complexes. We have therefore performed molecular
mass determinations of the two different El-
containing ori complexes using a combination of
glycerol gradient centrifugation and gel filtration as
well as cross-linking studies. The results of these
studies show that El in the absence of E2 binds to the
ori as a trimer. The formation of the trimer is induced
by the presence of the specific binding site for El and
does not occur in the absence of DNA. Interestingly,
this trimer of El is topologically linked to the DNA,
indicating that El forms a ring-like structure that en-
circles the DNA. In the presence of E2, El binds as a
monomer to the same binding site. High-resolution
footprinting as well as interference analysis demon-
strates that the monomer of El binds in an identical
position as one of the El molecules in the trimeric
complex, indicating that maybe the El-E2-ori is a
precursor for the trimeric El-ori complex.
Structure-Function Studies of
the El Initiator Protein
E. Gillitzer, A. Stenlund
Viral initiator proteins are characterized by a number
of biochemical activities that are required for initia-
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tion of DNA replication. These include sequence-
specific DNA-binding activity, DNA helicase ac-
tivity, on unwinding activity, and DNA-dependent
ATPase activity. In addition, El can interact with it-
self to form multimers and can also interact specifi-
cally with the E2 protein. Some of these activities are
associated with the monomeric El protein, whereas
other activities require homo association and forma-
tion of multimeric El complexes. We have initiated a
mutational analysis of the El polypeptide to define
the domains in El that are required for these different
activities. We are initially focusing on mapping the
domains of the El protein that are required for forma-
tion of the two different on complexes (El-ori and
El-E2-ori), i.e., DNA-binding activity, homo associ-
ation, and association with E2. By detailed deletion
analysis, we have so far identified a 17-kD minimal
DNA-binding domain that also contains the se-
quences required for interactions with E2.
Physical Interactions
between the El and
E2 Proteins
M. Berg, M. Da Costa, A. Stenlund
In most eukaryotic replicons that have been studied
so far, binding sites for transcription factors con-
stitute a part of the cis-acting sequences required for
replication activity. In the majority of cases, includ-
ing, for example, SV40, polyomavirus, and ARS ele-
ments from Saccharomyces cerevisiae, this auxiliary
activity can be supplied by various transcriptional
trans-activators with little apparent specificity. A
similar requirement exists also for papillomavirus
replicons; however, only the virus-encoded transcrip-
tion factor E2 can serve as an auxiliary factor for
replication. The requirement for E2 in replication of
BPV extends beyond a mere requirement for E2
bound to the ori: A physical interaction with El is
also required. This interaction can be detected as
cooperative binding of the two proteins to the ori,
when the respective binding sites are located in the
correct position relative to each other. Because the E2
proteins are well conserved between different papil-
lomaviruses and have a conserved overall structure,
we tested E2 proteins from other papillomaviruses for
interaction with BPV El and for replication. E2 from
HPV-11 failed to interact with BPV El in either of
these assays. This observation presented us with an
opportunity to map the regions of E2 that were re-
quired for this interaction by construction of chimeric
BPV/ HPV-11 E2 proteins. This approach has a dis-
tinctive advantage over conventional mutagenesis in
that the overall structure of the protein can be
maintained.
We have used this procedure to generate a large
number of chimeric E2 proteins. These chimeras
were tested for their ability to interact physically with
BPV El in a biochemical assay and for the ability to
support replication in vivo. The results from these ex-
periments have revealed a more complex situation
than we had anticipated. We find that (1) multiple
regions from both the amino-terminal trans-
activation domain of E2 and the carboxy-terminal
"hinge" and DNA-binding domain cooperate to gen-
erate a strong interaction with El; (2) the interaction
between the El and E2 proteins appears to take place
in a two-step process where an initial weak physical
interaction between El and the DNA-binding domain
of E2 allows a stronger, productive interaction to take
place between El and the activation domain of E2;
and (3) the specificity of the interaction between El
and E2 resides in the first step, i.e., in the interaction
between El and the DNA-binding domain of E2,
whereas the activation domains of both BPV E2 and
HPV-11 E2 are equally capable of interacting with
El.
Cellular Factors Required
for Replication of BPV
In Vitro
J. Sedman, A. Stenlund [in collaboration with T. Melendy
and B. Stillman, Cold Spring Harbor Laboratory]
The SV40 system has for a number of years served as
the paradigm for DNA replication in mammalian
cells. Replication of SV40 DNA relies on SV40
large-T antigen for on recognition, on unwinding,
and helicase activity. Using this system, a number of
cellular factors involved in DNA synthesis have been
purified and characterized. A minimal purified sys-
tem, which contains all the cellular factors that are re-
quired for SV40 replication, has been developed by
B. Stillman and co-workers. For a number of these
factors, an involvement in chromosomal DNA
replication has been demonstrated through genetic
experiments in S. cerevisiae.
To determine if BPV utilizes the same set of cel-
lular replication factors that are required for SV40
replication, we have tested the requirement for a
number of these factors in a BPV in vitro replication
system. All of the factors required for SV40 replica-
tion also appear to be involved in BPV replication;
however, the purified minimal system that can repli-
cate SV40 is not capable of replicating BPV, indicat-
ing that one or more additional factors are required
for BPV replication. In addition, the degree of depen-
dence on some of the known factors appears to be
different; for example, substantial amounts of replica-
tion can be achieved in the SV40 system in the ab-
sence of RFC or PCNA. The BPV system is essen-
tially devoid of activity in the absence of these fac-
tors. These results indicate that mechanistic dif-
ferences exist between the replication systems for
SV40 and BPV.
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TRANSCRIPTIONAL REGULATION
W. Herr S. Atanasoski M. Cleary
M. Tanaka D. Aufiero R. Freiman
R. Babb C. Hinkley
M. Boutros C. Huang
Y. Liu J. Reader
V. Meschan W. Tansey
L. Pena A. Wilson
We study the mechanisms of transcriptional regula-
tion in eukaryotes. To probe these mechanisms, our
studies focus on the interactions of viral and cellular
regulatory factors, particularly between the herpes
simplex virus (HSV) protein VP16 and its cellular
targets: When HSV infects cells, VP16, a virion
protein, is released into the infected cell, whereupon
it associates with two cellular proteins-Oct-1, a
POU-domain-containing transcription factor, and
HCF-on VP16-responsive elements in HSV imme-
diate-early (IE) promoters. Formation of this VP16-
induced complex results in activation of transcription
of the HSV IE promoters.
Our studies can be divided into three general areas:
(1) the study of how activators, such as VP16, and
the basal transcriptional machinery interact to stimu-
late transcription, (2) the mechanisms of formation of
the VP16-induced complex, and (3) the cellular func-
tions of the VP16-associated protein HCF. This sec-
tion also includes independent studies by M. Tanaka,
which probe promoter occupancy by transcription
factors in vivo.
Enhancer Function
S. Atanasoski, C. Hinkley, W. Tansey
In these studies, we examine how sequence-specific
activators that assemble on transcriptional enhancers
stimulate transcription through interactions with the
basal transcriptional machinery assembled on core
promoter elements. We have studied the generation
of two neural POU-domain enhancer-binding pro-
teins called N-Oct-3 and N-Oct-5 from a single open
reading frame, and the interaction of transcriptional
activation domains with their regulatory targets.
N-Oct 3 and N-Oct 5 were first identified in elec-
trophoretic mobility retardation assays through their
ability to bind to the octamer sequence ATGCAAAT.
These two N-Oct factors are detected in extracts from
tumor-derived and normal neural cells. They are
present differentially, however, in extracts from mel-
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anocytes and melanoma cells: N-Oct 3 is present in
extracts from both melanocytes and melanoma cells,
whereas N-Oct 5 is more evident in extracts from
metastatic melanoma cells. We have found in col-
laboration with A. Fontana and E. Schreiber (Univer-
sity of Zurich) that a cDNA encoding N-Oct 3 directs
synthesis of both the N-Oct 3 and N-Oct 5 proteins
and that the N-Oct 5 protein in neural and melanoma
cell extracts is also related to N-Oct 3. N-Oct 5, how-
ever, is apparently not expressed in vivo: It is not
detected if cells are rapidly lysed in SDS or if ex-
tracts are prepared with a cocktail of protease in-
hibitors that includes the serine-protease inhibitor 4-
(2-aminoethyl) benzenesulfonyl fluoride hydrochlor-
ide (AEBSF). These data suggest that the enhancer-
binding protein N-Oct 5 is a specific in vitro proteo-
lytic cleavage product of N-Oct 3 and is not directly
related to melanocyte malignancy. Thus, the cell-
specific appearance of N-Oct 5 may relate to the
levels of proteases in different cell types.
To study the interaction of the transcriptional ac-
tivation domains of enhancer-binding proteins with
regulatory targets, we are taking two approaches: a
global approach in which we probe these interactions
in yeast with the 2-hybrid assay and a directed ap-
proach in which we probe the interaction of activa-
tion domains with specific basal transcription factors.
In the latter experiments, we have focused on the in-
teraction of activation domains with the TATA box-
binding protein TBP. TBP has been shown to associ-
ate in vitro with many viral and cellular transcrip-
tional activation domains and has been frequently
suggested to be a direct target of transcriptional ac-
tivators. We examined the functional relevance of ac-
tivation domainTBP association by examining the
effects of mutations in TBP on activation domain as-
sociation. Figure 1 shows the results of such an ex-
periment. Mutations in a specific loop of TBP
(S3 ' /S4 ' ) disrupt association of TBP with activation
domains from both VP16 (see lane 5, Fig. 1A) and
the cellular tumor suppressor gene product p53 (not
shown). This mutation, however, does not affect the
response of TBP to these activators in vivo (see lane
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FIGURE 1 A double alanine substitution in human TBP dis-
rupts association with the VP16 activation domain in vitro
but does not affect response to VP16 in vivo. (A) Radioac-
tively labeled wild-type and mutant TBP molecules were
tested for association with agarose beads carrying
glutathione-S-transferase sequences alone (GST) or GST
sequences fused to the VP16 activation domain (GST-
VP16AD). Wild-type TBP (lane 1) and three of the four
mutant TBPs (lanes 2-4) bound to GST-VP16AD tightly and
specifically; binding of the S3' /S4' mutant TBP (lane 5) to
GST-VP16AD was reduced by 25- to 30-fold. (8) Wild-type
and mutant TBP molecules were analyzed for their ability to
support response to the VP16 activation domain in human
HeLa cells, using the altered-specificity TBP assay. The fig-
ure shows the results of an RNase protection analysis,
quantitating correctly initiated transcripts from a c-fos
reporter (c-fos) and from an a-globin internal control plas-
mid (a). (Lane 1) Activity of the c-fos reporter in the
presence of a GAL4-VP16AD fusion protein, but in the ab-
sence of altered-specificity TBP; (lane 2) rescue of tran-
scription by wild-type altered-specificity TBP. Note that all of
the mutant TBPs (lanes 3-6), including the S3' /S4'
mutant-which does not associate with the VP16 activation
domain in vitro-support wild-type levels of response to
GAL4-VP16AD in vivo.
6, Fig. 1B). These results suggest that the ability of
TBP to associate with activation domains in vitro is
not absolutely required for its ability to respond to ac-
tivators in vivo. One possibility is that association
with TBP is only one of multiple redundant pathways
for activation of transcription by activators and that
disruption of any one of these redundant pathways is
insufficient to disrupt transcriptional activation.
Viral Trans-activation
R. Babb, M. Cleary, C. Huang
To study viral trans-activation, we probe the struc
ture and function of the VP16-induced complex and
its individual components. One of those components
is Oct-1, which on its own recognizes a variety of cis-
regulatory sequences, including the 8-bp octamer se-
quence ATGCAAAT found in many enhancers and
promoters and the VP16-responsive TAATGARAT
(R = purine) motif found in HSV IE promoters. Oct-1
recognizes these regulatory elements via a bipartite
DNA-binding domain, called a POU domain. POU
domains contain an amino-terminal POU-specific
(POUs) domain, which in Oct-1 recognizes the
ATGC portion of the octamer sequence, tethered by a
hypervariable linker to a carboxy-terminal POU-type
homeo (POUH) domain, which recognizes the AAAT
portion of the octamer sequence. When bound to the
octamer sequence, the Oct-1 POU and POUH
domains do not touch one another, suggesting that
their interactions with DNA are largely independent
of one another. Consistent with this view, in previous
years, we have presented genetic studies which indi-
cate that the two POU subdomains can adopt dif-
ferent arrangements on different binding sites.
These results have placed particular interest on the
role of the POU domain linker in the binding of the
POU domain to DNA. For example, the linker could
influence how the POU subdomains can arrange
themselves on the DNA. To test this hypothesis, we
assayed the effects of progressive shortening of the
linker on binding to different sites. We assayed bind-
ing to two Oct-l-binding sites that we identified a
number of years ago in the SV40 enhancer, one
similar to the octamer sequence and one quite dif-
ferent from the octamer sequence. Using these sites,
we found that the length of the Oct-1 POU-domain
linker could have very different effects on Oct-1
binding to DNA: On the octamer-like site, shortening
the linker segment resulted in a progressive loss of
binding affinity, whereas on the site that bears little
octamer similarity, shortening the linker segment had
no deleterious effect until it was only four amino
acids long. These results suggest that the require-
ments of the linker vary depending on the positioning
of the two POU subdomains on DNA.
To physically probe the conformation of the Oct-1
POU subdomains on different binding sites, we
adopted, in collaboration with Shannon Pendergrast
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(CSHL), a protein-DNA cross-linking strategy devel-
oped by S. Pendergrast and R. Ebright at the
Waksman Institute. For this approach, a photoac-
tivatable cross-linking agent is covalently attached to
a unique cysteine in the protein of interest. The
modified protein is allowed to bind to DNA and is
then subjected to ultraviolet irradiation, which causes
the modified cysteine side chain to form a covalent
bond with nearby DNA. Protein-DNA complexes are
separated from free DNA, and the DNA is cleaved at
the site of cross-linking, giving precise information
about where a given protein or protein subunit con-
tacts DNA. These studies have shown that the POU
subdomains do indeed adopt different arrangements
on different binding sites: On a VP16-responsive
TAATGARAT site that bears little similarity to an
octamer sequence, the POU domain is positioned on
the side opposite of the POUH domain from where it
is positioned on an octamer site.
To study the role of VP16 in VP16-induced com-
plex formation, we have compared the activities of
two VP16 proteins: the HSV-1 VP16 protein and its
homolog from bovine herpesvirus 1 (BHV-1). We
have shown that these two Oct-1 coregulators possess
similar, if not identical, homeodomain recognition
properties but possess different virus-specific cis-
regulatory specificities: The HSV-1 VP16 protein ac-
tivates transcription from an HSV-1 VP16-response
element and the BHV-1 VP16 protein activates tran-
scription from a BHV-1 VP16-response element. A
distinct 3-bp segment, the "D" segment, lying 3' of
the canonical TAATGARAT motif, is responsible for
the differential cis-element recognition and transcrip-
tional activation by these two homeodomain coreg-
ulators. These results demonstrate how homologous
homeodomain coregulators can direct differential
transcriptional regulation by a single homeodomain
protein.
Cellular Functions
of HCF
M. Boutros, R. Freiman, Y. Liu, A. Wilson
Although the involvement of HCF during HSV infec-
tion is understood in some detail, little is known
about its role in uninfected cells. In previous years,
we have shown that HCF is a family of polypeptides,
the large majority of which range in size from 110
kD to 150 kD. These polypeptides are processed from
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a large precursor protein of approximately 300 kD.
The processed polypeptides represent amino- and
carboxy-terminal fragments resulting from proteo-
lytic cleavage at a series of centrally located 26-
amino -acid repeats called the HCF repeats. Curious-
ly, the amino- and carboxy-terminal HCF fragments
resulting from cleavage remain associated with one
another after cleavage.
Although HCF is a collection of large polypep-
tides, only the amino-terminal 380 residues of HCF
are required to associate with VP16 and stabilize
VP16-induced complex formation. This region con-
sists of a series of six repeats related to the GG motif
found in a variety of proteins. In other proteins, the
repeated GG motif (or related sequences) directs
formation of a "super-barrel" structure of six (3-
sheets, each made up from four 13-strands; each of the
six (3-sheets forms one blade of a propeller-like struc-
ture. Mutational analysis indicates that the six blades
of the propeller-like structure in HCF do not all have
the same role in stabilizing the VP16-induced com-
plex.
One of the roadblocks in the study of the cellular
functions of HCF has been the lack of a known cel-
lular function. Recently, however, a hamster cell line
that has a temperature-sensitive defect in cell prolif-
eration caused by a missense mutation in the IICF
gene has been discovered (H. Goto and T. Nishimoto,
Kyushu University). These cells stop proliferating at
39.5°C, but they can resume proliferating when
restored to the permissive temperature. The missense
mutation that causes the HCF defect lies within the
amino-terminal VP16-interaction domain (H. Goto
and T. Nishimoto, pers. comm.). We therefore asked,
in collaboration with Drs. Goto and Nishimoto,
whether this same mutation would influence VP16
function.
Indeed, in a transient expression assay, VP16 can
activate transcription in the mutant cells at the
permissive temperature but not at the nonpermissive
temperature. These results argue that HCF is indeed
important for VP16 activation of transcription in vivo
and that VP16 targets a part of the cell machinery im-
portant for cell proliferation. We next tested the ef-
fects of the HCF mutation on the ability of VP16 to
induce complex formation and found that the mutant
HCF, prepared from cells grown at the nonpermissive
temperature or synthesized by translation in vitro, is
defective for stabilization of the VP16-induced com-
plex. This defect in VP16-induced complex forma-
tion correlates with an inability of the mutant HCF
protein to associate with VP16 effectively. Thus, the
very same mutation that causes an arrest in cell
proliferation causes a defect in VP16 function. These
results lead us to hypothesize that VP16 binds to
HCF by mimicking an important cellular cofactor for
HCF function, a function that is related to cell
proliferation.
Enhancement of Activator
Binding to a Promoter
In Vivo by Cooperativity and
Activation Domain Function
M. Tanaka
Binding of transcriptional activators to a promoter is
an important process in transcriptional activation. I
have continued to investigate the in vivo deter-
minants of activator binding to a promoter in yeast
cells. A quantitative in vivo methylation protection
assay has previously led to the unexpected observa-
tion that activator binding to a promoter is enhanced
in vivo by transcriptional activation domains of ac-
tivators. An extension of the analysis has now
revealed another determinant: the number of acti-
vator-binding sites present in a promoter. Thus, mul-
tiple sites within a promoter can cooperatively recruit
cognate factors in vivo, and they do so regardless of
whether the factors contain an effective activation
domain.
Modulation of activator binding by these two
determinants-potency of activation domains of ac-
tivators and the number of binding sites present in a
promoter-plays an important role in determining
transcriptional responses of a promoter. For example,
potent activators can efficiently stimulate transcrip-
tion at low concentrations because they readily bind
to a promoter. Similarly, a promoter containing many
binding sites can direct high levels of transcription
because it effectively recruits activators. In contrast
to these in vivo results, neither of these determinants
showed an effect on activator binding to DNA in a
typical in vitro assay. It thus appears that, in vivo,
binding of activators to a promoter is determined not
only by direct interaction between activators and a
specific DNA sequence, but also by other interac-
tions, which may involve factors such as general tran-
scription factors and histones.
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RNA SPLICING
A.R. Krainer J. Caceres A. Mayeda T. -L. Tseng
A. Hanamura M. Murray I. Watakabe
D. Horowitz M. Pastrnak Q. Wu
MECHANISMS OF CONSTITUTIVE AND ALTERNATIVE
PRE-mRNA SPLICING
RNA splicing is a required step in the expression of
most eukaryotic protein-coding genes. The selection
and pairing of authentic splice sites within the
spliceosome occur with a very high degree of fidelity,
which requires that limited and dispersed sequence
information present throughout introns and exons be
precisely interpreted. The expression of many cellular
and viral genes occurs via alternative splicing, which
involves substantial flexibility in the choice of splice
sites, allowing the expression of multiple protein
isoforms from individual genes. The choice of alter-
native splice sites is commonly regulated to alter
gene expression, either tissue-specifically or in re-
sponse to a developmental program or to extracellular
signals. Both constitutive and alternative splicing
mechanisms involve multiple protein components, as
well as RNA components that are part of small nu-
clear ribonucleoprotein (snRNP) particles. Our lab
has focused on the identification, purification, and
molecular characterization of protein factors that are
necessary for the catalysis of splicing and/or for the
regulation of alternative splice site selection.
A major portion of our efforts has been devoted to
the characterization of three families of RNA-binding
proteins: the SR proteins, exemplified by SF2/ASF;
the hnRNP A/B proteins, of which the best character-
ized is hnRNP Al; and the more recently discovered
SF7 factors. Individual SR proteins function as essen-
tial constitutive splicing factors and are also involved
in constitutive or regulated enhancer-dependent splic-
ing. In addition, they modulate alternative splicing in
vivo or in vitro in a concentration-dependent manner.
This activity is antagonized by hnRNP A/B proteins
to modulate alternative 5' -splice site selection and
by SF7 proteins to determine alternative 3' -splice
site selection.
ROLE OF THE STRUCTURAL DOMAINS OF SR
PROTEINS IN SUBNUCLEAR LOCALIZATION
AND ALTERNATIVE SPLICING IN VIVO
J. Caceres used epitope-tagged SR protein cDNAs to
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analyze the role of different domains of SF2/ASF and
other SR proteins in alternative splicing in vivo and
in localization to the proper nuclear regions. Using
SF2/ASF mutants that he previously analyzed in
vitro, he examined their activity in HeLa cells by
transient overexpression and cotransfection of an
alternative splicing reporter gene. In collaboration
with T. Misteli and D. Spector (CSHL), he used in-
direct immunofluorescence and confocal microscopy
to measure the presence of wild-type or mutant
epitope-tagged proteins in the nucleoplasmic speckle
region. Surprisingly, the RS domain of SF2/ASF was
found not to be required for localization in the speck-
les. In contrast, the RS domains of other SR proteins
that, unlike SF2/ASF, contain a single RRM proved
to be essential, in agreement with work by other
laboratories. In general, an excellent correlation was
observed between the ability of mutant proteins to
localize to the speckles and their ability to affect
alternative splicing in vivo. In addition, SR proteins
lacking either RRM1 or RRM2 showed significant
alternative splicing activity in vivo. This apparent
discrepancy with our earlier in vitro studies could be
due either to improper folding of mutant proteins in
vitro or to the use of different substrates in the two
assays. Additional pre-mRNAs are being assayed to
address the issue of specificity and to determine
which domains contribute to such substrate specific-
ity.
ISOLATION AND CHARACTERIZATION OF
NOVEL SR PROTEINS
To gain insights into the unique properties of individ-
ual SR proteins, cDNAs for three new human SR
proteins were cloned and characterized, in collabora-
tion with Dr. John Bell (John Radcliffe Hospital, Ox-
ford) and his associate, Dr. Gavin Screaton, who did
a sabbatical in my laboratory (Screaton et al. 1995).
By use of reverse transcriptase-polymerase chain
reaction (RT-PCR) with degenerate primers, Screaton
cloned full-length cDNAs corresponding to human
SRp55 and SRp40 (for which partial peptide se-
quence or homologs from other species had been pre-
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FIGURE 1 Domain structure of human SR proteins and effect of selected SR
proteins on alternative splicing of adenovirus E1A in vivo. (Top) Schematic repre-
sentation of domain structures of all eight human SR proteins drawn to scale.
Gray shading represents RRMs. Thin dark vertical lines represent individual RS or
SR dipeptides. Thicker lines indicate clustering of RS or SR dipeptide repeats,
with the thickness being proportional to the number of consecutive repeats.
(Bottom, left) In vivo analysis of alternative splicing activity of cloned SR proteins.
HeLa cells were transiently cotransfected with the adenovirus E1A gene, and one
of the indicated SR protein cDNAs, subcloned in the pCG expression plasmid.
Total RNA was analyzed by RT-PCR, with 5' -end labeling of one of the primers.
(Lane 1) Mock transfection; (lane 2) control cotransfection with pCG lacking an
insert; (lanes 3-7) cotransfections with the indicated SR protein cDNAs. The
mobilities of unspliced pre-mRNA and of 13S, 12S, 10S, and 9S mRNAs are indi-
cated on the right. The diagram below shows the structure of the E1A gene, the
RT-PCR primers, and the major mRNAs generated by alternative 5 ' -splice site
selection. The 10S and 11S mRNAs arise from double splicing events and are not
shown in the diagram. The data were quantitated by Phosphorlmage analysis,
and the amounts of 13S, 12S, and 9S mRNAs are expressed as a percentage of
the sum of all three mRNA isoforms. (Bottom, right) Quantitation of relative use of
alternative E1A 5 -splice sites in response to SR protein overexpression.
viously described) and to a novel SR protein,
SRp30c, which has an unusually short RS domain.
The structures of known human SR proteins are
shown in Figure 1 (top). Additional cDNA clones for
SRp40 and SRp55 were also isolated, which reflect
extensive alternative splicing of the corresponding
pre-mRNAs. The predicted protein isoforms lack the
carboxy-terminal RS domain and might be involved
in feedback regulatory loops.
A. Mayeda and G. Screaton expressed the three
cDNAs encoding the full-length SR proteins in Es-
cherichia coli, and the purified recombinant proteins
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were shown to be active in general splicing, i.e., they
functionally complemented a He La cell S100 extract
deficient in SR proteins. In addition, J. Caceres and
G. Screaton used a transient cotransfection assay to
test the ability of human SRp30c, SRp40, and SRp55
to modulate alternative splicing in vivo. Comparison
with known SR proteins in this assay revealed strik-
ing differences that appear to reflect unique substrate
specificities. For example, SF2/ASF and SRp40 pro-
mote use of the adenovirus El A 13S 5 ' -splice site,
whereas SRp20 favors specifically the 12S 5' -splice
site (Fig. 1, bottom). We further showed that expres-
sion of the endogenous SR proteins is regulated dif-
ferentially in stimulated T lymphocytes, concomitant-
ly with changes in the alternative splicing patterns of
CD44 and CD45 cell surface molecules. FACS anal-
ysis revealed that individual T cells simultaneously
express CD44 and CD45 isoforms that represent op-
posite patterns of exon skipping and inclusion, sug-
gesting that different regulators (e.g., SR proteins or
their antagonists) control alternative splicing of these
pre-mRNAs or that perhaps the same regulator acts
on them with opposite polarity (Screaton et al. 1995).
The potential combinatorial effects of variations in
the concentrations of different SR proteins (eight hu-
man ones are currently known, not including alterna-
tively spliced isoforms), each with some measure of
substrate specificity, and of several antagonistic fac-
tors that act at either 5' - or 3' -splice sites (i.e., four
hnRNP A/B proteins and the SF7 factors, respective-
ly) are very large. In addition to the 32 pairwise com-
binations of SR and hnRNP A/B proteins, additional
specificity may arise from two or more members of
each family cooperating to affect the splicing of
certain substrates, or through interactions between
these proteins and gene-specific positive or negative
regulators. When yet more variables, such as regula-
tion of protein accessibility or localization, and
potential regulation of protein activity by changes in
phosphorylation are considered, the system gains a
complexity perhaps sophisticated enough to control
the numerous alternative splicing choices made in
living cells. In particular, these proteins may be
responsible for global regulatory mechanisms that af-
fect alternative splicing of large sets of pre-mRNAs
in different tissues, developmental stages, and/or in
response to external signals.
SR PROTEINS FROM PLANTS
In collaboration with A. Barta's group in Vienna, A.
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Mayeda characterized purified SR proteins isolated
from tobacco and carrot cells. In addition to the ob-
served cross-reactivity with antibodies directed to hu-
man SF2/ASF or to SR proteins, it was possible to
show that purified plant SR proteins are active in
constitutive and alternative splicing when assayed in
heterologous He La cell extracts, with either mam-
malian or plant pre-mRNAs. Although biochemical
studies of plant pre-mRNA splicing have been ham-
pered by the lack of in vitro systems, these studies
show that SR proteins are conserved in structure and
function between plant and animal kingdoms (Lopato
et al. 1996).
SEQUENCE-SPECIFIC RNA-BINDING PROPERTIES OF
hnRNP A/B PROTEINS
I. Watakabe is studying the sequence-specific binding
properties of hnRNP A/B proteins. SELEX experi-
ments showed that hnRNP A2 and B1 bind with high
affinity to short RNAs containing at least one copy of
a hexameric sequence related to the hnRNP Al
recognition site identified by G. Dreyfuss and col-
leagues. Filter-binding experiments showed that the
three proteins have similar sequence specificities and
selectivities. Mutational analysis of the consensus
high-affinity binding site shows that the hexamer is
necessary but not sufficient for high-affinity binding.
Analysis of hnRNP Al mutants that are inactive in
alternative splicing in vitro, but active in general
RNA binding, showed an excellent correlation be-
tween ability to switch alternative splice site use and
sequence-specific binding to the SELEX winner se-
quences. These results suggest that sequence-specific
RNA binding by hnRNP A/B proteins contributes to
their alternative splicing function.
YEAST AND HUMAN SPLICING FACTOR HOMOLOGS
AND NEW HUMAN SPLICING FACTORS
To characterize further the relationship between pre-
mRNA splicing in yeast and metazoans, we are using
different approaches to identify related splicing pro-
teins in humans and in yeast. The Prp18 protein is in-
volved in the second step of pre-mRNA splicing in
Saccharomyces cerevisiae and is a component of the
U5 snRNP. D. Horowitz recently identified a 343 -
amino -acid human protein, hPRP18, which has 30%
identity to yeast PRP18. The homology is primarily
in the carboxy-terminal third of the protein, which is
also conserved in rice and nematode ESTs. He ex-
pressed hPRP18 in E. coli and raised antibodies to it,
which were used to deplete hPRP18 from He La cell
nuclear extracts. Immunodepletion specifically and
completely blocked the second step of splicing, lead-
ing to accumulation of splicing intermediates. Re-
combinant hPRP18 restored the second step of splic-
ing, demonstrating that hPRP18 is essential for
catalytic step II. Recombinant yeast PRP18 also
restored activity to the depleted human extract, show-
ing that the yeast and human proteins are functional
homologs. However, hPRP18 cannot functionally re-
place yeast PRP18, either in vivo or in vitro. hPRP18
does not appear to be stably associated with snRNPs.
Unexpectedly, anti-hPRP18 antibodies cross-react
with a protein that appears to be a novel component
of U4/U6 and U4/U6U5 snRNP particles, which will
be purified and characterized.
T.-L. Tseng is searching for proteins with RS
domains in budding and fission yeast, with the ulti-
mate goal of studying the structure and function of
RS domain-containing splicing factors by genetic
methods. The rationale is based on the observation
that very few known proteins in the databases contain
significant repeats of alternating arginine and serine
residues, and most of these proteins have been direct-
ly or indirectly implicated in constitutive or regulated
splicing. Using two monoclonal antibodies that re-
cognize either phosphorylated or unphosphorylated
RS domains, several yeast proteins were found to
react with both antibodies and showed the appro-
priate sensitivity or resistance to phosphatase treat-
ment. These observations suggest that several pro-
teins containing phosphorylated RS domains exist in
both budding and fission yeast. Several candidate
proteins were purified on the basis of immuno-
reactivity, and partial amino acid sequence was ob-
tained in collaboration with R. Kobayashi (Protein
Chemistry Facility).
Tseng is focusing on a fission yeast protein that, in
addition to reacting with the above antibodies, con-
tains an RNA-recognition motif, as determined from
partial peptide sequence and nucleotide sequence of
RT-PCR fragments. Cosmid genomic and cDNA
clones have been obtained and are presently being
characterized.
We are continuing to purify and characterize addi-
tional protein factors that are essential for one or both
RNA cleavage-ligation reactions. M. Murray frac-
tionated a He La cell nuclear extract and obtained a
fraction in which a single, or a limited number of, re-
quired component(s) has been separated from known
protein splicing factors and snRNPs. This fraction is
required to complement cruder fractions containing
the remaining essential components, thus defining a
novel activity required for cleavage at the 5' -splice
site and lariat formation. Further purification of this
activity is in progress.
SPLICING OF PRE-mRNAs WITH NONCONSENSUS
SPLICE SITES
Q. Wu has been studying the biochemistry of splicing
of a very small class of introns with unique 5' - and
3 ' -splice sites that do not conform to the consensus
sequences. The few known examples share unique
5 ' , 3 ' , and putative branch site elements, and the
work of R. Padgett and colleagues suggests that these
introns require minor snRNAs, such as U12 and per-
haps U11, for processing in vivo. Interestingly, pre-
mRNAs that contain these nonconsensus introns also
contain conventional introns. Examples include the
human proliferating cell nucleolar antigen P120, a
cartilage matrix protein, an ion channel subunit, and
the Drosophila Prospero gene. J. Steitz and col-
leagues have recently described splicing of the P120
unusual intron in vitro and shown dependence on
U12 snRNA. We have also recently demonstrated ac-
curate splicing of the unusual intron in a sodium
channel subunit pre-mRNA in human extracts and are
currently characterizing the splicing pathway and
analyzing the requirement for specific snRNPs and
protein factors.
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PROTEIN SYNTHESIS
M.B. Mathews S. Brand M. Liu Y. Ramanathan
M. Greenberg Y. Ma D. Taylor
S. Gunnery L. Manche Q. Wang
B. Lee P. Nahreini P. Wendel
H.-J. Liao T. Pe'ery C. Yordan
Gene expression is controlled at a variety of levels
and through many different mechanisms. The re-
search in our laboratory is focused on several systems
which illustrate the diversity of regulatory processes
in human cells. Some of these systems involve viral
genes that interact with and modulate cellular path-
ways, thereby impinging on processes such as cel-
lular growth control and viral multiplication. The fol-
lowing paragraphs summarize the progress made in
1995 on each topic.
During the year, Mingsong Liu and Qizhi Wang
joined the laboratory while Piruz Nahreini left to take
up a position in the Biotech industry. Yuliang (Frank)
Ma completed his graduate training and took his
well-earned Ph.D. degree with him to Jim Fera-
misco's laboratory at the University of California,
San Diego.
Regulation of PCNA
B. Lee, M. Liu, P. Wendel, M.B. Mathews
The proliferating cell nuclear antigen, PCNA, is in-
timately linked to the processes of DNA replication
and cell cycle regulation. First discovered as an
antigen in autoimmune disease, PCNA is also known
as the DNA polymerase 8 auxiliary factor, and it
functions as a "sliding clamp" during DNA replica-
tion. PCNA synthesis is triggered by a variety of
growth stimuli, including cellular transformation by
the adenovirus ElA gene. PCNA induction by E1A is
a property of the 243-residue adenovirus ElA on-
coprotein (ElA 243R). This was initially observed
during the oncogenic transformation of quiescent ro-
dent cells and has since been studied in detail using
transient expression experiments in He La cells and
other cell types.
Transactivation of the PCNA promoter by the ElA
243R protein is mediated through a novel cis-acting
element termed the PERE (the PCNA E1A-
responsive element) lying about 50 nucleotides up-
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stream of the PCNA transcriptional start site. The
PERE contains a sequence resembling an activating
transcription factor (ATF)-binding site, and studies
reported last year established that it binds the tran-
scription factor ATF-1. Other PERE sequences may
bind an as yet unidentified transcription factor. In ad-
dition, an adjacent site located downstream from the
PERE was shown to bind the enhancer-associated
protein RFX1. Further work, by gel mobility shift
analysis, indicates that RFX1 binding is also in-
fluenced by a sequence located upstream of the
PERE. Furthermore, mutagenesis of this region im-
plies an interrelationship between the ATF and RFX1
sites. For example, the formation of the RFX1-
containing complex P1 is dependent on the integrity
of both the ATF and RFX1 sites. Experiments with
antibodies directed against the two factors have so far
failed to detect the simultaneous binding of ATF-1
and RFX1 to the same DNA probe. On the other
hand, measurements of the stability of DNA-protein
complexes raise the possibility that the complex con-
taining RFX1 may be able to compete with the
PERE-binding factor(s) in binding to the same DNA
sequence in vivo.
Mutational analysis of the ElA gene had sug-
gested that regions of the E1A 243R protein that bind
to cellular factors p300 and p107 are required for op-
timal PCNA induction by El A. To address the pos-
sible roles of these two proteins in PCNA transactiva-
tion directly, we obtained the cDNAs for both p300
and p107 and tested them in He La cells using
transient expression assays. Our results further impli-
cate p107 in the transactivation of the PCNA
promoter by E1A 243R. Transient expression of the
wild-type p107 protein reduced transactivation in a
dose-dependent manner. p107 mutants deficient in
their capacity to bind the ElA protein were equally
inhibitory, indicating that the reduced transactivation
is not simply due to sequestration of E1A 243R by
p107 in an inactive complex. Furthermore, a mono-
clonal antibody raised against p107 specifically su-
pershifted one of the DNA-protein complexes formed
on the PCNA promoter, providing evidence that p107
associates with the promoter in vitro.
The p300 protein has recently been shown to pos-
sess properties of known transcriptional adaptor
proteins. Overexpression of wild-type p300 had no
effect on transactivation of the PCNA promoter by
El A in transient expression assays. However, trans-
activation was impaired by p300 mutations that
abrogate E1A binding. transactivation by El A
mutants deficient in their ability to bind to wild-type
p300 was impaired to a similar degree, suggesting
that p300 can mediate El A transactivation of the
PCNA promoter. Taken together, these data support
the view that El A 243R transactivates the PCNA
promoter through more than one pathway (Fig. 1).
Regulation of HIV-1
Gene Expression
M. Greenberg, P. Nahreini, T. Pe'ery, Y. Ramanathan,
C. Yordan, M.B. Mathews
The human immunodeficiency virus, HIV-1, is the
causative agent of AIDS. It carries regulatory genes
which play important roles in its life cycle and
pathogenicity and operate by unprecedented mecha-
Cyclin A
nisms. The HIV-1 protein Tat stimulates transcription
from the HIV promoter, located in the viral long ter-
minal repeat (LTR). It increases the rate of transcrip-
tional initiation and augments elongation by over-
coming premature transcriptional termination. Tat's
antitermination function can be reproduced in a cell-
free system using purified, bacterially expressed Tat
to stimulate HIV transcription. This greatly facilitates
biochemical investigations of its mode of action. We
reported last year that the ability of Tat to trans-
activate in vitro depends on preincubation with cell
extract or S-100, implying that a cellular factor(s) is
required to "potentiate" Tat transactivation. Poten-
tiation could be due to the formation of a complex
between Tat and cell protein(s) or to covalent modifi-
cation of Tat. To understand the nature of this ac-
tivity, we have embarked on its purification. The ac-
tivity has been carried through several steps including
ammonium sulfate precipitation, ion exchange and
gel filtration chromatography, and glycerol gradient
centrifugation. Present information suggests that
potentiation activity may copurify with a small
protein (<30 kD). The purification studies are on-
going.
One attractive hypothesis to explain Tat trans-
activation is that in vitro it improves the processivity
of RNA polymerase complexes, possibly by recruit-
cd k2
FIGURE 1 Schematic representation of the human PCNA promoter and its interactions with the E1A
243R oncoprotein. E1A 243R transactivates the PCNA promoter via the PERE, an element which
binds the ATF-1 transcription factor. Transactivation by E1A 243R is apparently mediated through its
interactions with cellular proteins p300 and/or p107. Additionally, there is an upstream p53 binding
site through which the p53 transcription factor can transactivate PCNA in a manner that can be
repressed by E1A 243R.
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ing or modifying cellular elongation factors. Tat is
able to bind a cellular kinase, TAK, which phosphor-
ylates the carboxy-terminal domain (CTD) of RNA
polymerase II (pol II). Since phosphorylation of the
CTD is believed to trigger the transition from
polymerase complex assembly to the elongation
phase of transcription, this observation suggests a
mechanism whereby Tat could increase elongation
via TAK-catalyzed phosphorylation of the CTD. We
are also attempting to purify this activity. Our initial
approach was to try to deplete TAK from He La cell
extracts by an affinity chromatography method, but
TAK could not be removed efficiently from the ex-
tract under various experimental conditions. Sub-
sequently, we turned to conventional chromato-
graphic procedures and discovered that TAK sepa-
rated into more than one fraction, possibly because it
is assembled into several different complexes. During
the early steps of purification, TAK copurified with
TFIIH, which was recently shown to contain CAK
(cyclin-dependent activating kinase) as one of its
components. CAK has CTD kinase activity which is
associated with TFIIH. However, TAK can be dis-
tinguished from CAK by several different biochemi-
cal procedures, and it appears to be a novel kinase.
Translation of an RNA
Polymerase III Transcript
S. Gunnery, P. Wendel, M.B. Mathews
We have shown that a transcript generated by RNA
polymerase III (pol III) can be translated in vivo to
synthesize functional protein. The HIV-1 Tat-coding
sequence was placed under the control of the adeno-
virus VA RNA promoter, a strong pol III promoter.
When the pVA-Tat chimera was transfected into hu-
man cells, uncapped and nonpolyadenylated VA-Tat
RNA was produced, transported to the cytoplasm,
recruited by polysomes, and translated. The resultant
Tat protein was detected by its ability to transactivate
the HIV-1 promoter. As would be expected of a pol
Ill transcript, VA-Tat RNA lacks a poly(A) tract at
its 3' end and a cap structure at its 5' end. These find-
ings demonstrate that not all of the functional mRNA
in a cell must be made by pol II. Nevertheless, no
naturally occurring pol III-generated mRNAs have
been characterized. Why should this be?
64
One possible explanation is that RNAs generated
by pol III are relatively poor templates for protein
synthesis. As noted in last year's Annual Report, the
rate of initiation of translation on VA-Tat RNA is
low in comparison to mRNA made by pol II, proba-
bly because the terminal structures characteristic of
normal mRNAs (5' caps and 3' poly[A]) enhance
translational efficiency. A second possibility is that
intron removal from pol III-generated transcripts may
be an inefficient process. To test this hypothesis, we
asked whether a pol III transcript can be spliced in
vivo. The first intron sequence of the 13-globin gene
(130 by long) was inserted into the Tat-coding region
of pVA-Tat in such a way that its removal by splicing
would yield an uninterrupted Tat-coding sequence.
Cells transfected with this construct, pVA-Tat.int,
displayed no detectable Tat activity, whereas those
transfected with pCMV-Tat.int, an equivalent con-
struct transcribed by pol H, expressed Tat as ex-
pected. Examination of the transcripts by RNA pro-
tection analysis confirmed that RNA from cells trans-
fected with pVA-Tat.int was not spliced, unlike that
from pCMV-Tat.int-transfected cells. These results
imply that the pol III transcripts could not be spliced
in vivo, suggesting that they are not handled in the
nucleus in the same way as conventional mRNAs.
In the course of this work, we noticed that pol III
failed to terminate transcription at a site which
matches the published criteria defining a pol III
termination signal. These features, which were
deduced from a study of the Xenopus 5S ribosomal
RNA gene, include a run of four or more thymidines
in a GC-rich context; adenosine residues close to the
stretch of Ts were reported to be inhibitory. Since the
site had been introduced a short distance (30
nucleotides) downstream from the transcriptional B
box, we first considered the possibility that this
promoter element might occlude the termination sig-
nal or otherwise render it inactive. However, the nat-
ural VA RNA termination signal was not bypassed
when it was brought as close as 14 nucleotides to the
B box. Site-directed mutagenesis of the termination
signals showed that As in close proximity to the run
of Ts did not influence the efficiency of termination,
whereas Gs were very inhibitory. These findings sug-
gest that the mechanisms of termination are different
for the 5S rRNA and VA RNA genes; this difference
may reflect differences between these two pol III
genes in the architecture of their promoters and their
mechanism of transcriptional initiation.
Translational Control
D. Taylor, S. Brand, Q. Wang, L. Manche,
M.B. Mathews
The protein kinase DAI, the double-stranded RNA
(dsRNA)-activated inhibitor of translation, now gen-
erally known as PKR, is emerging as a pivotal regu-
lator of cell activity. It has been implicated in the
control of cell growth, transformation and differentia-
tion, apoptosis, and signal transduction, as well as
translation. PKR is a serine/threonine kinase, and
many of its actions are mediated via the phosphoryla-
tion of the protein synthesis initiation factor eIF2
(eukaryotic initiation factor 2). Phosphorylation of
eIF2 leads to the slowing or cessation of translation.
PKR is present in most cells and tissues in a latent
(inactive) state, and as its name implies, it is acti-
vated by RNA regulators. A current model posits that
PKR activation requires dimerization of the enzyme,
which allows intermolecular phosphorylation to oc-
cur. This autophosphorylation has been correlated
with the activation of PKR as an eIF2 kinase.
To understand the activation process in detail, we
have set out to characterize the autophosphorylation
sites. Seven such sites were identified through pep-
tide mapping and sequencing (conducted with Dan
Marshak and Georgia Binns, Protein Chemistry Core
Section), and each of them was mutated to alanine
(which cannot be phosphorylated) to explore their
roles in enzyme function. One site, Thr-258, appears
to play a role in the activation of the kinase. Experi-
ments conducted with Sean Lee and Mariano Esteban
(SUNY, Brooklyn) and with Patrick Romano and
Alan Hinnebusch (NICHD, Bethesda) showed that
mutation of this site decreased enzyme activity in
simian cells and in yeast. In a kinase assay, con-
ducted in vitro, mutation of the neighboring sites
(Ser-242 and Thr-255) had no effect on their own,
but these mutations exacerbated the deleterious effect
of the Thr-258 mutation. Thus, phosphorylation of
the three sites may act synergistically to activate the
enzyme, and they may comprise part of an autoregul-
atory region of the enzyme. Four additional sites lie
in the spacer region between the two RNA-binding
motifs that constitute the dsRNA-binding domain.
Mutation of these sites suggests that they do not play
a role in activation of the enzyme. We are also exam-
ining the effects of these mutations on cell growth
and tumorigenicity in mammalian cells.
eIF2 is not the only substrate for PKR, however:
Included in a growing list of proteins that can also be
phosphorylated by this kinase is IKB, the inhibitory
subunit of transcription factor NF-x13; an unidentified
90-kD protein from rabbit reticulocytes; and the HIV-
1 transactivator Tat, mentioned above. We have ex-
plored some of the characteristics of the interaction
between Tat and PKR, demonstrating that PKR can
bind and phosphorylate both the two-exon form of
Tat (Tat-86) and the single-exon form (Tat-72).
Phosphorylation of Tat by PKR is dependent on the
prior activation of the enzyme by dsRNA. Although
the amino-terminal region of Tat (residues 2-36) is
dispensable for binding, PKR did not bind or phos-
phorylate Tat mutants containing only the amino-
terminal 48 residues, suggesting that the interaction
between PKR and Tat may require the RNA-binding
region of Tat. Purified Tat-72 competed with eIF2 for
phosphorylation by activated PKR, and, reciprocally,
Tat was able to inhibit the activation of PKR. Current
efforts are aimed at determining the site(s) of Tat
phosphorylation and the significance of the phenome-
non for the activities of both Tat and PKR.
Virus-Host Interplay
H.-J. Liao, F. Ma, M.B. Mathews
PKR is an important component of the host antiviral
defenses. Its synthesis is induced by interferon, and it
is activated upon virus infection, with the result that
generation of viral progeny is curbed. In the face of
this threat to their survival, viruses have evolved
countermeasures to protect themselves against activa-
tion of the kinase. One of the best known of these is
the production by adenoviruses of small RNA mole-
cules, the virus-associated (VA) RNAs, some of
which serve to prevent PKR activation. In previous
years, we described how adenovirus 2 (Ad2) VA
RNA, blocks PKR activation and took a phylogenetic
approach to help determine structural features that are
critical to its function in vivo. We also explored the
structure and function of VA RNA, in vitro.
The related viral product, Ad2 VA RNA,,, is tran-
scribed from a neighboring gene and shares many
properties with VA RNA, yet it does not effectively
interfere with PKR activation. VA RNA is synthe-
sized by pol III, but much less abundantly than VA
RNA, Although most human adenoviruses produce
two VA RNAs, a minority of them (-20%) do not
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possess a VA RNAH gene. Whereas some viruses ap-
parently did not develop a second gene, in others it
seems to have been lost or inactivated secondarily.
Nevertheless, when the VA RNA!' gene is present, its
sequence is at least as highly conserved as that of
adenovirus VA RNA1; furthermore, VA RNAii
adopts a secondary structure different from that of
VA RNA! We therefore speculate that it plays a dif-
ferent role in virus infection, possibly one that is less
essential in some tissues or circumstances. To ad-
dress this hypothesis, we have begun to identify cel-
lular proteins (other than PKR) that interact with VA
RNA,/ and might shed light on its role.
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MOLECULAR MECHANISMS OF APOPTOSIS
Y. Lazebnik L. Faleiro J. Rodriguez
H. Fearnhead Y. Xu
Our laboratory focuses on the molecular mechanisms velopment and that causes disease including cancer
of apoptosis, a process that is critical for normal de- when it malfunctions. During apoptosis, a cell ac-
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tivates the machinery responsible for the cells self-
destruction, and it appears that a key part of this ma-
chinery are ICE-like proteases (ILPs), a family of
highly specific and closely related cysteine proteases.
ILPs are constitutively expressed in cells as inactive
precursors, and their activation appears to coincide
with the onset of apoptotic execution. We have devel-
oped a cell-free system that reproduces the execution
stage of apoptosis in vitro and provides a powerful
model for studying the role of ILPs in this process.
The goal of our laboratory is to identify and charac-
terize the ILPs that are involved in apoptosis and to
study their regulation. These studies will provide the
molecular framework with which to manipulate apo-
ptosis in order to selectively kill cancer cells.
During the last year, we were joined by Lavina
Faleiro and Joe Rodriguez as graduate students and
Howard Fearnhead as a postdoctoral fellow.
Identification of ILPs
Involved in Apoptosis
L. Faleiro, Y. Lazebnik
Although it is believed that ILPs are essential for
apoptosis in mammals, their identities and functions
are not well established. The current strategy to iden-
tify ILPs involved in apoptosis is to obtain the ILPs
on the basis of their homology with known ILPs and
then investigate whether each particular ILP plays a
part in apoptosis. Although this approach has been
extensively used, it is not known precisely which of
the growing number of cloned ILPs are involved in
apoptosis. To avoid characterizing ILPs not related to
apoptosis, we chose an approach based on biochemi-
cal activity. ILPs are expressed as latent precursors,
which are processed into active proteases. We de-
cided to use affinity probes to identify ILPs that are
activated during apoptosis. The ILP affinity probes
are biotin-labeled peptide inhibitors that bind irrever-
sibly to the catalytic site of active ILPs. The ILPs
labeled with such inhibitors can be visualized by
using electrophoresis followed by immunoblotting
and probing with avidin-peroxidase.
Using this technique, we found that multiple ILPs
are apparently activated during apoptosis. This con-
firmed our biochemical data which suggested that
multiple ILP activities with distinct specificity are in-
volved in cell destruction during the cell death. In
collaboration with Scott Lowe's laboratory (CSHL),
we are going to determine whether distinct sets of
ILPs were activated in different cells and following
different stimuli.
During the last year, we began to identify the ILPs
that are involved in apoptosis. In collaboration with
the laboratories of Dr. D. Nicholson (Merck Frosst,
Canada) and Dr. N. Thornberry (Merck, New Jersey),
we expanded upon our observation that an ILP which
is activated during apoptosis cleaves the nuclear en-
zyme poly(ADP-ribose) polymerase (PARP). This
ILP was purified by using an affinity probe that
mimics the cleavage site in PARP. The purified en-
zyme was identified by peptide sequencing as cpp32,
a previously cloned protease whose function was un-
known. We are continuing identification of other
ILPs activated during apoptosis.
A Cell-free System
That Reproduces
Apoptosis in
Human Tumor Cells
H. Fearnhead
The cell-free system of apoptosis that we developed
initially employed extracts made from a chicken cell
line. Despite the progress that we made using this
model system, we decided to develop a similar sys-
tem based on human tumor cells for the following
reasons: (1) Our long-term goal is to use apoptosis to
kill cancer cells in humans; (2) most of the research
on ILPs has been carried out with human or mouse
models; and (3) we envision that our research will
eventually merge with other fields, such as cell cycle,
DNA replication, and signal transduction, which rare-
ly use chicken as a model. Therefore, we reproduced
the cell-free system using extracts made from apop-
totic Jurkat cells, a well-characterized cell culture
model of human T-cell leukemia. All of the changes
that we observed in the chicken system, such as
changes in nuclear morphology, DNA cleavage, and
cleavage of PARP, were reproduced with the extracts
from Jurkat cells.
During the last year, our system was also repro-
duced in other laboratories by using a number of dif-
ferent cell types and ways to induce apoptosis. This
indicates that the apoptotic events reproduced by this
cell-free system are conserved in different cell types
and species.
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Activation of ILPs
at the Onset of
Apoptosis
H. Fearnhead
It appears that neither protein nor mRNA synthesis is
required to carry out apoptosis in many cell types.
This observation implies that apoptotic ILP precur-
sors are present in viable cells and are activated at the
onset of apoptosis. Having identified several active
ILP species in apoptotic cells, we wanted to know if
these enzymes are present in intact viable cells and
whether these enzymes can be activated in a cell-free
system.
We found that extracts made from untreated cells
contain ILPs required for apoptosis and that these
ILPs can be activated by adding exogenous ICE-like
enzymes. Intriguingly, activation of ILPs rendered
these extracts active in our cell-free assay of apop-
tosis. This indicated that the apoptotic machinery can
be activated directly through activation of ILPs and
independent of upstream signaling pathways. Thus,
ILPs are an attractive target for drugs designed to in-
duce apoptosis in cells where upstream signaling
pathways are blocked, for example, by a tumor virus.
Proteins Interacting
with ILPs
Y. Xu [in collaboration with H.R. Horvitz,
Massachusetts Institute of Technology]
Active ILPs are required for the onset of apoptosis.
Since ILPs are directly implicated in the destruction
of cell structures such as the nuclear lamina and since
specific inhibitors of ILPs prevent apoptosis, it is
likely that ILP activation is the event that occurs at
the end of the signaling pathways and is the first irre-
versible step inevitably leading to cell death. There-
fore, understanding the mechanism of ILP activation
is of paramount importance, because if this process is
blocked in a cancer cell, the cell will become resis-
tant to any cytotoxic drugs that induce apoptosis, for
example, the majority of currently used chemothera-
peutics. For the same reason, ILP activation is an at-
tractive target for pharmacological intervention to
circumvent defects in the apoptotic pathways up-
stream of the execution machinery, such as mutations
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in the p53 tumor suppressor. The mechanism and
regulation of ILP activation are not known. It is pos-
sible that this regulation is carried out by proteins that
interact with ILPs. Therefore, we began systematic
screening for the interacting proteins by using the
yeast two-hybrid system. In our initial screen, we
used CED-3, an ILP that is essential for apoptosis in
nematodes, and identified several proteins that inter-
act with this protease. We are currently determining
whether these proteins play a part in apoptosis.
Substrates and
Inhibitors of ILPs
J. Rodriguez
Apoptosis involves multiple processes, including
restructuring of the cytoskeleton, disassembly of the
nucleus, degradation of DNA, inhibition of protein
and RNA synthesis, and expression of antigens facili-
tating the engulfment of apoptotic cells by other cells.
If ILPs are triggering some of these changes, they
most likely do so by proteolytic cleavage of specific
substrates. Depending on the substrate, such cleav-
ages may have different effects, such as inactivation
or activation of the protein, alteration of the protein
structure and function, or disassembly of a cellular
structure. Only a few substrates for ILPs during apop-
tosis are known, and they provide insufficient insight
into how ILP activity causes cell death. Most of these
substrates were found by serendipity. During the last
year, we began to develop approaches that would al-
low us to screen for new ILP substrates.
We also began a search for cellular inhibitors of
ILPs. Although such inhibitors have not been identi-
fied, viral inhibitors of ILPs have been reported.
These proteins are potent inhibitors of apoptosis in
several experimental systems and appear to be part of
the viral anti-host defense mechanism, suggesting
that they mimic cellular proteins. Thus, identification
of viral and cellular inhibitors of ILPs should provide
new insights into how the activation of ILPs is regu-
lated.
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REGULATION OF CELL SIGNALING IN HIV PATHOGENESIS
J. Skowronski S. Bronson A.J. latrate
Y.-N. Chang M. Lock
AIDS is invariably associated with the depletion of
the regulatory subset of T cells that express CD4
protein on the cell surface. CD4+ T cells are prefer-
entially infected by the human immunodeficiency
virus (HIV), which suggests that viral infection may
be lethal for these cells. Our main interest is in the
molecular mechanisms underlying the development
of AIDS, in particular, in the functional consequences
of the interaction between immunodeficiency virus
proteins and the cellular regulatory machinery. In the
last year, our work continued to focus on two HIV-1
proteins, Nef and Env. Both proteins have profound
effects on the normal function and/or survival of
CD4+ T cells and these effects are likely to play an
important part in AIDS.
Nef is a small cytoplasmic protein found in all im-
munodeficiency viruses. Nef is important for efficient
virus replication in vivo but is dispensable for the
viral life cycle under in vitro conditions. The critical
in vivo function of Nef is not understood. We have
previously shown that Nef can alter the development
of CD4+ T cells when expressed in immature T-cell
precursors in the thymus. This effect correlated with
down-regulation of CD4 molecule expression on the
cell surface and disruption of the association of CD4
with the Lck protein tyrosine kinase. The CD4-Lck
complex is required for normal signaling by the T-
cell antigen receptor. These effects of Nef on CD4
and on the CD4-Lck complex will disrupt the normal
function of CD4+ T cells.
In the last year, we performed detailed genetic
analysis of the interaction between Nef and the T-cell
antigen receptor (TCR) machinery. These studies
demonstrated that in addition to disrupting the CD4 -
Lck complex, Nef also disrupts another aspect of
TCR function. This other effect of Nef involves a
membrane proximal block in TCR signaling that is
independent of Nef's ability to down-regulate CD4
expression. In a second development, we have con-
structed new lines of transgenic mice that express
Nef in peripheral T cells. This is an important model
because peripheral CD4+ T cells are the major targets
for HIV infection in humans. Finally, we have ini-
tiated genetic studies of the cytotoxic effect of HIV
Env expression in T cells.
Nef Alters the Normal Function
of Peripheral CD4+ T Cells
in Transgenic Mice
Y.-N. Chang, S. Bronson, A.J. lafrate, M. Lock
Little is known about the interactions between the
HIV-1 genes and the regulatory machinery in in-
fected cells. To address the consequences of Nef on
normal T cells in vivo, we directed expression of the
HIV-1 Nef protein to these cells in transgenic mice.
A T-cell-specific expression vector containing Nef-
coding sequences placed under control of transcrip-
tion control elements derived from the T-cell-specific
CD2 gene was permanently integrated into the mouse
germ line. Transgenic animals derived with this con-
struct showed high-level Nef protein expression in
the mature cells of the T lymphocyte lineage. This is
an important model because mature T cells that ex-
press CD4 protein on their surface are the major
target of HIV infection in humans.
A compilation of results from a detailed study of T
cells from CD2 N1 [NL43]#2 transgenic mice is
shown in Figure 1. Several lines of evidence from
these animals indicated that the Nef protein has a
dramatic effect on the development and function of T
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FIGURE 1 Altered T-cell subsets in CD2 N1(NL43)#2 mice.
The absolute number of lymph node cells (LN), T cells
(TCR), and CD4+ and CD8+ T lymphocytes in mesenteric
lymph nodes from transgenic animals (N+, closed circles)
and from littermate controls (N-, open circles) is shown. The
percent of cells that express the aii-TCR and CD4 or CD8
molecules was determined by three-color flow cytometry.
The absolute number of CD4 and CD8 T cells was calcu-
lated from the total number of cells recovered from lymph
nodes, as determined by hemocytometer counting. The ratio
of CD4 to CD8 T cells is also shown (4/8). Each mouse ana-
lyzed is represented by five dots and each dot represents a
result of a single determination.
cells that express the CD4 molecule. As shown in
Figure 1, the frequency of the mature T cells in the
thymus and in the lymph nodes of transgenic animals
was abnormally low (panel 1). This decrease was
largely due to an abnormally low frequency of CD4+
T cells, and the representation of CD8+ T cells was
found to be normal (compare panels 3 and 4). More-
over, expression of the CD4 protein on the majority
of transgenic CD4+ lymph node cells was threefold to
fourfold lower than that observed on CD4+ lympho-
cytes from littermate animals. CD4 is a component of
TCR, and it is likely that Nef-induced T-cell pertur-
bations reflect altered TCR function in Nef-express-
ing T cells. Our current studies address the effect of
Nef on TCR-regulated processes in T cells such as
the induction of proliferation and apoptosis.
Functional Analysis of Nef
Interaction with T-cell
Receptor Machinery
A.J. lafrate, S. Bronson
TRANSIENT ASSAY OF THE EFFECT OF NEF ON
T-CELL ACTIVATION
To confirm our observations from transgenic mice in
human T cells and to address the relationship be-
tween the effect of Nef on CD4 expression and on
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TCR signaling, we developed in vitro assays of Nef's
interaction with the TCR machinery using a human
CD4+ T-cell line. Because constitutive expression of
Nef in T-cell lines may result in a selection for
mutants in signal transduction pathways, we devel-
oped a transient expression system to study the effect
of Nef on TCR function. In this assay, expression
vectors encoding the wild-type, or mutant, Nef
proteins were introduced into CD4+ Jurkat T cells by
transfection. Subsequently, cells were stimulated via
TCR by overnight culture in the presence of cc -TCR
monoclonal antibody (MAb). One of the effects of
TCR signaling is the induction of the very early ac-
tivation antigen CD69 on the surface of stimulated
cells. Therefore, induction of CD69 expression pro-
vided a convenient indicator of TCR function. Flow
cytometric analysis of CD4 and CD69 expression
permitted us to quantitate the effect of Nef on CD4
and CD69 expression simultaneously.
NEF BLOCKS A MEMBRANE-PROXIMAL EVENT
RELATED TO CALCIUM SIGNALING IN THE
TCR PATHWAY
As illustrated in Figure 2, transfection of Jurkat T
cells with the CD3 NA7 vector, but not with a control
"empty" CD3-13 plasmid, resulted in an approximate-
ly 50-fold decrease in CD4 expression in a large frac-
tion of electroporated cells (compare panels 1 and 2).
The NA7 allele, like the NL43 allele, is a natural and
very potent allele of HIV-1 nef. We know from con-
trol experiments that the CD4I0 " cells reflected the
population of successfully transfected cells. ct-TCR
stimulation of the mock-transfected cells resulted in
an approximately six- to tenfold increase in CD69 ex-
pression, when compared to that in the unstimulated
population (compare panels 1 and 3). In contrast,
treatment of cells transfected with the CD3 NA7 vec-
tor resulted in induction of CD69 expression only in
the CD4high cells. CD69 expression in CD4I°w cells
was not increased (see panel 4). Thus, Nef blocks in-
duction of CD69 expression by TCR stimulation.
This effect of Nef was also observed with SIV Nef
protein (see Fig. 2B). Therefore, the blocking of TCR
signaling by Nef reflects a conserved function of the
viral protein.
Nef does not block CD69 induction following
stimulation with cc -TCR monoclonal antibody in the
presence of calcium ionophore, which bypasses the
TCR to induce calcium signaling. Thus, Nef appears
to suppress a membrane-proximal event that involves
calcium signaling. Interestingly, Nef did not interfere
The cleavage products remain noncovalently associ-
ated and move to the cell surface where they can bind
the CD4 protein expressed on the surface of an op-
posing cell. Env is toxic to the cells and Env-induced
death of cultured T cells appears to result from two
distinct effects. One effect involves the formation of
large multinucleated syncytia and results from the fu-
sion of cells bearing the gp120/gp41 envelope hetero-
dimer on their surface with cells expressing the CD4
molecule. This process involves adhesion of the two
cells mediated by gp120-CD4 interaction and mem-
brane fusion mediated by the gp41 Env subunit. The
other effect involves the death of individual cells and
occurs in the absence of syncytia formation.
To dissect the molecular basis for Env-induced
cell death, we have established an inducible Env ex-
pression system in a human T-cell line and developed
a simple assay to correlate Env expression with cell
death. As expected, induction of wild-type HIV-1
Env protein expression in this system, but not of
other control proteins, resulted in massive death of
productively transfected cells. The cell death oc-
curred rapidly, within hours, following the onset of
Env expression. In our system, Env-induced cell
death did not involve cell fusion and therefore was
likely to reflect cell-autonomous events that take
place in Env-expressing cells. Interestingly, two
mutant Env proteins that are deficient in binding to
CD4 and in mediating membrane fusion, respective-
ly, failed to induce cell death in our system. Our
results suggest a model where intracellular interac-
tion of Env with CD4 leads to membrane fusion
events within the cells and mediate the lethal effects
of the viral protein. Future work will be directed at
understanding downstream events in this pathway.
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BIOCHEMISTRY OF CELLULAR GROWTH AND DIFFERENTIATION
D.R. Marshak E. Araya S. Goren M. Pittenger
N. Carpino J. Kahler D. Rizzieri
N. Chester C. (Walker) Kelley C. van den Bos
T. Connolly
Our goal is to attack biological problems of the con-
trol of cell growth in several cell systems that are
models of different cancers. The members of this
laboratory conduct specific research on signal trans-
duction processes involved in cell growth and differ-
entiation. We use a multidisciplinary approach using
advanced methods of cell biology, analytical bio-
chemistry, and molecular biology. The projects in
this laboratory have been various, ranging from basic
research on protein phosphorylation, to myelogenous
leukemia, and to bladder cancer in connection with
parasitic infections. Most recently, we have begun
work on mesenchymal tissues, involving the mesen-
chymal stem cells, under a research agreement with
Osiris Therapeutics, Inc., in Baltimore. During 1995,
Dr. Marshak maintained a transitional status between
Cold Spring Harbor Laboratory and Osiris Therapeu-
tics, where he serves as the Senior Vice President,
Research and Development. By the end of 1995, the
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members of this laboratory had left Cold Spring Har-
bor or moved to other positions. During the past 10
years, Dr. Marshak and his laboratory groups have
been successful in the science of growth control, and
we all look forward to the new challenges ahead.
Cold Spring Harbor has been a fantastic environment
in which to grow, discover, and learn. Our thanks to
all our friends and colleagues for their support during
our transitional year, and we have no doubt that
many connections will remain intact.
Molecular Cloning and Expression
of Protein Kinase CKII Subunits
N. Chester, D.R. Marshak [in collaboration with J. Horton,
Cold Spring Harbor Laboratory]
Protein kinases are enzymes that catalyze the transfer
of phosphates from the y-phosphate position of ATP
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FIGURE 2 HIV-1 Nef interferes with two aspects of T-cell receptor machinery: CD4 expression, and induction of CD69 expres-
sion, on the cell surface. (A) Two-color FACS analysis of the effect of HIV-1 Nef on CD4 and CD69 expression. CD4 and CD69
expressions on the cell surface are shown on the ordinate and abscissa, respectively, in logarithmic scale. (B) Mutations sepa-
rate the effects of Nef on CD69 and on CD4 expression. (Panels 1-4) Two-color analysis of CD4 and CD69 expression in cells
transfected with plasmids comprising the wild-type SIV mac239 (mac239), or the mutant mac239.174 (mac239.174), alleles
and nonstimulated (Mock), or stimulated overnight with a-CD3 MAb (a-CD3). (Panels 5-6) Dose-response analysis of the ef-
fect of mutant HIV-1 Nef proteins (ts16, ts10,7.1Epi) on CD4 and C469 expression. The empty CD3-0 plasmid (vector) and
CD3 NA7 expression vector (NA7) were used as negative and positive controls, respectively. Jurkat T cells were coelec-
troporated with different amounts of expression plasmids (0 to 15 Rg, shown in the abscissa). (Upper panel) CD4 expression is
shown in the ordinate as peak channel number of CD4 fluorescence; (lower panel) CD69 expression on cells stimulated over-
night with indicated amounts of a-CD3 MAb is shown in the ordinate as peak channel number of CD69 fluorescence.
with induction by a-TCR
stimulation. Thus, Nef blocks only a subset of signals
emanating from the TCR. Further experiments to
define the Nef-induced biochemical defect in the
TCR pathway in Jurkat T cells are under way.
EFFECTS OF NEF ON CD4 AND CD69 EXPRESSION
CAN BE SEPARATED BY MUTATION
We identified mutations that disrupt preferentially the
effect of Nef on CD4 expression and on the induction
of CD69 expression, as shown in Figure 2. For exam-
ple, a single-amino-acid substitution in the 239.174
SIV Nef protein disrupted the effect of Nef on CD4,
but not on CD69 antigen expression (compare panels
1 and 2 and 3 and 4 in Fig. 2A). Results from dose-
response analysis of selected mutant HIV-1 Nef
proteins are shown in Figure 2B. The ts16 mutation
disrupted the effect of Nef on CD4, but not on induc-
tion of CD69 expression by a-TCR monoclonal
antibody (see ts16 in the upper and lower panels). In
contrast, the ts10 mutation had little effect on the
ability of Nef to down-regulate CD4 expression, but
disrupted the ability of Nef to block induction of
CD69. Finally, the 7.1EPI mutation disrupted both
the effect of Nef on CD4 and on CD69 expression.
These observations
two separate aspects of TCR machinery in T cells.
One effect of Nef is to down-regulate surface expres-
sion of CD4. The other effect is to block a mem-
brane-proximal event in the TCR pathway. It appears
that the ability of Nef to block TCR signaling is inde-
pendent from its ability to down-regulate CD4 ex-
pression. Current experiments address the molecular
mechanisms involved in these two effects of Nef on
the TCR machinery. How these two effects of Nef
modulate the normal function of CD4+ T cells in vivo
is being addressed in experiments with CD2
Nl [NL43] mice that express Nef protein in mature T
cells.
Mechanism of Cell Death
Induced by HIV-1
Env Protein
M. Lock
The envelope protein (Env) is produced as a large
precursor (gp160) that is subsequently cleaved in the
Golgi apparatus into two subunits, gp120 and gp41.
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to a hydroxyl moiety (serine, threonine, or tyrosine)
on proteins. The enzyme protein kinase CKII is a
protein serine/threonine kinase found in all eukary-
otic cells. Its ubiquitous distribution among species
and tissues implies a function central to all nucleated
cells. The enzyme consists of two subunits, a and (3,
with molecular masses of 37-44 kD and 24-28 kD,
respectively, with an apparent subunit composition of
a2(32. The a-subunit is found in two different forms,
known as a and a' , that arise from separate genes.
To answer questions about the mechanism of enzyme
regulation, we have cloned and expressed DNA
molecules coding for the full-length forms of the a
and (3 subunits, which has allowed us to insert the
coding sequences for the CKII subunits into various
expression vectors. Using these constructs, we have
expressed the proteins in large amounts in bacteria.
The purified, recombinant catalytic subunits are en-
zymatically active, and the activity is increased by
the regulatory subunit, (3. The catalytic and regulatory
subunits combine in a functional complex whether
mixed in vitro or co-expressed in the same bacterial
cells. We have purified large amounts of the
regulatory subunit for structural analysis. In col-
laboration with J. Horton, we found that a truncation
of the protein can occur during expression at a site
within the carboxy-terminal domain. Using carboxy-
terminal protein sequencing and mass spectrometry,
we were able to identify the sites of cleavage and
show the basis for production of full-length protein.
Dr. Horton has crystallized the (3-subunit of CKII in
forms that appear to diffract X-rays and has produced
larger crystals to solve the three-dimensional struc-
ture of this protein. Whereas the catalytic subunits of
CKII are homologous to other known protein serine/
threonine kinases, the 0-subunit is unique. We expect
that the structure of this regulatory subunit will be a
novel contribution to the field.
Subcellular Pools of
Casein Kinase II
N. Chester, D.R. Marshak
CKII enzyme activity is found both in cytosol and in
nuclei, and there are substrates identified in both
locations. Cytosolic substrates include proteins in-
volved in translational control (eIF-2, -3, -4B, -5),
metabolic regulation (glycogen synthase), and the
cytoskeleton (non-muscle myosin heavy chain, (3-
tubulin). Substrates found in the nucleus include
DNA topoisomerase II, RNA polymerases I and II,
oncoproteins such as Myc, Myb, and SV40 large T
antigen, and transcription factors such as serum
response factor. The extraordinary range of substrates
for this enzyme supports the contention that CKII has
a significant role in cell physiology. We have devel-
oped a large set of specific antibodies to synthetic
peptide antigens that react with the individual sub-
units of CKII. These antibodies allowed us to con-
tinue our studies of the subcellular localization of the
subunits of the enzyme during the cell division cycle
of HeLa cells. N. Chester has used the antibodies de-
veloped in the lab to do detailed immunoprecipitation
and immunoblots of the CKII subunits. First, he
found that the synthetic rate for the CKII (3-subunit is
significantly longer than that of the catalytic subunits,
whereas the degradation rates for all the subunits ap-
pear to be similar. Second, using steady-state metabo-
lic labeling, he identified different pools of CKII that
vary in subunit stoichiometry and activity. He has
performed experiments in HeLa cells to determine if
different pools of CKII are localized to different sub-
cellular compartments. There is evidence that the a'
subunit may have a higher relative concentration in
the nucleus. Previous work from Dr. Marshak in col-
laboration with J. Diaz-Nido in Madrid indicated that
this subunit may have unique regulation during
neuronal differentiation during embryonic develop-
ment.
Cell Cycle Regulation of
Protein Kinase CKII
C. van den Bos, D.R. Marshak [in collaboration with
A. Sutton, Cold Spring Harbor Laboratory,
and G. Russo, Naples, Italy]
During the past year, we have continued study of cell
cycle regulation of protein kinase CKII and its effect
on cyclin-dependent kinases in the control of cell
division. The enzyme p34cdc2 is a cyclin-dependent
kinase that is a key regulator of the G2-M transition
in the cell cycle, and appears to play a part in the G1-
S transition as well. We previously reported that hu-
man p34cdc2 is phosphorylated on Ser-39 during the
G1 phase of the HeLa cell division cycle. The en-
zyme apparently responsible for this phosphorylation
event is CKII, based on in vitro phosphorylation data,
substrate specificity, and correlation of the activities
in vivo. To evaluate the functional role of this phos-
phorylation event in eukaryotic cells, we turned to the
budding yeast, Saccharomyces cerevisiae, in which
we could genetically manipulate the homolog of
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mammalian p34.1c2, known as CDC28. In collabora-
tion with A. Sutton, we have demonstrated that the
homologous serine is phosphorylated on CDC28 in
yeast as on p34cdc2 in mammalian cells. To test the
functional role of this site in yeast, we constructed a
yeast carrying a mutation that results in the substitu-
tion of an alanine residue for the serine. The mutant
plasmid was introduced into a yeast defective for
wild-type CDC28. The phenotype of the mutant is a
small cell size, indicating a premature entry into S
phase. This result suggests that the phosphorylation
of the serine on CDC28 in yeast allows the cell to ex-
tend Gt. Further genetic and biochemical experi-
ments have indicated that this is not due simply to a
lesion in cyclin binding, as first put forward as an ex-
planation. Expression of human cyclin A in yeast
containing the serine-alanine mutation in CDC28
does not result in altered amounts of activity or
protein precipitating in CDC28/cyclin complexes.
Furthermore, CLN mutants in yeast do not have any
effect in combination with the serine-alanine CDC28
mutants. Thus, the exact mechanism of action
remains somewhat obscure. However, C. van den
Bos has succeeded in expressing the human cdc2 Ser-
39 mutants in He La cells, and his initial results indi-
cate that there is a similar size and cell cycle check-
point phenotype in this human cell line.
Biochemical Mechanisms in
Chronic Myelogenous
Leukemia
N. Carpino, S. Goren, J. Kahler, D.R. Marshak
[in collaboration with B. Clarkson, MSKI, New York,
and 0. Witte, University of California, Los Angeles]
Chronic myelogenous leukemia (CML) is a disease
characterized by the presence of a chromosomal
translocation in somatic cells of the hematopoietic
system. This chromosomal aberration causes the ex-
pression of a fusion protein, known as p210bcr'abi.
The p210b":abl fusion protein functions as an unregu-
lated tyrosine kinase, which is associated with pro-
liferation of myeloid progenitor cells. When patients
progress to blast crisis, there are massive numbers of
myeloid progenitors in the peripheral circulation with
a lack of differentiated myeloid cells and their cor-
responding functions in these hematopoietic lineages.
Our studies are aimed at understanding the action of
p210bcrtabl in two different ways.
First, S. Goren has taken the approach of trying to
characterize sites on the p210 protein that are phos-
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phorylated. She has identified what appear to be sites
for the cell-division-cycle-regulated protein kinase,
p34.dc2. These sites appear to be phosphorylated in
vitro and have sequences that match consensus phos-
phorylation sites for cyclin-dependent kinases.
Clones encoding mutant forms of the p210, or its
homolog, p185, were developed. The phenotypes of
the mutant proteins were characterized by assays with
retroviral vectors for transforming ability and sub-
cellular localization. So far, no distinct phenotype of
these mutants has been proven.
Second, N. Carpino has developed a purification
method for a protein that is hyperphosphorylated on
tyrosine residues in cells containing p210ber'abl, and
which may be a substrate for the abnormal tyrosine
kinase in leukemic cells. This protein, known as p62,
has been purified to apparent homogeneity using
phosphotyrosine antibodies and classical chromato-
graphic methods. Sequence analysis of the protein
was conducted with R. Kobayashi (CSHL), and N.
Carpino is cloning a cDNA encoding the protein.
This molecule may give us the first clue at the
downstream events in myeloid cells transformed with
p2i0bcriabl.
Schistosoma haematobium
Soluble Egg Antigens
and Bladder Cancer
D.R. Marshak, C. (Walker) Kelley [in collaboration with
T. Gaafar, Cairo, Egypt]
This project arose from a collaboration with Dr. T.
Gaafar in Cairo entitled "Biochemical, molecular,
and immunological characterization of the Schisto-
soma haematobium soluble egg antigens that induce
in vitro human granuloma formation," which has
been part of the Schistosomiasis Research Program.
This program is directed toward developing a vaccine
for schistosomiasis, a disease that plagues Africa and
Asia and is prevalent in Egypt. We chose to work on
the soluble egg antigens of the bladder form of the
disease, as candidates for synthetic vaccines. In addi-
tion, there is a high correlation between chronic S.
haematobium infection and bladder cancer, suggest-
ing a molecular connection between the immunologi-
cal response of the patient to chronic infection and
the ultimate formation of tumors. Our strategy has
been to isolate and characterize the antigens in hopes
of identifying peptides for vaccine materials and,
potentially, making a connection to bladder cancer.
Specific S. haematobium soluble egg antigens
(SEA) were previously identified by electrophoresis,
electroelution, and granuloma formation in vitro.
Protein bands were identified with relative mobilities
at 84, 66, 57, 40, and 30 kD. Proteinase digestion and
peptide maps by high-performance liquid chromatog-
raphy (HPLC) were performed on preparations of
each SEA protein. The chromatograph effluent was
monitored for ultraviolet absorbance at 214 nm and
280 nm. Peaks of absorbance were collected and ana-
lyzed for peptide content and structure. Sequence
analysis by repetitive Edman degradation was per-
formed on significant peaks. The primary sequence
information was used in two different ways. First, se-
quences were used to search the existing databases
including GENBANK, PIR, and Swiss Pro for
homologies with known proteins or open reading
frames in identified genes. Second, in cases where
the sequences are novel, synthetic peptides were
prepared by solid-phase methods, cleaved to solubil-
ize the products, and purified to apparent homogen-
eity. The identity of the peptide product was docu-
mented and validated by HPLC and plasma desorp-
tion mass spectrometry. Some of the peptides have
been used as antigens in rabbits to raise antisera that
react with the SEA protein. These results were docu-
mented by immunoblotting and immunohistochem-
istry by Dr. Gaafar and her students and colleagues in
Cairo. In addition, the synthetic peptides themselves
are candidates for use in vaccines directly, and they
can be tested in the rodent models of schistosomiasis
or in models of granuloma formation in vitro.
The 30-kD SEA protein was obtained in sufficient
amounts from preparative electrophoresis experi-
ments. Peptide maps of this protein produced 17 frac-
tions that were potential candidates for sequence
analysis, of which 11 were completed. Two of these
yielded very revealing amino acid sequence results
that show some homology between the 30-kD SEA
protein and a family of proteins known as 14-3-3.
The 14-3-3 proteins have been implicated in the
regulation of protein kinases involved in signal trans-
duction at the plasma membrane surface. Specifical-
ly, 14-3-3 may play a part in the interactions between
the tyrosine kinase receptors and the Ras protein-
stimulated mitogenic pathway that involves the
mitogen-activated protein kinases. It is known that
abnormally functioning Ras (such as arise from point
mutations) leads to cancer, and Ras was one of the
first cellular proto-oncogenes identified. In patients
that have chronic infection and immunological reac-
tion to the SEA, there are likely antibodies formed
against the 30-kD SEA. Because of the homology
with 14-3-3, these antibodies could contribute to dys-
function of the Ras signaling system, giving rise to
cellular transformation. One would suppose that this
effect is most intense near the site of the bladder
granulomas. These conjectures, based on the remark-
able homology data between the 30-kD SEA and 14-
3-3, may provide a clue as to the link between S.
haematobium infection and the high incidence of
bladder cancer.
Mesenchymal Stem Cells
D.R. Marshak, T. Connolly, M. Pittenger [in collaboration
with Osiris Therapeutics, Baltimore, Maryland]
Under a research agreement with Osiris Therapeutics,
we began the study of mesenchymal stem cells.
These cells are adherent, marrow-derived, fibroblas-
tic cells that appear to give rise to various lineages of
the mesenchymal tissues, including bone, cartilage,
muscle, tendon/ligament, fat marrow stroma, and
other connective tissues. The cells are difficult to iso-
late and to grow. During the first half of the year, we
initiated studies to examine the growth and differen-
tiation of the cells under various conditions. The cells
can differentiate down several mesenchymal lineages
in vitro, and they have been shown to regenerate
mesenchymal tissues in vivo. Cultures of these cells
are being developed for autologous cell-based im-
plants for regenerative tissue therapy.
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MOLECULAR GENETICS OF EUKARYOTIC CELLS
Members of this section study mainly the pathways of signal transduction that regulate growth, dif-
ferentiation, and gene expression. Nick Tonks and co-workers have determined the X-ray crystal
structure of the PTP1B phosphate bound to its substrate and developed mutants that bind and trap
substrates. They have studied the relation of phosphatases to the state of phosphorylation of the
catenins, intracellular proteins that may mediate signaling due to cell-cell contact. Linda Van
Aelst's group has identified new candidate targets of mammalian Ras and Rac proteins and has
begun the study of their involvement in malignant transformation, metastasis, and cellular morphol-
ogy. Michael Hengartner's laboratory has studied three aspects of programmed cell death (apo-
ptosis) in the nematode C. elegans, identifying potentially new suppressors of previously character-
ized mutants in the central apoptotic pathways and identifying two groups of mutations in genes re-
quired for the host to recognize the apoptotic cell. Michael Wigler's laboratory has identified the
function of new proteins in the Ras signaling pathways of yeasts and demonstrated the multi-
functionality of Ras in mammalian cells. Nikolai Lisitsyn's group, in collaboration with Dr. Wigler's
lab, has identified numerous new loci that are frequent sites of genetic alteration in human gastroin-
testinal and breast cancers. David Helfman's group has continued to explore the physiological role
of the various tropomyosin isoforms and to define the components of the splicing complexes that
determine the tissue-specific splicing patterns. David Spector's group has succeeded in visualiz-
ing the dynamic recruitment of factors to subnuclear compartments in the splicing and transcription
of RNA in vivo and developed cell-free systems for the manipulation and assay of these events.
MAMMALIAN CELL GENETICS
M. Wig ler L. Van Aelst D. Esposito M. Barr G. Asouline
E. Chang V. Jung K. Chang X. Duan
M. Hamaguchi R. Lucito K. O'Neill B. O'Connor
M. White M. Nakamura M. McDonough M. Riggs
C. Yen C. Nicolette J. Stolarov L. Rodgers
P. Barker W. Wei H. Tu J. Troge
D. Dong
Work in our group is divided into three parts. The
first is the study of the signal transduction pathways
that relate to the Ras proteins, small GTP/GDP-
binding regulatory molecules. Ras proteins are fre-
quently activated by mutation in human cancers. The
second is the application of representational dif-
ference analysis (RDA) to the definition of the ac-
quired genetic lesions of breast and gastrointestinal
cancers. RDA is a method, developed in collabora-
tion with Nikolai Lisitsyn, for the comparison of
similar genomes (Lisitsyn et al., Science 259: 946
[1993]). The third is the development of corn-
binatiorial techniques for the discovery of small
molecules capable of binding to and altering the
biological activity of signal transduction proteins.
These studies, emerging out of earlier work with
chemists at Columbia University, are conducted in
collaboration with Peter Nest ler (Ohlmeyer et al.,
Proc. Natl. Acad. Sci. 90: 10922 [1993]).
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Ras Signaling Pathways
L. Van Aelst, E. Chang, M. White, V. Jung,
C. Nicolette, M. Barr, K. O'Neill, J. Stolarov,
H. Tu, K. Chang, M. McDonough
Previous work from our group defined the effector
targets of the Ras proteins in the budding yeast Sac-
charomyces cerevisiae (Toda et al., Cell 40: 27
[1985]), the fission yeast Schizosaccharomyces
pombe (Wang et al., Mol. Cell. Biol. 11: 3554 [1991];
Van Aelst et al., Proc. Natl. Acad. Sci 90: 6213
[1993]; Chang et al., Cell 79: 131 [19941), and mam-
malian cells (Van aelst et al., Proc. Natl. Acad. Sci.
90: 6213 [1993]). Most recently, we provided the
most rigorous genetic evidence that one target for
Ras in mammalian cells is the Raf protein (White et
al. 1995). Our studies also provide clear evidence for
other targets important to the ability of Ras to induce
malignant transformation, morphological change,
mitosis, and gene expression (White et al. 1995;
Joneson et al. 1996). We have therefore directed con-
siderable effort to the discovery of, and analysis of,
other potential targets for Ras (Van Aelst et al. 1995).
The candidate targets are found by two hybrid inter-
actions (Fields et al., Nature 340: 245 [1989]). The
threshing of candidates proceeds by mutational anal-
ysis, coupled with gene transfer and tests for genetic
interactions.
In the paper by White et al. (1995), we demon-
strate a general genetic approach to testing the impor-
tance of particular protein/protein interactions. Using
the two-hybrid system, we generate allele-specific
mutations between genes encoding interacting pro-
teins. We are applying this approach to a number of
signal transduction problems, including an analysis of
the interactions between Raf and 14.3.3, a highly
conserved protein with which Raf interacts (Freed et
al., Science 265: 1713 [1994]; Irie et al., Science 265:
1716 [1994]) and an analysis of other candidate Ras
targets.
Concomitant with these mammalian studies, we
have continued our studies of the Ras pathway in
yeasts. In particular, we have identified a new gene
product that appears to facilitate the arrival of Ras at
its proper site within S. cerevisiae (Jung et al. 1995).
We continue to explore the function of Cap, an
adenylyl-cyclase-associated S. cerevisiae protein that
is required, in vivo, for Ras activation of adenylyl
cyclase (Field et al., Cell 61: 319 [1990]). Two-
hybrid and biochemical studies indicate that Cap can
bridge adenylyl cyclase to Slat, a yeast homolog of
mammalian talin. Mutational studies indicate that this
bridging function is required for the sensitivity of
adenylyl cyclase to Ras in vivo.
Our earlier studies in S. pombe revealed two dis-
tinct Ras-dependent pathways, one leading to activa-
tion of a MAP kinase module, through the direct ac-
tivation of the Byr2 protein kinase (Wang et al., Mol.
Cell. Biol. 11: 3554 [1991]; Van Aelst et al., Proc.
Natl. Acad. Sci. 90: 6213 [1993]), and one leading to
the activation of a Rho-like protein, Cdc42, through a
protein complex involving the Scdl and Scd2 pro-
teins (Chang et al., Cell 79: 131 [1994]). Both path-
ways are required for sexual conjugation. We have
identified a second component that interacts with
Byr2, namely Ste ;, a leucine zipper protein, and have
shown that Ste4 and Rasl both bind the regulatory
domain of Byr2, but at separable sites. The Ste4 and
Rasl proteins evidently act together, although they
can act partially independently to activate Byr2. Ste4
shows weak homology with Ste50, an S. cerevisiae
protein involved in sexual differentiation in that
organism. Ste50 binds Stel 1, the S. cerevisiae
homolog of Byr2, and Ste50, like Ste4, is capable of
homotypic interaction. We have hypothesized that
Ste4 (and perhaps Ste50) acts by causing the dimer-
ization of its target protein kinase.
A potential target for S. pombe Cdc42 has been
identified, the Shkl protein kinase (Marcus et al.
1995). It is the homolog of mammalian p6513AK and
S. cerevisiae Ste20, and genetic evidence suggests it
may mediate some (if not all) of the effects of Cdc42
on cell shape and conjugation. Thus, this kinase may
also be indirectly under the control of Rasl in S.
pombe, through the latter's effects on Scdl and Scd2.
Genomic Difference Analysis
of Human Cancer
M. Hamaguchi, R. Lucito, W. Wei,
C. Yen, P. Barker, D. Broek
In 1993, we published a powerful method for
genomic difference analysis called RDA (Lisitsyn et
al., Science 259: 946 [1993]). In collaboration with
N. Lisitsyn, we have utilized RDA to identify probes
for loci that undergo amplification, homozygous loss,
or loss of heterozygosity in tumor cell lines and in
tumor cells (Lisitsyn et al. 1995a,b). Several of the
loci we have identified are frequently the sites of ge-
netic alteration in cancers of gastrointestinal origin.
We are searching for transcripts from these loci.
Using RDA, we have also discovered several loci in
humans that appear to contain deletions (or inser-
tions) within the normal population.
Most of our effort now focuses on breast cancer,
using material sent to us from collaborators at Sloan-
Kettering Memorial Cancer Center (Dr. Larry
Norton) and North Shore University Medical Center
(Dr. Margaret Kemeny). From these sources, we have
identified greater than a half dozen loci, including
several previously unidentified, that become ampli-
fied in breast cancer, and greater than a half dozen
loci that appear to suffer repeated homozygous loss
in breast cancers. Together, these probes detect le-
sions in nearly 90% of aneuploid tumors. Our future
work will include continuing to identify loci that are
common sites of genetic alteration in breast cancer,
correlating these alterations with disease outcome
and response to therapy, and isolating the genes and
gene products that are the targets of these alterations.
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Combinatorial Chemistry
D. Dong
In 1993, together with the Still lab at Columbia Uni-
versity, we published a method for the efficient gen-
eration of libraries of organic molecules indexed with
molecular tags (Ohlmeyer et al., Proc. Natl. Acad.
Sci. 90: 10922 [1993]). Recently, Peter Nest ler from
the Still lab was appointed to the staff at Cold Spring
Harbor Laboratory. In collaboration with him, we
have planned to generate libraries of branched
peptide-like molecules in search of small molecules
that can behave locally like antibodies, i.e., that can
bind to directed protein targets with high specificity.
We are especially interested in targeting domains of
the Ras protein, in the hope of interfering with its
function. In preparation for this, we have generated
reagents and designed systems to detect the binding
between Ras and members of our libraries.
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SMALL G-PROTEINS AND SIGNAL TRANSDUCTION
L. Van Aelst M. McDonough
R. Packer
The Ras superfamily of small GTPases comprises a
group of molecular switches that regulate an aston-
ishing diversity of biological processes. In particular,
members of the Ras and Rho subfamilies are in-
volved in regulating signal transduction pathways
mediating processes such as transformation, differen-
tiation, metastasis, and cytoskeletal organization. The
molecular basis of most of these pathways remains to
be elucidated. We are interested in the mechanisms
by which Ras and Rac exert their wide variety of ac-
tivities.
The most extensively studied GTPases so far are
the Ras proteins. Cellular ras genes were found to be
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frequently activated by mutation in a wide variety of
human cancers. One major breakthrough was the
finding that the serine/threonine kinase Raf is a criti-
cal downstream target of Ras, required for Ras-
mediated transformation (Van Aelst et al., Proc. Natl.
Acad. Sci. 90: 6213 [1993]; White et al. 1995). How-
ever, it is now abundantly clear that additional func-
tions of Ras contribute to mammalian cell trans-
formation and that Raf activation is not required for
the Ras-mediated effects on morphology. One part of
our research is focused on the identification of other
Ras targets important for the Ras-mediated effects on
transformation and morphology.
The Racl proteins have moved to center stage with
recent discoveries of their involvement in morpho-
genesis, neutrophil activation, invasiveness, DNA
synthesis and transformation, transcriptional regula-
tion, and developmental processes. However, little is
known about the biochemical nature of the pathways
mediating these events and whether these pathways
are interconnected. So far, only a few Rac-interacting
proteins isolated have been shown to play a part in
Rac-mediated cellular processes. The Tiaml protein,
involved in T-cell invasion and the induction of
membrane ruffles, has recently been shown to be an
exchange factor for Rac (Michiels et al., Nature 375:
338 [1995]), and the serine/threonine kinase PAK,
which is stimulated by Rac in a GTP-dependent man-
ner, has recently been reported to be required for
JNK and p38 mitogen-activated protein kinase ac-
tivation (Bagrodia et al., J. Biol. Chem. 270: 1
[1995]; Zhang et al., J. Biol. Chem. 270: 23934
[1995]). To obtain a better understanding of Rac
function, a detailed identification and characteriza-
tion of Rac-interacting proteins will be required. We
have isolated several Rac interacting proteins and are
now in the process of further characterizing their
function.
Multiple Downstream
Effectors of Ras
L. Van Aelst
Despite the evidence that Raf is a critical downstream
effector of Ras function, we recently obtained evi-
dence that cellular transformation by Ras can be me-
diated through both Raf-dependent and -independent
pathways (in collaboration with M. Wig ler and C.
Der, University of North Carolina at Chapel Hill).
Two Ras effector domain mutants, Ras (12V,37G)
and Ras (12V,40C), which were defective for Raf
binding and activation, induced potent tumorigenic
transformation of some strains of NIH-3T3. These
Ras mutants induced a transformed morphology that
was similar to that induced by activated Rac proteins
(Khosravi-Far et al., Mol. Cell. Biol., in press
[1996]). The identity of these Raf-independent path-
ways has not been established. Recently, evidence
has been provided that Raf activation is not required
for the Ras-mediated effects on morphology (Joneson
et al., Science 271: 810 [1996]). This Raf-indepen-
dent pathway remains to be defined as well. Several
potential Ras effectors have been identified by us
using the two-hybrid system (Van Aelst et al. 1995).
Among these were RaIGDS, a global homolog of
RaIGDS, and a protein called AF6. AF6 has been
previously described in a single example as a fusion
partner for ALL1 in acute lymphoblastic leukemias
(Prasad et al., Cancer Res. 53: 5624 [1993]). The car-
boxyl terminus of AF6 shows homology with the tail
domain of myosin-1 isoform from yeast and myosin
heavy chain from D. discoideum. AF6 shows homol-
ogy with the GLGF repeat within this region. Inter-
estingly, AF6 is so far the only identified Ras-binding
protein able to interact with the Ras (12V,40C)
mutant. We are currently testing whether AF6 has a
role in Ras-mediated effects on transformation or
morphology using transfection and microinjection as-
says.
Regulators and Effectors
of Rac Function
M. McDonough, R. Packer, L. Van Aelst
We employed the yeast two-hybrid system to identify
Rac-binding proteins and to analyze interactions be-
tween Rac and previous identified and novel Rac-
binding proteins. To date, three classes of specific,
positive clones have been obtained. One class was
composed of a number of related library plasmids, all
of which encoded fusions between the GAL4 activa-
tion domain and a previously identified protein, D4.
This protein is 67% identical to the bovine rhoGDt
(GDP-dissociation inhibitor) protein and has been
shown to have GDI activity against Cdc42Hs and
Rac proteins in vitro (Adra et al., Genes Chromo-
somes Cancer 8: 253 [1993]). A second class of posi-
tive clones consisted of multiple isolates of plasmids
encoding fusions between the GAL4 activation
domain and a previously unknown protein. We called
this protein POR1 for partner of Racl (see below). In
collaboration with T. Joneson and D. Bar-Sagi
(SUNY, Stony Brook), we further analyzed the func-
tion of this protein (Van Aelst et al., EMBO J. in
press [1996]). We demonstrated that POR1 binds
directly to Racl in a GTP-dependent manner and that
a mutation in the Racl effector binding loop shown
to abolish membrane ruffling also abolishes interac-
tion with PORT.
79
Truncated versions of PORI inhibit the induction
of membrane ruffling by an activated mutant of Racl,
V12Racl, in quiescent rat embryonic fibroblast
REF52 cells. Furthermore, PORI synergizes with an
activated mutant of Ras, V12Ras, in their induction
of membrane ruffling. These results suggest a poten-
tial role for PORT in signaling events that lead to
membrane ruffling. The third class of positive clones
was represented by a single isolate. This library plas-
mid contained a cDNA insert of 500 bp, and se-
quence analysis also showed it to be a previously
unidentified gene. We recently obtained the full-
length gene and are presently further investigating
this clone.
To dissect further the physiological roles of Racl
and its interacting proteins, we are applying the two-
hybrid system to identify mutant Racl proteins that
show differential impairment of their ability to bind
to distinct Racl-interacting proteins, and we are test-
ing for the altered activity of these Racl mutants. To
date, four groups of Rac mutants have been obtained
that possess different binding profiles toward the fol-
lowing Racl-interacting proteins tested: PAK3, D4,
PORI, and POR2. We are currently testing the ac-
tivity profiles of these Racl mutants. These studies
will be very useful in defining which pathways con-
CANCER GENETICS
N. Lisitsyn N. Lisitsina
We are interested in the discovery of critical genes,
disrupted in cancer cells by various types of genetic
alterations, and in understanding the biological func-
tion of these genes. Our approach to detecting DNA
changes in tumors is based on the application of a
new powerful technology for finding the differences
between genomes, developed in M. Wigler's lab here
at the laboratory (Lisitsyn et al., Science 259: 946
[1993]). This year, our efforts have been focused on
finding and physical mapping of homozygous dele-
tions in DNA of colon and kidney tumors. We have
sought to identify new tumor suppressor genes en-
coded in deleted regions by positional cloning and
mutational analysis of candidate genes.
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tribute to certain processes such as transformation
and invasiveness.
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Identification and Physical Mapping
of Homozygous Deletions in
Colon and Kidney Tumors
N. Lisitsina, N. Lisitsyn [in collaboration with R. Lucito
and M. Wigler, Cold Spring Harbor Laboratory]
We have continued our extensive search for homo-
zygous DNA losses in kidney and colon cancer cell
lines and biopsies, using a new powerful technology
for finding the differences between the genomes,
called RDA (representational difference analysis).
This year, one new probe detecting homozygous loss
in a kidney cancer cell line has been discovered and
mapped to the 9q34 locus by fluorescence in situ
hybridization (in collaboration with D. Esposito,
CSHL).
Construction of cosmid/PAC contigs spanning the
regions of homozygous loss (200 kb long each) has
been completed for two previously identified homo-
zygous deletions located on chromosomes 3p14 and
20p11 and is under way for two deletions located on
chromosomes 9q34 and 11p15. Rapid construction of
contigs has been achieved by subtraction of yeast
DNA from YAC clones, selected with original RDA
probes, and cloning of sequence-tagged sites (STSs)
from difference products. These STSs have been se-
quenced and used for polymerase chain reaction
(PCR) search of overlapping P1 and PAC clones.
We have tested for the presence of several STSs
from each deleted region in a collection of DNAs iso-
lated from more than 100 cancer cell lines. Although
all four regions are known to suffer frequent losses of
heterozygosity in many types of tumors, frequent
homozygous losses have been detected only in the
chromosome 3p14 and chromosome 20p11 regions,
mainly in cell lines established from cancers of the
digestive tract. These studies may lead us to the dis-
covery of new genes and genetic pathways that have
an important role in regulation of growth, differentia-
tion, genomic stability, and other cellular processes.
Analysis of mutations inactivating these genes may
provide useful information for the development of
new efficient diagnostic and prognostic markers of
cancer.
Positional Cloning of a Potential
Tumor Suppressor Gene from the
3p14 Region
N. Lisitsina, N. Lisitsyn [in collaboration with
S. Thiagalingam and B. Vogelstein, The Johns Hopkins
Oncology Center, and M. Hamaguchi, R. McCombie,
and M. Wig ler, Cold Spring Harbor Laboratory]
We have identified the genomic region, frequently
deleted in tumors of the digestive tract, and con-
structed a cosmid/PAC contig spanning the region of
common loss. Based on the absence of the micro-
satellite instability phenotype in most colon cancer
cell lines with homozygous losses in the region, a
potential tumor suppressor gene has been proven to
be different from the mutL gene homolog (a gene
altered in patients with hereditary nonpolyposis colon
cancer, which is located in the same place).
We have made an attempt to clone candidate genes
from the region by cDNA subtraction approach
(RNA RDA). cDNAs prepared from five tumor cell
lines with homozygous deletions of the 3p14 locus
have been pooled and taken in large excess for sub-
traction of cDNAs isolated from two cell lines that
have at least one genomic copy of the locus. Ob-
tained difference products have been found to be
derived from irrelevant tumor-specific messages lo-
cated outside of the locus.
Overlapping cosmid and PAC clones, spanning the
region of homozygous loss, have been used for the
search of transcribed sequences by hybrid selection
and exon trapping methodologies. The sequence of
the central cosmid from the region of most frequent
losses has been determined and searched for the
presence of potential exons using the GRAIL pro-
gram. Expression of four potential exons has been
detected in colon and stomach cells, and sequences of
these exons have been used for cloning of full-length
cDNAs by library screening and RACE (rapid
amplification of cDNA ends). Full-length cDNA of
one candidate gene has been constructed, but further
analysis has ruled out this gene from the list of candi-
dates. Cloning and mutational analysis of three other
cDNAs are under way. We hope that these studies
will lead us to the cloning and characterization of one
of the most frequently mutated genes in human can-
cer.
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PROTEIN TYROSINE PHOSPHATASES AND THE CONTROL OF
CELLULAR SIGNALING RESPONSES
N.K. Tonks A.M. Bennett
M.A. Daddario
R.L. Del Vecchio
A.J. Flint
A.J. Garton
M.J. Gutch
Y.F. Hu
K.R. La Montagne
The phosphorylation of tyrosyl residues in proteins is
a key component of the regulation of signaling path-
ways that control many fundamental physiological
processes. Our lab is particularly interested in the role
of tyrosine phosphorylation in transducing an extra-
cellular signal into an intracellular response, such as
proliferation or differentiation. Protein phosphory-
lation is a reversible, dynamic process in which the
net level of phosphate observed in a target substrate
reflects not only the activity of the kinases that
phosphorylate it, but also the competing action of
protein phosphatases that catalyze the dephosphoryla-
tion reaction. We study the expanding family of pro-
tein tyrosine phosphatases (PTPs) which, like the
kinases, comprise both transmembrane, receptor-
linked forms and nontransmembrane, cytosolic spec-
ies and represent a major family of signaling en-
zymes. The structures of the PTPs indicate important
roles in the control of key cellular functions. We are
utilizing a variety of strategies to characterize the
normal physiological function of several members of
the PTP family.
During the last year, Sue Brady-Kalnay and Hong
Sun completed their postdoctoral studies and took up
faculty positions at Case Western and Yale, respec-
tively. We were joined by Anton Bennett and Tony
Tiganis as postdoctoral fellows.
Identification of PTP
Substrates
A.J. Flint, A.J. Garton, K.R. La Montagne
[in collaboration with David Barford, Oxford
University, United Kingdom]
Crystal Structure of PTP1B: In collaboration with
David Barford, we determined the crystal structure of
the catalytic domain of PTPIB. In 1995, we extended
this analysis by determining the structure of PTPIB
complexed with a high-affinity peptide substrate
representing an autophosphorylation site of the epi-
82
S.N. Mamajiwalla
A.A. Samatar
T. Tiganis
S.H. Zhang
dermal growth factor receptor. We observed that pep-
tide binding to the protein was accompanied by a
large conformational change in a surface loop at one
end of the substrate-binding cleft, which created a
recognition pocket that surrounded the phospho-
tyrosine in the substrate. In fact, PTP1B represents an
example of Koshland's concept of "induced fit" -
substrate binding induces a conformational change
that creates the catalytically competent form of the
enzyme. As we initially postulated, the depth of the
pTyr-binding pocket, which at approximately 9 A ex-
actly matches the length of a pTyr residue, is a major
determinant of specificity for phosphotyrosine. An-
other determinant of specificity is the presence of
nonpolar side chains lining the cleft that form
hydrophobic interactions with the phenyl ring of the
pTyr residue. Engagement of pTyr by the binding
pocket anchors the peptide to the peptide-binding
site. Hydrogen bonds between peptide main-chain
atoms and the protein contribute to binding affinity,
and specific interactions of acidic residues of the pep-
tide with basic residues on the surface of the enzyme
confer sequence specificity. However, the relatively
open structure of the peptide-binding site is con-
sistent with the ability of PTP1B to dephosphorylate
a variety of pTyr substrates.
From this structure, we were able to define a num-
ber of residues in the enzyme that were essential for
substrate recognition and catalysis. We generated a
series of point mutants in each of these residues, ex-
pressed and purified the mutant proteins, and exam-
ined the consequence of the mutation on catalytic
function. Through this approach, we have generated a
form of PTP1B that maintains a high affinity for sub-
strate but does not catalyze dephosphorylation effec-
tively. This has afforded us a unique approach to
identification of physiological substrates. Following
expression, the mutant PTP binds to its physiological
substrates in the cell but, because it is unable to
dephosphorylate the target, the mutant and substrate
become locked in a stable, "dead-end" complex. This
complex can be isolated by immunoprecipitation and
associated proteins identified by immunoblotting
with antibodies to phosphotyrosine (pTyr). In addi-
tion, immunoblotting lysates of cells expressing the
mutant PTP with antibodies to pTyr can be used to
identify proteins whose phosphorylation state is
altered as a consequence of expression of the mutant.
We have now initiated such an approach to substrate
isolation with intriguing results.
Identification of Substrates for PTP1B: Chronic
myelogenous leukemia (CML) is a clonal disorder of
the hematopoietic stem cell characterized by the
Philadelphia chromosome (Ph) in which the c-abl
proto-oncogene on chromosome 9, encoding a PTK,
becomes linked to the bcr gene on chromosome 22.
This results in the production of a fusion protein
termed p210 bcr:abl, the PTK activity of which is en-
hanced relative to c-Abl. Expression of p210 bcr:abl
produces the abnormal patterns of tyrosine phos-
phorylation that result in the dysfunctional matura-
tion of the hematopoietic stem cell that is the charac-
teristic of CML. Therefore, CML represents one of
the best defined examples in which aberrant tyrosine
phosphorylation is the underlying cause of a human
disease. We have observed that in cells expressing
p210 bcr:abl, the expression of PTP1B is enhanced
specifically severalfold. The intrinsic PTK activity of
p210 bcr:abl is essential for this effect. The changes
are specific for PTP1B and are not observed in the
closely related homolog TCPTP, which displays 74%
identity to PTP1B in its catalytic domain. Further-
more, the bcr:abl, leukemia-inducing form of the
PTK is required; v-Abl which shares the same PTK
domain does not alter PTPIB levels, neither do the
other oncogenic PTKs, such as Src, nor non-PTK on-
coproteins such as Myc that have been tested. Per-
haps most interestingly, this enhanced expression of
PTP1B has also been observed in Ph+ B lymphoid
cells derived from a CML patient, relative to Ph-
cells from the same patient. We have now been able
to show that, upon expression of the substrate-
trapping mutant form of PTP1B, we can isolate a
complex between p210 bcr:abl and the mutant
PTP1B, whereas the mutant does not trap v-Abl. Our
data suggest that PTP1B may be a specific cellular
antagonist of p210 bcr:abl function, and we are cur-
rently following this up by testing the effects of this
PTP on signal transduction and transformation events
triggered by the PTK.
We have also extended this analysis to PTP1B in
other cell systems. In COS cells, the substrate-
trapping mutant of PTP1B forms a complex with four
proteins from the spectrum of phosphotyrosyl pro-
teins in the cell. One of these is the receptor for
epidermal growth factor, which is one of the family
of ligand-activated receptor PTKs. One of the others,
p70, appears to be a substrate for the Src PTK, since
its phosphorylation state is enhanced in cells express-
ing the v-Src oncogenic PTK. We believe that these
phosphotyrosyl proteins are bona fide substrates of
PTP1B because other phosphotyrosyl proteins in the
cell do not form stable complexes with the mutant
and because the association is disrupted by the active
site-directed inhibitor, vanadate. We are currently ex-
amining which of the sites of tyrosine phosphoryla-
tion in the EGF receptor are recognized by PTPIB in
order to understand further the part played by PTP1B
in controlling cellular responses to EGF.
Identification of Substrates for PTP-PEST: Ini-
tial studies with the cytoplasmic enzyme PTP-PEST
also appear exciting. Following pervanadate treat-
ment of He La cells, to inhibit PTP activity and there-
by enhance phosphotyrosine levels in intracellular
proteins, 50-100 pTyr proteins, i.e., potential PTP
substrates, can be recovered. Upon treatment of the
resultant lysate with PTP-PEST in vitro, we observed
selective dephosphorylation of a 130-kD protein,
p130. Furthermore, the substrate-trapping mutant of
PTP-PEST was found to be capable of forming a
stable complex with p130 exclusively. We have now
identified this protein as p130Cas, which has an in-
tegral role in signaling events initiated by the v-Src
and v-Crk oncoproteins. We are now investigating
links between the dephosphorylation of p130Cas by
PTP-PEST and the control of cell growth.
These examples illustrate the power of this unique
approach to identification of physiological substrates
and thus to providing insights into the physiological
function of members of the PTP family. We are now
expanding this technology to identify physiological
substrates for a variety of receptor and cytoplasmic
PTPs currently being studied in the lab.
Identification of Regulators
of PTP Function
A.M. Bennett, R.L. Del Vecchio, Y.F. Hu, S.N. Mamajiwalla,
A.A. Samatar, T. Tiganis, S.H. Zhang
In general, the structure of PTPs can be described in
terms of a conserved catalytic domain to which is
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fused on either the amino- or carboxy-terminal side a
noncatalytic segment that serves a regulatory func-
tion and can be used to distinguish individual PTPs.
It is now apparent that PTPs are regulated at multiple
levels.
Receptor PTPs and Cell:Cell Contact: For the
receptor PTPs, the noncatalytic, extracellular seg-
ments present the potential for regulation of activity
by ligand binding. Although we and others have
begun to define potential ligands for these enzymes,
there are currently no examples in which engagement
of the extracellular segment of a receptor PTP alters
the activity of the intracellular catalytic segment. In-
stead, control of activity through control of sub-
cellular distribution is an important theme that ap-
pears to underlie regulation of PTP function. We
have characterized a receptor PTP, PTPR, which pos-
sesses an extracellular segment that has homology
with the immunoglobulin superfamily of cell adhe-
sion molecules, and have shown that it takes part in
homophilic binding interactions, i.e., the extracellular
DESTABILIZES ADHESION
Phosphorylated
cadherin/catenin
complex
segment of PT1.1 on one cell binds to the ex-
tracellular segment of PTPR on the surface of an ad-
jacent cell. In addition, through a portion of its in-
tracellular segment, it interacts with a distinct family
of cell adhesion molecules, the cadherin/catenin com-
plex. This association targets PTPR to specialized
points of cell:cell contact termed adherens junctions
at which it appears to regulate the adhesive and sig-
naling function of the cadherins. This observation is
provocative because tyrosine phosphorylation of the
cadherin/catenin complex has been observed under a
variety of physiological conditions potentially con-
tributing to transformation and metastasis. It appears
that PTPµ may provide the regulatory balance to this
phosphorylation event, thus maintaining the cad-
herin/catenin complex in its functional, dephosphory-
lated state (Fig. 1).
A second mechanism of control that we have ob-
served involving another broadly expressed receptor
PTP, DEP-1, is modulation of the level of PTP
protein. The most striking property of this enzyme is
that its expression is increased dramatically in dense
1 DP siP
PTPp
PROMOTES ADHESION
Dephosphorylated
cadherin/ catenin
complex
FIGURE 1 Schematic representation of the effects of tyrosine phosphorylation on the cadherins and
the role of PTIPIA in regulation of adhesion. Tyrosine phosphorylation of cadherins and catenins
(mediated by PTKs, such as possibly the EGF receptor) reduces adhesion. This event is opposed by
the activity of PTPs, such as PTIPp., which would promote adhesiveness by maintaining cadherins in
a functional dephosphorylated state. a, p, y represent a, 13, y catenin. (Reproduced from Brady-
Kalnay and Tonks, Curr. Opin. Cell Biol. 7: 650-657 [19951.)
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relative to sparse cell cultures, hence the name
Density Enhanced PTP-1. Thus, as cells approach
confluence and adjacent cells begin to touch each
other, surface expression of DEP -1 is enhanced.
These observations suggest that DEP-1, and possibly
PTP[t, may be important contributors to the mechan-
ism of contact inhibition of cell growth. As normal
cells reach confluence and make contact, they stop
growing; however, in cancer cells this growth inhibi-
tion is disrupted. Since tyrosine phosphorylation has
been implicated in promoting cell growth, PTPs as
the natural antagonists of PTK function may exert a
negative effect on growth-promoting signals by trig-
gering net dephosphorylation of proteins in the mem-
brane. Thus, receptor PTPs may be able to sense
directly cell:cell contact. Engagement of their ex-
tracellular segments may either modulate activity
directly or target the enzyme to specific junctional
complexes so as to trigger dephosphorylation of a
defined subset of pTyr proteins and initiate the
growth inhibitory response. We are currently trying
to define the important substrates of the receptor
PTPs in this process and characterize how complex
formation between PTPIA and the cadherins is regu-
lated.
Regulation of Cytoplasmic PTPs: This concept of
control of activity through control of subcellular loca-
tion also applies to the cytoplasmic PTPs. For exam-
ple, we have identified two Xenopus cytoplasmic en-
zymes, PTPX1 and PTPX10, which are characterized
by amino-terminal segments that have homology
with lipid-binding proteins and which are found asso-
ciated with intracellular membranes. In brain, these
PTPs associate with synaptic vesicles, suggesting a
role in control of synaptic function. The enzymes
SHPTP-1 and SHPTP-2 are characterized by the
presence of SH2 domains in their amino-terminal
segments. These are domains of 100 residues that
bind to phosphotyrosine residues in defined primary
sequence contexts and direct the association of these
PTPs with specific sites of tyrosine phosphorylation
in growth factor and cytokine receptors. Thus,
SHPTP-1 and SHPTP-2 are targeted to signaling
complexes in the plasma membrane. Although there
are some examples, such as these, where the structure
of the enzyme immediately suggests where it is
targeted and the other proteins with which it interacts,
in most cases, the binding partners have to be identi-
fied in order to characterize this regulatory feature.
We are taking an approach involving a combination
of classic protein purification techniques and
molecular biology, in particular the 2 hybrid screen in
yeast. Interesting observations are now beginning to
emerge.
The enzyme TCPTP, which is closely related to
PTPIB, occurs in two forms generated by alternative
splicing. In one form, p48TC, the noncatalytic seg-
ment terminates in a hydrophobic patch that targets
the enzyme to ER membranes. We have identified a
120-kD protein that binds to this form of TCPTP spe-
cifically and thus may control that particular targeting
function. We are in the process of characterizing this
protein. The second form lacks the hydrophobic
patch and is targeted to nuclei. We have identified a
complex between this form of the PTP, p45TC, and
the nuclear import factor p97. In addition, 2 hybrid
screens have detected an interaction between p45TC
and the nuclear import factor karyopherin a. We
have also defined the sequences within the non-
catalytic segment of p45TC that are essential for
binding. This may allow us to interfere specifically
with the ability of this enzyme to get to the nucleus.
We can examine the consequences of disrupting
translocation of p45TC to the nucleus on pTyr levels
in nuclear proteins and try to correlate such changes
with effects on cell function. In conjunction with the
substrate trapping technology, this should provide
important information on the cellular targets of
TCPTP and thus its physiological function. A number
of potential targets spring to mind, in particular the
STAT family of transcription factors that are crucial
mediators of the cellular response to cytokines and
growth factors.
A second example is an enzyme, PTPH1, first
characterized in my lab, that features a long non-
catalytic amino-terminal segment that displays fea-
tures of proteins that associate with the cytoskeleton.
We have shown that this segment associates in vivo
with a protein termed 14-3-3, which has been demon-
strated to play a crucial part as a scaffold upon which
signal transduction complexes are formed. In addi-
tion, enzymatic characterization of PTPH1 in vitro
reveals that this noncatalytic segment acts as an
autoinhibitory domain and directly modulates cataly-
tic activity. We are currently looking for binding
proteins that may relieve this autoinhibition. We hope
that these approaches will provide insights into
potential roles of PTPH1 in controlling signaling
events triggered by changes in the cytosketetal ar-
chitecture.
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Once again, we are expanding the scope of such
analyses to encompass other members of the PTP
family. As the examples illustrate, by gaining an
understanding of the regulatory proteins with which
a PTP interacts and its location within the cell, we
can accrue important insights into physiological func-
tion.
Dual Specificity Phosphatases and Growth Con-
trol: We are focusing on MKP-1 which is the product
of an immediate early gene, the expression of which
is induced rapidly following a variety of cell stimuli.
We have defined its point of action in vivo as being
the dephosporylation and inactivation of MAP
kinases. The MAP kinases have been implicated as
common and essential components of signaling path-
ways induced by diverse stimuli, suggesting that
MKP-1 will be a crucial, central player in the control
of cell function. As well as dephosphorylating MAP
kinase, it appears that MKP-1 may be a substrate for
MAP kinase.
We are currently characterizing the potential
regulatory significance of this dynamic interplay be-
tween the kinase and the phosphatase. In addition, we
are using MKP-1 as a tool to study the role of MAP
kinases in model systems for cell growth and differ-
entiation.
Characterization of Function
through Analysis of Gene
Disruption
M.J. Gutch
A variety of model systems can be used for a genetic
approach to analysis of PTP function. The model sys-
tem that we are using is the nematode Caenorhabditis
elegans, and the experiments are being performed in
collaboration with Michael Hengartner's lab here at
Cold Spring Harbor. An attractive feature of C.
elegans is that many of the properties of its signaling
pathways are conserved with those found in mam-
mals. Thus, the lessons learned in C. elegans should
be applicable to humans.
The strategy for this approach is first to perform
gene knockouts of PTPs in the nematode. Should the
PTP be an important regulator of a signal transduc-
tion pathway, then its elimination would be likely to
result in a mutant phenotype. This alone may provide
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information with respect to the specific signaling
pathway that the PTP is regulating. Moreover, the
analysis can be refined by chemical mutagenesis of
the PTP mutant nematodes to identify enhancers or
suppressors of the knockout phenotype. Mapping of
these enhancers or suppressors may also help to iden-
tify potential substrates of PTP. Our efforts are cur-
rently focused on two PTPs that have human
homologs; one contains SH2 domains and appears to
be a homolog of SHPTP-2 and the other, similar to
PTPH1, contains a band-4.1 domain found in
cytoskeleton-associated proteins. Currently, we have
created knockout strains for both PTPs and are char-
acterizing the mutant phenotypes.
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MOLECULAR CELL BIOLOGY
D.M. Helfman C. Chen W. Guo A. Rai J. Wang
M. Gimona J.P. Liu M. Selvakumar A. Watakabe
J. Grossman M. Meyer C. Temm-Grove
Our laboratory is interested in studying the regulation
and function of genes encoding the cytoskeletal and
contractile components of eukaryotic cells. These
components have important roles in cell movements,
muscle contraction, cell division, intracellular trans-
port, and regulation of cell shape. Eukaryotic cells
contain three major filamentous systems: actin fila-
ments, intermediate filaments, and microtubules.
Each of these filamentous systems contains a number
of different protein components, although different
cell types and tissues express specific protein
isoforms which comprise these structures. In particu-
lar, we have been interested in understanding the
regulation and function of tropomyosin (TM) gene
expression in muscle and nonmuscle cells. TMs are a
diverse group of actin-binding proteins with distinct
isoforms present in striated muscle (skeletal and car-
diac), smooth muscle, and nonmuscle cells. We now
know that at least 16 different TM isoforms are ex-
pressed from four separate genes in vertebrates by a
combination of alternative RNA splicing and alterna-
tive promoter usage. The research in our laboratory is
focused on two related problems in molecular and
cell biology: (1) the mechanisms responsible for the
generation of tissue-specific and developmentally
regulated patterns of alternative RNA splicing and (2)
the functions that the different isoforms of TM have
in various cell types.
During the year, two members of our group moved
on to new positions. Wei Guo has taken a postdoc-
toral position at The Scripps Research Institute, La
Jolla, California, and Constance Temm-Grove has
taken a faculty position at the University of Arizona,
Tucson. Below is a summary of our studies during
the past year.
Regulation of a Muscle-specific
Exon 0-TM in Pre-mRNA
Y.-C. Wang, J.P. Cu
We have been using the rat 13-tropomyosin (13-TM)
gene as a model system to study the mechanism of
alternative splicing. The rat 13-TM gene spans 10 kb
with 11 exons and encodes two isoforms, namely,
skeletal muscle (3 -TM and fibroblast TM-1. Exons
1-5, 8, and 9 are common to both mRNAs expressed
from this gene. Exons 6 and 11 are used in fibro-
blasts, as well as in smooth muscle cells, whereas ex-
ons 7 and 10 are used exclusively in skeletal muscle
cells. Previous studies suggested that the splicing of
exons 5-7 (skeletal muscle-type splice) is suppressed
in He La (nonmuscle) cells by a negative factor. We
have been developing an in vitro splicing system
from the mouse BC3H1 myogenic cell line in order
to understand the regulation of the splicing of 3 -TM
pre-mRNA in skeletal muscle cells. Using a com-
plementation assay of the BC3H1 nuclear extract or
its fractions added to the human 293 nonmuscle cell
nuclear extract, we have identified an activity in the
BC3H1 nuclear extracts that promotes the splicing of
exons 5-7. Efforts are under way to purify the fac-
tor(s) responsible for this activity.
Previous studies in vitro and in vivo suggest that
the critical cis-acting elements involved in the sup-
pression of the 3' splice site of exon 7 in nonmuscle
cells appear to be located in the 3' end of intron 6 and
the 5' end of exon 7. Transient expression in HeLa
cells of a chimeric minigene containing exon 7 and
its flanking intron sequences of [3-TM inserted be-
tween two adenovirus exons resulted in an RNA
splice product excluding exon 7. When the critical
cis-acting elements in intron 6 mentioned above were
mutated, exon 7 was then included in the splice prod-
uct, suggesting that the sequences in intron 6 through
exon 7 and part of intron 7 contain sufficient infor-
mation for the suppression of exon 7 in nonmuscle
cells (Guo and Helfman, Nucleic Acids Res. 21: 4792
[1993]). Similar results were obtained when the same
constructs were transfected into mouse NIH-3T3
fibroblasts. When the chimeric minigene was trans-
fected into myogenic cells, exon 7 was also excluded
from the spliced RNA product. These results suggest
that additional sequences are required for muscle-
specific splicing. We are now carrying out more in
vivo studies to identify the cis-acting elements re-
quired for use of exon 7 in muscle cells.
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A Multiprotein Complex Assembles
on the Cis-acting Sequences
Involved in Alternative
Splicing of it -TM Pre-mRNA
J. Grossman, M. Meyer
In previous studies, we identified one protein, the
polypyrimidine-tract-binding protein (PTB), that spe-
cifically interacted with sequences upstream of exon
7 that are involved in alternative splicing of (3-TM
pre-mRNA. To identify additional proteins that inter-
act with sequences within the pre-mRNA, [35S]me-
thionine-labeled nuclear extracts from He La cells
were mixed with nonbiotinylated RNAs, and the
RNA-protein complexes were recovered by im-
munoprecipitation using monoclonal antibodies to
PTB. The same protein patterns were observed using
biotinylated-RNA containing intron 6 and recovering
the RNA-protein complexes using streptavidin-
agarose beads. In addition to PTB, a novel set of
proteins were found to assemble and coprecipitate on
intron 6. Analysis of the proteins that assembled on
introns 5, 6, or 7 using biotin-RNA revealed a unique
set of proteins that interact with each of these se-
quences, indicating that different heterogeneous
nuclear RNP (hnRNP) proteins are bound to different
regions of the pre-mRNA. Comparison of the
proteins that assemble on introns from the a- and
TM genes which utilize distant branch points
revealed a common set of proteins that bound to these
introns. These studies identified a set of proteins, in
addition to PTB, that are likely involved in the use of
distant branch sites. In addition, experiments are in
progress to study the interaction of proteins obtained
from myogenic cells in order to identify cell-type-
specific factors that interact with distinct regions in
the (3-TM pre-mRNA.
Role of Exon Sequences
in Splice Site Selection
M. Selvakumar
In vitro studies using the 13-TM gene to study the
alternative splicing of exon 6 (nonmuscle/smooth
muscle-type splice) revealed that exons 5 and 6 can
be spliced together only if (1) a previous splicing
event joins exon 6 to 8 or (2) there is a poly(U) sub-
stitution in the intron upstream of the 3' splice site of
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exon 6. Thus, both intron and exon sequences can
contribute important cis-acting elements. Studies in
other systems have identified purine-rich motifs as
important sequence elements in exons. Such so-called
exonic enhancers are believed to act as binding sites
for cellular factors such as SR proteins. Examination
of sequences within exons 6 and 8 of the I3-TM gene
revealed the presence of several such motifs. Muta-
tional analyses indicate that some of these motifs are
essential for pre-mRNA splicing
When pre-mRNAs containing multiple exons and
introns (exons 5 through 8) are used, the major splice
product detected in vitro is exon skipping (splicing of
exon 5 to exon 8). However, exon 6 is included if a
poly(U) tract is included upstream of exon 6. Inter-
estingly, mutating the two purine-rich motifs in exon
6 resulted in exon skipping with this pre-mRNA.
Thus, sequences within exon 6 are required for
cooperation of the 3' and 5 ' splice sites flanking exon
6. RNA-binding assays are under way to identify fac-
tors that interact with these sequence elements. To
further characterize these mutations in an in vivo
context, experiments are under way using transient
transfection assays of minigenes in HeLa cells.
Preliminary data indicate that these purine-rich ele-
ments are essential in vivo.
Cis-elements That Block the Use
of a Skeletal Muscle-specific
Exon 7 in Nonmuscle Cells
C. Chen
In previous studies, we localized the critical elements
for preventing the use of exon 7 in nonmuscle cells to
sequences within exon 7 and the adjacent upstream
intron. We have constructed a number of pre-mRNAs
to better understand how mutations within these ele-
ments contribute to activation of the muscle-specific
exon in a nonmuscle environment. Two questions
were addressed: (1) How do mutations in exon 7 ac-
tivate the use of this exon in nonmuscle cells and (2)
can the 3 ' splice site of exon 7 be used when other
exons are substituted? To address the first question,
we took advantage of our observation that exon 5
cannot be spliced to exon 6 unless it is first spliced to
exon 8 (see above section). Pre-mRNAs containing
exon 5, intron 5, and exon 7 were also unable to be
spliced in vitro. In contrast, introduction of a mutated
exon 7 (Ex-1 mutation), which we previously demon-
strated leads to activation of the skeletal muscle exon
in nonmuscle cells in vivo, was now efficiently
spliced. Work is in progress to determine if the exon
mutation functions by alterations in RNA secondary
structure or by providing a binding site for a splicing
factor. In a second series of experiments, we studied
the 3' splice of exon 7 in its normal context. We have
shown that a pre-mRNA containing exon 5/intron 6/
exon 6/intron 6/exon 7 + exon 8 is spliced inefficient-
ly in vitro. Interestingly, substitution of exons 7+8
with sequences containing exons 6+8 leads to strong
activation of this 3' splice site. Thus, even in the
presence of the upstream elements previously shown
to inhibit the use of exon 7 in nonmuscle cells, the
presence of exon sequences containing a strong ex-
onic enhancer (see previous section) was able to lead
to efficient use of this 3' splice site. These results fur-
ther demonstrate that alternative splicing of exon 7
(skeletal muscle-specific splice) is regulated, in part,
by sequences within exon 7.
Stable Expression of
Epitope-tagged TMs
in REF52 Fibroblasts
M. Gimona
Rat fibroblasts express at least seven different iso-
forms of tropomyosin. To investigate the in vivo
utilization of the individual TM subunits, we epitope-
tagged a variety of rat muscle and nonmuscle TM
isoforms at their amino-terminal ends, cloned them
into mammalian expression vectors, and used these
constructs to transfect REF52 fibroblasts. The
isoforms containing a tag appear to be fully func-
tional in in vitro actin-binding experiments, retain
their ability to form dimers in vitro and in vivo, and
are able to incorporate in actin filaments in a fashion
indistinguishable from endogenous TM (Gimona et
al. 1995). We have now established stable cell lines
expressing various TM isoforms including fibroblast
FIGURE 1 Stable expression of epitope-tagged rat fibroblast TM-5 and skeletal muscle
--no in
REF52 cells. Cells expressing TM-5 (panels A and 8) and skeletal muscle It -TM (panels C and D)
were visualized using double-label immunofluorescence. TM-5 is found localized along actin stress
fibers as well as at the cell periphery (double arrows in panels A and 8). In contrast, the skeletal
muscle 0-TM is absent from membrane protrusions like lamellipodia (arrow in panels C and D). The
cells were double stained with anti-Ha antibody to visualize the epitope-tagged TM using GaM-FITC
(panels B and D) or with phalloidin-rhodamine to demonstrate the localization of F-actin (panels A
and C).
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TM-1, -2, -4, -5, -5a, or -5b; smooth muscle ot-TM;
and skeletal muscle a- or B-TM. The epitope tag
residing on each exogenous TM isoform allows us to
determine the cellular localization of specific TM
isoforms in the context of the entire complement of
the endogenously expressed subunits in REF52
fibroblasts (Fig. 1). Both muscle and nonmuscle TMs
were incorporated into actin stress fiber bundles. We
are using these cells to determine the distribution of
TM isoforms in dynamic states such as cell move-
ment and cell division. We have analyzed the
localization of individual TM isoforms in membrane
protrusions and leading lamellae. We show that only
the low-molecular-weight TMs, with the exception of
TM-4, are being incorporated into the terminal actin
structures and that micro spikes (short, thin arrays of
tightly bundled actin filaments within the leading
edge of migrating cells) are devoid of TM. We fur-
ther observed that in all cases, the association of TMs
with the actin filaments gave rise to a discontinuous
staining pattern, indicating zones ranging from 0.1 to
0.4 tam on actin bundles that are devoid of TM. The
observed pattern appears to complement that recently
shown for nonmuscle myosin which is likely to be
organized in these "bare zones," suggesting a "pseu-
do-sarcomeric" organization of contractile elements
in fibroblasts. The understanding of the spatial orga-
nization of actin and myosin and the definition of the
force-producing units in nonmuscle cells are essential
for the understanding of cytoskeletal modulations oc-
curring during cell motility in nonmuscle cells.
Ca++-dependent Interactions
of S100A2 with Muscle
and Nonmuscle TMs
M. Gimona [in collaboration with Ryuji Kobayashi,
Cold Spring Harbor Laboratory, Zeev Lando, Sigma, Israel,
Joel Vandekerckhove, University of Ghent Belgium, and
Apolinary Sobieszek, Institute of Molecular Biology, Austria]
We have purified the 10-kD Ca++-binding protein
S100A2 from porcine stomach smooth muscle tissue.
Zero-length chemical cross-linking using EDC
revealed the association with muscle and nonmuscle
TMs in vitro. The cross-linked product indicated the
formation of a 1:1 complex between S100A2 and TM
and the interaction was shown to be Ca++-dependent.
Monoclonal antibodies raised against S100A2 were
used to determine its cellular localization in the por-
cine epithelial cell line LLC PK1. The localization of
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S100A2 was observed to change with the differentia-
tion state of these cells. Whereas S100A2 was found
to be absent from actin stress fibers, it became
colocalized with the actin containing microvilli upon
differentiation. Immunoprecipitation of [35S]methio-
nine-labeled extracts failed to coprecipitate TM and
S100A2, indicating a transient association between
these two molecules. Affinity chromatography of cell
extracts on immobilized recombinant TMs, however,
supported the Ca++-dependent in vitro interaction be-
tween S100A2 and both muscle and nonmuscle TMs,
suggesting that the binding site resides in one of the
regions conserved among various TM isoforms en-
coded by exons 3-5 or 7-8. Our data demonstrate the
possible interaction of S100A2 and TM in the free
form, but not with the microfilament-associated por-
tion, and indicate a differentiation-related function
for S100A2.
Low-molecular-weight Fibroblast
TM-5: Localization and Coiled-coil
Interactions
C. Temm-Grove, W. Guo
Previous studies have shown that three distinct genes
encode six isoforms of tropomyosin in rat fibroblasts:
The a gene encodes TM-2, TM-3, TM-5a, and TM-
5b; the 13 gene encodes TM-1; and the TM-4 gene en-
codes TM-4. We report here the characterization of a
cDNA clone encoding the most recent rat fibroblast
TM to be identified, herein referred to as TM-5,
which is the product of a fourth gene that is
homologous to the human hTMnm gene, herein
referred to as the rat slow-twitch a-TM gene. When
fluorescently labeled TM-5 was microinjected into
living rat fibroblasts, it localized to the stress fibers
and ruffles of the leading lamella. The coiled-coil in-
teractions of TM-5 with other low-molecular-weight
(LMW) and high-molecular-weight (HMW) TM iso-
forms were studied. TM-5 and TM-4 were capable of
dimerizing with each other as well as with other
LMW isoforms (TM-5a and TM-5b), but not with the
HMW isoforms (TM-1, TM-2, and TM-3). In addi-
tion, TM-5a and TM-5b were unable to hetero-
dimerize with each other. Since the ratio of the vari-
ous TM isoforms is not stoichiometric in a particular
tissue or cell type, it is likely that different ratios of
homodimers and heterodimers occur. How the dif-
ferent combinations of subunits will affect the rela-
tive affinity of TM for actin, head-to-tail overlap, and
interaction with other proteins remains to be
determined.
Epithelial Cells Express a
Complex Pattern of TM
Isoforms That Exhibit
Distinct Localization
C.J. Temm-Grove [in collaboration with B.M. Jockusch,
Braunschweig Technical University, Germany]
We have used antibody studies to characterize the ex-
pression and localization of TM isoforms in various
kinds of epithelia, including brush border (BB) type
(e.g., LLC-PK1, Caco-2, and primary intestinal
epithelium) and non-BB (e.g., PtK2 and NRK-52E).
Analyses using a panel of antibodies directed against
HMW and LMW TMs revealed that HMW isoforms
(TM-1, TM-2, TM-3, TM-6) were localized to stress
fibers, but not to adhesion belts, whereas the LMW
isoforms (TM5b and TM5) were found in adhesion
belts in primary BB cells and LLC-PK1 cells. These
results were confirmed using epitope-tagged con-
structs for transient transfection followed by fluores-
cence microscopy. These results demonstrate that
epithelial cells express a complex pattern of TM
isoforms, which exhibit differential localizations
within the cells and different patterns or expression
depending on the origin and stage of differentiation
of the epithelia.
Characterization of TM-binding
Proteins in Brain
A. Watakabe [in collaboration with Ryuji Kobayashi, Cold
Spring Harbor Laboratory]
We have identified and characterized two proteins
that bind to the neuron-specific tropomyosin isoform,
TMBr-3. Western blotting using antibodies against
known TM-binding proteins showed that one of them
is tropomodulin, a TM-binding protein originally
identified in erythrocytes. When we tested the ex-
tracts derived from various tissues, tropomodulin was
present in other tissues, but the other TMBr-3-
binding protein was detected only in brain. To further
characterize this protein, we have purified it using a
TMBr-3 affinity column. By microsequencing, we
obtained several peptide sequences of this protein and
we cloned its cDNA from a rat brain cDNA library.
Nucleotide sequencing revealed that this is a novel
protein. Interestingly, this protein had 60% amino
acid sequence identity to tropomodulin. Considering
its sequence identity, similar molecular weight, and
ability to bind to tropomyosin, this protein is a novel
isoform of tropomodulin. We designated this isoform
as N-tropomodulin (N-Tmod). To distinguish the two
isoforms of tropomodulin, we termed the original
isoform a E-tropomodulin (E-Tmod). We have pro-
duced recombinant N- and E-Tmods and tested their
binding to TMBr-3. As expected, both proteins bound
to TMBr-3. In addition, both Tmods bound to two
other TM isoforms expressed in brain. Thus, there are
two highly related TM-binding proteins in brain, N-
Tmods and E-Tmods.
The pattern of E-Tmod expression is quite dif-
ferent from that of N-Tmod. E-Tmod is expressed
mainly in skeletal and cardiac muscles, and also in
brain, lens, and erythrocytes. Moreover, E-Tmod ex-
pression in brain starts after birth, unlike N-Tmod.
Recent reports demonstrated that E-Tmod is a
pointed-end capping protein of F-actin and that it is
necessary for the stabilization of the sarcomeric
structure of cardiac muscle. Considering the primary
sequence homology, it is likely that N-Tmod is also
an F-actin capping protein. In developing neurons,
the formation and reorganization of cytoskeletal
structures, especially actin filaments, are in a dynam-
ic state. N-Tmod likely plays an important part in
such processes. Experiments are currently in progress
to study its function.
Identification of TM-binding
Proteins
A.J. Rai
We are focusing our efforts on the detection of
proteins that bind to tropomyosins in an attempt to
delineate isoform-specific functions. Toward this
end, we are using several approaches to identify and
characterize proteins that interact with nonmuscle
TM isoforms. One approach is a gel overlay assay.
Briefly, proteins are resolved by SDS-PAGE and
transferred to a nitrocellulose membrane. The mem-
brane is probed with purified TM and then sub-
sequently incubated with antibodies that recognize
the specific isoform of interest. In this manner,
proteins that bind to TM can be detected. We are cur-
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rently using this approach to compare TM-binding
protein in normal and transformed cells. By identify-
ing such proteins, we hope to better understand the
transformed state.
Using the gel overlay assay, we have begun to
characterize a TM-binding protein present in trans-
formed fibroblasts. These cells exhibit an altered
cytoskeleton and a rounded morphology. Previous
studies have demonstrated that one of the HMW TM
isoforms (TM-1) is absent and two LMW isoforms
(TM-4 and TM-5b) are highly elevated. Preliminary
experiments from our lab showed that forced expres-
sion of TM-1 alone was not sufficient to restore
normal cytoskeletal structure and cell shape, suggest-
ing that other factors are involved in these aspects of
the transformed phenotype. Therefore, we have
begun to determine what other factors are responsible
for alterations in actin structure. Preliminary results
suggest the presence of a protein that interacts with
both HMW (284 amino acids) and LMW (248 amino
acids) TMs, which is detected only in the transformed
cells. Experiments are currently in progress to fully
CELL BIOLOGY OF THE NUCLEUS
D.L. Spector S. Huang P. Mintz
P. Lorenz T. Howard
T. Misteli J. McCann
Studies in our laboratory are focused on the struc-
tural-functional organization of the mammalian cell
nucleus. Our research program evolves around under-
standing the nuclear organization of factors associa-
ted with pre-mRNA splicing and the RNA substrates
with which these factors interact. The microscopy
core facility has been used extensively over the past
year and numerous collaborations are under way with
the excellent technical expertise of Tamara Howard.
Visualization of the Dynamic
Nature of Pre-mRNA
Splicing Factors in the
Mammalian Cell Nucleus
T. Misteli, D.L. Spector
Pre-mRNA splicing factors are distributed non-
homogeneously in 20-40 speckles of irregular shape
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characterize this protein and determine its role in the
transformed phenotype.
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in the mammalian cell nucleus. The morphological
appearance of the speckles is highly dependent on the
transcriptional activity of the nucleus, which suggests
that the speckles are dynamic nuclear structures. To
observe directly the dynamic movements of splicing
factors in the mammalian cell nucleus, we have taken
advantage of the recently described green fluorescent
protein (GFP). GFP is an auto-fluorescent protein
from the jellyfish Aequorea victoria which when ir-
radiated with blue light emits green light without the
requirement for any cofactors. We have generated fu-
sion proteins between the essential pre-mRNA splic-
ing factors SC35 and SF2/ASF and the GFP to study
the dynamic behavior of functional compartments
within the mammalian cell nucleus during interphase
by time-lapse fluorescence microscopy. This allows
for the first time the direct visualization of move-
ments of splicing factors within the cell nucleus.
GFP-SF2/ASF fusion proteins localize to endogenous
speckles and are phosphorylated in HeLa and BHK
cells. In actively transcribing interphase nuclei, the
speckles enriched in pre-mRNA splicing factors are
relatively stationary with respect to their position in
the nucleus. In contrast, dynamic reorganizations can
be detected at the periphery of speckles. Most promi-
nently, branches of pre-mRNA splicing factors can
be seen extending into the nuclear space. These ex
tensions may represent splicing factors which are
recruited from their storage sites in the larger speck-
les (interchromatin granule clusters) to the site of
transcription of active genes (perichromatin fibrils).
We are currently testing this hypothesis by using in-
ducible gene expression systems, and we are further
investigating the nature and significance of the ob-
served movements.
Semi-Intact Cells to Study
Nuclear Organization: A Role for
Ser/Thr Phosphatase 1 in the
Distribution of Pre-mRNA
Splicing Factors
T. Misteli, D.L. Spector
The organization of pre-mRNA splicing factors in
nuclear speckles has been well characterized by fluo-
rescence and electron microscopy. However, relative-
ly little is known about the molecular mechanisms in-
volved in the organization of pre-mRNA splicing fac-
tors in nuclear speckles. One reason for this has been
the inability to manipulate freely the experimental
conditions in the nucleus. In an attempt to overcome
this problem, we have developed a semi-intact cell
system to study the organization of pre-mRNA splic-
ing factors in the nucleus. HeLa cells are permeabil-
ized with detergent, and the soluble nucleoplasmic
factors are washed away. The nuclear environment is
then reconstituted by addition of a nuclear extract
from HeLa cells (Fig. 1A). Both transcription and
DNA replication occur in the semi-intact cells. In ad-
dition, the morphological rearrangements observed in
living cells upon inhibition of transcription or in the
presence of kinase inhibitors could be reproduced in
semi-intact cells. We found that the nuclear fraction
in the absence of soluble nuclear factors did not sup-
port any change in the organization of splicing fac-
tors but that soluble factors were required for this
process (Fig. 1B). One of the required soluble factors
was identified as a member of the serine/threonine
protein phosphatase 1 family (PP1) of phosphatases
by inhibitor titration experiments and sensitivity to
inhibitor-2 (Fig. 1C). This implies an important role
for phosphorylation/dephosphorylation in the organi-
zation of pre-mRNA splicing factors and is consistent
with the identification of two kinases which specifi-
cally phosphorylate the SR-family of essential pre-
mRNA splicing factors (for review, see Fu, RNA 1:
663 [1995]). Using the semi-intact cell system and in-
tact cells, it should be possible to characterize further
+ nuclear extract + nuclear extract
+ of -amanitin
+ nuclear extract
+ -amanitin
+ Inhibitor-2
FIGURE 1 Semi-intact cells show a typical speckled distribution pattern of splicing factors in the
presence of nuclear extract (A). Nuclear extract is required for the observed rounding up of nuclear
speckles after a-amanitin treatment (B). Inhibitor-2 prevents the rounding up of speckles, demonstrat-
ing a role for PP1 in the distribution of splicing factors (C). Bar, 10 gm.
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the role of phosphatases and kinases in the organiza-
tion of pre-mRNA splicing factors and to identify
other factors that have a role in the organization of
splicing factors in nuclear speckles.
Differential Localization of
Polypyrimidine Track-binding
Protein
S. Huang, D.L. Spector [in collaboration with
M. Ellisman and T. Deerinck, UCSD Microscopy
and Imaging Resource]
Polypyrimidine track-binding protein (PTB), also
known as the hnRNP I protein, has been character-
ized as an RNA-binding protein that forms a complex
with nascent RNA transcripts and is involved in
alternative splice site selection. Using a monoclonal
antibody that specifically recognizes PTB, we have
found that PTB shows a differential localization pat-
tern among different cell types. In primary human
fibroblast cell lines, such as Detroit 551 and WI-38,
PTB is localized in a diffuse nuclear pattern. How-
ever, when several transformed cell lines were exam-
ined, such as He La and 293 cells, PTB was found to
be localized in a half-moon-shaped cap on the surface
of the nucleoli in addition to being diffusely distrib-
uted throughout the nucleoplasm. Occasionally, a
portion of the cap appeared to extend into the
nucleoli. The percentage of transformed cells exhibi-
ting such a phenotype varied among different cell
lines. The number of caps within each nucleus ranged
from one to three. The presence of these structures
appears to be inherited as these structures are always
present in both daughter cells after cell division and
in small clonal populations of He La cells. In addition
to PTB, RNase P RNA, a small RNA involved in the
processing of tRNA, was also found in these cap
structures (Matera et al., J. Cell Biol. 129: 1181
[1995]). The presence of these structures in trans-
formed cells may be related to the altered physiology
of the cancer cell. However, their absence in primary
cells suggests that they are not required for funda-
mental cellular functions.
To understand further the structural characteristics
of this nuclear component, we have examined the
PTB-containing nucleolar cap at the electron micro-
scopic level using a recently developed photo-
oxidation method. This method allows for a direct
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correlation of the fluorescent and electron micro-
scopic images and results in excellent cellular preser-
vation. We have found that the PTB protein cap is
closely associated with the surface of the nucleolus.
The surface of the cap structure appears irregular in
shape, and a clearly defined boundary around the cap
structure was not observed. More interestingly, a
plate-like structure was observed between the nucleo-
lus and the PTB protein cap. This structure appears to
contain an array of short fibrils connecting the sur-
face of the nucleolus and the PTB protein cap.
Studies are currently under way to decipher the three-
dimensional organization of this site of interaction
between the nucleolus and the cap structure.
Visualization of Subdomains
within Nuclear Speckles
Enriched in Pre-mRNA
Splicing Factors
P. Mintz, D.L. Spector
We are interested in the functional and structural or-
ganization of pre-mRNA splicing factors in the mam-
malian nucleus. Immunofluorescence studies using
antibodies against pre-mRNA splicing factors have
revealed a speckled pattern and diffuse nucleoplas-
mic labeling in the mammalian nucleus. In addition,
nonsplicing factors such as poly(A)-binding protein
II (Krause et al., Exp. Cell Res. 214: 75 [1994]) and a
hyperphosphorylated form of RNA polymerase II
(Bregman et al., J. Cell Biol. 129: 287 [1995]) have
also been localized in a speckled pattern in the mam-
malian cell nucleus. Although the speckled regions
appear to contain many different factors when exam-
ined by standard immunofluorescence microscopy,
each speckle appears to be homogeneously labeled
for a particular factor. No information is available
with regard to the sublocalization of specific splicing
factors within speckles. Since it is possible that splic-
ing factors are further compartmentalized in these
regions, we have re-examined their distribution in
speckles by confocal laser scanning microscopy
using serial dilutions of antibodies against specific
factors. We have found that splicing factors are fur-
ther compartmentalized into numerous subunits with-
in a speckle that are heterogeneous in size and aver-
age between 0.2 vm and 0.4 gin in diameter (Fig. 2).
We have termed these components subspeckles. Sub-
FIGURE 2 Optical section showing the distribution of the U2 snRNP B' protein in
subspeckles. Note that in places loops and strings of subspeckles can be ob-
served.
speckles were also observed to be diffusely distrib-
uted throughout the nucleoplasm. In some cases,
strings and loops of subspeckles were observed to ex-
tend from the highly dense speckled regions. Upon
inhibition of RNA polymerase II transcription, the
strings and loops of subspeckles were no longer ob-
served. Subspeckles were also not observed in coiled
bodies.
To examine the functionality of these nuclear sub-
structures, we are currently evaluating their associa-
tion with sites of transcription of transiently ex-
pressed intron-containing transcripts.
Cell Biology of Antisense
Oligonucleotides
P. Lorenz, D.L. Spector [in collaboration with
C.F. Bennett, ISIS Pharmaceuticals]
Antisense oligonucleotides can be valuable tools to
inhibit specifically the expression of a target gene.
Their specific action is based on their ability to
hybridize to complementary regions in the target
RNA(s). Several mechanisms of action for antisense
molecules have been proposed, including interfering
with RNA processing, transport and/or translation,
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and degradation of the local hybrid by RNase H ac-
tivity. However, in vivo merely circumstantial evi-
dence of specific antisense activity has been pro-
vided. In particular, the interactions of antisense
molecules with their targets within the cell are barely
characterized in terms of stoichiometry and structure
of the complexes, where the interactions take place,
and what their fates are.
We have set out to characterize the intracellular
behavior and exact localizations of antisense oligonu-
cleotides and to relate the localizations to their ex-
erted antisense activity. Thus far, we have con-
centrated on phosphorothioate oligonucleotides (PS-
ONs) because of their stability to nucleases. We have
used PS-ONs directed against regions of an inducible
endogenous RNA, intercellular adhesion molecule 1
(ICAM-1), in He La cells. A fluorescent tag at the
5' or 3' end of the antisense molecule (20 mer) al-
lowed us to follow the distribution of the PS-ONs and
compare it on the single cell level to the exerted in-
hibition of ICAM-1 protein expression measured by
indirect immunofluorescence. Addition of the anti-
sense oligonucleotides to the culture medium resulted
in the PS-ONs ending up in vesicular structures in the
cytoplasm. These structures probably belong to the
endosomal/lysosomal compartment of the cell. No
decrease in ICAM-1 protein staining could be detect-
ed under these conditions. In contrast, administration
of the antisense molecules by addition to the culture
medium in the presence of cationic lipids (lipofectin)
or by direct microinjection into the cells efficiently
targeted the PS-ONs to the nuclei. Concomitantly
pronounced decreases of ICAM-1 protein could be
observed in these cells. These results suggested that
the antisense activity of the ICAM-1 oligonucleotides
was executed within the nucleus. The nuclear signals
of the PS-ONs consisted of an overall diffuse nucleo-
plasmic staining and numerous bright spherical struc-
tures. In situ fractionation of cells revealed that most
PS-ONs were bound to the nuclear matrix. The spher-
ical structures have been found to be unrelated to the
antisense activity as control PS-ONs, despite their
lack of such activity, also displayed the same local-
ization in the nucleus. In addition, these spherical
structures could not be assigned to known nuclear
structures such as speckles enriched in splicing fac-
tors, nuclear bodies, or centromeres. Interestingly,
when two different PS-ONs were introduced inde-
pendently of each other into cells, even by two dif-
ferent means, they could be found to colocalize at the
same spherical structures. We are currently trying to
visualize both the antisense oligonucleotides and
their specific target RNAs simultaneously in cells in
order to identify the specific sites of action of the
antisense molecules.
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GENETIC ANALYSIS IN CAENORHABDITIS ELEGANS
M. Hengartner T. Casci (URP) D. Hoeppner Q. Liu
S. Desnoyers G. Jefferis M. Spector
T. Gumienny J. Keller S. Tharin
Our laboratory uses the small nematode Caenorhab-
ditis elegans as a model organism for the study of in-
teresting biological problems. The two main areas
that we are currently investigating are (1) program-
med cell death (apoptosis) and (2) nervous system
function and development. Because important biolog-
ical processes are evolutionarily conserved, we be-
lieve that the general rules that we observe in C.
elegans will also prove to apply to humans.
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Programmed Cell Death
Programmed cell death (PCD, also known as apo-
ptosis) is a mechanism that multicellular organisms
have developed to eliminate cells that are not needed
or are potentially dangerous. PCD has important
roles in animal development and homeostasis and oc-
curs in a wide variety of tissues in both vertebrates
and invertebrates. Proper control of PCD is crucial:
Breakdown in the regulation of this process contrib-
utes to the pathogenesis of a number of diseases, in-
cluding cancer, auto-immunity, neurodegenerative
diseases, ischemic stroke, and myocardial heart in-
farct.
The worm C. elegans provides an attractive system
for the study of PCD, as its development has been ex-
tensively characterized and the animal is readily
amenable to genetic and molecular manipulations. So
far, we and others have identified 17 genes that affect
PCD in C. elegans (Fig. 1), and we have molecularly
characterized a number of these genes. For example,
we found that the gene ced-9, which is required to
prevent the death of cells that should survive, is a
homolog of the mammalian proto-oncogene bcl -2. In-
terestingly, bcl -2 is thought to have a similar function
in mammals as ced-9 has in C. elegans. Similarly,
CED-3, required for PCD in worms, is homologous
to a family of cysteine proteases required for apop-
tosis in mammals. The conservation in sequence and
function of these cell death genes strongly suggests
that the molecular mechanism for PCD has remained
conserved through evolution and that nematodes and
mammals share a common molecular pathway for
cellular suicide. Thus, the knowledge gained about
PCD in C. elegans promises to be relevant to our un-
derstanding of apoptosis in human development and
Individual cell types
disease. We are now searching for and characterizing
additional genes that function in this pathway and are
developing tools to continue these studies at the
biochemical level.
Identification of
Proteins That Interact
with CED-9
M. Spector, G. Jefferis, T. Casci
The CED-9/BcI-2 family members possess no known
enzymatic activity, suggesting that these proteins
might inhibit PCD by binding to other proteins and
altering their activities. To identify proteins that in-
teract with CED-9, we are using the yeast two-hybrid
system to screen a C. elegans cDNA library using
CED-9 fused to the LexA DNA-binding domain as a
bait. We have identified 11 independent clones that
specifically interact with the LexA-CED-9 bait. We
are currently confirming these interactions in vitro
and testing the interacting proteins for effects on C.
elegans cell death. To complement and assist the
two-hybrid studies, we have generated antibodies
against CED-9 that will be used to identify proteins
that coimmunoprecipitate with CED-9
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FIGURE 1 A genetic pathway for programmed cell death in C. elegans. Mutations in 17 genes affect programmed cell deaths.
These mutations divide the process of programmed cell death into four steps; genes that act in the last three steps are com-
mon to all programmed cell deaths, whereas genes that act in the first step affect only a few cells. Regulatory interactions
deduced from genetic studies are shown. (-) Positive regulation; (-I) negative regulation.
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Isolation and Characterization
of ced-9 Suppressors
D. Hoeppner, M. Spector, S. Desnoyers
We have previously shown that ced-9 is required to
protect C. elegans cells from death: In the absence of
ced-9, many cells that normally live undergo PCD,
eventually resulting in the death of the animal. Muta-
tions in ced-3 or ced-4 block the ectopic deaths and
the lethality associated with ced-9 loss-of-function
(If) mutants. To identify additional genes that func-
tion in PCD, we have screened for suppressors of the
ced-9(lf) maternal-effect lethality phenotype. So far,
we have isolated more than three dozen suppressors.
As expected, many of these are mutations in ced-3
and ced-4. We have also identified one mutation,
ced(n2431), that identifies a new cell death gene. The
mutation ced(n2431) suppresses the weak loss-of-
function alleles ced-9(n1950 n2161) and ced-
9(n1653), but it is unable to suppress ced-9 null al-
leles. Furthermore, ced(n2431) has no obvious phe-
notype on its own. These observations suggest that
ced(n2431) is only a weak suppressor of cell death
and that the wild-type gene might play a partially
redundant part in C. elegans cell death. We are cur-
rently determining the precise position of ced(n2431)
on the genetic map as a prelude to its cloning. We
plan to continue using this screening strategy and are
designing other genetic screens (e.g., screens for
dominant suppressors) to identify additional cell
death genes.
Programmed Cell Death
in the C. elegans Germ Line
T. Gumienny, M. Hengartner [in collaboration with
Erika Hartwieg, Massachusetts Institute of Technology
and Eric Lambie, Dartmouth University]
We have recently undertaken an in-depth study of
PCD in the germ line of C. elegans. Although pre-
vious studies of programmed cell death in C. elegans
have focused on developmental deaths, we have
found that PCD also has a major role in the germ
line. Germ cells are by far the most common cell type
to undergo PCD: During development, 131 somatic
cells die; in contrast, more than 300 germ cells die
during adulthood. Thus, during an animal's lifetime,
more PCDs occur in the germ line than in all the
somatic tissues combined.
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We have found that most, but not all, mutations
that affect PCD in the soma also affect germ cell
death. ced-3 and ced-4 are both required for germ
cells to die, whereas ced-9 is required to protect
oocytes from death: In the absence of ced-9, too
many germ cells die, resulting in sterility. In contrast,
genes that affect PCD only in specific somatic cells
(such as the ces genes and egl-1) do not affect germ
cell death. To understand how germ cells make the
decision between life and death, we are screening for
mutations that specifically affect PCD in the germ
line. Characterization of the genes identified by these
mutations promises to further our understanding of
how particular cells regulate activation of the death
machinery.
Genes Required for the
Engulfment of
Apoptotic Deaths
Q. Liu, T. Gumienny
One of the consequences of activation of the death
machinery is the generation of a signal by the dying
cell that allows neighboring cells to rapidly engulf
the apoptotic cell and remove it from the organism.
Swift elimination of dying cells by phagocytosis is an
important aspect of the apoptotic process: In the ab-
sence of phagocytosis, secondary necrosis of the
apoptotic bodies results in lysis of the dead cells,
leading to inflammation and possibly auto-immune
disease.
In C. elegans, mutations in several genes result in
persistent corpses (Fig. 1). In these mutants, many
dying cells fail to be engulfed and remain visible
within the animals for many hours or even days. We
are characterizing several of these genes at the genet-
ic and molecular levels, in the hope of understanding
the nature of the engulfment-promoting signals and
their effect on neighboring cells.
Reverse Genetic Studies of
Programmed Cell Death
Q. Liu [in collaboration with Kristin White,
Harvard University, and Hermann Steller,
Massachusetts Institute of Technology]
A number of cell death genes have been identified in
other organisms, such as mammals and Drosophila.
The observation that the pathway for PCD is con-
served between nematodes and mammals suggests
that these cell death genes might also function in C.
elegans. We have been using a variety of techniques
and approaches to test this hypothesis. The simplest
involves the generation of transgenic worms that ex-
press the "foreign" cell death gene. For example, we
have found that the Drosophila gene reaper can in-
duce cell death in C. elegans, and that reaper-
induced death requires ced-3 and ced-4 function.
Studies of this type promise not only to confirm that
the genes under study interact with, or are part of, a
conserved part of the cell death machinery, but they
can also be used to order the point of action of these
genes in the cell death pathway by testing the effect
of the transgenes in the various cell death mutant
backgrounds available in C. elegans.
Nervous System Function and Development
A second area under investigation in the lab is the
nervous system in C. elegans. The small size and rel-
ative simplicity of the nematode nervous system al-
low us to readily address complex questions at the
genetic and molecular levels.
Genes Required for Axonal
Outgrowth
S. Tharin
Genetic screens have identified a large number of
genes required for axonal outgrowth, fasciculation of
processes into bundles, and neuronal pathfinding in
C. elegans. Such genes might identify molecules im-
portant for the transduction of signals from the ex-
tracellular matrix to the growth cone or for the stabi-
lization of growth cones in response to such signals.
We have concentrated our attention on the gene
unc-69, which causes a severe uncoordinated pheno-
type. We have found that unc-69 function is required
for proper axonal fasciculation and outgrowth, as
unc-69 mutants are seriously defective in both pro-
cesses. We have cloned the unc-69 gene and found
that it encodes a 108-amino-acid protein. Although
the predicted UNC-69 protein does not contain any
obvious catalytic domain, the central region of UNC-
69 has a high likelihood of forming a coiled-coil
structure. Reporter fusion experiments suggest that
UNC-69 is most abundant in the major nerve fas-
cicles in C. elegans, known as the nerve ring and the
ventral nerve cord. The unc-69 expression pattern is
thus consistent with the hypothesis that UNC-69
functions in neuronal processes to promote axonal
outgrowth. Recently, we found that C. elegans UNC-
69 shares a high degree of sequence similarity (over
70% identity in the coiled-coil domain) to a set of hu-
man expressed sequence tags (ESTs). We are now
trying to determine whether conservation between C.
elegans UNC-69 and this putative mammalian
homolog extends to the functional level.
Learning and Memory
S. Tharin [in collaboration with John Connolly,
Tim Tully, Cold Spring Harbor Laboratory, and
Derek van der Kooy, University of Toronto, Canada]
We have recently started a research program on the
molecular basis of associative learning and memory
in C. elegans. We are pursuing this project in col-
laboration with the Tully and van der Kooy laborator-
ies. Our first step will be to set up an extensive genet-
ic screen based on a classical conditioning paradigm
developed by Derek van der Kooy. Mutants identi-
fied as defective in acquisition, short-term memory,
or long-term memory will be characterized at the be-
havioral, genetic, and molecular levels.
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GENETICS
Last year, we saw the continued spectacle of dramatic discovery of genes involved in human dis-
ease. Not only has the list of cancer genes grown more complete, but also entirely new metabolic
pathways are being uncovered with, for example, the finding of a gene involved in human obesity.
The academic geneticist can hardly fail to notice that some of the most exciting developments are
not occurring in his domain but in either private or public companies. This was not previously the
case. Some have derided this development and asked how we can compete with well-funded,
huge corporate teams. Such complaint is misguided and the taxpayer/patient probably applauds
the infusion of new funding in genetics. During the last year, a singular development took place that
has to some extent leveled the playing field for all. In an effort to head off an attempt by one small
company to "corner the genome market," a large pharmaceutical house funded a cDNA sequenc-
ing effort at Washington University. This work has reached some maturity and provides, to the inter-
national world of science, essentially free of charge and commercial restraint, a DNA sequence
bank consisting of at least fragments of most human genes. It proves to be extraordinarily useful
and cries foul at the complaint that private enterprise is taking over the study of our genes. The
work of the geneticists at Cold Spring Harbor Laboratory is described below.
EUKARYOTIC CELL CYCLE CONTROL
D. Beach S. Allan
M. Caligiuri
D. Casso
K. Dai
S. Davey
D. Demetrick G. Hannon B. Nefsky
H. Zhang J. Hofmann K. Okamoto
K. Galaktionov J. Hudson S. Salghetti
C. Gawel T.K. Kim M. Serrano
G. Hannon D. Lombardi
During the course of the year, Hui Zhang accepted a
faculty position at Yale University, Scott Davey took
a faculty position at Queens University, Kingston,
Canada, and Doug Demetrick returned to Canada,
taking a position as Assistant Professor at the Univer-
sity of Calgary. Brad Nefsky went to the laboratory
of Nancy Walworth at UMDNJ and David Casso
graduated and became a postdoctoral fellow in the la-
boratory of Tom Kornberg at the University of Cali-
fornia, San Francisco. T.K. Kim joined the labora-
tory of Tom Maniatis at Harvard, Craig Gawel and
Diane Lombardi departed to new positions, and
Gretchen Hannon left to have a baby. We were joined
by Dr. Roberta Maestro, a visiting scientist from Ita-
ly, and Greg Hannon was promoted to Staff Investi-
gator.
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Role of p16INK4a in Tumor
Development and Cell Mortality
M. Serrano, D. Beach
The cell cycle inhibitor pl6INK4a is inactivated in
many human tumors and in families with hereditary
melanoma and pancreatic cancer. To test directly the
impact of pl6INK4a inactivation on tumorigenesis, we
have generated in collaboration with Dr. Ronald
DePinho's laboratory (Albert Einstein College of
Medicine, New York) a mouse strain carrying a
targeted deletion of the INK4a gene. INK4a-deficient
mice are viable but develop spontaneous tumors at an
early age (7 months) and are highly sensitive to car-
cinogenic treatments. Histological analysis of the
tumors, done by Dr. Carlos Cordon-Cardo (Memorial
Sloan-Kettering Cancer Center, New York), indicates
that most of the tumors consist of sarcomas and
lymphomas. At the cellular level, INK4a-deficient
primary fibroblasts give rise to immortal cell lineages
with high efficiency. Interestingly, fibroblasts from
INK4a-deficient mice become tumorigenic following
the introduction of the activated Ha-ras oncogene.
This finding is in contrast to that of normal INK4a+
fibroblasts that require the introduction of at least two
cooperating oncogenes to become tumorigenic, and it
could be the basis for the high incidence of fibrosar-
comas in INK4a-deficient mice. INK4a-deficient
mice could provide a useful animal model to study
the development of these malignancies. Alterations in
the INK4a gene are common in human lymphomas
and sarcomas. Altogether, our results directly demon-
strate that the INK4a locus functions to suppress
neoplastic growth.
CDC25 Phosphatases, Signal
Transduction, and Cancer
K. Galaktionov, D. Beach
The ras and rafl proto-oncogenes transduce extra-
cellular signals that promote cell growth. cdc25 phos-
phatases activate the cell division cycle by dephos-
phorylation of critical threonine and tyrosine residues
within the cyclin-dependent kinases. We have shown
that cdc25A phosphatase associates with raft in so-
matic mammalian cells and in meiotic frog oocytes.
Furthermore, cdc25A phosphatase can be activated in
vitro in a Rafl-dependent manner. This observation
uncovers an evolutionarily conserved link between
the cell cycle and signal transduction and suggests
that activation of the cell cycle by the ras /raft path-
ways might be mediated in part by cdc25.
In rodent cells, human cdc25A or cdc25B but not
cdc25C phosphatases cooperate with either Ha-ras
(Val-12) or loss of Rbl in oncogenic focus formation.
Such transformants are highly aneuploid, capable of
growth in soft agar and form high-grade tumors in
nude mice. The ability of cdc25 phosphatases to
show oncogenic cooperation with either oncogenic
ras mutants or Rbl deletion mutants underscores the
potential significance of cdc25 overexpression in the
development of human malignancies. In support of
this suggestion, cdc25B was found to be highly ex-
pressed in 32% of the primary breast cancers. Tumor-
specific expression of the cdc25B in human breast
carcinomas correlates with less favorable prognosis
and survival of the patients. Our results suggest that
alterations in the function of cdc25A and cdc25B by
overexpression might promote oncogenic transforma-
tion in vivo and further suggest that cdc25 phospha-
tases (A and B) are novel potential oncogenes.
14-3-3 Proteins Associate
with cdc25 Phosphatases
D. Conklin, D. Beach
The potentially oncogenic cdc25 phosphatases have
key roles in cell cycle progression by activating
cyclin-dependent kinases. Cyclin-dependent kinases
are subject to inhibitory phosphorylations of threo-
nine and tyrosine residues (Thr-14 and Tyr-15) that
inhibit kinase activity and consequently cell cycle
progression. The cdc25 phosphatases remove these
inhibitory phosphate groups, activating the kinase
and bringing about cell cycle progression. Two mem-
bers of the 14-3-3 protein family have been isolated
in a yeast two-hybrid screen designed to identify
proteins that interact with the human cdc25A and
cdc25B phosphatases. Genes encoding the human
homolog of the 14-3-3E protein and the previously
described 14-3-313 protein have been isolated in this
screen. 14-3-3 proteins comprise a family of well
conserved eukaryotic proteins that were first isolated
in mammalian brain preparations and that possess
diverse biochemical activities related to signal trans-
duction. Recently, 14-3-3 proteins have been found to
associate with a number of oncogene products, in-
cluding Rafl, Bcr-abl, and middle T antigen. We
have found that cdc25 and 14-3-3 proteins physically
interact both in vitro and in vivo. 14-3-3 protein,
however, does not affect the phosphatase activity of
cdc25A. Instead, it appears to facilitate the associa-
tion of cdc25 with Rafl in vivo, playing an organiza-
tional part in linking mitogenic signaling and the cell
cycle machinery.
Identification of Proteins
That Interact with Cyclin G
K. Okamoto, D. Beach
The tumor suppressor protein p53 is regarded as one
of the most important tumor suppressors. Alterations
101
of p53 are among the most common genetic changes
found in human cancers. The importance of these
changes is implied by experiments with transgenic
mice in which both alleles of p53 have been dis-
rupted. These animals show a greatly increased fre-
quency of cancer. It has been demonstrated that p53
is involved in many biological functions, including
cell cycle arrest, apoptosis, genomic instability,
neural development, meiosis, and stress response.
Since p53 is known to function as a transcription fac-
tor, the plethora of biological phenomenon p53 is in-
volved in may be explained by a variety of transcrip-
tional target genes which p53 regulates. Although
several transcriptional target genes of p53 have been
identified (including p21, mdm2, mck, gadd45, and
bax), it is unlikely that these genes can fully explain
the function of p53. Many crucial target genes of p53
may still remain unidentified.
To identify other transcriptional targets of p53, we
have used a polymerase chain raction (PCR)-based
differential screening method, differential display.
We have found that one of the identified cDNAs en-
codes the mouse homolog of rat cyclin G. The ex-
pression of cyclin G was induced under a number of
different conditions which are known to activate the
p53 pathway. Using DNA-binding and transient
transfection assays, we have demonstrated that the
cyclin G gene is a transcriptional target of p53.
To understand the biological role of cyclin G, we
searched for proteins that can interact with cyclin G.
Through the screening of the two-hybrid cDNA li-
brary, we have identified two positive cDNAs. Se-
quence analysis showed that both of them encode
regulatory subunits of protein phosphatase 2A
(PP2A). We have demonstrated that cyclin G and
these proteins can interact both in vivo and in vitro,
and these interactions are unique among mammalian
cyclins. Projects are under way to understand the
biological role of these proteins in the context of a
p53-mediated pathway.
p21 Deficiency Compromises
Radiation-induced Cell
Cycle Arrest
G.J. Hannon, D. Beach
p21 is a dual inhibitor of cyclin-dependent kinases
and PCNA (proliferating cell nuclear antigen), both
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of which are required for cell proliferation. The
tumor suppressor, p53, a key mediator of the cellular
response to DNA damage, regulates the transcription
of the p21 gene. Thus, p21 was implicated as a
downstream effector of p53 in radiation-induced cell
cycle arrest and apoptosis. p21 has also been touted
as a component of cellular senescence and as a
mediator of cell cycle withdrawal following differen-
tiation.
In collaboration with Tyler Jacks at the Massachu-
setts Institute of Technology and Jeff Gordon at
Washington University, we investigated the role of
p21 in these processes using chimeric mice composed
partly of p21+/+ and partly of p21-/- cells. Im-
munohistochemical staining indicated that p21
deficiency did not affect terminal differentiation of
the four major intestinal epithelial cell types. In addi-
tion, loss of p21 did not prevent p53-dependent cell
death. However, p21-deficient fibroblasts were im-
paired in their ability to undergo cell cycle arrest fol-
lowing DNA damage. Our results not only suggest
that p21 is a major component of the mechanism by
which p53 controls cell cycle progression, but also
indicate the existence of additional p53-regulated
growth control pathways.
A significant effort during the last year has been
devoted to the development of a system that may al-
low the cloning of genes by genetic complementation
in mammalian cells. Complementation screening has
proven a highly effective way of dissecting biological
processes in yeast. Investigators working in mam-
malian systems have long suffered for the lack of a
similar approach.
Along with Doug Conklin and Peiqing Sun, we
have devised a system based on replication-deficient,
recombinant retroviruses that allows extremely high
gene transfer efficiencies into a wide variety of mam-
malian cell types. By linking the gene whose expres-
sion is desired to a marker gene in a bicistronic mes-
sage, the percentage of drug-resistant cells that also
express the gene of interest has been greatly en-
hanced. Furthermore, recombinase-based strategies
allow excision of the provirus both in vivo and in
vitro. This allows us to test the dependence of any
phenotype on the integrated retrovirus and also pro-
vides a convenient way to recover an integrated
provirus from the host genome. Work now in prog-
ress will apply this new technology to a variety of
biological problems.
Regulation of the Cdc10/Sct1
Transcription Complex
Requires the Cooperation
of the Cdc2 and Rani
Protein Kinases
M. Caligiuri, D. Beach
In the fission yeast, Schizosaccharomyces pombe, the
execution of Start and consequent commitment to the
mitotic cell cycle require the activities of the Cdc2
protein kinase and the Cdc10/Sctl transcription com-
plex. Inactivation of any of these genes leads to G,
arrest and activation of the mating pathway under ap-
propriate nutritional conditions. Cells that lack sctl,
unlike those that lack cdc2 or cdc10, will conjugate
even when grown on rich media and thus bypass the
normal requirement of nutritional deprivation for the
activation of the mating pathway. This phenotype is
reminiscent of that which results from the loss of an-
other cell cycle regulator, the Ranl protein kinase,
which functions to prevent the activation of the
mating pathway under conditions that promote
vegetative growth. We have been studying the rela-
tionship between these proteins to characterize, at the
molecular level, the events that lead to passage
through the Gi/S-phase transition and commitment to
cell division.
The Cdc10/Sctl complex activates the expression
of at least three genes required for DNA replication;
dissociation of this complex leads to a loss of DNA-
binding activity and consequent cell cycle arrest. We
have found that the formation of this heteromeric
complex requires both the Cdc2 and Rant protein
kinases. Inactivation of either of these kinases leads
to the dissociation of the Cdc10/ Sctl complex. Anal-
ysis of the primary structure of Cdc10 revealed a
single canonical Cdc2 phosphorylation site that is es-
sential for Cdc10 function. We have found that sub-
stitution of the serine within this site (Ser-196) with
alanine leads to inactivation of Cdc10, whereas sub-
stitution with aspartic acid, S196D, restores activity.
The phosphorylation of this site is therefore likely to
be required for Cdc10 activity. Metabolic labeling
experiments have demonstrated that this site is, in
fact, phosphorylated in vivo. We have found that the
expression of Cdc10 S196D alleviates the require-
ment of Cdc2 for Cdc10/Sctl complex formation,
suggesting that Cdc2 phosphorylates this site. Addi-
tional evidence indicating that Cdc10 may be a sub-
strate of Cdc2 comes from our observation that
Cdc10 binds to the CLN3-like cyclin, Pucl. Inter-
estingly, the association between Cdc10 and Pucl re-
quires Rani, but not Cdc2. Since Ranl is required for
Pucl (and presumably Cdc2) to bind Cdc10, we hy-
pothesized that conditions which render Cdc10/ Sctl
complex formation independent of Cdc2 (i.e., expres-
sion of Cdc10 S196D) might also obviate the require-
ment for Ranl for this process. We have found this
prediction to be true and therefore suggest that Ran 1
functions to promote vegetative cell growth by acti-
vating Cdc10/Sctl-dependent transcription through
Pucl/Cdc2 leading to DNA replication.
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CELL CYCLE CONTROL IN SACCHAROMYCES CEREVISIAE
B. Futcher J. Donovan B. Schneider T. Volpe
D. Germain G. Sherlock H. Wijnen
K. Hidaka B. Steiner Q.-H. Yang
Our main interest continues to be regulation of Start
and mitosis in Saccharomyces cerevisae. We are
most interested in the tethering of division to cell
growth and in the generation of basic cell cycle oscil-
lation. Many key cell cycle events are regulated by
protein kinase complexes formed between Cdc28 and
a cyclin. There are now more than a dozen known
yeast cyclins, and probably more to come. These fall
into two broad groups: the Gt cyclins, including
Clnl, Cln2, and Cln3, which regulate Start, and the
mitotic, B-type cyclins Clbl, C1b2, C1b3, and C1b4.
Two other cyclins, C1b5 and C1b6, are very important
for DNA replication, but they also have roles at Start
and perhaps also in early mitosis.
A second interest is yeast telomerase. This year,
we found telomerase activity in yeast and found that
Estl is associated with the activity.
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Substrates of the
Ubiquitin-conjugating
Enzyme Ubc9
J. Donovan
UBC9 encodes a ubiquitin-conjugating enzyme, and
we have previously shown that it is important for
degradation of mitotic cyclins (Seufert et al. 1995). A
temperature-sensitive ubc9 mutant arrests and dies in
G2 or M phase. However, cyclins lacking a destruc-
tion box, and so not degraded, do not cause lethality.
We are investigating whether the lethality of the ubc9
mutant is due to lack of degradation of some other
mitotic protein, for instance, the hypothetical "chro-
mosome glue" protein thought to hold sister chromo-
somes together until anaphase.
Mitotic Checkpoints
and Proteolysis
D. Germain
DNA damage causes a checkpoint arrest in G2 phase.
Phenotypically, the arrest resembles the arrest in a
ubc9 mutant. We wondered whether the mechanism
of the checkpoint arrest is failure of some essential
proteolysis. Therefore, we looked at C1b5, which is
one of the known substrates of Ubc9, to see if its
turnover was inhibited by UV radiation. C1b5 was in-
deed stabilized by UV radiation. This suggests that
the checkpoint works, at least in part, by inhibiting
the activity of Ubc9, and this prevents progress into
mitosis.
Yeast Vectors for Rapid
Disruption, Tagging, or
Promoter Insertion
B. Schneider, W. Seufert, B. Steiner, Q.H. Yang
We have developed a rapid new method for tagging
yeast proteins. We have built a plasmid carrying
URA3 flanked immediately on each side by direct
repeats of the triple hemagglutinin (HA) tag. Poly-
merase chain reaction primers are used to amplify
this cassette, and homology with the gene of interest
is built into the 5' ends of the primers. Yeast are
transformed with the amplified fragment, which then
integrates into the gene of interest, giving a Ura+
phenotype. Finally, we put the transformants on 5-
FOA plates, selecting for Ura cells. The two directly
repeated tags recombine with each other, popping out
the URA3 gene, and leaving one copy of the triple
HA tag in the desired position. A minor modification
gives us an equivalent method of disrupting genes
and recovering a Ura strain. We have built plasmids
allowing tagging with a triple HA epitope or a triple
myc epitope; we have also built a plasmid allowing
insertion of the GAL1,10 promoter.
The Cdk Inhibitor Sici Links
S Phase to Start
B. Schneider, Q.-H. Yang
Sicl is an inhibitor of Cdc28-mitotic cyclin com-
plexes, but it does not inhibit Cdc28 -Gt cyclin com-
plexes. In yeast, both S phase and M phase depend on
Cdc28-mitotic cyclin activity, and so Sicl must be in-
activated before S and M can proceed. Sicl is lost
shortly after Start, and this loss depends on the
ubiquitin-conjugating enzyme Cdc34. We find that
Sicl becomes phosphorylated at Start and that this
phosphorylation depends on the Cdc28-G1 cyclin
complexes. In the absence of the Gt cyclins, Sici is
not phosphorylated and also not destroyed. This sug-
gests that Sicl is a substrate of Cdc28 at Start and
that the phosphorylation targets Sicl for proteolysis
by the ubiquitin system. Strikingly, inactivation of
Sici is the only essential function of the G1 cyclins
Clnl, Cln2, and Cln3, because whereas a clnl cln2
cln3 triple mutant is dead, a sicl clnl cln2 cln3 qua-
druple mutant is alive (Fig. 1).
Substrates of Cdc28
G. Sherlock
We have done a computer screen of the S. cerevisiae
genome to find proteins with multiple clustered con-
sensus sites for Cdc28 phosphorylation. Many of the
proteins found in this screen are known to have a role
in the cell cycle. We are mutating the sites in some of
these proteins to see if there is a phenotype. So far,
we have knocked out sites in Cin8, a kinesin-like
motor protein, and Cdc6, a protein involved in initia-
tion of DNA synthesis. The cin8 site mutant has no
obvious phenotype. However, the Cdc6 site mutant
does have phenotypes. The mutant is sick and ap-
pears to have more Cdc6 protein than normal. Al-
though we do not yet know whether it is a lack of
phosphorylation that accounts for these phenotypes, it
is possible that phosphorylation helps target Cdc6 for
proteolysis, as is true for a number of other proteins.
Analysis of WHI3:
A New Size Control Gene
T. Volpe
The whi3 mutation was isolated some years ago by
Rob Nash, and we are continuing its characterization.
Like other whi mutants, it gives a small-cell pheno-
type, which may be because whi3 mutants overex-
press CLN1 and CLN2 01 cyclins. Overexpression of
WH13 turns off CLNI and CLN2 and is lethal. How-
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FIGURE 1 A sicl deletion rescues the lethality of the clnl c/n2 cln3 triple mutant.
ever, the reason for the lethality is not the lack of
CLNI and CLN2 expression, because when CLN2 is
expressed from a heterologous promoter, this fails to
rescue the lethality of GAL-WH13. The Whi3 protein
contains RNP-1 and RNP-2 RNA-binding motifs but
otherwise has no homology with other proteins. We
are trying to understand the mechanism of WHI3 ac-
tion.
Mechanisms of Transcriptional
Activation by Cyclin-Cdc28
Complexes
H. Wijnen
One effect of the Cln3-Cdc28 complex-perhaps the
only effect-is to induce transcription of a family of
genes that includes CLNI, CLN2, CLB5, and CLB6.
We are trying to discover the mechanism of induc-
tion. The promoters of the CLN3-inducible genes all
include binding sites for the Swi4 transcription fac-
tor, or for its close relative Mbpl. The Swi4 and
Mbpl DNA-binding proteins each forms a complex
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with another protein called Swi6; these two com-
plexes are called the SBF or MBF transcription fac-
tors. Genetic results argue that Cln3 somehow acts
through Swi6 to activate the transcription factor. We
are trying to understand the mechanism of this.
Est1 Is a Protein Component
of Yeast Telomerase
B. Steiner, K. Hidaka
The ESTI gene (Ever Shorter Telomeres) was identi-
fied many years ago in a screen for telomere mainte-
nance mutants. Cells lacking ESTI suffer a gradual
shortening of telomeres and then senesce and die.
This has led to speculation that the Estl protein might
be a component of yeast telomerase.
We tested this idea by tagging Estl with an
epitope and then immunoprecipitating. Northern blots
show that the immunoprecipitates contain the yeast
telomerase RNA. When immunoprecipitates are
resuspended in a reaction mix containing telomere-
like oligonucleotides, dTTP, and 32P-labeled dGTP,
the oligonucleotides are elongated to give a telomer-
ase-like ladder of reaction products. The activity is
sensitive to RNase digestion; it is specific for im-
munoprecipitates from tagged Estl strains; and it
fails to elongate most nontelomeric oligos. When the
sequence of the template in the telomerase RNA is
changed to include dG residues, the activity coprecip-
itated with Estl begins to incorporate dC residues.
Curiously, there seem to be two telomerase-like
activities. They are distinguishable in that one is
specific for telomeric primers ending in GGG,
whereas the other recognizes all yeast telomeric se-
quences. The "GGG" activity is completely depen-
dent on the presence of the TLC1 gene, which en-
codes the telomerase RNA, whereas the other activity
is not dependent on TLC1 . There may be two
telomerases with different template RNAs, or the sec-
ond activity may be some other kind of activity.
Since Estl appears to be a component of the com-
plex, we have done a two-hybrid screen to find other
protein components. A number of different genes
have been identified, and these are being character-
ized. Finally, a homolog of Estl was recently identi-
fied by the yeast genome sequencing project. We are
analyzing this homolog and its relationship to Estl
and to telomerase.
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REGULATION OF GROWTH AND CELL CYCLE
COMMITMENT IN BUDDING YEAST
K.T. Arndt C.J. Di Como M. Luke
A. Doseff F. Della Seta
T. Zhong E. Tegins
F. Lin
Our research mostly focuses on the regulation of the
G, phase of the cell cycle. For most eukaryotic
organisms, it is during G, that decisions are made as
to whether or not to divide. For these studies, we use
the model organism Saccharomyces cerevisiae,
which is commonly called budding yeast. Budding
yeast cells that have executed the late G, event(s)
termed Start are committed to initiate DNA
synthesis, form a bud, and divide. Start is the point
where growth signals and mating pheromones control
entry into the cell division cycle. The execution of
Start seems to require some threshold level of Gt
cyclin/CDC28 kinase activity, which is determined in
large part by the rate and levels at which the G,
cyclin RNAs accumulate during late Gt. However,
very little is known about the mechanisms that
determine if Gt cyclin RNAs accumulate and the rate
at which G, cyclin RNAs accumulate.
Many cell cycle events are controlled by the
regulation of the phosphorylation of certain key
proteins. Protein phosphatases are proteins that
remove phosphate groups from phospho-serine,
phospho-threonine, or phospho-tyrosine residues in
other proteins. In many cases, removal of the
phosphate activates the protein substrate. In other
cases, removal of the phosphate inactivates the
protein substrate. In my lab, we study three protein
phosphatases: type 1 (PP1), type 2A (PP2A), and
SIT4. All three of these phosphatases remove
phosphate groups primarily from phospho-serine and
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phospho-threonine residues. Most of our effort is
focused on the SIT4 phosphatase. We have found that
SIT4, which is a type-2A-related phosphatase, is re-
quired during G, for the execution of Start, for bud
formation, for the initiation of DNA synthesis, and
for spindle pole body duplication. SIT4 is required
for the execution of Start because it is required for
the expression of the CLN1 and CLN2 G1 cyclin
genes. CLNI and CLN2 proteins bind to CDC28,
thereby activating the kinase activity of CDC28.
When some threshold level of CLN/CDC28 kinase
activity is achieved, Start is executed and the cells are
committed for DNA synthesis and the completion of
the cell cycle. Our major goals are to determine how
growth signals control the ability of SIT4 to promote
Start and bud initiation and to determine the
downstream targets of SIT4 that function for Start
and bud initiation.
Function and Regulation
of the SIT4 Phosphatase
during the Cell Cycle
M. Luke, F. Della Seta, C.J. Di Como, K. Arndt
SIT4 is a protein phosphatase catalytic subunit whose
levels are constant throughout the cell cycle. There-
fore, the activity of SIT4 might be regulated in the
cell cycle by association with regulatory subunits. In
G, daughter cells, SIT4 exists mostly as monomeric
uncomplexed SIT4. During late G5, at a time close to
Start (when SIT4 is required for G, cyclin expres-
sion), SIT4 associates in separate complexes with
three high-molecular-mass phosphoproteins termed
SAP155, SAP185, and SAP190 (Sit4-associated
protein, apparent mass in kilodaltons). Near or just
after mitosis, SIT4 is again found primarily as
monomeric uncomplexed SIT4.
SAP155 and SAP190 were purified by large-scale
affinity purification of epitope-tagged SIT4 followed
by SDS-polyacrylamide gel separation. R. Kobayashi
(see Structure and Computation Section) obtained
partial peptide sequences for both proteins, and this
information was used to clone the SAP155 and
SAP190 genes. The predicted SAP155 and SAP190
proteins show no significant homology with other
proteins in the current databases. However, SAP155
and SAP190 are homologous to each other, with
about 30% identical amino acids over the entire
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A. SAP protein data
pr
Glu
E
Asp
D
Asn
N
total
amino acids
predicted
mass (kDa)
SAP190 3.91 116 118 74 1,033 117.0
5AP185 4.01 127 107 79 1,058 121.3
SAP155 4.27 77 96 113 1,000 114.8
SAP4 4.35 62 78 55 818 94.7
B. Percent Identity C. Similarity Tree
SAP190 SAP185 SAP155 SAP4 SAP190
SAP190 142% 1 26% 22% SAP185
SAP185 1456 2156
SAP155 136%1
SAP155
SAP4
SAP4
FIGURE 1 (A) SAP protein data; (B) percent identity; (C)
similarity tree.
lengths of the proteins. Moreover, we also identified
two additional SAP genes in budding yeast by homol-
ogy: SAP185 from the budding yeast genome project
and another SAP gene by polymerase chain reaction
(PCR) using degenerate primers. We have shown that
SAP185 encodes a 185-kD protein that associates
with SIT4. We currently do not know if SAP4 associ-
ates with SIT4, although we suspect that it does.
Molecular information for the four SAPs is shown in
Figure 1. All four SAPs are acidic.
With the SAP genes in hand, we could determine if
the SAPs function positively with SIT4 (and turn
SIT4 on near Start) or if they function negatively
with SIT4 (and turn SIT4 off near Start). Three lines
of evidence show that the SAPs function positively
with SIT4. First, all four SAP genes in high copy
number suppress the temperature-sensitive phenotype
of sit4-102 strains. Second, the phenotypic effects
due to the loss of all four SAP genes are identical to
the loss of SIT4. Third, in terms of the genetic inter-
actions with deletion of CLN3, BEM2, SIS2, or
PI-1085, the loss of the SAPs is the same as the loss
of SIT4. These findings indicate that the SAPs are re-
quired for SIT4's cellular function. The loss of the
SAPs is not at all similar to the effects due to over-
expression of SIT4.
By sequence similarity, the SAPs fall into two
groups: the SAP4/SAP155 group and the SAP185/
SAP190 group. The effects due to deletion of various
combinations of the SAP genes show that this se-
quence similarity is also a functional grouping of the
SAPs. Further analysis shows that the SAPs (and
hence SIT4 also) are providing two functions: one
function provided by SAP185 and SAP190 and an-
other function provided by SAP155 (perhaps along
with SAP4). Deletion of SAP185 by itself or deletion
of SAP190 by itself causes no decrease in the growth
rate of the cells. However, deletion of both SAP185
and SAP190 causes a slow-growth-rate phenotype.
Importantly, although either SAP185 or SAP190 on
either a low-copy-number cen plasmid or a high-
copy-number plasmid restored the growth rate of a
Asap185 Asap190 strain to wild type, neither SAP4
nor SAP155 could stimulate the growth rate of this
strain. Therefore, SAP155, even when overexpressed,
cannot provide the function provided by SAP185/
SAP190. In addition, the overexpression of SAP185
or SAP190 cannot stimulate the slow growth rate of
Asap155 strains. Therefore, the SAPs are providing at
least two cellular functions.
We have prepared antibodies that specifically
recognize SAP155, SAP185, or SAP190. With the
tools (antibodies and mutations in the genes) to ana-
lyze SAP155 and SAP190 in hand, we can now ad-
dress the following important questions. Do SAP155
and SAP190 regulate, positively or negatively, the
activity of SIT4 toward its in vivo substrates? Are
SAP155 and SAP190 substrates of SIT4? Interesting-
ly, SAP155, SAP185, and SAP190 become hyper-
phosphorylated in the absence of SIT4 function. How
is the association of SIT4 with SAP155, SAP185, and
SAP190 regulated? Via phosphorylation of the
SAPs? How do growth signals and cell cycle signals
regulate the association of SAP155 and SAP190 with
SIT4?
We have found that the amount of the SAPs that
are associated with SIT4 is regulated not only by cell
cycle position, but also by cellular growth signals: by
carbon source (glycerol/ethanol versus glucose), by
the presence or absence of amino acids in the growth
medium, and during saturation of the cultures. Pos-
sibly, the SAPs are involved in transducing nutrient
growth signals via their association with SIT4, there-
by linking nutrient growth signals with G1 cyclin ex-
pression, bud formation, and other late G1 processes.
The elucidation of such a signal transduction pathway
will require the determination of how the association
of the SAPs with SIT4 is regulated and what
downstream processes are regulated by the SAPs and
SIT4.
TAP42: An Essential 42-kD
Protein That Interacts with
Both SIT4 and the Type-2A
Catalytic Subunits
C.J. Di Como
To identify cellular substrates and/or regulatory sub-
units of SIT4, we isolated genes that, when present
on a high-copy-number plasmid, suppress the temper-
ature-sensitive phenotype of a sit4-102 mutant. From
this scheme, we isolated three genes. One gene is
SAP155, which encodes the 155-kD subunit of SIT4
(see above). High-copy-number SAP190 also sup-
presses the sit4 mutant, but we did not isolate
SAP190 from this screen because SAP190 is not pres-
ent in the high-copy-number library. The second gene
is HCS26. HCS26 encodes a G1 cyclin that binds not
to CDC28, but to the CDC28-related kinase PH085.
Other cyclins (CLN1, CLN2, ORFD, and CLB5) in
high copy number are not able to rescue the
temperature-sensitive phenotype of the sit4 mutant.
In addition, suppression of the sit4-102 strain by
overexpression of HCS26 requires PH085, suggest-
ing that an increase in the HCS26/PH085 kinase ac-
We have two models to explain
why overexpression of HCS26 does suppress,
whereas overexpression of CLN2 does not suppress,
the sit4-102 mutant. In model no. 1, the HCS26/ -
PH085 kinase can phosphorylate substrates that
CLN2/CDC28 cannot. In model no. 2, the HCS26/ -
PH085 kinase does not require SIT4, whereas the
CLN2/CDC28 kinase does require SIT4.
The third gene is a previously unidentified gene
which we term TAP42 (for two A phosphatase-
associated protein) because it encodes a 42-kD
protein that associates with both SIT4 and the type-
2A catalytic subunit (we also isolated TAP42 as a
gene that in high copy number suppressed the
temperature-sensitive phenotype of a temperature-
sensitive pp2a mutant; see below). The TAP42
protein has similarity to the mouse oc4 protein, which
becomes phosphorylated in response to activation of
the B-cell receptor. The budding yeast TAP42 gene is
essential, and germinating Atap42 cells arrest as four
to eight unbudded cells. Immunofluorescence micros-
copy was used to show that TAP42 is enriched in the
nucleus, but it is also present in the cytoplasm.
The association of TAP42 with SIT4 does not re-
quire the SAP proteins. Moreover, we have not been
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able to find any TAP42 in SAP immunoprecipitates.
These findings show that TAP42/SIT4 complexes are
distinct from SAP/SIT4 complexes. In addition, asso-
ciation of TAP42 with PPH21 or PPH22 (the type-2A
PPase catalytic subunits) does not require TPD3 (an
A-like subunit) or CDC55 (a B-like subunit). Togeth-
er, these findings indicate that TAP42 interacts with
the catalytic subunit of SIT4 (type-2A-related
PPases) and with the type-2A catalytic subunits and
that this interaction does not require any of the
known phosphatase subunits. Moreover, this TAP42
interaction is specific to these phosphatases because
TAP42 does not coimmunoprecipitate with the type-1
phosphatase catalytic subunit.
Genetic interactions and in vivo tests indicate that
TAP42 functions positively with SIT4 and with the
two PP2A catalytic subunits. We propose that the
TAP42/phosphatase interactions result in a new ac-
tivity that is not present in TAP42 by itself and in
SIT4 or the PP2A catalytic subunits by themselves.
Possibly, TAP42 might direct the phosphatases to
dephosphorylate particular substrates.
Because rapamycin arrests cells in late G1, and
temperature-sensitive sit4 mutants arrest in late G1,
we have been interested in a possible connection be-
tween SIT4 and the signaling pathway (TOR1/TOR2)
that is inhibited by rapamycin. We have isolated one
temperature-sensitive allele of TAP42. Interestingly,
similar to the TOR mutants that give rapamycin
resistance, we have found that the temperature-
sensitive tap42 mutant is almost completely resistant
to rapamycin. Moreover, rapamycin rapidly causes
the dissociation of TAP42 from SIT4 (but it does not
decrease the SAP155/SIT4 association). These find-
ings raise the possibility that the TAP42/SIT4 inter-
action is a possible downstream process in TOR sig-
naling.
Future experiments will be directed at further
elucidation of the TAP42/phosphatase interaction for
cell cycle progression.
Identification of Genes
Functioning in the SIT4
Pathway for Bud Formation
A. Doseff
sit4 mutants arrest as large unbudded G1 cells
blocked at Start. In contrast, if CLN2 is expressed
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from a SIT4-independent promoter, sit4 mutants are
able to execute Start and replicate their DNA. How-
ever, they are still blocked for bud initiation. We used
a synthetic lethal screen to identify genes that func-
tion in the SIT4 budding pathway. This approach was
based on the fact that although in certain strain back-
grounds SIT4 is essential, in some backgrounds, SIT4
is not essential, but the cells grow very slowly with a
greatly expanded G1 phase. The viability or invia-
bility of Asit4 strains results from a polymorphism at
a single genetic locus that we termed SSD1. The al-
leles of SSD1 which allow viability in the absence of
SIT4 are called SSD1-v. We isolated mutations that,
like sit4 mutations, are lethal in the absence of SSD1-
v. From this screen, we isolated 75 mutants termed
LAS (for lethal in the absence of SSD1) that fell into
six complementation groups. Importantly, one of the
complementation groups contained mutations in the
SIT4 gene, confirming the rationale of the screen.
The complementation group with the most members
had mutations in the LAS1 gene. LAS1 encodes an es-
sential protein with a predicted molecular mass of 59
kD. Loss of Lasl function causes the cells to arrest as
80% unbudded cells and 20% large budded cells. The
large budded cells have many secretory vesicles at
the mother-daughter neck. Presumably, these vesicles
accumulate because they are blocked for fusion with
the cell membrane. Overexpression of Lasl results in
the formation of extra cell surface projections in the
mother cell, alterations in the localization of com-
ponents (such as actin and Spa2) that are known to be
involved in bud formation, and the accumulation of
electron-dense structures along the periphery of the
cell. Further evidence of a role of Lasl in bud forma-
tion is that overexpression of Lasl promotes bud
formation in sit4 mutants. Because LAS1 localizes to
the nucleus, our current model is that LAS1 functions
in bud formation and morphogenesis via the regula-
tion of the expression of components that function
directly in these processes. Very little is known about
how components involved in bud initiation are regu-
lated during the cell cycle. LAS1 is a phosphoprotein
and, importantly, LAS1 becomes hyperphosphory-
lated in sit4 mutants. Therefore, LAS1 might be a
substrate of SIT4.
Our next goal is to determine if SIT4 can de-
phosphorylate LAS1 in vitro (the LAS1 for these ex-
periments will be isolated from a sit4 mutant and will
be hyperphosphorylated). In addition, we will try to
identify genes involved in bud initiation that might be
regulated by LAS1.
Role of Type-2A Phosphatase
in the Actin Cytoskeleton
and in Entry into Mitosis
F. Lin
PP2A (or type 2A) is a major class of protein
phosphatase. PPH22, a gene encoding a catalytic
subunit of PP2A (type-2A protein phosphatase) in
budding yeast, had been previously isolated in our
lab. Later, we identified a second gene, PPH21, that
encodes a PP2A catalytic subunit. Deletion of either
PPH21 or PPH22 alone caused no detectable effect,
but deletion of both genes resulted in a slow growth
defect and a leaky temperature-sensitive phenotype at
37°C. Only deletion of PPH21, PPH22, and a PP2A-
related gene, PPH3, was lethal. To investigate
whether PP2A is involved in cell cycle events, we
prepared a temperature-sensitive PP2A mutant,
pph21-102. At the restrictive temperature, the pph21-
102 cells arrested predominately with small or aber-
rant buds, and their actin cytoskeleton and chitin
deposition were abnormal. The defects in actin orga-
nization might be responsible for both the aberrant
bud morphology and the abnormal chitin deposition
in the arrested pph21-102 cells.
After a shift to the nonpermissive temperature, the
pph21-102 cells were blocked in 02, with inactive
C1b2/Cdc28 complexes. Even though CLB2 and
CDC28 were present at normal levels and interacted
normally with each other, they had a dramatically
reduced kinase activity. Therefore, PP2A is required,
directly or indirectly, for activating the kinase ac-
tivity of CLB2/CDC28 complexes, possibly via a
posttranslational modification or the removal of an
inhibitor of the complex. The Tyr-19 to phenylala-
nine alteration in CDC28 does not cure the defect in
CLB2/CDC28 kinase activity seen in the absence of
PP2A function. Therefore, PP2A is required for the
activation of the kinase activity of CLB2/CDC28
complexes via a mechanism that does not involve
dephosphorylation of Tyr-19.
To help understand the cellular functions of PP2A,
we isolated two high-copy-number suppressors of the
temperature-sensitive phenotype of pph21-102 cells.
One of these is SBE2 (which is required for bud
emergence) and the other is TAP42. As mentioned
above, TAP42 is an essential protein that physically
interacts with the catalytic subunit of PP2A and with
SIT4 (a type-2A-related phosphatase). The interac-
tion of TAP42 with PP2A does not require the A
(TPD3) or the B (CDC55) subunit of PP2A. We are
in the process of determining the cellular functions of
TAP42. For SBE2, we are determining if, like
TAP42, it also physically interacts with PP2A. In ad-
dition, we are determining if SBE2 might be a sub-
strate of PP2A. The isolation of SBE2 as a suppressor
may be related to the role of PP2A in bud growth.
Identification of the Proteins
That Interact with the Type-1
(PP1) Protein Phosphatase
Catalytic Subunit
E. Tegins
Budding yeast has a single known type-1 phosphatase
catalytic subunit. This protein is essential. We have
found that the epitope-tagged type-1 catalytic subunit
coimmunoprecipitates with eight major proteins. We
purified these proteins by large-scale immunoprecip-
itation followed by electrophoresis through SDS-
polyacrylamide gels. Peptides from these proteins are
currently being sequenced by R. Kobayashi (see
Structure and Computation Section). From the com-
(due in
very early 1996), we will be able to use PCR to
rapidly obtain the open reading frame for each type-1
phosphatase-associated protein. These clones will be
used both to delete the gene encoding each protein
and to overexpress each protein.
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INITIATION AND TERMINATION OF TRANSCRIPTION
IN HUMAN snRNA GENES AND HIV-1
N. Hernandez T.L. Calhoun R. Mital F.C. Pessler
E. Ford V. Mittal C.L. Sadowski
R.W. Henry D.J. Morrison S. Sepheri
B. Ma P.S. Pendergrast M.-W. Wong
The human small nuclear (sn)RNA genes share very
similar promoters, yet some of them are transcribed
by RNA polymerase II, whereas others are tran-
scribed by RNA polymerase III. We are characteriz-
ing the trans-acting factors involved in transcription
of the RNA polymerase II and III snRNA genes and
comparing them to the transcription factors involved
in RNA polymerase II transcription of mRNA-
encoding genes and RNA polymerase III transcrip-
tion of typical RNA polymerase III genes such as the
adenovirus 2 (Ad2) VAI gene. As described in more
detail below, we find that the RNA polymerase II and
III snRNA promoters share transcription factors that
are not used by other types of promoters. By identify-
ing the members of the snRNA transcription initia-
tion complexes and comparing them to factors used
in transcription from other promoters, we can address
how RNA polymerase specificity is determined.
The promoter of human immunodeficiency virus
type 1 (HIV-1) can direct the synthesis of two classes
of RNA molecules: full-length RNAs that extend
through the entire transcription unit, and short RNAs
that end approximately 60 nucleotides downstream
from the transcription start site, just 3' of a stable
stem-and-loop structure that encompasses the first 59
nucleotides of the RNA. Synthesis of the short trans-
cripts is dependent on a bipartite element, the inducer
of short transcripts (IST), which is located down-
stream from the transcription start site. Mutations in
1ST reduce the transcriptional output of the HIV-1
promoter by selectively debilitating the synthesis of
short transcripts while leaving the synthesis of full-
length transcripts unaffected. Thus, IST activates
transcription from the HIV-1 promoter, but the RNA
molecules resulting from this transcription activation
are short. IST, then, is not a termination signal. Rath-
er, it appears to activate the formation of transcrip-
tion complexes that are incapable of efficient elonga-
tion. We are interested in characterizing the biochem-
ical mechanisms that govern IST function.
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Characterization of the
SNAP45 Subunit of SNAP,
C.L. Sadowski, R.W. Henry, R. Kobayashi, N. Hernandez
The basal RNA polymerase II snRNA promoters
consist of only one essential element, the proximal
sequence element or PSE. The basal RNA polymer-
ase III snRNA promoters contain in addition a TATA
box. We have identified and purified a factor we
refer to as the SNAP complex (SNAP,) that recog-
nizes the PSE and is required for both RNA polymer-
ase II and III transcription from snRNA promoters.
This factor consists of four tightly associated sub-
units, SNAP43, SNAP45, SNAP50, and SNAP190,
as well as the TATA-box-binding protein, which ap-
pears to be more loosely associated. We have pre-
viously obtained peptide sequences for some of these
subunits and cDNAs corresponding to the SNAP43
subunit. We have now isolated a cDNA correspond-
ing to the SNAP45 subunit. Antibodies directed
against the cloned protein retard the mobility of the
SNAPe-PSE complex in an electrophoretic mobility
shift assay, indicating that it is indeed part of SNAI)c.
SNAP45 is exceptionally proline-rich; in fact,
prolines are, together with alanines, the most
abundant amino acids, each representing 14% of the
total number of residues. Database searches revealed
no striking homologies with any available protein se-
quence, but the protein contains an intriguing motif
constituted by proline residues spaced identically as
in the heptade repeat present at the carboxyl terminus
of the large subunit of RNA polymerase
SNAP45 is specifically coimmunoprecipitated in
nondenaturing immunoprecipitations from nuclear
extracts performed with anti-SNAP43 antibodies, and
reciprocally, SNAP43 is specifically coimmunopre-
cipitated with anti-SNAP45 antibodies. Thus, these
two proteins are part of the same complex, although
they do not appear to interact directly with each other
as determined by GST pull-down experiments. How-
ever, both proteins interact directly with TBP.
To determine whether the SNAP45 subunit is re-
quired for transcription of snRNA genes by both
RNA polymerases II and III, we depleted a nuclear
extract with anti-SNAP45 antibodies attached to
beads and tested the depleted extract for its ability to
direct transcription from the RNA polymerase II Ul
and RNA polymerase III U6 snRNA promoters.
Transcription from both promoters was debilitated,
whereas transcription from the RNA polymerase II
adenovirus 2 major late promoter and from the RNA
polymerase III VAI promoter was unaffected. Thus,
the SNAP complex appears to be required specifical-
ly for transcription of genes that contain a PSE. In ad-
dition, these data show that if slightly different ver-
sions of the SNAP complex are involved in RNA
polymerase II and III transcription from snRNA
promoters, they both contain the SNAP43 and the
SNAP45 subunits.
Characterization of
the SNAP50 Subunit
of SNAP,
R.W. Henry, C.L. Sadowski, R. Kobayashi, N. Hernandez
We have recently isolated a full-length cDNA clone
corresponding to the 50-kD subunit of SNAP,.
SNAP50 interacts with both SNAP43 and SNAP45 in
GST pull-down experiments. As soon as anti-
SNAP50 antibodies become available, we will be
able to test the role of SNAP50 in RNA polymerase
II and III transcription of human snRNA genes.
Characterization of
the SNAP190 Subunit
of SNAP,
M.-W. Wong, R.W. Henry, R. Kobayashi, N. Hernandez
In our original SNAP, preparation, which involved
several chromatographic steps, we detected a 190-kD
polypeptide whose abundance peaked with DNA-
binding activity. However, this protein appeared to be
substoichiometric with SNAP43, SNAP45, and
SNAP50. To determine whether SNAP190 is indeed
part of SNAP,, we purified SNAP, in just three steps,
using immunoprecipitation with either anti-SNAP43
or anti-SNAP45 antibodies as the last purification
step. In each case, we could detect a 190-kD polypep-
tide that specifically coimmunoprecipitated with both
SNAP43 and SNAP45. It is therefore clear that this
polypetide is indeed part of SNAP,. We have scaled
up the purification to obtain enough material for mi-
crosequencing.
Characterization
of TFIIIB
R. Mital, R. Kobayashi, N. Hernandez
TFIIIB is a poorly characterized fraction required for
transcription by RNA polymerase III. We have pre-
viously shown that the TFIIIB fraction contains two
separable activities. One of these is a TBP-containing
complex and is required for RNA polymerase III
transcription of genes with internal promoter ele-
ments but not for transcription of the human U6 gene,
whose promoter is entirely located in the 5' -flanking
region.
We have purified this TBP-containing complex
near homogeneity. It contains TBP and a tightly asso-
ciated protein of approximately 90 kD. We obtained
the peptide sequence for this 90-kD polypeptide and
used the information to isolate several cDNAs that
encode two protein sequences highly related to
BRF1, the TBP-associated, 67-kD subunit of yeast
TFIIIB. One of these sequences is (nearly) identical
to that of TFIIIB90, a TBP-associated protein in-
volved in RNA polymerase III transcription recently
cloned by the R. Roeder and colleagues. The other
sequence encodes a protein (TFIIIB90b) that is four
amino acids longer than TFIIIB90 and diverges from
TFIIIB90 in the first nine amino-terminal residues.
Intriguingly, TFIIIB90b does not contain a cystein
that is part of a putative zinc finger present in the first
30 amino acids of TFIIIB90 and conserved in yeast
BRF1 as well as in the related protein TFIIB.
We have generated anti-bodies directed against
several peptides common to TFIIIB90 and
TFIIIB90b, as well as against the divergent amino
termini. Together, the TFIIIB90- and TFIIIB90b-
encoding cDNAs and the antibodies will be invalu-
able reagents to determine whether these proteins
have a role in U6 transcription.
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The POU Domain
Potentiates the
Binding of the
SNAP Complex
V. Mittal, M. Cleary, W. Herr, N. Hernandez
Both the RNA polymerase II and III snRNA pro-
moters contain a distance sequence element (DSE)
which serves as an enhancer. The DSE is character-
ized by the presence of an octamer motif, the binding
site for the trans-activator Oct-1, a POU domain
protein. R. Roeder and colleagues have shown that on
a probe containing adjacent octamer and PSE sites,
the POU domain of Oct-1 binds cooperatively with
PTF, a factor that appears to be related or identical to
the SNAP complex. In collaboration with M. Cleary
and W. Herr (see Transcriptional Regulation in the
Tumor Viruses Section), we have pursued this obser-
vation.
The POU domain is a bipartite DNA-binding
domain consisting of a POU-homeo (POUR) domain
and a POU-specific (POUR) domain joined by a flexi-
ble linker. We showed that the Oct-1 POU domain,
but not the related pituitary Pit-1 POU domain, can
facilitate the binding of SNAP, to the PSE by in-
creasing its on-rate. The effect depends largely on
one of many amino acid differences between the Oct-
1 and Pit-1 POU domains. Thus, exchange of the
glutamic acid at position 7 in the Oct-1 POUR domain
for its Pit-1 counterpart, an arginine, inactivated the
ability of the Oct-1 POU domain to recruit SNAP, to
the PSE. Reciprocally, substituting the arginine at
position 7 in the Pit-1 POUR domain with the
glutamic acid present at the corresponding position in
the Oct-1 POUR domain imparted onto Pit-1 the
ability to recruit SNAP,. The effect is most probably
due to protein-protein interactions, as an antibody
that recognizes the amino terminus of the Oct-1
POUR domain disrupts the ability of the Oct-1 POU
domain to recruit SNAP, to the PSE. Remarkably,
the abilities of wild-type and mutant POU domains to
enhance snRNA gene transcription in vitro correlated
directly with their abilities to recruit SNAP, to the
PSE. Transcriptional activators usually consist of
separable DNA-binding and activation domains. Our
results show that the ability to activate transcription,
a property generally thought to be the exclusive
hallmark of activation domains, can also be displayed
by a DNA-binding domain.
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Characterization
of a Novel
PSE-binding Activity
E. Ford, N. Hernandez
In nuclear extracts, we can detect, in addition to
SNAP,, a second PSE-binding complex of slower
mobility. We have characterized this complex and
shown that it consists of SNAP, and Oct-1. Thus, al-
though Oct-1 on its own cannot bind to the DNA
probe used in these experiments, it can associate with
the SNAP,-PSE complex. We are characterizing the
protein-protein and protein-DNA interactions that
stabilize the Oct-l-SNAP,-PSE complex on this
probe. In particular, we are determining whether Oct-
1 contacts DNA and which of the SNAP, subunits it
contacts directly.
Characterization
of Human
RNA Polymerase III
S. Sepheri, N. Hernandez
To reconstitute RNA polymerase III transcription in a
completely defined system, we need highly purified
RNA polymerase III. In addition, to study protein-
protein interactions that lead to the recruitment of
RNA polymerase III to specific promoters, we need
antibodies directed against human RNA polymerase
III. Such antibodies are presently not available. To
generate anti-human RNA polymerase III antibodies
that may be useful both for the purification of RNA
polymerase III and for the study of RNA polymerase
III recruitment, we have isolated a partial cDNA
clone corresponding to the largest subunit of human
RNA polymerase III.
We are currently trying to obtain full-length cDNA
clones as well as using the sequence information we
already have to generate anti-peptide antibodies. If
such antibodies recognize the native enzyme, we will
use them to study protein-protein interactions be-
tween RNA polymerase III and different RNA
polymerase III transcription factors. We will also at-
tempt to develop a simple protocol for the purifica-
tion of RNA polymerase
Factors Required for snRNA
Transcription by RNA Polymerase II
T.L. Calhoun, N. Hernandez
In the RNA polymerase II snRNA promoters, a single
element, the PSE, is capable of directing basal levels
of transcription. We know that the SNAP complex
binds to the PSE and is required for RNA polymerase
II transcription. Which other transcription factors are
involved? To answer this question, we are testing
general RNA polymerase II transcription factors in-
volved in mRNA transcription for their ability to
reconstitute RNA polymerase II snRNA gene tran-
scription in vitro and to assemble on the Ul snRNA
promoter.
Identification and Purification of
ISTBF, a Factor That Specifically
Recognizes the 1ST
F.C. Pessler, N. Hernandez
We have identified an IST-binding factor (ISTBF)
whose binding to wild-type and mutated versions of
the IST correlates well with short transcript forma-
tion. ISTBF has been purified to near homogeneity
and consists of a single polypeptide whose size is
identical to that of a polypeptide which can be specif-
ically cross-linked to the IST in partially purified
fractions. This factor binds to a number of cellular
promoters in addition to the HIV -1 promoter.
As a first step to show directly that ISTBF is in-
deed required for formation of short transcripts in the
HIV -1 LTR, we have developed an in vitro transcrip-
tion system in which the synthesis of short transcripts
is dependent on IST. Short transcripts are synthesized
by RNA polymerase II as determined by a-amanitin
sensitivity studies, and they are not generated by con-
structs containing mutations in the 1ST. We can now
determine whether depletion of ISTBF results in spe-
cific inhibition of the formation of short transcripts.
Isolation of cDNAs
Corresponding to ISTBF
D.J. Morrison, R. Kobayashi, N. Hernandez
To elucidate the function of ISTBF in formation of
short transcripts, we need to obtain corresponding
cDNAs such that we can overexpress the protein and
use it for functional studies and to raise specific
antibodies.
As a first step toward this goal, we have scaled
up the purification of ISTBF and obtained the peptide
sequence. We are using the sequence information to
design degenerate primers for use in polymerase
chain reactions (PCRs). If we obtain a specific PCR
fragment, we will use it as a probe for the screening
of cDNA libraries.
TBP Domains Required for
Tat Trans-activation
and 1ST Function
P.S. Pendergrast, D.J. Morrison, W.P. Tansey,
M. Sheldon, N. Hernandez
HIV -1 is regulated in large part by a viral activator
known as Tat. Tat recognizes an RNA target named
TAR and is encoded close to the transcription start
site. Whereas IST appears to direct the formation of
transcription complexes that are incapable of efficient
elongation, Tat appears to have the opposite effect: In
the presence of Tat, the number of full-length tran-
scripts is greatly increased and the number of short
transcripts is decreased, suggesting that Tat counter-
acts the activity of IST by promoting the formation of
transcription complexes that are capable of efficient
elongation.
The HIV -1 promoter contains a TATA box. To
determine whether the TATA-box-binding protein
(TBP) is required for synthesis of both short and full-
length transcripts in the absence and presence of Tat,
we used an in vivo assay based on a triple-amino-acid
substitution in TBP. This mutation, first described by
Dr. Struhl and colleagues, creates an altered specific-
ity TBP (TBPAS) that can bind to both the wild-type
TATA box and a mutated TATA box. Reporter
promoters containing the altered TATA box can be
used to test the effects of mutations in other parts of
the protein on transcription. We inserted the altered
TATA box in the HIV-1 promoter and showed that
synthesis of both short and long transcripts was
debilitated. Cotransfection of a TBPAs-expressing
vector restored the synthesis of short and long trans-
cripts in the absence of Tat as well as activation by
Tat, indicating that TBP bound to the TATA box is
required for all of these processes. Full-length human
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TBP could be replaced by the carboxy-terminal
DNA-binding domain of human TBP and by full-
length yeast TBP, indicating that the TBP residues
important for all transcription from the HIV-1 LTR
reside in the carboxy-terminal domain of TBP and
are conserved between yeast and humans. Various
mutations in TBP affected the synthesis of short and
full-length transcripts as well as Tat activation
similarly, and the effects correlated with the pre-
viously described effects of these mutations on bind-
ing of TBP to the largest subunit of TFIID,
TAF11250, which is essential for the assembly of the
TFIID complex.
Together, these data suggest that if the HIV-1
promoter generates short and full-length transcripts
by assembling different transcription complexes,
these transcription complexes both use TBP similar-
ly, probably as part of TFIID.
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TELOMERASE BIOCHEMISTRY AND REGULATION
C.W. Greider C. Autexier K. Collins
A.A. Avilion J. Hemish
M.A. Blasco A. Kass-Eisler
K. Buchkovich S. Le
R. Pruzan
N. Sareen
S.K. Smith
Telomeres were defined in the 1930s as essential
components at chromosome termini that stabilize
chromosomes against degradation and recombina-
tion. Around the same time, chromosomal rearrange-
ments were shown to be prevalent in tumors and
were suggested to play a part in cancer development.
In the last 5 years, the connection between telomere
function, chromosome rearrangements, and cancer
pro-gression has begun to be elucidated. Two obser-
vations set the stage for the recent rapid progress on
telomere function in cancer and aging: Telomeres
shorten with progressive rounds of cell division in
vivo and in vitro and telomere length is shorter in
tumor tissues than in normal adjacent tissue. The
mechanism of telomere length regulation in eukary-
otes has been established from work in a number of
labs using single-cell eukaryotes such as ciliates and
yeast as experimental organisms. Telomeric DNA
consists of tandemly repeated simple G-rich se-
quences in a wide variety of eukaryotes. The exact
sequence of the repeats varies between species, for
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example, TTGGGG in Tetrahymena and TTAGGG
in mammals. Since conventional DNA polymerases
require an RNA primer and polymerize only in the
5' to 3' direction, chromosomes cannot be fully
copied at their ends and thus are predicted to shorten
after each duplication. In single-cell eukaryotes,
telomere length is maintained by the de novo addi-
tion of telomere repeats onto chromosome ends.
Thus, telomere length reflects a dynamic balance be-
tween telomere shortening and telomere lengthening.
Telomerase is the ribonucleoprotein DNA poly-
merase that elongates telomeres. Telomerase, first
characterized in Tetrahymena, consists of both
proteins and an essential RNA that provides the
template for the synthesis of telomere repeats. The
Tetrahymena telomerase RNA contains nine nucleo-
tides, 5' -CAACCCCAA-3 ' , that allow synthesis of
telomeric TTGGGG repeats. Alterations in the se-
quence of this template region alter the sequence of
telomere repeats in vivo and in vitro. The telomerase
RNA component has been isolated from several
ciliates in addition to Tetrahymena, from two yeasts,
and last year, we reported the cloning of the human
and mouse telomerase RNA components.
In 1990 we showed that telomere length shortens
as primary human cells divide in culture. This obser-
vation suggested that telomerase may be absent from
primary cells and that telomeres may shorten due to
the end replication problem. Subsequent work from a
number of labs including our own has shown that
many primary cells and tissues lack telomerase ac-
tivity. The lack of detectable telomerase activity in
primary tissues may explain the short telomeres in
tumor cells compared to normal tissue. During the
multiple cell divisions a tumor must undergo, in the
absence of telomerase, telomeres are expected to
shorten. When primary cells are immortalized after
transfection with a variety of viral oncogenes,
telomeres initially shorten and no telomerase activity
is detected. Just before and during crisis, many end-
to-end associations of chromosomes and ring
chromosomes are found, suggesting telomere defects.
After crisis, both telomere length and the karyotype
are stabilized and telomerase activity is detected.
These experiments suggested that there is a strong se-
lection at crisis for cells that can re-express telomer-
ase and maintain telomere length. Furthermore, the
results suggest that telomerase activity may be re-
quired for the growth of immortalized cells. In the
absence of telomerase, telomeres may shorten, and
cells may re-enter crisis and die.
In the past year, we have continued our detailed
biochemical analysis of the Tetrahymena telomerase
enzyme to understand the mechanism of this unusual
DNA polymerase. In addition, we have expanded our
studies to elucidate the regulation of mammalian
telomerase in tumorigenesis and in normal develop-
ment using the mouse as a model system.
Functional Dissection
of the Tetrahymena
Telomerase RNA
C. Autexier
Using an in vitro reconstitution assay in which
Tetrahymena telomerase activity can be recovered
from micrococcal nuclease-treated protein extracts
and in vitro transcribed telomerase RNA, we have
previously identified two functional domains within
the nine-nucleotide "template," a template, and an
alignment region. In the past year, we continued to
use the in vitro reconstitution assay to study the func-
tional requirements of the telomerase RNA. First,
mutations in the template and alignment regions were
analyzed to characterize further the function of the
residues in these regions. Second, mutants in a con-
served region upstream of the template were tested.
Third, deletions and changes were made in the
telomerase RNA to test the function of predicted
secondary structures. Results indicate that the
template region can be increased and decreased in
length, suggesting a flexibility in the sequence of the
template domain. Circular permutations of the
template region suggest that the telomerase RNA can
have different alignment regions, more 3 ' to the pre-
viously defined alignment region. The relaxed speci-
ficity and flexibility of the alignment and template
domains of telomerase RNA in the recognition and
elongation of substrate DNA may be important in
vivo. Telomerase directly adds telomeric DNA de
novo onto nontelomeric sequences during develop-
mentally controlled chromosome healing in Tetrahy-
mena and in mammalian cells. Perhaps, in vivo, non-
telomeric or non-G-rich substrates align with the 3' -
flanking region of the alignment region or alternative
regions of the RNA.
There is a six-nucleotide sequence 5 ° -(CU)
GUCA-3 ' , two residues upstream of the template
region, which is conserved among the ciliate
telomerase RNAs. Changing the spacing (normally
two residues) between the template region and this
conserved region (42+U) moved the 5 ' boundary of
the template more 5' (arrow in Fig. 1), suggesting
that the location of this conserved sequence is impor-
tant in determining the 5' boundary of the template.
For example, deleting a spacer residue (residue 42)
resulted in the exclusion of a residue normally part of
the template (43). Changing the sequence of the
spacer residues did not affect the 5' boundary of the
template (42G). Mutating the sequence of the con-
served region (38-40AGU) resulted in the aberrant
regulation of the 5 ' template boundary, suggesting
that some sequence-specific interactions between this
conserved region and either RNA or protein are im-
portant in preventing polymerization beyond the
5' end of the template. This is the first identification
of a functional region of the telomerase RNA, other
than the template domain.
Deletions potentially disturbing predicted higher-
order structures at the 5 ' (8-base deletion) and
3' ends (13-base deletion) of the RNA do not affect
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WT 3.-AACCCCAA
42G 3'-AACCCCAAC
542 3'-AACCCCAA
543
43U 3'-AACCCCAAU
42+U 5-AACCCCAACU-5'
38-40AGU 3'-AACCCCAACULTEM=5'
el/MEM
MINKON
3'-AACCCCAA-5'
FIGURE 1 The position and sequence of the conserved se-
quence determine the 5' boundary of the template. The
nine-nucleotide template and alignment domains (residues
43-51 in the full-length wild-type Tetrahymena telomerase
RNA) are shown with the upstream conserved region
5' CUGUCA-3 ' (residues 35-40; open box) and the spacer
residues (residues 41 and 42; stippled box). The sequence
is written in a 3 ' to 5' direction. An arrow indicates the
5' boundary of the template. The wild-type sequence is
compared to the sequence of mutant RNA5. In the 38-
40AGU mutant, the mutated sequence (hatched box) is
shown.
template specificity but alter the efficiency of the
elongation activity of telomerase, as compared to
wild type. Work is currently in progress to address
the function of other predicted secondary structures.
Terminal and internal deletions of conserved stem-
loop structures and sequences are being analyzed.
Understanding the role of the RNA component of
telomerase is critical in understanding the role of
telomerase in DNA replication in both normal and
cancer cells.
Utilization of Ribonucleotides
and RNA Primers by
Tetrahymena Telomerase
K. Collins
In vitro, Tetrahymena telomerase can elongate single-
stranded DNA primers processively: One primer can
be extended by multiple rounds of template copying
before. product dissociation. Telomerase will in-
corporate dNTPs or ddNTPs and will elongate any G-
rich, single-stranded primer DNA. In this past year,
we described a new activity of the Tetrahymena
telomerase; we showed that Tetrahymena telomerase
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can incorporate a ribonuceotide, rGTP, into elonga-
tion products. Synthesis of the product d(TT)r
(GGGG) was processive, suggesting that the chimer-
ic product remained associated with the enzyme both
at the active site and at a second, previously charac-
terized, template-independent product-binding site.
As predicted by this finding, RNA-containing
oligonucleotides served as primers for elongation.
More than three nucleotides of RNA at a primer
3' end decreased the quantity of product synthesis
but increased the affinity of the primer for
telomerase. Thus, RNA-containing primers were ef-
fective as competitive inhibitors of DNA primer
elongation by telomerase (Fig. 2). These results sup-
port the possible evolutionary origin of telomerase as
an RNA-dependent RNA polymerase.
Regulation of Human
Telomerase Activity
and RNA Levels
A. Avilion [in collaboration with Jyothi Gupta
and Dr. Silvia Bacchetti, McMaster University, and
Drs. Mieczyslaw Piatyszek and Jerry Shay, University
of Texas Southwestern Medical Center at Dallas]
We followed the levels of human telomerase RNA
(hTR) during cellular immortalization in vitro. In col-
laboration with Dr. Silvia Bacchetti's group, we used
a sensitive polymerase chain reaction (PCR)-based
assay for telomerase activity to reexamine telomerase
activity in the HEK cells described above that had
been transfected with SV40 T antigen. The precrisis
cells did not have detectable telomerase activity,
whereas the postcrisis cells had significant levels of
telomerase activity. In human B cells infected with
Epstein-Barr virus (EBV), telomerase activity was
also elevated postcrisis. In both cases, however, the
hTR levels were initially high and did not increase
significantly after crisis. We further looked at 22 dif-
ferent human tumor samples and 6 normal tissues in
collaboration with Dr. Jerry Shay's group and found
that the level of the telomerase RNA did not parallel
the level of telomerase activity in these samples. In
all cases, tumors that had telomerase activity had
detectable levels of hTR. However, some tumors with
very low levels of activity had very high levels of
hTR (Fig. 3). These discrepancies indicate that hTR
levels cannot be used as a marker for the presence of
telomerase activity.
A
1 2 3 456 7 8 9 101112 B 1 2 3 4 5 6 7 8 91011 12 1314151617 18
MNase 111L_J
primer 0.5 5 0.5 5 055 0.5 5
- -
0 0.5 5 05 5 0.5 5 0.5 5 p.N1 competitor
rT"
_V
M Ca
FIGURE 2 Elongation of d(G3T2G)3 in the absence or presence of competitor RNA and
chimeric RNA/DNA primers. (A) Elongation of RNA and chimeric RNA/DNA primers alone.
Reactions were mock-treated (-MNase) or treated (+MNase) with micrococcal nuclease be-
fore inactivation of the nuclease and addition of primer to reactions. Primers were assayed at
either 0.5 or 5 mm concentration. (8) Elongation of d(G3T2G)3 in the absence (lanes 1,2) or
presence of competitor RNA and chimeric RNA/DNA primers. Reactions were done in dupli-
cate and loaded in adjacent gel lanes. All reactions contained 0.5 mm d(G3T2G)3 with the indi-
cated competitor RNA or chimeric RNA/DNA primer at 0.5 or 5 mm concentration. Reactions
were precipitated and electrophoresed on an 11% acrylamide, 7 M urea gel. (A,B) From the
same gel and exposure. Arrowheads indicate the migration of the predominant product from
elongation of the 12-nucleotide chimeric primer d(GT2G4)r(U2G3).
Differential Regulation of
Telomerase Activity and
Telomerase RNA during
Multistage Tumorigenesis
M. Blasco [in collaboration with M. Rizen and
D. Hanahan, University of California, San Francisco]
To determine when telomerase is activated during
tumor development and progression, we examined
telomerase activity and mouse telomerase RNA
(mTR) expression in two well-characterized trans-
genic mouse models of multistage tumorigenesis, de-
veloped by Doug Hanahan's lab: K14-HPV-16 trans-
genic mice and RIP1-TAg2 transgenic mice. These
mouse models allow examination of many indepen-
dent tumors at different stages in tumor progression
from genetically identical individuals. K14-HPV-16
transgenic mice express the early region of the hu-
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FIGURE 3 Human telomerase RNA levels in tumor vs.
normal tissues. Total RNA was made from different tissues,
and 25 lig of each was analyzed by Northern blot analysis.
The asterisk indicates normal tissues tested, whereas the
other tissues are from tumors. The graph shows the relative
amounts of telomerase RNA (Relative hTR) in different
tumors normalized to the amount of 5S RNA. Telomerase
activity levels plotted on the right with a 0, for no activity, or
1-4 to indicate the relative level of telomerase activity
detected. Extracts that showed activity at 0.06 !..tg were
designated 4 for telomerase activity. Extracts that had weak
activity at higher concentrations (6 lig) were designated 1
for weak activity, 2 for strong activity at 6 lig, or 3 for strong
activity at 0.6.
man papillomavirus type 16 (HPV-16) in basal
keratinocytes, resulting in multistage induction of
squamous cell carcinomas of the epidermis that show
the histological hallmarks of squamous epithelial
cancer in humans. Initially, diffuse hyperplastic le-
sions develop, which are followed by dysplastic le-
sions, papillomas, and subsequently two classes of
carcinoma, well differentiated (WD-SCC) and mod-
erate to poorly differentiated squamous cell car-
cinoma (M/PD-SCC). In the second model, RIP1-
TAg2 mice develop pancreatic f3 cell islet carcinomas
along a multistage pathway elicited by expression of
the SV40 T-antigen oncogene. The pathway models
the progression of human carcinoma-in-situ lesions;
the stages arise sequentially and are statistically
separable. Initially, uniform expression of the T-
antigen oncogene elicits focal hyperproliferation in a
subset of the islets, and then a subset of these hyper-
plastic islets switch on angiogenesis and a few pro-
gress to solid tumors.
In both models of multistage tumorigenesis, telo-
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TABLE 1 Telomerase Activity during Multistage
Tumorigenesis in Transgenic Mice
Transgenic
system Stage
Islet cell carcinoma normal islets'
(RIPi-TAg2) angiogenic isletsb
islet tumor
Squamous cell
carcinoma
(K14-HPV-16)
Telomerase positive
samples/total tested
hyperplastic back skin
dysplastic ear
peritumor dysplasia
well differentiated-SCC
moderately differentiated-SCC
poorly differentiated-SCC
lymph nodes°
0/1
0/1
13/17
0/5
0/6
0/2
0/3
1/2
2/2
2/3
'Pool of islets from ten nontransgenic mice.
bPool of angiogenic islets from six transgenic mice.
bThe lymph node from mouse 64395 was demonstrated by histology
to contain a metastatic lesion. The nodes from mouse 62015 were
found to be 'reactive,' but no metastatic cells could be detected by
histology.
merase activity was detected only in late-stage
tumors (Table 1). In contrast, mTR levels were up-
regulated in the early preneoplastic stages and further
increased during progression. The mTR levels did not
parallel the levels of telomerase activity, and a subset
of tumors lacked telomerase activity and yet ex-
pressed telomerase RNA. These results suggest that
although telomerase RNA is required for enzyme ac-
tivity, the regulation of telomerase activity is
separable from expression of its RNA component.
Together with the results from human cells, this sug-
gests that the level of telomerase RNA cannot be
used as a marker for the presence of telomerase ac-
tivity during tumor progression.
Surprisingly, when we examined mTR levels in
histologically normal tissue from transgenic and non-
transgenic parental mouse lines, we found that mTR
levels were significantly higher in the transgenic
animal tissues. In the K14-HPV-16 transgenic mice,
mTR levels in normal back skin, ear, and lymph node
were markedly higher than those in a nontransgenic
control parental FVB/n mouse. Brain tissue from
both control and the transgenic mice showed very
low levels of mTR as expected since brain does not
express the HPV-16 oncogene or have detectable
telomerase activity (Fig. 4). Similarly, when we com-
pared mTR levels in histologically normal islets from
RIP1-TAg2 transgenic mice and control parental
nontransgenic C57BL/6 mice, mTR was detected in
the RIP1-TAg2 transgenic islets but not in the control
mTR and telomerase activity in
K14-HPV16 mice
FIGURE 4 mTR and telomerase activity levels during tumor
progression in K14-HPV-16 transgenic mice and in normal
mice. Northern blots were done using RNA isolated from
various stages of tumor progression in four K14-HPV-16
transgenic mice and from normal tissues from a parental
nontransgenic strain (asterisk). The amount of mTR in each
lane was normalized to the amount of 5S RNA and quanti-
fied using a Fuji Phospholmager. The level of mTR is ex-
pressed in arbitrary units. Telomerase activity was also as-
sayed in the same tissue samples from transgenic and non-
transgenic mice. Activity was classified into four levels ac-
cording to the amount of activity detected at two different
tissues extract dilutions: (0) no detectable activity; (1) low
activity visible only at high extract concentrations; (2) mod-
erate activity seen at high and low protein concentrations;
(3) high activity when strong activity signal was detected on
short exposures at all protein concentrations tested.
mouse islets. These observations suggest that up-
regulation of mTR in the preneoplastic stages of
tumor formation may be a direct consequence of on-
cogene expression.
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Molecular and Genetic
Analysis of the Maize
Indeterminate Gene
J. Colasanti, V. Sundaresan
The life cycle of higher plants consists of a vegetative
phase and a reproductive phase. Very little is known
about the mechanisms that mediate the transition
from vegetative to reproductive growth. To better un-
derstand how this process is controlled at the molecu-
lar level, we are analyzing the indeterminatel gene
(idl) of maize, which is required for the vegetative to
reproductive transition. Mutants that are defective for
normal Id] gene function are unable to undergo
normal reproductive development; i.e., id] mutants
continue to form leaves long after normal plants have
flowered and, given enough time, severe id] mutants
form aberrant floral structures with vegetative char-
acteristics. Therefore, Id] is required for the transi-
tion to reproductive development in maize and, pos-
sibly, in all higher plants. In a previous report, we de-
scribed the isolation of a transposon-tagged idl al-
lele, idl-ml, that is the result of a Ds2 transposable
element insertion into the Idl gene. The sequence
near the Ds2 insertion encodes a putative zinc finger
DNA-binding motif, similar to regulatory proteins
found in several other species. In addition, we
demonstrated that the severity of the idl-ml
phenotype is alleviated by the presence of an Ac ele-
ment, which provides transposase function and
promotes Ds element transposition. The absence of
defined sectors of revertant tissue suggests that the
Idl gene can act non-cell autonomously; i.e, the ID1
protein, or a target of the IDI protein, can diffuse
from one location to another to mediate its function.
Here, we report further evidence for this result, and
we show preliminary findings about the Id] gene
structure and expression pattern.
EFFECT OF AC DOSAGE ON Idl-ml MUTATION
It was observed that id1-m1 mutants that have Ac ele-
ments in the background had a less severe id]
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phenotype relative to idl-ml siblings with no Ac.
This characterization has been extended by analyzing
the effect of Ac dosage on flowering time of idl-ml
mutants. The Ac transposable elements of maize ex-
hibit a negative dosage phenomenon for transposi-
tion. For example, the bz2-m2 allele, the result of a
Ds2 insertion into the aleurone pigmentation gene,
Bz2, will exhibit large revertant sectors on the kernel
in the presence of one Ac element. However, the
aleurone sectors are smaller and less abundant with
increasing copies of Ac, demonstrating that higher
doses of Ac cause Ds excisions to occur later and less
frequently during development. We wanted to deter-
mine if the idl-ml phenotype exhibited a similar neg-
ative dosage effect. An idl-ml bz2-m2 homozygous
plant that carried one Ac was self-crossed, and a fam-
ily of kernels was obtained that segregated one Ac
element (large aleurone spots), two to three Ac ele-
ments (tiny spots), or no Ac elements (no spots). As
reported previously and shown in Figure 1, kernels
with no spots (0 Ac) had the most severe idl
phenotype; i.e., they made many more leaves than
wild-type plants and they formed reproductive struc-
tures with vegetative characteristics. However, plants
grown from kernels with large spots gave rise to id]
mutants that flowered relatively early (although later
than wild type), but tiny-spotted kernels gave rise to
plants with an id] phenotype only slightly less severe
than the 0 Ac mutant siblings (Fig. 1). This observa-
tion suggests that different doses of Ac result in dif-
ferent levels of functional Idl gene expression.
Presumably, the plants from large-spotted kernels
have large somatic sectors of normal plant tissue with
restored Id] function, and small-spotted kernels give
rise to plants with smaller sectors of Id] tissue. In ad-
dition, in support of the suggestion that Idl acts non-
cell autonomously, revertant sectors of normal flow-
ering tissue on id] mutant plants have never been ob-
served. Rather, the whole plant uniformly flowers
earlier or later, depending on Ac dosage. These obser-
vations suggest a possible mechanism where the Idl
gene product is produced in revertant sectors of the
leaves and is transmitted to the shoot apex, or,
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FIGURE 1 Effect of Ac dosage on idl-ml flowering time. Kernels homozygous for
idl-ml that carried either one Ac element (large spots), two to three Ac elements
(small spots), or no Ac elements (no spots) were planted, and the flowering time
of the resulting plants was recorded as a function of leaf number. Each rec-
tangular box represents one plant. Boxes with dots in them represent plants with
less severe idl phenotypes with relatively normal flowers that could be crossed.
Boxes with clover symbols represent plants with severe idl mutant phenotypes
that exhibited aberrant floral development and extensvie reversion to vegetative
growth. One plant from the "0 Ac" plants (box near five-pointed star) flowered at
the same time as wild-type plants with 12 leaves and it had completely normal
flowers. This plant is the germinal revertant described in the text.
alternatively, by regulating the production of a signal
that diffuses to the shoot apex, to mediate the transi-
tion from vegetative to reproductive growth. Further-
more, the observation that idl-ml mutants with a
higher Ac dose have a mutant phenotype almost as
severe as plants with no Ac reveals that critical levels
of Idl gene product are required to mediate the
transition to flowering.
IDENTIFICATION OF A GERMINAL REVERTANT
Further proof that the cloned sequence encodes a part
of the Idl gene was obtained by the isolation of a
germinal revertant. As described above, some Ac-
bearing idl-ml mutant plants flowered with a suffi-
ciently normal phenotype that they could be crossed
to each other, thereby generating idl-ml homozygous
kernels. The progeny of these crosses segregated
spotted and bronze kernels in a ratio which suggested
that a single Ac element was present in the original
parents; i.e., 3/4 spotted kernels, 1/4 bronze kernels.
When these kernels were planted, all but one plant
exhibited the idl phenotype, and as observed in the
above experiment, spotted kernels give rise to plants
with a less severe phenotype than plants from bronze
kernels. Among the plants derived from bronze
kernels (0 Ac), a single exception was found that had
a completely wild-type phenotype; i.e., it made as
many leaves and flowered at the same time, with
completely normal flowers, as its wild-type siblings
(Fig. 1). We assume that this is a true revertant allele
because the parent of this plant was crossed in the
field more than 5 weeks after all wild-type plants had
shed out, eliminating the possibility of contaminating
pollen. In addition, since there is no Ac element pres-
ent in this plant to cause somatic reversion, it is not
the result of a very large somatic sector. Southern
blot analysis of this plant showed that it had both the
4.2-kb band (a Sac! genomic fragment with the Ds2
element insertion) and the 2.9-kb band that hybri-
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dized to Ds2 flanking DNA, consistent with excision
of Ds2 from one of the idl -ml loci. Whereas South-
ern analysis showed that all the other plants from
bronze kernels had a single 4.2-kb Sac' band, typical
of idl -ml homozygous mutants, one bronze kernel
plant that had a severe idl phenotype had both 4.2-kb
and 2.9-kb bands, as was found in the putative
germinal revertant.
The DNA flanking the former Ds2 insertion site in
both of these plants was amplified by PCR, cloned,
and sequenced. The idl mutant plant had a footprint
identical to a previously described stable null allele,
idl-X, and therefore is the result of an imprecise
germinal excision (Annual Report, 1994). The puta-
tive revertant plant, however, had no footprint; i.e., it
had the same sequence as the wild-type allele. Given
that contamination with normal pollen is highly im-
probable since all normal plants had shed out long
before, we assume that this new allele is a germinal
revertant that has restored Id1 function. It is possible
that, since the Ds2 element is inserted into an exon
very close to the zinc finger consensus region (see
below), an excision that causes an insertion or dele-
tion of even one amino acid could result in a defec-
tive gene product, and only precise excisions can re-
store gene function completely. In addition to
revertant alleles, it is possible that Ds2 excision from
idl -ml , or its reinsertion into other parts of the Idl
gene, will result in the generation of new idl mutant
alleles that will give clues about how the Idl gene
product functions.
DETERMINATION OF THE Idl TRANSCRIBED REGION
Analysis of the structure of the Idl gene and its pat-
tern of expression will reveal something about how
this gene acts to mediate the conversion of a vegeta-
tive meristem to a reproductive meristem. We have
not been able to identify Idl mRNA by Northern blot
Ds2
1.3 kb intron
analysis, perhaps because it is expressed at very low
levels. In lieu of obtaining or constructing cDNA li-
braries derived from many different plant tissues and
screening for cDNA clones by hybridization, the
technique of RT-PCR was used to ascertain (1) in
which tissues the Idl gene is expressed most abun-
dantly, relative to other tissues, and (2) the regions of
genomic sequence that are transcribed. The 2.9-kb
genomic region flanking the Ds2 element was se-
quenced, and primers complementary to both strands
were synthesized along its length at 200-400-bp in-
tervals.
Reverse transcriptase was used to synthesize
cDNA from poly(A)+ mRNA obtained from shoot
apex, young leaf (from plants with 8-10 leaves), and
root tissue. Various combinations of primers were
used in PCRs to map transcribed regions. The initial
selection of primer pairs was based on potential open
reading frames (ORFs) that were found in the
genomic sequence. This analysis has revealed the fol-
lowing information about the Idl transcript: (1) The
Ds2 transposable element is inserted within an exon,
7 by upstream of an exon/intron junction (Fig. 2).
The intron is 1.3 kb in length and is followed by an
exon of approximately 500-600 bp. The remainder of
the genomic 2.9-kb genomic fragment is intron se-
quence. (2) RT-PCR confirmed that the Idl mRNA is
not expressed abundantly in any of the tissues exam-
ined. This semiquantitative assessment was made rel-
ative to the expression of the maize cell division
cycle gene, cdc2, which is present at easily detectable
levels in all tissues tested. The Idl mRNA is found at
its highest levels in young leaf tissue. Shoot apices
were second in abundance for Idl expression, but the
tissue used for the isolation of RNA had a small
amount of surrounding leaf tissue, and therefore is
not composed entirely of apical cells. Idl mRNA was
not detectable in roots. These results support the idea
that Idl regulates a flowering signal that originates
outside the shoot apex, possibly in the leaves.
FIGURE 2 Schematic representation of the 4.9-kb Sacl (S) genomic fragment.
Boxed area represents the known transcribed regions of the genomic clone. The
1.3-kb Ds2 transposon is inserted 7 by upstream of the exon/intron junction.
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IDENTIFICATION OF idl-Muml, A Mutator-TAGGED
ALLELE OF idl
Recently, a newly identified idl allele, idl-Muml ,
was made available to us by Dr. Guri Johal (Univer-
sity of Missouri, Columbia) who found it segregating
in a family of plants that segregated Mutator trans-
posable elements. Southern analysis with probes
derived from Ds2-flanking genomic DNA revealed
that idl mutant plants from this Mutator family con-
tain a large insertion in the 2.9-kb region. Using vari-
ous primers specific to this genomic region and
primers specific to the ends of all known Mutator
transposons, we have found that idl -Muml has a Mu
element inserted approximately 700 by distal to the
Ds2 insertion site of the idl -ml allele; i.e., approxi-
mately in the middle of the 1.3-kb intron. These
results provide further evidence that the cloned frag-
ment contains a portion of the Id1 gene. The idl-
Muml mutation also provides another mutant allele
of id1 which will be used to study Id] gene function.
Genetic Analysis of Embryogenesis
in Arabidopsis Using Gene-Trap and
Enhancer-Trap Transposon Tagging
S. Woody, V. Sundaresan
We are using a gene-trap/enhancer-trap transposon
tagging system (Sundaresan et al., Genes Dev. 9:
1797 [1995]) to identify and characterize embryo-
specific gene expression in Arabidopsis. To date, we
have produced approximately 20,000 F, seeds
derived from more than 300 Ac x DsE (enhancer-
trap) or Ac x DsG (gene-trap) crosses. About 13,000
of these have been grown and harvested, and the F2
seeds are being screened for new transposant lines at
a rate of 400 families per week; in total, we have
screened 8500 F2 families and isolated 1650
transposant lines. These lines, as well as others gen-
erated by the Martienssen, Ma, and Grossniklaus labs
here at the Laboratory, are being examined for
embryo-specific GUS expression and for evidence of
Ds-induced emb (embryo-defective) mutations.
We have identified eight transposant lines (five
gene-trap [GT] and three enhancer-trap [ET] lines) in
which the GUS reporter gene of the transposed DsE
or DsG element is expressed primarily in developing
embryos. These expression patterns included uniform
staining of the embryo, staining restricted to apical or
Figure 3 Examples of localized GUS reporter gene expres-
sion. (Top) Expression confined to suspensor; (bottom) ex-
pression localized to progenitor cells of root meristem.
basal domains, and staining confined to groups of
cells within the developing embryo (see Fig. 3).
Further characterization of the GUS expression
patterns in these lines is ongoing, aimed toward a
more precise determination of the developmental
stage(s) in which expression is induced and toward
identification of the particular cell types in the em-
bryo and other tissues where the tagged genes are ex-
pressed. The Ds elements in some of these lines have
been remobilized by back-crosses to Ac-bearing
plants; it is possible that short-distance transposition
events might create more severe alleles that would
cause a mutant phenotype. Finally, TAIL-PCR and
RACE-PCR methods are being used to isolate
Arabidopsis sequences flanking the Ds insertion
sites; these will be used to probe cDNA and genomic
libraries to identify the tagged genes.
The transposant lines are also being screened for
emb mutants. By inspection of nearly mature siliques,
in which transmission of an emb allele is expected to
result in 25% defective (white or pale green) seeds,
we have found emb lines at a frequency of approxi-
mately 1-2% (>1000 lines screened). Unfortunately,
no exceptional phenotypes have been observed so far:
In some cases, embryo development is delayed rela-
tive to that of phenotypically wild-type siblings but
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nevertheless proceeds to maturity. In some lines in
which embryogenesis is arrested, the terminal pheno-
type, while variable, is similar to that observed in
many previously described emb mutants: arrest at the
globular stage, followed by disorganized proliferation
of interior cells. Cosegregation of kanamycin resist-
ance (specified by the Ds element) and the emb
phenotype were examined in 11 candidate lines. Con-
sistent cosegregation was observed in 2 lines; results
in the other 9 cases were consistent with unlinked
segregation of an emb locus and kanamycin resist-
ance. Although the presence of multiple Ds elements
in these lines, only one of which tags an emb locus,
would yield similar results, another possibility is that
some of these emb mutants are not tagged with Ds.
Of the two lines in which the emb loci are poten-
tially tagged, one is an albino mutant and shows no
morphological defect indicative of an effect on em-
bryogenesis per se. The other line, ET339, arrests at
the globular stage as described above. Although GUS
activity is observed in other tissues, we have been un-
able to detect GUS expression in ET339 embryos.
This may indicate that the tagged gene is expressed
only transiently or at very low levels during em-
bryogenesis; alternatively, it is possible that the DsE
element in ET339 disrupts a locus required for em-
bryogenesis, but the minimal promoter driving GUS
expression is responding to an enhancer other than
the one that might regulate expression of the emb
locus. We have crossed ET339 to an Ac line to
remobilize the element and hope to recover a deriva-
tive allele that causes a similar embryogenesis defect
but now displays embryo-specific GUS expression
prior to or during the globular stage. In the meantime,
we continue to screen new and existing transposant
lines for additional emb mutants.
Transfer of the Mutator
Elements from Maize to
Other Plants
Z. Yuan, V. Sundaresan
The Mutator (Mu) elements of maize constitute an
exceptionally active transposon system with some
very unusual characteristics (e.g., see Annual Report,
1992, p.164). A detailed molecular analysis of this
transposon system would be greatly facilitated if this
transposon system could be transferred from maize
into a plant species that is more amenable to trans-
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formation. We have now generated transgenic tobac-
co and Arabidopsis plants carrying the element
MuDR, which is the autonomous regulator of the Mu
system (Hershberger et al., Genetics 140: 1087
[1995]). Modified MuDR elements, in which the
transcripts are driven by strong promoters, were also
introduced into tobacco and Arabidopsis. These
transgenic plants are being crossed to transgenic
plants carrying the nonautonomous element Mu1, in-
serted within a marker gene encoding resistance to
streptomycin. Transposition of Mul will be assayed
by monitoring excisions, which should result in sec-
tors of the plants that are resistant to streptomycin,
and also by screening for new Mul insertions using
Southern blots.
Gene-trap and Enhancer-trap
Patterns in the Arabidopsis
Shoot Apex
P. Springer, A. Wells (URP Program), R. Martienssen
The shoot apical meristem (SAM) is a small group of
cells at the apex of the plant that gives rise to all
postembryonic structures of the shoot. The SAM of
Arabidopsis is initiated during embryogenesis and is
organized into three layers that are maintained during
vegetative growth. Little is known about the mechan-
ism by which the SAM is established and maintained,
but conventional genetic screens have identified a
handful of genes required for meristem differentia-
tion. It is likely that some genes required for SAM
function will also be required at earlier stages of de-
velopment, but these genes would not be identified in
seedling screens for meristem mutants because they
would die before reaching the seedling stage. Enhan-
cer traps represent a unique way to identify these
genes, as the GUS expression pattern is visible in vi-
able heterozygous plants, even if the insertion causes
homozygous lethality. We are screening our
transposant collection for lines that have GUS ex-
pression patterns in the meristem and early leaf
primordia. Lines that stain will be examined for lethal
phenotypes, as well as for morphological mutations
affecting the seedling meristem.
In a pilot screen, 22 of 1300 lines had GUS ex-
pression in the shoot apical meristem and 28 lines
had GUS expression in leaf primordia. The expres-
sion pattern in these lines is being examined in more
detail. Examples of some GUS expression patterns
FIGURE 4 Gene-trap and enhancer-trap reporter gene expression patterns in the
shoot apex. Seedlings were stained for GUS activity (dark staining) and cleared in
ethanol. (A) Apical view and (8) longitudinal section through the apex of a GT185
seedling. GUS expression is present in a ring of cells surrounding the base of each
leaf primordium. (C) Leaf primordia; (D) shoot-root junction; (E) root tip, from ET79.
GUS activity is localized to individual cells in vascular and root cap tissues that un-
dergo cell death. (F) Root tip from prolifera showing GUS activity localized to the
nucleus in some cells of the root epidermis.
are shown in Figure 4. Line GT185 has GUS expres-
sion in a small group of cells surrounding the base of
each leaf primordium (Fig. 4A,B), thus marking the
boundary between the shoot apical meristem and leaf
primordia. ET79 shows GUS expression in a single
cell at the tip of each leaf primordium (Fig. 4C). In
older leaves, GUS activity expands to several cells in
the same position, and expression is found through-
out the seedling in individual xylem cells of the vas-
culature, and in all root cap cells (Fig. 4D,E). These
tissues undergo extensive cell death, so that one pos-
sible interpretation of this unusual pattern is that this
gene may be involved in a cell death pathway.
Because gene traps result in transcriptional and
translational fusions, they can be used to determine
the subcellular localization of gene products. Last
year, we described the cloning and characterization
of the PROLIFERA (PRL) gene. Since PRL is a
member of the MCM2-3-5 family, it is predicted to
be nuclear-localized. We have shown that the pr1::
DsG insertion results in a translational fusion that is
localized to the nucleus in at least some cells (see
Fig. 4F).
Gene-trap Hierarchies
in the Shoot Apex
P. Springer, D. Tracey, R. Martienssen [in collaboration
with G. Chuck and S. Hake, Plant Gene
Expression Centre, Albany]
A powerful application of gene-trap methodology is
the placement of individual genes in a genetic hierar-
chy based on existing regulatory mutations. For ex-
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ample, if the expression pattern is altered in the ab-
sence of a regulatory gene product, this indicates that
the gene in question probably acts downstream from
the regulatory function. We have performed crosses
between ten ET and GT lines with SAM expression
and plants mutant for the previously identified genes
shoot meristemless (stm) and clavatal (c1v1). The
STM gene is required for the formation of a SAM
(Barton and Poethig, Development 119: 823 [1993]),
whereas the CLV1 gene is required for meristem or-
ganization (Clark et al., Development 119: 397
[1993]). Twenty six SAM and leaf primordia expres-
sing lines have also been crossed to plants ectopically
expressing the Arabidopsis KNAT1 gene. KNATI
belongs to the KNOTTED1 family of homeobox
genes (Lincoln et al., Plant Cell 6: 1859 [1994]) and
is expressed in the SAM, but not in the leaf or the
root. Ectopic expression of KNAT1 leads to altera-
tions in leaf cell fate, and direct targets of KNATI are
expected to be uniformly expressed (or repressed) in
all plant tissues in progeny from these crosses.
Although no direct targets have yet been found by
this criteria, we have identified several genes whose
expression pattern is altered as a consequence of con-
stitutive expression of KNAT1. Ectopic expression of
KNATI results in a highly lobed leaf with ectopic
stipules at the leaf margin. We have identifed two
genes normally expressed at the base of the leaf
(GT185 and GT254) that are expressed in the leaf
blade in the KNATI overexpresser. These results sug-
gest that ectopic expression of KNAT1 affects pattern
elements along the proximodistal axis of the leaf,
causing proximal structures to be formed in distal
positions. The PROLIFERA gene is expressed in
proliferating cells and disappears from an expanding
leaf primordium in a basipetal pattern (tip to base). In
the KNAT1 overexpresser, PROLIFERA is lost from
the leaf acropetally (base to tip). These results show
that cell division patterns are drastically altered and
that the leaf may have become more meristem-like as
a result of ectopic KNATI expression.
Enhancer-Trap Detection of
Stomatal-specific Gene
Expression Patterns
Q. Gu, R. Martienssen
Arabidopsis leaves are organized into several distinct
tissue types, including upper and lower epidermal
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layers, photosynthetic mesophyll tissues, and a cen-
tral reticular vascular system. Several classes of
epidermal cells can be readily found in the
Arabidopsis leaf, including pavement cells, trichome
cells, and stomatal guard cells. Pavement cells are
jigsaw-shaped and make up the majority of cells
within the shoot epidermis, whereas trichomes are
regularly spaced epidermal hairs. Two kidney-shaped
guard cells and several subsidiary cells form the
stomatal complex. Opening of stomates via guard cell
turgor facilitates gas exchange during photosynthesis
and respiration.
The stomatal complex is formed by virtue of a
stereotypical pattern of meristemoidal cell divisions.
In the cotyledon, stomata are closely packed, sepa-
rated by only one or two subsidiary cells. In leaves
and stems, however, the spacing pattern of stomatal
complexes is not random and they are regularly sepa-
rated by several pavement cells. The mechanism con-
trolling stomatal patterning in the leaf is not known,
but it is likely that cell-cell interactions and lateral in-
hibition are involved (Bunning, The growth of leaves.
Butterworths, London [1956]). We are interested in
understanding stomatal patterning mechanisms using
enhancer-trap mutagenesis. Among the 750 enhanc-
er-trap transposant lines screened in the last year (in-
cluding 200 lines screened together with the 1995
summer Arabidopsis course at CSHL), about 60 lines
displayed a tissue-specific or cell-type-specific ex-
pression pattern. A handful of these accumulated
GUS activity predominantly in the stomatal cells. No
stomatal-specific lines were found in the 550 gene-
trap lines screened.
GUS expression in ET492 is specifically localized
to the guard cells in all organs of the shoot, including
cotyledons (Fig. 5B,C), leaves, stems, and floral
organs (not shown). Some staining is also present in
the root epidermis (Fig. 5B). In contrast, expression
in the stomata of ET169 is restricted to hydathodes
(Fig. 5A). Preliminary observation suggests that
ET169 and ET492 retain normal stomatal spacing. In
these cases, the activation of the enhancer-trap
reporter gene could result from transposon insertion
outside of the coding region. In an attempt to make
derivative alleles, we are remobilizing the transposon
in these lines by crosses to Ac transposase.
In two additional lines, stomatal-specific expres-
sion is accompanied by a stomatal defect. GUS ex-
pression in ET1967 is detected in cotyledons and
leaves, predominantly in the guard mother cells
(GMC) as well as in mature guard cells (not shown).
FIGURE 5 Enhancer-trap reporter gene expression in
stomatal cells. (A) ET169, only those stomata in the
hydathode stain in 8-day-old cotyledons; (8) ET492, GUS
staining in stomatal cells of an 8-day-old seedling; (C)
ET492, GUS localization in the adaxial epidermis of the
cotyledon; (D) GUS staining in a leaf of the patchwork
mutant. Patches of black dots indicate GUS localization in
guard cells. In addition, the surface of the leaf is rough and
the margins are disorganized.
A putative mutant phenotype resulting in clustering
of two to four stomatal complexes is found in this
line, but it appears to be conditional and is affected
by humidity (not shown). In line ET1370, GUS ac-
tivity is localized to the stomatal cells in the mature
leaf and in vascular tissue of the flower (not shown).
This line segregates for a severe mutant phenotype
affecting the leaf epidermal surface and flower struc-
ture. On the surface of mutant leaves, patches of
stomatal cells are intermingled with stomata-free
zones. Due to the aberrant distribution of stomatal
cells and other cell types in mutant leaves, this
mutant line has been named patchwork (pwk). This
phenotype is noticeable in leaves produced during the
transition from vegetative phase to reproductive
phase. The phenotype persists during the reproduc-
tive phase, but juvenile stages show no defects as
compared to the wild type. The pwk mutant has been
backcrossed to wild type, and segregation in the F2
shows that the pwk mutant phenotype is genetically
linked to the Ds insertion. We are currently screening
for genetic revertants and wild-type sectors in the
presence of transposase. Molecular cloning of the
PWK gene will help us to understand its role in cell-
cell communication and spacing differentiation. The
origin of the patches of stomata-free cells is of partic-
ular interest as reporter gene expression is not ob-
served in these mature cells. This may indicate that
the gene product acts nonautonomously to affect their
differentiation.
Exon Trap cDNA Sequencing
P. Springer, A. Wells (URP Program), C. Yordan,
R. Martienssen [in collaboration with M. Lodhi and
R. McCombie, Cold Spring Harbor Laboratory]
We are constructing a database of exon trap tags
using gene-trap transposon mutagenesis. Each entry
will include a reporter gene expression pattern,
mutant phenotype, and chromosomal exon sequence
fused to the reporter gene in a given line. We are at-
tempting direct sequencing of RACE PCR products
from each line to rapidly obtain the exon trap se-
quence data. Fifteen lines that had strong reporter
gene expression were selected for direct sequencing
of RACE PCR products. Total RNA was prepared,
and nested RACE PCR products were directly se-
quenced using dye terminators and a variety of
primers. Six lines were selected that were known to
have insertions into prolifera (Springer et al. 1995),
or into T-DNA marker genes that resulted in strong
reporter gene expression driven by T-DNA promoters
(Sundaresan et al. 1995). In four out of five T-DNA
insertions, and for prolifera, sequence reads of
50-500 nucleotides beyond the Ds element were ob-
tained, in one case extending to the start point of tran-
scription. prolifera products were predominantly
spliced (Springer et al. 1995), whereas T-DNA inser-
tion transcripts were unspliced (T-DNA has no intro-
ns). In the remaining nine lines, reporter transcripts
were unspliced or multiply spliced (which led to
mixed sequence reads). In five of nine lines, sequenc-
ing primers from the intron gave a readable sequence
which extended beyond the Ds element by 30-200
bp. One sequence matched a phosphofructokinase
gene (a result confirmed by sequencing cloned PCR
products), whereas a second sequence matched an
EST from Caenorhabditis elegans. One advantage of
using cDNA rather than genomic DNA as a substrate
for gene-trap sequencing is that an exon sequence,
rather than an intron sequence, is always obtained,
avoiding ambiguities in identifying the trapped gene.
However, given that many products appear to be un-
spliced or alternately spliced, DNA-based methods
may be a more efficient procedure for most lines.
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Remobilization of Gene-trap
Transposons
J. Montagu, C. Yordan, H. Cross (URP Program),
P. Springer, R. Martienssen [in collaboration with the
McCombie laboratory, Cold Spring Harbor Laboratory]
One of the most important goals of Arabidopsis
genome sequencing is to establish a function for the
genes identified. This can be achieved by local
saturated mutagenesis using transposable elements.
Such methods have been widely used in Drosophila
and C. elegans as well as in maize (Das and
Martienssen 1995). In addition, many enhancer-trap
transposon insertions have no mutagenic effects be-
cause they are inserted near but not within the gene
of interest. Remobilization would allow disruption of
nearby genes to help determine their function. In a
pilot study, we have remobilized the DsG gene-trap
transposon at the prolifera locus on chromosome IV
by crosses to transposase, which is removed by
counter-selection in F, seedlings. In this case, the
DsG transposon is not flanked by the counter-
selectable marker, so that short-range transpositions
are preferred. Using a strong transposase source, at
least 20 new transpositions have been recovered in
only 53 doubly resistant plants. This is a high enough
frequency to enable PCR-based selection of inser-
tions into genes of interest in pools of a few hundred
plants. The complete sequence of a 25-kb contig sur-
rounding the prolifera locus (see report from
McCombie laboratory) will provide a molecular
"target" for larger-scale mutagenesis now in progress.
Role of the Hcf106 Gene in
Chloroplast Membrane Protein
Trans location in Maize
A.M. Settles, R. Martienssen [in collaboration with
R. Voelker and A. Barkan, University of Oregon;
and R. Henry and K. Cline, University of Florida]
Chloroplast biogenesis is regulated by nuclear genes
during leaf development and requires the assembly of
a large number of nuclear- and chloroplast-encoded
gene products in the thylakoid membrane. High
chlorophyll fluorescence (hcf) mutants affect the
biogenesis of the photosynthetic apparatus, and
hcf706 mutants show reduced levels of photosystem
I, photosystem II, and cytochrome b6f membrane
protein complexes. hcf706 membranes have lost their
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structural heterogeneity and are thought to have a
defect in protein translocation. The hcf706 gene has
been cloned by transposon tagging using the hcf106-
muml allele, and antisera to Hcf106 have been
raised. By sequence analysis, subfractionation, and
protease protection, the Hcf106 protein has been
shown to be a chloroplast integral membrane protein
in both the thylakoid and the inner envelope.
At least three pathways for targeting proteins to
the thylakoid membrane have been distinguished in
biochemical studies (Cline et al., EMBO J. 12: 4105
[1993]). These pathways have different requirements
for NTPs, stromal factors, and the pH gradient across
the thylakoid membrane (ApH). The biochemical re-
quirements of two of these pathways resemble the
azide-sensitive general secretory (sec) pathway of
bacteria in one case and SRP-mediated translocation
across the endoplasmic reticulum in the other. The
third pathway is thought to be unique to chloroplasts.
In pea, thylakoid targeting of plastocyanin (PC) and
the 33-kD subunit of the oxygen evolving complex
(0E33) is mediated by the sec pathway. In contrast,
the 23-kD and 17-kD subunits of the oxygen evolv-
ing complex (0E23 and 0E17) require only the ApH
and are targeted via the third pathway. In-vivo-
labeled hcf106-muml homozygous seedlings ac-
cumulate precursors or intermediates of OE23 and
0E17 but accumulate only mature PC and 0E33
(Voelker and Barkan, EMBO J. 14: 395 [1995]). This
suggests that mutant chloroplasts are defective in the
third targeting pathway.
The hcf106-muml phenotype is leaky, perhaps be-
cause it is suppressed in cells that lose mutator
transposon activity. Three derivative alleles were iso-
lated by site-directed transposon mutagenesis (Das
and Martienssen 1995). Two of these new alleles are
independent of Mu activity and behave as nulls.
These new alleles have similar protein phenotypes to
hcf106-muml , suggesting that the leaky phenotype of
hcf106-muml is due to the nature of the ApH-
dependent pathway, rather than the nature of the al-
lele. We are using the deletion allele, hcf106-mum3,
for biochemical and genetic analysis of Hcf106 func-
tion in wild-type plants. We are testing the interaction
of hcf106 mutants with other hcf mutations. In partic-
ular, we have crossed hcf706-mum3 to thal, a muta-
tion in chloroplast SecA (R. Voelker and A. Barkan,
pers. comm.). thal has been shown to affect the ac-
cumulation of Sec precursors (PC and 0E33), but not
ApH-dependent precursors (0E17 and OE23).
We have begun to examine the biochemical pro-
2Myb-domain
Cl
v-Myb
Cl
v-Myb
LKAGRWTAEEDQLLANYIAEHGEGSWRSLPRNAGLLRCGKSCRIRWINTLRAD
V...A..SR..DA..A.VKA....R..EV.QR...R .......... L....PN
.NK.P..K....RVIEHVQKY.PRR.SDIA.HLK-G.I..Q..E..H.H.NPE
112
ir
VKAGNISREEEDIIIKLHATLG-NRWSLIASHLP-GRTDNEIKNYWNSHLSRQ
IR YD. .L..R. RL - GR T G R
..RTSWTE..DR..YQA.KR..-...AE..KL..- ..... AV..H...TMR.K
hhhhhhhhhhhhhh hhhhhhhh hhhhhhhhhh
helix 1 helix 2 helix 3
FIGURE 6 Structure of the P protein and sequence comparisons between different Myb domains.
The Myb domain of P (light gray) is formed by two repeats about 52 residues long each. (Dark gray)
An acidic sequence able to activate transcription in yeast. The amino acid sequences of the two
Myb repeats of the maize P and Cl proteins and the AMV v-Myb protein are shown. Residue identity
with P is indicated by a dot. The positions of the a-helices are indicated with hhhh, and the positions
of the critical residues so far identified as important for the DNA-binding specificity of P and v-Myb
are indicated by a number.
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perties of the mutant seedlings using in vitro chloro-
plast import protocols that we have adapted from
studies in pea. The preliminary in vitro import data
suggest that in mutant hcf106-mum3 chloroplasts, the
ApH-specific precursors (0E17 and 0E23) are shunt-
ed to the Sec pathway normally used by PC and
0E33. This is because mutant chloroplasts process
0E17 and 0E23 precursors with reduced efficiency,
and this processing is sensitive to azide, which
normally only affects the processing of Sec precur-
sors. Through database searches, we have found that
Hcf106 protein shows homology with three bacterial
ORFs and an Arabidopsis EST. This suggests that the
ApH-dependent protein translocation pathway may be
conserved in evolution, instead of being unique to
chloroplasts.
Transcriptional Regulation
by P Does Not Require Other
Maize-specific Factors
E. Grotewold
The P gene encodes a Myb domain protein required
for the transcriptional regulation of a subset of the
flavonoid biosynthetic genes regulated by Cl (Grote-
wold et al., Cell 76: 543 [1994]), including C2,
CHIT, and Al. Cl, however, does not regulate tran-
scription by itself and requires a member of the R or
B gene families (encoding proteins with bHLH
domains) for its activity. In agreement with the genet-
ic evidence, P does not require R protein for the
regulation of A /. Either P protein alone or Cl protein
(in the presence of R/B) is able to activate efficiently
a minimal 35S promoter containing the high-affinity
P-binding sites identified in the Al promoter, when
transiently expressed in embryonic callus or BMS
cells (Grotewold et al., Cell 76: 543 [1994]). In addi-
tion to these P-binding sites, other Al promoter ele-
ments are required for normal regulation of Al by P
and by Cl proteins (Grotewold et al., Cell 76: 543
[1994]; Tuerck and Fromm, Plant Cell 6: 1655
[1994]), yet those promoter elements are not recog-
nized by P in vitro.
P and Cl share more than 83% identity in their
Myb domains (Fig. 6), the region responsible for the
interaction between Cl and R (Goff et al., Genes
Den. 6: 864 [1992]). Does P require a partner, as Cl
does? I decided to approach this problem by investi-
gating the possibility that P would function in a heter-
ologous system, and for that purpose, I have chosen
yeast. I introduced a reporter lacZ gene downstream
from a dimeric high-affinity P-binding site (with a
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cyc TATA box) into the yeast chromosome. When P
was expressed in yeast cells carrying this reporter
construct, a very efficient activation of the reporter
was obtained (>130-fold). There was no activation
when the plasmid carrying the P cDNA was absent
(1-fold), nor when the P-binding sites were replaced
by a dimer of a sequence to which P does not bind in
vitro.
These observations are a strong indication that P is
sufficient to activate transcription from promoters
carrying high-affinity P-binding sites. These results
are not in contradition with the observation that other
promoter elements are important for the regulation by
P in plant cells. Yet, they suggest that for promoters
carrying high-affinity P-binding sites, there is no
need to invoke a P partner.
Not all P-regulated genes have P-binding sites. In
fact, I have not been able to identify sequences to
which P binds in vitro in the promoter of the CHIT
gene, which is dependent on the presence of P for its
expression in the pericarp (Grotewold and Peterson,
Mol. Gen. Genet. 242: 1 [1994]). This could possibly
mean that P regulates this promoter through a dif-
ferent mechanism, which could be similar to the
mechanism by which Al is regulated in the absence
of high-affinity P-binding sites. These alternative
ways of regulation by P could involve the existence
of accessory factors that recruit P to promoter ele-
ments or that change the DNA-binding specificity of
P.
Altering the DNA-binding
Properties of Myb Domain
Proteins
C.E. Williams (Dowling College), E. Grotewold
The maize P gene encodes a Myb domain protein re-
quired for flavonoid pigmentation in some floral
organs. In plants, a large number of Myb domain
proteins have been isolated, and they are involved in
a variety of cellular functions through the activation
of specific sets of target genes. Myb domains are
usually formed by two or three 52-residue-long
repeats, containing three a-helices each (Fig. 6). The
second and third helices of each repeat form a helix-
turn-helix motif, similar to the one found in homeo-
domain proteins or in the X repressor. The third helix
of each repeat makes contact with DNA. Nuclear
magnetic resonance studies carried out on the Myb
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domain of c-Myb indicate that each repeat recognizes
a half binding site, in such a way that the second Myb
repeat recognizes the AAC core in a very sequence-
specific fashion, whereas the first Myb repeat recog-
nizes the last G of the ATAACGG sequence (Ogata
et al., Cell 79: 639 [1994]). These studies, however,
failed to explain why Myb domains with highly con-
served DNA-recognition helices (Fig. 6) bind DNA
with different sequence specificities (Grotewold et
al., Cell 76: 543 [1994]). Despite the fact that P and
v-Myb share more than 45% identity in their DNA-
binding domains, they bind DNA with different
specificities: v-Myb preferentially binds the con-
sensus sequence G/j/cAACGG, and the sequence
present in the Miml gene promoter (ATAACGG)
bound by v-Myb, but not by P, provides a convenient
probe to assay v-Myb DNA-binding activity; P pref-
erentially binds the consensus sequence ACC /TT /A
ACC and the sequence present in the Al gene
promoter (ACCTACCAACC) bound by P, but not by
v-Myb, provides a good probe to assay P DNA-
binding activity (Grotewold et al., Cell 76: 543
[1994]). We approached the problem of how Myb
domain proteins with very similar DNA-binding
domains direct different patterns of gene expression
through the interaction with particular elements in the
regulated genes, by using the P and v-Myb proteins
as model systems. The corresponding Myb domains
are sufficient for these different DNA-binding prefer-
ences, as shown by expressing the corresponding
regions of P and v-Myb as poly-histidine fusions in
Escherichia coli and defining the corresponding
DNA-binding consensus. These studies provide a
convenient framework to identify the particular
residues in the Myb domain that are involved in
sequence-specific DNA binding.
We first tried to address this question by generat-
ing chimera Myb domains between the Myb domains
of v-Myb and of P (which have different DNA-
binding preferences). When the first Myb repeat of P
(Fig. 6, R1) was fused to the second Myb repeat (Fig.
6, R2) of v-Myb (P1Myb2), a chimera Myb domain
protein was obtained with novel DNA-binding pref-
erences: It bound both the P-binding sites present in
the Al promoter and the c-Myb-binding site present
in the Miml gene. In addition, a DNA sequence was
identified (CTTAACTC) which is only bound by
P1Myb2, but not by P or v-Myb. These findings indi-
cate that by combining Myb repeats of proteins with
different DNA-binding preferences, novel DNA-
binding specificities can be achieved.
We analyzed the effect of residue changes in the
DNA-recognition helix of the first Myb repeat. In
particular, we focused our attention on the E residue
present at position 132 in v-Myb (Fig. 6), since it is
the only residue from this recognition helix that was
proposed to be in direct contact with DNA, in addi-
tion to stabilizing a cooperative interaction of both
Myb repeats with DNA (Ogata et al., Cell 79: 639
[1994]). In P, as well as in most plant Myb domain
proteins, this position is occupied by a L residue. The
change of this L residue to E completely abolished
binding to the P-binding sites but allowed the mutant
P protein to bind very weakly to the Myb-binding
sites. When the corresponding change was done on v-
Myb (E132 to L), binding to the Myb-binding sites
was not affected, but binding to the P-binding sites
became significant. These observations indicate (1)
that E132 does not have a fundamental role in the
cooperative interaction of the Myb repeats, as sug-
gested (Ogata et al., Cell 79: 639 [1994]), since v-
Myb(E132L) binds the Myb-binding sites with an af-
finity similar to that of v-Myb, and (2) that L55 in P
plays a part in sequence-specific DNA recognition.
Next, we changed particular residues in the DNA-
recognition helix of the second Myb repeat of v-Myb
to the corresponding residues present in P (Fig. 6).
Interestingly, when the three residues that are dif-
ferent in this region in these two proteins were
changed in v-Myb to the corresponding residues of P
(A, V, and H to E, I, and Y; Fig. 6), binding to DNA
was completely lost. Accordingly, the Myb chimera
domain Myb1P2 (first Myb repeat of v-Myb fused to
the second Myb repeat of P) did not bind DNA either.
These results indicate that the corresponding Myb
repeats of P and v-Myb are not equivalent, and
preliminary data suggest that the presence of the E55
residue in the first Myb repeat, together with the
E132 residue in the second Myb repeat, is somehow
interfering with proper folding of the Myb domain or
binding to DNA, although both positions (55 and
132) seem to be important for sequence-specific
DNA binding. These possibilities are currently being
tested.
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ARABIDOPSIS FLOWER DEVELOPMENT
H. Ma H. Choi A. Hameed
S. Damanan Y. Hu
H. Fan H. Huang
R. Farkas M. Kim
C. Flanagan
Y. Mizukami R. Thomas
D. Rosa M. Tudor
P. Rubinelli C. Weiss
R. Salins E. White
We are interested in understanding the molecular
control of cell fates during development, using the
small weed Arabidopsis thaliana as the experimental
system. In particular, we have been characterizing the
function of members of a conserved transcription fac-
tor gene family (the MADS-box genes) during flower
development. Considerable progress has been made
in the understanding of the molecular mechanisms
controlling early flower development (Coen and
Meyerowitz, Nature 353: 31 [1991]; Ma, Genes Dev.
8: 745 [1994]). Mutations in one of the Arabidopsis
floral homeotic genes, AGAMOUS (AG), cause dou-
ble-flower phenotypes, where the stamens are con-
verted to extra petals and the ovary is replaced by a
new flower. The deduced AG protein (Yanofsky et
al., Nature 346: 35 [1990]) has strong sequence
similarity to the DNA-binding domains of transcrip-
tion factors from humans, suggesting that the AG
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protein is also a transcription factor. The conserved
region between AG and the transcription factors is
called the MADS-box. Other MADS-box genes were
isolated using AG as a probe and have been desig-
nated AGLI through AGL6 for AG-Like. We have
continued our analyses of AG, AGLI, AGL2, and
AGL3.
Because flower development is a complex process,
it is likely that many other regulatory genes are also
needed. We have recently isolated a new Arabidopsis
mutant, fonl (floral organ number), which has an in-
creased number of reproductive floral organs. Fur-
thermore, to identify new genes required for flower
development, we are collaborating with Drs. V.
Sundaresan, R. Martienssen, and U. Grossniklaus
(CSHL) to generate a large number of independent
enhancer trap/gene trap transposon insertional lines.
In an alternative approach to isolate new genes that
function during late floral organ development, we
have begun a new project aimed at identifying genes
specifically expressed in carpels or stamens. These
genes are likely to be involved in cell differentiation
during late flower development, and they provide
molecular markers for specific cells or tissues of the
reproductive organs.
In 1995, in addition to the people previously intro-
duced, several undergraduate students participated in
our research. Matt Tudor from Cornell, who has been
here twice before, was again extremely productive,
carrying out several projects concurrently. Rebecca
Farkas from Yale was our URP in the summer, and
she did a beautiful piece of work on in situ RNA
hybridization of floral genes in font mutant flowers.
Renate Thomas, Rohan Salins, and Sonia Damanan
from SUNY Stony Brook, Henry Choi from Colum-
bia, and Michael Kim from Wesleyan were very
helpful to our enhancer/gene trap project and other
experiments. In addition, Aliyah Hameed from Bryn
Mawr participated in our gene trap and subtraction
projects, and Elyssa White from Lehigh worked with
Catherine Weiss on the localization of the GPA1
protein.
We bid farewell to our postdoc Catherine Weiss,
who has taken a job with American Cyanamide. Last
Fall, Dominik Rosa, a senior at Commack High,
joined us as one of the Partners for the Future, work-
ing with Peter Rubinelli on the analysis of stamen-
specific cDNA clones. Finally, we welcome our new
postdoctoral fellow, Hua-ying Fan. She is a native of
Taiwan and just finished her Ph.D. training from
New York University.
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Generation and Characterization
of Enhancer/Gene Trap
Transposants
C. Flanagan, Y. Hu, Y. Mizukami, H. Fan, H. Choi, M. Kim,
A. Hameed, R. Thomas, R. Salins, S. Damanan, H. Ma
To be able to identify new genes important for Arabi-
dopsis flower development, we have participated in
the collaboration with three other plant labs here at
the laboratory: those of Drs. Sundaresan, Martiens-
sen, and Grossniklaus. We have obtained about
50,000 Ft seeds from crosses between three different
Ac lines and four different Ds lines. We have planted
about 14,000 of the Ft seeds and have harvested the
F2 seeds from them. Using the NAM/Kan double se-
lection, we have generated about 1500 independent
insertional lines, or transposants. Our goal is to gen-
erate a total of 4000 transposants, 3000 of which will
be obtained before the end of 1996.
We have examined the expression patterns of the
Ds-borne GUS reporter gene in the first 900 trans-
posants from the four labs. The staining patterns have
also been examined in the inflorescences, individual
mature flowers, seed pods, and cauline leaves (as a
control for vegetative tissue). Overall, nearly 50% of
the lines have a staining pattern in these tissues. A
large majority of these stained anthers and/or pollen
grains, which is consistent with findings of other in-
vestigators that a large number of genes are ex-
pressed in anthers and/or pollen (e.g., in tobacco,
25,000 transcripts are expressed in the anthers,
11,000 of which are specific; and in maize, 20,000
transcripts are found in pollen, 7000 of which are
specific; Scott et al., Plant Science 80: 167 [1991]).
Nevertheless, we would like to verify that such a high
frequency of anther/pollen-only staining truly reflects
the endogenous situation. Even if the anther/pollen
patterns are excluded, about 20% of the gene trap and
30% of the enhancer trap lines stain elsewhere in the
flower. GUS staining was observed in almost every
combination of first, second, third, and fourth whorl
floral organs and of early, intermediate, and late
stages of flower development, with that in the
reproductive organs and at intermediate-to-late stages
being the most common. It is interesting that truly
constitutive expression was rare. Furthermore, there
are many different patterns within single organs,
reflecting cell- or tissue-specific GUS expression. For
instance, within the gynoecium, various lines stain
the stigmatic papillae, style, carpel valves, valve
margins, transmitting tissue, or septum. This wealth
in the number and variety of expression patterns
within the flower will be a great resource for our in-
vestigations of flower development.
Expression of the AGLI Gene
in Wild-type and Mutant
Arabidopsis Flowers
C. Flanagan, Y. Hu, R. Thomas, H. Choi, H. Ma
AGLI is one of the Arabidopsis MADS-box genes
cloned by their homology with AG, and it is preferen-
tially expressed in flowers. To obtain clues about the
function of AGLI, we have characterized extensively
its spatial and temporal expression pattern in both
wild-type and mutant flowers using RNA in situ
hybridization. Our results indicate that AGLI expres-
sion is restricted to only one type of floral organ, the
gynoecium composed of two fused carpels. AGLI is
expressed in only one of the four floral organs; most
of the others are expressed in two (e.g., AG) or four
(e.g., AGL2) types of organs. AGLI expression arises
late in flower development, detectable at the tip of
stage-7 (of 12 floral stages) gynoecia. At stage 10,
AGLI is expressed in four narrow areas along the
length of the inner carpel wall. Later, AGLI expres-
sion can also be seen in the developing ovule primor-
dia, in the funiculus, and in the outer integument
primordia, but not in the inner integument primordia
and the nucellus. In mature flowers, AGLI expression
is primarily in the ovules, along the surfaces of the
septum, and as vertical stripes along the margins of
each carpel. Some expression can also be seen in the
transmitting tissue of the gynoecium and in the nec-
taries. Within the ovules of mature flowers, AGLI is
expressed at the chalazal end, near the micropyle, and
in the endothelium. AGLI expression is also seen
along the edges of the funiculus, in continuum with
the edges of the septum of the gynoecium. At a
slightly later stage, AGLI expression in the endothel-
ium is particularly pronounced.
It is known that AG is expressed interior to the
second whorl in both wild-type and ag mutant flow-
ers even though the floral organ identities are dif-
ferent in these two backgrounds. AGLI expression
occurs in the gynoecium of fused carpels that normal-
ly occupy the fourth whorl. Is AGL1 expression con-
trolled by the identity or the position of the organs?
To address this question, we examined AGLI expres-
sion in ap2, ap3, and ag mutant flowers. In the
homeotic mutants ap2 and ap3, AGLI is expressed in
both normal and ectopic carpels, and in ag flowers,
AGLI is not expressed in the sepals that occupy the
fourth whorl, indicating that AGLI expression is
regulated by the identity, rather than the position, of
the organs. It is worth noting that AGLI is still ex-
pressed in the nectaries of ag flowers, indicating that
AG function is not required for AGLI expression in
some cells.
The specific AGLI expression pattern in the wild
type suggests that AGLI may have regulatory func-
tions in formation of the anterior-posterior axis of the
ovule; nutritional supply to the ovule and embryo
sac; pollen tube guidance; structural definition of the
carpel margins, which could include such processes
as congenital fusion of carpels, septum, and placenta
formation, and abscission within the siliques. Analy-
sis in mutant flowers indicates that AGLI expression
depends on the carpel identity, not on the position of
the organs.
Function of the FON1 Gene in
Floral Organ Development
H. Huang, H. Ma
We previously reported the isolation of an Arabidop-
sis floral organ number mutant, fonl, among the T-
DNA insertional lines that we generated (H. Huang
and H. Ma, 1993 and 1994 Annual Reports). To un-
derstand FONI function in flower development, we
have analyzed in detail the fonl mutant phenotype
using scanning electron microscopy. The fonl mutant
plants have normal inflorescence meristems; in addi-
tion, the early flower development from stages 1 to 5
in a fonl mutant is normal. At stage 6, after the third
whorl stamen primordia are formed, while the wild-
type floral meristem terminates by forming the
gynoecium primordium at the center, the fonl floral
meristem continues to be active, giving rise to extra
stamen primordia. The center of the fon] floral
primordia does eventually produce carpel primordia,
but they are abnormal and often have ectopic stamen
primordia or are chimeric. These phenotypes indicate
that the FONT gene regulates the duration of the flo-
ral meristem and the organization of floral organ
primordia. We are currently in the process of analyz-
ing phenotypes of double mutants between fonl and a
number of other floral mutations.
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Characterization of AG
Function in Determination
of Floral Meristem Identity
Y. Mizukami, H. Ma
It is known that the Arabidopsis reproductive organ
identity gene AG is also required for the control of
floral meristem determinacy, because ag mutations
and antisense AG RNA cause the production of in-
determinate double flowers. Meristem determinacy
and the production of floral organs instead of lateral
meristems are important characteristics of the floral
meristem; thus, it is possible that the ag mutation af-
fects floral meristem identity. To understand AG
function in controlling floral meristem identity, we
have analyzed the effects of a recessive loss-of-func-
tion ag mutation and dominant gain-of-function AG
transgenes. Previously, ag mutant flowers of plants
grown under short-day photoperiods were shown to
produce inflorescence shoots with lateral flowers in
the indeterminate center. Our detailed observations
revealed that the formation of inflorescence at the
center of ag mutant flowers is due to the reversion
from floral meristems to inflorescence meristems. We
also found that the ag floral meristem is reversible
throughout plant development. These observations
demonstrate that AG is indeed required for determin-
ing floral meristem identity. Furthermore, we found
that ectopic AG expression in wild-type Arabidopsis
plants converts apical inflorescence meristems into
floral meristems, indicating that AG can promote a
determinate floral meristem identity.
Identity of the Arabidopsis floral meristem is first
specified by the floral meristem identity genes, such
as LFY and AP1. LFY and API together control
proper AG expression, suggesting that AG acts
downstream from LFY and AP1; therefore, it is pos-
sible that AG can replace LFY and API to specify
determinate floral meristem identity. To test this, we
analyzed the effects of a 35S-AG transgene on floral
meristem formation in /fy ap1 double-mutant plants.
Whereas in lfy apl plants without the 35S-AG trans-
gene all flowers were replaced by indeterminate
shoots producing leaf-like organs and lateral meri-
stems, plants ectopically expressing AG produced
determinate flowers, although early arising flowers
had a few lateral floral meristems. This observation
indicates that AG function requires neither LFY nor
API function for promoting floral meristem deter-
minacy. We conclude from these results that, consid-
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ering the fact that AG is normally only expressed at
the center of the floral meristem, Arabidopsis floral
meristem identity is initially specified by genes such
as LFY and AP1, which inhibit lateral meristem
formation and activate floral organ identity genes;
subsequently, the floral meristem is further defined
by AG, which specifies reproductive organ identity
and controls meristem determinacy.
In Vitro and In Vivo Analysis
of AG Functional Domains
Y. Mizukami, H. Huang, M. Tudor, Y. Hu,
H. Choi, H. Ma
The AG protein can be divided into five regions on
the basis of sequence similarity with other MADS
domain proteins (Fig. 1). To assay the contribution of
each region to AG function in vitro and in vivo, we
generated AG constructs that encode amino-terminal
and carboxy-terminal truncated AG proteins. Using
our previously described in vitro DNA-binding assay
system and AG proteins expressed in Escherichia
coli, we found that the AG MADS domain and the I
region are required for DNA binding but that the N,
K, and C regions are not. We have also demonstrated
that AG binds to DNA either as a homodimer or as a
heterodimer with any AGL1, AGL2, and AGL3 pro-
teins. Although the K and C regions, which are found
in nearly all plant MADS domain proteins, are not re-
quired for DNA binding in vitro, they may affect
binding in vivo or have other activities.
To understand the in vivo function of the regions
not required for DNA binding, we introduced several
AG truncation constructs into wild-type plants and
characterized the effects of transgenes. We show that
transgenic plants with 35S-AG constructs encoding
an AG protein lacking the amino-terminal domain
produce ap2-like flowers (Fig. 2B) similar to flowers
ectopically expressing an AG protein retaining the N
domain. This suggests that the N region is not re-
quired for producing ap2-like flowers. Transgenic
plants with 35S-AG constructs encoding an AG
protein lacking the C region produced ag-like flowers
(Fig. 2C), indicating that the carboxy-terminal trun-
cation behaves like a dominant negative mutation.
The plants carrying a transgene encoding AG protein
lacking both K domain and C regions had flowers
with more stamens and carpels (Fig. 2D), as seen in
ag-11+ heterozygous plants, suggesting that this trun-
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FIGURE 1 Analysis of AG functional domains. The AG protein and its truncated forms are
shown schematically, with each of the five regions represented by a box: (N) amino-
terminal region; (MADS) MADS domain; (I) I region; (K) K domain; (C) carboxy-terminal
region. The numbers indicate the boundaries of the regions and the positions of the AG
truncations. The double-headed arrows indicate the AG regions for DNA binding and
dimerization. NT indicates not tested. The reason for the failure to bind DNA by the
proteins starting at position 1, which is not the native amino terminus of AG, is not known,
although it is possible that the artificial amino terminus may have an inhibitory effect. Posi-
tion 34 corresponds to the amino termini of several MADS domain proteins. Phenotypes:
(ap2-like) conversion of sepals and petals to carpels (or carpelloid sepals) and stamens
(or staminoid petals); (ag-like) conversion of stamens and carpels to petals and sepals,
and/or indeterminacy; (ag*-like) increased number of reproductive organs.
FIGURE 2 Phenotypes of transgenic flowers with AG trunca-
tions. Shown are scanning electron micrographs. (A) Wild
type; (8) ATG-MADS, lacking the N region. Note that the first
whorl organs have stigmatic papillae (arrows), characteristic
of carpels. (C) 1M-I-K, lacking the C region. The flower is in-
determinate and exhibits conversion of stamens and carpels
to petals (p) and sepals. (D) 1M-I, lacking both the K domain
and C region. The flower has seven rather than six stamens
(s) and three unfused carpels (c) instead of two.
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cated AG protein can only partially inhibit normal
AG function. These results demonstrate that the K
domain and the C region both have important yet dis-
tinct in vivo functions.
Isolation of Organ-specific
cDNAs by Subtractive
Hybridizations
P. Rubinelli, Y. Hu, M. Kim, A. Hameed,
D. Rosa, H. Ma
We have carried out further characterization of the
anther-specific clones we isolated using a subtractive
hybridization procedure, as described in previous an-
nual reports. We have performed two sets of experi-
ments. The expression pattern of several genes was
analyzed using RNA in situ hybridizations. We found
that among these anther-specific genes, four (A7,
A20, A26, A27) have highly localized expression in
the tapetum cell layer, which surrounds the develop-
ing pollens. Two other genes (A18, A21) are ex-
pressed only in the pollen grains within the flower.
We have isolated full-length cDNAs for these six
genes. On the basis of the similarity to known se-
quences, A7 is likely to encode a new lipotransferase,
and the predicted A27 protein is probably a gluco-
sidase. A20 and A26 encode glycine-rich proteins;
glycine-rich sequences have been found in structural
proteins, such as elastin and plant cell wall proteins.
Both A18 and A21 encode proteins with novel se-
quences.
These clones represent genes that are specifically
or predominantly expressed in anthers. Because the
anther has several specialized cell types, some of the
genes are likely to be important for the differentiation
and/or function of some of these cells. The tapetum
layer is important for pollen development, and thus
some of the tapetum-specific genes may be needed
for pollen development. For example, during pollen
development, complex lipoproteins are deposited on
the surface of the pollen; it is possible that the A7
lipotransferase plays a part in this process. Lipotrans-
ferases have previously been found to be anther-
specific, but the A7 sequence suggests that it may be
a new enzyme, perhaps having a unique activity. As
the pollen matures, the tapetum cells die and
degenerate, and it is believed that hydrolytic enzymes
are required for this process. The sequence of A27
suggests that, being a potential glucosidase, it could
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participate in the developmentally regulated cell
death of tapetum cells. Further studies, such as those
using transgenic plants, are needed to help provide
clues to the function of these genes.
Biochemical Characterization
of the G Protein GPal
C. Weiss, E. White, H. Ma
We have continued our characterization of the sub-
cellular localization of GPal using fractionation
methods and immunofluorescence. Multiple frac-
tionation experiments and enzymatic assays have
determined that GPal is associated with the plasma
membrane, as well as with the endoplasmic reticulum
(ER). This is consistent with the observation from
immunofluorescence experiments. The plasma mem-
brane association is similar to the well-characterized
G proteins in mammalians cells, and it suggests pos-
sible signaling functions for GPal. In mammalian
cells, small and heterotrimeric G proteins have been
shown to be associated with the Golgi network, sug-
trafficking, but only small
G proteins (Rabl, Rab2) are known to associate with
the ER compartment. The fact that GPal is found
with ER suggests that in plants, heterotrimeric G
proteins may perform additional functions.
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HIGHER-ORDER CHROMOSOME DYNAMICS
T. Hirano M. Hirano
Genomic DNA is organized and packaged into a
higher-order structure inside the cell. Virtually all
chromosomal events, including DNA replication,
gene expression, and chromosome segregation, re-
quire faithful regulation of higher-order chromosome
dynamics. Our laboratory is particularly interested in
the molecular mechanisms of mitotic chromosome
condensation, an essential process for maintaining
the integrity of genetic information during mitosis.
To address this problem, we established a cell-free
system derived from Xenopus laevis (African toad)
eggs in which higher-order chromosome structures
can be reconstituted in vitro in a cell-cycle-dependent
manner. This unique system provided us with both a
simple procedure for chromosome isolation and a
powerful functional assay. Using this system, we
recently identified two chromosomal polypeptides,
XCAP-C and XCAP-E, that have a fundamental role
in mitotic chromosome condensation (XCAP stands
for Xenopus chromosome-associated polypeptides).
Sequence analysis revealed that they share common
structural motifs and belong to a recently identified
protein family, the SMC family. Genetic studies in
other laboratories showed that yeast homologs of
XCAP-C and XCAP-E are required for chromosome
condensation and segregation in vivo. Other mem-
bers of this protein family were found to be involved
in many aspects of higher-order chromosome struc-
ture and function, including dosage compensation
and recombinational DNA repair.
We are now focusing our efforts on biochemistry
and cell cycle regulation of the chromosome con-
densation protein complex containing XCAP-C and
XCAP-E and are trying to understand how the
dynamic behavior of chromosomes is regulated dur-
ing the cell cycle.
Purification and Characterization
of the Chromosome Condensation
Protein Complex Containing
XCAP-C and XCAP-E
T. Hirano
XCAP-C and XCAP-E were originally identified as
major components of mitotic chromosomes assem-
bled in Xenopus egg extracts and were subsequently
shown to be present in the same protein complex.
They share structural motifs common to all members
of the SMC family, which include an amino-terminal
nucleotide-binding motif (the P-loop) and two long
coiled-coil regions. No obvious DNA-binding motif
is found in either polypeptide. Moreover, no SMC
proteins have been purified to homogeneity from any
organism. Thus, although our functional blocking ex-
periments showed that XCAP-C and XCAP-E are re-
quired for both assembly and structural maintenance
of mitotic chromosomes in vitro, detailed biochemi-
cal activities of this class of proteins are currently un-
known.
As an initial step toward an understanding of the
biochemical processes of mitotic chromosome con-
densation, we established a purification scheme for
the protein complex containing XCAP-C and XCAP-
E. In this scheme, we took advantage of immuno-
affinity column chromatography using anti-peptide
antibodies specific for the carboxy-terminal se-
quences of either XCAP-C or XCAP-E. Interestingly,
a highly purified fraction contained not only XCAP-
C and XCAP-E, but also three additional polypep-
tides. We tentatively named them p150, p130, and
p100 based on their apparent molecular weights.
Sucrose gradient centrifugation revealed that the
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FIGURE 1 Subunit composition and cell cycle regulation of the chromosome con-
densation protein complex. XCAP-C and XCAP-E exist in multiple forms in
Xenopus egg extracts: (1) the 4S form contains XCAP-E only; (2) the 8S form
represents a heterodimer of XCAP-C and XCAP-E; and (3) the 13S form contains
an additional three subunits, p150, p130, and p100. These three subunits, which
become phosphorylated in a mitosis-specific manner, may be responsible for the
targeting of this complex to chromosomes.
fraction could be further fractionated into three dis-
tinct populations: (1) the first 4S peak contained
XCAP-E only; (2) the second 8S peak contained
XCAP-C and XCAP-E; and (3) the third 13S peak
contained XCAP-C, XCAP-E, p150, p130, and p100
(see Fig. 1). No freeXCAP-C was detected. Thus,
XCAP-C and XCAP-E existed in multiple forms in
the egg extracts, and a significant population of them
(>50%) was present in a large protein complex con-
taining additional three subunits. Preliminary experi-
ments suggested that, like XCAP-C and XCAP-E, the
other three subunits were also recovered as major
components of mitotic chromosomes assembled in
vitro. They seem to have an important role in cell
cycle regulation of the protein complex function (see
below). We speculate that the 8S and 13S forms
represent a core complex (XCAP-C/E) and a holo-
complex (XCAP-C/E plus "regulatory" subunits),
respectively, and that both are required for mitotic
chromosome assembly in vitro.
Having established the purification scheme de-
scribed above, we are now in a good position to start
characterizing the biochemical activities of this
chromosome condensation protein complex. The fol-
lowing specific questions are to be addressed: (1)
Does the complex interact directly withDNA? If so,
is there any sequence specificity or sequence prefer-
ence? (2) The XCAP-C and XCAP-E subunits con-
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taro a putative nucleotide-binding motif. What is the
role of nucleotide binding and hydrolysis in protein
function? (3) How do the two activities (DNA bind-
ing and nucleotide binding) contribute to changes of
higher-order chromosome structure? (4) What is the
functional relationship between the 8S and 13S
forms?
Cell Cycle Regulation of the
Chromosome Condensation
Protein Complex
T. Hirano
Chromosome condensation is a cell-cycle-dependent
event in the cell. If the protein complex containing
XCAP-C and XCAP-E is directly involved in this
process, its function should be tightly regulated in the
cell cycle. We found that this was the case. We used
cell-cycle-specific extracts, namely, mitotic and inter-
phase extracts, and assembled mitotic chromosomes
and interphase chromatin structures in vitro. When
the two structures were isolated and fractionated on
an SDS-polyacrylamide gel, XCAP-C and XCAP-E
were detected only in mitotic chromosome fractions,
showing that chromosomal targeting of the protein
complex is mitosis-specific. In addition, pharmaco-
logical experiments with inhibitors for protein
kinases and phosphatases suggested that the targeting
is regulated by mitosis-specific phosphorylation.
Whereas phosphorylation of XCAP-C and XCAP-E
was barely detectable by immunoprecipitation of 32P-
labeled extracts, we found that p150, p130, and p100
were heavily phosphorylated in a mitosis-specific
manner. No subunit rearrangement was observed be-
tween the mitotic and interphase forms. Taken to-
gether, we propose that mitosis-specific phosphoryla-
tion of the "regulatory" subunits has a key role in
recruiting this protein complex to chromosomes dur-
ing mitosis. The phosphorylated 13S complex may in
fact have a higher affinity for DNA. It is also pos-
sible, however, that additional or redundant regu-
latory mechanisms exist by which the protein com-
plex is targeted to chromosomes strictly during
mitosis. For example, mitotic chromatin may have a
"receptor" -like protein for the phosphorylated com-
plex. Candidates for such a receptor include histones
H1 and H3, both of which are known to be hyper-
phosphorylated during mitosis.
Cloning of cDNAs Encoding
the Subunits of the
Chromosome Condensation
Protein Complex
M. Hirano, T. Hirano [in collaboration with R. Kobayashi,
Cold Spring Harbor Laboratory]
To better understand the structure and function of the
chromosome condensation protein complex, we are
now cloning cDNAs encoding the newly identified
three subunits. We isolated the protein complex by
immunoprecipitation and raised mouse polyclonal
antibodies against each polypeptide purified from an
SDS-polyacrylamide gel. We obtained an antibody
specific for p130, which was then used to screen a
Xenopus ovary cDNA expression library. The full-
length cDNA encoded an acidic polypeptide with a
calculated molecular mass of 116 kD. No significant
homology was found with other proteins available in
the databases. One exception was a yeast polypeptide
with unknown function that was identified in the
genome sequencing project. The homology between
the Xenopus and yeast polypeptides was relatively
weak but was observed throughout the whole
molecules. More recently, in collaboration with R.
Kobayashi of the CSHL Protein Chemistry Facility,
we obtained several peptide sequences for p150 and
p100. The information is now being used to design
degenerate primers for cloning the corresponding
cDNAs by polymerase chain reaction (PCR). Full-
length sequence information and antibodies raised
against expressed proteins will be valuable tools for
further characterization of this protein complex.
Hirano, T. 1995. Biochemical and genetic dissection of
mitotic chromosome condensation. Trends Biochem.
Sci. 20: 357-361.
Hirano, T., T.J. Mitchison, and J.R. Swedlow. 1995. The
SMC family: From chromosome condensation to dosage
compensation. Curr. Opin. Cell Biol. 7: 329-336.
Vernos, I., J. Raats, T. Hirano, J. Heasman, E. Karsenti, and
C. Wylie. 1995. Xklp1, a chromosomal Xenopus kinesin-
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STRUCTURE AND COMPUTATION
Scientists in this section are engaged in basic research and methodology development in gene
discovery and in gene and protein functional analysis. The program is comprehensive and has
major programs both in the experimental and computational aspects of gene discovery and in the
analysis and prediction of gene and protein structure and function. The main scientific thrust and
overall goals of this section are to develop and apply methods that
establish chromosomal position of heritable disease genes by linkage and segregation
analysis of affected families
automate high-speed DNA sequencing over long contiguous regions of genomic DNA
automate the detection of segments of genomic DNA sequences that have specific biologic
content
predict gene function by homology/analogy to existing sequences
isolate and characterize minuscule amounts of proteins for cloning genes using degenerate
PCR techniques
use X-ray diffraction patterns with crystalline proteins to determine their three-dimensional
structure with the goal of understanding their function
COMPUTATION
T. Marr W. Chang J. Heimlich C. Reed
S. Cozza T. Iwasaki J. Salit
D. Cuddihy R. Koskela A. Tracy
E. Hackborn M. Mallison
The focus of our group is in the continued develop-
ment of a major computer program which we call
Genome Topographer (GT). GT has been designed to
be a general-purpose scientific computing system
used to study complex problems in human genetics
and disease, such as cancer, diabetes, psychiatric dis-
orders, and infectious diseases. A major design goal
with GT was to build a computer system that could
support such studies from start to finish, i.e., from
epidemiological and genetic analysis to functional
analysis of candidate genes.
GT enables users to carry out the following: (1)
Query, gather, and systematically organize data from
all of the major publicly available genome databases
containing genetic and physical mapping data, in-
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eluding the nascent data required to construct and in-
terpret the maps (e.g., pedigree and genotyping data),
and DNA and protein sequences. GT can also be used
to store relevant data as gleaned from the scientific
literature or from patient interviews, for example,
using the powerful editing and viewing tools found in
GT. (2) Customize and integrate GT, using network-
based collaboration tools, into their own local labor-
atory operations, including direct interfacing into
laboratory instruments for automated data gathering.
(3) Manipulate, perform sophisticated analyses, and
visualize all data stored in the database in informative
ways. Taken together, these features allow users to
construct, with relative ease, online databases of the
primary data needed to study a genetic disease from
the stage of family collection and diagnostic as-
certainment through cloning and functional analysis
of candidate genes, including mutational analysis and
screening for biochemical interactions with candidate
molecules.
Our work with GT has been funded as a research
project for many years, but this year, we converted
our research grant into a resource grant. This was
done by standard NIH peer review. This new and
substantial grant enabled us to establish the CSHL
Human Genome Informatics Research Resource,
which is the only one of its kind in the United States,
perhaps the world. We are working on documentation
and training and the other things that need to be done
before software can be made generally available.
Our software is in beta test at several major
laboratories, including a major cancer research lab in-
volved in gathering mutation and phenotype informa-
tion from laboratories around the world that are
engaged in breast cancer susceptibility gene research.
We are scheduled for our first widely available soft-
ware release in September 1996.
Dana Foundation Consortium
on the Genetic Basis of
Manic Depressive Disorder
T. Marr (1), J.R. DePaulo (2), C.J. Friddle (3),
D. Botstein (3), M. Gschwend (3), R.J. Koskela (1),
M.G. McInnis (2), F.J. McMahon (2), D.A. Meyers (2),
S.G. Simpson (2), O.C. Stine (2), J.D. Watson (1)
(1) Cold Spring Harbor Laboratory, Structure and
Computation Program
(2) Johns Hopkins University, School of Medicine,
Dept. of Psychiatry
(3) Stanford University, School of Medicine,
Dept. of Human Genetics
The Dana Foundation Consortium on the Genetic
Basis of Manic Depressive Disorder (MDD) is an ex-
citing new multi-institutional project dedicated to
finding genes involved in susceptibility to manic
depressive disorder. This is the first major program at
CSHL involving clinicians, computers scientists, hu-
man geneticists, and quantitative biologists.
MDD is a mood disorder consisting of alternating
periods of elevated and depressed moods. During
these episodes, affected individuals can become
seriously impaired both socially and in the work-
place. There are three distinct subtypes of related dis-
orders in MDD. The first is Major Depressive Dis-
order. The lifetime risk of suffering at least one major
depressive episode is 10-25% in women and 5-12%
in men. Risk is unrelated to ethnicity, income, educa-
tion, or marital status and is 1.5 to 3 times higher in
first-degree biological relatives of people who have
major depressive disorder. Concordance is higher in
monozygotic twins than in dizygotic twins, indicating
at least a moderate genetic component.
The second subtype is Bipolar I (BPI) disorder,
which in simplistic terms is indicated when a person
suffers at least one manic episode and at least one
major depressive episode. Bipolar II is a distinct,
recognizable (by a rigorously trained psychiatrist)
subtype which again involves at least one major
depressive episode but is accompanied by a milder
form of elevated mood called hypomania.
Prevalence of BPI varies from 0.4 to 1.6 and is
about 0.5% for BPII. Twin and adoption studies show
strong evidence of a heritable component. First-
degree biological relatives of a BPI have a 4-24% in-
crease for BPI, 1-5% increase for BPII, and 4-24%
increase risk for major depressive disorder. Little is
known about the relative risk of BPII persons.
MDD appears to exhibit complex genetic features
in many ways. Many genes appear to be involved.
The disease can manifest itself in different ways
depending on the parent origin of disease alleles.
Some studies indicate that genetic anticipation is in-
volved in MDD. Our study was designed to reduce
the potential genetic complexity of the disease by
studying only those families in which the disease is
transmitted through only one parental line. Further-
more, only BPI probands were used to screen for
study families. We set out to collect 50 such families
for genetic analysis.
We have done genotyping on more than half of the
50 families and have found interesting linkage results
on two regions on human chromosome 18, one on the
p-arm and one on the q-arm. The q-arm linkage find-
ing was most strong in those families where the dis-
ease was transmitted by fathers. We will be close to
completion of a complete genome scan of all of the
families by the end of 1996.
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SEQUENCE-BASED ANALYSIS OF COMPLEX GENOMES
W.R. McCombie N. Kaplan M. Lodhi
S. Till A. Johnston
J. Hoffman
The long-term goal of our lab is to develop new tools
and strategies for high-throughput DNA sequencing
and to use them to analyze the structure of complex
genomes. Our program is therefore divided into tech-
nology development and sequence analysis compon-
ents. The technology development effort is develop-
ing new technology to increase the speed at which we
can analyze complex genomes. The sequencing effort
uses what is the best available technology at the time
to analyze organisms of biological interest. We have
been sequencing the genome of the fission yeast
Schizosaccharomyces pombe. In this past year, we
began a project to sequence human genomic DNA as
part of a test project coupled with our technology de-
velopment efforts. We also expanded our efforts in
Arabidopsis genome analysis from the characteriza-
tion of the sequence surrounding transposon insertion
sites to Arabidopsis genome sequencing.
Technology Development
A. Johnson, M. Lodhi, W.R. McCombie
The ability to determine the sequence of any region
of DNA by the use of a custom oligonucleotide to
prime a sequence reaction is a powerful tool in many
sequencing applications ranging from genome se-
quencing to the sequencing of particular cDNAs of
interest. Most large-scale projects, however, rely on
cloning techniques devised to allow sequencing using
universal primers (the same primer for each clone se-
quenced). This is due to the expense, time, and man-
agement burden associated with the use of large num-
bers of custom synthesized oligonucleotides. We
have been developing the use of a small number of
short modular primers used in combination, rather
than standard 18-20-base primers. There are only
4096 possible hexamers. The use of such modular
primers was originally developed for sequencing with
radioisotopes by Kieleczawa et al. (Science 258:
1787 [1992]). This technology if successfully devel-
oped will allow us to combine any three hexamers
from our library of all possible hexamers to form the
appropriate 18 mer in situ to prime a sequencing
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reaction. This has the potential not only to improve
genome sequencing technology, but also to allow
rapid and inexpensive sequencing of cDNAs, using
hexamer-based primer walking. We have been devel-
oping this technology on both single- and double-
stranded templates.
Automated DNA Sequencing
of Single-stranded Templates
Primed with Strings of Hexamers
M.A. Lodhi, W.R. McCombie
Last year, we reported the use of strings of three
hexamer primers, instead of one long primer, for se-
quencing single-stranded M13mp18. Since then, we
have made several changes to the protocol. Our cur-
rent protocol has been tested with a wide variety of
hexamer string primers and it has been found to be
very robust and produces substantially longer read
lengths than we previously obtained. We have used
32 primers composed of 3 hexamers each that were
picked from different sites on M13 to test the reliabil-
ity of the current protocol for sequencing from any
site on a single-stranded template. These hexamer
strings were chosen from strings initially used suc-
cessfully in radioisotopic sequencing but which pro-
duced varying signal strengths (J. Kieleczawa and B.
Studier; pers. comm.). To compare the read lengths
obtained with hexamer primer strings, 12 long
primers (18 mers) corresponding to a subset of the
hexamer strings were also tested in standard Se-
quenase dye terminator sequencing reactions. The
two-cycle Sequenase dye ter-minator reaction starts
with incubation on ice for 5 minutes to stabilize the
hexamer string on the tem-plate. The reaction is then
incubated at room temper-ature for 10 minutes and
heated at 65°C for 2 minutes. One unit of Sequenase
is added and again incubated at room temperature for
10 minutes. At the end, Pronase is added to destroy
the single-strand binding protein used to stabilize the
template. The reaction is then precipitated and run on
an ABI 373 or 377 DNA sequencer using standard
procedures.
The overall success rate of priming with 32
hexamer string primers was 97%, with the failure of
only one string (S12). The reason for the failure of
S12 is not clear and our attempt to sequence with a
corresponding long primer (S12L) also failed. The
average read length from reactions successfully
primed with 31 hexamer string primers was 461
bases (max = 610 bases) with greater than 99% base-
calling accuracy, whereas the average read length ob-
tained with long primers was 492 bases (max = 590
bases) with the failure of only one primer (S12L). To
simplify these reactions, we used 15 two-hexamer
string primers in our standard hexamer sequencing
procedure. The average read length from reactions
primed with 14 strings was 465, with the failure of
only one string. We believe that the current protocol
is robust enough to be used at the end stages of se-
quencing projects for gap filling and resolving base
ambiguities which follows the shotgun sequencing
portion of a large-scale sequencing project. It could
also be used in any other application involving
primer walking on single-stranded templates such as
the sequencing of cDNA clones. We are currently
testing this technology in the finishing stage of three
S. pombe cosmids sequenced at different levels of
shotgun sequencing with single- and double-stranded
templates.
Sequencing with Hexamer
Primers on Double-stranded
Templates
A. Johnston, W R. McCombie
In addition to single-stranded templates, we have also
applied the principle of hexamer string priming to
fluorescence-based sequencing on double-stranded
templates. Double-stranded sequencing is advanta-
geous because it enables one to easily obtain se-
quence information from both strands of a particular
DNA fragment. Previous work in this area had only
limited applicability to a fluorescence-based ap-
proach. During the past year, we have successfully
developed a robust hexamer string primer sequencing
protocol for double-stranded templates that uses fluo-
rescent T7 (Sequenase) dideoxy terminators. The key
to success with these reactions was the linearization
of the plasmid clones with a rare cutting restriction
enzyme prior to primer extension. This protocol has
been tested extensively on the sequencing vector
pUC19 with a wide variety of hexamer strings. As
part of this work, we have successfully walked
around the entire length of pUC19 (2686 bases) on
both strands. The success rate of these reactions was
75%, which is comparable to that obtained with cus-
tom synthesized long primers and Sequenase dye ter-
minator chemistry. The sequencing of pUC19 on
both strands required 28 successful primer walks.
Current read lengths vary between 350 and 450 bases
with an average accuracy of 98%. We are now incor-
porating this protocol into the finishing phase of our
production sequencing efforts on a human cosmid.
Genome Sequence
Analysis
J. Hoffman, A. Johnson, N. Kaplan, M. Lodhi,
S. Till, W.R. McCombie
In the past year, we have finished the sequencing of
several cosmids from S. pombe. One 31-kb segment
of cosmid DNA that was finished last year was
checked and submitted to Gen Bank this year. This
cosmid, 359, had a region of about 8 kb that had not
yet been connected to the larger 31-kb finished se-
quence. We determined that this was due to a repeat
sequence that made automated assembly of this
region difficult. We filled this gap in the sequence by
using PCR to amplify across the gap using cosmid
DNA as the template. We then primer walked across
the PCR product to fill the gap in an unambiguous
manner. This additional 8 kb of sequence will be sub-
mitted to Gen Bank shortly. Two cosmids in which
the shotgun phase of sequencing was completed at
the beginning of this year (1198 and 1683) were com-
pleted and submitted to Gen Bank as well. These cos-
mids, along with the 31 kb of PGAA, represent an
85,837-base-pair contig that was completed and sub-
mitted to Gen Bank in 1995. The next cosmid in this
contig is 660. This cosmid is being sequenced and
has a single gap of about 1.2 kb (based on PCR anal-
ysis) which will be completed shortly. The next cos-
mid, 800, has been completed and submitted to Gen-
Bank. The sequence from cosmid 800 is 40,438 base
pairs. This makes a total of 126,275 base pairs of S.
pombe genomic DNA completed and submitted to
Gen Bank in the past year. In addition, we have begun
sequencing the next four cosmids from S. pombe
chromosome II. A diagram of the current state of this
contig is shown in Figure 1.
We have begun analysis of this sequence in collab-
oration with Michael Zhang in Tom Marr's lab here
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FIGURE 1 Diagram showing the status of sequencing a region of S. pombe chromosome II. Solid black bars represent cos-
mids or partial regions of cosmids which were completed and submitted to GenBank in the past year (such as cosmid 1683).
Solid gray bars (such as cosmid 660) represent cosmids or regions of cosmids that are in the final finishing phase of se-
quencing. Hatched bars such as cosmid 1773 represent cosmids in the shotgun data collection phase of sequencing. The
axis shows approximate size of the region in kilobases pairs.
at the Laboratory. The initial computer analysis of the
contig represented by cosmids 359, 1198, and 1683 is
shown in Figure 2. We will continue working with
Dr. Zhang to analyze the additional sequence we are
generating and begin carrying out experimental anal-
ysis of the sequence based on these predictions. The
initial conclusion from this analysis supports the pre-
diction that the S. pombe genome is gene-rich, with
about one gene every 2 kb. This demonstrates that
continued sequencing of the S. pombe genome is a
cost-effective method for the identification of all of
the genes contained in this important model organ-
ism.
Our initial efforts in collaboration with the plant
biology group (Martienssen and Sundaresan labs,
CSHL) was to sequence the insertion sites of
transposons inserted in the Arabidopsis genome.
These results are described in the progress report of
the Martienssen lab. This project has expanded into
genome sequencing in Arabidopsis. We obtained an
Arabidopsis genomic library from the Arabidopsis
stock center. This library was composed of 81 "chap-
ters" which were pools of 500 cosmids each. We car-
ried out PCR on these chapters using primers derived
from the PROLIFERA gene which we had previously
sequenced. Positive chapters were plated and 4 x 96
clones from each chapter gridded in a 96-well pat-
tern. Clones from each plate were again screened
using the PCR primers from PROLIFERA. Positive
plates were broken down into column pools, and
clones from positive columns were eventually tested
to identify PROLIFERA containing cosmids. One of
these was selected for genome sequencing. The shot-
gun portion of this sequencing is completed and we
are currently filling gaps and finishing the sequence.
We have begun an initial analysis on the partially fin-
ished sequence. In addition to PROLIFERA, we have
also identified a gene in this sequence that encodes a
protein similar to the Escherchia colt MutS gene (mu-
tator). A homolog of this gene is implicated in human
colon cancer. The role of this gene in plant growth
and development is not yet understood. However, our
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identification of its position near PROLIFERA should
enable us to work with the Martienssen lab to identify
transposon insertions in this gene, which will be an
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FIGURE 2 Diagram showing predicted genes in an 85,837 -
base -pair contig from S. pombe. Solid boxes indicate pre-
dicted genes that have significant matches to genes in the
publicly available database. Cross-hatched boxes indicate
the predicted structure of genes that are not similar to any
previously known gene. Boxes above the axis indicate
genes predicted to be transcribed in the forward orientation
relative to the contig, and boxes below the axis are predic-
ted to be transcribed in the reverse direction relative to the
sequence. Numbers indicate the distance from the most
telomeric end of the contig in kilobase pairs. Large per-
pendicular lines are placed to divide some predicted genes
that cluster close to one another (between 60 and 70 kb).
Note the presence of a number of predicted genes contain-
ing introns.
important step in identifying its function in Arabidop-
sis. We have also identified putative homologs of the
gene Sari and a hexose sugar transport protein by
analyzing the sequence of this cosmid. In addition to
finishing the sequence of this cosmid, we will be ex-
panding our sequencing on the short arm of Arabi-
dopsis chromosome IV. We have made arrangements
PROTEIN CHEMISTRY
R. Kobayashi G. Binns P. Kearney
H. Cai C. Kelley
N. Carpino N. Poppito
J. Kehler
This year brought many changes in our group.
Camille Kelley joined the protein chemistry core fa-
cility and is working in the protein sequencing sec-
tion. G. Binns remains as Lab Facility Manager for
peptide synthesis. Since Dan Marshak moved to
Osiris Therapeutics in Baltimore, sections of his two
program projects with Memorial Sloan-Kettering
Cancer Center and New York University moved to
our group this year.
Protein Chemistry
Core Facility
C. Kelley, N. Poppito, G. Binns, R. Kobayashi
Collaboration with other scientists at Cold Spring
Harbor Laboratory is a major activity in our labor-
atory. Because internal sequence analysis of proteins
has an essential role in the strategy of cloning a
specific gene, this technique has been used extensive-
ly at Cold Spring Harbor since 1992 and has been
very successful. Not only has there been a significant
increase in the use of the facility, but also the protein
required for internal sequence analysis has been im-
proved to the submicrogram level of protein at the
stage of polyacrylamide gel electrophoresis. Since we
began using the 1-mm microbore high-performance
liquid chromatography (HPLC) column for peptide
mapping, it has become routine to obtain sequence
information of 10-20 pmoles proteins. Changing the
particle size from 5 [AM to 10 tm of silica reduces
to receive bacterial artificial chromosome clones
(BAC) containing large Arabidopsis inserts derived
from this part of the genome from the European
Scientists Sequencing Arabidopsis consortium, par-
ticularly Mike Bevan (John Innes Center, Norwich
England) who heads this group. We will begin se-
quencing these clones in the coming year.
back pressure and enables the HPLC to run without
modification. The microbore column has better
recovery for a small amount of peptides than the 2.1-
mm narrow bore column and thus using the micro-
bore column for peptide mapping became critically
important for low amounts of protein. We are
enthusiastically expecting to have matrix-assisted
laser desorption mass spectrometry in 1996 (shared
instrumentation grant for NIH grant is pending). This
instrument will strengthen the core facility capability
significantly and will be a powerful instrument for
analyzing posttranslational modification, which has
an important role in macromolecule interactions by
modulating the charge, hydrogen-bonding capabil-
ities, and conformational changes of molecules.
Method Development for
Protein Sequence Analysis
J. Kehoe, H. Cai, R. Kobayashi
This project is to develop a more sensitive method
than Edman degradation by utilizing highly sensitive
chemiluminescence detection. To use the chemilu-
minescence detection system, a chemiluminergic
(fluorescence) compound must be introduced into se-
quencing products. We synthesized two promising
fluorescent isothiocyanates to replace the phenyl-
isothiocyanate that had been used in Edman degrada-
tion. We are currently examining this new reagent to
determine whether it is usable for protein sequencing.
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GAP-associated p62 in Chronic
Myelogenous Leukemia
N. Carpino, J. Kehler, R. Kobayashi [in collaboration
with B. Clarkson, Memorial Sloan-Kettering
Cancer Center]
Chronic myelogenous leukemia is a blood disease
caused by an oncogenic tyrosine kinase. A reciprocal
translation between chromosome 9 and 22 in a single
primitive myeloid progenitor cell activates the abl
kinase. In due course, the progeny of this progenitor
cell, all of which bear the Philadelphia chromosome,
populate the entire hematopoietic system. During an
early phase of the disease, the affected cells retain
their ability to function normally and their prolifera-
tion can be controlled by drug treatment. However,
almost without fail, the disease progresses to a fatal
stage characterized by undifferentiated, dysfunctional
Ph+ cells.
We hypothesize that the activated abl kinase dis-
rupts signal transduction pathways which control
normal myeloid cell development. It accomplishes
this by phosphorylating intracellular substrates, some
of which might be involved in the regulation of
hematopoiesis. Aberrant phosphorylation can lead to
the abnormal arrangement and disregulated activity
of molecules witnin the cells that contain the Phila-
delphia chromosome. Our goal is to identify the im-
mediate substrates of the activated abl kinase. In
doing so, we hope to unravel the mechanism by
which the activated abl causes chronic myelogenous
leukemia.
In collaboration with Dr. Bayard Clarkson at the
Memorial Sloan-Kettering Cancer Center, we have
identified five candidate proteins that appear to be
targets of the abl kinase. We have chosen to focus our
efforts on one of these proteins, termed p62, because
it is the most prominent and consistently tyrosine-
phosphorylated molecule that appears in the blood
cells of patients during the early stages of the disease.
We have demonstrated that in cells which express the
activated abl, p62 interacts abnormally with another
signaling molecule known as p120 ras GAP. This in-
teraction appears to be due to the presence of
phosphotyrosine within the molecule. We intend to
address the functional significance of this abnormal
interaction. To do so, it is necessary to purify and
clone p62. We have purified p62 from tissue culture
cells that express the activated abl kinase, obtained
partial amino acid sequences of the molecule, and are
presently in the midst of cloning the cDNA encoding
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p62. Our future experiments will address the question
of how the abnormal modification of this protein con-
tributes to the pathogenesis of chronic myelogenous
leukemia.
Study of 5-HT1A Receptor
Signal Transduction
Mechanism
P. Kearney, R. Kobayashi [in collaboration with
E. Azmitia, New York University]
We set out to study the expression, regulation, and
modification of the serotonin (5-HT1A) receptor by
developing a model for expression. Our study of the
5 -HTIA receptor began with experiments using stab-
ly transfected mouse fibroblast cells (LZD-7) ex-
pressing the rat 5-HT1A receptor protein. To find a
better model and to be able to use the expression sys-
tem in other mammalian cells, we decided to develop
an expression system utilizing the cytomegalovirus
(CMV) promoter. The genomic gene for the rat 5-
HT1A receptor (P. Albert et al., J. Biol. Chem. 265:
5825 [1990]) was used in the construction of the ex-
pression system. The gene is intronless, but it con-
tained a larger stretch of noncoding region prior to
the start codon which we removed. The clone was
then inserted into a plasmid containing the CMV
promoter.
Transformed primary human embryonal kidney
293 cells were chosen for the host of our expression
system. The CMV promoter is very progressive in
these cells, and the natural low basal expression of
the 5-HT1A receptor made the cells a good candidate
because the correct machinery for receptor interac-
tion would be more likely present. The rat 5-HT1A
receptor gene was transiently transfected into human
kidney 293 cells via coprecipitation of calcium phos-
phate and plasmid DNA. Western blot analysis using
specific antibodies to the receptor showed high levels
of expression and thus the model will be used to
study the structure and function of the receptor.
PUBLICATIONS
Bell, S.P., J. Mitchell, J. Leber, R. Kobayashi, and B.
Stillman. 1995. The multidomain structure of Orcl p
reveals similarity to regulators of DNA replication and
transcriptional silencing. Cell 83: 563-568.
Collins, K., R. Kobayashi, and C.W. Greider. 1995. Purifica-
tion of Tetrahymena telomerase and cloning of genes
encoding the two protein components of the enzyme.
Cell 81: 677-686.
Cullmann, G., K. Fien, R. Kobayashi, and B. Stillman. 1995.
Charcterization of the five regulation factor C genes
from S. cerevisiae. Mol. Cell. Biol. 15: 4661-4671.
Henry, R.W. and R. Kobayashi. 1995. SNAPc-A novel TBP-
TAF complex required for transcription by RNA poly-
merase II and III. Exp. Med. 13: 2179-2182.
Henry, R.W., C.L. Sadowski, R. Kobayashi, and N. Hernan-
dez. 1995. A TBP-TAF complex required for transcrip-
tion of human snRNA genes by RNA polymerases II and
III. Nature 374: 653-656.
Kassavetis, G.A., S.T. Nguyen, R. Kobayashi, A. Kumar, E.P.
Geiduschek, and M. Pisano. 1995. Cloning, expression,
and function of TFC5, the gene encoding the B' com-
ponent of the Saccharomyces cerevisiae RNA polymer-
ase III transcription factor TFIIIB. Proc. Natl. Acad. Sci.
92: 9786-9790.
Kaufman, P.D., R. Kobayashi, N. Kessler, and B. Stillman.
1995. The p150 and p60 subunits of chromatin assemb-
ly factor I: A molecular link between newly synthesized
histones and DNA replication. Cell 81: 1105-1114.
Latter, G.I., T. Boutell, P.J. Monardo, R. Kobayashi, B.
Futcher, C.S. Mclaughlin, and J.I. Garrels. 1995. A Sac-
charomyces cerevisiae Internet protein resource now
available. Electrophoresis 16: 1170-1174.
Loo, S., C.A. Fox, J. Rine, R. Kobayashi, B. Stillman, and S.
Bell. 1995. The origin recognition complex in silencing,
cell cycle progression, and DNA replication. Mol. Biol.
Cell 6: 741-756.
Sueyoshi, T., R. Kobayashi, K. Nishio, K. Aida, R. Moore, T.
Wads, H. Hands, and M. Negishi. 1995. A nuclear fac-
tor (NF2d9) that binds to the male-specific P450 (Cyp
2d-9) gene in mouse liver. Mol. Cell. Biol. 15: 4158-
4166.
Yee, A., M.A. Nichols, L. Wu, F.L. Hall, R. Kobayashi, and Y.
Xiong. 1995. Molecular cloning of CDK7-associated
human MAT1, a cyclin-dependent kinase-activating
kinase (CAK) assembly factor. Cancer Res. 55: 6058-
6062.
Yokomori, N., R. Kobayashi, R. Moore, T. Sueyoshi, and M.
Negishi. 1995. A DNA methylation site in the male-
specific P450 (Cyp 2d-9) promoter and binding of the
heteromeric transcription factor GABP. Mol. Cell. Biol.
15: 5355-5362.
Zhang, H., R. Kobayashi, K. Galaktionov, and D. Beach.
1995. p19SkPi and p45SkP2 are essential elements
of the cyclin A-CDK2 S phase kinase. Cell 82: 915-
925.
In Press
Brownell, J.E., J. Zhou, T. Ranalli, R. Kobayashi, D.G. Ed-
mondson, S.Y. Roth, and C.D. Allis. 1996. Tetrahymena
histone acetyltransferase A: A transcriptional coactiva-
tor linking gene expression to histone acetylation. Cell
(in press).
Sadowski, C.L., R.W. Henry, R. Kobayashi, and N. Hernan-
dez. 1996. The SNAP45 subunit of the snRNA activating
protein complex (SNAPc) is required for RNA polymer-
ase II and III snRNA gene transcription and interacts
with TBP. Proc. Natl. Acad. Sci. (in press).
Yee, A., L. Wu, L. Liu, R. Kobayashi, Y. Xiong, and F.L. Hall.
1996. Biochemical characterization of the human cyclin-
dependent protein kinase activating kinase. J. Biol.
Chem. 271: 471-477.
MACROMOLECULAR CRYSTALLOGRAPHY
X. Cheng J. Horton K. McCloy
L. Jokhan M. O'Gara
Y. Liu R. Ventura
T. Malone R. Xu
Our goal is to determine the structures of a number of
biologically important proteins to atomic resolution
for a better understanding of their functions in cel-
lular processes. The following two new structures
were solved during the 1995 year: the DNA-binding
domain of Mbpl, a transcription factor in the yeast
Saccharomyces cerevisiae that activates the tran-
scription of genes encoding S-phase proteins, and the
catalytic domain of casein kinase I from Schizosac-
charomyces pombe in complex with a protein kinase
inhibitor.
Eukaryotic Multiprotein
Transcription Factors
We are studying the mechanisms of transcriptional
regulation in eukaryotes and are focusing on two sys-
tems: the Mbpl-Swi6 complex from the budding
yeast S. cerevisiae and the VP16-induced complex
from herpes simplex virus (HSV) type 1. The Mbpl-
Swi6 complex is a transcription factor important for
progression from Gt to S phase in the budding yeast.
The HSV-encoded virion protein VP16 associates
with two cellular proteins, Oct-1 and HCF, to form a
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multiprotein complex that activates HSV immediate-
early gene expression. We will determine how these
two multiprotein-DNA regulatory complexes are as-
sembled.
Structure of the DNA-binding
Domain of Mbpl
R. Xu [in collaboration with C. Koch and K. Nasmyth,
Institute of Molecular Pathology, Vienna, Austria]
We have determined the three-dimensional structure
of the DNA-binding domain of Mbpl, a transcription
factor involved in the regulation of G5 to S cell cycle
progression in S. cerevisiae. Mbpl associates with
Swi6 to form a transcriptional activation complex
termed MBF (MCB binding factor). MBF activates
the transcription of many genes encoding S-phase
proteins by binding to copies of the MCB element
(ACGCGTNA) in the promoters of these genes.
Mbpl consists of three functional regions: (1) a 124-
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residue amino-terminal region (termed Mbp1A1-124)
that binds to the MCB element, (2) a central region
that contains copies of the 33-residue ankyrin repeat
found in many different regulatory proteins and im-
plicated in protein-protein interactions, and (3) a
carboxy-terminal region that is important for interac-
tion between Mbpl and Swi6.
The structure reveals that Mbp1A1-124 contains a
helix-turn-helix DNA-binding motif (Fig. 1). It has a
short 13-strand amino-terminal to the motif and a pair
of antiparallel 13-strands carboxy-terminal to the
motif. Such an arrangement of secondary structure
elements is also found in other helix-turn-helix DNA-
binding proteins, including the carboxy-terminal
domain of the catabolite gene activator protein
(CAP), the globular domain of the linker histone H5
(GH5), and the DNA-binding domain of the hepato-
cyte nuclear factor-3 (HNF-3)/fork head family of
eukaryotic transcription factors. These proteins prob-
ably form a subfamily of the helix-turn-helix class of
DNA-binding proteins. Aligning the helix-turn-helix
FIGURE 1 Schematic ribbon diagram of the structure of the DNA-binding domain of
Mbpl . The similar regions among Mbpl , CAP, GH5, and HNF-3 are shown shaded.
motif of Mbpl with that of CAP and HNF-3 reveals
major groove contact of DNA by the recognition
helix within the helix-turn-helix motif, as well as
minor groove contact by the loop between the pair of
13-strands carboxy-terminal to the motif. The current
model includes residues 5-100, and the model is
being refined against a dataset to 1.7 A resolution,
which should allow more residues to be included in
the model.
Viral Protein VP16
Y. Liu, K. Mc Cloy [in collaboration with C. Huang
and W. Herr, Cold Spring Harbor Laboratory]
The HSV protein VP16 is one of the most potent
transcriptional activators identified in eukaryotes. It
forms a multiprotein complex with cellular proteins
Oct-1 and HCF to activate viral immediate early gene
transcription by binding to TAATGARAT elements
in the immediate early promoters. This binding
enables the activation domain of VP16 to interact
with the basal transcriptional machinery and activate
transcription. Since transcription regulation is in-
timately related to cell growth, cell cycle control, and
oncogenesis, VP16 has been the subject of intensive
studies.
We have crystallized the central region (amino
acids 48-412) of VP16 which is sufficient for VP16-
induced complex formation but lacks the activation
domain. This VP16 subunit crystallizes in the orthor-
hombic space group P212121, with unit cell dimen-
sions of a = 60 A, b= 77 A, c = 83 A. We have col-
lected X-ray diffraction data in our laboratory with an
R-AXIS imaging plate area detector and rotating
anode generator. Datasets from HgCl2 and p-chloro-
mercuriphenyl-sulfonate-soaked crystals showed
mercury site(s) in isomorphous difference Patterson
maps. Mercury derivatives constitute the basis of our
approach to solving the phase problem. A trial set of
Phases were then used to calculate a 3 A resolution
electron density map. Regions of the map could be
interpreted as cc helices. Experiments are under way
to improve the interpretability of the map.
To overcome the limitations of our laboratory X-
ray source, we used the facilities at beamline XI2C at
the National Synchrotron Light Source (NSLS),
Brookhaven National Laboratory (BNL). More than
45,439 measurements from a single crystal, frozen at
a liquid nitrogen temperature of 95K, resulted in
18,757 unique reflections between 20 A and 2.1 A
with an overall R-merge of 4.8%. The data are 85.8%
complete between 20 A and 2.1 A with 1/a(I) > 1.
Casein Kinases
Casein kinases I and II are the major multipotential
protein kinases recognizing serine/threonine amino
acids situated in an acidic environment in the sub-
strate. The nomenclature is derived from the sub-
strate, dephosphorylated casein, which was used in
initial studies to purify the enzymes. The two en-
zymes appear to be ubiquitous in eukaryotes and
have been found in all cell types and species exam-
ined. We are studying their structures, functions, and
regulations.
Structural Basis for Selectivity
of the Isoquinoline Sulfonamide
Family of Protein Kinase Inhibitors
R. Xu [in collaboration with G. Carmel and J. Kuret,
Northwestern University Medical School]
A large family of isoquinoline sulfonamide com-
pounds inhibits protein kinases by competing with
ATP, yet interferes little with the activity of other
ATP-using enzymes such as ATPases and adenylate
cyclases. One such compound, N-(2-aminoethyl)-5-
chloroisoquinoline-8-sulfonamide (CKI7), is selec-
tive for casein kinase I (CKI) isolated from a variety
of sources. We have solved the crystal structure of
the catalytic domain of S. pombe CKI complexed
with CKI7, refined to a crystallographic R-factor of
17.8% at 2.5 A resolution.
In the CKI-CKI7 structure, the overall folding of
CKI and the spatial positions of its ordered side
chains closely resemble those found in the CKI-
MgATP complex described previously (Xu et al.
1995). The root-mean-square deviation is 0.39 A
when the Ca atoms of the two structures are least
squares aligned. In this superposition, CKI7 is found
to occupy the same cleft that binds ATP. The iso-
quinoline ring replaces the adenine ring, and the
ethylamine sulfonamide chain of CKI7 points away
from the triphosphate moiety of ATP (Fig. 2). Thus,
it is structurally confirmed that CKI7 and presumably
the entire family of isoquinoline sulfonamide inhib-
itors bind their respective protein kinases stoichio-
metrically by competing with ATP for its binding
cleft.
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FIGURE 2 Schematic representation showing the specific
interactions observed between (top) CKI and ATP (pdb
code 1csn) and (bottom) CKI and CKI7 (pdb code 2csn).
For clarity, hydrophobic and van der Waals' contacts are not
shown. The ring N2 atom of CKI7 occupies the same posi-
tion where N1 of ATP is anchored and makes the same
hydrogen bond with the main-chain amide of Leu-88, sug-
gesting that this interaction makes an important contribution
to the binding affinity of CKI7.
The structure provides new insights into the mech-
anism of ATP-competing inhibition and the origin of
such inhibitors' selectivity toward different protein
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kinases. Selectivity for protein kinases versus other
enzymes is achieved by hydrophobic contacts and
hydrogen bonding between the protein kinase and the
isoquinoline ring. We propose that the hydrogen
bond involving the ring nitrogen-2 atom of the iso-
quinoline must be preserved but that the ring can flip
depending on the chemical substituents at ring posi-
tions 5 and 8. Selectivity for individual members of
the protein kinase family is achieved primarily by in-
teractions with these substituents.
Casein Kinase II
J. Horton [in collaboration with D. Marshak, Osiris
Therapeutics, Inc.]
During this past year, increasing evidence has shown
that casein kinase II (CKII) has a critical role in cell
regulation and may be involved in tumorigenesis.
CKII is known to phosphorylate a variety of proteins.
Most of its substrates are nuclear proteins, particular-
ly those that are involved in DNA replication and
transcription, whereas some are cytosolic and include
those involved in protein synthesis and signal trans-
duction.
CKII is composed of a catalytic a and regulatory 13
subunit that combine to form a native co, holoen-
zyme. The amino acid sequences of both subunits are
highly conserved in organisms evolutionarily distant
as yeast, Drosophila, and humans. In fact, its primary
sequence is nearly 100% conserved in vertebrates.
Among protein kinase families, CKII is more akin to
the cyclin-dependent kinase family than any other:
This similarity includes sequence homology in both
the catalytic and regulatory subunits, the use of GTP
as a phosphate donor, and more substantially, a
quaternary composition, including catalytic and ac-
tivating subunits. Recent experiments by D.C. Seldin
and P. Leder (Science 267: 894 [1995]) have pro-
vided strong evidence that disruption of the regula-
tion of the activity of CKIIa contributes to cellular
transformation in mice.
We recently improved the quality of CKIII3 crys-
tals and were able to grow larger, more stable crystals
of this protein at 16°C. These crystals are primitive,
hexagonal with unit cell dimensions of a = 79 A, b =
79 A, c= 269 A, a =13 = 90°, and y = 120°, and they
can be cryogenically preserved during data collec-
tion. Small crystals (<0.2 mm along edge, <0.06 mm
thick) diffracted to approximately 3.5 A at the XI2C
beamline (at the NSLS, BNL).
A larger crystal (>0.5 mm long) has recently been
grown. Crystallization conditions are being further
refined. To solve the phase problem and determine
the structure of CKII13, selenomethionyl CKII13 has
been produced.
DNA Methylation
DNA methyltransferases (Mtases) transfer methyl
groups from S-adenosyl-L-methionine (Ado Met) to
specific positions on bases in double-stranded DNA.
The DNA Mtases fall into two major classes, defined
by the position methylated. The members of one class
methylate a pyrimidine ring carbon yielding C5-
methylcytosine (e.g., Hhal Mtase). Members of the
second class methylate exocyclic amino nitrogens,
forming either N6-methyladenine (e.g., Taql Mtase
or T4 Dam) or N4-methylcytosine (e.g., Pvull
Mtase). The Mtases of the two classes were expected
to be substantially different from each other, based on
the fact that their targets of methyl transfer are very
different. Structural analysis, however, has found
striking similarities between the DNA Mtases of the
two classes.
Universal Catalytic Domain
Structure of Ado Met-dependent
Mtases
M. O'Gara, K. Mc Cloy, T. Malone [in collaboration with
W. Saenger, Freie Uniyersitat, Germany]
Our structural comparison has revealed that the
catalytic domains of the bilobal proteins, Hhal and
Taql Mtases, have similar folding with an a/(3 struc-
ture containing a mixed central 13-sheet. The func-
tional residues are located in equivalent regions at the
carboxyl ends of the parallel (3-strands. The Ado Met-
binding sites are almost identical and the essential
catalytic amino acids coincide. The comparable
protein folding and the existence of equivalent amino
acids in similar secondary and tertiary positions indi-
cate that many (if not all) Ado Met-dependent Mtases
have a common catalytic domain structure. This
permits tertiary structure prediction of other DNA,
RNA, protein, and small-molecule AdoMet-depen-
dent Mtases from their amino acid sequences.
Structure-guided Sequence
Analysis among DNA
Amino-Mtases
T. Malone [in collaboration with R.M. Blumenthal,
Medical College of Ohio]
Guided by the above common structure, we per-
formed a multiple sequence alignment of 42 amino-
Mtases (N6-adenine and N4-cytosine). This com-
parison revealed nine conserved motifs, correspond-
ing to motifs I-VIII and X previously defined in C5-
cytosine Mtases. The amino and C5-cytosine Mtases
thus appear to be more closely related than has been
previously appreciated. The amino-Mtases could be
divided into three groups based on the sequential or-
der of motifs. This variation of the motif order may
explain why only two motifs were previously recog-
nized in the amino-Mtases. The Mtases grouped in
this way show several other group-specific proper-
ties, including differences in amino acid sequence,
molecular mass, and DNA sequence specificity.
These results have implications for the catalytic me-
chanisms, evolution, and diversification of this fam-
ily of enzymes. Furthermore, a comparative analysis
of the Ado Met and adenine/cytosine-binding pockets
suggests that, structurally and functionally, they are
remarkably similar to one another. Whether this ac-
tually occurs is currently being explored, as several
more DNA Mtases are undergoing crystallographic
analysis.
Pvull N4-Cytosine Mtase
M. O'Gara [in collaboration with R.M. Blumenthal,
Medical College of Ohio]
The Pvull Mtase recognizes the DNA sequence 5 ' -
CAGCTG-3 ' . The enzyme acts on the internal C of
the sequence and converts the cytosine to N4-
methylcytosine, which has been found in a broad
range of bacterial species. N4-methylcytosine may
present particular advantages to thermophilic bacteria
since it is more resistant to heat-induced deamination
than cytosine or C5-methylcytosine.
The 38.3-kD Pvull Mtase has been overexpressed
in Escherichia coli as a mixture of a longer (5%) and
shorter (95%) form because in the full-length open
reading frame (ORF), there are two initiation sites for
translation, 14 amino acids apart. The shorter form
alone has been overexpressed and purified. This was
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made possible by using the overexpressing construct
that lacks the alternative translation initiator, which
Gail Adams made in Blumenthal's laboratory. Crys-
tallization trials were performed with the purified
shorter form of Pvull Mtase, complexed with its
cofactor Ado Met, at a concentration of 20-30 mg/ml.
A sparse matrix screening method was used to search
for initial conditions for crystallization by the
hanging-drop vapor diffusion technique. Crystals
were initially observed under two conditions at 16°C.
These conditions were refined to produce single crys-
tals that grew to 0.7 x 0.2 x 0.05 mm3. The crystals
diffract to approximately 3.1 A, but they decay in the
X-ray beam and so were frozen for data collection.
The protein crystallizes in the space group P2t, with
cell dimensions a = 48.75 A, b = 112.36 A, c = 59.25
A, and 13 = 109.21°.
Because attempts to isolate heavy atom derivatives
proved unsuccessful, the selenomethionine derivative
protein was overexpressed, purified, and crystallized
in an effort to apply the phasing method of multi-
wavelength anomalous diffraction (MAD). MAD
data were collected on one crystal, at three different
wavelengths near the Se K absorption edge, at beam-
line XI2C (at the NSLS, BNL). The isomorphous
and anomalous difference Patterson maps show a
number of peaks, corresponding to possible selenium
sites. The maps are currently being interpreted.
Mechanistic Implications
of New Crystal Structures
for Hhal Mtase-DNA-AdoHcy
Complexes
M. O'Gara, K. McCloy [in collaboration
with R.J. Roberts, New England Biolabs, Inc.]
The refined crystal structures of Hhal Mtase com-
plexed with cognate and methylated DNA in the
presence of S-adenosyl-L-homocysteine (AdoHcy),
along with the previously solved binary and covalent
ternary structures (Cheng et al., Cell 74: 299 [1993];
Klimasauskas et al., Cell 76: 357 [1994]), offer a
detailed picture of the active site throughout the reac-
tion cycle. This picture supports and extends a pro-
posed mechanism for C5-cytosine methylation that
may be general for the whole family of C5-cytosine
Mtases. The structures of these two complexes have
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been refined to crystallographic R-factors of 0.189
and 0.178, respectively, at 2.7 A resolution. We ob-
serve that both unmethylated 2' -deoxycytidine and
5- methyl -2' -deoxycytidine completely flip out of the
DNA helix and fit into the active site of the enzyme.
The C5 methyl group of the flipped 5- methyl -2' -
deoxycytidine is bent out of the plane of the cytosine
ring and toward the sulfur of AdoHcy. This unusual
position is probably due to the partial spa character at
C5 and C6 and to the steric effects of the conserved
amino acids Pro-80 and Cys-81. Two water mole-
cules are held near the hydrophobic edge (C5 and C6)
of the flipped cytosine by two conserved amino acids
(Gln-82 and Asn-304) and the phosphoryl oxygen of
the phosphate group 3' to the flipped nucleotide, and
one of them may serve as the general base for
eliminating the proton from C5. Protonation of the
cytosine N3 during the methylation reaction may in-
volve Glu-119, which itself is protonated via a water-
mediated interaction between the terminal carboxyl
group of Glu-119 and the amino group of the
methionine moiety of AdoMet. This cofactor thus has
two key roles in the reaction.
Cell Cycle Proteins
J. Horton, R. Ventura, T. Malone [in collaboration with
G. Hannon and D. Beach, and S. Waga and B. Stillman,
Cold Spring Harbor Laboratory]
We continue our endeavors toward the structural
determination of several proteins involved in the cell
cycle. Mainly, our goal has been the crystallization of
the CDIs (cyclin-dependent kinase inhibitors) p16
and p21, alone and with one of their protein partners,
such as the cyclins and PCNA (proliferating cell
nuclear antigen). We have encountered many ob-
stacles toward obtaining workable crystals, including
protein insolubility, difficulty in purification, and in-
ability of crystallization possibly due to molecular
flexibility or a polydisperse character of the protein
in solution. We overcame the problem of very low
expression of p16 in E. coli by fusing it with
glutathione-S-transferase, and a large amount of the
protein has been purified. Unfortunately, no crystal
was obtained even after screening several hundred
crystallization conditions. Many attempts to solubil-
ize cyclin D1 have also been fruitless.
Pre-mRNA Splicing Factors
R. Xu, L. Jokhan [in collaboration with A. Mayeda and
A. Krainer, Cold Spring Harbor Laboratory]
Pre-mRNA splicing machinary involves a complex
assembly of small nuclear ribonuclear particles and a
number of proteins known as splicing factors. Two
proteins, U2AF65 and SF2/ASF, are among the most
studied splicing factors to date. Both proteins are re-
quired in early splicing complex assembly, essential
for 3' and 5' splicing site selection, respectively, and
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STRUCTURAL BIOLOGY
L. Joshua-Tor
Our focus is to study the molecular basis for regula-
tory processes in terms of molecular recognition. We
are using tools of structural biology and biochemistry
in a combined approach to look at proteins and pro-
tein complexes associated with these processes. X-
ray crystallography, our primary technique, enables
us to obtain a very accurate three-dimensional struc-
ture of our proteins and the interactions in which they
are involved. We use biochemistry to study proper-
ties predicted by the structure and to direct our struc-
tural studies in an iterative manner. We are also com-
bining information from molecular biology and ge-
netics in collaborative efforts to study their functions.
are involved in regulating alternative splicing.
SF2/ASF belongs to a family of splicing factors that
have a characteristic serine-arginine repeat (termed
SR proteins) at their carboxyl termini and a con-
served RNA-recognition motif (RRM) near their
amino termini. However, U2AF65 consists of one
serine-arginine repeat followed by three RRMs. In an
effort to understand how these pre-mRNA splicing
factors achieve their specific functions from a struc-
tural point of view, we have purified U2AF65, and
some members of the SR proteins. A search for crys-
tallization conditions is currently under way.
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The Yeast Bleomycin
Hydrolase, Ga16
L. Joshua-Tor [in collaboration with W. Zheng and
S.A. Johnston, Southwestern Medical Center]
Resistance to anti-neoplastic drugs is a central prob-
lem in the treatment of human cancers. Bleomycin
hydrolase was first recognized due to its ability to
detoxify the anti-cancer drug bleomycin and to limit
its use. Tissues with low levels of this enzyme, par-
ticularly lung, are very sensitive to bleomycin, and
tumors with high levels of the enzyme become
resistant to the drug. Bleomycin hydrolase is found in
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FIGURE 1 Three-dimensional structure of the Ga16 hexamer. The six subunits are
arranged in a ring with 32-point group symmetry that creates a prominent central
channel along the threefold axis of the molecule.
all mammals, birds, and reptiles and in all tissues
tested. The recent discovery of homologs of this
protein in yeast and bacteria implies a conserved cel-
lular function for this protein; yet, the only known
natural substrate, bleomycin, is almost never seen by
any of these cells. The yeast homolog Gal6 is an in-
tracellular, primarily nuclear, protease that binds
DNA and acts as a repressor in the expression of gal
genes.
The cellular function of this ubiquitously ex-
pressed protein is still unknown. In recent years,
there has been considerable interest in intracellular
proteases, since they seem to be involved in impor-
tant regulatory processes. Bleomycin hydrolase, with
its many functions, including its unusual DNA-
binding activity, adds another dimension of com-
plexity to these proteases.
We have recently solved the three-dimensional
structure of the yeast bleomycin hydrolase, Ga16, a
300-kD hexamer, by X-ray crystallography. The
structure was surprising and remarkable in that it
revealed a hexameric structure in which the protease
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and DNA-binding activities are structurally inter-
twined (see Fig. 1). This was highly unexpected
since, in the few cases known so far in which more
than one activity resides in a single protein, the dif-
ferent activities tend to reside in separable domains
of the protein, whereas in this case they are in-
separable and influence each other. We are now
trying to understand the functional coupling of these
two activities in Gal6, its DNA recognition, and the
determinants of recognition and hydrolysis of the
anti-cancer drug bleomycin.
The most accurate way of understanding how Gal6
binds single-stranded DNA and the effect on the
protein conformation is to obtain a co-crystal struc-
ture of the complex of Gal6 with a single-stranded
oligonucleotide that we know it binds. Crystals of
this complex which diffract to a moderate resolution
have been obtained, and we are now improving crys-
tallization conditions and pursuing the structure
determination. On the basis of the crystal structure of
the native protein, we have also prepared a mutant of
Gal6 deficient in its protease activity that will enable
us to study a stable complex between the protein and
bleomycin. These studies will foster an understanding
of how bleomycin hydrolase functions in tumor drug
resistance and provide insight into its basic cellular
functions.
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ENCODED COMBINATORIAL LIBRARIES
H.P. Nest ler D.L. Dong
R. Liu
R. Sherlock
Encoded combinatorial "One-bead-One-Structure" li-
braries have opened a new dimension for the study of
intermolecular interactions of synthetic receptors of
low molecular weight with chemical and biological
ligands. Although biological research has known the
use of pools of proteins or genes for some years, the
use of complex mixtures of small organic molecules
has been hindered by the problems of purifying ac-
tive compounds and of elucidating their structures.
"Split synthesis" solves part of this problem by creat-
ing "One-Bead-One-Structure Libraries" that have
the individual library members physically separated
on beads of a solid support resin. Split synthesis is
characterized by iterative cycles of splitting the resin
into portions and reacting each portion with a dif-
ferent set of reagents. After completion of the reac-
tions, the portions of the resin are combined and
mixed thoroughly. The resin is then redistributed for
the next synthesis cycle, thus yielding a com-
binatorial increase of the diversity of structures. As
each bead reacts with only one set of reagents per
synthesis cycle, each bead carries an individual struc-
ture which is determined by the series of reactions
that occurred during the synthesis. Active library
members can be identified by selecting beads
detected in assays performed on the beads. Neverthe-
less, the problem of structure determination for the
compounds thus isolated restricts split synthesis li-
braries to the incorporation of single-chain sequen-
cible oligomers, such as peptides or oligonucleotides.
The molecular tagging of the individual beads in
the libraries was a breakthrough that lifted the restric-
tion for structures that can be included in the combi-
natorial libraries: Easily detectable molecular tags are
attached to the resin beads as they proceed through
the split synthesis during the library construction,
thereby recording the reaction history of each indi-
vidual bead. After the screening of the library, the
molecular tags can be cleaved from each of the
selected beads and analyzed to report the structures
of the library members on each of these beads.
In our initial studies, we have elaborated encoded
combinatorial libraries of low-molecular-weight re-
ceptors with branched peptidic structure and have
shown examples of highly specific interactions be-
tween these receptors and small peptide ligands. We
intend to explore these systems to derive small
molecules that bind proteins of physiological impor-
tance at specific functional sites.
Synthesis of Encoded
Combinatorial Receptor
Libraries
H.P. Nest ler, R. Liu, R. Sherlock
We have set up our laboratory to generate, assay, and
analyze encoded combinatorial libraries. The starting
materials necessary for the synthesis and encoding of
libraries have been prepared. As our initial studies
have shown that simple molecules displaying two
short peptide or peptide-like chains can provide rea-
sonable affinities and selectivities toward peptide
substrates, we will base our first investigations on li-
braries that contain receptors with forceps and multi-
arm designs. To avoid obstacles during library gener-
ation, the synthesis schemes will mostly utilize pep-
tide chemistry, which is well-developed. Further-
more, the variety of available peptide and peptide
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analog building blocks will allow for sufficient diver-
sity in our libraries. The generated libraries will be
screened for molecules that interact with proteins of
physiological importance. Two envisioned physiolog-
ical targets are the binding and modulation of Ras
proteins, and the interaction with proteins that are in-
volved in the decision point of programmed cell
death.
Small Synthetic Receptors
That Recognize Peptides
H.P. Nest ler [in collaboration with W.C. Still,
Columbia University, New York, and B. Salom and
C. Gennari, University of Milano, Italy]
Conformational analyses of vinylogous sulfonyl pep-
tides (VSPs), a new class of peptide analogs, show
that even the vinylogous sulfonyl tripeptides adapt a
well-ordered three-dimensional structure. Therefore,
we hoped that short single-chain VSPs might show
distinct intermolecular interactions.
Encoded combinatorial libraries provide us with a
simple test system for the preliminary examination of
the binding capacity of receptors with novel design:
Individual examples of potential receptor families are
synthesized and screened against a combinatorial li-
brary of about 50,000 derivatized tripeptides. We use
the affinity and the selectivity that we find in this as-
say as an index for the capacities of the new receptor
class.
Although none of the five single-chain VSPs that
we prepared showed affinity to members of our
tripeptide library, we were able to obtain molecules
that bind selectively to peptides by joining two VSP
chains with a spacer, thus generating molecules with
a forceps-like architecture. A prime question in our
investigation of VSPs was to understand how much
the substitution of peptides by peptide analogs effects
the binding profile of otherwise similar receptors. We
therefore synthesized the peptidic analog of one of
our forceps molecules. This branched peptide also
binds to members of our tripeptide library selectively:
Whereas the strength of the interactions lies within
the same range as the affinity of the VSP molecule,
the selectivity profile has changed completely.
Encouraged by these results, we developed a
synthetic method that will enable us to incorporate
the VSP-building blocks into encoded combinatorial
libraries, and thus make them available to further
evaluation of their biological potential.
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Screening of Combinatorial
Libraries with GFP-fusion
Proteins
H.P. Nest ler, D.L. Dong [in collaboration with M.H. Wig ler,
Cold Spring Harbor Laboratory]
In the past, secondary antibodies coupled to alkaline
phosphatase have been used for detection of interac-
tions between proteins and the beads. However, there
are several drawbacks to this protocol. First, some li-
brary members may bind to the secondary antibody
or its conjugate. Second, the procedure is cumber-
some and requires multiple washings during which
the protein binding to beads may become diminished.
Third, after alkaline phosphatase staining, the beads
cannot be reused since it is not possible to wash the
precipitated colored substrate away. Therefore, we
have tested whether we could detect the binding of
proteins to beads using fluorescent fusion proteins.
For this purpose, we utilized a stable and in-
tensively fluorescent mutant of the green fluorescent
protein (GFP) as a marker. GFP was originally isolat-
ed from the jellyfish Aeguorea victoria and fluores-
ces green upon stimulation by blue light. We ex-
pressed the mutant GFP in Escherichia coli as a T7
epitope fusion protein carrying a His tag that allowed
for the easy purification. The purified protein was
first cross-linked to several types of supports to es-
tablish the feasibility for the fluorescence assay. In
the second stage, antibodies to the T7 epitope were
cross-linked to Tentagel beads: We were able to iden-
tify the beads carrying antibody easily under a fluo-
rescence microscope after they had been incubated
with the GFP-T7 fusion protein.
A series of GFP fusion proteins (including Ha-Ras,
Rsb2, and functional domains of Ras) were con-
structed and expressed in E. coli and are available for
the screening of combinatorial libraries of small
molecules.
Microradiographic Screening
of Combinatorial Libraries
H.P. Nest ler, R. Sherlock, D.L. Dong [in collaboration
with H. Wennemers and W.C. Still, Columbia University,
New York, and M.H. Wig ler, Cold Spring Harbor Laboratory]
We have had good success screening encoded com-
binatorial libraries for receptors to peptides using
peptides coupled to dyes as ligands, when these as-
says have been conducted in organic solvents. How-
ever, we have had difficulties applying this straight-
forward protocol in aqueous phase. Although the
labeling of proteins with hydrophilic dyes, such as
fluorescein and rhodamine, is a commonly used
protocol for biochemical studies, members of the li-
braries binding the dye instead of the peptide ligands
have predominated in our assays, thus interfering
with efficient screening.
Radioactive labeling is an elegant approach to tag
compounds without altering their molecular structure,
and the use of 14C as radioisotope allows for the gen-
eral incorporation of radioactivity into organic com-
pounds. We could show that individual radioactive
beads can be easily identified by microautoradiog-
raphy. To prove the efficacy of our approach, we
radioactively labeled a previously described, dye-
conjugated receptor using a 14C-linker between the
receptor and the dye. A bead-supported tripeptide li-
brary was equilibrated with a solution of the receptor
and assayed by microradiography. Only beads that
had picked up color showed a characteristic black
halo after exposure and photographic processing. As
the signal intensity in the microradiographic process
can be increased easily by extending the exposure
times, our method promises to trace unambiguously
even very weak interactions that might escape detec-
tion using X-ray film or the phosphoimager techni-
ques.
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NEUROSCIENCE
The marriage between vertebrate and invertebrate neuroscience is flourishing, nourished by a
healthy diet of molecular biology. Electrophysiological work by the Zhong lab has defined for the
first time a clear role for the Ras/Raf/MAP Kinase pathway in neuronal function. Consistent with this
observation, behavioral experiments in the Silva lab have shown defective learning in mice mutant
for the NF1 gene, which appears to participate in the Ras/Raf pathway and which produces
heritable learning disabilities in children. Thus, work in flies and mice once again has converged to
yield important insight to human cognitive function.
The Silva, Malinow, and Cline labs continue to elucidate the role of CaMKII in neural plasticity.
In part by using a recombinant gene delivered to frog neurons by vaccinia virus vectors, Cline et al.
have shown that CaMKII functions both pre- and postsynaptically to regulate arbor growth during
development of the visual system. In vertebrates, Malinow et al. have discovered a novel process,
calcium-evoked dendritic exocytosis, which also is mediated by CaMKII and which may have a role
in synaptic plasticity. Finally, the Silva lab has extended its seminal work on CaMKII and synaptic
plasticity in the mouse hippocampus by showing that this enzyme mediates synaptic plasticity in
the cortex.
The Enikolopov lab has recently shown that, in addition to its role in regulating the NGF-
mediated switch from proliferation to cytostasis, nitric oxide (NO) protects differentiated neurons
from apoptosis. Using pharmacological agonists and antagonists of NO and transgenic flies carry-
ing three different versions of Drosophila nitric oxide synthase (NOS)-two of which were generated
by Dr. Michael Regulski in the Tully lab-Enikolopov et al. also have shown that NO regulates the
number of mitotic cell divisions during adult leg development. These elegant in vivo experiments
finally have demonstrated a clear role for NO during development.
Molecular cloning of new genes involved with associative learning in Drosophila reached an im-
portant milestone in the Tully lab. The learning defect in mutant linotte flies has been eliminated by
inducing the expression of a /io+ transgene in adults. This constitutes the first "rescue" of a learning
defect via gene therapy. The Tully and Yin labs also continue their work on the role of CREB during
memory formation. The Yin lab has concentrated its efforts on the regulation of endogenous CREB
function during long-term memory formation, and both labs are applying molecular techniques to
identify the downstream genes involved with long-term memory formation.
We have said farewell to two neuroscientists this year: Dr. Hiro Nawa has moved to Niigata Uni-
versity, Japan, as Professor of Neuropharmacology, and Dr. Dan Marshak has moved to Osiris
Therapeutics, Baltimore, as Senior Vice President of Research and Development. To balance these
losses, however, Dr. Jerry Yin accepted a Senior Staff Investigator position at CSHL to continue his
work on CREB and memory.
MOLECULAR NEUROBIOLOGY OF LEARNING AND
MEMORY IN DROSOPHILA
T. Tully C. Jones M. Del Vecchio J. Christensen H. Tobin
G. Bolwig J. Connolly (Cambridge) Z. Asztalos B. Svedberg
S. Pinto M. Regulski N. Arora (URP) R. Mihalek
K. Velinzon J. Dubnau J. DeZazzo C. Hogel (Wellington College)
Our work on the molecular mechanism(s) of memory important points. First, memory retention is con-
formation during the last 2 years has established two posed of several genetically distinct temporal phases.
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In particular, a permanent, long-term memory (LTM)
coexists for a few days in parallel with a slow-
decaying anesthesia-resistant memory (ARM). Sec-
ond, the consolidation of early memory into LTM is
regulated by the relative amounts of activator and
repressor isoforms of the CREB transcription fac-
tor(s). Too much CREB repressor blocks and too
much CREB activator enhance the formation of
LTM.
We continue this genetic analysis of memory
formation in Drosophila with further experiments on
CREB transgenic flies and with behavioral evalua-
tions of disruptions of other genes involved with this
form of olfactory learning. Of note is our "rescue" of
the learning/memory defect of linotte (lio) mutants by
inducing the expression of a lio+ transgene 3 hours
before training. More generally, this represents the
first "cure" of a learning disability via gene therapy in
any species.
dCREB2-mediated
Enhancement
of LTM Depends on
Associative Learning
T. Tully, M. Del Vecchio, H. Tobin, J. Dubnau
[in collaboration with J. Yin, Cold Spring
Harbor Laboratory]
Genetic dissection of memory formation after olfac-
tory learning has revealed that a newly acquired ex-
perience is processed sequentially first through short-
term memory (STM) and then through middle-term
memory (MTM). At this point, processing branches
into two parallel paths: one that yields anesthesia-
resistant memory (ARM) and one that yields long-
term memory (LTM). With this general view, two
aspects of LTM become clear. First, LTM is formed
in normal flies only after ten repetitions of the usual
training session. In addition, these ten training ses-
sions must be spaced by at least a 10-minute rest in-
terval to form maximal LTM. If no rest interval oc-
curs during repetitive training (massed training), then
no amount of training sessions will produce LTM.
Thus, spaced training is necessary to form LTM. Sec-
ond, all earlier memory phases (STM, MTM, and
ARM) decay away within 4 days after ten massed or
spaced training sessions. LTM after ten spaced train-
ing sessions, however, shows no decay for at least 1
week. Thus, 7-day retention is a direct measure of
LTM unobscured by earlier memory phases.
Transgenic flies expressing copious amounts of
CREB repressor do not form LTM even after ten
spaced training sessions. In contrast, transgenic flies
overexpressing CREB activator form maximal LTM
after only one training session. The latter gain-of-
function effect constitutes a strong argument that
CREB acts as a molecular switch during LTM induc-
tion. Implicit to this argument, however, is the notion
that the CREB switch is activated in response to an
associative learning event. Alternatively, induced ex-
pression of CREB activator 3 hours before training
simply may produce an up-regulation of downstream
CREB target genes, which then "prime" the associa-
tive learning process, rather than the LTM process
per se.
We tested this notion by exposing normal flies or
transgenic flies expressing CREB activator (CREB-a)
to unpaired presentations of the odors and elec-
troshock stimuli. Tully and Quinn (J. Comp. Physiol.
157: 263 [19851) have shown that a 45-second inter-
val between the presentation of odors and elec-
troshock is sufficient to eliminate associative learn-
ing. With this procedure, then, flies experience odors
and shock, but the stimuli are not associated in time.
After ten spaced but unpaired training sessions, both
normal and CREB-a transgenic flies showed no
LTM, as measured by 7-day memory retention. Thus,
induced expression of CREB-a in transgenic flies did
not produce enhanced LTM by nonspecifically
"priming" the associative learning process. Ten
spaced but unpaired training sessions followed by
one paired training session in normal flies also pro-
duced no LTM. Thus, experience with odors and
shock in the absence of a temporal association be-
tween them did not "prime" normal flies to induce
LTM after one subsequent paired training session.
CREB-a transgenic flies, in contrast, showed en-
hanced LTM after similar training.
Currently, we are advancing our understanding of
the molecular mechanism of the CREB LTM switch
by assessing which serine/threonine phosphorylation
sites on CREB-a are involved with the enhanced
LTM effect. We also are expressing CREB-repressor
in restricted regions of the adult brain to determine
where LTM is stored. Finally, we are searching for
CREB downstream genes, the expression of which is
regulated during LTM formation.
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Identification of New
Genes Involved with
Associative Learning
T. Tully, R. Mihalek, C. Jones, S. Pinto, J. Christensen,
G. Bolwig, J. DeZazzo, B. Svedberg, K. Velinzon
In September 1991 when our group arrived here at
the Laboratory, we brought with us four learning/
memory mutants identified from a mutagenesis that
we initiated at Brandeis University. Genetic and
cytological analyses revealed that these four mutants
defined four autosomal genes, linotte, latheo, nalyot,
and golovan. To date, we have cloned and definitive-
ly identified the transcription units of linotte and
latheo via rescue of their mutant learning/memory
defects after induced expression of lio or lat+ trans-
genes (see Fig. 1 for results from linotte experi-
ments).
DNA sequencing of the lio and lat genes indicates
that each encodes a novel protein. Thus, we have
achieved one major long-term goal: discovery of new
genes involved with learning and memory. The next
step in this analysis is an arduous one. We must pur-
sue molecular, genetic, and biochemical clues to un-
derstand the biological function of these new genes.
To this end, preliminary data indicate that associative
learning is disrupted much more severely in rut; lio
double mutants than in either single-gene mutant,
suggesting that rut and lio define two different "in-
put" paths to the associative process. We also have
determined that the lat gene product interacts physi-
cally with tyrosine hydroxylase, suggesting a mod-
ulatory role for lat in neurotransmitter synthesis.
The transcription units of nalyot and golovan have
been tentatively identified. The nalyot and golovan
mutations (as well as the latheo and linotte muta-
tions) were generated by transposon insertions into
the genome. Cloning of the nalyot transposon
revealed that it was inserted in an intron of the Adf-1
gene, which encodes an HTH transcription factor that
binds to the promoter regions of Alcohol dehydro-
genase (Adh) and Dopa decarboxylase (Ddc). Clon-
ing of the golovan transposon revealed that it was in-
serted 70 by 5' of extra machrochaetae (emc), a neg-
ative regulator of the daughterless, achaete, and scute
transcription factors, which are involved in sex and
neuronal determination.
Planned rescue experiments will determine
whether disruptions of these transcription units are
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FIGURE 1 Rescue of the linotte (lio) learning (A) and 3-hour
memory retention (B) defects after induced expression of a
lio+ transgene. Before heat shock induction (-hs), two inde-
pendently derived hs-lio+ transgenic lines (lio; 16 and lio;3)
yielded olfactory learning and memory scores similar to
those of the original linotte (lio) mutant, all three of which
were significantly lower than those of normal (Can-S) flies.
When trained 3 hours after heat shock, however, the learn-
ing and memory scores of both transgenic lines were no dif-
ferent from those of normal flies. These data indicate that
the linotte gene functions acutely during adult olfactory
learning.
responsible for the learning/memory defects of nalyot
or golovan mutants. Induced expression of the rescu-
ing transgenes at various times throughout develop-
ment will determine whether the learning/memory
defects derive primarily from their function during
associative learning or secondarily from maldevelop-
ment.
Characterization of Extant
Mutants in Signal
Transduction Pathways
T. Tully, M. Del Vecchio, C. Hogel [in collaboration
with D. Kalderon, Columbia University, and K. Kaiser,
University of Glasgow]
Previous experiments on several extant mutants have
outlined the involvement of the cAMP cell signaling
pathway in olfactory associative learning. Mutations
in dunce, rutabaga, and DCO all disrupt olfactory
learning, and the corresponding genes encode a
cAMP phosphodiesterase, an adenylyl cyclase, and a
catalytic subunit of cAMP-dependent protein kinase
(PKA), respectively. In collaboration with Dr. K.
Kaiser, we have extended this behavior-genetic anal-
ysis of the cAMP pathway by showing that mutations
in the RI regulatory subunit of PKA also disrupt ol-
factory learning.
We have studied a temperature-sensitive allele of
DCO in collaboration with Dr. D. Kalderon. This
mutation affects olfactory learning and memory at
both permissive and restrictive temperatures. The
temperature-shift-specific effect on memory forma-
tion, however, appears to correspond specifically
with the MTM phase. Consistent with this observa-
tion, the temperature-shift-specific memory decay
curve of DCOts mutants is similar to that of amnesiac
mutants, which we previously have shown also to
disrupt MTM.
We also have studied turnip mutants, which were
isolated as defective in olfactory learning and have
been reported to be defective in phospholipid-
dependent protein kinase (PKC). We have shown that
task-relevant assays for sensorimotor responses are
abnormal in these mutants. In short, turnip flies are
sluggish. Such an effect precludes the notion that
turnip (and PKC activity) underlies olfactory associa-
tive learning in fruit flies.
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Behavioral Properties
of Learning and Memory
in Normal and Mutant
Flies
T Tully, N. Arora, Z. Asztalos, C. Jones,
J. Connolly [in collaboration with D. Yamamoto,
Mitsubishi Kasei, and K. O'Kane,
Cambridge]
Genetic dissection of the behavioral properties of
learning and memory progresses. To complement our
olfactory habituation assay, we have developed an ol-
factory sensitization assay. Thus, we now can study
various mutants in both of these forms of nonassocia-
tive learning and compare such results with those
from olfactory associative learning. In collaboration
with Dr. D. Yamamoto, for instance, we have shown
normal dishabituation but no sensitization in mutant
fickle flies, thereby demonstrating a genetic dissec-
tion between these two behavioral phenomena. More-
over, habituation in fickle mutants is faster than
normal, which is consistent with the long-standing
hypothesis that habituation results from a "two-
opponent process." Further behavioral analyses of
fickle mutants will reveal whether associative learn-
ing also is defective.
We also have shown a disruption of olfactory asso-
ciative learning when a constitutively active Gs.
protein is expressed in the mushroom bodies. Olfac-
tory learning is normal when Gs. is expressed in
other anatomical regions of the central brain. This
result confirms other studies implicating the
mushroom bodies in olfactory associative learning
and demonstrates for the first time an involvement of
G protein in the underlying second-messenger cas-
cade. In contrast, olfactory habituation is normal even
when mushroom bodies are chemically ablated, in-
dicating that the anatomical focus for olfactory
habituation lies elsewhere.
CREB as a memory modulator: Induced expression of a
dCREB2 activator isoform enhances long-term memory
in Drosophila. Cell81: 107-115.
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LONG-TERM MEMORY FORMATION IN DROSOPHILA
J. Yin J. Wallach
M. Stebbins
H. Zhou
The highlight of our inaugural year was a paper de-
scribing the enhancement of long-term memory
(LTM) formation after induction of the Drosophila
CREB activator. This paper followed our previous
finding that induced expression of the CREB blocker
prevented LTM formation, and together provide
strong evidence for the crucial involvement of this
transcription factor in LTM formation. Our work now
focuses on three aspects of CREB: (1) What signal
transduction pathways "upstream" of CREB are ac-
tivated during learning, and how do they affect the
activity/amounts of CREB? (2) Where does all of this
occur in the brain? (3) What molecular cascade oc-
curs "downstream" from CREB after it is activated
and begins the process of LTM formation?
Upstream Activation
of CREB
H. Zhou, J. Yin
Two experiments demonstrate that changing the
amounts of the fly CREB isoforms has dramatic ef-
fects on long-term memory formation. If a naturally
occurring, dominant-negative "blocking" form of
CREB is induced just prior to behavioral training, it
specifically and totally prevents the formation of
LTM, without affecting other phases of memory.
Conversely, if an activator is induced prior to train-
ing, formation of LTM is accelerated, resulting in full
levels of LTM after just a single training trial, instead
of requiring the usual ten trials. These transgenic
manipulations demonstrate the pivotal role of CREB
in the process of LTM formation and suggest that
some aspect of the amount of activator protein is rate-
limiting. They also suggest that the activator/blocker
(A/B) ratio is important for full levels of LTM forma-
tion.
To complement our work on changing the amounts
of activator and blocker proteins, we have initiated
studies testing the effects of phosphorylation on the
activities of each isoform. Sequence comparisons be-
tween the fly CREB gene and its mammalian
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counterparts indicate that only two regions of the
molecule have a significant amount of one-to-one
amino acid conservation: the carboxy-terminal basic
region-leucine zipper (dimerization and DNA-
binding region) and the internal phosphorylation
region. Examination of the phosphorylation domain
shows that a number of residues which are known to
be substrates of various kinase pathways are con-
served. These conserved residues include putative
phosphorylation sites for calcium/calmodulin kinase
II, glycogen synthase kinase-3, and casein kinase, in
addition to the well-characterized cAMP-dependent
protein kinase site (Ser-133). These kinases may
represent the nuclear end of signal transduction path-
ways which are activated (and cross-talk) during
learning and are involved in the regulation of CREB
activity. We have mutated these conserved serine/
threonine residues to the nonphosphorylatable residue
alanine in both of the inducible activator and blocker
genes, made transgenic flies, and are ready to test
them for behavioral effects.
Two mutations are of particular interest. Mutation
of Ser-133 on the mammalian blocker molecule in-
creases its activity, implying that phosphorylation of
the blocker may normally decrease its activity.
Therefore, the same kinase may activate the activator
isoform and decrease the activity of the blocker
protein by phosphorylating Ser-133 on each respec-
tive molecule, providing a very efficient way to
change the A/B ratio.
Work from Tim Tully's lab here at the Laboratory
shows clearly that two behavioral parameters are es-
sential to induce full levels of long-term memory:
repetitive training and rest intervals between each of
the training trials (spaced vs. massed training). This
requirement for a rest interval may be quite universal,
since it is part of the standard protocol for induction
of protein-synthesis-dependent long-term facilitation
in Aplysia and long-lasting long-term potentiation (L-
LTP) in hippocampal slices. Recently, it has been
shown that in certain cell lines, CREB activity can be
inhibited by CaM kinase II-mediated phosphorylation
of a conserved Ser-142 residue. This inhibition is
"dominant" to the activating phosphorylation that oc-
curs on Ser-133. This finding provokes the intriguing
hypothesis that during each training trial, neurons in
the LTM circuit are activated, Ca++ influx occurs, a
CaM kinase family member is activated, and CREB
is inactivated through Ser-142 phosphorylation. Dur-
ing the rest interval which defines spaced training,
the appropriate phosphatase dephosphorylates Ser-
142, allowing activation of the molecule if Ser-133 is
still phosphorylated. This molecular model provides a
simple explanation for the seemingly universal re-
quirement for a rest interval in protein-synthesis-
dependent, CREB-dependent processes in neurons.
The direct prediction of this model is that the Ser-142
to alanine mutation on the activator transgene will al-
low LTM formation after massed training. We are
currently testing this hypothesis, along with the in-
volvement of other nuclear kinases predicted from
the sequence conservation.
tioned and developed for P-galactosidase staining, the
same complex pattern of staining is seen for all lines,
implying that the insulators are functioning. When
transgenic lines are isolated that contain reporters
containing 6, 9, or 15xCRE sites, the staining pattern
is a superset of that seen with the 3xCRE reporter. In
addition, the staining in the cells that are common to
all of the reporters is darker. These results imply that
by increasing the number of binding sites, a more
sensitive reporter is created and more and more cells
are recruited to the staining pattern. This result sug-
gests that this set of transgenic reporters may
represent reporters which have increasing sensitivity
to CREB activation and will be useful in the effort to
detect CREB activation during the formation of long-
term memory. In principle, this strategy can be ap-
plied to the mouse system, and we have begun to test
its feasibility.
The Long-term Memory Cells
J. Wallach, H. Zhou, J. Yin
We believe that the cells which participate in long-
term memory formation are likely to be a very small
subset of the neurons in the brain. Therefore, the
identification of "downstream" target genes of CREB
may be difficult due to a signal-to-noise problem, un-
less these genes are totally unexpressed in untrained
flies. The identification of the "memory cells" not
only is an intrinsically interesting problem, since they
represent the "engram," but may also contribute sig-
nificantly to efforts to identify "downstream" genes.
Our current efforts are directed at the identification of
these cells, with the eventual goal of their enrichment
or purification, facilitating molecular analysis.
We are using CREB-responsive transcriptional
reporters to identify cells in which CREB is activated
during long-term memory formation. To facilitate
comparison of different transgenes, we have tested
the efficacy of "insulator" elements first described by
Paul Schedl's lab. When these discrete pieces of
DNA flank an eye color gene, independent transgene
insertions show the same levels of expression, in-
dicating that the insulators are overcoming the effects
of (random) "position effects" on transgene expres-
sion. We have made five independent transgenic lines
that contain three wild-type CRE (3xCRE) sites in
front of a truncated promoter and the P-galactosidase
gene. When adult heads from these lines are sec-
Spatial/Temporal Regulation
of Expression
M. Stebbins, H. Zhou, J. Yin
One of the most important problems in transgenic
analysis is the refinement of current technology to
achieve greater specificity in the induction of trans-
genes. Spatial (cellular), temporal, and subcellular
regulation of the delivery of transgenic products is re-
quired for better analysis of complex phenotypes. We
have begun the process of combining spatial and
temporal regulation of genes. The currently available
heat shock promoter system for temporal control of
gene expression, while rapid and reproducible, suf-
fers from the flaw that many processes, including
learning and memory formation, are affected by the
heat shock itself. To avoid this problem, we are
trying to combine the recently developed tetracy-
cline-inducible system with the existing enhancer-
trap system to achieve spatial-temporal regulation of
transgene expression.
The tetracycline-inducible system has been shown
to work in transgenic plants and mice. However, one
of the problems with the existing systems, whether
"forward" (add tetracycline to induce genes) or
"reverse" (remove tetracycline to induce genes), is
that the expression levels of the trans-activator are
very low. Analysis of the trans-activator RNA
reveals that most of it is cryptically spliced into non-
productive forms. Mutations that destroy the cryptic
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splicing sites allow high levels of RNA and protein
expression. We have combined these changes with
the recently described "forward" system and are cur-
rently generating the appropriate constructs and
transgenic flies to test the system. In addition, by
placing the trans-activator under the control of gal4
binding sequences (which are activated by gal4 genes
under control of spatially defined enhancers), it is
possible to limit induction spatially. The feasibility of
this further refinement is under investigation.
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NEURAL BASIS OF LEARNING AND MEMORY
Y. Zhong L. Luo Y. Wang
F. Guo N. Wright
Our research interest is to understand the neural basis
of learning and memory. Our approach is to analyze
Drosophila learning and memory mutants. During
the last two decades, a number of Drosophila
mutants have been isolated on the basis of their poor
performance in a classic conditioning task. Some of
these mutations affect learning, and other mutations
affect memory. How functions of the nervous system
are altered in these mutants must be elucidated in or-
der to gain insight into the neural basis of learning
and memory. However, electrophysiological record-
ings from the Drosophila brain have been impossible
because of the small size of the fly's brain. In facing
such a challenge, we are taking three different ap-
proaches.
First, we want to determine the cellular functions
of these mutant genes in the nervous system, specifi-
cally for their roles in neurotransmission. To address
this question, we will study not only the synapses in-
volved in learning and memory, but also preparations
that are more accessible to electrophysiological re-
cordings, such as neuromuscular junctions and cul-
tured neurons. Second, we are trying to overcome the
technical difficulty of electrophysiological recordings
due to the small-sized brain and neurons and thus be
able to study how synaptic transmission and synaptic
plasticity are affected in these mutants at synapses
that have been shown to be critical for fly learning
and memory. Third, we are exploring the possibility
of turning the disadvantage of the small-sized brain
into an advantage by developing an optic recording
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method, which may allow us to study neural network
properties that are important for learning and mem-
ory.
Our work in the last year has focused mainly on
the first approach, but we have made significant ef-
fort toward the development of preparations suitable
for the other two approaches, as further detailed be-
low.
Neuropeptidergic Transmission:
Involvement of Ras and
Rut-Adenylyl Cyclase
F. Guo, Y. Zhong
The rut gene, isolated as a learning and memory
mutant, encodes a Ca"/CaM-sensitive adenylyl
cyclase (Rut-AC). Biochemical study by M.S.
Livingstone has shown that Rut-AC is not involved
in the cAMP synthesis activated by monoamine
transmitters, such as dopamine, 5-HT, and oc-
topamine. We therefore examined the possibility that
Rut-AC may be activated by a neuropeptide. Our
study has demonstrated that at the larval neuromus-
cular junction, a pituitary adenylyl cyclase-activating
polypeptide (PACAP38)-like neuropeptide activates
both Rut-AC and Ras/Raf pathways to modulate K+
currents synergistically. PACAP38-induced 100-fold
enhancement of K+ currents was eliminated in rut,
ras, and raf mutants (Fig. 1). Enhancement was also
induced when both pathways were coactivated by ex-
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FIGURE 1 PACAP38-induced enhancement of Ic- currents
is abolished in rut, Rast, and NF1 mutants. The arrow indi-
cates focal application of PACAP38 (10 vm). "Control" cur-
rent traces were recorded before application of PACAP38.
The time in seconds after pressure-ejection of PACAP38 is
indicated at the top of current traces. Data were recorded
with the bath saline containing 1 mm Ca*+ .
pressing the active raf transgene and adding cAMP.
The result not only indicates that Rut-AC is activated
by the neuropeptide, but also suggests that the
Ras/Raf pathway is essential for neurotransmission.
This suggestion is further supported by our study of
octopamine transmission.
Octopamine is an insect neurotransmitter and is
present at the Drosophila neuromuscular junction.
revealed that octopamine also in-
duced 100-fold enhancement of K+ currents, but it
did so by activating the non-Rut-AC and Ras/Raf
pathways. Octopamine-induced response is normal in
the rut mutant. On the basis of these studies, we have
proposed the model depicted in Figure 2. Both the
PACAP38-like peptide and octopamine activate the
Ras/Raf pathway via the G15 complex, and each
transmitter activates different types of adenylyl
cyclase via the Ga subunit. The two coactivated path-
ways then modulate K+ currents synergistically. We
are now trying to understand how the Ras/Raf path-
way is activated by G-protein and how K+ currents
are modulated by the two pathways. One obvious im-
plication from this study is the possibility of the in-
volvement of the Ras/Raf pathway in learning and
memory. This possibility is further delineated by the
finding that NF1 is involved in PACAP38-like pep-
tide transmission. NF1 is the neurofibromatosis 1
gene, a frequently encountered neurogenetic disorder.
About 30-40% patients show a specific learning dis-
ability. Although it has been demonstrated biochemi-
cally and genetically that NF1 has Ras GAP activity,
its physiological function remains to be elucidated.
Our experiment revealed that PACAP38-like neuro-
octopamine PACAP
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FIGURE 2 A model of dual signal transduction pathways ac-
tivated by PACAP38-like neuropeptide and octopamine for
modulation of 10- currents. Question marks indicate mole-
cules whose functions have not been tested in the
PACAP38-induced modulation. Dashed arrows indicate that
where the cAMP and Ras/Raf pathways converge, to chan-
nels directly or to an intermediate target, remains to be
determined.
peptide transmission is eliminated by mutations of
the Drosophila NF1 homologous gene (see Fig. 1).
We will continue to investigate the mechanism of the
NF1 involvement.
Cloning the Gene
Encoding PACAP38-like
Neuropeptide
L. Luo [in collaboration with L. Pena, Sloan-Kettering
Cancer Center]
The result that PACAP38-like neuropeptide transmis-
sion is defective in rut and NF1 mutants raises the
possibility that this peptide transmitter may be in-
volved in learning or memory. To test this possibility,
we will clone the gene encoding this peptide and gen-
erate mutants or transgenic flies, which will then al-
low us to test learning and memory of those flies with
an altered expression of this peptide.
After failing to isolate the Drosophila homolog of
the vertebrate PACAP38 peptide by using polymer-
ase chain reaction (PCR), we are now purifying the
Drosophila PACAP38-like peptide on the basis of
cross-immunoreactivity with vertebrate antibody.
Western analysis has identified a PACAP38 immuno-
167
15pA
6sec
FIGURE 3 5-HT and Amn peptide-induced membrane cur-
rents in cultured CNS neurons. The top current trace is an
example of 5-HT response. The bottom current trace is in-
duced by Amn peptide. For these recordings, the mem-
brane voltage was clamped at -80 mV. The bar over the
current traces indicates the period during which transmitters
were perfused. Bar, vertical 20 pA/horizontal 4 s
reactive band with a size similar to that of PACAP38,
which was highly enriched by high-performance liq-
uid chromatography purification. We are
going to test the physiological function of this pep-
tide and then obtain the sequence of the peptide for
cloning the gene.
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Neurotransmission in
Cultured CNS Neurons
N. Wright
To extend a similar research of the neuromuscular
junction into CNS neurons, we studied responses of
identified cultured CNS neurons to various neuro-
transmitters. Currently, analysis is focusing on 5-HT
and the neuropeptide encoded by the memory mutant
gene amnesiac (amn). Both 5-HT and the Amn pep-
tide induced similar responses: a hyperpolarization
followed by modulation of K+ currents. This hyper-
polarization is caused by closing an Na+-dependent
leakage current (Fig. 3) gated via cation channels
whose reversal potential is approximately 0 mV and
whose conductance is 24 pS. This study provides a
foundation for further investigation of whether and
how other learning and memory mutant genes are in-
volved in these central neurotransmissions.
Synaptic Transmission in
the Mushroom Body
Y. Wang, N. Wright
Several lines of evidence have indicated that the
mushroom body is the CNS structure carrying out
olfactory-related associative learning in insects. By
FIGURE 4 Mushroom body neurons revealed by the expression of green fluores-
cence protein. In this whole-brain preparation, mushroom body perikarya, calyx, and
a, p, 8 lobes are clearly identifiable by green fluorescence.
expressing green fluorescence protein in the GAL4
enhancer-trap lines, we have been able to identify
mushroom body neurons in a whole-brain preparation
(Fig. 4). This has allowed us to apply extracellular
and intracellular recordings to these small neurons
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CELLULAR MECHANISMS OF ACTIVITY-DEPENDENT
NEURONAL DEVELOPMENT
H. Cline B. Burbach S. Witte
J. Edwards Y. Wu
I. Miloslayskaya D.-J. Zou
E. Pinches (URP)
The role of neuronal activity in shaping circuits
within the brain has been apparent since the pioneer-
ing work of Hubel and Weisel, who demonstrated
that visual experience governs the formation of
synaptic connections within visual cortex. Despite the
widespread recognition that the developing brain can
be influenced by activity, we have little understand-
ing of the how neurons translate "experience" into
modified neuronal growth and the strengthening of
synaptic connections.
The focus of my research is to determine the cel-
lular mechanisms by which neuronal activity modi-
fies the development of structure and function in the
central nervous system (CNS). We perform our
studies using the developing retinotectal projection of
the frog Xenopus. I have recently applied several
analytical approaches to this system which allow us
to assess and manipulate the coordinated develop-
ment of neuronal morphology and synaptic transmis-
sion in the CNS. One approach is to use imaging of
single retinal axons or tectal neurons in the intact
anesthetized animal to observe their morphological
development for up to 5 days in vivo with time-lapse
confocal microscopy. A second approach is to use a
whole brain preparation to take whole-cell patch
clamp recordings from neurons at different stages in
the process of maturation. We can record from tectal
neurons as they receive their first synaptic contact
from retinal afferents and track the development of
the synaptic connections as they mature. This is one
of the only experimental systems that permits direct
recordings of synapse formation and maturation in
the intact CNS. Furthermore, I have developed the
ability to use viral vectors to deliver genes of interest
into frog neurons. We are now using this range of
techniques to test the hypothesized roles of synaptic
activity and activity-regulated proteins in the coor-
dinated development of the structure and function of
the CNS.
My research has been directed toward testing the
following working hypothesis: Retinal axons form
initial synapses with tectal neurons, and these initial
synapses are only maintained if their activity is corre-
lated with other converging synapses. The selection
process for recognizing and maintaining correlated
synapses is based on NMDA receptor activity, which
requires significant depolarization in order to relieve
the voltage-dependent magnesium block of the asso-
ciated channel. The resultant calcium influx through
NMDA channels into tectal cell dendrites is hypothe-
sized to trigger biochemical events that result in the
stabilization of the coactive synapses. The hypothesis
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predicts that the structural and functional dynamics of
the system should be modified in an NMDA recep-
tor- and calcium-dependent fashion.
Dynamic Growth of
Normal Axons
H. Stier, I. Miloslayskaya, S. Witte, H. Cline
To test for rapid activity-dependent changes in neur-
onal morphology, we needed to observe directly the
dynamic rearrangements of retinal axon arbors and
tectal cell dendrites growing with the intact animal.
Albino Xenopus are ideally suited for in vivo imaging
studies. Because the animal is transparent, the CNS
can be observed in the intact anesthetized animal by
placing it on the stage of a laser scanning confocal
microscope. We take confocal images of single axons
or tectal neurons labeled with the fluorescent dye,
DiI. Use of the confocal microscope permits us to ac-
quire high-resolution images of the three-dimensional
structure of the growing neurons. By taking images at
intervals ranging from several minutes to several
days, we have collected data on the continuum of
events underlying the elaboration of the arbor.
Changes in neuronal structure can contribute to the
plasticity of neuronal connections in the developing
and mature nervous system; however, the expectation
that changes in neuronal structure would occur slow-
ly precluded many from considering structural
changes as a mechanism underlying the synaptic
plasticity that occurs over a period of minutes to
hours. We have taken time-lapse confocal images of
retinotectal axon arbors to determine the time course,
magnitude, and distribution of changes in axon arbor
structure within living Xenopus tadpoles. Images of
axons were collected at intervals ranging from 3
minutes, 30 minutes, and 2 hours over total observa-
tion periods up to 8 hours. Branch additions and
retractions in arbors imaged at 3- or 30-minute inter-
vals were confined to shorter branches. Sites of addi-
tions and retractions were evenly distributed through-
out the arbor. The average lifetime of branches was
about 10 minutes. Branches of up to 10 [km could be
added to the arbor within a single 3-minute observa-
tion interval. In arbors imaged at 2-hour intervals
over a total of 8 hours, morphological changes in-
cluded longer branches tens of microns in length. An
average of 50% of the total branch length in the arbor
was remodeled within 8 hours. The data suggest that
the elaboration of the arbor occurs by the random ad-
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dition of branches throughout the arbor, followed by
the selective stabilization and elongation of a small
fraction of the new branches and the retraction of the
majority of branches.
Growth cones have been implicated in branch
formation and process extension; however, these
structures have not been observed in retinal axon ar-
bors as often as might be expected given the high de-
gree of branch addition and elongation in these ar-
bors. One possibility is that growth cone structure
may be transient and previous observations at inter-
vals of 1 hour or more may have been too infrequent
to detect specializations at the growing branchtips.
Observations of arbors at 3-minute intervals show
rapid changes in the structure of branchtips, including
transitions from lamellar growth cones to more
streamlined tips, growth cone collapse, and re-
extension. Simple branchtips that may not be readily
identifiable as growth cones in single images ap-
peared motile and capable of exploratory behavior
when viewed in time-lapse movies. These data indi-
cate that branchtip morphology is dynamic in vivo
and suggest that identification of tips as "growth con-
es" requires a more functional analysis of motility,
rather than an analysis of structure at a infrequent
time points.
Calcium Imaging in Retinal Arbors
J. Edwards, H. Cline
Now that we have documented the rates of mor-
phological changes in retinal axon arbors and in
growth cones, we have begun to test whether changes
in [Ca+li correlate with neuronal growth and growth
cone navigation in vivo, and whether experimentally
decreasing [Ca++]; changes these aspects of neuronal
development. We have been able to image changes in
[Ca in the growing axon arbors and growth cones
in vivo. Our initial experiments in this project indi-
cate that branch additions are spatially and temporal-
ly correlated with transient increases in local calcium.
Development of Glutamatergic
Retinotectal Synapses
G.-Y. Wu, H. Cline [in collaboration
with R. Malinow, Cold Spring Harbor Laboratory]
The development of glutamatergic synapses in the
CNS has been difficult to study because most experi-
mental systems are relatively intractable during the
period of synaptogenesis. To test the hypothesis that
the maturation and stabilization of retinotectal syn-
apses require NMDA receptor activity, and sub-
sequent calcium-dependent events, we developed a
preparation of the isolated intact tadpole brain in
which we can examine developmental changes in
synaptic connections. The tadpole optic tectum is
particularly advantageous for the study of neural de-
velopment because new neurons are constantly being
generated in the caudal region of the tectum. Con-
sequently, at any time in tadpole development, there
exist neurons in the tectum at a wide range of devel-
opmental stages, arranged conveniently along the
rostrocaudal axis of the tectum. Neurons in the caudal
part of the tectum have recently differentiated: They
are morphologically simple and have just received
their first retinotectal synaptic contacts. Neurons in
rostral tectum are relatively mature: They are mor-
phologically complex, they have many retinotectal
inputs, and they process visual information. We have
taken whole-cell patch clamp recordings from tectal
neurons at all stages of maturation present in the tec-
tum of stage 44-50 tadpole brains.
G.-Y. Wu analyzed evoked retinotectal synaptic
currents recorded from tectal neurons at different
positions along the rostrocaudal axis of the tectum.
Retinotectal evoked synaptic currents recorded from
neurons in rostral tectum show classical glutamater-
gic voltage sensitivity and pharmacology, indicating
that both the NMDA and non-NMDA (or AMPA)-
type glutamate receptors are present on the mature
neurons. However, our recordings from younger
neurons in caudal tectum suggest that the first
glutamatergic retinotectal synapses are mediated
purely by NMDA receptors and that synapses devel-
op progressively from pure NMDA responses to
gradually acquire mixed AMPA/NMDA responses.
One interpretation of these data is that the maturation
of glutamatergic synapses involves the addition of
AMPA receptors to preexisting synapses where
synaptic transmission was initially mediated solely
by NMDA receptors.
Alternative hypotheses are that the maturation
process that we observe is due to the development of
the presynaptic mechanism of neurotransmitter
release or changes in the rate of removal of glutamate
from the synaptic cleft. We have begun additional ex-
periments to determine whether AMPA receptors are
present in the membrane of immature neurons in
caudal tectum.
A Signal Transduction
Mechanism Mediating
Neuronal Maturation
D.J. Zou, G.-Y. Wu, I. Miloslauskaya,
B. Burbach, H. Cline
Calcium entry through the NMDA receptor might
trigger the stabilization of synaptic connections and
neuronal morphology, by activating calcium-sensitive
protein kinases such as calcium calmodulin-depen-
dent kinase type II (CaMKII). CaMKII is a develop-
mentally regulated protein kinase implicated in con-
trol of neuronal growth, synaptogenesis, and synaptic
plasticity. CaMKII is activated by calcium entry
through NMDA receptors and has several substrates
relevant to neuronal development, including cyto-
skeletal proteins and the AMPA receptor. We are
testing the hypothesis that CaMKII activity in tectal
neurons may be part of the signal transduction path-
way that mediates activity-dependent changes in
synaptic physiology and neuronal structure.
Control of Synaptic
Maturation by CaMKII
G.-Y. Wu, H. Cline [in collaboration
with R. Malinow, Cold Spring Harbor Laboratory]
To test the role of CaMKII in the maturation of
retinotectal glutamatergic synapses, we have in-
creased CaMKII activity selectively in tectal neurons
by infecting them with a recombinant vaccinia virus
carrying the gene for the constitutively active trun-
cated form of CaMKII (tCaMKII). The truncated
CaMKII is no longer regulated by calcium/calmod-
ulin. Expression of tCaMKII in tectal neurons in-
creases the calcium/calmodulin-independent CaMKII
activity by about 30%. G.-Y. Wu has taken patch
clamp recordings from infected tectal neurons located
in either mature (rostral) or immature (caudal) tec-
tum. Our results indicate that expression of tCaMKII
transforms synaptic responses in neurons from caudal
tectal that normally have a low AMPA/NMDA ratio
into responses that are comparable to those of mature
neurons from rostral tectum, assessed by a smaller
fraction of pure NMDA synapses and a larger
AMPA/NMDA ratio. We found no neurons with pure
NMDA responses in animals expressing tCaMKII. In
control experiments, recordings from neurons that
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were infected with a recombinant virus carrying only
the gene for the marker protein, P-galactosidase,
show that synaptic transmission was indistinguish-
able from that of uninfected neurons. These exciting
data suggest that calcium entry through the NMDA
receptor in young neurons triggers the addition of or
uncovers functional AMPA receptors at postsynaptic
sites.
Control of Neuronal
Growth by CaMKII
G.-Y. Wu, D.-J. Zou, I. Miloslayskaya,
B. Burbach, H. Cline
Developing neurons must coordinate their mor-
phological and functional development. If CaMKII
activity were involved in the activity-dependent con-
trol of neuronal growth as well as synapse matura-
tion, this may be a pathway by which neurons could
coordinate various aspects of their development. Here
again, we used a recombinant vaccinia virus contain-
ing the gene for tCaMKII to increase kinase activity
selectively in tectal neurons without directly chang-
ing the kinase activity in the presynaptic retinal
axons. D.-J. Zou has taken in vivo time-lapse confo-
cal images of retinal axons to observe directly the ef-
fect of increased postsynaptic CaMKII activity on the
elaboration of axonal morphology. These experi-
ments have demonstrated that elevated tectal cell
CaMKII activity results in retinal axons that have
simpler morphologies due to a selective retraction of
short branchtips.
G.-Y. Wu has also examined the effect of increas-
ing CaMKII activity on the development of tectal
neuron morphology. Our results indicate that neurons
expressing tCaMKII have simpler morphologies than
normal neurons. In contrast to the effect of elevated
tectal cell CaMKII activity on presynaptic axon arbor
growth, it appears that the elevated CaMKII activity
in tectal cells specifically prevents the addition of
new branches and the elongation of preexisting
branches, but does not cause retraction of branches.
These observations on neuronal morphology,
taken together with the electrophysiology data, in
which it appears that elevated CaMKII promotes the
maturation of synapses, suggest the following type of
coordinated regulation of neuronal structure and
function: When NMDA receptors are active and there
is calcium influx, the resultant increase in CaMKII
activity has two distinct effects on the tectal cell. One
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is to promote the maturation of the synaptic physiol-
ogy and the other is to deter additional growth of the
dendrite at the local site where CaMKII activity was
elevated. As a result of the decreased branch addition
and branch extension in the tectal neurons, the retinal
axons retract the newly added short branchtips that
have failed to establish synaptic contacts with target
neurons. In our experiments, we increase CaMKII ac-
tivity throughout the tectal cell, but in the normal
neuron, NMDA receptor activity, calcium influx, and
CaMKII activity would occur at discreet sites within
the arbor corresponding to sites of converging inputs.
This would result in highly localized control of
synapse maturation and neuronal growth.
Activity-regulated
Genes
H. Cline, B. Burbach [in collaboration with
P. Worley, Johns Hopkins University,
and E. Nedivi, The Weismann Institute]
In addition to allowing us to examine the role of
CaMKII in neuronal development, the gene-transfer
method with vaccinia opens up the possibilities of
testing the postulated roles of several activity-
regulated proteins in neuronal plasticity. I have estab-
lished collaborations with Paul Worley at Johns Hop-
kins University and El ly Nedivi at the Weismann In-
stitute, each of whom has isolated several genes and
their protein products that are regulated by neuronal
activity and during development. We are beginning
to make recombinant vaccinia virus constructs with
several of these genes. These collaborations will test
the roles of these proteins in activity-dependent neur-
al development and plasticity in vivo.
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THE BIOLOGY OF LEARNING AND MEMORY
A. Silva P. Chen J. Kogan K.P. Giese
J. Coblentz Y. Cho R. Lundston
N. Fedorov E. Friedman
Our laboratory is studying the mechanisms of learn-
ing and memory. Our working hypothesis is that
changes in cell-to-cell communication (synaptic plas-
ticity) in the brain are at the heart of learning and
memory and that pathological conditions as diverse
as epilepsy, learning disabilities, and memory deficits
could result from deregulation of these mechanisms.
Most of our studies have been focused on the func-
tion of the hippocampus, a structure that is critical for
the formation of new memories in humans and mice.
I summarize below our efforts during the past year to
uncover the molecular, physiological, and behavioral
mechanisms involving the acquisition and storage of
information in the hippocampus.
THE HIPPOCAMPUS IS INVOLVED IN SPATIAL
LEARNING AND IN COGNITIVE PLANING IN MICE
Studies in rats have demonstrated that lesions of the
hippocampus disrupt learning of spatial information.
For example, rats with hippocampal lesions are un-
able to learn and remember the location of an escape
platform in a maze. Similarly, in this last year, we
have demonstrated that mice with hippocampal le-
sions are profoundly impaired in spatial learning
tasks. Even small lesions of the hippocampus (>20%)
completely abolish spatial learning while not affect-
ing performance in other control learning tasks.
These results were important because they confirmed
that it is justified to look for electrophysiological
deficits in mutant mice with specific spatial learning
impairments.
Surprisingly, we found that mice with hippocam-
pal lesions that were first trained to swim to a marked
platform (we marked it with an object on it) were
subsequently able to find an unmarked platform by
using distal objects in the walls of the room. Thus,
mice with prior training on the maze seemed to be
able to learn spatial information despite the lesion of
the hippocampus. This unexpected result indicates
that the hippocampus may be required to design cog-
nitive strategies for solving complex problems and
that it may not be essential to learn spatial informa-
tion itself. This finding has important implications for
the design of therapies for human patients with tem-
poral lobe lesions. These patients normally show a
profoundly incapacitating amnesia with very few
available therapies.
GENERATION OF A POINT MUTATION IN THE
CALMODULIN-BINDING DOMAIN OF ciCAMKII
Gene-targeting studies of learning and memory have
been based on mice with complete or partial deletions
of chosen genes. However, to test specific functional
hypothesis, it is often very useful to alter instead
specific functional domains of an otherwise intact
gene. For example, studies based on mutants with a
complete deletion of the aCaMKII indicated that this
enzyme has a key role in the modulation of both
short- and long-term synaptic plasticity, as well as in
learning and memory. To further explore the function
of this enzyme in neuronal cells, we have generated a
mouse with a single-amino-acid mutation in a critical
domain of this kinase. At basal calcium levels, un-
phosphorylated CaMKII is inactivated in less than a
second, whereas autophosphorylated CaMKII might
remain active for minutes or even hours. After auto-
phosphorylation at Thr-286, the affinity of the en-
zyme for Ca/CaM increases 1000-fold. Previous bio-
chemical studies showed that the substitution of Thr-
286 by alanine (aCaMKIIT286A) does not disturb en-
zyme function in high Ca/CaM, but blocks its ability
to trap Ca/CaM and to remain active without in-
creased Ca/CaM levels. Using the Cre/Lox system,
we have generated this mutation in embryonic stem
cells and have derived the mutant mice. With this
mutant, we are currently studying how the biochem-
istry of this enzyme affects the electrophysiological
properties of neuronal cells. For example, we postu-
lated that the increase in neurotransmitter release ob-
served in the aCaMKII+/- mutants (mice heterozy-
gous for a null mutation of the aCaMKII) is due to
less calmodulin trapping caused by the partial loss of
aCaMKII. Consequently, the aCaMKIIT286A mutant
should have enhanced release because the calmodu-
lin-binding domain is impaired. This and other relat-
ed mutants will provide an array of related physio-
logical phenotypes that will be useful to test hypo-
theses about the function of this enzyme in the modu-
lation of synaptic plasticity and in learning and
memory.
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REQUIREMENT FOR aCaMKII IN EXPERIENCE-
DEPENDENT PLASTICITY OF MOUSE CORTEX
In collaboration with Kevin Fox's group at the Uni-
versity of Minnesota, we have recently analyzed the
impact of the aCaMKII mutation on experience-
dependent plasticity in the somatosensory cortex,
where neurons modify their response properties ac-
cording to changes in sensory experience. We pre-
viously showed that LTP is affected in aCaMKII
homozygous animals, both in the hippocampus and in
the neocortex. To determine whether CaMKII and/or
LTP were involved in experience-dependent neocort-
ical plasticity, we studied changes in neocortical
responses after changing patterns of tactile impute to
the barrel cortex. Our findings showed that despite
the lack of this kinase with a prominent role in synap-
tic plasticity, the neocortical responses of young
mutants to changes in tactile inputs are normal. In
contrast, adult mice are profoundly abnormal in these
responses, suggesting that the CaMKII is necessary
for the induction or the expression of plasticity in
adults.
Interestingly, studies done in collaboration with
the laboratory of Michael Stryker at the University of
California, San Francisco, revealed evidence that
aCaMKII may have a role in neocortical plasticity of
visual cortex even in young animals. In this case, the
sensory deprivations that trigger the plasticity
changes involve shorter periods than in the experi-
ments with the somatosensory cortex, and therefore,
they may be a more stringent test for neocortical
plasticity in these mutants. It is important to note that
in either the somatosensory or the visual cortex, we
did not find evidence for gross developmental ab-
normalities in these mutants: Both the topography
and columnar organization of the somatosensory and
visual cortices appear to be normal in the mice. Our
results show that in adult mice, just as in adult
monkeys and humans, changes in sensory perception
can drive neuroanatomic changes in neocortical
structure and that the plasticity of these events is de-
pendent on aCaMKII
SPACED TRAINING RESCUES THE LONG-TERM
POTENTIATION AND THE MEMORY DEFICITS OF MICE
MUTANT FOR THE cAMP-RESPONSIVE ELEMENT
BINDING PROTEIN (CREB)
Studies in Aplysia, Drosophila, and mice indicate that
the transcription factor CREB has a key role in both
long-term synaptic plasticity and long-term memory.
Recent findings in Aplysia and Drosophila suggest
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that CREB activity levels are rate-limiting during
learning, so that increases in its activity obviate the
requirement for multiple spaced training sections and
thus facilitate the induction of long-term memory.
This year, we confirmed that the CREB mutation has
a dramatic impact on long-term memory formation in
mice.
Mice with an intact CREB gene can remember the
context in which they receive a foot shock with only
a single trial. The memory of this experience is not
only robust, but also long-lasting. Despite intact
nociceptive reactions, the same single trial can trigger
a memory that lasts no more than 60 minutes in
mutants lacking the a and the 8 CREB proteins. Not
even five trials given 1 minute apart, which in wild-
type mice induces maximum performance levels in
contextual memory tests, can compensate for the
profound amnesia of these mutants. Surprisingly, as
little as two spaced trials can trigger almost normal
24-hour contextual memory in the mutants (see Fig.
1) This result is consistent with a model, also sug-
gested by findings in Aplysia and Drosophila, claim-
ing that CREB activity levels are rate-limiting during
learning and that increases in its activity can under
certain conditions obviate the requirement for spaced
training in the induction of long-term memory.
The electrophysiological analysis of the CREB
mice reverberate the behavioral findings summarized
above: In hippocampal slices from wild-type mice,
spaced tetanization is not required to induce stable L-
LTP: Either spaced (10-min ITIs) or massed (1-min
ITIs) can induce similar levels of stable 7-hour LTP.
In contrast, only spaced tetanization can induce
normal L-LTP in CREB mutants. Massed tetanization
results in smaller L-LTP that by 5-7 hours is in-
distinguishable from L-LTP induced in the presence
of a protein-synthesis inhibitor (see Fig. 2). The
provocative parallels between the behavioral and the
electrophysiological results in mice, as well as related
electrophysiological results in Aplysia and behavioral
results in Drosophila, indicate that CREB transcrip-
tion is required for long-term synaptic changes in-
volved in memory.
THE INVOLVEMENT OF THE NF1 ras PATHWAY
IN LEARNING
Children with neurofibromatosis type 1 (NF1) show
clear learning disabilities of unknown etiology. These
cognitive deficits have a devastating economic and
personal cost. Because of the difficulty with studying
this problem in humans, we decided to study mice
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FIGURE 1 24-hour contextual memory triggered with three different conditions. (A) CREB-/- mice
and littermate controls were trained with a single trial, and contextual conditioning was tested 24 hr
later. Shown here are the results for each minute of a 5-minute observation period. (8) CREB -/- mice
and controls were trained with two trials with 1-hr interval between trainings. (C) CRE13-1- mice and
controls were trained with five trials with 1-minute intervals. The results show that CREB-/- mutants
have a profound deficit in long-term memory that can be compensated for with additional spaced
training, but not with massed training.
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FIGURE 2 Effect of interval in 7-hr LTP of CREB-/- mutants and controls. (A) Hip-
pocampal field EPSPs were collected every 5 min in the CA1 region (stratum
radiatum) of slices from wild-type and CREB-/- mutants. LTP was induced with
three tetanic trains of ten theta bursts with a 1-min interval between each tetanus.
(8) Hippocampal field EPSPs were collected every 5 min in the CA1 region (stratum
radiatum) of slices from wild-type and CREB-/- mutants. LTP was induced with
three tetanic trains of ten theta bursts, but in this case, we used 10-min intervals
between each tetanus. These results indicate that similar to memory, spaced but
not massed tetanization can compensate for the LTP defect of the CREB-/-
mutants.
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with a genetic lesion similar to that present in NF1
patients. We started by determining whether there
were parallels between the behavioral phenotypes of
mice and humans. Since NF1 is highly expressed in
the hippocampus, we concentrated our efforts on
learning and memory tasks sensitive to lesions of this
structure. Our studies showed that NF1 heterozygotes
have highly specific spatial cognitive learning defi-
cits, even though we and others could not identify
any significant brain neuroanatomic pathology. It is
important to note that NF1 mice, just as NF1 patients,
A)
B)
,-, 60
50
40
E 30
2 20
E 10 -
P 0
do not have a complete loss of spatial cognitive
abilities. Instead, we found that they need much more
training than littermate controls to reach comparable
levels of performance (see Fig. 3). Control tests
showed that vision, motor coordination, and motiva-
tion are normal in these mice. Interestingly, just as
with NF1 patients, memory seems to be unaffected
by the NF1 mutation in mice, since tests showed that
once trained, the NF1 mutants retain spatial informa-
tion as well as controls. Since NF1 is known to regu-
late ras, we also tested directly whether the mutation
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FIGURE 3 Performance of NF1` - mu ants and controls in the water maze. (A) Two
trials each day training in the hidden platform version of the water maze. The mice
were given two trials each day for 14 days. Both NF1+/- mutants and controls im-
proved throughout training, but controls were significantly better than mutants
(ANOVA; p<0.05). (B) Probe trial given after 10 days of training. The controls show
greater selectivity for the training quadrant (left panel; ANOVA p<0.001) and they
cross the exact site of the platform (right panel; ANOVA p<0.001) more often than
controls. (C) Probe trial given after 14 days of training. Both controls and NF1' /-
mutants show similar selectivity for the training quadrant (left panel; ANOVA
p>0.05) and they both cross the exact site of the platform with similar frequencies
(right panel; ANOVA p<0.05). (t) Training quadrant; (ar) adjacent quadrant to the
right of t; (al) adjacent left; (op) opposite.
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of ras could also affect spatial learning. We chose to
study first mice lacking N-ras because studies of
these mice showed that this mutation did not affect
viability, and it seemed not to result in gross behav-
ioral abnormalities. Our studies showed that the N-
ras deletion does not have a general impact on the
behavior of these mice but that it does have a
profound effect on their performance in the spatial
version of the Morris water maze. Recently, we have
also found evidence that mice mutant for Ki-ras have
a similar phenotype.
To further the analysis of the involvement of the
ras pathway in learning and memory, we have recent-
ly generated mutants for a brain-specific exchange
factor called GRF. This protein is thought to be ac-
tivated by calcium/calmodulin, and it is therefore an
important link between the calcium-mediated second-
messenger pathways and ras-dependent pathways.
The null mutants should result in less active ras in
response to increases in neuronal calcium. We are
currently analyzing the behavioral and electrophys-
iological effects of this mutation.
THE GENERATION OF A NULL MUTANT FOR THE
SUBUNIT OF POTASSIUM CHANNELS
Most studies. of the cellular basis of learning and
memory have focused on synaptic plasticity. How-
ever, cells express a complex variety of electrophys-
iological properties that may also be involved in in-
formation storage and retrieval. For example, hip-
pocampal neurons have a highly complex array of ion
channels that control their firing properties. These
neurons can show surprisingly intricate rhythmic be-
haviors that may be involved in coordinating the
responses of neuronal ensembles. Thus, the modula-
tion of intrinsic ion channels might be important for
learning/memory.
Potassium channels show the highest diversity
among ion channels, and there is indirect evidence
that their modulation is crucial for cognitive pro-
cesses. Thus, we decided to generate a mouse lacking
the modulatory potassium channel subunit Kvpl.
Kvfil associates with Shaker-related potassium chan-
nel subunits, which form voltage-gated potassium
channels (A channels or delayed rectifiers). The
presence of KvI31 leads to an A-type inactivation and
to a decrease in recovery time of these channels.
Kv131 is expressed at high levels in the caudate
putamen and in the hippocampal CA1 region. We ob-
tained homozygous null mutants in a Mendelian ratio
and could not detect any overt phenotype. We tested
the mutants in several behavioral paradigms and
found a very specific phenotype: The mutants be-
haved normally in an open field, showed no ab-
normalities in contextual conditioning (24 hr or 11
days after training), and were not affected in spatial
learning in the Morris water maze. However, the
mutants were impaired in reversal learning in the
Morris water maze, as if acquired information is less
flexible in the absence of this channel subunit. Initial
electrophysiological studies show that CA1 neurons
in hippocampal slices have decreased spike accom-
modation and there are also changes in hyperpolar-
ization.
Altogether, the results summarized here, as well as
results from previous years and from other
laboratories, demonstrate that genetics is an effective
approach in the search for the cellular mechanisms
underlying learning and memory.
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NEUROTROPHIC FACTORS IN NEURAL PLASTICITY
AND DEVELOPMENT
H. Nawa K. Mizuno
R. Lundsten
M. Waga
A large variety of neurotrophic factors have been
identified in the central nervous system (CNS) and
are now being extensively studied with respect to
their application to neurological deseases. Many of
these polypeptide factors were initially identified by
monitoring their activity to promote neuronal sur-
vival and are thus called "neurotrophic factors."
However, neurotrophic factors have other activities
that influence synaptic transmission, organization,
and plasticity. In addition, many growth factors and
various cytokines can also exert similar activities in
the CNS. Such polypeptide factors must therefore be
understood as general signal mediators in all types of
intercellular responses in the CNS. The number of
neurotrophic factors, cytokines, and growth factors
found in the brain totals more than 30. These factors
have been proven to influence synaptic plasticity and
development and contribute to learning and memory
processes in the brain. Some of the factors act direct-
ly on the synapse and quickly alter amounts of neuro-
transmitter release, whereas other factors change
neurotransmitter and its receptor synthesis by regulat-
ing their gene expression.
Our latest studies have shown that brain-derived
neurotrophic factor (BDNF), which belongs to the
nerve growth factor family (i.e., neurotrophin),
elevates expression of inhibitory neuropeptides and
glutamate receptors in cultured forebrain neurons. In
contrast, activin, which is a member of the transform-
ing growth factor (TGF) family, suppresses the ex-
pression of the receptors as well as various protein
kinases. Our findings suggest that such polypeptide
factors in the brain positively and negatively regulate
production of synaptic molecules and are involved in
synaptic development and plasticity.
Our current efforts have been focused on the three
projects: (1) molecular mechanism of neurotrophins'
activities in synaptic functions, (2) physiological sig-
nificance of neurotrophins' activities in vivo, and (3)
regulation of synaptic development by neurotrophic
factors. These studies will elucidate how such
neurotrophic factors contribute to neural plasticity
such as learning and memory processes.
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Effects of BDNF on
Hippocampal Kindling
H. Nawa [in collaboration with D. Antoine,
University Louis Pasteur, France]
It has been well demonstrated that production of
BDNF is regulated by neuronal activity, i.e., stimula-
tion of glutamate receptors increases BDNF mRNA
in neurons from various parts of the brain as do sei-
zures and intense bursts of high-frequency afferent
activity. These observations raise the possibility that
BDNF might mediate various activity-dependent pro-
cesses, including synaptic plasticity and neuronal cir-
cuit reorganization. We have previously shown that
one of the remarkable activities of BDNF on
forebrain neurons is to regulate expression of the
putative inhibitory neuropeptide, neuropeptide Y, and
somatostatin.
To investigate the physiological consequences of
the BDNF increase after seizures, chronic in-
trahippocampal perfusion of BDNF was carried out
in the dorsal hippocampus kindling model in the rat.
A 7-day perfusion of BDNF, in the region of the
stimulating electrode, blocked the development of
kindling during the perfusion period and for the fol-
lowing 15 days. Timm's staining revealed that the in-
duction of axonal sprouting in the dentate gyrus was
observed in kindled animals but not in the BDNF-
treated animals or nonkindled controls. These obser-
vations suggest that the neurotrophic factor is in-
volved in prevention of kindling epileptogenesis
presumably by regulating neurochemical features of
hippocampal synapses.
Downstream Genes of BDNF
in Synaptic Organization
K. Mizuno, M. Waga [in collaboration with K. Okamoto,
Cold Spring Harbor Laboratory]
BDNF can influence the pattern of thalamocortical
projection and may be involved in the synaptic orga-
nization or stabilization in the developing neocortex.
Although such phenomena have been well studied at
a cellular level, the molecular mechanism of the
BDNF function remains to be determined. To address
the question, we are characterizing downstream genes
of BDNF by using the differential display polymerase
chain reaction (PCR) method. Cultured neocortical
neurons prepared from rats at late embryonic stages
were treated with BDNF, as well as another neuro-
trophin, NGF, and mRNA was extracted from these
cultures. After displaying the PCR products from the
mRNA, we have identified more than ten bands of
cDNA that were more efficiently amplified from
mRNA extracted from the BDNF-treated neurons
than from mRNA extracted from the NGF-treated or
untreated neurons. Northern analysis revealed that
mRNA from clones CB4 and CB15 was most mark-
edly induced by the treatment of BDNF among all
clones isolated. CB4 mRNA is expressed preferen-
tially in the brain and the muscle, whereas CB15
mRNA is widely distributed in almost all the tissues.
Currently, we are trying to isolate their full-length
cDNA clones to elucidate the entire nucleotide se-
quences.
Activin Regulates Development
of Cortical Pyramidal Neurons
R. Lundsten, H. Nawa
Embryonic development is known to be regulated by
a variety of polypeptide factors. Among them, mem-
bers of the TGF family are extensively studied on
germ-layer differentiation. We have examined effects
of the family on immature neocortical neurons. In
cultured neocortical neurons prepared from rat em-
bryos, activin, but not TGF-I3 nor bone morphogenic
proteins (BMPs), decreased protein levels of calmod-
ulin-dependent protein kinase II, AMPA receptors,
and glutaminase, which are all expressed predomi-
nantly by cortical pyramidal neurons. Expression of
activin itself is regulated in the neocortex during de-
velopment. The highest expression of activin mRNA
was found in neonatal rats, and its level decreases
sharply in the postnatal period. Moreover, activin
receptor-like immunoreactivity was found in pyra-
midal neurons in cortical layers These results
therefore suggest that activin might play a part as a
negative regulator for coordinate development of im-
mature neocortical neurons.
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TRANSMISSION AND PLASTICITY IN MAMMALIAN
CENTRAL SYNAPSES
R. M a linow N. Dawkins T. Koothan M. Maletic-Savatic
B. Frenguelli D. Liao A. Shirke
H. Hinds Z. Mainen A. Weissmann
We address issues directed toward an understanding
of learning and memory by studying the physiology
of synapses. We study synaptic transmission in rat
brain slices, which is complex enough to show
glimpses of emergent properties as well as simple
enough to allow hard-nosed biophysical scrutiny. It is
our philosophy that synapses have some key proper-
ties whose understanding is possible and that such an
understanding will provide insight into phenomena at
higher levels of complexity.
The skeleton of synaptic transmission and
plasticity involves (1) invasion of a presynaptic ter-
minal by an action potential, (2) opening of presynap-
tic calcium channels and rise in presynaptic calcium,
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(3) interaction of calcium with release machinery
producing release of transmitter, (4) postsynaptic
receptor binding of transmitter and channel opening,
(5) entry of calcium with activation of calcium-
activated enzymes if certain postsynaptic channels
are opened, and (6) long-lasting changes at these
synapses triggered by these enzymes. At each of
these steps, there is the possibility for modulation,
and thus we want to understand each step completely.
Our second year here at the Laboratory has been
exhilarating. One postdoc left (Bruno Frenguelli) for
a job as assistant professor at the University of
Dundee, Scotland. One postdoc arrived (Zach
Mainen) from the University of California at San
Diego.
Dendritic Exocytosis Is
Mediated by Activation
of aCaMKII
M. Maletic-Savatic, R Malinow
We have described a novel cell biological process in
neurons using the fluorescent dye FM1-43. This dye
is applied in the medium and taken into cultured
neurons by endocytosis. If neurons are exposed to
this dye for more than 16 hours, most (>95%) of the
internalized dye ends up in intracellular compart-
ments in the dendrites and cell bodies. We have
found that a rise in intracellular calcium (produced by
application of a calcium ionophore, A23187) causes
fusion of these intracellular compartments with the
plasma membrane and exocytosis of the internalized
dye. We call this process calcium-evoked dendritic
exocytosis (CEDE). We know that CEDE is ex-
ocytosis because it is blocked by tetanus toxin, a se-
lective inihibitor of exocytosis.
CEDE is developmentally regulated: Only neur-
ons cultured 9 days (9 DIV) or longer show CEDE;
younger neurons will take up FM1-43 but will not
release it when exposed to calcium ionophore. We
have sought to find what factors allow 9 DIV neurons
to show CEDE and believe that this may be due to
the presence of the enzyme aCaMKII. We find that
aCaMKII is expressed in dendrites only when CEDE
is present. CEDE can be blocked by KN-62, an in-
hibitor of aCaMKII. The most conclusive experiment
is one in which we take neurons that are 7 DIV,
which neither have aCaMKII nor show CEDE, and
infect them with a recombinant vaccinia virus that
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makes aCaMKII. These infected neurons now show
CEDE. What is the role of CEDE? See below.
Is CEDE Involved In Long-term
Potentiation?
A. Shirke, R. Malinow
CEDE is triggered by postsynaptic calcium and
mediated by aCaMKII. Similarly, long-term synaptic
potentiation (LTP) also requires a rise in postsynaptic
calcium, and aCaMKII is thought to be both neces-
sary and sufficient to generate this synaptic plasticity.
To test directly if CEDE is necessary for LTP, we
have conducted a series of experiments using several
well-characterized toxins. We are currently determin-
ing the exact role of CEDE in synaptic plasticity.
What Is The Basis of the Trial-to-Trial
Variability in Transmitter Release?
B. Frenguelli, R. Malinow
It has been known for some time that the release of
transmitter is a probabilistic phenomenon, i.e., from
trial to trial, there is great fluctuation in transmitter
release. We have asked if the rise in presynaptic cal-
cium produced by an action potential is always the
same or varies from trial to trial. Even small fluctua-
tions in calcium could be important because the
release of transmitter depends on the fourth power of
calcium concentration.
We have addressed this issue by obtaining simulta-
neous patch-clamp and optical measurements from
cortical slice neurons. With such recordings, we can
assess the role of the variability in calcium rise on
transmitter release. Boutons on axon collaterals were
visualized and rises in intracellular calcium, assessed
by Fura-2, were observed in response to single-action
potentials. Calcium responses showed trial-to-trial
variability and occasional failures despite the faithful
conduction of the action potential. These results sug-
gest that a factor contributing to the fluctuation in
transmitter release is the variability with which
depolarization of a presynaptic terminal produces an
increase in intraterminal calcium. Such a fluctuation
may be due to the presence of a small number of cal-
cium channels in such structures, and the small prob-
ability that any calcium channel will open with an ac-
tion potential. It will be interesting to determine if
this fluctuation in calcium rise can be modulated by
activity or pharmacological agents.
"Silent" Synapses
and LTP
D. Liao, R. Malinow
The synapses we study (which are similar to and
serve as a model for most excitatory synapses in the
vertebrate brain) use glutamate as the neurotransmit-
ter and have two types of postsynaptic glutamate-
sensitive receptors: AMPA-type and NMDA-type
receptors. These receptors differ in their activation
properties as well as their permeation (what they al-
low to pass into the cell once activated). AMPA-type
receptors need only glutamate to open; NMDA-type
receptors require both glutamate and membrane
depolarization. This year, we published direct evi-
dence that a large fraction of the synapses we study
have only NMDA-type receptors. These synapses
will thus be silent (even if transmitter is released)
when the postsynaptic cell is at resting membrane
potential (most of the time), because the postsynaptic
receptors will not open if only transmitter is released.
We have reached this conclusion by looking at failure
rates during transmission elicited when the post-
synaptic cell is held at hyperpolarized and depolar-
ized potentials. If there were AMPA-type receptors at
all synapses, the failure rates should be the same; we
find twice as many failures at hyperpolarized poten-
tials. This difference is not present if NMDA-type
receptors are blocked. This, and several other pieces
of evidence, indicates that there are synapses with
only NMDA receptors. We recently published several
lines of evidence that pure NMDA synapses add
AMPA receptors during LTP.
More recently, we have looked at the develop-
mental progression of these pure NMDA synapses.
We find that earlier in development in the hip-
pocampus, there are more synapses that are pure
NMDA. These results have led to a specific
hypothesis of synapse formation and modulation of
gain by LTP: We predict that initial synapses form
with only NMDA receptors. These synapses will
transmit information only if coactive with other
synapses (which have AMPA receptors). If the pure
NMDA-receptor synapses are potentiated by LTP,
they will now have AMPA receptors added to them
and will be able to transmit information without the
need for coactivation with other synapses.
Is Synaptic Transmission in the
Brain a Point-to-Point Process?
Z. Mainen, R. Malinow
Although the traditional view of a synapse is that
each presynaptic terminal releases transmitter that af-
fects receptors on a single postsynaptic spine, there
have been recent suggestions that this may not be so.
It could be that transmitter released from one
presynaptic terminal affects receptors on many
nearby synapses. This is made plausible by the obser-
vation that some glutamate receptors (NMDA-type)
have a 100-fold greater affinity for glutamate than
other receptors (AMPA-type). Thus, any spillover of
glutamate from one synapse could activate NMDA
receptors on nearby synapses. This would have
several important implications regarding information
transfer and mechanisms of plasticity (e.g., since
NMDA receptors need to be activated to induce
LTP). Furthermore, this view would allow us to
reinterpret the findings regarding "silent synapses"
described above. We have begun to address this and
several other related issues concerning basic mechan-
isms of synaptic function using a novel compound,
caged glutamate. This synthetic compound is inert to
neurons in its native form. When exposed to UV
light, a bond is broken and glutamate is instantly
released. By exposing neurons to caged glutamate
and flashing UV light, known amounts of transmitter
can be delivered to synapses in a manner that mimics
presynaptic release of transmitter. We have evidence
that the kinetics of an NMDA response depends on
the concentration of transmitter to which it is ex-
posed. We can thus determine the concentration of
"flashed" transmitter that mimics the synaptic
response. We have preliminary evidence that (1) pure
NMDA synaptic responses exist because there are
only functional NMDA receptors at some synapses
and not because of spillover and resulting lower con-
centrations of transmitter at nearby synapses; (2)
transmitter concentration during presynaptic release
may be considerably lower than previously thought
(by 100-fold); and (3) increases in probability of
release produces release of more than one vesicle per
synapse. With this handle on synapses, several re-
lated issues, including the locus of change during
LTP, may be amenable to direct observation.
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Use of Recombinant Viruses to
Elucidate Mechanisms in LTP
T. Koothan, H. Hinds, R. Malinow
We continue to use recombinant vaccinia virus to test
specific hypotheses regarding synaptic function and
plasticity. In particular, we are generating constructs
that will allow us to test whether AMPA receptors are
rapidly delivered to the postsynaptic membrane dur-
ing the generation of LTP. We will make an AMPA
receptor with green fluorescent protein (GFP) on the
extracellular part of the receptor. Similar fusion
proteins have been made successfully by others. In
addition, we will insert a thrombin cleavage site be-
tween the receptor and the GFP. Thus, if this con-
struct is exposed to the extracellular membrane, it can
be cleaved by thrombin and GFP will be released.
We therefore plan to express this construct in neurons
and expose them to thrombin and will then monitor
fluorescence during the induction of LTP. A decrease
in fluorescence will indicate that this construct was
delivered to the plasma membrane (exposing it to ex-
tracellular thrombin).
We have begun to see if we can rescue LTP in
slices from CaMKII knock-out animals by introduc-
ing CaMKII in slices with a recombinant vaccinia
virus.
Chimeric Constructs to
Study the Role of CaMKII
in Neuronal Function
A. Weissmann, R. Malinow [in collaboration with
Grigori Enikolopov, Cold Spring Harbor Laboratory]
Chimeric proteins containing steroid-binding do-
mains and protein kinase catalytic domains are being
designed. We are making a virus that will generate
such a construct and expect that the resulting protein
will only show catalytic activity in the presence of
the hormone. In this manner, we should be able to ex-
press this construct in neurons and activate the kinase
by exogenous application of the hormone. The ac-
tivation should occur quickly (within minutes). This
will allow localized activation (e.g., localized den-
dritic or cell body application of the hormone with a
pipette) to determine the region of the cell that re-
quires kinase activity to produce effects on synaptic
transmission.
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CaMKII Promotes Maturation
and AMPAfication of
Developing Synapses
R. Malinow [in collaboration with Gang-Yi Wu and
Hollis Cline, Cold Spring Harbor Laboratory]
The tadpole optic tectum provides several oppor-
tunities to analyze the physiological development of
synapses. These synapses resemble hippocampal
synapses (same transmitter and receptors). However,
the tectal cells are much more compact and thus af-
ford considerably better signal-to-noise resolution in
electrophysiological measurements. In addition, the
cell bodies are conveniently placed in a developmen-
tal pattern: Older cells are more rostra].
We find that initial synapses appear to be pure
NMDA and that AMPA responses appear during de-
velopment. This developmental process appears to
mimic plasticity in hippocampus: LTP causes the ad-
dition of AMPA receptors to pure NMDA synapses.
Furthermore, we find in the tectum that expression of
a constitutive CaMKII construct in postsynaptic cells
promotes physiological maturation: Young cells ex-
pressing constitutive CaMKII show AMPA re-
sponses. The ability to make detailed recordings and
to perturb the system with molecular precision should
allow a comprehensive understanding of the physio-
logical maturation of synaptic transmission.
In conclusion, we are continuing to elucidate the
basic mechanisms involved in central synaptic trans-
mission. Such an understanding is necessary to derive
a mechanistic flowchart of plastic processes. We also
continue to probe the role of CaMKII in synaptic
plasticity.
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SIGNAL TRANSDUCTION AND NEURONAL DIFFERENTIATION
G. Enikolopov J. Chubb B. Kuzin
N. Hellman N. Peunova
S. John Y. Stasiv
P. Krasnov A. Weissmann
In our laboratory, we are interested in the molecular
mechanisms responsible for linking the activity and
differentiation of neuronal cells. In particular, we are
studying signal transduction by diffusible messenger
molecules to determine whether they provide such a
link. We have shown that one of these molecules,
nitric oxide (NO), mediates the survival functions of
growth factors in neuronal cells and that it partici-
pates in the normal development of Drosophila. This
is the first indication that gaseous messengers are im-
portant for development.
We are also developing new tools to dissect and
manipulate complex signaling pathways in neurons.
Our particular focus is on the role of protein kinases
in regulatory cascades in neurons. We are trying to
design conditionally active forms of proteins and to
target chimeric proteins to the terminals of neuronal
cells. We have found protein motifs that are neces-
sary and sufficient for transporting proteins to nerve
terminals and are using them now to uncouple signal-
ing cascades at the terminal from the rest of the
neuronal cell.
Nitric Oxide Mediates
Survival of Neuronal Cells
N. Peunova, S. John, G. Enikolopov
Programmed cell death by apoptosis regulates normal
development and tissue homeostasis in eukaryotes.
Differentiated neuronal cells are dependent on
growth factors for survival. Nerve growth factor
(NGF) is a survival factor for sympathetic neurons
and for PC12 cells, and when NGF-differentiated
PC12 cells are deprived of growth factors, they un-
dergo apoptosis. We have recently shown that NO
mediates the NGF-driven neuronal differentiation of
PC12 cells by initiating growth arrest during the early
stages of NGF action. Now we have found that dur-
ing the later stages of NGF action, in fully differen-
tiated PC12 cells, NO also mediates the survival
functions of NGF.
We have observed that NO, like growth factors,
can inhibit apoptosis of differentiated PC12 cells
after NGF withdrawal. When NO-releasing com-
pounds were added to fully differentiated cells before
or immediately after withdrawal of NGF, cell death
was markedly reduced, demonstrating that NO can
partially substitute for NGF in preventing apoptosis.
This suggests that endogenously produced NO, like
that produced by NO donors, could contribute to cell
survival. Indeed, inhibition of nitric oxide synthase
(NOS) in fully differentiated cells led to massive
death by apoptosis. Importantly, no apoptosis was ob-
served when a similar treatment was applied to naive
PC12 cells or to cells that had been treated with NGF
for 2 days (and hence, had only just begun the differ-
entiation process). Similarly, inhibition of NOS did
not impair the survival of mutant U2 cells, which
retain the early steps of the response to NGF but have
lost the capacity to differentiate; they are also im-
paired in the ability to induce NOS expression in
response to NGF, and their capacity to differentiate
can be rescued by applying NO. Together, our results
with differentiated, naive, and mutant cells indicate
that NOS mediates the survival functions of NGF.
Fully differentiated PC12 cells develop a dependence
on NO production for their survival, so that inhibition
of NOS activity leads to cell death.
A possible explanation of the role of NO in pre-
venting apoptosis may involve its antiproliferative
properties. NO may prevent cells from traversing the
cell cycle, thereby keeping them from reaching a crit-
ical point where mitogenic signals contradict the es-
tablished cytostatic condition of the cells, and
prompting them to undergo apoptosis. Indeed, within
6-12 hours after the addition of the inhibitor and be-
fore any morphological signs of apoptosis are seen, a
large fraction of cells (>30%) started to incorporate
bromodeoxyuridine (BrdU). This represents a five- to
sixfold increase compared with the results obtained
with control NGF-treated cells, consistent with the
idea that the antiproliferative properties of NO con-
tribute to the repression of the cell cycle machinery in
differentiated neuronal cells.
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An additional mechanism for the inhibition of
apoptosis by NO may involve direct activation of an
anti-apoptotic program by NO, for example, by
changing the levels of expression of proteins that pre-
vent or promote apoptosis. We tested whether treat-
ment of PC12 cells with NO changes the expression
of genes involved in regulating programmed cell
death and whether these changes paralleled those in-
duced by NGF. Prolonged treatment of PC12 cells
with NGF leads to an increase in the level of Bcl -x /L,
a product that, like Bcl -2, can prevent apoptosis in
many cell types. At the same time, the amount of
Bax, a protein that counters the ability of Bcl -2 and
Bcl -x /L to repress apoptosis, decreased with a similar
time course. In contrast, the levels of these proteins
are unchanged in the mutant U2 cells. Thus, NGF-
induced differentiation of PC12 cells changes the ex-
pression of genes involved in the cell death program
in favor of products that prevent apoptosis. This may
lead to a switch of the cell program toward preven-
tion of cell death, in line with the known role of NGF
as a survival factor.
To determine whether part of the effect of NGF on
the apoptosis machinery can be mediated by NO, we
subjected PC12 cells to sustained treatment with NO
donors. The changes in expression of a panel of
apoptosis-related proteins were very similar to the
changes evoked by NGF treatment. When the same
donors were added to U2 cells (NGF-treated and un-
treated), the changes observed were identical to those
seen in wild-type PC12 cells. Taken together, the
responses of mutant and wild-type cells to NGF and
NO indicate that NO can prevent apoptosis both by
contributing to the growth arrest of the cells and by
actively inducing their anti-apoptotic defense, further
supporting the hypothesis that NO mediates part of
the survival functions of NGF.
In the brain, NO production is associated with the
death of neurons by necrosis and apoptosis after an
ischemic stroke and, perhaps, neurodegenerative dis-
eases. Paradoxically, NOS-positive neurons in the
brain are remarkably resistant to damage, and most of
them are spared after exposure to strong insults and
diseases that kill other cells. Our results suggest that
preexposure to sustained NO production may be
responsible for the increased resistance of NOS-
positive neurons to damage. Although apoptosis can
be initiated by numerous different stimuli, both the
control mechanisms and the execution mechanisms
of programmed cell death seem to be remarkably
uniform and appear to involve a relatively limited set
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of genes. The ability of NO to induce an anti-
apoptotic program and prevent programmed cell
death after withdrawal of growth factor may reflect
its physiological function in the brain during disease.
We propose that the unusual resistance of NOS-
positive neurons in the brain is related both to the
role of NO in maintaining growth arrest and to its
ability to fortify the cellular anti-apoptotic defense,
which may later protect the cells from insults.
Nitric Oxide Is Essential for the
Development of Drosophila
B. Kuzin, N. Peunova, Y. Stasiv, G. Enikolopov
[in collaboration with I. Roberts, Cambridge University]
We have recently found that NO can affect differen-
tiation in neuronal cells by inducing growth arrest
and by mediating the survival function of growth fac-
tors. Now we want to examine whether NO has a
similar role during the normal development of
organisms, acting as an essential antiproliferative
agent during cell differentiation.
We have chosen Drosophila as a model organism
for our developmental studies. We have found that at
the late stages of larval development, in the third in-
star larvae, and during the early stages of metamor-
phosis, the imaginal disks and the brain both accumu-
late high levels of diaphorase activity, indicating the
presence of NO synthase (NOS). The diaphorase
staining starts at the beginning of the third instar and
intensifies toward the end of the third instar and the
early stages of pupation. The staining pattern grad-
ually becomes more defined, with some segments of
the developing appendages, eyes, and the brain ac-
quiring a very characteristic pattern of staining.
The highest levels of diaphorase staining occur
during the period of development when DNA
synthesis and cell division in most of the cells of the
imaginal disks and the brain slow down. DNA
synthesis and cell division resume during early pupa-
tion and then stop again before the final stages of cell
differentiation occur. A very specific pattern of NOS
distribution suggests that perhaps NO has a role as an
antiproliferative agent, inhibiting DNA synthesis and
supporting temporary cytostasis during the switch to
metamorphosis.
If NO indeed acts to suppress cell division during
the late stages of fly development, then inhibition of
NOS might trigger excessive growth of organs and
tissues, whereas ectopic overexpression of the NOS
gene might lead to reduced growth of organs and tis-
sues.
To test this hypothesis, we inhibited NOS activity
in the developing larvae by injecting NOS inhibitors
at the end of the third period, several hours before
metamorphosis. The resulting adult flies had ex-
hibited numerous changes, the most dramatic being
enlargements of the appendages, especially in the
third pair of legs. Certain segments of the legs in-
creased three- to fourfold in diameter, reflecting an
almost tenfold overall increase in size. The number of
bristles also increased, confirming that hyper-
proliferation of the tissue had occurred. Identical
changes were observed when we used two structural-
ly unrelated inhibitors of NOS, thereby confirming
the specificity of their action. The segments most af-
fected were those whose primordia had the highest
levels of NOS at the early pupal stages.
For the reciprocal approach, the ectopic up-
regulation of NOS activity, we used transgenic
Drosophila lines that contain the mouse gene for
NOS2 (inducible NOS) under the control of a heat
shock promoter, which were generated by Dr. Ian
Roberts (Cambridge University). When transgenic
larvae were heat-shocked shortly before pupation
(approximately at the time when the action of the in-
hibitor is most effective), some segments of the
resulting imago flies (the legs in particular) were
reduced in size. Remarkably, the segments most often
affected by the overexpression of NO were those that
were not affected by the NOS inhibitors and whose
precursors in the larval and pupal stages demonstrat-
ed particularly low levels of diaphorase staining.
The distributions of the segments that increased in
size when NOS activity was inhibited and the seg-
ments that decreased in size when NOS activity was
ectopically up-regulated were complementary and
corresponded to the distribution of NOS. Taken to-
gether, these results support the hypothesis that NOS
acts as an antiproliferative agent during cell differen-
tiation and normal development of the fly.
The manipulation of NOS activity in the develop-
ing fly led to numerous changes not only in ap-
pendages, but in various other organs of the imago as
well. These changes were again consistent with the
hypothesis that NO acts as an antiproliferative agent
during development. We are particularly interested in
the role of NO in differentiating neurons, and our fu-
ture experiments will focus primarily on elucidating
the role of NO in the developing brain.
In addition to genetic experiments, we are trying to
understand the molecular mechanisms of NO action
in fly development, in particular, which genes regu-
late the synthesis of NO during development and
what the molecular targets of NO action are during
development.
Protein Transport to the
Nerve Terminals
P. Krasnov, J. Chubb, N. Hellman, G. Enikolopov
The main goal of this project is to find protein motifs
that are necessary and sufficient for transporting
proteins to the nerve terminals, including synapses
and growth cones. We intend to use these motifs to
target chimeric proteins to the terminals. Our particu-
lar interest is to deliver to the terminal those proteins
that can directly modify signal transduction path-
ways, such as protein kinases, protein phosphatases,
and their inhibitors. In this way, we want to modulate
the signal transduction cascades at the nerve terminal,
but at the same time, we want to uncouple these
perturbations from the signaling in the rest of the
neuronal cell.
We tested synaptic vesicle proteins by tagging
them with the HA epitope, transfecting recombinant
constructs into neuronally differentiated PC12 cells,
and visualizing the distribution of the chimeric
molecules using immunocytochemistry. We chose
one of the synaptotagmin isoforms that was especial-
ly efficient at accumulating at the nerve terminal. The
distribution pattern of the recombinant tagged protein
did not differ from the distribution of endogenous
synaptotagmin.
We prepared a large number of deletions covering
the entire coding region of the synaptotagmin gene
and compared their distribution in the cell by im-
munocytochemistry. We found two signals, at the
transmembrane domain and at the carboxy-terminal
domain of the protein, that are necessary for the cor-
rect trafficking of the recombinant synaptotagmin
molecule to the neuronal cell terminal.
By testing a set of more subtle deletions at the car-
boxyl end of the synaptotagmin molecule, we identi-
fied the amino acid residues that are crucial for trans-
port to the nerve terminal. Deletion of as few as eight
amino acids within the carboxy-terminal domain was
enough to prevent the tagged recombinant molecules
from accumulating at the terminal.
To test whether the signals identified as critical for
transport to the nerve terminal are also sufficient for
such transport, we prepared a series of constructs in
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which more than two thirds of the entire molecule
was deleted, leaving only the putative signal se-
quences intact. The intracellular distribution of these
constructs was similar to (if not indistinguishable
from) the distribution of the original recombinant
synaptotagmin molecule and the endogenous synap-
totagmin. These results demonstrate that the two
identified signals are not only necessary but also suf-
ficient for the targeting of a recombinant chimeric
protein molecule to the nerve terminal.
To determine which interactions make the car-
boxy-terminal sequences crucial for the accumulation
of recombinant molecules at nerve terminals, we
studied the distribution of subcellular particles con-
taining recombinant synaptotagmin by centrifugation
in sucrose and glycerol gradients and compared it
with the distribution of endogenous components of
the synaptic vesicles. There was little difference be-
tween recombinant synaptotagmin molecules and the
endogenous synaptotagmin or synaptophysin, unless
the deletions covered the transmembrane domain.
This suggests that recombinant synaptotagmin mole-
cules, even those that do not reach the nerve terminal,
are incorporated into the correct organelles. A pos-
sible explanation of these data is that the synaptotag-
min molecule itself is responsible for the transport of
subcellular particles to the nerve terminals. Recent
data indicate that synaptotagmin is transported to the
synapse as a component of a specialized transport
particle, which contains some, but not all, of the
synaptic proteins. Such particles, whose components
are later incorporated into complete synaptic vesicles,
are driven to the terminal by specialized kinesin-like
motor proteins. Synaptotagmin might play the part of
a cargo for these proteins, taking some (but not all)
components of the synaptic vesicle along. We are
currently testing this hypothesis.
Synaptotagmin molecules also bind to neurexins,
which are plasma membrane proteins preferentially
localized in nerve terminals. The signal we identified
in the carboxy-terminal domain of the synaptotagmin
molecule overlaps with the region of neurexin bind-
ing. The interaction between the carboxy-terminal
domain of synaptotagmin and neurexin might provide
the means for retaining synaptotagmin, and perhaps
the whole vesicle, in the nerve terminal. We are
presently investigating whether synaptotagmin-neur-
exin interactions have a role in the accumulation of
recombinant synaptotagmin molecules at the nerve
terminal.
One of the goals of this project is to use the identi-
fied motifs to target chimeric proteins to the nerve
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terminals. We have prepared a set of constructs that
contain protein kinases and recombinant protein
kinase inhibitors connected to the protein domains
responsible for targeting to the terminal. We are also
testing whether the accumulation of such molecules
at the nerve terminal restricts signal transduction cas-
cades to this region of the nerve cell.
Chimeric Constructs to Study
the Role of Protein Kinases
in Neuronal Function
A. Weissmann, G. Enikolopov [in collaboration with
R. Malinow, Cold Spring Harbor Laboratory]
We are designing a system for expressing condi-
tionally active forms of proteins in mammalian cells.
We are constructing a vaccinia virus vector that will
allow proteins to be expressed as fusions with the
ligand-binding domains of steroid hormone receptors.
Our current experiments concentrate mostly on the
Drosophila ecdysone receptor. The steroids that are
agonists of the ecdysone receptor do not cross-react
with the mammalian steroid receptors. We hope that
this will make it possible to maintain low basal levels
of functional activity of chimeric proteins in mam-
malian cells and to activate them by adding insect
hormone. These vaccinia virus vectors will then be
used to deliver chimeric proteins to the cells and tis-
sues. We will use them primarily to study the role of
protein kinases in long-term potentiation in the brain.
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NEURONAL GROWTH AND DIFFERENTIATION
D.R. Marshak E. Araya
L. Pena
This laboratory has conducted research on the
biochemical basis of neuronal growth and differentia-
tion. Overall, the questions that we approach in our
research involve the decisions of neuroblasts to cease
proliferation and to subsequently elaborate neuritic
processes prior to terminal differentiation. These
questions thus involve understanding how signal
transduction systems that control cell proliferation in
the neuroblast are altered upon becoming postmitotic,
as well as learning which growth factor molecules
control these switches within cells. Specifically, we
are interested in the action of a growth-stimulating
protein, S100(3, that is produced by astrocytes in the
brain. The involvement of such neurotrophic factors
in degenerative diseases, such as Alzheimer's dis-
ease, has prompted our interest in the role of such
factors in neuropathological processes. During this
year, we completed our work on the Program Project
grant from the National Institute on Aging to conduct
studies on the mechanism of action of S100(3, a
polypeptide growth factor produced by glial cells in
the brain. This is a multisite program grant that
brings together anatomists, pharmacologists, patho-
logists, molecular biologists and biochemists that
work on S100I3. Our lab discovered a function of this
molecule several years ago and have more recently
discovered its abnormal levels in Alzheimer's dis-
ease. Our work is central to understanding the poten-
tial role of this factor in the pathology of neuro-
degenerative disease.
REGULATION OF S10013 BY g-AMYLOID
In Alzheimer's disease and Down syndrome, severely
afflicted brain regions exhibit up to 20-fold higher
protein levels of S100(3, and astrocytes surrounding
neuritic plaques exhibit higher protein levels of
S10013. A major constituent of the plaques is 13-
amyloid protein, which has been reported to have
both neurotrophic and neurotoxic effects in vitro. We
examined the responses of central nervous system
glia to a (3-amyloid peptide. Primary astrocyte cul-
tures obtained from neonatal rats and rat C6 glioma
cells were synchronized by serum deprivation and
treated with (3A(1-40), a synthetic fragment of p-
amyloid. A weak mitogenic activity was observed, as
measured by [3H]thymidine incorporation. Northern
blot analysis revealed increases in sloop mRNA
within 24 hours, in a dose-dependent manner.
Nuclear run-off transcription assays showed that
13A(1-40) specificially induced new synthesis of
S100(3 mRNA in cells maintained in serum but
caused a general elevation of several mRNA species
in cells maintained under serum-free conditions. At
the protein level, corresponding increases in sloop
protein synthesis were observed in response to the
13A(1-40) peptide, measured by immunoprecipitation
of 35S-labeled cellular proteins. The data indicate that
S10013 expression can be influenced directly by p-
amyloid.
Protein Kinase Modulation
during Neuronal Differentiation
L. Pena, D.R. Marshak [in collaboration with
A. Rossomando, West Haven, Connecticut]
We have continued our studies of protein kinase
responses to growth factors in neuronal cells. A com-
plete study of p34cdc2 kinase and MAP kinases in
PC12 cells that respond to nerve growth factor (NGF)
has been conducted by A. Rossomando. The rat
pheochromocytoma cell line, PC12, undergoes mor-
phological and biochemical differentiation into sym-
pathetic neurons in culture under the influence of
NGF. The enzyme p34cdc2 kinase, which is critical to
the induction of mitosis, appears to be down-regu-
lated during NGF-stimulated differentiation. The pre-
viously identified p46 protein seems to be a form of
MAP kinase, which is known to be stimulated indi-
rectly by growth factor receptor tyrosine kinases and
associated molecules. These studies will enable us to
work out pathways of signaling from the surface of
the neuron to the genome.
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CSH LABORATORY JUNIOR FELLOWS
In 1986, Cold Spring Harbor Laboratory began a Junior Fellow program to encourage independent
research by outstanding young scientists who, during their graduate studies, displayed exceptional
promise of becoming leading scientists of the future. The purpose of this program is to provide an
opportunity for these young scientists to work independently at the Laboratory for a period of up to
3 years on projects of their choice. Junior Fellows are provided with a salary, research support, and
technical assistance so that they can accomplish their goals free from other distractions. The inter-
action among research groups at the Laboratory and the program of courses and meetings on
diverse topics in molecular biology contribute to a research environment that is ideal for innovative
science by these Fellows.
Two previous Cold Spring Harbor Fellows, Dr. Adrian Krainer (1987) and Dr. Carol Greider
(1988), are currently members of the scientific staff at the Laboratory. Dr. David Barford, our Junior
Fellow since 1991, left in 1994 to go to Oxford University (Laboratory of Molecular Biophysics) as a
university lecturer. Dr. Ueli Grossniklaus joined us in 1994 from the Department of Cell Biology, Uni-
versity of Basel, Switzerland. Our newest Fellow, Dr. Scott W. Lowe, comes from the Center for
Cancer Research at the Massachusetts Institute of Technology.
U. Grossniklaus
S.W. Lowe
Dissection of Arabidopsis
Ovule and Gametophyte
Development by
Enhancer Detection
U. Grossniklaus, J. Moore, W. Gagliano
In flowering plants, the ovule is composed of tissues
derived from both phases of the plant life cycle, the
diploid sporophyte and the haploid gametophyte. The
ovule is the site of megasporogenesis and megaga-
metogenesis, the processes that lead to the formation
of the mature embryo sac containing the egg cell. A
single cell within an ovule primordium differentiates
into a megaspore mother cell, undergoes meiosis, and
produces four megaspores, three of which die. The
fourth divides through three consecutive mitoses to
form the embryo sac harboring eight nuclei in a syn-
cytium. These eight nuclei are partitioned into seven
cells: one oocyte, two synergids, three antipodals,
and a binucleate central cell whose nuclei fuse prior
to fertilization (Fig. 1A). After double fertilization of
both the egg and the central cell, the ovule develops
into a seed. The seven sister cells of the female
gametophyte are highly specialized. It is likely that
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the development of each cell type is significantly in-
fluenced by its position within the embryo sac and by
cell-cell communication. Proper development of the
gametophyte appears to depend on interactions be-
tween gametophytic and sporophytic tissues of the
ovule.
Very little is known about the control of ovule and
gametophyte development in angiosperms. Recent
genetic screens have identified sporophytically re-
quired female sterile mutations that primarily affect
the ontogenesis of the integumental cell layers. A few
of these mutations also affect the female gameto-
phyte, but virtually nothing is known about the genet-
ic and molecular events involved in pattern forma-
tion, cell specification of the cell types in the embryo
sac, and the signaling events thought to be crucial for
these processes.
The goal of our research is the identification and
characterization of genes required for ovule and
megagametophyte development. We are performing a
large-scale enhancer detection/gene-trap screen in or-
der to identify genes that are expressed during mega-
sporogenesis and megagametogenesis in a temporally
or spatially restricted fashion.
FIGURE 1 Selected GUS expression patterns in Arabidopsis ovules. (A) Schematic representation of a mature ovule. The cen-
tral haploid gametophyte is surrounded by several layers of diploid sporophytic tissue, the endothelium, and the inner and out-
er integuments. The megagametophyte contains seven cells: three antipodals (an), two synergids (sy), an oocyte (oo), and a
large central cell (cc). (fu) funiculus; (ch) chalazal pole; (mi) micropyle. (B) ET 760 shows expression in the entire gametophyte
with the strongest level in the egg apparatus consisting of the two synergids and the oocyte. The reporter gene is first ex-
pressed during cellularization, and depending on how far this process has proceeded, we find GUS expression either
restricted to the egg apparatus or in the entire gametophyte. (C) ET 179: reporter gene expression is restricted to the
synergids. (D) ET 1117 shows expression early during ovule development in the subepidermal megaspore. (E,F) ET 252 is ex-
pressed throughout ovule development as soon as primordia arise. (E) At integument initiation, GUS expression is strong in the
nucellus and the inner integument primordium, weaker in the outer integument primordium, and absent from the prospective
funiculus. (F) In mature ovules, reporter gene expression has resolved into a bipolar mode of expression at the micropylar and
chalazal pole. (G) ET 1131 shows expression in a ring of endothelial cells that undergo a last round of cell division. (14) ET
1111: GUS activity is restricted to the medial part of the funiculus. (/) ET 77: only a small patch of cells on the ventral surfaceof
the funiculus expresses GUS.
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ENHANCER DETECTOR/GENE-TRAP MUTAGENESIS
Enhancer detection and gene-trap systems are widely
used in Drosophila and mouse developmental biol-
ogy. Enhancer detection relies on a mobile genetic
element carrying a reporter gene (in our case GUS)
under the control of a weak constitutive promoter. If
this promoter comes under the control of genomic
cis-regulatory elements, the reporter gene is ex-
pressed in a specific temporal and spatial pattern.
This pattern reflects the expression of a nearby gene
controlled by the same regulatory elements and thus
allows the identification of genes based on their pat-
tern of expression, rather than on a mutant pheno-
type. Gene traps are a modification of this approach
involving the generation of transcriptional fusions to
the reporter gene. Enhancer/gene traps have been es-
pecially useful in identifying genes required both ear-
ly and late during development and in processes char-
acterized by high complexity and redundancy.
The plant group here at the laboratory has devel-
oped an enhancer/gene-trap system for Arabidopsis
thaliana which is based on the Ac /Ds transposon of
maize (Sundaresan et al., Genes Dev. 9: 1997
[1995]). In brief, a Ds element acting as an enhancer
detector or gene-trap transposon can be mobilized by
crossing a Ds-containing line to a line bearing an im-
mobile Ac element producing transposase. Self-
pollination of these Ft plants will result in some F2
progeny containing a transposed Ds element (trans-
posants). A positive/negative selection system allows
the identification of the plants that contain a Ds ele-
ment at a new location. The enhancer detector/gene-
trap mutagenesis system is a means of creating ran-
dom insertions in the Arabidopsis genome. An inser-
tion in or close to a gene of interest (as defined by its
expression pattern and/or mutant phenotype) provides
an entry point to both its molecular and genetic char-
acterization.
So far, we have focused on the generation of more
than 3300 independent transposants carrying enhan-
cer or gene-trap elements. This is a very laborious
process and most of our effort in the past year was
directed toward this goal (Table 1). In close to 2000
Table 1 Enhancer/Gene-Trap Mutagenesis
F1 seeds generated 50,000
F2 families harvested 20,037
F2 families screened 15,392
Transposants isolated 3,302
enhancer traps 1,995
gene traps 1,307
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crosses, I generated approximately 50,000 F1 seeds of
which 20,000 were grown up individually to harvest
their F2 seeds. More than 15,000 of these F2 families
have been put through the positive/negative selection
system to recover transposants. About one in four to
five families yielded a new unlinked transposition
event. To assure independence of events, usually only
one transposant per family was isolated.
EXPRESSION PATTERNS IN OVULES
In a pilot screen, we analyzed the expression of the
GUS reporter gene in mature ovules of the first 1000
transposants that were collectively generated by the
Cold Spring Harbor plant group. Carpels harboring
mature ovules were dissected and stained for GUS
activity. Stained carpels were mounted for compound
microscopy in a lactate-based clearing solution. All
transposants that showed staining in mature ovules
were rescreened, and a developmental series was ana-
lyzed. Approximately 11% of the enhancer-traps
(511) and 3% of the gene-traps (478) show a spatially
restricted expression in mature ovules. Several lines
show GUS expression patterns specific to individual
cell types of the female gametophyte (oocyte,
synergids, and antipodals; Fig. 1B,D), suggesting a
role in cell specification and determination. Alterna-
tively, the corresponding gene products may be in-
volved in the specific functions performed by the dif-
ferent cell types of the female gametophyte. The ex-
pression patterns observed in enhancer transposants
are summarized in Table 2. Almost two thirds of the
lines staining in the gametophyte do so only after fer-
tilization and also stain in the pollentube. GUS ac-
tivity detected in the degenerating synergid after it
has been penetrated by the pollentube could be
paternally produced. These patterns may reflect male
rather than female gametophyte-specific expression.
The majority of expression patterns in the sporo-
phytic tissues of the ovule show a highly polar distri-
bution: Some of these are specific to the chalazal or
micropylar pole, and a few patterns show differential
expression along the dorsoventral axis (Fig. 1E-I).
These patterns reflect regional gene expression and
patterning in the developing ovule. The correspond-
ing genes may be involved in establishing or
maintaining the polarity of ovule and gametophyte or
in localized signaling processes. Two lines are of par-
ticular interest since they express the reporter gene at
a very early stage of ovule ontogenesis. ET 252
shows GUS expression in the distal half of emerging
Table 2 Spatially Restricted Expression Patterns
(Enhancer Traps only)
Female gametophyte 14
entire gametophyte 2
egg apparatus
oocyte
5
synergids
megaspores
32
2
Sporophyte 13
ovule proper 5
funiculus 8
Sporophyte and Gametophyte 4
Degenerating synergid (after
fertilization, pollentubes)
23
ovule primordia and could be involved in early pro-
cesses of pattern formation. Its expression is main-
tained throughout ovule development in a dynamic
pattern (Fig. IE,F). ET 363 shows GUS activity
restricted to a dorsal patch of cells in mature ovules.
It starts to be expressed on one side of elongated
finger-like ovule primordia in a small group of cells.
Expression starts before any morphological dif-
ference between future dorsal and ventral sides of the
ovule can be detected and represents the earliest
marker for the prospective dorsal side. Among the
sporophytic patterns, we found a surprisingly high
number of lines staining in the funiculus, the struc-
ture that connects the ovule to the maternal tissue of
the carpel (Fig. 1H,I). The funiculus is a structure of
simple architecture and morphology, yet it appears to
be highly patterned as judged from the array of ex-
pression patterns we found. We identified genes that
are expressed in different domains along both the
dorsoventral and proximodistal axis of the funiculus.
The unexpected variety of expression patterns in the
funiculus may be related to its complex interactions
with the pollentube.
MOLECULAR CHARACTERIZATION OF
SELECTED LINES
We have adapted a novel polymerase chain reaction
(PCR)-based method, thermal asymmetric interlaced
PCR (TAIL PCR) (Liu et al., Plant Journal 8: 457
[1995]), to isolate genomic regions flanking the Ds
insertions. We designed nested primers to isolate
both 5 ' - and 3 ' -flanking regions that are used in
combination with an arbitrary degenerate primer.
Using a single arbitrary primer, we were able to iso-
late genomic fragments for 52 Ds insertions cor-
responding to a 75% success rate in a single attempt.
It should be possible to recover the remaining frag-
ments by using a different arbitrary primer. The frag-
ment lengths range from 130 by to 1200 by with an
average of 450 bp. In collaboration with Muhammad
Lodhi and Dick McCombie here at the Laboratory,
35 fragments representing 23 loci were directly se-
quenced. A database search revealed that seven Ds
insertions were close to or in a known Arabidopsis
gene. Three of these show a spatially restricted ex-
pression within the ovule and have homology with
the MADS box gene family and two Arabidopsis
ESTs of unknown function, respectively. The remain-
ing four belong to the class that is primarily ex-
pressed in the male gametophyte and the penetrated
synergid. They are insertions into the U3C snRNA
gene, the genes encoding S12 ribosomal protein, the
basal transcription factor TFIIB, and an Arabidopsis
EST of unknown function.
Ds-Induced Mutations
Affecting Gametophyte
Development and
Function
J. Moore, W. Gagliano, U. Grossniklaus
We take advantage of the fact that Ds elements act as
insertional mutagens and screen transposants for
semisteriles and F3 families for female sterile muta-
tions. A mutation affecting megagametophyte devel-
opment or function fails to transmit through the fe-
male gametophyte. Consequently, the ovule arrests
and no seed develops. In a heterozygous plant, one
half of the ovules will receive the mutant allele
resulting in a semisterile phenotype. Fully female
sterile mutations correspond to genes that show a
sporophytic requirement for ovule development. Last
year, we dedicated most of our growth space to the
generation of transposants, and our screen for sterile
mutations has not progressed very much. We have
identified 10 male sterile mutations in the first 600 F3
families but no female sterile mutant yet. In contrast,
we have screened more than 4000 transposants for a
semisterile phenotype and identified 150 candidates
(Table 3). Since semisterility can result from poor en-
vironmental conditions, reciprocal translocations,
191
Table 3 Mutations Affecting Gametophyte Development
or Function
Transposants screened for semisterility 4344
Semisterile candidates 153
Tested for segregation distortion (SD) 149
Lines with mild SD (Kans/Kanr 0.6 to 0.8) 39
Lines with strong SD (Kans/Kanr 0.8) 22
sporophytically required female sterile mutations
with a low penetrance, or mutations affecting the fe-
male gametophyte, we subject all our candidates to a
second test. If a mutation is not transmitted through
the female gametophyte but normally through the
male, the mutant allele should be segregating in one
half of the progeny from a heterozygote. This devia-
tion from a normal Mendelian segregation ratio
(segregation distortion) is a hallmark of a mutation
affecting the gametophyte. We can use the kanamy-
cin resistance marker present on the Ds element to as-
say segregation distortion. This allows us to focus
immediately on semisterile mutations that are linked
to the Ds element. We have identified about 60 muta-
tions displaying both a semisterile phenotype and dis-
torted segregation. Based on the semisterility, they
appear to affect the female gametophyte. To test
whether the mutant allele also shows reduced trans-
mission through the male or whether the defect is
specific to the megagametophyte, we will perform
reciprocal outcrosses to wild type and determine
transmission frequencies through both gametophytes.
Characterization of medea,
a Maternal Effect Mutation
in Arabidopsis
U. Grossniklaus, W. Gagliano
One of our semisterile lines, GT 584, shows a unique
phenotype where all ovules initiate seed development
but then half of them abort during embryogenesis.
These shriveled seeds contain embryos arrested at an
early torpedo stage. The 1:1 segregation of normal to
aborted seeds indicates a gametophytic control of the
defect. If a heterozygous GT 584 plant is pollinated
with wild-type pollen, the same phenotype is ob-
served, whereas all seeds develop normally in the
reciprocal cross. Thus, GT 584 displays a classical
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maternal effect embryo lethal phenotype. Moreover,
this phenotype is controlled by the female gameto-
phyte rather than sporophyte and can be termed a
gametophytic maternal effect. The mutation cannot
be rescued by an additional wild-type copy intro-
duced through the male by using a tetraploid pollen
donor. Since the genotype of the female gametophyte
("mother") determines whether the developing em-
bryo will die or live, we named this mutation medea
(mea) after the priestess Medea, daughter of the
Greek king Aeetes, who killed her own children
(Euripides, 430 BC).
We have fortuitously isolated two alleles of mea
from the same F2 family. Both lines contain a Ds in-
sertion that is tightly linked to the mea phenotype
(<0.6 cM) but inserted at a different genomic location
as judged from Southern blots. Both lines are derived
from a single F1 plant, suggesting that we are dealing
with a tagged mutable mea allele carrying the Ds ele-
ment at the locus and a stable derivative allele where
the Ds reinserted close by, but the excision event did
not restore mea function. The former should be re-
vertible by reintroducing Ac transposase, and the lat-
ter should display a stable phenotype. Indeed, mea-1
is mutable and we have isolated five independent
revertants, whereas mea-2 is a stable mutation. We
isolated genomic DNA flanking the Ds insertion of
mea-1 by TAIL PCR and are currently characterizing
the molecular organization of the gene.
The developing seed harbors both products of dou-
ble fertilization, and it is difficult to distinguish
whether a mutation primarily affects embryo or endo-
sperm development. We have morphologically ana-
lyzed the developing seeds in mea. The endosperm
appears to go through regular free nuclear division
cycles and then cellularizes as in wild type. Embryos
derived from mea eggs are indistinguishable from
wild-type embryos until the time of arrest at the early
torpedo stage. We can culture arrested embryos and
have obtained homozygous mea plants producing
siliques with 100% aborted seeds. Homozygous
plants show a normal vegetative phase and produce
wild-type flowers, indicating that mea is specifically
required during embryogenesis. We speculate that
mea is an imprinted gene that gets silenced in the
male germ line. Thus, wild-type embryos are essen-
tially hemizygous for MEA, the only active copy
being transmitted through the female gametophyte. In
mea mutants, this active copy is mutated, leading to
arrest during embryogenesis.
Genetic Screen for Arabidopsis
Mutants Displaying Apomictic Traits
U. Grossniklaus [in collaboration with R.E. Pruitt,
Harvard University]
Seeds are generally considered to be the result of sex-
ual reproduction. Their successful formation requires
the coordinated development of embryo and endo-
sperm, the products of double fertilization, and of the
seed coat which is derived from the sporophytic tis-
sues of the ovule. In more than 300 plant species,
however, these events occur independent of fertiliza-
tion in a process termed apomixis. Gametophytic
apomixis closely resembles the sexual reproduction
pathway, but meiosis is impaired or absent. Con-
sequently, a diploid cell undergoes gametophyte de-
velopment to produce a mature embryo sac. The
diploid egg cell develops without fertilization into an
embryo, and a viable seed is produced that is geneti-
cally identical to the mother plant. Differences be-
tween sexual and apomictic reproduction appear to be
controlled by a single regulatory locus that controls a
cascade of events leading to the formation of an un-
reduced oocyte and the initiation of the seed develop-
ment program in the absence of fertilization. The
transfer of apomixis into a sexual crop would allow
clonal reproduction through seed and the immediate
fixation of any desired heterozygous genotype. This
would completely revolutionize breeding strategies
and agriculture.
To identify genes that are relevant to apomictic
reproduction, we performed a pilot screen for
mutants showing seed development in the absence of
fertilization. We took advantage of a tight tempera-
ture-sensitive male sterile mutation that was isolated
in Bob Pruitt's laboratory. Under restrictive condi-
tions, homozygous plants do not produce any seeds
and their seed pots do not elongate. Homozygous
seeds were mutagenized and M1 plants were grown
under the defined conditions in the growth chambers
at Harvard. The plants were screened for sectors that
showed silique elongation, indicating seed develop-
ment under the restrictive temperature. Plants produc-
ing such sectors were shifted to the permissive
temperature to allow self-fertilization and rescue of
the mutation. Among the 1582 plants that we
screened, 26 putative mutants were isolated. We ex-
pect to find two different classes of mutations: (1)
mutations suppressing the male sterility defect allow-
ing the production of functional pollen (these should
give rise to viable seeds) and (2) mutations allowing
full or partial seed development in the absence of fer-
tilization. Such mutations are expected to show a
gametophytic requirement. Upon self-fertilization, 21
of 26 putative mutants produced 50% wild-type and
50% aborted seeds, indicating a gametophytic control
of the defect. We are currently analyzing the in-
heritance characteristics of these mutants. Since seeds
produced under the restrictive temperature are not vi-
able, the seed development program appears to be ac-
tivated only partially in these mutants. What part(s) is
initiated autonomously (embryo, endosperm, or seed
coat development) can be determined by microscopic
inspection of the seeds. Whereas mutations that allow
part of the program to occur independently of fertiliz-
ation are recovered at a high frequency (1.6% in our
pilot screen), we expect fully apomictic or partheno-
genetic mutants to be extremely rare. The powerful
screen we have established will allow the rapid anal-
ysis of very large numbers of Ml plants such that the
recovery of these rare mutations should be possible.
Apoptosis, Cancer, and
Chemosensitivity
S.W. Lowe, M. McCurrach, J. Polyakova,
T. Connor, A. Lin, A. Samuelson
It is now apparent that cell death can occur by a pro-
grammed process known as apoptosis. This knowl-
edge has important implications for our understand-
ing of developmental biology and tissue homeostasis,
for it implies that cell numbers can be regulated by
genes that influence cell survival as well as those that
control proliferation and differentiation. That apo-
ptosis is regulated implies that cell death, like other
metabolic or developmental programs, can be dis-
rupted by mutation. Indeed, mutations that suppress
apoptosis-for example, deregulated bc1-2 expression
or inactivation of p53-can promote tumorigenesis.
As the objective of cancer therapy is to destroy
malignant cells, factors that modulate cell death in
tumors may also influence the efficacy of anticancer
agents. Although the toxicity of anticancer agents has
been attributed to their debilitating effects on prolif-
erating cells, we now know that most anticancer
agents induce apoptosis. This revelation has profound
implications for cancer therapy, for it raises the pos-
sibility that agents with distinct primary targets
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ultimately kill through similar effector mechanisms.
Consequently, mutations in apoptotic programs may
produce a general resistance to anticancer agents.
Our research is based on the premise that apoptosis
provides a natural defense against tumor develop-
ment and underlies the cytotoxicity of most current
anticancer agents. Our laboratory investigates the
molecular control of apoptosis in tumor cells, with
the ultimate goal of identifying determinants of radia-
tion and chemosensitivity and perhaps new targets for
therapeutic intervention. Earlier studies focused on
the p53 tumor suppressor gene and its anti-neoplastic
activities. Using model systems, we identified p53 as
an important regulator of apoptosis in tumor cells.
Role of p53 in Apoptosis
J. Polyakova, T. Connor, M. McCurrach, S. Lowe
In fibroblasts and in most normal tissues, p53 func-
tions in a cell cycle checkpoint that limits prolifera-
tion following genomic damage induced by radiation
(Kastan et al., Cell 71: 587 [1992]). In contrast,
thymocytes undergo apoptosis following irradiation;
in this setting, p53 is required for efficient cell death
(Lowe et al., Nature 362: 847 [1993]). These obser-
vations suggest that the role of p53 in apoptosis can
be tissue-specific. However, E1A-expressing fibro-
blasts undergo p53-dependent apoptosis following ir-
radiation, indicating that El A alters p53 function
from facilitating growth arrest to promoting apoptosis
(Lowe et al., Cell 74: 954 [1993]). Many cytotoxic
agents also induce p53-dependent apoptosis in
El A/ras-transformed mouse embryo fibroblasts
(Lowe et al., Cell 74: 954 [1993]), demonstrating that
p53 is a determinant of radio- and chemosensitivity.
Using transplanted tumors derived from oncogenical-
ly transformed fibroblasts expressing or lacking p53,
we demonstrated that p53 mutations can reduce the
efficacy of anticancer agents in vivo (Lowe et al.,
Science 266: 807 [1994]).
If the murine model system described above ac-
curately mimics the consequences of p53 inactivation
in human tumors, then p.53 mutations should contrib-
ute to radiation and drug resistance in human cancer.
In the past 2 years, a considerable amount of clinical
evidence associates p53 mutations with shortened
survival (for review, see Lowe 1995). For example,
p53 mutations are linked to drug resistance in breast
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cancer and several hematologic malignancies; pa-
tients harboring p53 mutant tumors respond poorly to
adjuvant therapy and die much sooner than patients
with wild-type p53. The role of p53 in apoptosis pro-
vides a compelling model to explain these correla-
tions; conversely, the ability of the E1A model sys-
tem to predict these associations supports its utility
for identifying processes important in tumorigenesis
and chemosensitivity. Therefore, we are currently
using this model to identify other components of
apoptotic programs.
p53 Uses Distinct Effector
Genes in Promoting Growth
Arrest or Apoptosis
M. McCurrach, S. Lowe in collaboration with
L. Attardi and T. Jacks, Massachusetts Institute
of Technology]
Although p53 functions as a transcription factor, con-
troversy exists as to whether this activity is important
for apoptosis. We recently obtained strong evidence
suggesting that apoptosis results from p53's tran-
scriptional activity. Microinjection of wild-type p53
induces apoptosis in p53-1- populations expressing
E1A, but p53 deletion mutants lacking the amino-
terminal trans-activation domain are defective (At-
tardi et al. 1996). Most importantly, chimeric proteins
consisting of a heterologous trans-activation domain
(VP16) fused to the amino-terminal deletion mutant
restores apoptosis. Therefore, this study provides
definitive evidence that p53 promotes apoptosis by
regulating transcription.
p53 facilitates cell cycle arrest, at least in part, by
increasing transcription of the p211Cipl IWAF1 cy-
clin-dependent kinase inhibitor (see, e.g., Brugarolas
et al., Nature 377: 552 [1995]). To test whether p21
might also function in apoptosis, we introduced E1A
into wild-type, p53-1-, and p21-1- mouse embryo
fibroblasts (MEFs) by retroviral gene transfer. As ex-
pected, E1A-expressing p53+/+ MEFs were suscep-
tible to apoptosis in low serum or the chemothera-
peutic drug adriamycin, whereas p53-1- populations
were resistant. p21÷ populations expressing ElA
were comparable to their wild-type counterparts.
Thus, p53-dependent cell-cycle arrest and apoptosis
utilize distinct effector genes (Attardi et al. 1996).
We are currently assessing other candidate genes that
might act downstream from p53 in apoptosis.
Oncogenic Changes Alter
Chemosensitivity
A. Lin, A. Samuelson, M. McCurrach, S. Lowe
Anticancer agents are effective only when tumor cells
are more readily killed than normal tissue. If the ef-
ficacy of anticancer agents is partly determined by
their ability to induce apoptosis, then tumor cells
must be more susceptible to apoptosis than the tissue
from which they arose. Evidence from our laboratory
and elsewhere is emerging to suggest that increases
in cellular susceptibility to apoptosis are tightly
linked to tumorigenesis itself. For example, the
adenovirus ElA oncogene deregulates cellular
proliferation and simultaneously promotes apoptosis
in response to many physiologic and toxic agents
(Lowe et al., Cell 74: 954 [1993]; Lowe et al., Proc.
Natl. Acad. Sci. 91: 2026 [1994]). Since analogous
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changes are found only in neoplastic cells, their
ability to enhance apoptosis may explain why tumor
cells can be specifically killed by cytotoxic agents
(Lowe 1995). In contrast, oncogenic mutations that
suppress apoptosis (e.g., p53) promote resistance to
anticancer agents-not by preventing the cellular
damage produced by these agents, but rather the cel-
lular response to this damage. These observations
suggest that tumor cell chemosensitivity is
determined, in part, by the combined effects of on-
cogenic mutations on apoptosis.
Our laboratory continues to use the ElA oncogene
to mimic oncogenic changes occurring during
spontaneous tumorigenesis and to modulate cellular
susceptibility to apoptosis. We have recently op-
timized retrovirus-mediated gene transfer to intro-
duce ElA into whole populations of primary cells for
immediate analysis of cellular susceptibility and
resistance to apoptosis. E1A-expressing populations
Apoptosis correlates spatially with hypoxia
in p53-expressing tumors
EF-5 TUNEL
FIGURE 2 Nude mice were inoculated with p53-expressing (p53+/+; top) and p53-deficient
(p53-/-; bottom) mouse embryo fibroblasts made tumorigenic by coexpression of the
adenovirus ElA and activated ras oncogenes. Upon formation of tumors, animals were in-
jected with the compound EF5, which is metabolically activated to bind macromolecules in a
low-oxygen (hypoxic) environment. One hour after injection of EF5, tumors were isolated and
prepared for histological analysis. Tumor sections were stained using both an anti-EF5
antibody to identify hypoxic regions (left, light gray) and TUNEL assay to identify apoptotic
cells (right bright spots). Apoptosis colocalizes with hypoxia in p53-expressing tumors but not
in p53-deficient tumors.
195
rapidly become sensitive to the induction of p53-
dependent apoptosis following serum depletion or
treatment with radiation or chemotherapeutic agents.
We anticipate that this system will facilitate the dis-
section of apoptotic programs active in transformed
cells.
p53 Modulates Apoptosis
in Response to Hypoxia
S. Lowe [in collaboration with T. Graeber and
A. Giaccia, Stanford University]
Our previous work suggested that p53-dependent
apoptosis might provide a brake on tumor growth
(Lowe et al., Proc. Natl. Acad. Sci. 91: 2026 [1994];
Symonds et al., Cell 78: 703 [1994]). In a collabora-
tive study that was completed following our arrival at
Cold Spring Harbor, we asked whether oncogenes
such as E1A or c-myc could promote apoptosis under
physiological conditions prevalent during tumor de-
velopment. Fibroblasts expressing c-myc or trans-
formed by ElAlras rapidly undergo apoptosis when
placed in low oxygen (hypoxia), and Bcl -2 over-
expression or p53 inactivation suppresses hypoxia-
induced cell death (Graeber et al. 1996). Cells with
defects in apoptosis survived hypoxia; thus, El A/ras-
transformed cells lacking p53 outgrow El Airas-
transformed cells expressing p53 in a low-oxygen en-
vironment. Using a transplanted tumor model, we
demonstrated that hypoxia and apoptosis correlate
spatially in p53-expressing tumors but not in p53-
deficient tumors (Fig. 2).
Hypoxia in the center of tumors has long been as-
sociated with necrosis. However, that low oxygen
also induces apoptosis, a regulated form of cell death,
implies that hypoxic stress may play a causal part in
tumor evolution. As developing tumors outgrow their
blood supply, they encounter hypoxia. Our results
suggest that further tumor growth is limited by
hypoxia-induced apoptosis. In this view, cells acquir-
ing mutations that suppress this response have a sur-
vival advantage and begin clonal expansion within
the tumor. Since p53 promotes hypoxia-induced
apoptosis, p53 mutations enhance survival in a low-
oxygen environment. Inactivation of p53 also reduces
apoptosis induced by many cytotoxic agents; thus, se-
lection for hypoxia-resistant variants may simulta-
neously select for drug-resistant tumors. Perhaps this
explains why many solid tumors, which must over-
come hypoxic stress, are inherently difficult to treat.
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Future Perspectives
S.W. Lowe
Since p53 mutations occur in greater than 50% of hu-
man tumors, the effects of p53 loss on treatment ef-
ficacy may represent a significant obstacle in the
treatment of human malignancy. However, several
rational approaches can be envisioned to overcome
the consequences of p53 loss. Among these are (1)
identifying ways to restore the p53-dependent apo-
ptotic program to p53 mutant cells and (2) identifying
agents that are effective in the absence of p53 func-
tion. Practical application of these concepts will re-
quire a better understanding of p53-dependent and
-independent apoptotic programs. To this end, we
will continue to study the El A oncogene as a model
for understanding the molecular control of apoptosis
in tumor cells. Preliminary studies suggest that apo-
ptosis in El A/ras-transformed cells can be induced
by p53-dependent and -independent pathways, and
the molecular characterization of these pathways is
our primary objective in the coming year.
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COLD SPRING HARBOR 
MEETINGS AND COURSESי
ACADEMIC AFFAIRS
The academic program at Cold Spring Harbor Laboratory comprises a wide-ranging series of postgraduate
laboratory and lecture courses, workshops, large meetings, and a summer research program for un-
dergraduates. The program now extends from a spring session of courses starting early in March through a
fall session of courses ending in November. Thus, the academic year at the Laboratory now lasts as long
as those at universities and colleges around the country. Each year, thousands of students, postdoctoral
fellows, faculty, and staff scientists from around the world come to Cold Spring Harbor to participate in the
various courses and meetings.
Several new courses and meetings were started this year and new facilities were extensively utilized. All
of the neurobiology laboratory courses are now being held in the Howard Hughes Medical Institute (HHMI)
teaching laboratories in the Beckman Neuroscience Center. These spacious and modern laboratories are
now home to 15 molecular biology and neurobiology courses. A new course, Advanced Genome Se-
quence Analysis, was held in March in the HHMI teaching labs and was ably taught by Ellson Chen,
Richard Gibbs, Dick McCombie, and Rick Wilson. This course, which will be held again next year, served
to extend the academic year yet again and filled the teaching labs with large numbers of DNA sequencers
(both human and automated). A new lecture course on brain mapping was taught by John Mazziotta and
Arthur Toga and was held at the Banbury Center, along with the Laboratory's other neurobiology lecture
courses. In all, the Laboratory held 24 courses this year, whose instructors, students, and lecturers are
listed in the following pages.
The success of the courses is due in large part to instructors who work extensively, creatively, and for
extremely long hours during their courses. This year, several scientists who have taught here for at least
five years will be retiring, although we expect them to return to the Laboratory to give seminars and advice
in the future. These include Jim Kadonaga and Dan Marshak, two of the original instructors of the course on
Protein Purification and Characterization; Stan Malloy, Valley Stewart, and Ron Taylor who taught Advanced
Bacterial Genetics; and Mark Learned, an instructor in the Advanced Molecular Cloning course.
The courses are supported by, and would not be possible without, a series of grants from federal and
private sources. The summer molecular genetics courses have been supported for many years by grants
from the National Institutes of Health and the National Science Foundation, and a grant from the National In-
stitute of Mental Health has supported several of the neurobiology courses. However, it has been a large
education grant (renewed again this year) from HHMI that has provided stable support for the neurobiology
program and has allowed the Laboratory to begin to expand its series of spring and fall courses. The
Laboratory also has an award from the Esther and Joseph A. Klingenstein Fund for the support of
neurobiology courses. As has been the case for several years, the Grass Foundation provided funds for
scholarships for students in neurobiology courses. Grants from the Departments of Energy and Agriculture
have also helped in the funding of the courses in Macromolecular Crystallography and Molecular Markers
for Plant Breeding. In addition, the Laboratory receives valuable support from many companies that donate
supplies and lend equipment for the courses.
Although conferences at the Laboratory started with the Symposium some 62 years ago, they have
grown to 15 meetings per year, covering a wide range of topics. This year's Symposium on Protein Kinesis
provided an opportunity for scientists to present their latest work and synthesize ideas in this rapidly
moving area of research. Special highlights of the year included a new meeting on Tyrosine Phosphoryla-
tion and Cell Signaling, organized by Nick Tonks and Ben Neel, as well as a meeting on Molecular
Genetics of Bacteria and Phages which celebrated 50 years of phage at Cold Spring Harbor. This confer-
ence, arranged by Susan Gottesman, Carol Gross, Peter Model, Bill Reznikoff, and Jeff Roberts, brought
together individuals ranging from graduate students to scientists who were instrumental in starting the field
of molecular biology with their research on phage and bacteria.
Other meetings covered a broad array of topics ranging from Eukaryotic DNA Replication to Neurobiol-
ogy of Drosophila. Several of the meetings were in fact heavily subscribed, and Grace Auditorium was filled
to capacity as more than 400 scientists met to discuss their research. These meetings included Genome
Mapping and Sequencing, RNA Processing, Retroviruses, and the Cancer Cells Meeting on Regulationof
Eukaryotic Transcription. The success of the meetings really depends on all of the scientists who serve as
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organizers (listed in the following pages) and on the enthusiastic participation of all of the visiting scientists.
As in past years, support from the Laboratory's Corporate Sponsor Program and from NIH, NSF, and the
Department of Energy was important in helping scientists at all levels of their careers to attend the meet-
ings. Contributors to the various meetings are listed in the pages that follow.
While graduate students, postdoctoral fellows, and faculty participate in the courses and meetings, the
Undergraduate Research Program (URP) provides an opportunity for college undergraduates to spend 10
weeks at the Laboratory during the summer. The program, headed by Winship Herr, allows students to do
research in the laboratories of staff scientists.
The large numbers of courses and meetings proceed with skill and efficiency, thanks to the collabora-
tive efforts of a large number of people at the Laboratory. The staff of the Meetings Office, headed by David
Stewart, Director of Meetings and Courses, coordinates the arrangements for all of the visiting scientists.
This enormous job, which seems to grow every year, is carried out not only extremely efficiently, but most
pleasantly as well. The staff, including Micki McBride, the Course Registrar, Diane Tighe, Marge Stel-
labotte, Andrea Stephenson, Nancy Weeks, Jim Koziol, Drew Mendelson, and Lesley Cook, as well as staff
from several other departments, are crucial to the success of the meetings and courses. These include
Herb Parsons, Ed Campodonico, and the audiovisual staff; Cliff Sutkevich and his staff who set up and
maintain course equipment; Edie Kappenberg, the course coordinator; Mary Horton of the Grants Office;
and Lee Martin of Cold Spring Harbor Laboratory Press.
Terri Grodzicker
Ira Herskowitz entertaining Symposium participants in Grace Auditorium.
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60th COLD SPRING HARBOR SYMPOSIUM
ON QUANTITATIVE BIOLOGY
Protein Kinesis: The Dynamics of Protein Trafficking and Stability
May 31-June 7 389 participants
ARRANGED BY Bruce Stillman, Cold Spring Harbor Laboratory
The way individual cells look and function follows directly from the program of cell-type-dependent
gene expression and the nature of the proteins that are expressed. Once synthesized, however,
the proteins themselves take on a life of their own that is determined by their amino acid sequence
and their environment. Proteins have varied life times, cellular locations and interactions with other
proteins, or cellular structures such as membranes, each of which can influence cell physiology
directly. Thus, the life of proteins in the cell is an important topic that has deserved much attention.
At the last Symposium that dealt with these issues, in 1981, the focus was on the structure of the
cytoskeleton and general observations of protein trafficking within the cell, such as cell surface
polarity and axonal transport. The science was dominated by microscopy and was primarily ob-
servational. The field was crying out for an influx of biochemistry and genetics to present a more
detailed understanding of the mechanisms of protein stability, movement, and organization.
With remarkable results, the biochemists and geneticists heeded the call. During the last 14
years, we have witnessed a dramatic increase in knowledge about the mechanisms of protein
movement within the cell. It was therefore prime time to dedicate the topic of the Symposium to the
dynamic aspects of protein function. The title "Protein Kinesis" was invented to reflect the many
aspects of protein modification, trafficking, stability, localization, and organization. Knowledge of
the mechanisms of protein transport either through the endoplasmic reticulum and golgi to the cell
surface or into the nucleus has progressed rapidly in recent years. The understanding is sufficient
that we can now begin to appreciate links between these processes in different cell types and un-
derstand how protein kinesis influences human disease processes, a topic that will dominate fu-
ture discussion and directions.
The program was arranged with the generous help of Gunter Blobel, Jim
Rothman, Randy Schekman, Mary-Jane Gething, Susan Gottesman, Ulrich Hartl,
Ira Melman, and Ron Laskey. The formal program consisted of 87 talks and 189
poster presentations, and the meeting attracted a total of 389 participants. This
year also saw the inaugural Reginald G. Harris Lecture, given by Randy Schek-
man. When Director of the Biological Laboratories at Cold Spring Harbor, Regin-
ald Harris started the Symposia in 1933 to foster a quantitative approach to biol-
ogy and promote interactions between scientists from diverse fields. The mod-
ern day success of these meetings stems directly from his foresight. Indeed,
many Symposia have profoundly influenced the future of biology in general.
Essential funds that supported this meeting were obtained from the U.S. De-
partment of Energy and the National Institutes of Health. Additional support
came from our ever more important and needed Corporate Sponsors: American
Cyanamid Company; Amgen Inc.; BASF Bioresearch Corporation; Beckman In-
struments, Inc.; Becton Dickinson and Company; Bristol-Myers Squibb Compa-
ny; Chugai Pharmaceutical Co., Ltd.; Chugai Research Institute for Molecular
Medicine, Inc.; Diagnostic Products Corporation; The DuPont Merck
Pharmaceutical Company; Forest Laboratories, Inc.; Genentech, Inc.; Glaxo;
Hoffmann-La Roche Inc.; Human Genome Sciences, Inc.; Johnson & Johnson;
Kyowa Hakko Kogyo Co., Ltd.; Life Technologies, Inc.; Marion Merrell Dow Inc.;
202
J. Beckwith
G. Blobel G. Pa lade, B. Stillman W. Neupert
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Mitsubishi Kasei Institute of Life Sciences; Monsanto Company; New England BioLabs, Inc.; On-
cogene Science, Inc.; Pall Corporation; The Perkin-Elmer Corporation; Pfizer Inc.; Research
Genetics, Inc.; Sandoz Research Institute; Schering-Plough Corporation; SmithKline Beecham
Pharmaceuticals; Sumitomo Pharmaceuticals Co., Ltd.; The Upjohn Company; The Wellcome Re-
search Laboratories, Burroughs Wellcome Co.; Wyeth-Ayerst Research; Zeneca Group PLC.
PROGRAM
Welcoming Remarks: Bruce Stillman
Introduction
Chairperson: D. Sabatini, New York University School of
Medicine
Protein Folding and Modification in the ER
Chairperson: H. Pelham, Medical Research Council,
Cambridge, United Kingdom
Reginald G. Harris Lecture: 'Protein Sorting and Vesicle
Budding from the ER"
Speaker: R. Schekman, Howard Hughes Medical Institute,
Berkeley, California
Protein Trafficking
Chairperson: A. Helenius, Yale University School of
Medicine
Protein Trafficking at the Synapse
Chairperson: K. Simons, European Molecular Biology
Laboratory, Heidelberg, Germany
Later Stages of Protein Trafficking
Chairperson: T. SOdhof, University of Texas Southwestern
Medical Center
Protein Translocation and Folding
Chairperson: S. Gottesman, NCI, National Institutes of
Health
Protein Degradation
Chairperson: M.-J. Gething, University of Melbourne,
Australia
Protein Trafficking at the Cell Surface
Chairperson: M. Farquhar, University of California, San
Diego
Peptide and Protein Translocation
Chairperson: I. Mellman, Yale University School of
Medicine
Dorcas Cummings Lecture: 'How Proteins Find Their
Addresses in the Cell'
Speaker: Gunter Blobel, Howard Hughes Medical
Institute, Rockefeller University
Polarity
Chairperson: J. White, University of Virginia,
Charlottesville
Nuclear Trafficking
Chairperson: G. Schatz, Biozentrum, University of Basel,
Switzerland
Membrane Dynamics
Chairperson: S.L. Schmid, Scripps Research Institute,
La Jolla, California
Protein Import into Organelles
Chairperson: J. Beckwith, Harvard Medical School
Molecular Motors
Chairperson: B. Stillman, Cold Spring Harbor Laboratory
Summary: George Palade, University of California, San
Diego
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MEETINGS
Molecular and Behavioral Biology of Aplysia and Related Molluscs
April 19-April 23 90 participants
ARRANGED BY Leonard Kaczmarek, Yale University School of Medicine
Eric Kandel, Columbia University College of Physicians & Surgeons
Richard Scheller, Stanford University and Howard Hughes Medical Institute
This fourth international meeting continued the trend of including presentations on data gleaned
from work with identifiable neurons of Aplysia, Squid, and Lymnaea, as well as with some
crustacean and annelid preparations. For the neurobiologist, the major advantage to using these
preparations is the large size of their somata, which allows intracellular injection of enzymes and
other reagents to probe synaptic transmission and other aspects of neuronal plasticity. This feature
has allowed workers to gain numerous insights into the mechanisms of exocytosis of synaptic
vesicles. In addition, the fact that the nerve cells of these animals are readily identifiable from prep-
aration to preparation allows them to be used to determine the changes that occur in neuronal
properties during learning and other prolonged changes in animal behavior.
This meeting was funded in part by the National Institute of Neurological Disorders and Stroke,
a division of the National Institutes of Health, and the National Science Foundation.
PROGRAM
Plenary Lecture
Chairperson: R. Jahn, Yale University, New Haven,
Connecticut
Synaptic Transmission
Chairperson: J. Kehoe, Ecole Normale Superieure, Paris,
France
Modulation of Excitability and Synaptic Transmission
Chairperson: H. Gerschenfeld, Ecole Normale Superieure,
Paris, France
Neuronal Circuitry and Behavior I
Chairperson: W. Geraerts, Vrije Universiteit, Amsterdam,
The Netherlands
Peptides and Other Neurotransmitters
Chairperson: P. Haydon, Iowa State University
Neuronal Circuitry and Behavior II
Chairperson: P. Benjamin, University of Sussex, United
Kingdom
Development
Chairperson: R. Scheller, Stanford University, Howard
Hughes Medical Institute
Database Meeting
Learning
Chairperson: E. Mayeri, University of California, San
Francisco
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The Cytoskeleton and Cell Function
April 26-April 30 214 participants
ARRANGED BY David Heitman, Cold Spring Harbor Laboratory
Elizabeth Raff, Indiana University
The Cytoskeleton and Cell Function meeting brought together scientists working on the cytos-
keleton in invertebrate and vertegrate systems. Although much information is now available con-
cerning the structural and molecular bases for the various cytoskeletal components, it is only
recently that the function and regulation of these components in cellular processes is beginning
to be understood. The meeting highlighted topics in actin filament assembly and dynamics, cell
motility, microtubule assembly and dynamics, cell division, intermediate filaments, molecular
motors, intracellular trafficking, signal transduction, membrane-cytoskeleton interactions, and
development and differentiation. Various experimental approaches were presented, including
biochemistry, genetics, and molecular biology. The sessions encompassed the most recent ad-
vances in the field and made for an intense and stimulating exchange of information. Another
meeting is planned for 1997.
This meeting was funded in part by the March of Dimes Birth Defects Foundation; The Coun-
cil for Tobacco Research-U.S.A., Inc.; Department of the Navy, Office of Naval Research; and
the National Science Foundation.
PROGRAM
Role of the Cytoskeleton in Development and Differentiation
Chairperson: L. Cooley, Yale University Medical School
Actin Filament Assembly and Dynamics
Chairperson: P.A. Rubenstein, University of Iowa College of
Medicine
Microtubule Assembly and Dynamics
Chairperson: E.C. Raff, Indiana University
Molecular Motors
Chairperson: M. Porter, University of Minnesota Medical
School
Cell Division
Chairperson: J.R. McIntosh, University of Colorado, Boulder
Motile Systems
Chairperson: G.M. Langford, Dartmouth College
Cytoskeletal Dynamics
Chairperson: U. Aebi, University of Basel, Switzerland
Signal Transduction: Membrane-Cytoskeleton Interactions
Chairperson: B. Geiger, Weizmann Institute of Science,
Rehovot, Israel
'11
C. Nokes, A. Weeds L. Tilney, M. Tilney
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Tyrosine Phosphorylation and Cell Signaling
May 3-May 7 338 participants
ARRANGED BY Nick Tonks, Cold Spring Harbor Laboratory
Ben Neel, Beth Israel Hospital
This was the first meeting on "Tyrosine Phosphorylation and Cell Signaling" at Cold Spring Har-
bor and it marked the fifteenth anniversary of the discovery of tyrosine phosphorylation by Tony
Hunter, Bart Sefton, and colleagues. As such, it was particularly appropriate that Tony Hunter
opened the meeting with a keynote address providing an overview of historical perspective, cur-
rent progress, and future directions in the field. The format of the meeting provided a combined
emphasis on the physiological roles of protein tyrosine kinases and phosphatases and how their
actions are integrated to modulate signaling events in vivo. The sessions were based around
physiological processes and cellular functions, rather than around particular categories of en-
zymes, so as to try to provide biological context to the data. The program included scientists
from the United States, Europe, Far East, and South Pacific. Sixty three speakers presented their
data in sessions that dealt with receptor protein tyrosine kinase signaling, cytokine-induced sig-
naling, the cytoskeleton, signaling in lymphocytes, cell cycle and development, neuronal signal-
ing and tyrosine phosphorylation and disease. A variety of systems were described with great
progress reported in genetic and biochemical approaches to the characterization of physiologi-
cal functions for tyrosine phosphorylation. The meeting was so successful that Tony Hunter and
Bart Sefton have decided to organize a conference with the same format at The Salk Institute in
1996, with the aim of continuing with an annual meeting on "Tyrosine Phosphorylation" that
alternates in venue between Cold Spring Harbor and The Salk.
This meeting was funded in part by the National Institute of Diabetes and Digestive and Kid-
ney Diseases, National Cancer Institute, National Institute of General Medical Sciences (all divi-
sions of the National Institutes of Health), and the National Science Foundation.
PROGRAM
Keynote Address: Tony Hunter, Salk Institute
Receptor PTK Signaling I
Chairperson: J. Brugge, Ariad Pharmaceuticals, Cambridge,
Massachusetts
Cytokine Signaling
Chairperson: B. Neel, Harvard Medical School, Boston,
Massachusetts
Cytoskeleton
Chairperson: T. Parsons, University of Virginia,
Charlottesville
Lymphocyte Signaling
Chairperson: M. Thomas, Washington University, St. Louis,
Missouri
Cell Cycle and Development-
Chairperson: H. Piwnica-Worms, Washington University, St.
Louis, Missouri
Neuronal Signaling
Chairperson: M. Greenberg, Harvard Medical School,
Boston, Massachusetts
Tyrosine Phosphorylation and Disease
Chairperson: A.M. Pendergast, Duke University Medical
Center, Durham, North Carolina
Receptor PTK Signaling II
Chairperson: S. Courtneidge, EMBL, Heidelberg, Germany
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Genome Mapping and Sequencing
May 10-May 14 452 participants
ARRANGED BY David Bentley, Sanger Centre
Eric Green, National Institutes of Health
Robert Waterston, Washington University
More than 300 abstracts were presented at this eighth annual meeting, which covered a broad
array of topics related to genome analysis of a number of organisms. The major advances in the
field of genome analysis prompted the establishment of new approaches for presenting the
wealth of incoming data and information at the meeting. For example, a poster symposium was
once again held, in this case as the format for presenting the large amount of data being gener-
ated in the construction of physical maps of human chromosomes. This session included a high-
ly interactive open forum among the presenters and meeting attendees that addressed a num-
ber of key issues relevant to the completion of human chromosome maps and the initiation of
large-scale sequencing of the human genome. The rapidly expanding field of computational
genomics creates a challenge in terms of devising meaningful ways of presenting the latest de-
velopments. New to this year's meeting was the use of projection-style computer demonstrations
in Grace Auditorium (presented each afternoon), which allowed a highly interactive forum for
learning about the informatics tools being developed for genome research.
Another major highlight of the meeting was the keynote session, where Maynard Olson and
John Sulston summarized key aspects of genome mapping and sequencing, respectively.
These talks focused on the central issues related to the construction of high-resolution physical
maps of human DNA and the initiation of large-scale sequencing. These keynote talks, which
were new to the 1995 meeting, were an excellent addition to the meeting and stimulated many
further discussions among the attendees.
The overall tone of the meeting was highly optimistic. There seemed to be general con-
sensus that the DNA sequences of a number of model organisms are nearing completion, that
efforts to complete the physical maps of human and mouse chromosomes are on track, and that
the time has arrived to initiate efforts to sequence the human genome. This meeting was funded
in part by the National Center for Human Genome Research, a division of the National Institutes
of Health. Additional support was provided by QuantumSoft, a division of General Atomics.
tqa
First interactive computer demonstration in Grace Auditorium.
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PROGRAM
Gene Discovery and Transcript Mapping
Chairpersons: R. Gibbs, Baylor College of Medicine;
B. Soares, Columbia University
Mapping Methods and Technologies
Chairpersons: E. Green, National Institutes of Health;
C. Huxley, St. Mary's Hospital
Computer Demonstrations I
Moderator: T. Marr, Cold Spring Harbor Laboratory
Informatics
Chairpersons: M. Boehnke, University of Michigan;
M. Boguski, National Institutes of Health
Human Chromosome Mapping Poster Symposium
Chairpersons: D. Page, Whitehead Institution; B. Trask,
University of Washington
Computer Demonstrations II
Moderator: M. Boehnke, University of Michigan
ELSI Panel Discussion
Moderator: N. Wexler, Columbia University
Presentations: Lori Andrews, Chicago-Kent College of Law
RNA Processing
Genetic Privacy
Neil Holtzman, Johns Hopkins University, Transition of
Testing from Research to Practice
Troy Duster, University of California, Berkeley Role of
Bench Scientists in the Exploration of ELSI Issues
DNA Sequencing
Chairpersons: D. Bentley, Sanger Centre; R. Wilson,
Washington University
Model Organisms: Mapping and Biology
Chairpersons: S. Brown, St. Mary's Hospital; P. Hieter,
Johns Hopkins University
Computer Demonstrations Ill
Moderator: M. Boguski, National Institutes of Health
Keynote Addresses
Speakers: Maynard Olson, University of Washington; John
Sulston, Sanger Centre
Human Genetics and Biology
Chairpersons: V. van Heyningen, MRC Human Genetics
Unit, R. Waterston, Washington University
May 17-May 21 449 participants
ARRANGED BY Brenda Bass, University of Utah School of Medicine
lain Mattaj, EMBL, Germany
Michael Rosbash, Brandeis University and Howard Hughes Medical Institute
Jo Ann Wise, Case Western Reserve University
Exciting developments in several major areas of pre-mRNA splicing research were reported.
First, protein factors that promote the transition between pre-splicing complexes and the mature
spliceosome were discussed, including several new interactions involving the heterotrimeric U2
snRNP protein complex. A second focus of attention was the chemical requirements for splicing,
with the identification of conditions under which synthetic half-introns react in trans. This ap-
proach represents a powerful new route to unraveling the contributions of individual functional
groups. Third, there were several reports of the dynamic rearrangements involving small nuclear
RNAs and their RNA or protein partners. Of particular interest was evidence that the excision of
a new class of introns is mechanistically similar to the splicing of standard introns, but it involves
a distinct set of snRNAs.
Recent research in the editing field suggests that a dsRNA adenosine deaminase is
responsible for editing glutamate receptor mRNAs as well as the hepatitis delta virus
antigenome. However, it is not known whether the dsRNA adenosine deaminase previously
purified from mammals and frogs is the enzyme responsible for these editing events. Nor is it
known how many additional factors may be required for editing in vivo.
Significant advances in 3 ' -end formation included an electron microscopic analysis of
poly(A) binding protein (PABII) binding to poly(A) tails. Consistent with the idea that the number
of PABII molecules in a polyadenylation complex determines poly(A) length, electron micro-
graphs showed PABII forming spherical oligomeric particles that protect -260 adenine residues,
a length corresponding to that of newly synthesized poly(A) tails in vivo.
The beginnings of a definition of an RNA export pathway from the nucleus are emerging with
the report of a cellular RNA-binding factor directly involved in RNA export. Also, there were the
reports of signals in cellular and viral proteins implicated in RNA export. The viral protein was
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also reported to interact with a protein resembling a nucleoporin. Taken together, these observa-
tions suggest an outline for some of the interactions required to move an RNA out of the nucleus.
The analogy between snRNAs and pre-mRNA splicing on the one hand and snoRNAs and
pre-rRNA processing on the other was extended with the demonstration that base-pairing be-
tween two snoRNAs and the pre-rRNA is required for its processing. The number of different
snoRNAs encoded in pre-mRNAs continues to rise. The fact that some of them are proposed to
pair with important segments of mature rRNA predicts that these snoRNAs may not function to
promote specific cleavage/processing steps but to prevent RNA misfolding during ribosome as-
sembly.
The meeting concluded on Sunday morning with a session on RNA catalysis. Studies of
ribozymes currently involve an emphasis on the tertiary interactions and conformational changes
that appear required for certain catalytic events. Similar to protein enzymes, ribozymes achieve
catalysis through substrate destabilization as well binding interactions that provide entropic fixa-
tion. There was also the exciting development of an in vitro system that reconstitutes the initial
steps of intron mobility.
This meeting was funded in part by the National Science Foundation.
PROGRAM
Modification, Editing, and 3' End Formation
Chairperson: S.L. Hajduk, University of Alabama,
Birmingham
Mechanisms of Splicing
Chairperson: R. Reed, Harvard Medical School, Boston,
Massachusetts
Workshop I: Straight Talk from NIH-Review of Postdoctoral
Fellowships
Dr. Camilla Day, Scientific Review, National Institutes of
Health
Transport, Localization, and Turnover
Chairperson: G. Dreyfuss, University of Pennsylvania School
of Medicine, Philadelphia
Regulation of Splicing
Chairperson: P. Grabowski, University of Pittsburgh,
Pennsylvania
Workshop II: Straight Talk from NIH-R01/R29 Navigation
Basics
Dr. Camilla Day, Scientific Review, National Institutes of
Health
RNA Structure and RNA-Protein Interactions
Chairperson: E. Wahle, University of Basel, Switzerland
Stable RNAs AND RNPs
Chairperson: D. Tollervey, EMBL, Heidelberg, Germany
RNA Catalysis
Chaff person: A.M. Pyle, Columbia University, New York,
New York
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Retroviruses
May 23-May 28 436 participants
ARRANGED BY Hung Fan, University of California, Irvine
Alan Rein, National Cancer Institute-Frederick Cancer Research Facility
This year's Retroviruses meeting covered many aspects of the replication of retroviruses and the
mechanisms by which they cause disease in animals and man. One particularly important fea-
ture of the meeting is the interchange of information between researchers studying human
retroviruses and those studying animal retroviruses.
Significant advances were reported in areas ranging from the three-dimensional molecular
structure of viral proteins to the natural history of the AIDS virus in high-risk human populations.
In particular, an X-ray crystallographic analysis of integrase, an essential enzyme in retrovirus
replication, was reported for HIV-1, the causative agent of AIDS, and also for an avian retrovirus.
This information should prove invaluable in the design of new classes of antiviral drugs. Other
studies gave rise to new insights as to the mechanism by which HIV-1 and other retroviruses ex-
port some mRNA molecules to their cytoplasm without splicing, in contrast to the majority of cel-
lular mRNAs. Several laboratories reported important advances in the experimental study of as-
sembly of viral particles, including the apparent reproduction of this phenomenon in the test
tube. Finally, a virus from a previously unknown retrovirus family has been isolated from fish.
Contributions from the Corporate Sponsors provided core support for this meeting.
PROGRAM
Pathogenesis
Chairpersons: J. Overbaugh, University of Washington,
Seattle; K. Radke, University of California, Davis
Envelope/Receptors
Chairpersons: W.F. Anderson, University of Southern
California, Los Angeles; P. Bates, University of
Pennsylvania, Philadelphia
Reverse Transcriptase and Reverse Transcription
Chairpersons: S. LeGrice, Case Western Reserve University
J. Levin, NICHD, National Institutes of Health
Nuclear Import/Integration/Integrase
Chairpersons: F. Bushman, Salk Institute for Biological
Studies; D. Grandgenett, St. Louis University Medical
Center
Transcription/Tat/Tax
Chairpersons: K. Conklin, University of Minnesota,
Minneapolis; N. Hernandez, Cold Spring Harbor
Laboratory
J. Coffin, J. Staye
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Posttranscriptional Events/Rev/Rex
Chairpersons: K. Beemon, Johns Hopkins University M.-L.
Hammarskjold, University of Virginia, Charlottesville
Potpourri
Chairpersons: J. Dudley, University of Texas, Austin; J.
Luban, Columbia University, New York
Assembly I
Chairpersons: E. Barklis, Oregon Health Sciences
Yeast Cell Biology
University, Portland; J. Wills, Pennsylvania State
University, Hershey
Assembly II/Antivirals
Chairpersons: H. Gott linger, Dana-Farber Cancer Institute;
K.-T. Jeang, NIAID, National Institutes of Health
Other Accessory Genes
Chairpersons: N. Landau, Aaron Diamond AIDS Research
Center, D. Trono, Salk Institute for Biological Studies
August 15-August 20 383 participants
ARRANGED BY Trisha Davis, University of Washington
Mark Rose, Princeton University
Tom Stevens, University of Oregon
The conference on Yeast Cell Biology was the fifth biannual international meeting devoted to
major aspects of cell biology in yeast. This conference is unique in that the study of all major
areas of cell biology are integrated in a single simple eukaryotic organism, Saccharomyces
cerevisiae. A common interest in one organism allowed for extensive cross-fertilization of ideas
and methodologies. Important insights were further gained by studies in the fission yeast
Schizosaccharomyces pombe as well as other yeasts. The impending completion of the se-
quencing of the Saccharomyces genome had a profound impact on the conference, greatly fa-
cilitating the identification of genes identified by their effects on critical cellular processes. One
major area of interest included the functions of the actin cytoskeleton particularly with respect to
cell polarity and organelle movement. A second area that was extensively described concerned
the roles of microtubules and associated proteins and organizing structures in chromosome and
nuclear movement. Third was targeting and sorting of proteins in the secretory, endocytotic and
nuclear localization pathways.
One major discovery, described at the meeting, was the critical role of ubiquitination in the
endocytosis of cell surface proteins and their eventual degradation by vacuolar, and not
proteasomal, hydrolases. The integrated control of these various processes was described in
several sessions devoted to the cell cycle, global regulatory networks, ion transport and signal-
ing, and mating pathways. All in all it was a very exciting meeting with 383 scientists in at-
tendance. Some 295 abstracts were presented, including 115 talks and 180 posters.
This meeting was funded in part by Anheuser-Busch Companies, Inc.
T. Davis J. Becker, J. Warner, T. Fox M. Rose
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PROGRAM
The Actin Cytoskeleton and Cell Polarity
Chairperson: A. Bretscher, Cornell University
Mating Pathways and Sporulation
Chairperson: J. Thorner, University of California, Berkeley
Endocytosis and Protein Sorting
Chairperson: M. Cyert, Stanford University
Ions, Signaling, and Cell Wall
Chairperson: F. Solomon, Massachusetts Institute of
Technology
Microtubules, Centromeres, Chromosome Segregation and
Genome
Chairperson: D. Botstein, Stanford University
Functions of the Nuclear Envelope: Microtubule Organization
and Nuclear Transport
Chairperson: J. Warner, Albert Einstein College of Medicine
Protein Folding/Degradation and Organelle Biogenesis
Chairperson: E. Jones, Carnegie Mellon University
Secretion
Chairperson: J.A. Wise, Case Western Reserve University
Global Regulatory Networks
Chairperson: J. Woolford, Carnegie Mellon University
Cell Cycle
Chairperson: D. Levin, Johns Hopkins University
Molecular Genetics of Bacteria and Phages
August 22-August 27 391 participants
ARRANGED BY Susan Gottesman, National Cancer Institute, National Institutes of Health
Carol Gross, University of California, San Francisco
Peter Model, Rockefeller University
William Resznikoff, University of Wisconsin, Madison
Jeff Roberts, Cornell University
This year's meeting on Molecular Genetics of Bacteria and Phages celebrated the roots of mod-
ern molecular biology and a long tradition of scientific discussion and experimentation on bac-
teriophage at Cold Spring Harbor-50 years since the first phage course in 1945, and nearly as
long since the first CSH phage meeting. In addition to the presentation of over 300 abstracts in
posters and short talks, each session was introduced by a scientist who has played an important
part in the development of the field. A special historic session allowed longer talks by particular
luminaries; Francois Jacob, Seymour Benzer, Frank Stahl, Gunther Stent, Rollin Hotchkiss, and
Manny Delbruck. The subjects of these perspectives ranged from Evelyn Witkin's reminiscences
of life at Cold Spring Harbor in 1945 to Frank Stahl's reconsideration of Edgar's discovery of am-
ber suppressors in phage T4. Scientific sessions featured the customary summary of exciting
progress in microbial molecular biology and two sessions on bacterial genome sequencing and
analysis. The result was an exciting meeting that gave new generations of scientists a living in-
troduction to the intellectual roots of molecular biology, and also celebrated the personalities
and styles of the founders of the science.
This meeting was funded in part by National Institute of General Medical Sciences, National
Science Foundation, U.S. Department of Energy, Genetics Computer Group, Inc., and Promega
Corporation.
PROGRAM
Replication, Recombination, and Mutagenesis
Historical Introduction: G. Mosig, Vanderbilt University
Chairperson: M. Lieb, University of Southern California
Medical School
RNA Polymerase
Historical Introduction: P. Geiduschek, University of
California, San Diego
Chairperson: L. Rothman-Denes, University of Chicago,
Illinois
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Transcription Activation
Historical Introduction: B. Magasanik, Massachusetts In-
stitute of Technology
Chairperson: A. Ullmann, Institut Pasteur
The Bacterial Genome
Historical Introduction: W. Szybalski, University of Wisconsin
Medical School
Chairperson: J. Roth, University of Utah
R. Hotchkiss, W. Szybalski S. Benzer
G. Stent F. Jacob, J.D. Watson
E. Witkin J. Roberts, W. Resznikoff
Genome Software and Database Workshop
Chairperson: M. Berlyn, Yale University
Panel Discussion: "Community Needs, Interconnectivity, and
Cooperative Efforts
Phage and Cell Surfaces
Historical Introduction: N. Zinder, Rockefeller University
Chairperson: M. Yarmolinsky, National Institutes of Health
DNA Structure
Historical Introduction: A. Campbell, Stanford University
Chairperson: N. Kleckner, Harvard University
Panel Discussion: Microbial Molecular Genetics-Past,
Present, and Future
Panel: D. Botstein, J. Beckwith, J. Roth, L. Rothman-Denes
Global Control
Historical Introduction: E. Witkin, Rutgers University
Chairperson: T. Silhavy, Princeton University
S. Gottesman
Posttranscriptional Control
Historical Introduction: D. Kaiser, Stanford University
Chairperson: J. Beckwith, Harvard Medical School
Elongation, Termination, and Antitermination
Historical Introduction: C. Yanofsky, Stanford University
Chairperson: J. Miller, University of California, Los Angeles
Historic Session: Reflections on Fifty Years of Phage Re-
search In and Out of Cold Spring Harbor
Chairperson: J.D. Watson, Cold Spring Harbor Laboratory
Speakers
R. Hotchkiss, Rockefeller University
S. Benzer, California Institute of Technology
F. Jacob, Pasteur Institute
F.W. Stahl, Institute of Molecular Biology, University of
Oregon
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Mechanisms of Eukaryotic Transcription
August 30-September 3 432 participants
ARRANGED BY Winship Herr, Cold Spring Harbor Laboratory
Robert Tjian, University of California, Berkeley
Keith Yamamoto, University of California, San Francisco
The 1995 Cancer Cells meeting, Mechanisms of Eukaryotic Transcription, was the fourth biennial
meeting devoted to mechanisms of transcriptional regulation in eukaryotes. This conference,
which benefits from the commonality of transcriptional regulatory mechanisms in eukaryotic
species, attracted scientists from around the world studying transcription in species as diverse
as yeast, plants, and invertebrate and vertebrate animals. Although there are many common
mechanistic themes, the diversity of approaches to uncover these mechanisms is great, includ-
ing structural biology, molecular genetics, biochemistry, and cellular biology. Important ad-
vances in our understanding of transcriptional regulation were presented, including the structure
of the core region of the basal transcription factor TFIIB either alone or in complex with TBP and
DNA; the roles of chromatin in transcriptional regulation; the relationship of the mammalian
elongation factor elongin and the Von Hippel-Lindau tumor suppressor protein; detailed topo-
graphical studies of the regions of TBP important for interaction with RNA polymerase and other
basal factors; and the structure of the alia2 regulatory complex to list only a few. The meeting
was elegantly summarized by Steven McKnight. The meeting was funded in part by National In-
stitute of General Medical Sciences and National Institute of Child Health and Human Develop-
ment, both branches of National Institutes of Health.
PROGRAM
Basal Promoter Apparatus
Chairperson: N. Hernandez, Cold Spring Harbor Laboratory
Regulation of RNA Polymerase Activity
Chairperson: T. Maniatis, Harvard University
Coupling of Activators and the Initiation Machinery
Chairperson: R. Roeder, Rockefeller University
Induction and Repression
Chairperson: B. Graves, University of Utah
Higher Order Template Structure and Function
Chairperson: E. O'Shea, University of California, San
Francisco
Site-specific Regulatory Complexes
Chairperson: A. Berk, University of California, Los Angeles
Noncovalent Modulation of Transcription Factors
Chairperson: M. Ptashne, Harvard University
Covalent Modification of Transcription Factors
Chairperson: M. Levine, University of California, San Diego
R. Ebright, K. Yamamoto
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Eukaryotic DNA Replication
September 6-September 10 349 participants
ARRANGED BY Thomas Kelly, Johns Hopkins University School of Medicine
Bruce Stillman, Cold Spring Harbor Laboratory
This was the fifth biannual meeting on Eukaryotic DNA Replication held at Cold Spring Harbor
Laboratory. The field of eukaryotic DNA replication is undergoing a renaissance, and this has
become the premier meeting on this subject. Particularly obvious at this meeting was the strong
focus on the mechanisms of initiation of cellular DNA replication and the links between this pro-
cess and the control of the cell cycle. These also were the beginnings of studies on the identi-
fication of the DNA sequences that determine the initiation of DNA replication in vertebrate cells,
including human, and the identification of the proteins that potentially interact with these se-
quences. A mainstay of the field has been the study of the replication of viral genomes, and this
year significant progress was reported in this area. Equally important was the characterization of
chromosomal elements such as telomeres and the enzyme telomerase that maintains the in-
tegrity of the chromosome ends. A potentially interesting link of this enzyme to cancer progres-
sion was discussed. The meeting saw a record 349 participants and 262 presented abstracts.
This reflects the strength of the meeting and the interest in this field at the moment.
Essential funding, increasingly to support Graduate Students, was from the National Institute
of Child Health and Human Development, the National Institute of General Medical Sciences,
and the National Cancer Institute (all within the National Institutes of Health), as well as from the
National Science Foundation.
PROGRAM
Initiation of Cellular DNA Replication
Chairperson: S. Gerbi, Brown University
Replication Proteins
Chairperson: M. Wold, University of Iowa
Telomeres and Repair
Chairperson: C. Newton, UMD-New Jersey Medical
School
Control of DNA Replication
Chairperson: J. Li, University of California, San Francisco
Chromosome Replication
Chairperson: U. HQbscher, University of ZOrich, Switzerland
Regulation
Chairperson: J. Hamlin, University of Virginia School of
Medicine, Charlottesville
Replication Protein Mechanisms
Chairperson: P. Burgers, Washington University, St. Louis
Viruses and Organelles
Chairperson: S. Weller, University of Connecticut Health
Center, Farmington
R. Laskey C. Newlon, J. Campbell, E. Fanning
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Molecular Approaches to the Control of Infectious Diseases
September 13-September 17 160 participants
ARRANGED BY Fred Brown, USDA, Plum Island Animal Disease Center
Dennis Burton, Scripps Research Institute
John Mekalanos, Harvard Medical School
Er ling Norrby, Karolinska Institute, Sweden
The annual meeting on Molecular Approaches to the Control of Infectious Diseases highlighted
recent developments in a number of related areas. Infectious disease has once more become a
major health concern. AIDS is now the prime cause of death in the 25-44 year old age group in
the United States, Lyme disease is widespread, new viruses such as the Sin Nombre hanta virus
have emerged, older viruses such as Ebola have re-emerged, and antibiotic-resistant bacteria
are seen ever more frequently. The challenge to basic and more applied science is being taken
up vigorously as shown at this meeting.
There is ever-increasing awareness of the importance of both humoral and cellular
responses to many pathogens. A session on immunity to viruses revealed some of the essential
features of immune memory in the T-cell compartment. This theme was complemented in a ses-
sion on HIV which suggested that long-term progression in some HIV-seropositive individuals
was associated with strong cytotoxic T cell response to the virus. A session on antibodies was
focused on the generation, in vitro evolution, and evaluation of recombinant antibodies using
phage display technology. Recombinant human antibodies are close to immunoprophylactic
evaluation in the clinic. Structural studies revealed the interaction of antibodies with rhinovirus at
the molecular level. Vaccination with naked DNA has seen such an explosion of activity since its
first presentation at this meeting in 1992 that two sessions were devoted to the approach. As
feasibility has been established, several groups are now searching for understanding. Individual
sessions were devoted to bacterial and parasite vaccines. Ingenious strategies were described
in both areas which could have major impact.
Many important infections take place via mucosal surfaces and several papers described
studies on mucosal immunity and the generation of vaccines designed to elicit mucosal im-
munity. Increasingly, the similarities between primary isolates of HIV and SIV are appreciated
and a vigorous session dealt with vaccine protection against SIV and its implications for HIV.
The full spectrum of infectious disease was covered with papers on the prion protein, the puta-
tive agent of diseases of protein conformation. This meeting was funded in part by American
Cyanamid Company and Pharmacia LKB Biotechnology.
B. Stillman, W. Bess ler, P. Doherty
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R. Chanock, H. Sabin L. Babiuk, E. Norrby
PROGRAM
Immunity and Viruses
Chairperson: P.C. Doherty, St. Jude Children's Research
Hospital
DNA Immunization I
Chairperson: L.A. Babiuk, Veterinary Infectious Disease
Organization, Saskatoon, Canada
DNA Immunization II
Chairperson: F. Brown, USDA, Plum Island Animal Disease
Center
Bacterial Vaccines
Chairperson: J.J. Mekalanos, Harvard Medical School
Recombinant Antibodies
Chairperson: C.F. Barbas III, Scripps Research Institute
Keynote Speaker: T. Smith: Antigen-Antibody Interactions
Mucosal Immunity and Delivery Systems
Chairperson: J.R. McGhee, University of Alabama,
Birmingham
SIV
Chairperson: R. Desrosiers, New England Regional Primate
Research Center, Harvard Medical School
Programmed Cell Death
Parasite Vaccines
Chairperson: R.S. Nussenzweig, New York University
Medical Center
HIV
Chairperson: B.D. Walker, Massachusetts General Hospital
and Harvard Medical School
Albert B. Sabin Vaccine Foundation Award Ceremony and
Memorial Lecture
Welcoming Remarks: Dr. James D. Watson, Cold Spring
Harbor Laboratory
Award Ceremony
Mr. H.R. Shepherd, Albert B. Sabin Vaccine Foundation; Dr.
P.K. Russell, Albert B. Sabin Vaccine Foundation; Mrs.
Heloisa Sabin
1995 Albert B. Sabin Memorial Lecture
Dr. Robert M. Channock, NIAID, National Institutes of Health
Closing Remarks: Dr. James D. Watson, Cold Spring Harbor
Laboratory
September 20-September 24 340 participants
ARRANGED BY Stanley J. Korsmeyer, Washington University School of Medicine
Eileen White, Rutgers University
H. Robert Horvitz, Massachusetts Institute of Technology
The field of programmed cell death (apoptosis) has blossomed over the last several years such
that the timing was very appropriate for a large Cold Spring Harbor-style meeting. The meeting
brought together diverse members of the field to present and critically discuss their findings.
The highlights of the meeting included inroads into the function of the Drosophila Reaper gene
product, which may act similarly to the death domain of Fas antigen in mammalian cells. The
identification of genetic suppressors of reaper was reported. The Fas and TNF signaling of
apoptosis was further elucidated with the identification of Fas death domain binding proteins.
Downstream from Fas and TNF is the ICE family of cysteine proteases, first implicated in apop-
tosis through the discovery of sequence homology with the C. elegans Ced-3 apoptosis-
promoting gene product. The poxvirus CrmA ICE inhibitor blocks apoptosis by Fas in other set-
tings, and new evidence was reported that the baculovirus p35 gene product may have the
same function. New Bcl -2- related proteins were reported, one of which has only a BH3 domain.
The BH3 domain was found by several groups to be sufficient for interactions between Bcl -2
family members and a region slightly larger than BH3 of Bak was also sufficient for induction of
cell death. The phenotype of the Bax knock-out mouse was reported to consist primarily of
thymic hyperplasia and male sterility, suggesting redundancy in function among the BcI-2-
related apoptosis promoters. These and other discoveries, with discussion thereafter, produced
a meeting of extraordinary intellectual interest and value to the field that we hope to recreate in
1997.
This meeting was funded in part by National Science Foundation; U.S. Department of Ener-
gy; and National Institute on Aging, National Institute of General Medical Sciences; and National
Institute of Allergy & Infectious Diseases (all branches of the National Institutes of Health).
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S. Nagata, P. Krammer
PROGRAM
Invertebrate Development
Chairperson: H. Steller, Massachusetts Institute of
Technology
Immunology/Neurology
Chairperson: S. Nagata, Osaka Bioscience Institute, Japan
bcl -2 Family
Chairperson: S. Cory, Walter and Eliza Hall Institute of
Medicine, Australia
Biochemistry
Chairperson: J. Yuan, Massachusetts General Hospital
East
Signaling in Plant Development
116,
M. -C. Hsu, E. White
Viral
Chairperson: G. Evan, Imperial Cancer Research Fund,
London, United Kingdom
Oncogenesis
Chairperson: A. Levine, Princeton University
Vertebrate Development
Chairperson: M. Raff, University College, London, United
Kingdom
Disease
Chairperson: A. Wyllie, University Medical School,
Edinburgh, United Kingdom
September 27-October 1 174 participants
ARRANGED BY Nam-Hai Chua, Rockefeller University
June Nasrallah, Cornell University
Venkatesan Sundaresan, Cold Spring Harbor Laboratory
This meeting was organized to highlight recent advances in understanding the mechanisms by
which external and internal signals can regulate plant development. The absence of mobility in
higher plants has resulted in the evolution of elaborate developmental responses to environmen-
tal cues. Developmental programs in plants either require particular signals for initiation or are
modulated by sets of signals that can evoke different types of developmental responses. This
theme was stressed repeatedly during the course of the meeting, which covered every aspect of
plant development regulated by signaling processes. Sessions were held on germination,
photomorphogenesis, vegetative growth, flowering, pollination, and embryogenesis. In addition,
plant responses to special conditions such as stress, and to pathogens and symbionts, were ex-
plored in separate sessions. Highlights of the meeting included announcements of the cloning of
several regulatory loci controlling key signaling processes, such as genes that regulate
responses to gibberellins, abscisic acid, light, cell-cell recognition and signaling, flowering time,
embryo development, and pathogen recognition. Other highlights were descriptions of ad-
vances in technology, such as in vitro fertilization and patch clamping, that will permit more
detailed investigation of these processes in the future.
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V. Sundaresan, C. Dean, S. Long R. Fischer, J. Nasrallah
The meeting was funded in part by grants from the Department of Energy, the National
Science Foundation, and the United States Department of Agriculture. Contributions of financial
support for graduate students were received from Ciba-Geigy Corporation, E.I. Du Pont de
Nemours and Company, and Pioneer Hi-Bred International Inc.
PROGRAM
Germination
Chairperson: D. McCarty, University of Florida, Gainesville
Photomorphogenesis
Chairperson: X.-W. Deng, Yale University
Vegetative Growth I: Communications
Chairperson: J. Schroeder, University of California, San
Diego
Vegetative Growth II: Shoots, Roots, and Leaves
Chairperson: K. Barton, University of Wisconsin, Madison
Flowering
Chairperson: C. Dean, John trines Centre, United
Kingdom
Neurobiology of Drosophila
Pollination and Fertilization
Chairperson: D. Preuss, University of Chicago
Embryogenesis
Chairperson: B. Fischer, University of California, Berkeley
Altered Developmental Programs I: Environmental Effectors
Chairperson: R. Hangarter, Indiana University, Bloomington
Altered Developmental Programs II: Biological Effectors-
Microbial Signals
Chairperson: J. Dangl, University of North Carolina
Altered Developmental Programs III: Biological Effectors-
Host Responses
Chairperson: B. Baker, PGEC-USDA, University of
California, Berkeley
October 5-October 9 267 participants
ARRANGED BY James Posakony, University of California, San Diego
Kalpana White, Brandeis University
The primary goal of this year's meeting on Drosophila neurobiology was to provide a forum for
exchange of ideas, techniques, and new discoveries within the field of Drosophila neurobiology.
The meeting consisted of platform and poster presentations by 267 junior and established inves-
tigators. The platform sessions were arranged to reflect the exciting advances that have been
made in understanding the molecular mechanisms underlying cell-cell communication, synaptic
cell biology, ion channel function, signal transduction, and behavior. The work presented in-
cluded genetic, cell biological, molecular, neurophysiological, and behavioral approaches to ad-
dress questions that spanned nervous system development to nervous system function. The
highlights of the meeting included presentation of exciting new developments in several areas,
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J. Thomas, P. Taghert M. Gonzales-Gatan, M. Gho
including biological rhythms, learning and memory, glial determination, plasticity, and synaptic
cell biology. Also noteworthy were several new behavioral paradigms and technical advances in
targeted cell ablation. The setting of the meeting provided for ample opportunities for informal
discussions. The high quality of presentations and the novel findings in many areas made it
amply clear that this format, which is inclusive of all aspects of neurobiology, is extremely useful
to young and seasoned scientists, as it provides as ideal opportunity to cover all the different
aspects of Drosophila neuroscience.
This meeting was funded in part by the National Science Foundation and the National In-
stitute of Neurological Disorders and Stroke, a branch of the National Institutes of Health.
PROGRAM
Behavior
Chairperson: B.J.Taylor, Oregon State University
Sensory Transduction, Learning, and Memory
Chairperson: C. Zuker, Howard Hughes Medical Institute,
University of California, San Diego
Channels, Receptors, and Synaptic Transmission
Chairperson: L.M. Hall, State University of New York, Buffalo
Cell-Cell Signaling in Development
Chairperson: M.W. Young, Howard Hughes Medical
Institute, Rockefeller University
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Cell-Cell Interaction: Axons and Glia
Chairperson: U. Heberlein, University of California, San
Francisco
Transcriptional and Posttranscriptional Regulation
Chairperson: S. Crews, University of North Carolina, Chapel
Hill
Cell Biology of the Neuron
Chairperson: H. Bellen, Howard Hughes Medical Institute,
Baylor College of Medicine
H. Ellis, J. Posakony
POSTGRADUATE COURSES
The summer program of Postgraduate Courses at Cold Spring Harbor Laboratory is aimed at meet-
ing the special need for training in interdisciplinary subjects that are either so new or so specialized
that they are not adequately treated by universities. Our aim is to provide intensive study in the
most recent developments and techniques in these subjects and to prepare students to enter
directly into research in a particular area. To ensure up-to-date coverage of current research work,
we bring together a workshop staff from many laboratories around the world and supplement this
staff with a series of seminar speakers.
Advanced Genome Sequence Analysis
March 14-27
INSTRUCTORS
Chen, El !son, Ph.D., Perkin Elmer Corporation
Gibbs, Richard, Ph.D., Baylor College of Medicine
McCombie, W. Richard, Ph.D, Cold Spring Harbor Laboratory
Wilson, Richard, Ph.D., Washington University School of Medicine
ASSISTANTS
Fitzgerald, Michael, Massachusetts General Hospital
Johnson, Arthur, Cold Spring Harbor Laboratory
Johnson, Douglas, Washington University School of Medicine
Kaplan, Nancy, Cold Spring Harbor Laboratory
Lodhi, Muhammad, Cold Spring Harbor Laboratory
Muzny, Donna, Baylor College of Medicine
Parson, Jeremy, Washington University School of Medicine
Went land, Meredith, Baylor College of Medicine
Zho, Lin, Sequana Therapeutics
Recent advances in the automation of DNA sequencing have opened new possibilities for the anal-
ysis of complex genomes at the DNA sequence level. This 2-week course provided intensive train-
ing in this rapidly evolving field. The course emphasized techniques and strategies for using auto-
mated sequencers to sequence large, contiguous genomic regions. Students carried out all of the
steps in the sequencing process from preparing cosmid DNA to computer analysis of the finished
sequence.
Topics included subclone library generation, large-scale template purification, sequencing
reactions, gel analysis on automated sequencers, sequence assembly, gap filling, and conflict
resolution. Students worked in groups to sequence a 44,913-base cosmid insert from fission yeast
and through this process were trained in crucial project and data management techniques. A
series of lecturers discussed their applications of these techniques as well as alternate strategies
for high-speed automated DNA sequencing.
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PARTICIPANTS
Ballard, W., Ph.D., CSIRO, Australia
Ben Asher, E., Ph.D., Weizmann Institute of Science, Israel
Gaudierei, S., Ph.D., University of Western Australia, Austra-
lia
James, C., Ph.D., University of Manchester, United Kingdom
Krall, J., B.S., Amersham Life Sciences, Inc., Cleveland, Ohio
Latinwo, L., Ph.D., Florida A&M University
Lau, C.H., B.S., M.S., National University of Singapore
McPherson, J., Ph.D., University of California, Irvine
Meyers, B., B.A., M.S., University of California, Davis
SEMINARS
Caskey, T., Merck Research Laboratories, West Point,
Pennsylvania. Triplet repeat diseases.
Dusterhoft, A., Qiagen GmbH., Germany. New developments
in template purification for genome sequencing projects.
Marr, T., Cold Spring Harbor Laboratory. From pedigrees to
sequences: Dissection of complex genetic diseases by
computer.
Roe, B., University of Oklahoma. Human genomic sequenc-
ing: Strategies, results, analyses, and lessons learned from
approximately one megabase.
Smith, D., Collaborative Research, Inc., Waltham, Massa-
Myerson, J., B.S., M.S., Merck Research Laboratories
Paricio, N., Ph.D., University of Valencia, Spain
Schramm, S., B.S., GenPharm International, Mt. View, Califor-
nia
Silvey, M., B.S., University of East Anglia, United Kingdom
Singh, R., Ph.D., National Research Council of Canada, Can-
ada
Tian, J., B.D., M.S., National Institute of Standards and Tech-
nology, Gaithersburg, Maryland
Young, A., Ph.D., Whitehead Institute for Biomedical Re-
search, Cambridge, Massachusetts
chusetts. Large-scale multiplex sequencing.
Smith, R., Baylor College of Medicine. Sequence alignment
and database searching: A practical guide for molecular
biologists.
Studier, W., Brookhaven National Laboratory, Upton, New
York. DNA sequencing by primer walking with hexamer
strings.
Watson, J., Cold Spring Harbor Laboratory. How the Human
Genome Project got started.
Weiss, R., University of Utah. Automated multiplex sequenc-
ing: Technology development and applications.
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Cloning and Analysis of Large DNA Molecules
March 30-April 12
INSTRUCTORS
Birren, Bruce, Ph.D., Whitehead Institute/MIT Center for Genome Research
Abderrahim, Hadi, M.D., Ph.D., Cell Genesys, Inc.
Vollrath, Douglas, M.D., Ph.D., Stanford University
ASSISTANTS
Dewar, Ken, Laval University, Canada
Friddle, Carl, Stanford University School of Medicine
Funke, Roel, University of Tennessee
This course covered the theory and practice of manipulating and cloning high-molecular-weight
DNA. The course focused on the use of yeast artificial chromosome (YAC), bacterial artificial
chromosome (BAC), and bacteriophage P1 cloning systems for library construction and techniques
of pulsed field gel electrophoresis (PFGE). Lectures and laboratory work included an introduction
to yeast genetics, the isolation and manipulation of high-molecular-weight DNA from a variety of
sources, and preparative and analytical PFGE. Clones were produced and characterized by
several approaches including library screening, contig assembly, long-range restriction mapping,
and recovery of YAC ends. Lectures by outside speakers on topics of current interest supple-
mented the laboratory work.
PARTICIPANTS
Alexopoulou, L., B.S., Hellenic Pasteur Institute, Greece
Antoch, M., Ph.D., Northwestern University, Evanston, Illinois
Aragona, M., Ph.D., Instituto Sperimentale Patologia
Vegeta le, Italy
Bursell, C., B.S., University of Goteborg, Sweden
Boren, J., M.D., Ph.D., Gladstone Institute for Cardiovascular
Research, San Francisco, California
Cappellano, C., Ph.D., Lepetit Research Center, Italy
Ferrario, S., Ph.D., University of Milan, Italy
Gayle, M., B.A.,M.S., Darwin Molecular Corporation, Bothell,
Washington
Jongstra, J., Ph.D., University of Toronto, Canada
Koi, M., Ph.D., National Institutes of Health, Bethesda,
Maryland
Leaves, N., B.Sc., Oxford Public Health Laboratory, United
Kingdom
Liu, X., B.S., M.S., University of Connecticut
Ma, J., Ph.D., Harvard Medical School
Mendiola, J., Ph.D., University of Minnesota
Serratosa, J., M.D., Ph.D., University of California, Los
Angeles
Terryn, N., Ph.D., University of Gent, Belgium
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SEMINARS
Ecker, J., University of Pennsylvania. Physical and generic
mapping of Arabidopsis genome.
Green, E., National Institutes of Health, Bethesda, Maryland.
YAC-based physical mapping of human chromosomes.
Lai, E., University of North Carolina, Chapel Hill. BAC cloning
of mammalian DNA, the true story.
Michelmore, R., University of California, Davis. Clusters of
disease resistance genes in lettuce.
Shepherd, N., Glaxo Research Institute, Research Drive,
North Carolina. Genetics and drug discovery.
Shizuya, H., California Institute of Technology. How to BAC.
Strauss, W., Beth Israel Hospital, Boston, Massachusetts.
Transgenesis: The next generation.
Protein Purification and Characterization
March 30-April 12
INSTRUCTORS
Burgess, Richard, Ph.D., University of Wisconsin, Madison
Kadonaga, James, Ph.D., University of California, San Diego
Lin, Sue Hwa, Ph.D., University of Texas/M.D. Anderson Cancer Center
Marshak, Daniel, Ph.D., Cold Spring Harbor Laboratory
ASSISTANTS
Carpino, Nicholas, Cold Spring Harbor Laboratory
Earley, Karen, University of Texas
George, Catherine, University of California, San Diego
Burke, Thomas, University of California, San Diego
Grabski, Anthony, University of Wisconsin, Madison
This course was intended for scientists who were not familiar with techniques of protein isolation
and characterization. It was a rigorous program that included laboratory work all day and a lecture
with discussion session every evening. Each student became familiar with each of the major techni-
ques in protein purification by actually performing four separate isolations, including (1) a
regulatory protein from muscle tissue; (2) a sequence-specific, DNA-binding protein; (3) a recom-
binant protein overexpressed in Escherichia coli; and (4) a membrane-bound receptor. A variety of
bulk fractionation, electrophoretic, and chromatographic techniques were employed, including pre-
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cipitation by salts, pH, and ionic polymers; ion exchange, gel filtration, hydrophobic interaction,
and reverse-phase chromatography; lectin affinity, oligonucleotide affinity, and immunoaffinity
chromatography; polyacrylamide gel electrophoresis and electroblotting; and high-performance
liquid chromatography. Procedures were presented for solubilizing proteins from inclusion bodies
and refolding them into active monomeric forms. Methods of protein characterization were utilized
including immunological and biochemical assays, peptide mapping, amino acid analysis, protein
sequencing, and mass spectrometry. Emphasis was placed on strategies of protein purification
and characterization rather than on automated instrumental analysis. Guest lecturers discussed
protein structure, modifications of proteins, methodologies for protein purification and characteriza-
tion, and applications of protein biochemistry to cell and molecular biology. Guest lecturers were A.
Courey, A. Kornberg, S.-H. Lin, N. Pace, G. Rose, B. Stillman, and N. Tonks.
PARTICIPANTS
Ansari, A., Ph.D., Harvard University
Burk, R., M.D., Albert Einstein College of Medicine, Bronx,
New York
Cheung, A., Ph.D., USDA, National Animal Disease Center,
Ames, Iowa
Dietmeier, K., Ph.D., University of Freiburg, Germany
Gong, M.C., Ph.D., University of Virginia
Gravel, A., B.S., M.S., CHUL Research Center, Canada
High, K., M.D., University of Pennsylvania School of Medicine
Hughes, T., Ph.D., Baylor College of Medicine, Houston,
SEMINARS
Burgess, R., University of Wisconsin, Madison. Overview of
protein purification methods.
Courey, A., University of California, Los Angeles. Transcrip-
tion factors.
Kornberg, A., Stanford University School of Medicine. En-
zyme purification.
Lin, S.-H., University of Texas, M.D. Anderson Cancer Cen-
ter. Membrane protein purification.
Texas
Hwang, L.-Y., Ph.D, University of Texas Southwestern Medi-
cal Center
Jain, R., Ph.D., Harvard Medical School
Jiang, R., B.S., Columbia University
Lukacs, G., Ph.D., University of Toronto, Canada
Michels, C., Ph.D., CUNY, Queens College
Miyoshi, E., B.S., University of California, Los Angeles
Strunnikov, A., Ph.D., Carnegie Institute of Washington
Wang, T., Ph.D., Massachusetts General Hospital
Pace, N., Texas A&M University. Protein folding.
Rose, G., Johns Hopkins University Hospital. Protein struc-
ture.
Stillman, B., Cold Spring Harbor Laboratory. DNA replication
protein.
Tonks, N., Cold Spring Harbor Laboratory. Protein tyrosine
phosphatases.
Early Development of Xenopus laevis
April 4-13
INSTRUCTORS
Grainger, Robert, Ph.D., University of Virginia
Sive, Hazel, Ph.D., Whitehead Institute
ASSISTANTS
Amaya, Enrique, University of California, Berkeley
Gammill, Laura, Whitehead Institute
Papalopulu, Nancy, Salk Institute for Biological Studies
This course provided extensive laboratory exposure to the biology, manipulation, and use of em-
bryos from the frog, Xenopus laevis. The course was suited both for investigators who have had no
experience with Xenopus and for those who have worked with Xenopus and wished to expand their
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repertoire of techniques. All students had current training in molecular biology and some knowl-
edge of developmental biology. The course consisted of intensive laboratory sessions, supple-
mented by daily lectures and demonstrations from experts in both experimental and molecular em-
bryology. Six areas were covered: (1) care and handling of adults and embryo isolation; (2) stages
of embryonic development and anatomy; (3) whole mount in situ hybridization and im-
munocytochemistry; (4) microinjection of eggs and oocytes, including mRNA and antisense
oligonucleotides; (5) micromanipulation of embryos, including induction and transplantation as-
says; and (6) preparation and use of cell cycle extracts. Lecturers and co-instructors included Enri-
que Amaya, Rick Elinson, Janet Heasman, John Gurdon, Richard Harland, Ray Keller, John New-
port, and Nancy Papalopulu.
PARTICIPANTS
Andreazzoli, M., Ph.D., Ospedale San Raffaele, Italy
Antonelli, M., Ph.D., University of Chile, Chile
Aronheim, A., Ph.D., University of California, San Diego
Avis, J., Ph.D., University of Manchester, United Kingdom
Devchand, P., Ph.D., University of Lausanne, Switzerland
Dominguez, M.I., Ph.D., Harvard Medical School
Hamada, H., M.D., Ph.D., Cancer Institute, Japan
Hill, C., Ph.D., Imperial Cancer Research Fund, United King-
dom
Hopp ler, S., Ph.D., University of Washington School of Medi-
SEMINARS
Elinson, R., University of Toronto, Canada. Cytoplasmic orga-
nization of the egg and dorsoventral polarity of the embryo.
Grainger, R., University of Virginia. Completing the body
plan: Inductive mechanisms during organogenesis.
Gurdon, J., Cambridge University, United Kingdom. Induc-
tion of the mesoderm in Xenopus.
Harland, R., University of California, Berkeley. Molecular na-
ture of Spemann's organizer: Role of peptide factors in
Xenopus development.
cine
Humbert-Lan, G., M.S., Georg August University, Argentina
Koster, R., M.D., MPI Biophysikolisch Chemie, German
Nastos, A., B.S., University of Essen, Germany
Sullivan, S., Ph.D., George Washington University
Sun, B., Ph.D., Whitehead Institute, Cambridge, Massachu-
setts
Suzuki, A., B.S., M.S., Hokkaido University, Japan
Zucker, S., B.S., Albert Einstein College of Medicine, Bronx,
New York
Heasman, J., University of Minnesota. Maternal control of de-
velopment of Xenopus.
Keller, R., University of California, Berkeley. Morphogenesis
in the early Xenopus embryo.
Newport, J., University of California, San Diego. Cell cycle
control mechanisms in Xenopus.
Sive, H., Whitehead Institute, Cambridge, Massachusetts.
Anteroposterior patterning in Xenopus.
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Molecular Embryology of the Mouse
June 9-29
INSTRUCTORS
Behringer, Richard, Ph.D., University of Texas, M.D. Anderson Cancer Center
Papaioannou, Virginia, Ph.D., Columbia University
CO-INSTRUCTORS
Koopman, Peter, Ph.D.,University of Queensland, Australia
Magnuson, Terry, Ph.D., Case Western Reserve University
Nagy, Andras, Ph.D., Mount Sinai Hospital, Canada
ASSISTANTS
Nichols, Jenny, University of Edinburgh, United Kingdom
Shaw lot, William, University of Texas, M.D. Anderson Cancer Center
This course was designed for biologists interested in applying their expertise to the study of mouse
embryonic development. Laboratory components provided an intensive introduction into the techni-
cal aspects of working with and analyzing mouse embryos, and lecture components provided the
conceptual basis for current research. Procedures that were described included isolation and cul-
ture of pre- and postimplantation embryos, oviduct and uterus transfer, formation of aggregation
chimeras, isolation of germ layers in gastrulation-stage embryos, establishment, culture, and genet-
ic manipulation of embryonic stem cell lines, in situ hybridization to whole mounts of embryos, im-
munohistochemistry, microinjection of DNA into pronuclei, and microinjection of embryonic stem
cells into blastocysts. Last year's speakers were A. Bradley, M. Bronner-Fraser, N. Jenkins, T. Jes-
sell, R. Lovell-Badge, L. Parada, A. McLaren, A. McMahon, J. Mann, G. Rinchik, L. Robertson, J.
Rossant, P. Soriano, S. Strickland, P. Wassarman, and D. Wilkinson.
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PARTICIPANTS
Biggs, W., B.A., Ph.D., University of California, San Diego
Collinge, J., B.S., M.D., St. Mary's Hospital Medical School,
United Kingdom
Gow, A., B.S., M.S., Ph.D., Mt. Sinai School of Medicine, New
York, New York
Incerti, B., M.D., Telethon Institute of Genetics & Medicine,
Milan, Italy
Johnson, R., B.S., Ph.D., Harvard Medical School
Kasarskis, A., B.S., B.A., Ph.D., University of California,
Berkeley
SEMINARS
Bradley, A., Baylor College of Medicine, Houston, Texas.
Mouse embryonic stem cells.
Mechanisms of homologous recombination.
Behringer, R., University of Texas, M.D. Anderson Cancer
Center. Genetic factors that organize pattern in the mouse.
Bronner-Fraser, M., University of California, Irvine. Lineage
studies of the neural crest.
Efstratiadis, A., Columbia University. The function of insulin-
like growth factors during mouse embryogenesis.
Hogan, B., Vanderbilt University Medical School, HHMI,
Nashville, Tennessee.
Preimplantation development and implantation.
Bone morphogenetic proteins and mouse development.
Jessell, T., Columbia University College of Physicians &
Surgeons. Pattern formation in the vertebrate nervous sys-
tem.
Joyner, A., New York University Medical Center. Genetic
analysis of the vertebrate nervous system.
Koopman, P., University of Queensland, Australia. Sox genes
and mouse development.
Lovell-Badge, R., National Institute for Medical Research,
United Kingdom.
Sex determination in mammals.
Functional analysis of the Sox gene family.
Magnuson, T., Case Western Reserve University, Cleveland,
Advanced Bacterial Genetics
Larsson, N.-G., M.D., Ph.D., Stanford University School of
Medicine
Luc, L., B.S., Ph.D., University of California, Los Angeles
McDonald, D., B.S., Ph.D., Wichita State University
Meagher, M., B.S., Ph.D. University of Washington, Seattle
Memet, S., M.S., Ph.D., Institute Pasteur, France
Obermayr, F., M.S., Imperial Cancer Research Fund, United
Kingdom
Rauch, T., M.S., Hungarian Academy of Sciences, Hungary
Yueh, Y.G., Ph.D., Mayo Clinic, Scottsdale
Ohio. Mutations that alter germ layer formation in the
mouse.
Mann, J., Beckman Research Institute, Duarte, California.
Molecular analysis of genomic imprinting during mouse
embryogenesis.
McMahon, A., Harvard University. Mechanisms of embryonic
induction.
Nagy, A., Mount Sinai Hospital, Ontario, Canada. Genetic
analysis of N-mcy during mouse organogenesis.
Papaioannou, V., Columbia University. Mouse chimeras in
experimental embryology.
Rastan, S., Hammersmith Hospital, United Kingdom. X
chromosome inactivation.
Solter, D., Max-Planck Institute of Immunology, Germany.
Genomic imprinting.
Soriano, P., Fred Hutchinson Cancer Research Center,
Seattle, Washington. Insertional mutagenesis in the mouse.
Tam, P., Children's Medical Research Institute, Australia.
Postimplantation development.
Cell lineage analysis in early mouse embryogenesis.
Wilkinson, D., National Institutes of Medical Research, United
Kingdom. Mechanisms of segmentation in the nervous sys-
tem and paraxial mesoderm.
Woychik, R., Oak Ridge National Laboratory, Oak Ridge,
Tennessee. Mouse models for human disease.
June 10-30
INSTRUCTORS
Maloy, Stanley, Ph.D., University of Illinois, Urbana
Stewart, Valley, Ph.D., Cornell University
Taylor, Ronald, Ph.D, Dartmouth Medical School
ASSISTANTS
Darwin, Andrew, Ph.D., Cornell University
Skorupski, Karen, Ph.D., Darmouth Medical School
Zahrt, Thomas, M.S., University of Illinois, Urbana
The laboratory course demonstrated genetic approaches that can be used in diverse bacterial sys-
tems to analyze biological processes and their regulation, as well as detailed structure/function re-
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lationships of genes. Techniques covered included isolation, characterization, and mapping of
mutations; use of transposable genetic elements as mutagens, linked selectable markers, and port-
able regions of homology; construction and analysis of operon and gene fusions; use of bac-
teriophage in genetic analysis; molecular cloning and restriction endonuclease mapping; allele ex-
change; Southern blot analysis; polymerase chain reaction; and site-specific mutagenesis. The
course consisted of a series of experiments that employed these techniques in the genetic analysis
of diverse bacterial and bacteriophage species. Lecturers and discussions concentrated on the
application of genetic analysis to contemporary questions in bacterial physiology, diversity, and
pathogenesis.
Last year's guest lecturers were B. Bass ler, S. Highlander, T. Silhavy, H. Shuman, M. Winkler,
and J. Westpheling.
PARTICIPANTS
Barbieri, J., B.S., Ph.D., Medical College of Wisconsin
Darby, C., B.A., Ph.D., University of Washington, Seattle
Edwards, R., B.S., Ph.D., University of Pennsylvania
Galloway, D., B.S., Ph.D., Ohio State University
Gavigan, J.-A., B.A., Universidad de Zaragoza, Spain
Honda lus, M., D.V.M., Ph.D., Temple University of Medicine,
Philadelphia, Pennsylvania
Hong, K., B.S., Ph.D., University of California, Los Angeles
Konkel, M., B.S., M.S., Ph.D., Washington State University
SEMINARS
Bass ler, B., Princeton University. Intercellular communication
in luminous bacteria:
Jacobs, W., Albert Einstein College of Medicine, HHMI,
Bronx, New York. A 1914 penny, lotto, and tuberculosis
control.
Manoil, C., University of Washington, Seattle. TnphoA.
Roth, J., University of Utah. Recombination.
Mikulskis, A., M.S., Ph.D., Harvard Medical School
Miyagi, H., B.A., B.S., University of Illinois, Urbana
Moors, M., B.S., Ph.D., University of Pennsylvania
Norregaard-Madsen, M., M.S., Odense University, Denmark
Schmitz, R.A., B.S., Ph.D., University of California, Berkeley
Sullam, P., B.A., M.D., University of California, San Francisco
Widdel, F., B.S., Ph.D., MPI Fur Marine Microbiology,
Germany
Zdych, E., B.A., B.S., University of Konstanz, Germany
Silhavy, T., Princeton University. PRL suppressors and the
in E. coll.
Trun, N., National Cancer Institute, Bethesda, Maryland.
Counting chromosomes in E. coli.
Weinstock, G., University of Texas Health Sciences Center.
Bacterial genometry.
Youderian, P., University of Idaho. Challenge phage.
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Molecular Approaches to Ion Channel Structure,
Expression, and Function
June 10-30
INSTRUCTORS
Liman, Emily, Ph.D., Harvard Medical School
Margulies, Jody, Ph.D., University of Hawaii
Ruben, Peter, Ph.D., Utah State University
ASSISTANT
Ono, Joyce, Ph.D., California State University
This intensive laboratory/lecture course was designed to introduce students to the combined use of
molecular biological techniques and electrophysiological analysis for the study of ligand-gated and
voltage-gated ion channels. The course covered expression of cloned channels and receptors in
Xenopus oocytes and cultured cells, including in vitro preparation of RNA transcripts, microinjec-
tion into oocytes, site-directed mutagenesis, and characterization of channels and receptors using
two-electrode voltage clamp and patch clamp. Lectures covered molecular biology and elec-
trophysiology techniques as well as the theory and analysis of ionic currents. Students were en-
couraged to bring their own samples to study using the techniques taught in the course. Guest lec-
turers last year included M. Bennett, F. Bezanilla, C. Czajkowski, A. Goldin, R. MacKinnon, G.
Mandel, J. Nerbonne, D. Papazian, F. Sigworth, and M. White.
PARTICIPANTS
Anegawa, N.J., B.A., University of Pennsylvania School of
Medicine
Beck, C., B.S., Ph.D., Vanderbilt University, Nashville, Ten-
nessee
Chaves, D., B.S., M.S., University of Guelph, Canada
Featherstone, D., M.S., B.S., University of Hawaii
Grichtchenko, I., M.S., Ph.D., New York University Medical
Center
Saeki, M., B.A., Ph.D., Baylor College of Medicine, Houston,
Texas
Shuey, D., B.S., Wyeth-Ayerst Research, Monmouth Junc-
tion, New Jersey
Stuart, A. B.A., Ph.D., University of North Carolina, Chapel
Hill
Takahashi, M., B.S., University College London, United King-
dom
Tottene, A., B.S., University of Padova, Italy
Yang, W.-P., B.S., Ph.D., Bristol-Myers Squibb Pharmaceuti-
cal Research Institute, Princeton, New Jersey
Yuan, X.-J., M.D., Ph.D., University of Maryland School of
Medicine
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SEMINARS
Akabas, M., Columbia University. Structure of Ach and
GABA receptor pore lining domains.
Bennett, P., Vanderbilt University Medical Center, Nashville,
Tennessee. Structure-function and pharmacology of hu-
man sodium channel.
Bezanilla, F., University of California, Los Angeles. Voltage-
dependent gating of channels.
MacKinnon, R., Harvard Medical School. Using mutant
cycles to measure the pore of potassium channels.
Mandel, G., State University of New York, Stony Brook.
Regulation of neuronal excitability through transcriptional
silencing.
Brain Mapping
Papazian, D., University of California, Los Angeles. A
strategy for determining the package of transmembrane
segments in Shaker potassium channels.
Rayner, M., University of Hawaii. Modeling the gating mech-
anisms of voltage-gated ion channels.
Robertson, G., University of Wisconsin, Madison. The Eag
family of K channels: Functional diversity and clinical
relevance.
Role, L., Columbia University School of Medicine. Composi-
tion of neuronal nicotinic Ach receptor subunits.
Snutch, T., University of British Columbia, Canada. Molecular
mechanisms of calcium channel modulation.
June 12-18
INSTRUCTORS
Mazziotta, John, M.D., Ph.D., University of California, Los Angeles
Toga, Arthur, Ph.D., University of California, Los Angeles
The aim of this lecture course was to describe the rapidly evolving developments in brain mapping
that have been applied to the problem of mapping the structure and function of the brain, both to
understand its normal function and to evaluate neurological, neurosurgical, and psychiatric disease
states. This course described new methods as well as the application of traditional techniques to
the study of brain structure and function. Methodologies that were discussed included magnetic
resonance imaging (including functional, spectroscopic, and angiographic approaches), positron
emission tomography, electrophysiological techniques, optical intrinsic signal imaging, digital ap-
proaches to conventional postmortem neuroanatomical investigations, data analysis, statistical
analysis, statistical approaches, visualization, and stereotaxy. The course was not designed to
simply describe methods, but rather to discuss how brain mapping strategies can be employed in
combination with biological models for understanding the structure and function of the brain. Find-
ings relevant to the function of the visual, motor, language, memory, and cognitive brain systems,
as well as diseases that adversely affect them, were discussed. Specific hypotheses and experi-
mental designs were developed by the students for mock execution, and as an actual experiment
during a field trip to an imaging laboratory. Invited speakers included world leaders in each of the
respective brain mapping subspecialties.
PARTICIPANTS
Chen, G., M.D., University of Minnesota
Doetsch, F., B.S., Ph.D., Rockfeller University, New York,
New York
Haist, F., B.A., Ph.D., University of California, San Diego
Hanson, C., B.S., University of Minnesota
Kandel, A., B.A., Rutgers University, Newark, New Jersey
Larisch, R., M.D., Institute of Medicine and Research, Julich,
Germany
Lewis, J., B.S., Washington University School of Medicine, St.
Louis, Missouri
Moses, P., B.A., University of California, San Diego
Posse, S., B.S., Ph.D., Research Center Julich GmbH.,
Germany
Robertson, E., B.S., University of Oxford, United Kingdom
Sanders, I., B.S., M.D., Mt. Sinai Medical Center, New York,
New York
Saron, C., B.A., M.S., Albert Einstein College of Medicine,
Bronx, New York
Smith, H., B.A., M.D., University of North Carolina, Chapel
Hill
Tommerdahl, M., B.S., M.S., Ph.D., University of North Caro-
lina, Chapel Hill
Yeh, E., B.S., Case Western Reserve University, Cleveland,
Ohio
Zimmermann, E., B.S., Ph.D., German Primate Center,
Germany
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SEMINARS
Cherry, S., University of California, Crump Institute, Los
Angeles. PET methods, Uses and limits of PET studies.
Cohen, M., University of California Medical School, Los
Angeles. MRI methods. Uses and limits of MRI studies.
Frackowiak, R., Hammersmith Hospital, United Kingdom.
PET applications. Uses and limits of PET studies.
Friston, K., MRC Cyclotron, United Kingdom. Data Analysis,
statistics.
Mazziotta, J., University of California School of Medicine, Los
Angeles.
Brain mapping issues.
Time & space, in vivo imaging: PET, SPECT, MRI, CT.
Brain atlases.
Pascual-Leone, A., Universite de Neurobiologie, Spain.
Transcranial magnetic stimulation.
Peterson, S., Washington University School of Medicine.
Study design, hypothesis testing, cognitive studies.
Prichard, J., Yale University School of Medicine. MRI ap-
plications. Uses and limits of MRI studies.
Toga, A., University of California School of Medicine, Los
Angeles.
General principles, microtechniques: 01S, histology,
cryomacrotome.
Reconstruction, registration, segmentation, display.
Brain atlases.
Tootell, R., Massachusetts General Hospital, NMR. Mi-
cro/macro brain mapping, visual system.
Woolsey T., Washington University School of Medicine. Micro
mapping, vascular mapping.
Zeffiro, T., Sensor Systems, Inc., Sterling, Virginia. Analysis,
software.
Structure, Function, and Development of the Visual System
June 21-July 4
INSTRUCTORS
Bonhoeffer, Tobias, Ph.D., Max-Planck Institute, Germany
Fitzpatrick, David, Ph.D., Duke University
This lecture/discussion course explored the functional organization and development of the visual
system as revealed by the use of a variety of anatomical, physiological, and behavioral methods. It
was designed for graduate students and more advanced researchers who wished to gain a basic
understanding of the biological basis for vision and to share in the excitement of the latest develop-
ments in this field. Topics included phototransduction and neural processing in the retina; func-
tional architecture of striate cortex; cellular basis of cortical receptive field properties; the anatomy,
physiology, and perceptual significance of parallel pathways; functional parcellation of extrastriate
cortex; sensory-motor integration in the superior colliculus; and role of patterned neuronal activity in
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the development of central visual pathways. Past lecturers included B. Chapman, D. Dacey, C, Gil-
bert, C. Gray, D. Hubei, L. Katz, K. Martin, J. Maunsell, T. Movshon, K. Nakayama, C. Shatz, M.
Stryker, A. Thomson, D. Van Essen, and R. Wong.
PARTICIPANTS
Abel, P., B.S., University of Washington, Seattle
Baharloo, S., B.S., M.S., Ph.D., University of California, San
Francisco
Bosking, W., B.A., Duke University, Durham, North Carolina
Brecht, M., B.S., Max-Planck Institute, Germany
Burrows, A., B.A., M.D., Ph.D., University of Texas
Dan, Y., B.S., Ph.D., Rockefeller University
Joris, P., B.S., M.D., University of Wisconsin, Madison
SEMINARS
Bonhoeffer, T., Max-Planck Institute, Germany. Development
of functional architecture in visual cortex.
Chapman, B., University of California, Davis. How visual
cortex got its stripes.
Dacey, D., University of Washington, Seattle. The primate
retina: Cell types, circuits, and color coding.
Fitzpatrick, D., Duke University Medical Center. Local circuits
in visual cortex: Relating patterns of connectivity to func-
tional maps.
Gilbert, C., Rockefeller University, New York, New York. Spa-
tial integration and cortical dynamics.
Gray, C., University of California, Davis. Response syn-
chronization in visual cortex and its mechanism of genera-
tion.
Hubei, D., Harvard Medical School. Form, color, and
stereopsis in visual cortex.
Katz, L., Duke Univetsity Medical Center. Constructing
columns and circuits in the visual cortex.
Platt, M., B.A., Ph.D., New York University
Rachel, R., B.S., Ph.D., Columbia University
Samantha R., Deborah, B.A., Yale University
Sax, C., B.S., Ph.D., National Institutes of Health, Bethesda,
Maryland
Shmuel, A., B.S., M.S., Weizmann Institute of Science, Israel
Zhou, Y.-X., M.S. Ph.D., New York University
Martin, K., MRC Anatomical Neuropharmacology Unit, United
Kingdom. Making sense of cortical microcircuitry.
Maunsell, J., Baylor College of Medicine, Houston, Texas.
Representing image and target in primate visual cortex.
Movshon, T., New York University. Neural foundations of
visual perceptual judgment.
Nakayama, K., Harvard University. Visual surface represen-
tation: A critical link between lower-level and higher-level
vision.
Shatz, C., University of California, Berkeley. Constructing the
visual system from scratch: Early steps in brain wiring.
Thomson, A., Royal Fee Hospital School of Medicine, United
Kingdom. Temporal and spatial properties of local circuits
in neocortex.
Van Essen, D., Washington University School of Medicine.
Organization and function of primate visual cortex.
Wong, R., Washington University School of Medicine. Retinal
development: From cell birth to making connections.
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Arabidopsis Molecular Genetics
July 3-23
INSTRUCTORS
Deng, Xing-Wang, Ph.D., Yale University
Last, Robert, Ph.D., Boyce Thompson Institute, Cornell University
Preuss, Daphne, Ph.D., University of Chicago
ASSISTANTS
Von Arnim, Albrecht, Yale University
Wilhelmi, Laura, University of Chicago
Zhao, Jianmin, Boyce Thompson Institute, Cornell University
This course provided an intensive overview of topics in plant growth and development, focusing on
molecular genetic approaches to understanding plant biology. It emphasized recent results from
Arabidopsis thaliana and other model plants and provided an introduction to current methods used
in Arabidopsis research. The course also demonstrated the use of microbial systems in plant re-
search, including Agrobacterium, Escherichia coli, Saccharomyces cerevisiae, and plant
pathogens. It was designed for scientists with experience in molecular techniques or in plant biol-
ogy who wish to work with Arabidopsis. The course consisted of a vigorous lecture series, a hands-
on laboratory, and informal discussions. Speakers provided both an in-depth discussion of their
own work and a review of their specialty.
Discussions of important topics in plant research were presented by the instructors and by in-
vited speakers. These seminars reviewed plant anatomy; plant development (including develop-
ment of flowers, roots, meristems, embryos, and the epidermis); perception of light and photomor-
phogenesis; responses to a variety of environmental stresses including pathogens, UV-B and
ozone; synthesis and function of secondary metabolites and hormones; nitrogen assimilation;
unique aspects of plant cell biology; the importance of transposons and Agrobacterium for
manipulating plant genomes; and current approaches to genome analysis.
The laboratory sessions provided an introduction to important techniques currently used in
Arabidopsis research. These included studies of Arabidopsis development, mutant analysis,
studies of epidermal features, in situ detection of RNA, subcellular localization of proteins, analysis
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of secondary metabolites, transformation with Agrobacterium, transient gene expression in plant
cells, expression of plant proteins in microorganisms, detection and analysis of plant pathogens,
and techniques commonly used in genetic and physical mapping.
Past speakers included J. Bender, A. Britt, T., C. Chapple, J. Chory, G. Drews, J. Ecker, S.Y.
He, A. Lloyd, H. Ma, R. Martienssen, J. Medford, T. Mitchell-Olds, P. Quail, J. Schiefelbein, R.
Scholl, B. Staskawicz, D. Stern, I. V. Sundaresan, Sussex, T. Voelker, V. Walbot, and P. Zambryski.
PARTICIPANTS
Agarwal, A., B.S., Ph.D., The Monsanto Company, Chester-
field, Missouri
Curtis, M., B.S., Ph.D., University of Queensland, Australia
Dodgson, S., B.S., Ph.D., University of Pennsylvania School
of Medicine
Heard, J., B.S., Ph.D., Boston College
Hooks, M., B.A., Ph.D., University of Glasgow, Scotland
Mishkind, M., B.A., Ph.D., Bennington College, Bennington,
Vermont
Oyama, T., B.S., M.S., Kyoto University, Japan
SEMINARS
Bender, J., Whitehead Institute/Massachusetts Institute of
Technology, Cambridge. Yeast methods for cloning genes.
Britt, A., University of California, Davis. DNA damage and
repair.
Chapple, C., Purdue University. Secondary metabolites.
Chory, J., Salk Institute, La Jolla, California. Nucleus-
organelle communication.
Colasanti, J., Cole Spring Harbor Laboratory. Floral
determination in maize.
Deng, X.-W., Yale University. Photomorphogenesis.
Drews, G., University of Utah. Female gametophyte develop-
ment and embryo development.
Ecker, J., University of Pennsylvania. Hormones.
He, S.-Y., University of Kentucky. Plant pathogens.
Last, R., Boyce Thompson Institute at Cornell University.
Plant stress responses.
Amino acid biosynthesis.
Lloyd, A., Stanford University. The epidermis.
Ma, H., Cold Spring Harbor Laboratory. Floral development.
Martienssen, R., Cold Spring Harbor Laboratory. Enhancer
traps in Arabidopsis.
Molecular Cloning of Neural Genes
Preuss, S., B.A., Ph.D., University of California, Davis
Ramonell, K., B.S., Ph.D., Louisiana State University
Richeson, A., B.S., National Science Foundation
Shukla, V., B.S., Ph.D., Washington University
Strayer, C., B.S., University of Virginia
Ticknor, C., B.A., Yale University
Winge, P., M.S., University of Trondheim, Norway
Ye, Q., B.S., M.D., Dartmouth College
Zhu, X.-Z., B.S., M.S., Weizmann Institute of Science, Israel
Medford, J., Pennsylvania State University. Shoot meristems.
Mitchell-Olds, T., University of Montana.
QTLs and natural variation.
Mapping complex phenotypes.
Preuss, D., University of Chicago. Pollen development and
fertilization.
Quail, P., USDA, Albany, New York. Light perception.
Schiefelbein, J., University of Michigan. Root development.
Scholl, R., Ohio State University. Arabidopsis resources.
Staskawicz, B., University of California, Berkeley. Plant
defenses.
Stern, D., Cornell University. Plastid genomes and gene ex-
pression.
Sundaresan, V., Cold Spring Harbor Laboratory. The cell
cycle.
Sussex, I., University of California, Berkeley. Plant anatomy.
Voelker, T., Calgene Inc. Fatty acids and genetic engineer-
ing in plants.
Walbot, V., Stanford University. Transposons.
Zambryski, P., University of California, Berkeley. Agrobac-
terium.
July 3-23
INSTRUCTORS
Boulter, Jim, Ph.D., Salk Institute for Biological Studies
Chao, Moses, Ph.D., Cornell University Medical College
Edwards, Robert, Ph.D., University of California, San Francisco
Julius, David, Ph.D., University of California, San Francisco
Lai, Cary, Ph.D., Scripps Research Institute
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ASSISTANTS
Elgoyhen, Ana Be len, Institute de Investigaciones Farmacologicas, Argentina
Kong, Haeyoung, University of Pennsylvania
This intensive laboratory and lecture course was intended to provide neuroscientists at all levels
with an introduction to the techniques of molecular biology. The course consisted of daily
laboratory exercises, morning and afternoon discussions on the practical aspects of molecular biol-
ogy, and a series of evening research seminars presented by invited speakers. This lecture series
emphasized the variety of ways in which recombinant DNA methodologies have been successfully
applied to the study of invertebrate and vertebrate nervous systems.
The laboratory portion of the course included isolation and characterization of poly(A)+ RNA;
isolation and characterization of genomic, plasmid, phagemid, and viral DNAs; synthesis of com-
plementary DNA and construction, plating and screening of expression libraries; gel elec-
trophoresis of nucleic acids; use of DNA modification and restriction enzymes; Southern and North-
ern blotting; hybridization of RNA and DNA using radioactively labeled nucleic acid probes; plas-
mid and genomic DNA mapping; ligations, transformations, and subcloning; oligonucleotide de-
sign, synthesis, purification, and utilization; DNA sequencing and computer-assisted sequence
analysis; polymerase chain reaction methods and applications; in vitro transcription for RNasepro-
tection, in situ hybridization and Xenopus oocyte injections; evaluation of subtractive hybridization
protocols; differential display of cellular RNAs; and in vitro transfection of cultured mammalian
cells. Sleeping was optional. Last year's guest lectures were presented by M.M. Poo, H. Cline, J.
Morgan, J. Eberwine, A.M. Quinn, L. Niswander, K. Zinn, G. Lemke, B. Barres, H. Ingraham, G.
Weinmaster, and K. O'Malley.
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PARTICIPANTS
Bezprozvanny, I., M.S., Ph.D., Stanford University Medical
Center
Burd, G., B.A., Ph.D., University of Arizona
Chang, W., B.A., Ph.D., University of California, San Diego
Chiu, A., B.A., Ph.D., City of Hope National Medical Center,
Duarte, California
Cline, H., B.A., Ph.D., Cold Spring Harbor Laboratory
Firestein, S., B.S., Ph.D., Columbia University
Grice, D., M.D., Yale University Child Study Center
Hammonds-Odie, L., B.S., University of Alabama, Birming-
ham
Hay, M., B.A., Ph.D., University of Texas Health Science
SEMINARS
Burden, S., New York University Medical Center. Signaling at
neuromuscular junctions.
Craig, A.M., University of Illinois, Urbana. Heterologous gene
expression in primary cultured neurons.
Darnell, R., Rockefeller University, New York, New York. Ex-
pression cloning of neural disease antigens.
Fields, S., State University of New York, Stony Brook. Yeast
hybrid methods.
Hoffman, B., National Institutes of Mental Health. Expression
cloning and molecular studies of neurotransmitter trans-
porters.
Neurobiology of Drosophila
Center
Livesey, F., B.S., Medical Research Council, United Kingdom
Marcus, R., B.A., Ph.D., Columbia University College of
Physicians & Surgeons, New York, New York
Messersmith, E., B.S., M.A., Ph.D., University of California,
Berkeley/HHMI
Popov, S., M.S., Ph.D., University of Illinois at Chicago
Richards, L., B.S., Ph.D., Salk Institute, La Jolla, California
Shrager, P., B.A., B.S., Ph.D., University of Rochester Medi-
cal Center
Woo, K., B.A., M.S., California Institute of Technology
Lemke, G., Salk Institute, La Jolla, California. Receptor
tyrosine kinases and neural development.
Mandel, G., State University of New York, Stony Brook.
Regulation of a neuronal sodium channel through tran-
scriptional repression.
Mombaerts, P., Columbia University. Targeting olfaction.
Quinn, A.M., Yale University Medical School. Strategies for
searching gene databases on the World Wide Web.
Worley, P., Johns Hopkins University School of Medicine.
Identification of novel brain immediate early genes using
subtractive hybridization and differential cloning strategies.
July 3-July 23
INSTRUCTORS
Bieber, Alan, Ph.D., Purdue University
Taghert, Paul, Ph.D., Washington University
Hardie, Roger, Ph.D., Cambridge University, United Kingdom
ASSISTANT
Schaefer, Anneliese, Washington University
This laboratory/lecture course was intended far researchers at all levels who want to use
Drosophila as an experimental system for studying neurobiology. Daily seminars introduced the
history behind special topics and further developed those topics by including recent contributions
and outstanding questions. Guest lecturers brought original preparations for viewing and discus-
sion and/or direct lab exercises and experiments in their areas of special interest,
The course introduced students to various preparations useful for studying Drosophila
neurobiology: the larval and adult nervous systems for studying physiology and behavior and the
embryonic and metamorphosing nervous systems for studying development. Students learned a
broad range of methods including electrophysiological, anatomical, and behavioral techniques that
are critical for the study of Drosophila neurobiology. Topics and techniques of special value in
Drosophila (e.g., an introduction to genetics, early ernbryogenesis, spreading of chromosomes,
and embryo injections) were also included.
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In last year's course, physiological emphasis was given to the genetics and molecular biology
of excitability, developmental emphasis to neurogenesis, axonal pathfinding, and synaptogenesis,
and behavioral emphasis to courtship, learning and memory, and biological rhythms.
Last year's guest lecturers included J. Campos-Ortega, J. Carlson, M. Dickinson, R. ffrench-
Constant, V. Hartenstein, L. Iverson, R. Jackson, H. Keshishian, N. Patel, L. Restifo, M. Sokolowski,
N. Strausfeld, B. Taylor, J. Truman, T. Tully, V. Venkatesh, C. F. Wu, and Y. Zhong.
PARTICIPANTS
Bhat, M., M.S., Ph.D., Baylor College of Medicine
Bohm, R., B.S., University of Texas at Austin
Callaerts, P., B.S., Ph.D., Biozentrum, Switzerland
Coleman, M., B.S., University of Pennsylvania School of Med-
icine
Dormand, E.-L., B.A., University of Cambridge, United King-
dom
Hardiman, K., B.A., University of Michigan, Ann Arbor
Levine, J., B.A., Ph.D., Worcester Foundation for Experimen-
SEMINARS
Bieber, A., Purdue University. Axon pathfinding.
Bloch linger, K., Fred Hutchinson Cancer Research, Seattle,
Washington. Histogenesis of the nervous system.
Cagan, R., Washington University School of Medicine. Eye
development.
Dickinson, M., University of Chicago. Flight behavior.
Ganetsky, B., University of Wisconsin, Madison. Introductory
physiology, ion channels.
Hardie, R., Cambridge University, United Kingdom. Visual
system.
Hall, J., Brandeis University. Circadian rhythms.
Hartenstein, V., University of California, Los Angeles. Em-
bryonic development.
Kaiser, K., University of Glasgow, Scotland. The adult brain
Kernan, M., State University of New York, Stony Brook.
Mechanosensory systems.
Keshishian, H., Yale University. Synaptogenesis.
tal Biology, Shrewsbury, Massachusetts
Marcolla Araujo, H., B.S., Ph.D., Federal University of Rio Je
Janeiro, Brazil
McCabe, B., B.A., University of Cambridge, United Kingdom
Raghu, P., M.B., B.S., National Centre for Biological
Sciences, India
Wurmbach, E., B.S., Universitat Hohenheim, Germany
Xu, H., B.S., M.S., Queen's University, Canada
Laurent, G., California Institute of Technology. Neural in-
tegration.
Meinertzhagen, I., Dalhousie University, Nova Scotia, Cana-
da. The adult brain I.
Restifo, L., University of Arizona. Metamorphosis of the ner-
vous system.
Taylor, B., Oregon State University. Sex determination and
behavior.
Taghert, P., Washington University Medical School. Neuro-
transmitters/neuromodulators.
Tully, T., Cold Spring Harbor Laboratory. Learning and
memory.
Yin, J., Cold Srping Harbor Laboratory. CREB and long-term
memory formation in Drosophila.
Wu, C.-F., University of Iowa. Motor systems.
Zhong, Y., Cold Spring Harbor Laboratory. Neuromech-
anisms underlying Drosophila learning and memory.
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The Biology of Memory: From Molecules to Behavior
July 7-20
INSTRUCTORS
Bryne, Jack, Ph.D., University of Texas-Houston Medical School
Mauk, Michael, Ph.D., University of Texas-Houston Medical School
Pearson, Keir, Ph.D., University of Alberta, Canada
Squire, Larry, Ph.D., University of California, San Diego
This lecture course provided an introduction to cellular, molecular, and systems approaches to
learning and memory. It was suited for graduate students in molecular biology, neurobiology, and
psychology as well as research workers who are interested in an introduction to this field. The
course covered topics ranging from behavioral considerations of learning and memory to gene
regulation in the nervous system. The lectures provided an intensive coverage of six selected
areas: (1) an introduction to modern behavioral studies of learning and memory; (2) an overview of
the cell biology of neuronal plasticity and second messenger systems; (3) the regulation of gene
expression; (4) cellular and molecular mechanisms of simple forms of learning and memory in in-
vertebrates and vertebrates; (5) cellular and molecular mechanisms of long-term potentiation and
depression in various regions of the mammalian brain; and (6) systems approaches to learning in
vertebrates and humans. Lecturers included G. Ball, M. Baer, A. Doupe, H. Eichenbaum, C. Gil-
bert, W. Greenough, P. Holland, E. Kandel, P. Pfaffinger, M. Raichle, C. Rankin, H. Schulman, J.
Steinmetz, and T. Tully.
PARTICIPANTS
Buffalo, E., B.A., University of California, San Diego
Christensen, J., B.S., Cold Spring Harbor Laboratory
Cobain, M., B.S., Wyeth Research Ltd., United Kingdom
Connolly, C., B.S., Ph.D., University College London, United
Kingdom
Garren, J., B.A., Brown University
Gusev, P., B.S., N.V. Lomonosov State University, Russia
Hittner, J., B.A., University of California, Irvine
Hudmon, A., B.S., M.S., University of Texas Health Science
Center
Kabotyanski, E., Ph.D., University of Texas-Houston Medical
School
Murphy, M., B.S., Ph.D., Walter & Eliza Hall Institute, Austra-
lia
Plasterk, R., Ph.D., Netherlands Cancer Institute, The Nether-
lands
Rogove, A., B.S., State University of New York, Stony Brook
Setlow, B., B.A., University of California, Irvine
Stubbs, L., B.S., Ph.D., Oak Ridge National Laboratory
Yamakawa, K., B.S., Ph.D., Cedars-Sinai Medical Center,
Los Angeles, California
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SEMINARS
Ball, G., Johns Hopkins University. Ethological approaches
to learning.
Byrne, J., University of Texas-Houston Medical School.
Introduction to the cellular study of learning.
Overview of membranes and synaptic transmission I.
Overview of membranes and synaptic transmission II.
Classical conditioning in Aplysia.
Bear, M., Brown University. Mechanisms of long-term
depression.
Doupe, A., University of California, San Francisco. Bird-song
learning.
Eichenbaum, H., State University of New York, Stony Brook.
Role of the hippocampus and hippocampal long-term
potentiation in learning.
Gilbert, C., Rockefeller University. Functional reorganization
in visual cortex.
Greenough, W., University of Illinois, Urbana. Morphological
correlates of learning and experience.
Holland, P., Duke University.
Introduction to learning theory I.
Introduction to learning theory II.
Kandel, E., Columbia University.
Nonassociative learning in Aplysia I.
Nonassociative learning in Aplysia II.
Developmental Neurobiology
Long-term potentiation I.
Long-term potentiation II.
Mauk, M., University of Texas-Houston Medical School.
The structure and function of ion channels.
Plasticity in the vestibulo-ocular reflex.
Pearson, K., University of Alberta, Canada. Mechanisms of
motor learning.
Pfaffinger, P., Baylor College of Medicine.
Cloning of genes important to learning I.
Cloning of genes important to learning II.
Raichle, M., Washington University School of Medicine, St.
Louis. Neuropsychology of cognition.
Rankin, C., University of British Columbia, Canada. Genes
and behavior of C. elegans.
Steinmetz, J., Indiana University. Classical conditional of the
nictatating membrane.
Squire, L., University of California, San Diego.
Memory in nonhuman primates.
Human memory and disorders of memory.
Tully, T., Cold Spring Harbor Laboratory. Genetic ap-
proaches to study associative learning in Drosophila.
Schulman, H., Stanford University. Overview of second mes-
senger systems and their role in learning and memory.
July 24-August 6
INSTRUCTORS
Lemke, Greg, Ph.D., The Salk Institute
O'Leary, Dennis, Ph.D., The Salk Institute
The aim of this lecture course was to discuss established principles and recent advances in devel-
opmental neurobiology. Major topics considered were proliferation, migration, and aggregation of
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neurons; determination and differentiation of neural cells; trophic interactions in neural develop-
ment; patterns; gradients and compartments; genetic programs for development; the guidance of
axons to targets; and the formation of synaptic connections. These topics were considered within
the context of the development of both invertebrate and vertebrate neural systems. Students had a
background in neurobiology or molecular biology. Speakers included Y. Barde, C. Goodman, M.E.
Hatten, N. Heinz, T. Jesse II, C. Kintner, G. Lemke, D. O'Leary, J. Rubenstein, J. Sanes, C. Shatz,
and L. Zipursky.
PARTICIPANTS
Ahlgren, S., B.A., Ph.D., University College London, United
Kingdom
Araujo, H.M., M.S., Ph.D., Brazilian Federation for Experi-
mental Biology, Brazil
Arber, S., B.S., Friedrich Miescher Institute, Germany
Belliveau, M., B.S., Harvard Medical School
Collignon, J., Ph.D., Harvard University
Craig, C., B.S., Ph.D., University of Toronto, Canada
Dale, J., B.S., Ph.D., National Institute for Medical Research,
United Kingdom
Delaney, C., B.S., University of Wisconsin, Madison
Dokucu, M., M.D., Washington University School of Medicine
Episkipou, V., B.S., Ph.D., MRC Clinical Sciences Center,
SEMINARS
Barde, Y., Max-Planck Institute, Germany. Neurotrophins and
their receptors in development.
Goodman, C., University of California, Berkeley. Establishing
the specificity of the neuronal connections.
Hatten, M. and N. Heinz, The Rockefeller University. Cellular
interactions in cortical and cerebellar development.
Jesse'', T., Columbia University. Induction and cell patterning
in the vertebrate nervous system.
Kinter, C., The Salk Institute, La Jolla, California. Neural in-
duction and early A-P patterning of the nervous system.
Lemke, G., The Salk Institute. Myelin and myelination.
United Kingdom
Forjanic, J.P., B.S., Max-Planck Institute, Germany
Frade, J., B.S., Ph.D., Cajal Institute, Spain
Lustig, M., B.A., New York University Medical Center
Meijer, D., M.D., Erasmus University, The Netherlands
Mombaerts, P., M.D., Ph.D., Columbia University
Olsson, M., B.S., University of Lund, Sweden
Patapoutian, A., B.S., Ph.D., California Institute of Technol-
ogy
Pe les, E., M.S., Ph.D., Sugen Inc., Redwood City, California
Pierani, A., Ph.D., Institut Curie, France
Wallace, V., B.S., Ph.D., Medical Research Council, United
Kingdom
O'Leary, D., The Salk Institute. Systems development: Devel-
opment of the cerebral cortex.
Rubenstein, J., University of California, San Francisco. Seg-
mentation of the nervous system.
Sanes, J., Washington University School of Medicine. Devel-
opment of neuromolecular junction.
Shatz, C., University of California, Berkeley. The generation
and maintenance of synaptic connections.
Zipursky, S.L., University of California, Los Angeles. Cell fate
choice and specification of the Drosophila eye.
Advanced Molecular Cloning and Expression of Eukaryotic Genes
July 25-August 14
INSTRUCTORS
Burtis, Kenneth, Ph.D., University of California, Davis
Learned, Marc, Ph.D., University of California, Davis
Smale, Stephen, Ph.D., University of California, Los Angeles
ASSISTANTS
Connolly, Erin, University of California, Davis
Kae lin, Christopher, University of California, Davis
This course focused on both the cloning and characterization of eukaryotic genes to probe their
structure, function, and expression. As a model system, the students examined cis- and trans-
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acting components involved in the regulation of eukaryotic gene expression. Eukaryotic transcrip-
tion factors were expressed in E. coli and purified by affinity chromatography. Mutations were gen-
erated in the DNA-binding domain of these factors by oligonucleotide-directed mutagenesis proce-
dures and characterized by DNA sequencing and DNA-binding assays. Using both the wild-type
and mutant proteins, students learned the techniques and theory for detecting and characterizing
the interaction between regulatory DNA sequences and trans-acting protein factors, including
mobility shift assays, DNase I footprinting, and methylation interference. Regulation of gene expres-
sion by nuclear proteins was examined both by in vitro transcription assays using cell-free extracts
and by transfection of cloned DNA into mammalian tissue culture cells. Analytical techniques for
these expression studies included primer extension, nuclease protection, and enzymatic assays for
reporter proteins.
Finally, expression libraries from various organisms were prepared and screened with recogni-
tion site probes for specific DNA-binding proteins as a means of learning the theoretical and practi-
cal aspects of constructing cDNA libraries. Guest lecturers discussed present current problems in
eukaryotic molecular biology as well as technical approaches to their solution. Experience with
basic recombinant DNA techniques was a prerequisite for admission to this course. Seminar
speakers included S. Bell, S. Burley, M. Carey, V. Chandler, L. Freedman, C. Greider, D. Gilmour,
N. Hernandez, R. Sen, and K. Struhl.
PARTICIPANTS
April, C., B.S., University Cape Town, South Africa
Bazhenova, 0., B.S., Ph.D., New England Deaconess Hospi-
tal
Bernstein, L., B.A., Ph.D., National Cancer Institute
Brunson, D., B.S., M.S., D.V.M., University of Wisconsin
School of Veterinary Medicine
Buxbaum, J., B.S., M.S, Ph.D., Rockefeller University
Carpino, N., B.A., Cold Spring Harbor Laboratory
Crosby, J., B.S., University of Chile, Chile
Ekengren, S., B.S., Stockholm University, Sweden
Gallicano, I., B.S., Ph.D., Arizona State University
Greenberg, A., B.A., M.D., Tufts University
Keinanen, R., M.S., Ph.D., University of Kuopio, Finland
Kontoyiannis, D., M.D., Harvard Medical School
Losordo, D., B.A., M.D., Tufts University
Mahal, S., B.S., St. Mary's Hospital Medical School, United
Kingdom
Watts, R., B.S., National University of Singapore, Singapore
Zander, C., B.S., Karolinska Hospital, Sweden
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SEMINARS
Bell, S., Massachusetts Institute of Technology. Initiation of
DNA replication in yeast.
Burley, S., The Rockefeller University. X-ray crystallographic
studies of eukaryotic transcription factors.
Carey, M., University of California, Los Angeles. A mechan-
ism for eukaryotic gene activation and synergy.
Chandler, V., University of Oregon. Multiple levels of regula-
tion of the maize anthocyanin pathway.
Freedman, L., Memorial Sloan-Kettering Institute, New York,
New York. Modulation of nuclear receptor target gene se-
lectivity by receptor dimerization.
Greider, C., Cold Spring Harbor Laboratory. Isolation and
characterization of telomerase genes.
Gilmour, D., Pennsylvania State University. In vivo and in
vitro analyses of the hsp70 promoter reveal interactions in-
volved in establishing transcriptional potential.
Hernandez, N., Cold Spring Harbor Laboratory. TBP-
containing complexes in transcription by RNA polmerases
II and III.
Sen, R., Brandeis University. Factors regulating Ig gene ex-
pression.
Struhl, K., Harvard Medical School. Molecular mechanisms
of transcriptional regulation in yeast.
Imaging Structure and Function in the Nervous System
July 25-August 14
INSTRUCTORS
Augustine, George, Ph.D., Duke University Medical Center
Lichtman, Jeff, Ph.D., Washington University School of Medicine, St. Louis
Smith, Stephen, Ph.D., Stanford University
ASSISTANTS
Culican, Susan, Washington University School of Medicine, St. Louis
Eilers, Jens, University of Saarlandes, Germany
Finch, Beth, Duke University Medical Center
Handran, Shawn, Washington University School of Medicine, St. Louis
Advances in optical microscopy, digital image processing, and the development of a variety of
powerful fluorescent probes presented expanding opportunities for visualizing the structure and
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function of neurons, synapses, and networks in the brain. This intensive laboratory/lecture course
provided participants with the theoretical and practical tools to utilize these emerging technologies.
The primary emphasis of the course was on optical microscopy, including fluorescence, differential
interference (Normarski), phase, and confocal microscopy, and the application of different kinds of
video cameras and digital image processing to enhance microscopic images. To learn the princi-
ples of light microscopy, students built and operated an optical bench microscope. In other
laboratory exercises, students used calcium-sensitive probes (e.g., fura-2), "caged" compounds,
exocytost's tracers, whole-cell patch clamp methods to microinject fluorescent indicators into
single cells, and other methods to explore neuronal function. A variety of neural systems, including
living animals, brain slices, peripheral synapse preparations, acutely dissociated neurons, and cul-
tured cells, were used in our experiments.
Lecturers included W. Betz, J. Connor, S. Fraser, F. Fay, L. Cohen, G. Ellis-Davies, J. Heuser, T.
Inoue, L. Katz, A. Konnerth, F. Lanni, R. Lewis, M. Minsky, J. Nerbonne, J. Swedlow, R. Y. Tsien, W.
Webb, and J. White.
PARTICIPANTS
Cohen, U., B.A., National Institutes of Health, HHMI
Deisseroth, K., B.S., Stanford University
Dresbach, T., B.S., Max-Planck Institute for Brain Research.
Germany
Gan, W., B.E., Ph.D., Columbia University
Martin, K., B.A., M.D., Ph.D., Columbia University, HHMI
Mintz, I., Ph.D., Boston University School of Medicine
Mochida, S., M.A., Ph.D., Tokyo Medical College, Japan
SEMINARS
Augustine, G., Duke University Medical Center.
Calcium indicators. Calibration of fluorescent Ca indicator
dyes.
Exploring synaptic function with optical methods.
Laser principles.
Betz, W., University of Colorado School of Medicine. Fluores-
cence measurements of synaptic vesicle cycling.
Cohen, L., Yale University School of Medicine. Voltage-
sensitive dyes.
Conner, J., Roche Institute of Molecular Biology, Nutley, New
Jersey, Calcium imaging in brain slices.
Ellis-Davis, G., Oregon Health Sciences University. Design of
caged compounds.
Heuser, J., Washington University School of Medicine. Inter-
ference reflection microscopy.
Inoue, T., Universal Imaging Corporation, West Chester,
Pennsylvania. Image analysis of software,
Katz, L., Duke University Medical Center. Flash photolysis in
brain slices.
Konnerth, A., Physiologisches Institut, Germany. Patch
clamp measurements from CNS neurons in slices.
Lanni, F., Center for Light Microscope Imaging.
Standing wave fluorescence microscopy.
Near-field optical scanning.
Evanescent wave microscopy.
Lewis, R., Stanford University School of Medicine. Calcium
signaling pathways.
Lichtman, J., Washington University.
Optical principles.
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Murthy, V., B.T., M.S., Ph.D., Salk Institute, La Jolla, Califor-
nia
Otis, T., B.S., M.S., Ph.D., University of Wisconsin Medical
School
Pedarzani, P., M.D., Ph.D., University of Oslo, Norway
Sinha, S., B.S., Baylor College of Medicine
Uchitel, 0., M.D., University of Buenos Aires, Argentina
The light microscope.
Resolution.
Fluorescence principles.
Fluorescence microscopy and phototoxicity.
In vivo imaging.
Introduction to confocal microscopy.
Minsky, M., Massachusetts Institute of Technology. Develop-
ment of the confocal microscope.
Oshiro, M., Hamamatsu Photonic Systems, Inc., Bridgewater,
New Jersey. Low-light-level cameras.
Smith, S., Stanford University.
The measurement of light.
Video signals and standards.
The digitized image.
Polarized light.
Contrast from transparent specimen.
Life-support systems.
Multi-site time lapse.
Laser confocal microscopy.
Imaging studies of dendrite growth and synaptogenesis.
Swedlow, J., University of California, San Francisco.
Digital image restoration.
Volume rendering.
Tsien, R., Howard Hughes Medical Institute. Design and ap-
plication of indicator dyes.
Webb, W., Cornell University. 2-photon microscopy princi-
ples.
White, J., Integrated Microscopy Resources, Madison, Wis-
consin. 2-photon microscopy applications.
Yeast Genetics
July 25-August 14
INSTRUCTORS
Adams, Alison, Ph.D., University of Arizona
Kaiser, Chris, Ph.D., Massachusetts Institute of Technology
Gottschling, Daniel, Ph.D., University of Chicago
ASSISTANTS
Bickle, Steve, Massachusetts Institute of Technology
Davis, Dana, University of Arizona
Diede, Scott, University of Chicago
The major laboratory techniques used in the genetic analysis of yeast were studied, including the
isolation and characterization of mutants, tetrad analysis, complementation, and mitotic recombina-
tion. Micromanipulations used in tetrad analysis were carried out by all students. Molecular genetic
techniques, including yeast transformation, gene replacement, and analysis of gene fusions, were
applied to the analysis of yeast DNA. Indirect immunofluorescence experiments were done to iden-
tify the nucleus, microtubules, and other cellular components. Lectures on fundamental aspects of
yeast genetics were presented along with seminars given by outside speakers on topics of current
interest.
PARTICIPANTS
Bauer, M., M.D.,. Universitat Munchen, Germany
Bentley, D., Ph.D., University of Toronto, Canada
Folkerts, 0., B.S., M.S., Ph.D., DowElanco, Indianapolis, Indi-
ana
Foskel, D., B.A., Ph.D., University of California, Irvine
Heinrich, J., B.A., Ph.D., American Cyanamid Co., Prince-
ton, New Jersey
Holkeri, H., M.S., University of Helsinki, Finland
Li, Q., M.S., M.D., Karolinska Institute, Sweden
Pember, S., B.S., Ph.D., E.I. Dupont Company
UCK LABORCTORY
Shimizu, K., B.S,. Ph.D., Osaka University, Japan
Stahl, G., Ph.D., CNRS-URA 1354, France
Stafford, G., B.A., Ph.D., State of New York Department of
Health
Sun, Z., B.S., M.S., Yale University
Vasconcelles, M., B.A., M.D., Harvard Medical School
Weissman, J., B.A., Ph.D., Yale University/HHMI
White, T., B.S., Ph.D., University of California, San Francisco
Zuk, D., M.S., Ph.D, University of Massachusetts Medical
School
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SEMINARS
Adams, A., University of Arizona. Genetic analysis of the ac-
tin cytoskeleton.
Cherry, M., Stanford University. The Saccharomyces genome
database.
Fields, S., State University of New York, Stony Brook. Yeast
hybrid methods to analyze protein-protein, peptide-
peptide, and protein RNA interactions.
Fink, G., Whitehead Institute, Cambridge, Massachusetts.
The information superhighway, How they get from here to
there.
Futcher, B., Cold Spring Harbor Laboratory. The yeast cell
cycle engine.
Gottschling, D., University of Chicago. The secrets of si-
lence.
Heiter, P., Johns Hopkins University. Determinants of
chromosome transmission in yeast and humans.
Herskowitz, I., University of California, San Francisco. Control
of cell specialization in yeast.
Kaiser, C., Massachusetts Institute of Technology. Life, secs,
and then you die!
Michaelis, S., Johns Hopkins School of Medicine. Biogen-
esis of the A-factor mating pheromone.
Mitchell, A., Columbia University. Regulators that govern
meiosis in yeast.
Petes, T., University of North Carolina, Chapel Hill. Macro-
and micro-rearrangements of the yeast genome.
Rose, M., Princeton University. Nuclear fusion in yeast.
Sherman, F., University of Rochester School of Medicine.
Cytochrome c, the complete story.
Struhl, K., Harvard Medical School. Molecular mechanisms
of transcriptional regulation in yeast.
Weinert, T., University of Arizona. Checkpoints in yeast.
Winston, F., Harvard Medical School. Analysis of histones,
TATA-binding protein, and other transcription factors of
yeast.
Neurobiology of Human Neurological Disease:
Mechanisms of Neurodegeneration
August 8-14
INSTRUCTORS
Choi, Dennis, M.D., Ph.D., Washington University School of Medicine
Mobley, William, M.D., Ph.D., University of California, San Francisco
Why do neurons and glia die in specific acute or chronic human neurological disorders? Do dif-
ferent pathological deaths share common mechanisms? What practical treatments can be con-
templated? This lecture course explored possible answers to these important questions. Recent
advances in molecular and cell biology have begun to shed light on the mechanisms that underlie
nervous system injury in disease states such as Alzheimer 's disease, Huntington's disease,
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amyotrophic lateral sclerosis, and stroke. Taking advantage of small class size and extensive dis-
cussion, invited faculty lecturers examined critical issues in their areas of expertise. Overview was
provided, so course participants did not need to be familiar with neurological diseases. The course
focused on the specific hypotheses and approaches driving current research, and emphasized the
highly dynamic interface between basic and clinical investigations, including the interdependence
of clinical research and disease model development, and the value of disease research for under-
standing the nature of the normal nervous system. Last year's faculty were D. Bredesen, M. Chalfie,
V. Dawson, K. Fischbeck, E. Johnson, D. Landis, J. McNamara, H. Monyer, D. Price, S. Prusiner,
and D. Selkoe.
PARTICIPANTS
Adams, A., B.S., Vanderbilt University, Nashville, Tennessee
Ahn, Y.S., M.D., Ph.D., Yonsei University College of Medi-
cine, Korea
Arnold, C.S., B.S., University of Alabama, Birmingham
Bertorelli, R., B.S., Shering Plough Corporation, Milan, Italy
Burns, C., B.S., Vanderbilt University
Campos, L., M.D., MRC Cambridge, United Kingdom
Cheung, V., B.S., M.D., University of California, Los Angeles
Filburn, C., B.A., Ph.D., National Institutes of Health
Herdegen, T., M.D., Ph.D., University of Heidelberg,
Germany
Krause, B.J., M.D., Research Center Julich, Germany
Maciel, P., B.S., University of Porto, Portugal
Mahanthappa, N., B.A., Ph.D., Cambridge Neuroscience,
Inc., Cambridge, Massachusetts
SEMINARS
Bredesen, D., La Jolla Cancer Research Foundation, La
Jolla, California. Control of neural apoptosis.
Chalfie, M., Columbia University. Genetically determined
neurodegeneration.
Choi, D., Washington University School of Medicine, St.
Louis. Excitotoxicity.
Dawson, V., John Hopkins University School of Medicine.
Nitric oxide and neurodegeneration.
Fischbeck, K., University of Pennsylvania School of Medi-
cine. Molecular genetics of neurological diseases.
Johnson, E., Washington University School of Medicine, St.
Louis. Programmed cell death.
Landis, D., Case Western Reserve School of Medicine,
Majeed, A.B. Abdul, Ph.D., University Sains, Malaysia
Marraccino, R., B.S., Ph.D., Roche Institute of Molecular Biol-
ogy, Nutley, New Jersey
Meldahl, A.-S., Ph.D., University of Oxford, United Kingdom
Moechars, D., M.S., Katholieke University van Leuven, Bel-
gium
Schmitt, B., M.D., University Zurich, Switzerland
Schneider, H., B.S., Ph.D., Schering AG, Berlin, Germany
Shirsat, N., M.S., Ph.D., Tata Institute, India
Tekirian, T., B.S., University of Kentucky
Tompkins, M., B.S., Medial College of Georgia
Yan, H., B.S., Ph.D., Amgen, Inc., Thousand Oaks, California
Zacharias, D., B.S., M.S., Mayo Graduate School, Rochester,
Minnesota
Cleveland, Ohio. Role of glia in CNS injury.
McNamara, J., Duke University Medical Center. Epilepsy and
ammon's sclerosis: Chicken and egg.
Mobley, W., University of California School of Medicine, San
Francisco, Neuronal growth factors.
Monyer, H., University of Heidelberg, Germany. Glutamate
receptors in health and disease.
Price, D., Johns Hopkins University School of Medicine.
Motor neuron disease and Alzheimer's disease.
Prusiner, S., University of California School of Medicine, San
Francisco. Prions.
Selkoe, D., Brigham and Womens's Hospital, Boston, Massa-
chusetts. Molecular pathogenesis of Alzheimer's disease.
Advanced In Situ Hybridization and Immunocytochemistry
October 12-25
INSTRUCTORS
Hough, Paul, Ph.D., Brookhaven National Laboratory
Jacobson, Ken, Ph.D. University of North Carolina, Chapel Hill
Mastrangelo, Iris, Ph.D., Brookhaven National Laboratory
Spector, David, Ph.D., Cold Spring Harbor Laboratory
Ried, Thomas, Ph.D., National Institutes of Health
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ASSISTANTS
Howard, Tamara, Cold Spring Harbor Laboratory
Sheets, Erin, University of North Carolina, Chapel Hill
This course focused on specialized techniques in microscopy related to localizing DNA sequences
and proteins in cells and preparing DNA and DNA-protein spreads for microscopic examination.
The course emphasized the use of the latest equipment and techniques in epifluorescence micro-
scopy, confocal laser scanning microscopy, electron microscopy, and digital image processing.
The aims of the course were designed to provide state-of-the-art technology and scientific ex-
pertise in the use of microscopic applications to address basic questions in genome organization
and cellular and molecular biology. The course was designed for the molecular biologist who is in
need of microscopic approaches and for the cell biologist who is not familiar with the practical ap-
plication of the advanced techniques presented in the course. Among the methods presented was
the preparation of tagged nucleic acid probes, fixation methods, detection of multiple DNA se-
quences in single nuclei or chromosome spreads, comparative genomic hybridization, use of a va-
riety of reporter molecules and nonantibody fluorescent tags, and indirect antibody labeling detec-
tion of multiple proteins in a single cell. In addition, molecular electron microscopy was used to ex-
amine DNA-protein interactions. In each method, several experimental protocols were presented
allowing the students to assess the relative merits of each and to relate them to their own research.
Students were encouraged to bring nucleic acid or protein probes to the course which were used
in addition to those provided by the instructors. The laboratory portion of the course was supple-
mented by invited lecturers who gave up-to-the-minute reports on current research using the tech-
niques being presented in the course.
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PARTICIPANTS
Cass, D., A.B., M.D., Children's Hospital of Pennsylvania
Jin, Y., M.D., Ph.D., University of Texas Southwestern Medi-
cal Center, Dallas
Kerr, J., B.A., Ph.D., DuPont Merck Pharmaceutical Compa-
ny, Wilmington, Delaware
Lightfoote, M., B.A., Ph.D., Food and Drug Administration
Lanoil, B., B.A., Oregon State University
Miotke, J., B.S., University of California, Irvine
Nepveu, A., B.S., M.S., Ph.D., McGill University, Canada
O'Driscoll, K., B.S., Ph.D., Columbia University
SEMINARS
Bagasra, 0., Thomas Jefferson University, Philadelphia,
Pennsylvania. In situ PCR and its applications in research
and diagnosis.
Brinkley, W., Baylor College of Medicine. Organization of the
kinetochore.
Hough, P., Brookhaven National Laboratory. Image produc-
tion in the electron microscope and brief overview of dif-
ferent applications.
Jacobson, K., University of North Carolina, Chapel Hill.
Basic introduction to light microscopy and video micro-
scopy. Fluorescence microscopy and low-light-level
cameras.
Murray, J., University of Pennsylvania. Principles of confocal
Macromolecular Crystallography
Ogryzko, V., M.S., Ph.D., National Institutes of Health
Oh Is, R., B.A., M.D., University of Florida College of Medicine
Platt, K., B.S., M.S., Ph.D., University of California, Riverside
Salin, T., M.S., Karolinska Institute, Sweden
Shel bourne, P., B.S., Ph.D., Stanford University
Shmueli, 0., B.S., M.S., Weizmann Institute, Israel
Solovei, I., M.S., Ph.D., University of St. Petersburg, Russia
Wolda, S., B.S., Ph.D., ICOS Corporation, Bothell, Washing-
ton
microscopy and deconvolution techniques.
Ried, T., National Institutes of Health. Comparative genomic
hybridization.
Singer, R., University of Massachusetts Medical School.
Cytoplasmic organization of mRNA.
Spector, D., Cold Spring Harbor Laboratory. Immunocyto-
chemistry. An integrated microscopic approach to examin-
ing nuclear organization.
Waggoner, A., Biological Detection, Inc., Pittsburgh,
Pennsylvania. Development of fluorochromes and filters for
fluorescence microscopy.
White, J., University of Wisconsin, Madison. 2-photon mi-
croscopy.
October 12-25
INSTRUCTORS
Furey, William, Ph.D., V.A. Medical Center
Gilliland, Gary, Ph.D., Center for Advanced Research in Biotechnology
McPherson, Alexander, Ph.D., University of California, Riverside
Pflugrath, James, Ph.D., Molecular Structure Corporation
ASSISTANT
Kjeldgaard, Morten, Aarhus University, Denmark
Crystallography and X-ray diffraction yield a wealth of structural information unobtainable through
other methods. This "intensive" laboratory/computational course focused on the major techniques
used to determine the three-dimensional structures of macromolecules. It was designed for
scientists with a working knowledge of protein structure and function, but who were new to macro-
molecular crystallography. Topics that were covered included crystallization (proteins, nucleic
acids, and complexes), crystal characterization, X-ray sources and optics, crystal freezing, data
collection, data reduction, anomalous dispersion, multiple isomorphous replacement, phase
determination, solvent, flattening, molecular replacement, and averaging, electron density inter-
pretation, structure refinement, and molecular graphics. Participants learned through extensive
hands-on experiments where they crystallized and determined a protein structure, along with lec-
tures and informal discussions on the theory behind the techniques.
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PARTICIPANTS
Batchelor, A., Ph.D., Johns Hopkins Medical School
Bordo, D., Ph.D., University of Groningen, The Netherlands
Briggs, S., B.S., Eli Lilly and Company, Indianapolis, Indiana
Eakin, A., B.A., Ph.D., University of Puerto Rico School of
Medicine
Gonnella, N., A.B., Ph.D., Ciba-Geigy Corporation, Summit,
New Jersey
Grabarek, Z., M.S., Ph.D., Boston Biomedical Research In-
stitute, Boston, Massachusetts
Hall, T., B.S., Ph.D., Johns Hopkins University School of
Medicine
SEMINARS
Brunger, A., Yale University. Protein solvation and discrete
disorder observed at high resolution using experimental
phases.
Cheng, X., Cold Spring Harbor Laboratory. DNA modification
by methyltransferases.
Clore, G.M., National Institutes of Health. Molecular basis of
46 XY sex reversal from the structure of the SRY-DNA com-
plex.
Edwards, A., McMaster University, Ontario, Canada. Crystal
structure of the origin binding protein EBNA1 bound to
DNA suggests a mechanism for replication origin unwind-
ing.
Freer, A., University of Glasgow, Scotland. Membrane
proteins in bacterial photosynthesis: A circular arrange-
Norwich, A., A.B., M.D., Yale University School of Medicine
Kanellopoulos, P., Ph.D., EMBL, Germany
Lehtonen, J., M.S., University of Turku, Finland
MacKinnon, R., B.A., M.D., Harvard Medical School
Rabijns, A., Ph.D., Catholic University of Leuven, Belgium
Rizvi, S., B.S., M.S., Ph.D., University of Pennsylvania School
of Medicine
Sayre, P., M.D., Ph.D., University of California, San Francisco
Song, Y.-H., B.S., Ph.D., University of Toronto, Canada
Weiss, M., A.B., Ph.D., University of Chicago
ment.
Gilliland, G., National Institute of Standards & Technology,
Rockville, Maryland. Engineering of subtilisin BPN and its
foldase prosegment for increased stability, calcium inde-
pendence, and efficient folding.
Newcomer, M., Vanderbilt University. Determination of the
quaternary structure of the transthyrein/retinol-binding
protein complex.
Sweet, R., Brookhaven National Laboratory, Upton, New
York. Laue diffraction as a tool for study of dynamic effects
in protein crystals.
Ramakrishnan, V., University of Utah School of Medicine.
Toward the structure of the ribosome: Structure of the
ribosomal proteins and initiation factor 3.
YACs in Structural and Biological Genome Analysis
October 12-25
INSTRUCTORS
Huxley, Clare, Ph.D., St. Mary's Hospital Medical School, United Kingdom
Lovett, Michael, Ph.D., University of Texas Southwestern Medical Center
Reeves, Roger, Ph.D., Johns Hopkins University
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ASSISTANTS
Cabin, Deborah, Johns Hopkins University
Clines, Greg, University of Texas Southwestern Medical Center
Simpson, Kaetrin, St. Mary's Hospital Medical School, United Kingdom
Yeast artificial chromosomes (YACs) are an essential tool in genome analysis involving physical
mapping, contig building, gene isolation, and functional analysis of cloned DNA. This lab-based
course covered techniques used in physical mapping, including the basics of growth and storage
of YACs, analysis of YACs by pulsed-field gel electrophoresis, creation of nested derivatives by
fragmentation at repeat sequences, contig building by STS content mapping, and end-clone res-
cue. Gene identification was carried out by direct cDNA selection from purified cosmid, YAC, and
total chromosomal DNA, and exon trapping was covered in lectures. Techniques for functional
analysis of YAC DNA included introduction of YACs into mouse cells by fusion with yeast
spheroplasts, lipofection into mouse cells with gel-purified DNA, and preparation of YAC DNA for
pronuclear injection. YACs were also manipulated by homologous recombination for the introduc-
tion of specific modifications. Lectures on complementary topics were given by invited speakers
who are prominent researchers in the field and who then spent time talking individually to the
participants. There was also structured discussion of how to apply the current technology to the
specific research projects of the participants.
PARTICIPANTS
Albarosa, R., Ph.D., Instituto Nazionale Neurologico'C. Bes-
ts,' Italy
Black, D., B.S., Zeneca Pharmaceuticals, United Kingdom
Engels, P., B.S., Ph.D., Sandoz Pharma Ltd., Switzerland
Guillemot, F., B.S., CNRS, UPR 420, France
Hiraga, A., M.D., Tohokku University, Japan
Kelavkar, U., M.S., Ph.D., Clark Atlanta University
Leister, D., M.S, Max-Planck Institute, Germany
Lenge ling, A., B.S., University of Bielefeld, Germany
Mjumder, K., B.S., M.S., Ph.D., Baylor College of Medicine
Maurici, D., B.S., Brigham and Women's Hospital
Peitz, G., B.S., M.D., Ph.D., Roche Bioscience, Palo Alto,
California
Queimado, L., M.S., M.D., New University of Lisbon, Portugal
Rayl, E., B.S., Ph.D., Yale University
Richter, A., B.S., Ph.D., University of Montreal, Canada
Sidjanin, D., B.S., Ph.D., University of Pennsylvania
Wang, G., B.S., Ph.D., Loma Linda University
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SEMINARS
Buckler, A., Massachusetts General Hospital. Physical and
transcription mapping with exons.
Green, E., National Institutes of Health. Mapping human
chromosomes with YACs.
Huxley, C., St. Mary's Hospital Medical School, United King-
dom. Transfer of YAC DNA into mammalian cells and
transgenic mice.
Lovett, M., University of Texas Southwestern Medical Center.
Gene isolation by cDNA selection.
Reeves, R., Johns Hopkins University. Functional analysis of
Computational Genomics
YAC DNA in mammalian cells.
Riethman, H., The Wistar Institute, Philadelphia, Pennsyl-
vania. RARE cleavage and long-PCR-based analysis of
subtelomeric DNA.
Rothstein, R., Columbia University. Yeast genetics.
Trask, B., University of Washington, Seattle. Chromosomal
mapping of YACs.
Wilson, R., Washington University School of Medicine. Ge-
nome analysis by means of large-scale DNA sequencing.
November 1-6
INSTRUCTORS
Marr, Thomas, Ph.D., Cold Spring Harbor Laboratory
Pearson, William, Ph.D., University of Virginia
Smith, Randall, Ph.D., Baylor College of Medicine
This course provided a comprehensive overview of the methods used to identify genes and to infer
their function and evolutionary history. Today, the most powerful technique for characterizing a new
DNA or protein sequence is by similarity searching for homologous proteins; the course presented
the theory and practice for similarity searching using the BLASTP, FASTA, and Smith-Waterman al-
gorithms. Students were able to see the structural implications of protein sequence homology by
viewing homologous proteins in three dimensions on state-of-the-art UNIX workstations. Talks on
protein evolution and the computer programs used to discover homologous proteins were ex-
tended with lectures on the statistics of sequence similarity scores, multiple alignment techniques,
and phylogenetic methods. The course was expanded this year to include discussions of recent
advances in statistical techniques for multiple sequence alignment and consensus sequence iden-
tification. In addition, a lecture and workshop focused on the identification of protein coding genes
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in anonymous DNA sequences. This year, the Computational Genomics course provided additional
"hands-on" problems by splitting the group into five teams and providing each team with a different
and challenging protein identification problem. This course was intended for people with a solid
fundamental knowledge of UNIX who wanted to acquire advanced skills in DNA and protein se-
quence analysis. This course provided both practical examples and problems in sequence analy-
sis using methods that are available today and a foundation in the algorithmic approaches that are
likely to produce new methods in the future. The course was ideal for computer core directors and
staff, for molecular biology and genetics resources, for biologists who wished to acquire advanced
skills in genome analysis, and for computer scientists who wanted an overview of the state of the
art in this area.
PARTICIPANTS
Aman, P., Ph.D., University of Lund, Sweden
Atrian, S., B.S., Ph.D., University of Barcelona, Spain
Bergstrom, T., B.S., University of Uppsala, Sweden
Brefort, G., M.D., Ph.D., Rhone-Poulenc Rorer, France
Bringas, R., M.S., Center for Genetic Engineering and
Biotechnology, Cuba
Caruso, A., B.S., Genetics Institute, Cambridge, Massachu-
setts
Cueto, M., B.A., Ph.D., Sandoz Research Institute, East
Hanover, New Jersey
Kawai, T., M.S., Ph.D., ImmunoPharmaceutics, Inc., San
Diego, California
Leshkowitz, D., Ph.D., Weizmann Institute of Science, Israel
SEMINARS
Altschul, S., National Library of Medicine. Statistics of
similarity scores.
Davison, D., University of Houston. Approaches to phylogeny
reconstruction.
Kececioglu, J., University of Georgia. Multiple sequence
alignment: Optimal approaches.
Lawrence, C., Wadsworth Center, New York Department of
Health, Albany, New York.
Statistical approaches to multiple sequence analysis.
Workshop: Sequence comparison. Searching with different
programs, comparison of results
Marr, T., Cold Spring Harbor Laboratory. Integration of
biological information, from sequences to maps to function.
Pearson, W., University of Virginia.
Introduction and overview.
Lieb, M., B.A, M.D., Mount Sinai School of Medicine
Lindqvist, A.-K., M.S., University of Uppsala, Sweden
Nel, L., B.S., Ph.D., University of Pretoria, South Africa
Prasad, R., M.S., Ph.D., Thomas Jefferson University, Phila-
delphia, Pennsylvania
Vallejo, R., B.S., M.S., Ph.D., United States Department of
Agriculture
Van Wiemeersch, L., B.S., University of Gent, Belgium
Vass, K., B.S., Ph.D., Glasgow University, United Kingdom
Viguera, E., B.S., Ph.D., Centre de Investigaciones
Biologicas, Spain
Zou, J., M.S., Ph.D., Hoffman-La Roche, Inc., Nutley, New
Jersey
Protein evolution: Biology.
Biological sequence comparison: Algorithms.
Practical issues in protein sequence searching.
Workshop: Getting sequences, searching with sequences,
identifying distant homologs.
Smith, R., Baylor College of Medicine.
Hierarchical multiple alignment approaches.
Workshop: Multiple sequence alignment using both
MSA2.1, ClustalV and PIMA approaches.
Stormo, G., University of Washington, Seattle.
Finding patterns in unaligned sequences.
Workshop: Finding promoters, regulatory sites, and protein
motifs. Gene parsing.
Workshop: Multiple sequence alignment/HMM.
Workshop: Gene identification.
Molecular Markers for Plant Breeding and Plant Genetics
November 8-21
INSTRUCTORS
Burr, Ben, Ph.D., Brookhaven National Laboratory
Doerge, Rebecca, Ph.D., Cornell University
Tingey, Scott, Ph.D., DuPont Experimental Station
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ASSISTANT
Jung, Mark, DuPont Company
The course was designed to explore both theoretical and practical concepts for the use of
molecular markers in plant genetics and plant breeding. This was accomplished through invited
lectures, lab work, interactive instruction, and computational analysis. Participants learned ap-
proaches to problems such as single gene introgression, analysis of genetic diversity, gene map-
ping, and quantitative trait analysis. The techniques employed included DNA amplification-based,
simple sequence repeat polymorphisms, RAPDS, RFLPs, and bulk segregant analysis. Computa-
tional work included utilization of databases, gene mapping, quantitative trait mapping, and
germplasm analysis. A variety of mapping techniques from both plant and animal systems were ex-
amined with respect to their strengths for specific purposes. Experimental design and potential fu-
ture strategies were emphasized. Last year's lecturers included W. Beavis, M. Clegg, D. Duvick, M.
Gale, B. Mazur, R. Michelmore, A. Rafalski, J. Romero-Severson, R. Sederoff, S. Tanks ley, and J.
Wendel.
PARTICIPANTS
Brule-Babel, A., B.S., Ph.D., University of Manitoba, Canada
Byrum, J., B.S., M.S., Asgrow Seed Company, Ames, Iowa
Chin, D., B.S., M.S., University of California, Davis
Crouch, J., B.S., Ph.D., International Institute Tropical Agri-
culture, United Kingdom
Elliott, P. (Beth), M.S., Ph.S., Cold Spring Harbor Laboratory
Hobart, B., A.S., Pioneer Hi-Bred International, Inc.,
Johnston, Iowa
Hunt, M., B.S., Ph.D., Ciba Agricultural Biotechnology, Re-
search Triangle Park, North Carolina
Johnston, S., B.S., Rogers Seed Company, Gilroy, California
Krone, T., B.S., M.S., Ph.D., Asgrow Seed Company, Ames,
Iowa
Lawson, D., B.S., M.S., Ph.D., Cornell University
Phillips, D., B.S., Pioneer Hi-Bred International, Inc.
Piper, T., B.S., Ph.D., Pioneer Hi-Bred International, Inc
Sebastian, S., Ph.D., E.I. DuPont de Nemours Company,
Newark, Delaware
Shimosaka, E., B.A., Hokkaido National Agriculture Experi-
mental Station, Japan
Van Gysel, A., B.S., Ph.D., University of Gent, Belgium
Vogelaar, A., M.S., Rilk Zwaan, The Netherlands
254
SEMINARS
Ausubel, F., Harvard Medical School. Positional cloning of
defense-related genes in Arabidopsis.
Beavis, W., Pioneer Hi-Bred International, Inc. QTL mapping
in plant breeding populations: Lessons from experimental
populations.
Briggs, S., Pioneer Hi-Bred International, Inc. Genetics of
plant-pathogen interactions.
Dooner, H., Rutgers University. Use of the maize transposon
activator to tag genes in other species.
Kochert, G., University of Georgia. Germplasm variation and
utilization in peanuts.
Mazur, B., DuPont Company. Commercializing the products
of plant biotechnology.
Michelmore, R., University of California, Davis. Molecular
markers and the manipulation of disease resistance.
Rafalski, A., DuPont Company. Comparative analysis of
marker systems in mapping and germplasm characteriza-
tion applications.
Sederoff, R., North Carolina State University. Use of molec-
ular markers in genetics of forest trees.
Vogel, J., DuPont Company. Multiplexed polymorphism
detection: AFLP and SAMPL.
Phage Display of Combinatorial Antibody Libraries
November 8-21
INSTRUCTORS
Barbas, Carlos, Ph.D., Scripps Research Institute
Burton, Dennis, Ph.D., Scripps Research Institute
Silverman, Gregg, M.D., University of California, San Diego
ASSISTANTS
Nayak, Jayakar, University of California, San Diego
Pilkington, Glenn, Intracel Corporation, Boston
Recent advances in the generation and selection of antibodies from combinatorial libraries allow for
the rapid production of antibodies from immune and nonimmune sources. This laboratory/lecture
course focused on the construction of combinatorial antibody libraries expressed on the surface of
phage and selection of desired antibodies from the library. Students learned the theoretical and
practical aspects of constructing combinatorial antibody libraries as well as the construction of
synthetic antibody libraries. Antibodies were selected from the library by panning. Production,
purification, and characterization of Fab fragments expressed in E. coli were also covered. The lec-
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ture series presented by a number of invited speakers focused on PCR of immunoglobulin genes,
the biology of filamentous phage and the utility of surface expression libraries, expression of
antibodies in E. co /i and mammalian cells, antibody structure and function, catalytic antibodies, the
whole biology and molecular genetics of antibody activity, and recent results on the use of
antibodies in therapy.
PARTICIPANTS
Ansari, K., B.S., University of Toronto, Canada
Bieboer, S., B.S., Utrecht University, The Netherlands
Dreier, B., B.S., University of Erlangen, Germany
Hunt, A., B.S., M.S., National Center for Infectious Diseases
Jung, S., B.S., University of Zurich, Switzerland
Leelayuwat, C., ES., Ph.D., University of Western Australia,
Australia
Mamalaki, A., B.S., Hellenic Pasteur Institute, Greece
Mobini, R., B.S., Goteborgs University, Sweden
Olsson, J., B.S., University of Lund, Sweden
SEMINARS
Carter, P., Genentech, Inc. Expression of antibodies and
antibody fragments.
Marquis, D., La Jolla Pharmaceutical. Phage display.
Model, P., Rockefeller University. Phage biology.
Ness ler, P., Cold Spring Harbor Laboratory. Combinatorial
chemistry.
Persson, M., Karolinska Hospital, Sweden. Combinatorial li-
Rondon, I., B.S., Ph.D., Harvard Medical School
Sleister, H., B.S., Ph.D., Pioneer Hi-Bred International, Inc.,
Johnston, Iowa
Turksen, K., B.S., Ph.D., Ottawa Civic Hospital, Canada
Valvatne, H., B.S., M.S., University of Bergen, Norway
Watzka, H., B.S., Ph.D., University of Stuttgart, Germany
Yamaguchi, S., D.D.S., Ph.D., Japanese Foundation for Can-
cer Research, Japan
Du Putlitz, J., M.D., Harvard Medical School
braries from macaques.
Sanz, I., University of Texas Health Science Center. Genera-
tion and features of antibody recognition.
Scanlon, T., University of California, San Francisco. Catalytic
antibodies.
Wilson, I., Scripps Research Institute. Structural basis of
antigen recognition by antibody.
The Laboratory would like to acknowledge the generosity of the following companies who loaned
equipment and reagents to the various courses:
Adams & List Assoc. Ltd.
Ambion, Inc.
Amersham Corporation
AMRESCO Inc.
Applied Biosystems
Applied Precision
Axon Instruments
Baxter Scientific
Beckman Instruments
Becton Dickinson
Bio 101 Inc.
Bio Metra
Bio-Rad Laboratories
Boehringer-Mannheim Biochemicals
Brinkmann Instruments
Carl Zeiss, Inc.
CBS Scientific, Co., Inc.
Chrome Technology
Corning/Costar Corp.
Dage-MTI, Inc.
Drummond Scientific Co.
DuPont/New England Nuclear
Epicentre Technologies
FMC Bioproducts
Gatan Inc.
Gelman Sciences Inc.
General Valve Corporation
Genetix
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GIBCO Life Technologies
Grass Instrument Co.
Hamamatsu Phonic Systems
Hampton Research
Hewlett-Packard Co.
Hitachi
Hoefer Scientific Instruments
Institute Genomics
Instrutech
Invitrogen Corp.
Kodak/IBI
Leica
Leitz/Leica
LI-COR Inc.
Life Technologies, Inc.
Ludl Electronic Products
Matrix Technologies Corp.
MJ Research
Molecular Probes Inc.
Molecular Research Center Inc.
Morrell Instrument Co. Inc.
Nalge Co.
Narishige USA Inc.
New England Biolabs, Inc.
Nikon Inc.
NORAN Instruments Inc.
Novagen Inc.
Olympus America Inc.
Omega Optical Inc.
Optronics Engineering
Owl Scientific Inc.
PCR Inc.
Perkin-Elmer
PerSeptive Biosystems
Pharmacia Biotech Inc.
Promega Corp.
Protein Solutions Inc.
Qiagen Inc.
Replicatech
Research Genetics
Robbins Scientific Corp.
Savant Instruments Inc.
SGI
Sigma Chemical Co.
Stoelting Co.
Stratagene Cloning Systems
Sutter Instrument Co.,
Universal Imaging Corp.
University of California, San Francisco
USA/Scientific Plastics Inc.
Vector Laboratories Inc.
VWR Scientific
Vysis
Wal lac Inc.
Warner Instrument Corp.
SEMINARS
Invited Speaker Program
Each year, Cold Spring Harbor Laboratory invites speakers from outside the institution to present
their latest findings on a weekly basis. These seminars keep the CSHL staff current on the latest
developments and broaden their perspectives. Graduate students and postdoctoral fellows meet
with the seminar speakers for lunch immediately after the seminar, allowing an opportunity for the
exchange of ideas in an informal setting.
1995
January
Jim lhle, St. Jude's Children Hospital, Memphis. JAKs and
STATs in cytokine signaling. (Host: Henry Sadowski)
Leon Avery, University of Texas, Southwestern. Genetics of
neurotransmission in the C. elegans pharynx. (Host:
Michael Hengartner)
Stephen Doxsey, University of Massachusetts. Molecular
function of centrosomes: The role of pericentrin. (Host:
Michael Wig ler)
George Rose, Johns Hopkins University Medical School.
The protein folding problem: New results. (Host: Winship
Herr)
February
Charles Gilbert, Rockefeller University. Spatial integration
and cortical dynamics. (Host: Holly Cline)
Bruce Mc Naughton, University of Arizona. Ensemble coding
for spatial memory: The stuff dreams are made of. (Host:
Alcino Silva)
John Lisman, Brandeis University. Synaptic plasticity is
greatly enhanced during cholinergic brain oscillations.
(Host: Robert Malinow)
Mark Estelle, Indiana University. Genetic studies of auxin
action in Arabidopsis. (Host: Hong Ma)
March
Daniel Storm, University of Washington, Seattle. Calcium
regulated adenylyl cyclases: Their role in neuroplasticity.
(Host: Grisha Enikolopov)
Bruce Paterson, Laboratory of Biochemistry, NCI, NIH.
Studies on the dimerization specificity of the myogenic
bHLH proteins. (Host: Ueli Grossniklaus)
Yuy-li Wang, Worcester Foundation. Regulation of cortical
dynamics during cytokinesis. (Host: David Helfman)
Francine Per ler, New England Biolabs, Inc. Protein splicing:
Control, mechanism, and prospects. (Host: Adrian
Krainer)
Charles Weissmann, University of Zurich. The role of PrP in
susceptibility to scrapie. (Host: Adrian Krainer)
April
Xing-Wang Deng, Yale University. Mechanism of light-
mediated development switch (Host: Hong Ma)
October
Nam-Hai Chua, Rockefeller University. Genetic and bio-
chemical dissection of the phytochrome phototransduc-
tion pathway (Host: Lavine Faleiro)
David Goeddel, Tularik Inc., San Francisco. TNF receptor
signal transduction. (Host: Bruce Stillman)
November
Frederick Ausubef, Harvard Medical School. A multi-host
pathogen (Pseudomonas aeruginosa) that infects plants,
nematodes, and mice (Host: Hong Ma)
Gerald Rubin, University of California, Berkeley. Signal
transduction during fly eye development. (Host: Hong Ma)
December
Robin Lovell-Badge, MRC, London. The SRY gene family,
sex determination and neural development. (Host: Win-
ship Herr)
Kim Nasmyth, IMP, Research Institute Molecular Pathology,
Vienna. Determinants of mother-cell-specific mating-type
switching in the budding yeast S. cerevisiae. (Host: Bruce
Stillman)
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In-House Seminar Program
Cold Spring Harbor In-House Seminars were initiated to provide a semiformal avenue for communi-
cation between the various research groups at the Laboratory. They are particularly useful for re-
search personnel who have recently joined the Laboratory. The seminars also afford a necessary
opportunity for the graduate students and postgraduate staff to develop their skills in organizing,
presenting, and defending their research.
1995
January
Konstantin Galactionov, Cold Spring Harbor Laboratory. A
direct link between cell cycle machinery and signal trans-
duction.
Eric Chang, Cold Spring Harbor Laboratory. Cooperative in-
teraction of S. pombe proteins required for mating and
morphogenesis.
Sui Huang, Cold Spring Harbor Laboratory. Functional orga-
nization of RNAs in the mammalian cell nucleus.
Erich Grotewold, Cold Spring Harbor Laboratory. Maize
Myb-domain proteins: Transcription in color."
February
Peter Barker, Cold Spring Harbor Laboratory. Detection of
gene amplification in human breast cancer.
Bruce Futcher, Cold Spring Harbor Laboratory. The yeast
cell cycle engine.
Harriet Feilotter, Cold Spring Harbor Laboratory. The search
for genes associated with manic depressive illness using
linkage to physical markers through the human genome.
Dick McCombie, Cold Spring Harbor Laboratory. Technol-
ogy development and S. pombe genome sequencing.
March
Ariel Avilion, Cold Spring Harbor Laboratory. Talking about
telomerase for the 13th time.
Bill Henry, Cold Spring Harbor Laboratory. SNAPc: A protein
complex required for transcription of human snRNA
genes.
Masafumi Tanaka, Cold Spring Harbor Laboratory. Un-
expected determinants of the binding of transcriptional
activator proteins to their target DNA in vivo.
Shobha Gunnery, Cold Spring Harbor Laboratory. Func-
tional mRNA can be generated by RNA polymerase III.
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Joe Colasanti, Cold Spring Harbor Laboratory. In search of
"florigen": The maize indeterminate gene and the transition
to flowering.
April
Andrea Doseff, Cold Spring Harbor Laboratory. LAS1, a
nuclear protein involved in bud formation.
Tim Tully, Cold Spring Harbor Laboratory. Fly fishing for the
engram.
October
David Horowitz, Cold Spring Harbor Laboratory. A new hu-
man protein required for the second catalytic reaction of
pre-mRNA splicing.
Peter Nest ler, Cold Spring Harbor Laboratory. Ex Pluribus
Unum-The combinatorial quest for the optimal receptor.
Mario Gimona, Cold Spring Harbor Laboratory. How to zip
and unzip tropomyosin: The selectivity of dimer formation,
and interaction with S100-like CA"-binding proteins.
November
Frank Pessler, Cold Spring Harbor Laboratory. The long and
the short of HIV-2 transcription.
David Beach, Cold Spring Harbor Laboratory. Oncogene
cooperation.
December
May Luke, Cold Spring Harbor Laboratory. A family of SIT4-
associated proteins: The SAPs are required for the in vivo
functions of the SIT4 phosphatase.
Chantal Autexier, Cold Spring Harbor Laboratory. Functional
analysis of Tetrahymena and human telomerase RNAs.
UNDERGRADUATE RESEARCH
An important aspect of the summer program at the Laboratory is the participation of college un-
dergraduate students in active research projects under the supervision of full-time laboratory staff
members. The program was initiated in 1959. Since that year, 440 students have participated in
the course, and many have gone on to productive careers in biological science.
The objectives of the program are to provide (1) a greater understanding of the fundamental
principles of biology; (2) an increased awareness of experimental approaches to science; (3) a
deeper understanding of the major issues in the fields of biochemistry and genetics, and
molecular and cellular biology; and (4) a personal acquaintance with research, research workers,
and centers for study.
The following students, selected from over 280 applicants, took part in the program, which was
supported by Bio-Rad Laboratories, Burroughs-Wellcome Fund, C. Bliss Memorial Fund, The Gar-
field Internship, Hanson Industries, Libby Internship, National Science Foundation, Phillips
Petroleum Foundation, Inc., Powers Foundation, William Shakespeare Internship, and Frederica
von Stade Internship.
Jennifer Ames, University of Pittsburgh
Advisor: David Beach
Sponsor: Burroughs-Wellcome Fund
Cell immobilization.
Neeraj Arora, Cambridge University
Advisor: Timothy Tully
Sponsor: Robert P. Olney Memorial Cancer Fund
Planimetric analysis of brain structures in the Drosophila
learning mutants latheo and linotte.
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Rebecca Blankenburg, California Institute of Technology
Advisor: Yi Zhong
Sponsor: Jephson Education Trust
Ras signal transduction pathway involvement in Drosophila
synaptic plasticity and cell patterning.
Tanita Casci, University of Glasgow
Advisor: Michael Hengartner
Sponsor: Federica von Stade Internship
Programmed cell death in C. elegans.
Michelle Da Costa, Yale University
Advisor Arne Stenlund
Sponsor: National Science Foundation
Examining the interaction of the BPV E2 hinge with the El
protein.
Katharine Eklof, Rice University
Advisor: Richard McCombie
Sponsor: Burroughs-Wellcome Fund
Analysis of open reading frame expression in S. pombe.
Rebecca Farkas, Yale University
Advisor: Hong Ma
Sponsors: Bliss Memorial Fund
Phillips Petroleum Foundation, Inc.
FON1 and floral developmental genetics.
Christine Ford, Bellarmine College,
Advisor Erich Grotewold
Sponsor: National Science Foundation
Characterization of proteins in the flavonoid biosynthetic
pathway.
Nathan Hellman, Yale University
Advisor: Grigori (Grisha) Enikolopov
Sponsor: Burroughs-Wellcome Fund
Targeting synaptotagmin II to synaptic vesicles.
Brian D. Hoerneman, University of Wisconsin-Madison
Advisor Bruce Stillman
Sponsor: Burroughs-Wellcome Fund
Construction and utilization of multicopy libraries to screen
for suppressors of a conditional mutation in the 58-kD sub-
unit of Pol-a/primase.
Emmitt R. Jolly, Tuskegee University
Advisor: David Helfman
Sponsor: National Science Foundation
Comparisons of protein factors in muscle and nonmuscle
cell types that may regulate alternative RNA splicing.
John Kehoe, Northwestern University
Advisor: Ryuji Kobayashi
Sponsor: Burroughs-Wellcome Fund
A chemiluminescent approach to protein sequencing.
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George Laszlo, Oberlin College
Advisor Alcino J. Silva
Sponsor: National Science Foundation
Learning and memory in NF1-deficient mice.
Miro Pastrnak, Wabash College
Advisor: Adrian R. Krainer
Sponsor: Cold Spring Harbor Laboratory
Expression of human SR proteins in yeast.
Loren del Mar Pena, Duke University
Advisor: Winship Herr
Sponsor: National Science Foundation
Cloning the C. elegans HCF gene.
Elizabeth Pinches, King's College, Cambridge
Advisor: Holly Cline
Sponsor: William Shakespeare Internship
Synapse distribution on the retinotectal projection of
Xenopus.
Cynthia Snyder, Colorado State University
Advisor: Carol Greider
Sponsor: National Science Foundation
Human telomerase RNA.
Hans Sugimoto, Wellesley College
Advisor: Kim L. Arndt
Sponsor: Libby Internship
Sequencing of SAP4 and isolation of SAP190 is mutants.
Pei Lin Tan, Mount Holyoke College
Advisor: Shobha Gunnery
Sponsor: The Garfield Internship
Termination signal of RNA polymerase III (Pol III) transcrip-
tion.
Rachel Ventura, Harvard University
Advisor: Xiaodong Cheng
Sponsor: National Science Foundation
Toward solving the three-dimensional structure of p16: Crys-
tallization trials.
Kevin Wang, Stanford University
Advisor: Venkatesan Sundaresan
Sponsor: Burroughs-Wellcome Fund
Isolation and characterization of embryo-specific genes in
Arabidopsis using insertional trap transposons.
Audrey Wells, University of New Mexico
Advisor: Rob Martienssen
Sponsor: National Science Foundation
Characterization of the Arabidopsis genome.
NATURE STUDY PROGRAM
The Nature Study Program gives elementary and secondary school students the opportunity to ac-
quire a greater knowledge and understanding of their environment. Through a series of special-
ized field courses, younger students can engage in introductory programs such as Nature Bugs,
Nature Detectives, and Nature Discovery, and older students can enroll in more advanced pro-
grams such as Marine Biology and Nature Photography.
During the summer of 1995, a total of 426 students participated in 28 courses within the pro-
gram. The classes were held outdoors, weather permitting, at the West Side School. The
Laboratory has equipped and maintains classroom and laboratory facilities as well as a darkroom
at West Side School. This facility is used as a base for the students' exploration of the local en-
vironment. Field classes are held on Laboratory grounds, St. John's Preserve, Fire Island National
Seashore, Caumsett State Park, the Cold Spring Harbor Fish Hatchery and Aquarium, as well as
other local preserves and sanctuaries.
In addition to the three, two-week sessions, the Adventure Education course meets on two Fri-
days for trips. The students go on a 10-mile bicycle hike to Sagamore Hill and a 12-mile canoe trip
on the Nissequogue River.
PROGRAM DIRECTOR
William M. Payoski, M.A., Adjunct Professor, Nassau Community College
REGISTRAR
Amy Anderson, Cold Spring Harbor Laboratory
INSTRUCTORS
Kimberly Bennett, M.S., Science Teacher, Locust Valley School District
Michelle Malich, B.A., Elementary School Candidate
Marjorie Medwed, M.S., Science Teacher, Locust Valley School District
Donna Pandaliano, M.S., Science Teacher, Valley Stream School District
Linda Payoski, M.S., Science Teacher, Uniondale School District
Brian Withers, Fine Arts Teacher, New York City School System.
COURSES
Nature Bugs
Nature Detectives
Nature Discovery
Ecology Explorers
Frogs, Flippers, and Fins
Pebble Pups
Freshwater Life
Seashore Life
Marine Biology
Nature Photography
Adventure Education
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BANBURY CENTER
DIRECTOR'S REPORT
During the 18 years of the Banbury Center's existence, there has been an extraordinary increase in
the ways scientists communicate with each other. The number of journals continues to rise without
end in sight; there are meetings on every topic; and the Internet and World Wide Web are now
providing an instant, global means of exchanging information. Paradoxically, Banbury Center's
role-promoting research by providing a quiet haven where small groups of scientists can
meet-has become even more important in this period of overwhelming information dissemination.
Meetings and Participants
The year 1995 must have been a record year for the use of Banbury Center. We held no fewer than
19 science-related meetings with a proportionate number of participants-almost 600-who came
from all over the world. Almost 100 came from outside the United States, principally from the United
Kingdom (42), Germany (16), and France (12). In addition, the Center was used on 11 other occa-
sions and for 5 neurobiology courses during the summer.
Human Genetics
In 1989, Banbury Center was the site of a discussion meeting that was important in the early devel-
opment of the Human Genome Project. It was exciting that in 1995, the Human Genome Organiza-
tion (HUGO) came to Banbury, just prior to the main Genome Mapping and Sequencing meeting,
for the Human Gene Map Workshop II. The workshop presented an up-to-the-minute snapshot of
progress in genome centers in the United States and in Europe.
Scientists hunting human disease genes are facing two major hurdles, each of which was the
topic of a meeting this year. Localizing genes by means of genetic linkage is now relatively
straightforward (although still difficult in practice) for disorders believed to arise from mutations in
one gene. What is not clear, however, is the most effective strategy to be followed when dealing
with complex disorders in which mutations in several genes contribute to the phenotype. Looking
to the Next Generation of Genetic Analysis (funded by the Charles A. Dana Foundation) at-
tempted to gaze into the crystal ball to see how technical developments in genetics analysis (math-
ematical modeling) and genomic technologies (analyzing DNA) are going to affect the ways genes
are localized.
Finding Genes: Experimental and Computational Methods was concerned also with genetic
analysis strategies, in this case with how to find a gene once genetic linkage methods have local-
ized it to a region of a chromosome. These regions are typically on the order of 2 million base pairs
in length and finding a gene within such a region is not trivial. The meeting reviewed experimental
strategies (selecting cDNAs, trapping) and computational methods (identifying genes in DNA se-
quence). It is likely that computational methods will become more important as it becomes easier to
sequence large amounts of DNA, and this in turn will lead to more accurate recognition of se-
quence motifs that characterize genes.
Cancer
Two meetings dealt specifically with cancer. DNA Repair and Genetic Instability in Cancer
reviewed the exciting findings that human cancers are caused in part by mutations in the enzymes
and other proteins involved in the repair of DNA damage and by alterations in sequences, such as
trinucleotide repeats, that are unstable. It was a special pleasure to have as participants two indi-
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viduals who had significant roles in the life of Cold Spring Harbor Laboratory-John Cairns and Joe
Sambrook.
Banbury Center held an important meeting on neurofibromatosis in 1990, the NF1 gene having
just been cloned and its relationship to the ras pathway recognized. Now, 5 years later, in
Neurofibromatosis: How to Develop Therapies, we examined what progress has been made in
elucidating of neurofibromatosis with a special emphasis on what these new data mean
for developing treatments. The focus of the meeting was to determine what needs to be done to
translate research findings into therapies. This requires not only continued research, but also, per-
haps, new funding strategies to encourage interdisciplinary collaborations. Bruce Stillman played a
critical part in the last session, forcing participants to face up to this task.
Protein Degradation
At one time, it was thought that protein degradation occurred by some nonspecific breakdown pro-
cess, but about 10 years ago, it was realized that careful regulation of protein degradation was just
as important as regulation of protein synthesis. In 1988, Banbury Center held a meeting on the ubi-
quitin system and this year we held a follow-up: The Targets and Regulation of the Ubiquitin
System. The most notable change has been the realization of ubiquitin's role in key areas of cell
function. For example, a session was devoted to the part played by ubiquitin in control of cell cycle
control proteins like the cyclins.
Infectious Diseases
Two very different topics come under this heading. In March, we held a meeting in our continuing
series on Lyme disease, Lyme Disease: Molecular and Immunologic Aspects of Detection and
Vaccine Development. Each meeting is a marker of the increasing knowledge that we have of the
genetics and immunology of the Burgdorferi spirochaete, knowledge that we hope will be used to
develop vaccines. This meeting still covered a broad range of topics, but the time has now come to
look in detail at just one or two topics.
The subject of our second meeting is still enigmatic. Prions, infectious protein particles devoid
of nucleic acid, are believed to be the causative agents of diseases such as Kuru in human beings
and scrapie in sheep, and in the outbreak of bovine spongiform encephalopathy in the United
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Kingdom. The latter has raised public health concerns about this type of infectious agent on a new
and dramatic scale. The Molecular Biology of Prions and Pathology of Prion Diseases meeting
was held at a most exciting time for the field when data from transgenic models are becoming
available and intensive investigations are under way of prion-like proteins in yeast.
Plant Molecular Biology
Banbury Center has held several meetings on plant molecular biology but not enough to reflect the
importance and intrinsic interest of plant science. The potential benefits of genetic manipulations of
crop plants is enormous, and Molecular Biology of Disease Resistance Genes in Plants was an
example of that potential. The topic was suggested to me by Richard Michelmore when we met at
the International Genetics Conference in Birmingham, United Kingdom, in 1993. Fortuitously, the
delay in holding the meeting worked to our advantage as the first of these resistance genes was
cloned in the period leading up to the meeting. Beginning in 1996, we shall try to rectify our com-
parative neglect of plant science. A small group of key companies has contributed to the Plant Cor-
porate Associates Program that will fund at least one meeting each year on plant science.
Meetings in Neurobiology
Within the broad field of "neurobiology," we held two meetings that could hardly have been further
apart and yet one, CREB and Memory, points the way in which basic research is beginning to
tackle topics like that of the second meeting, Genetics of Human Behavior. The premise of the
latter meeting was that we need to understand the scientific basis of various claims for the role of
genetics in influencing, or even determining, human behavior, in order to assess those claims. We
brought together behavoral scientists, psychologists, geneticists, and sociologists, both sceptics
and supporters of this research.
Another approach to studying the functioning of our brains uses the tools of recombinant DNA
to probe molecular systems that may underlie such functions as learning and memory. This ap-
proach is developing rapidly. In particular, the CREB transcription appears to have a key role in the
development of memory, and this meeting reviewed the data on CREB and learning in a variety of
organisms.
Cocktails during CREB and CREM meeting.
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Visualizing the Working Body
In vivo imaging is a technique that is becoming increasingly important for scientists wishing to ex-
amine the working human brain. It is now possible to see how different areas of the brain change
their metabolism as the subject performs some task. However, as our meeting Advances in Imag-
ing and Their Application showed, this is only a small part of the imaging picture. These tech-
niques are also used extensively in cancer and cardiovascular studies. Most of the meeting was
taken up with discussions of future developments that must take place if imaging is to be used
even more widely. In particular, increased resolution and decreased response time are going to be
essential if living processes are to be analyzed in real time.
Educational Activities
Breast cancer is a major concern throughout the nation and especially on Long Island, which has
one of the nation's higher rates. The 1 in 9 Breast Cancer Group provides support and promotes
research on breast cancer, some of which is done at the Laboratory. Because of the intense inter-
est aroused by the cloning and characterization of the BRCA1 and BRCA2 genes, Banbury Center
and the DNA Learning Center collaborated in holding a 1-day Workshop on Genetics for mem-
bers of the Group.Twenty-three members of 1 in 9 attended, and in addition to learning some of the
fundamentals of human genetics, they fingerprinted their own DNA using PCR and heard of the
latest research from Elizabeth Claus from Yale.
We could not have held the workshop for 1 in 9 members without the experience we have
gained with our series of Human Molecular Genetics workshops, supported by the Ethical, Legal,
and Social Issues Program of the Department of Energy's Human Genome Project. These work-
shops have brought information about genetics to people from a remarkable range of back-
grounds. Participants have included print and broadcast journalists, Congressional staff,
bioethicists, patient groups, lawyers, philosophers, sociologists, high school teachers, and
physicians from primary care facilities. Despite the success of the workshops, this, the sixth in the
series, was the last to be funded from this grant. For the second time, we concentrated on
physicians who come from hospitals and institutions that do not have ready access to the latest ad-
vances in genetics, and we went nationwide, with participants coming from as far afield as Louis-
iana and North Dakota. This is an opportune time to thank all our invited speakers who made these
workshops especially memorable.
Science and Policy Meetings
The first Banbury Center meetings on environmental hazards examined the scientific basis of is-
sues that had important policy implications and such hybrid meetings have continued to the pres-
ent. Four such meetings were held in 1995. Three of these dealt specifically with how the fruits of
modern biomedical research are going to be implemented in a health care system that is undergo-
ing a radical restructuring.
The first of these was HIV and the Pathogenesis of AIDS. This was a remarkable meeting that
set out to analyze the current status of eight areas of research, to propose the key questions that
have to be answered in each area, and to suggest the specific experiments that need to be done
to provide the answers. The meeting was structured so that only one third of the time was given
over to formal presentations, of which there were only two for each topic. The participants included
key scientists from Europe as well as North America, but in the end, it was not clear how to imple-
ment the radical restructuring and rethinking that the field requires.
There is increasing public interest in the uses of modern human genetics in medicine. In part,
this increased awareness is due to the realization that genetic information may be used by HMOs
and insurance companies in making decisions about care. The Robert Wood Johnson Foundation,
the leading foundation in heath care area, funded two meetings at Banbury Center to examine
these issues. The first meeting, held in 1994, concluded that many potential problems could be
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avoided or alleviated if the quality of genetics education was improved in medical and nursing
schools. The second meeting, Incorporating Genetics into Medicine and Nursing Education
and Practice held in April, 1995, examined this issue in more detail. We reviewed the current state
of genetics education and how it should be improved for both physicians and nurses. It was an out-
standing meeting, which included representatives of the main professional organizations which set
the curricula in medical and nursing schools.
One genetic topic that has received much public attention is breast cancer. With the cloning
and sequencing of two genes (BRCAl and BRCA2) involved in familial breast cancer, there is a
strong movement to applying these findings in diagnostic tests. However, this is highly con-
troversial because of concerns that results are difficult to interpret and treatments are few and in-
effective. The Molecular Diagnosis of Inherited Breast Cancer meeting held in October covered
topics ranging from the mutations in these genes to, once again, how to use this information in
health care. It was particularly noteworthy for the strong representation from the United Kingdom
where I like to think these issues are dealt with in a particularly rational manner.
Our final meeting in this science-policy group was supported by the Albert B. Sabin Vaccine
Foundation. In 1994, Banbury Center held a meeting that reviewed the current status of vaccine
production, examining all those factors that determine how a vaccine is developed, produced, and
distributed. The 1995 meeting, Vaccine Development and Delivery in the Era of Managed Care,
faced up to the fact that the rapidly changing nature of health care provision in the United States is
having a profound effect on the ways in which long-term, preventative strategies like vaccination
are going to be implemented and paid for.
The Executives' Conference
J.P. Morgan honored us by sponsoring Infectious Diseases: Ancient Plagues, New Epidemics,
the tenth in this series of meetings. It was a particularly timely meeting as evident from the suc-
cesses of The Hot Zone and The Coming Plague, and Outbreak starring Dustin Hoffman! Our meet-
ing was also of star quality, covering a wide range of topics, from Richard Horton's historical per-
spective to Don Wiley's X-ray crystallography via Ham Smith's genome sequencing. Pursuing the
film theme, Don Ganem was able to weave a scene from Beverly Hills Cop into his review of her-
pesviruses!
Other Meetings
Once again the local community made use of the Center. Of the two Lloyd Harbor Seminars, the
Laboratory contributed one of these when Jerry Latter (Director, Computer Center), John Inglis (Ex-
ecutive Director, Cold Spring Harbor Laboratory Press), and I did a presentation on the Internet, in-
cluding a "live" demonstration of net surfing. In addition, the Lloyd Harbor Conservation Board,
Heckscher Museum, Huntington Hospital, the Cold Spring Harbor School District, and West Side
School used the facility.
Funding
Support for our 1995 program was strong and drawn from many quarters, demonstrating the wide
recognition of Banbury Center as the preeminent small meeting place for molecular biology and
genetics. The Cold Spring Harbor Laboratory Corporate Sponsor Program again provided the fund-
ing for six Banbury Center meetings (for a full listing of the members of the Program, see the Finan-
cial Support Section). Suffice to write here that without the generosity of these companies, the Ban-
bury Center program would be very much the poorer and the scientific world deprived of a unique
resource.
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Some of these same companies (Glaxo, Pfizer, SmithKline Beecham, Zeneca), together with
Merck and Sequana, made contributions to the HUGO Human Gene Map Workshop II. This meet-
ing was also supported by funds from the Department of Energy and the National Institutes of
Health, and from Europe, the European Commission, the Wellcome Trust, and the Medical Re-
search Council.
A similar combination of federal and private enterprise support funded the meeting on Lyme
Disease. The former included the Centers for Disease Control, Food and Drug Administration, Med
Immune, and the National Institute of Allergy and Infectious Disease, whereas the latter included
Connaught Laboratories, Fort Dodge Laboratories, and SmithKline Beecham Clinical Laboratories.
The meeting on HIV and the Pathogenesis of AIDS was supported by contributions from
Mothers' Voices, the Office of AIDS Research (NIH), the Albert B. Sabin Foundation, Pediatric AIDS
Foundation, and Viaticus, Inc. These groups not only were generous in their support, but also com-
mitted the funds at very short notice.
The Department of Energy also funded the last in the series of Genetics Workshops for non-
scientists. This was a very successful venture that provided a grounding in genetics to a very
diverse range of individuals.
Foundations had a prominent role in the year. The Robert Wood Johnson Foundation, The Wil-
liam Stamps Farish Fund, the Charles A. Dana Foundation, and the Albert B. Sabin Foundation
each funded a meeting in its entirety. The very successful meeting on Neurofibromatosis was
supported by the National Neurofibromatosis Foundation and the Wilson Foundation, together with
private contributions.
Robertson House provides dining and housing accommodations at Banbury Center.
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Sammis Hall
J.P. Morgan generously funded the Executives' Conference. Two other meetings were funded
by individual companies. DNA Repair and Genetic Instability was supported by OncorMed, Inc.,
and Advances in Imaging and Their Applications was funded by the Finisterre Fund. These
meetings are, in all senses, Banbury Center meetings, with the same rigorous standards of
participants' selection and program design applied to them. It may be that we will increase the
numbers of such meetings as a means of being able to hold first-class meetings on a greater vari-
ety of topics.
Acknowledgments
This sustained level of activities could not be maintained without the dedicated help of many
people. All the organizers worked hard, sometimes at very short notice, to make sure their meet-
ings were a success; Bea To liver, Ellie Sidorenko, and Katya Davey kept the Center running
smoothly; Chris McEvoy and Bill Bishop kept the grounds looking beautiful; and Jim Hope (Cater-
ing) and Art Brings (Buildings & Grounds) and their staff coped with a very tight schedule.
Looking Forward to 1996
We have some very exciting meetings planned for 1996, including ones on DNA base Tipping,*
plant reproductive biology, and triplet repeat and polyglutamine tract diseases. Although the
framework of the 1996 program is in place, we continue to add meetings. One of the great ad-
vantages that Banbury Center has over other meetings venues is its flexibility. If there are rapid de-
velopments in a subject that require critical analysis, we can organize a discussion meeting at very
short notice. This can be done only because of the support provided by the scientists of the
Laboratory, and I would like to acknowledge that support, on behalf of myself and all the scientists
who attend our meetings.
Jan Witkowski
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MEETINGS
1-in-9 Breast Cancer Group: A Genetics Workshop
January 28
FUNDED BY
Cold Spring Harbor Laboratory
ARRANGED BY
M. Bloom, DNA Learning Center, Cold Spring Harbor Laboratory
D. Mick los, DNA Learning Center, Cold Spring Harbor Laboratory
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory
SESSION 1
M. Bloom and D. Mick los, DNA Learning Center, and J.A.
Witkowski, Banbury Center, Cold Spring Harbor Labor-
atory: Laboratory: Fingerprinting your own DNA.
SESSION 2
D. Mick los, DNA Learning Center, Cold Spring Harbor
Laboratory: Mendelian genetics and why you aren't your
parents.
Harbor Labor-
atory: What is a gene?
J.A. Witkowski, Banbury Center, Cold Spring Harbor Labor-
atory: Diagnosis using DNA.
SESSION 3
E.B. Claus, Yale University, New Haven, Connecticut:
Breast cancer genetics.
M. Bloom and D. Mick los, DNA Learning Center, and J.A.
Witkowski, Banbury Center, Cold Spring Harbor Labor-
atory: Laboratory: Results of DNA-fingerprinting experi-
ment.
B. Hummel-Rossi, L. Levine, R. Schaefer I. Kritchek
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DNA Repair and Genetic Instability in Cancer
January 29-January 31
FUNDED BY
OncorMed, Inc.
ARRANGED BY
D. Dolginow, OncorMed, Inc., Gaithersburg, Maryland
D. Sidransky, Johns Hopkins University, Baltimore, Maryland
SESSION 1
Chairperson: D. Sidransky, Johns Hopkins University, Baltimore, Maryland
J. Cairns, Radcliffe Infirmary, Oxford, United Kingdom:
Mutation, promotion, and the kinetics of carcinogenesis.
SESSION 2
Chairperson: P. Modrich, Howard Hughes Medical Institute,
ter, Durham, North Carolina
B. Vogelstein, The Johns Hopkins Oncology Center, Balti-
more, Maryland: DNA-repair and genetic instability in
colorectal cancer.
L.A. Loeb, University of Washington, Seattle: Multiple muta-
tions in cancer.
S.N. Thibodeau, Mayo Clinic, Rochester, Minnesota: Clinical
significance of microsatellite instability.
T.D. Petes, University of North Carolina, Chapel Hill: Genetic
control of genetic instability in yeast.
Duke University Medical Cen-
P. Karran, Imperial Cancer Research Fund, Herts, United
Kingdom: Mismatch repair, drug resistance, and colon
cancer.
A.M. Carr, Sussex University, Falmer, United Kingdom: Cell
cycle checkpoints in yeast and response to DNA damage.
T.A. Kunkel, National Institute of Environmental Health
Sciences, Research Triangle Park, North Carolina:
Studies of DNA replication fidelity and mismatch repair in
human cell extracts.
J.E. Cleaver, J. Cairns
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SESSION 3
Chairperson: J.E. Cleaver, University of California, San Francisco
P. Modrich, Howard Hughes Medical Institute, Duke Univer- D. Toczyski, University of Washington, Seattle: Adaptation to
sity Medical Center, Durham, North Carolina: Mismatch the RAD9-dependent checkpoint in the presence of an ir-
repair deficiency and genetic destabilization in tumor cells. reparable dsDNA break.
G. Bedi, Johns Hopkins University School of Medicine, Balti- B.A. Donahue, Stanford University, California: Role of tran-
more, Maryland: Microsatellite instability in AIDS-related scription in nucleotide excision repair.
neoplasms. P. Peltomaki, University of Helsinki, Finland: Microsatellite in-
D. Monckton, Baylor College of Medicine, Houston, Texas: stability in colorectal adenomas and carcinomas.
Triplet repeat instability in myotonic dystrophy. J.H. Miller, University of California, Los Angeles: Mechanisms
of base-change damage in mutagenesis.
SESSION 4
Chairperson: B. Vogelstein, The Johns Hopkins Oncology Center,
J.E. Cleaver, University of California, San Francisco: DNA
repair and gene expression studies involving the XPA J.
photoproduct-specific DNA-binding protein.
N. Arnheim, University of Southern California, Los Angeles:
Germ-line trinucleotide repeat instability.
P.L. Foster, Boston University School of Medicine, Massa- L.
chusetts: Mechanisms of adaptive mutation in Escherichia
coll.
D. Sidransky, Johns Hopkins University, Baltimore, Maryland:
Baltimore, Maryland
Tumor instability in cancer detection.
Jiricny, IRBM P. Angeletti, Pomezia, Italy: G-T mismatch
binding activities present in HELA cell extracts.
.M. Liskay, Oregon Health Sciences University, Portland,
Oregon: Mutation and cancer avoidance.
A. Hedrick, Johns Hopkins University, Baltimore, Maryland:
Mutational analysis of repair genes in endometrial car-
cinoma.
SESSION 5
Chairperson: J. Cairns, Radcliffe Infirmary, Oxford, United Kingdom
L.H. Thompson, Lawrence Livermore National Laboratory,
California: Characterization of human repair genes in terms
of genetic instability.
N.G.J. Jaspers, Erasmus University, Rotterdam, The Nether-
lands: Nucleotide excision-repair deficiency in man.
E. Alani, Dana-Farber Cancer Institute, Boston, Massachu-
setts: Yeast and human mutators genes.
The Targets and Regulation of the Ubiquitin System
February 12-February 15
FUNDED BY
Cold Spring Harbor Laboratory Corporate Sponsor Program
ARRANGED BY
P. Howley, Harvard Medical School, Boston, Massachusetts
A. Varshaysky, California Institute of Technology, Pasadena
SESSION 1: UBCs and Cell Cycle Control
Chairperson: P. Howley, Harvard Medical School, Boston, Massachusetts
S. Jentsch, Heidelberg University, Germany: A ubiquitin-
conjugating enzyme involved in the degradation of both S-
and M-phase cyclins.
D. Finley, Harvard Medical School, Boston, Massachusetts:
Induction of ubiquitination in erythroid differentiation.
F. Cross, The Rockefeller University, New York, New York:
Degradation of the CDC28 inhibitor FAR1.
A. Murray, University of California, San Francisco: The
spindle assembly checkpoint and cyclin proteolysis.
A. Hershko, Technion-Israel Institute of Technology, Haifa:
Mechanisms and regulation of cyclic degradation.
M. Ellison, University of Alberta, Edmonton, Canada: Placing
the mechanism of protein ubiquitination within a structural
context.
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SESSION 2: Targets of Ubiquitination
Chairperson: A. Hershko, Technion-lsrael Institute of Technology, Haifa
D. Bohmann, European Molecular Biology Laboratory,
Heidelberg, Germany: Ubiquitin-dependent degradation of
Jun.
P.A. Baeuerle, Albert-Ludwigs-University of Freiburg,
Germany: Role of proteolysis in the activation of transcrip-
tion factor NF-Kb.
T. Maniatis, Harvard University, Cambridge, Massachusetts:
Ubiquitin and proteasome-dependent activation of NF -Kb.
SESSION 3: Regulation of Ubiquitination
Chairperson: C.M. Pickart, State University of New York, Buffalo
A. Varshaysky, California Institute of Technology, Pasadena:
Substrates and functions of the N-end rule pathway.
J. Becker, University of Tennessee, Knoxville: Involvement of
UBR 1 in the transport of peptides in yeast.
V. Chau, Wayne State University School of Medicine, Detroit,
Michigan: Mechanistic analyses with a reconstituted N-end
rule pathway.
J. Huibregtse, Harvard Medical School, Boston, Massachu-
M. Hochstrasser, University of Chicago, Illinois: Ubiquitin and
proteasome-mediated degradation of the yeast MATa2
transcriptional regulator.
M. Scheffner, Deutsches Krebsforschungszentrum, Heidel-
berg, Germany: Regulation of p53 stability.
K. Madura, Robert Wood Johnson Medical School, UMDNJ,
Piscataway: Ubiquitin-dependent degradation of yeast
G-a.
setts: A class of proteins structurally and functionally re-
lated to the Eb-AP protein ligase.
A. Ciechanover, Technion-lsrael Institute of Technology,
Haifa: Novel ubiquitin-protein ligates (E3s).
R. Vierstra, University of Wisconsin-Madison: Targeted
degradation: Potential new method for selective protein
degradation.
SESSION 4: Ubiquitination Targets and Related Topics
Chairperson: A.L. Goldberg, Harvard Medical School, Boston, M
K.L. Rock, Dana Farber Cancer Institute, Boston, Massachu-
setts: Role of ubiquitin-proteasome pathway in the
degradation of cellular proteins and the generation of MHC
class -I- presented peptides.
M. Rechsteiner, University of Utah, Salt Lake City: KEKE
motifs, proteolysis, and antigen presentation.
A. Weissman, National Institutes of Health, Bethesda, Mary-
land: Ubiquitination and early events in T-cell activation.
assachusetts
L.A. Guarino, Texas A&M University, College Station:
Phospholipid anchors ubiquitin to the membranes of viral
particles.
A.L. Haas, Medical College of Wisconsin, Milwaukee: Ubi-
quitin cross-reactive protein (p15), an interferon-induced
ubiquitin homolog.
P. Coffino, University of California, San Francisco: Ornithine
decarboxylase: Regulating degradation without ubiquitin.
M. Rechsteiner, A. Hershko
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SESSION 5: Protein Degradation
Chairperson: A. Varshaysky, California Institute of Technology,
E. Craig, University of Wisconsin, Madison: Relationship be-
tween molecular chaperones and the ubiquitin system.
A.L. Goldberg, Harvard Medical School, Boston, Massachu-
setts: Protein degradation.
G.N. De Martino, University of Texas Southwestern Medical
Center, Dallas: Regulatory proteins of the proteasome.
C. Pickart, State University of New York, Buffalo: Mechanism
Genetics of Human Behavior
Pasadena
of proteolytic targeting by multiubiquitin chains.
K.D. Wilkinson, Emory University School of Medicine, Atlanta,
Georgia: Processing of polymeric ubiquitin: The UCH and
UBP gene families.
C.A. Slaughter, Howard Hughes Medical Institute, University
of Texas Southwestern Medical Center, Dallas: High-
molecular-weight modifiers of proteasome activity.
March 5-March 8
FUNDED BY
The William Stamps Farish Fund
ARRANGED BY
E. Balaban, The Neurosciences Institute, La Jolla, California
J. Beckwith, Harvard Medical School, Boston, Massachusetts
L.N. Geller, Harvard Medical School, Boston, Massachusetts
K.S. Kendler, Virginia Commonwealth University, Richmond
N.J. Risch, Yale University School of Medicine, New Haven, Connecticut
J.D. Watson, Cold Spring Harbor Laboratory
SESSION 1: Phenotypes
Moderators: E. Balaban, The Neurosciences Institute, La Jolla, California and
K. Merikangas, Yale Family Study Center, New Haven, Connecticut
K.S. Kendler, Virginia Commonwealth University, Richmond: Animal behavior.
Assessment of psychiatric disorders in a genetic context. E. Balaban, The Neurosciences Institute, La Jolla, California:
E. Ostrander, University of Seattle, Washington: Respondent.
J.S. Alper, J. Beckwith, P.R. Billings N.J. Risch, I. Gottesman
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SESSION 2: Estimating Genetic Contributions
Moderators: M. Feldman, Stanford University Medical School, California and
C.R. Cloninger, Washington University School of Medicine, St. Louis, Missouri
T. Reich, Washington University School of Medicine, St.
Louis, Missouri: Family studies.
N.G. Martin, Queensland Institute of Medical Research, Bris-
bane, Australia: Twin studies.
L.J. Eaves, Virginia Commonwealth University, Richmond:
Twin-family studies.
D.W. Fulker, University of Colorado, Boulder: Colorado adop-
tion study.
M. Feldman, Stanford University Medical School, Stanford:
Respondent.
SESSION 3: Linkage, Association, etc.
Moderator: N.J. Risch, Yale University School of Medicine, New Haven, Connecticut
P. McGuffin, University of Wales College of Medicine, Cardiff,
United Kingdom: Detecting and locating QTL and genes of
small effect.
G. Ebers, University Hospital, London, Ontario, Canada: Sib-
pair studies in MS and sexual orientation.
E.S. Gershon, National Institute of Mental Health, National In-
stitutes of Health, Bethesda, Maryland: Positive results in
complex inheritance traits.
J. Crabbe, Oregon Health Sciences University, Portland: QTL
approaches with animal models.
SESSION 4: Presentation of Results to the Public
Moderators: G. Carey, University of Colorado, Boulder and J. Beckwith, Harvard Medical
School, Boston, Massachusetts
D. Nelkin, New York University, New York: The gene as a cul-
tural icon.
T. Duster, University of California, Berkeley: The public re-
ception of the genetic revolution.
HIV and the Pathogenesis of AIDS
R.W. Cooke, Newsday, Inc., Melville, New York: A journalist's
perspective.
I.I. Gottesman, University of Virginia, Charlottesville: Respon-
dent.
March 19-March 22
FUNDED BY
Mothers' Voices, Office of AIDS Research, National Institutes of Health,
Pediatric AIDS Foundation, The Albert B. Sabin Vaccine Foundation,
and Viaticus, Inc.
ARRANGED BY
D.D. Ho, Aaron Diamond AIDS Research Center, New York, New York
S.M. Wolinsky, Northwestern University Medical School, Chicago, Illinois
Introductory remarks: D.D. Ho, Aaron Diamond AIDS Research Center,
New York, New York, and S.M. Wolinsky, Northwestern University
Medical School, Chicago, Illinois.
SESSION 1: Viral Dynamics
Chairperson: J.M. Coffin, Tufts University School of Medicine, Boston,
Massachusetts
J.M. Coffin, Tufts University School of Medicine, Boston,
Massachusetts: Introduction
G.M. Shaw, University of Alabama at Birmingham: Review.
General discussion and summary of key questions and ex-
periments.
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W.E. Paul, R.A. Weiss
SESSION 2: Mechanism of CD4 Destruction
Chairperson: S. Wain-Hobson, Institut Pasteur, Paris,
France
S. Wain-Hobson, Institut Pasteur, Paris, France: Introduction.
M. Feinberg, Gladstone Institute of Virology/Immunology,
San Francisco, California: Review.
General discussion and summary of key questions and ex-
periments.
SESSION 3: CD4 Regeneration
Chairperson: W.E. Paul, AIDS Research, National Institutes
of Health, Bethesda, Maryland
W.E. Paul, AIDS Research, National Institutes of Health,
Bethesda, Maryland: Introduction.
B.F. Haynes, Duke University, Durham, North Carolina:
Review.
General discussion and summary of key questions.
SESSION 4: Correlates of Protection/Host Resistance
Chairperson: A.S. Fauci, NIAID, National Institutes of
Health, Bethesda, Maryland
A.S. Fauci, NIAID, National Institutes of Health, Bethesda,
Maryland: Introduction.
R.A. Koup, Aaron Diamond AIDS Research Center, New
York, New York: Review.
General discussion and summary of key questions and ex-
periments.
SESSION 5: Issues of Vaccine Development
Chairperson: D.P. Bolognesi, Duke University Medical
Center, Durham, North Carolina
D.P. Bolognesi, Duke University Medical Center, Durham,
North Carolina: Introduction.
K.S. Steimer, Biocine-Chiron, Emeryville, California: Review.
General discussion and summary of key questions and ex-
periments.
SESSION 6: Implication for/of Treatment Studies
Chairperson: R.T. Schooley, University of Colorado Health
Sciences Center, Denver, Colorado
R.T. Schooley, University of Colorado Health Science Center,
Denver: Introduction.
D.D. Richman, University of California, San Diego: Review.
General discussion and summary of key questions and ex-
periments.
SESSION 7: Viral Compartments and Transmission
Chairperson: A.T. Haase, University of Minnesota,
Minneapolis
A.T. Haase, University of Minnesota, Minneapolis:
Introduction.
J.I. Mullins, University of Washington, Seattle: Review.
General discussion and summary of key questions and ex-
periments.
SESSION 8: Antigenic Diversity and Viral Variation
Chairperson: M.A. Nowak, University of Oxford, United
Kingdom
M.A. Nowak, University of Oxford, United Kingdom: Introduc-
tion.
B.T.M. Korber, Los Alamos National Laboratory, New Mexi-
co: Review.
General discussion and summary of key questions and ex-
periments.
SESSION 9: Conclusions and Future Prospects
Chairperson: R.A. Weiss, Institute of Cancer Research,
London, United Kingdom
Summary
J.M. Coffin, A.T. Haase, D.D. Ho
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Lyme Disease: Molecular and Immunologic Aspects of Detection
and Vaccine Development
March 26-March 29
FUNDED BY
Centers for Disease Control, Connaught Laboratories, Inc., Food and Drug
Administration, Fort Dodge Laboratories, Med Immune, Inc..
National Institute of Allergy and Infectious Diseases,
and SmithKline Beecham Clinical Laboratories
ARRANGED BY
J.J. Dunn, Brookhaven National Laboratory, Upton, New York
S.E. Schutzer, UMDNJ-New Jersey Medical School, Newark
SESSION 1: Molecular Biology
Chairperson: J.J. Weis, University of Utah School of Medicine,
S. Casjens, University of Utah Medical School, Salt Lake City:
Structure and diversity of the B. burgdorferi (sensu lato)
genome.
C.J. Luke, University of Texas Health Science Center, San
Antonio: Alternative candidate antigens for vaccine devel-
opment.
Salt Lake City
B. Stevenson, Rocky Mountain Laboratories, NIH, Hamilton,
Montana: Molecular mechanisms of Osp variation, regula-
tion of expression.
E. Fikrig, Yale University School of Medicine, New Haven,
Connecticut: Immunogenicity of new surface antigens.
SESSION 2: Immunology
Chairperson: P.K. Coyle, State University of New York, Stony Brook
B. Wilske, Max von Pettenkofer- Institut, Munich, Germany: duals.
Immune response to OspC. T.G. Schwan, Rocky Mountain Laboratories, NIAID, NIH,
S.E. Schutzer, UMDNJ-New Jersey Medical School, Newark: Hamilton, Montana: Osp expression in ticks.
Immune responses to OspA in previously infected indivi-
M.M. Simon, S.P. Nickell, E.S. Raveche, E. Fikrig
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SESSION 3: Vaccine
Chairperson: J. Soreth, U.S. Food and Drug Administration,
B. Johnson, Centers for Disease Control, Fort Collins,
Colorado: Humoral response and protection to key
epitopes of Bb proteins.
S.W. Barthold, Yale University School of Medicine, New
Haven, Connecticut: Immunization against tick-borne
Lyme borreliosis.
Rockville, Maryland
M. Hanson, Medlmmune Inc., Gaithersburg, Maryland: Pro-
tective immunity via recombinant chimeric OspA BCG vac-
cine.
F. Maurice, SmithKline Beecham Pharmaceuticals, King of
Prussia, Pennsylvania: SKB vaccine trial data.
SESSION 4: Special Discussion: Infection and Autoimmunity in Chronic Lyme Disease
Moderator: M.T. Philipp, Tulane Regional Primate Research Center, Covington, Louisiana
Commentaries: F.S. Kantor, Yale University School of Medicine, New Haven, Connecticut,
and J.J. Weis, University of Utah School of Medicine, Salt Lake City
SESSION 5: Animal Models
Chairperson: E. Fikrig, Yale University School of Medicine, New Haven, Connecticut
R.H. Jacobson, Cornell University College of Veterinary Med-
icine, Ithaca, New York: Immune response and Bb-
specific immune complexes in dogs.
J. Radolf, University of Texas Southwestern Medical Center,
Dallas, Texas: The human Lyme disease vaccine, OspA,
protects mice against tick transmission of infection with
SESSION 6: Pathogenesis I
Chairperson: F.S. Kantor, Yale University School of Medicine,
Y.-W. Chiang, Fort Dodge Laboratories, Iowa: Dog models of
Lyme disease.
E.S. Raveche, UMDNJ-New Jersey Medical School, Newark:
Bacterial induction of autoimmune response.
J.L. Benach, State University of New York, Stony Brook: Eva-
sion mechanisms of Bb.
R.J. Dattwyler, State University of New York, Stony Brook: In-
fluence of antimicrobials on the immune response.
L. Bochenstedt, Yale University School of Medicine, New
homologous but not heterologous strains of B. burgdorferi.
M.T. Philipp, Tulane Regional Primate Research Center,
Covington, Louisiana: Lyme disease and immune response
in rhesus monkey.
S.W. Barthold, Yale University School of Medicine, New
Haven, Connecticut: Evolution of Bb antigens in the host.
New Haven, Connecticut
Haven, Connecticut: Antigen variation.
P.K. Coyle, State University of New York, Stony
dence for early and persistent infection in neurologic Lyme
disease.
M.M. Simon, Max-Planck Institut fur Immunobiologie,
Freiburg, Germany: Cellular interaction.
J.J. Weis, University of Utah School of Medicine, Salt Lake
City: Mechanisms of Bb persistence.
SESSION 7: Special Discussion: Immune Response to Unique versus Many Proteins
Moderator: M.T. Philipp, Tulane Regional Primate Research Center, Covington, Louisiana
Commentary: B. Johnson, Centers for Disease Control, Fort Collins, Colorado
SESSION 8: Pathogenesis II/Recombinant Proteins
Chairperson: R.J. Dattwyler, State University of New York, Stony Brook
J.J. Dunn, Brookhaven National Laboratory, Upton, New
York: Construction of Bb cosmid library.
D.H. Parsing, Mayo Clinic, Rochester, Minnesota: Genetic
stability of Bb in animal model.
B.J. Luft, State University of New York, Stony Brook: Chimeric
molecules for detection and vaccination.
S.P. Nickell, Johns Hopkins School of Hygiene and Public
Health, Baltimore, Maryland: T-cell response.
SESSION 9: Special Discussion: Entry and Endpoints for Antibiotic and Vaccine Trials
Moderator: M.T. Philipp, Tulane Regional Primate Research Center, Covington, Louisiana
Commentaries: J. Collins, Glaxo Inc. Research Institute, Research Triangle Park, North
Carolina, and R.J. Dattwyler, State University of New York at Stony Brook
SESSION 10: Discussion and Future Directions and Chronic Lyme Disease
Chairperson: E. McSweegan, National Institute of Allergy and Infectious Diseases,
Bethesda, Maryland
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Incorporating Genetics into Medicine and Nursing Education
and Practice
April 3-April 6
FUNDED BY
The Robert Wood Johnson Foundation
ARRANGED BY
N.A. Holtzman, The Johns Hopkins Medical Institutions, Baltimore, Maryland
SESSION 1
Chairperson: N.A. Holtzman, The Johns Hopkins Medical Institutions, Baltimore, Maryland
N.A. Holtzman, The Johns Hopkins Medical Institutions, Balti-
more, Maryland: Introductory remarks.
F.S. Collins, National Center for Human Genome Research,
National Institutes of Health, Bethesda, Maryland: Current
state of human genetics and genetics education.
SESSION 2: Report of Survey Findings
N.A. Holtzman, The Johns Hopkins Medical Institutions, Baltimore, Maryland: Analysis of
survey. Discussion of implications and summary.
SESSION 3: Defining the Issues: Incorporating Genetics in Primary Care Practice (Panel
Discussion)
Chairperson: S. Feetham, National Institute of Nursing Research, National Institutes of
Health, Bethesda, Maryland
S. Feetham, National Institute of Nursing Research, National J.R. Allen, American Medical Association, Chicago, Illinois
Institutes of Health, Bethesda, Maryland: Introductory R.E. Pyeritz, American College of Medical Genetics,
remarks. Pittsburgh, Pennsylvania
J.G. Davis, N. Fisher
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SESSION 4: Group discussions on Genetics in Primary Care Practice
Group 1: Chairperson: C. Scanlon, American Nurses As-
sociation, Washington, D.C.
Rapporteur: N.L. Fisher, Medical Genetic Services,
Seattle, Washington
Group 2: Chairperson: W.L. Freeman, American Academy
of Family Physicians, Albuquerque, New Mexico
Rapporteur: G. Anderson, Shriver Center for Mental Retar-
dation, Waltham, Massachusetts
SESSION 5: Reports of Discussion Groups
Chairperson: N.A. Holtzman, The Johns Hopkins Medical Institutions, Baltimore, Maryland
Group 1: Rapporteur: N.L. Fisher, Medical Genetic Ser-
vices, Seattle, Washington
Group 2: Rapporteur: G. Anderson, Shriver Center for
Mental Retardation, Waltham, Massachusetts
SESSION 6: Needs and Implementation of Genetics Education (Panel Discussion)
Chairperson: N.A. Holtzman, The Johns Hopkins Medical Institutions, Baltimore, Maryland
M. Grey, Yale School of Nursing, New Haven, Connecticut
F. McCurdy, University of Nebraska Medical Center, Omaha
M. Genel, Yale University School of Medicine, New Haven,
Connecticut
J.G. Davis, New York Hospital-Cornell University College of
Medicine, New York
SESSION 7: Group Discussions of Genetics Education
Group 1: Chairperson: S. Feetham, National Institute of
Nursing Research, National Institutes of Health, Bethes-
da, Maryland
Rapporteur: C.M. Hanson, American College of Nurse
Practitioners, Statesboro, Georgia
Group 2: Chairperson: J.R. Allen, American Medical Asso-
ciation, Chicago, Illinois
Rapporteur: P. Rappo, American Academy of Pediatrics,
North Easton, Massachusetts
SESSION 8: Reports of Discussion Groups
Chairperson: J.R. Allen, American Medical Association,
Chicago, Illinois
Group 1: Rapporteur: C.M. Hanson, American College of
Nurse Practitioners, Statesboro, Georgia
Group 2: Rapporteur: P. Rappo, American Academy of
Pediatrics, North Easton, Massachusetts
SESSION 9: Setting Out Future Goals: Preliminary Discussion
SESSION 10: Future Goals: Defining Proposals
Chairperson: S. Feetham, National Institute of Nursing
Research, National Institutes of Health, Bethesda, Maryland
N.A. Holtzman, The Johns Hopkins Medical Institutions,
Baltimore, Maryland: Closing remarks. N.A. Holtzman, J.R. Allen
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Molecular Biology of Disease Resistance Genes in Plants
April 9-April 12
FUNDED BY
Cold Spring Harbor Laboratory Corporate Sponsor Program
ARRANGED BY
S.P. Briggs, Pioneer Hi-Bred International, Inc., Johnston, Iowa
R.W. Michelmore, University of California, Davis
B. Staskawicz, University of California, Berkeley
SESSION 1: Genetics and Evolution of Plant-Pathogen Interactions
Chairperson: S.P. Briggs, Pioneer Hi-Bred International, Inc., Johnston, Iowa
S.P. Briggs, Pioneer Hi-Bred International, Inc., Johnston,
Iowa: Remarks.
I. Crute, Horticulture Research International, Warwick, United
Kingdom: The genetics of pathogenic specificity to host
species and higher-order host taxa.
R.W. Michelmore, University of California, Davis: Clusters of
resistance genes of lettuce.
C. Gebhardt, Max-Planck-Institut fur Zuchtungsforschung,
Kohn, Germany: Present state of map-based cloning of
the nematode resistance gene G1 and the fungal
resistance gene R1 in potato.
SESSION 2: Receptor-related Disease Resistance Genes
Chairperson: R.W. Michelmore, University of California, Davis
G.B. Martin, Purdue University, West Lafayette, Indiana:
Characterization of the Pto resistance gene family in
tomato.
B.J. Baker, USDA/ARS, Albany, California: The product of the
tobacco mosaic virus disease resistance gene N:
Similarity to toll and the interleukin-1 receptor.
F.M. Ausubel, Massachusetts General Hospital, Boston:
RPS2 and other Arabidopsis defense-related genes.
J.D.G. Jones, John Innes Centre, Norwich, United Kingdom:
S. Hulbert, Kansas State University, Manhattan: Evolutionary
events at the Rp1 complex.
P. Schulze-Lefert, Biologie I, Aaachen, Germany: Genes re-
quired for function of resistance genes to powdery mildew
infection in barley.
P. Vos, Keygene N.V., Wageningen, The Netherlands: State
of the art of positional gene isolation technology.
J. Howard, University of Cologne, Germany: Origin and
maintenance of variation in class I genes of the vertebrate
MHC.
Characterization of the Cf9, Cf2, and RPP5 disease
resistance genes.
B. Staskawicz, University of California, Berkeley: Signal
transduction events specifying plant disease resistance.
J. Ellis, CSIRO Plant Industry, Canberra, Australia: The L and
M rust resistance genes from flax.
P. Ronald, University of California, Davis: The rice Xa21
locus: Isolation of a multigene family with striking similarity
to dicot disease resistance genes.
S. Hulbert, J. Ryals, D.C. Baulcombe
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SESSION 3: Characterization of Additional Resistance Genes
Chairperson: B.J. Baker, USDA/ARS, Albany, California
B.J. Baker, USDA/ARS, Albany, California: Remarks. they true homologs?
J. Dangl, Max-Delbruck-Laboratorium in der MPG, Koln, G.S. Johal, University of Missouri, Columbia: What art thou, o
Germany: Arabidopsis and Pseudomonas syringae loci mimics?
controlling pathogen recognition and cell death. S.P. Briggs, Pioneer Hi-Bred International, Inc., Johnston,
R. Innes, Indiana University, Bloomington: Comparison of the Iowa: Inactivation of candidate defense genes.
Arabidopsis RPS3 and soybean RPG1 genes. Are
SESSION 4: Pathogen Determinants of Avirulence
Chairperson: J. Dangl, Max-Delbruck-Laboratorium in der MPG, Koln, Germany
D.C. Baulcombe, The Sainsbury Laboratory, Norwich, United
Kingdom: Virus-encoded elicitors of resistance.
P.J.D.M. de Wit, Wageningen Agricultural University, The
Netherlands: Avirulence gene products of Cladosporium
fulvum and their receptors in plants.
B. Valent, The Du Pont Company, Wilmington, Delaware:
Gene-for-gene interactions in the rice blast system.
SESSION 5: The Oxidative Burst and Systemic Acquired Resistance
Chairperson: B. Staskawicz, University of California, Berkeley
U.G. Knaus, The Scripps Research Institute, La Jolla, Califor- I. Raskin, Rutgers University, New Brunswick, New Jersey:
nia: Regulation of the oxidative burst in human leukocytes. Salicylic acid as a signal in disease resistance.
P.S. Low, Purdue University, West Lafayette, Indiana: Signal D.F. Klessig, Rutgers University, Piscataway, New Jersey: A
transduction pathways during the oxidative burst. mechanism of action of salicylic acid in plant disease
C.J. Lamb, Salk Institute for Biological Studies, San Diego, resistance.
California: Mechanism and function of the oxidative burst X. Dong, Duke University, Durham, North Carolina: Genetic
in the hypersensitive response. dissection of systemic acquired resistance response using
D. Shah, Monsanto Company, St. Louis, Missouri: Engineer- Arabidopsis mutants.
ing disease resistance through manipulation of active J. Ryals, Ciba Agricultural Biotechnology, Research Triangle
oxygen in potato. Park, North Carolina: Signaling and signal transduction in
acquired resistance.
SESSION 6: Disease Resistance Physiology and Signal Transduction
Chairperson: J.D.G. Jones, John Innes Centre, Norwich, United Kingdom
R. Fluhr, The Weizmann Institute of Science, Rehovot, Israel:
The tomato 12 locus and pathways to the pathogenesis
response.
G. De Lorenzo, Universita "La Sapienza", Roma, Italy:
Polygalacturonase-inhibiting proteins (PGIPs): Plant
proteins specialized for recognition of fungal pathogens.
C.A. Ryan, Washington State University, Pullman: Systemin:
A mobile wound signal in plants.
J.C. Walker, University of Missouri, Columbia: Signal trans-
duction in plants: The interaction of protein kinases and
phosphatases.
J.R. Ecker, University of Pennsylvania, Philadelphia:
Ethylene signal transduction.
General discussion: Signaling in disease resistance.
G.S. Johal, J. Dangl
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Human Gene Map Workshop II
May 9-May 10
FUNDED BY
European Commission, Glaxo, Merck, Pfizer Inc., Sequana Therapeutics, Inc.,
SmithKline Beecham, Wellcome Trust, United Kingdom Medical Research Council,
United States Department of Energy, United States National Institutes of Health,
and Zeneca Pharmaceuticals
ARRANGED BY
R.H. Waterston, Washington University School of Medicine, St. Louis, Missouri
SESSION 1: EST Reports/Libraries
R. Wilson, Washington University School of Medicine, St.
Louis, Missouri
M.B. Soares, Columbia University, New York, New York
K. Okubo, Osaka University, Japan
C. Auffray, CNRS, Villejuif, France
K. Gibson, HGMP Resource Center, Cambridge, United
Kingdom
SESSION 2: Reports on Mapping of ESTs
D.R. Cox, Stanford University School of Medicine, California:
Introduction.
J. Weissenbach, Laboratoire des Maladies Genetiques
Humaines, Evry, France
K. Schmitt, University of Cambridge, United Kingdom
D.R. Cox, Stanford University School of Medicine, California
SESSION 3: Informatics
M. Boguski, National Center for Biotechnology Information,
Bethesda, Maryland: Introduction.
K.O. Elliston, Merck Research Laboratories, Rahway, New
Jersey
M. Boguski, National Center for Biotechnology Information,
Bethesda, Maryland
G. Cameron, The European Bioinformatics Institute, Cam-
bridge, United Kingdom
SESSION 4: Conclusions/Future Plans
G. Lennon, Lawrence Livermore National Laboratory, Cali-
fornia: IMAGE update.
Discussion:
Moderator: R.H. Waterston, Washington University School
of Medicine, St. Louis, Missouri
D.R. Cox, M.S. Guyer, D.A. Smith
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M. Adams, The Institute for Genomic Research,
Gaithersburg, Maryland
M.H. Polymeropoulos, National Center for Human Genome
Research, National Institutes of Health, Bethesda,
Maryland
H. Shizuya, California Institute of Technology, Pasadena
T.J. Hudson, Whitehead Institute, Massachusetts Institute of
D.R. Bentley, The Sanger Centre Hinxton Hall, Cam-
bridgeshire, United Kingdom
M.R. James, The Wellcome Trust Centre for Human
Genetics, Oxford, United Kingdom
Y. Tateno, DNA Research Center, National Institute of
Genetics, Mishima, Japan
C.A. Fields, National Center for Genome Resources, Santa
Fe, New Mexico
K.H. Buetow, Fox Chase Cancer Center, Philadelphia,
Pennsylvania
K. Fasman, Genome Data Base, Baltimore, Maryland
CREB and Memory
June 8-June 11
FUNDED BY
Cold Spring Harbor Laboratory Corporate Sponsor Program
ARRANGED BY
T. Tully, Cold Spring Harbor Laboratory
J. Yin, Cold Spring Harbor Laboratory
SESSION 1: Behavior I
Chairperson: G. Schutz, German Cancer Research Center, Heidelberg, Germany
D. Bartsch, HHMI, Columbia University, New York, New York:
Long-term facilitation in Aplysia neurons requires coor-
dinated transcriptional activation by Af-I and derepression
of ApCREB-2.
C. Bailey, Columbia University, New York, New York: Struc-
tural changes during long-term memory.
T.J. Carew, Yale University, New Haven, Connecticut: Paral-
lel processing of short-term and long-term synaptic facilita-
tion in Aplysia.
J. Yin, Cold Spring Harbor Laboratory: CREB and the forma-
tion of long-term memory in Drosophila.
E.J. Nest ler, Yale University School of Medicine, New Haven,
Connecticut: Regulation of CREB expression: In vivo evi-
dence for a functional role in the brain.
SESSION 2: CREB/CREM
Chairperson: M.E. Greenberg, Children's Hospital, Boston, Massachusetts
J.F. Habener, HHMI, Harvard Medical School, Boston, Mass- P. Sassone-Corsi, I.G.B.M.C., Strasbourg, France: Molecular
achusetts: Alternative exon splicing generates alternative and physiological aspects of the transcriptional response
activator and repressor isoforms of CREB in the testis. to cAMP.
M. Montminy, The Salk Institute, La Jolla, California: Tran- N.S. Foulkes, I.G.B.M.C., Strasbourg, France: Regulation of
scriptional regulation by cAMP. CREM and circadian rhythms.
G. Schutz, German Cancer Research Center, Heidelberg, E. Lalli, I.G.B.M.C., Strasbourg, France: CREM in endocrine
Germany: Molecular genetic analysis of cAMP-dependent glands.
gene expression in development.
E. Kandel, D. Bartsch, D. Michael R. McKay, T. Tully
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SESSION 3: Downstream
Chairperson: J. Yin, Cold Spring Harbor Laboratory
J. Lundblad, Vollum Institute, Oregon Health Sciences Uni-
versity, Portland: The cAMP:CREB:CBP pathway: A target
of DNA and RNA tumor viruses.
R. Kwok, Vollum Institute, Oregon Health Sciences Univer-
sity, Portland: Differential utilization of the CREB:CBP
pathway allows specific activation of viral versus cellular
promoters.
J.P. Hoeffler, University of Colorado Health Science Center,
Denver: Elucidating in vivo promoter-binding specificity of
CREB/ATF proteins.
T. Hai, Ohio State University, Columbus: ATF3 and ATF4: The
ebb and flow of transcriptional regulation by ATF.
SESSION 4: Transduction
Chairperson: D.R. Storm, University of Washington School of Medicine, Seattle
D.D. Ginty, Johns Hopkins University School of Medicine,
Baltimore, Maryland: CREB confers growth factor activa-
tion of gene expression.
G. Enikolopov, Cold Spring Harbor Laboratory: NO, CREB,
and cAMP in short- and long-term signaling.
M.E. Greenberg, Children's Hospital, Boston, Massachu-
setts: ORES: A mediator of neurotrophin and neurotrans-
mitter signaling.
C.J. Fiol, Indiana University School of Medicine, Indianapolis:
Molecular mechanisms in hierarchal phosphorylations.
R. Maurer, Vollum Institute, Oregon Health Sciences Univer-
sity, Portland: Differential regulation of CREB by
Ca±±/calmodulin-dependent protein kinases.
SESSION 5: PKA
Chairperson: M. Montminy, The Salk Institute, La Jolla, California
S.S. Taylor, University of California, San Diego: cAMP- sity, Portland: Neuronal targeting of kinases and
dependent protein kinase: Structure and subcellular phosphatases: Their role in postsynaptic events.
localization. R.Y. Tsien, HHMI, University of California, San Diego:
H. Bayley, Worcester Foundation, Shrewsbury, Massachu- Fluorescence imaging of cAMP and gene expression in
setts: Functional diversity of cAMP-dependent protein single cells.
kinases in Aplysia. M. Bollen, Afdeling Biochemie, Campus Gasthuisberg,
R.L. Idzerda, University of Washington, Seattle: Targeted dis- Leuven, Belgium: Nuclear Ser/Thr protein phosphatases
ruption of protein kinase A subunits. and their substrates.
J.D. Scott, Vollum Institute, Oregon Health Sciences Univer-
SESSION 6: General Discussion
Discussion Leaders:
T. Curran, Roche Institute of Molecular Biology, Nutley, New Jersey
E. R. Kandel, HHMI, Columbia University, New York, New York
T. Tully, Cold Spring Harbor Laboratory
SESSION 7: Behavior II
Chairperson: J. Yin, Cold Spring Harbor Laboratory
K. Deisseroth, Stanford University, Palo Alto, California:
CREB phosphorylation during synaptic plasticity.
H. Bito, Stanford University, Palo Alto, California: CREB
phosphorylation pathways in action-potential-driven hip-
pocampal neurons.
D.R. Storm, University of Washington School of Medicine,
Seattle: Role of cAMP and Ca**-sensitive adenylyl
cyclase for neuroplasticity.
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A. Silva, Cold Spring Harbor Laboratory: CREB and long-
term memory in mice.
E.R. Kandel, HHMI, Columbia University, New York, New
York: CREB and its role in implicit and explicit memory
storage.
R. McKay, LMB/NINDS, National Institutes of Health,
Bethesda, Maryland: Constructing a chimeric hip-
pocampus.
Molecular Diagnosis of Inherited Breast Cancer
October 10-October 13
FUNDED BY
Cold Spring Harbor Laboratory Corporate Sponsor Program
ARRANGED BY
B.J. Ponder, University of Cambridge, United Kingdom
C.S. Richards, Baylor College of Medicine, Houston, Texas
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory
SESSION 1: Mutations in BRCA1
Chairperson: S.H. Friend, Fred Hutchinson Cancer Research Center, Seattle, Washington
B.J. Ponder, University of Cambridge, United Kingdom: Intro-
duction.
D. Easton, Institute of Public Health, Cambridge, United
Kingdom: Contribution of BRCA1, BRCA2, and other
breast cancer genes to familial and nonfamilial breast
cancer.
C. Szabo, University of Washington, Seattle: Mutations in
SESSION 2: Mutations in Other Genes
Chairperson: J.E. Garber, Dana Farber Cancer Institute, Boston
B.J. Ponder, University of Cambridge, United Kingdom:
Introduction.
D.A. Tag le, National Center for Human Genome Research,
National Institutes of Health, Bethesda, Maryland: The AT
gene: Its functions and contributions to breast cancer.
BRCA1.
L.C. Brody, National Center for Human Genome Research,
National Institutes of Health, Bethesda, Maryland: BRCA1
mutations in the Ashkenazi Jewish population.
B.J. Ponder, University of Cambridge, United Kingdom: Sum-
mary.
Discussion of BRCA mutations.
, Massachusetts
B.E. Henderson, University of Southern California School of
Medicine, Los Angeles: Estrogen metabolism genes and
BRCA1.
Discussion of genes other than BRCA1 and breast cancer.
SESSION 3: Populations in Screening
Chairperson: J.E. Garber, Dana Farber Cancer Institute, Boston, Massachusetts
E.B. Claus, Yale University School of Medicine, New Haven,
Connecticut: Risk estimates/individuals at risk/identifying
women at risk of BRCA1, etc.
W.W. Grody, University of California, Los Angeles, School of
Medicine: Population carrier screening in a complex
gene: The CF experience.
P.D. Murphy, OncorMed, Inc., Gaithersburg, Maryland: The
approach OncorMed uses for BRCA1 testing.
Discussion of screening strategies.
SESSION 4: Technologies for Detecting Mutations
Chairperson: C.S. Richards, Baylor College of Medicine, Houston, Texas
J. Shumaker, Baylor College of Medicine, Houston, Texas:
Comparative DNA sequencing by APEX.
R.A. Gibbs, Baylor College of Medicine, Houston, Texas: Im-
provements in DNA sequencing for mutational analysis.
A.-C. Syvanen, National Public Health Institute, Helsinki, Fin-
land: Solid-phase minisequencing: A promising tool for
large-scale DNA diagnostics.
Discussion of sequencing.
R.G.H. Cotton, Murdoch Institute, Melbourne, Victoria, Aus-
tralia: Gene-specific databases: How do we ensure they
are online and update?
J. Gordon, Abbott Labs, Abbott Park, Illinois: Simple rapid
technologies for readout of complex mutations.
P. Devi lee, University of Leiden, The Netherlands: Per-
formance of the protein truncation test in screening out
BRCA1 mutations: The Dutch experience.
Discussion of other tests.
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SESSION 5
Chairperson: B.J. Ponder, University of Cambridge, United Kingdom
J.E. Garber, Dana Farber Cancer Institute, Boston, Massa-
chusetts: Clinical Issues in BRCA1 testing.
M.J. Ellis Kahn, Richmond, Virginia: Making personal deci-
sions.
B. Bowles Biesecker, National Center for Human Genome
Research, National Institutes of Health, Bethesda,
Maryland: Informed consent issues in BRCA1 testing.
M.S. Watson, Washington University School of Medicine, St.
Louis, Missouri: Considerations in test transition into clini-
cal service.
J. Chamberlain, Institute of Cancer Research, Sutton, Surrey,
United Kingdom: What can be offered to premenopausal
women with molecular diagnosis of inherited breast
B.B. Biesecker, J. Chamberlain,
C.S. Richards, M.J.E. Kahn
cancer?
C. Eng, Mount Sinai School of Medicine, New York, New
York: Acceptance of genetic screening in the Ashkenazi
Jewish popu'ation.
M. Bobrow, Addenbrooke's Hospital, Cambridge, United
Kingdom: Implementing genetic screening and testing in
the National Health Service.
P. Reilly, Shriver Center for Mental Retardation, Waltham,
Massachusetts: DNA-based testing and managed care.
General Discussion:
Moderator: B.J. Ponder, Cambridge University, United
Kingdom
Neurofibromatosis: How to Develop Therapies?
October 15-October 18
FUNDED BY
The National Neurofibromatosis Foundation, Inc., The Wilson Foundation,
and private contributions
ARRANGED BY
F. McCormick, Onyx Pharmaceuticals, Richmond, California
B.R. Seizinger, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New
Jersey
SESSION 1: Clinical Clues for Intervention in NF1
Chairperson: B.R. Korf, Children's Hospital, Boston, Massachusetts
B.R. Korf, Children's Hospital, Boston, Massachusetts: Clini- K.N. North, Children's Hospital, Boston, Massachusetts: Cur-
cal clues that suggest opportunities for intervention in rent understanding of cognitive dysfunction in patients with
NF1. NF1: Implications for research and therapy.
A. Rubenstein, Mt. Sinai School of Medicine, New York, New P.C. Phillips, Children's Hospital of Philadelphia, Pennsyl-
York: Clinical clues to therapy in NF1: Data and data col- vania: NF1 clinical trials: Progress and problems.
lection.
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SESSION 2: Molecular Genetic and Cell Biological Aspects of NF1 (Other Than Ras)
Chairperson: N.G. Copeland, National Cancer Institute-Frederick Cancer Research Cen-
ter, Maryland
D.H. Gutmann, Washington University School of Medicine, search Institute, Princeton, New Jersey: Toward the devel-
St. Louis, Missouri: Tumor suppressor gene products and opment of a new generation of more specific anti-cancer
the cytoskeleton: Potential avenues for cancer therapy. drugs based on rational insights into the signaling path-
L.F. Parada, University of Texas Southwestern Medical Cen- ways of tumor suppressor genes: p53.
ter, Dallas, Texas: Role of the NF1 gene in neuronal sur- K.M. Shannon, University of California, San Francisco: NF1 in
vival. myeloid growth control and leukemogenesis.
F. McCormick, Onyx Pharmaceuticals, Richmond, California: R.L. White, Howard Hughes Medical Institute, University of
Regulators and effectors of Ras proteins. Utah Medical Center, Salt Lake City: Analysis of NF1 muta-
B.R. Seizinger, Bristol-Myers Squibb Pharmaceutical Re- tions in yeast and mammalian cells.
SESSION 3: NF1 Function and Ras Signaling: (A) Ras-Farnesylation Inhibitors
Chairperson: B.R. Seizinger, Bristol-Myers Squibb Pharmaceutical Research Institute,
Princeton, New Jersey
N. Ratner, University of Cincinnati, Ohio: In vitro systems to
test therapeutic agents in NF1-deficient cells.
S. Sebti, University of Pittsburgh School of Medicine,
Pennsylvania: Farnesyltransferase inhibitors induce
cytoplasmic accumulation of inactive Ras/Raf complexes.
J.B. Gibbs, Merck Research Laboratories, West Point,
Pennsylvania: Farnesyltransferase inhibitors as potential
cancer chemotherapeutics.
D. Leopold, Parke-Davis Pharmaceutical Research, Ann Ar-
bor, Michigan: Inhibitors of Ras-related signal transduction
and challenges to evaluation of their therapeutic potential.
SESSION 4: NF1 Function and Ras Signaling: (B) Other Aspects
Chairperson: J.B. Gibbs, Merck Research Laboratories, West Point, Pennsylvania
F. McCormick, Onyx Pharmaceuticals, Richmond, California:
A novel therapeutic approach for p53-defective cancers.
J. De Clue, National Cancer Institute, Bethesda, Maryland:
Roles of neurofibromin and tuberin as tumor suppressor
gene products and regulatory GAP proteins.
N. Wright, Cold Spring Harbor Laboratory: The Ras pathway
in synaptic transmission.
SESSION 5: Animal Models for NF1
Chairperson: A. Rubenstein, Mt. Sinai School of Medicine, New York
A. Silva, Cold Spring Harbor Laboratory: Genetic, elec- A. McClatchey, Massachusetts Institute of Technology, Cam-
trophysiological, and behavioral studies of NF1 mutant bridge: Toward a mouse model for NF1.
mice. M. Henkemeyer, Mt. Sinai Hospital, Toronto, Ontario, Cana-
N.G. Copeland, National Cancer Institute-Frederick Cancer da: Synergy of Gap and NF1 mutations in embryonic de-
Research Center, Maryland: A mouse model for NF1- velopment and tumor formation.
associated juvenile chronic myelogenous leukemia.
F. McCormick, L.F. Parada, B.R. Seizinger
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SESSION 6: NF2
Chairperson: B.R. Seizinger, Bristol-Myers Squibb Pharmaceutical Research Institute,
Princeton, New Jersey
N. Kley, Bristol-Myers Squibb Pharmaceutical Research In-
stitute, Princeton, New Jersey: Molecular genetic analysis
of the NF gene.
V. Ramesh, Massachusetts General Hospital, Charlestown:
Expression and cellular localization of the NF2 protein
Merlin.
A. McClatchey, Massachusetts Institute of Technology, Cam-
bridge: Consequences of a targeted mutation at the NF2
locus.
SESSION 7: Funding
Chairperson: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory
B. Stillman, Cold Spring Harbor Laboratory
F. McCormick, Onyx Pharmaceuticals, Richmond, California
Advances in Imaging and Their Applications
October 22-October 24
FUNDED BY
Finisterre Fund
ARRANGED BY
P.P. Antich, University of Texas Southwestern Medical Center at Dallas
R.W. Parkey, University of Texas Southwestern Medical Center at Dallas
J.E. Smith, Kingston, New Hampshire .
Keynote address: F.J. Bonte, University of Texas Southwestern Medical Center at Dallas
SESSION 1: Issues in Clinical Functional Imaging
Chairperson: R.W. Parkey, University of Texas Southwestern Medical Center at Dallas
C.L. Partain, Vanderbilt University Medical Center, Nashville,
Tennessee: Functional imaging.
D.M. Wieland, University of Michigan Medical Center, Ann
Arbor: Clinical applications of neuronal mapping with PET.
A. Alavi, University of Pennsylvania Hospital, Philadelphia:
Role of modern imaging techniques in the management of
patients with brain tumors.
H.W. Strauss, Stanford University, California: Cardiac infec-
tion imaging.
R.M. Peshock, University of Texas Southwestern Medical
Center, Dallas: Integrated assessment of cardiac function
with MRI.
R. Foster, University of Alabama at Birmingham: Applications
of magnetic resonance to the cardiovascular system.
General Discussion: Impact of Functional Imaging on Fu-
ture Patient Care
Moderator: F.J. Bonte, University of Texas Southwestern
Medical Center at Dallas
SESSION 2: Issues in Functional Imaging: Modalities, Quantitation, Therapy
Chairperson: P.P. Antich, University of Texas Southwestern Medical Center at Dallas
J.G. McAfee, National Institutes of Health, Bethesda,
Maryland: Peptides, growth factors, and cytokines in
nuclear medicine.
B.C. Lent le, Vancouver Hospital Health Sciences Center,
Canada: 511KeV SPECT with F-18 FDG.
E. Hahn, German Cancer Research Center, Heidelberg,
Germany: Functional imaging in oncology.
N.A. Lassen, Bispebjerg Hospital, Copenhagen NV, Den-
mark: Co-registration of SPECT and MRI.
J. Fowler, Brookhaven National Laboratory, Upton, New York:
PET and neuropharmacology.
H.F. Kung, University of Pennsylvania, Philadelphia: CNS
290
receptor imaging with SPECT.
Panel: Functional Imaging in Basic Science Studies
Moderator: W.C. Eckelman, National Institutes of Health,
Bethesda, Maryland
J.A. Barrett, DuPont Merck Radiopharmaceuticals, North Bil-
lerica, Massachusetts
P.P. Antich, University of Texas Southwestern Medical Center
at Dallas
E.M. Stokely, University of Alabama at Birmingham
N.D. Burns, Merck Research Laboratories, West Point,
Pennsylvania
L. Partain, H.F. Kung, F.J. Bonte, J.G. McAfee
SESSION 3: Issues in Functional Imaging: Contrast Agents and Radiopharmaceuticals
Chairperson: J.E. Smith, Kingston, New Hampshire
T.J. Brady, Massachusetts General Hospital-NMR Center,
Charlestown: Target-specific MR contrast agents.
W.C. Eckelman, National Institutes of Health, Bethesda,
Maryland: The uses of 18F and 99mTc radiopharmaceuti-
cals as biochemical probes.
K. Linder, Bracco Diagnostics USA, Princeton, New Jersey:
Imaging hypoxia with technetium-nitroimidazoles.
A. Davison, Massachusetts Institute of Technology, Cam-
bridge: Technetium-based radiopharmaceuticals: Is it
reasonable to expect further advances in the chemical
design of imaging agents?
M.J. Welch, Mallinckrodt Institute of Radiology, St. Louis,
Missouri: Receptors in oncology: Receptor ligands for
therapy.
Panel: Biology, Physics, Chemistry: Inroads and Barriers
Moderator: J.G. McAfee, National Institutes of Health, Bethesda,
Maryland
R.M. Peshock, University of Texas Southwestern Medical Center at
Dallas
J.A. Barrett, DuPont Merck Radiopharmaceuticals, North Bellerica,
Massachusetts
H.D. Burns, Merck Research Laboratories, West Point, Pennsyl-
vania
J.P. Morgan & Co. Incorporated/Cold Spring Harbor Laboratory
Executive Conference on Infectious Diseases: Ancient Plagues,
New Epidemics
October 28-October 30
ARRANGED BY
J.D. Watson, Cold Spring Harbor Laboratory
J.A. Witkowski, Cold Spring Harbor Laboratory
SESSION 1
R. Horton, The Lancet, London, United Kingdom: Plagues
and epidemics in human society.
SESSION 2
R. Berkelman, National Center for Infectious Diseases, Cen-
ters for Disease Control and Prevention, Atlanta, Georgia:
Ebola, Marburg, and other newly emerging viruses.
M.J. Blaser, Vanderbilt University School of Medicine, Nash-
ville, Tennessee: Thinking about ulcers as an infectious
disease.
H. Wendt, J. Karabellas, J.D. Watson
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D. Ganem, HHMI, University of California, San Francisco:
Herpesviruses old and new: Challenges and opportuni-
ties.
B. Bloom, Howard Hughes Medical Institute, Albert Einstein
College of Medicine, Bronx, New York: The dangers of
antibiotic-resistant bacteria.
SESSION 3
D. Mick los and M. Bloom, DNA Learning Center, Cold Spring
Harbor Laboratory: Laboratory experiment: Making
antibiotic-resistant bacteria.
SESSION 4
D.T. Jamison, University of California, Los Angeles: The eco-
nomic impact of infectious diseases.
H.O. Smith, Johns Hopkins University School of Medicine,
Baltimore, Maryland: Sequencing bacteria and viruses: A
new approach to understanding infectious agents.
D.C. Wiley, Howard Hughes Medical Institute, Harvard Uni-
versity, Cambridge, Massachusetts: Atomic models:
Providing clues about infectious and human immunity, and
suggesting therapies.
Molecular Biology of Prions and Pathology of Prion Diseases
November 5-November 8
FUNDED BY
Cold Spring Harbor Laboratory Corporate Sponsor Program
ARRANGED BY
P. Gambetti, Case Western Reserve University, Cleveland, Ohio
S.B. Prusiner, University of California, San Francisco
R.B. Wickner, National Institutes of Health, Bethesda, Maryland
Opening remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, and
S.B. Prusiner, University of California, San Francisco, School of Medicine
SESSION 1: Human Genetics and Neuropathology
Chairperson: S.J. De Armond, University of California, San Francisco
B. Ghetti, Indiana University Medical Center, Indianapolis:
Neuropathology of the PrP amyloidoses.
P. Gambetti, Case Western Reserve University, Cleveland,
Ohio: Molecular pathology of FF1 and other prion dis-
eases.
R. Gabizon, Hadassah University Hospital, Jerusalem, Israel:
Biochemistry of the inherited prion disease E200K.
SESSION 2: Prion Protein Structures'
Chairperson: C. Weissmann, University of Zurich, Switzerland
M.A. Baldwin, University of California, San Francisco:
Covalent structure of PrP isoforms, spectroscopy of PrP
peptides, and molecular models.
J. Safar, National Institutes of Health, Bethesda, Maryland:
Conformational mechanisms in PrPSc formation and in-
fectivity.
B. Caughey, National Institutes of Health Rocky Mountain
Labs, Hamilton, Montana: In vitro protease-resistant PrP
formation.
D. Riesner, Heinrich-Heine University of Dusseldorf,
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J.-L. Laplanche, Hospital St. Louis, Paris, France: Molecular
basis of sheep susceptibility to natural scrapie in France.
G. Wells, Central Veterinary Laboratory, Surrey, United King-
dom: Neuropathology of BSE and oral transmission.
D. Dormont, Service De Neurovirologie, Fontenay-aux-Roses
Cedex, France: Polyene antibiotics in prion diseases.
Germany: Conformation and solubility of PrP.
F. Tagliavini, Institute Nazionale Neurologico 'Carlo Besta,'
Milan, Italy: Aggregation and biological properties of PrP
peptides.
T.L. James, University of California, San Francisco, School of
Medicine: Conformational transitions of PrP and peptides
studied by NMR.
P.T. Lansbury, Massachusetts Institute of Technology, Cam-
bridge: Molecular mechanisms of amyloid formation.
C. Weissmann, B. Ghetti
SESSION 3: Prion Protein Structures
Chairperson: R.F. Marsh, University of Wisconsin, Madison
D. Wemmer, University of California, Berkeley: PrP peptide
structure determination with solid-state NMR.
SESSION 4: Transgenic and Gene-targeted Mice
Chairperson: B.F. Marsh, University of Wisconsin, Madison
C. Weissmann, University of Zurich, Switzerland: Role of PrP
in experimental scrapie.
J. Manson, Institute for Animal Health, Edinburgh, United
Kingdom: PrP in gene-targeted mice.
P.T. Lansbury, D.A. Harris
K. Kaneko, University of California, San Francisco: Conver-
sion of PrPC into a PrPSQlike molecule.
G. Telling, University of California, San Francisco: Prion
propagation and protein X in transgenic mice.
A. Aguzzi, Institute of Neuropathology, Zurich, Switzerland:
PrPSc in brain grafts.
SESSION 5: Yeast Prions
Chairperson: R.B. Wickner, National Institutes of Health, Bethesda, Maryland
F. Lacroute, CNRS, Gif-sur-Yvette, France: Genetic back- S. Liebman, University of Illinois, Chicago: Variability of yeast
ground on URE3 appearance frequency. prion-like elements affecting translational fidelity.
R.B. Wickner, National Institutes of Health, Bethesda, Y.O. Chernoff, Georgia Institute of Technology, Atlanta:
Maryland: URE3 and PS1 as prions of yeast: Genetic evi- Propagation of PS1 and chaperones.
dence. S.L. Lindquist, HHMI, University of Chicago, Illinois: Hsp104
D.C. Masison, National Institutes of Health, Bethesda, and maintenance of yeast prions.
Maryland: Prion-inducing domain of yeast Ure2p and M.F. Tuite, University of Kent, United Kingdom: The genetics
protease resistance of Ure2p in prion-containing cells. of PS1: A non-Mendelian phenomenon explained?
SESSION 6: Cell Biology of Prion Protein Isoforms and Molecular Chaperones
Chairperson: P. Gambetti, Case Western Reserve University, Cleveland, Ohio
R.B. Petersen, Case Western Reserve University, Cleveland,
Ohio: Effects of PrP mutations on PrP metabolism.
W.J. Welch, University of California, San Francisco: Molec-
ular chaperones and prion propagation.
A. Taraboulos, The Hebrew University of Jerusalem, Nadas-
sah Medical School, Israel: Cholesterol in the cellular me-
tabolism of the PrP isoforms.
D.A. Harris, Washington University Medical Center, St. Louis,
Missouri: Cell biology of prion diseases.
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SESSION 7: Strains of Prions and Molecular Pathogenesis
Chairperson: P. Gambetti, Case Western Reserve University, Cleveland, Ohio
R.F. Marsh, University of Wisconsin, Madison: Strain-specific
neuropathology of TME.
G.A. Carlson, McLaughlin Research Institute, Great Falls,
Montana: Host genetics and prion diversity.
S.J. De Armond, University of California, San Francisco:
Transgenic models of prion disease pathogenesis.
S.B. Prusiner, University of California, San Francisco, School
of Medicine: Closing comments.
Vaccine Development and Delivery in the Era of Managed Care
November 12-November 15
FUNDED BY
The Albert B. Sabin Vaccine Foundation
ARRANGED BY
H. Bailit, Aetna Health Plans, Hartford, Connecticut
E.K. Marcuse, Children's Hospital and Medical Center, Seattle, Washington
M.T. Osterholm, Minnesota Department of Health, Minneapolis
P.K. Russell, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, Maryland
T. Vernon, Merck & Company, Inc., West Point, Pennsylvania
Opening remarks: P.K. Russell, School of Hygiene and Public Health, The Johns Hopkins
University, Baltimore, Maryland and H.R. Shepherd, Albert B. Sabin Vaccine Founda-
tion, New Canaan, Connecticut
SESSION 1: Vaccine Delivery in Pediatric and Family Practice
Chairperson: E.K. Marcuse, Children's Hospital and Medical Center, Seattle, Washington
B. Guyer, School of Hygiene & Public Health, The Johns
Hopkins University, Baltimore, Maryland: Interaction of
parental and provider factors in explaining vaccination
coverage: Implications for policy.
B. Harvey, Palo Alto, California: Barriers to vaccine delivery
in the private sector.
J.R. Almquist, Virginia Mason Pediatrics, Federal Way,
Washington: Problems faced by practitioners.
S. Berman, University of Colorado, Children's Hospital, Den-
ver: The doctors' dilemmas: Immunization barriers from a
primary care provider's perspective.
S.L. Katz, Duke University Medical Center, Durham, North
Carolina: Flexibility in new vaccine schedules.
SESSION 2: Vaccine Financing and Delivery by the Insurance and Managed Care Industry
Chairperson: H.L. Bailit, Aetna Health Plans, Hartford, Connecticut
C.M. Grant, Connaught Laboratories, Inc., Swiftwater, R.A. Hansen, Aetna Health Plans, Hartford, Connecticut:
Pennsylvania: Partnerships in adult and pediatric im- How we factor the cost of immunization services into the
munization services, consumer expectations. CLI can em- price for managed care benefit plans at Aetna Health
phasize 'adult" vaccines if you have coverage for Plans.
pediatrics. D. Siegel, Health Alliance Plan of Michigan, Detroit:
A. McCollam, The Prudential Insurance Co. of America, Managed care perspectives on enhancing appropriate im-
Roseland, New Jersey: A managed care perspective on munization administration through managed care vehicles.
vaccine coverage and reimbursement.
SESSION 3: Successes and Problems in National and State Vaccination Programs
Chairperson: W.A. Orenstein, Centers for Disease Control & Prevention, Atlanta, Georgia
R.H. Bernier, Centers for Disease Control, Atlanta, Georgia:
Current status of the Childhood Immunization Initiative.
D.K. Alfano, Kansas Department of Health & Environment,
Topeka: A states perspective.
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M. Sheehan, Minnesota Department of Health, Minneapolis:
Providing chilhood immunizations in a managed care en-
vironment: The Minnesota experience.
D. Siegel, D.A. Henderson
SESSION 4: Government/Industry Relationships
Chairperson: M.T. Osterholm, Minnesota Department of Health, Minneapolis
J.J. Totten, Mercer Management Consulting, Inc., Washing-
ton, D.C.: Government/industry relationships and the im-
pact on U.S. vaccine industry economics.
L.B. Hackett, Mercer Management Consulting, Inc., Wash-
ington, D.C.: Children's immunization initiative.
S.K. Sharma, United States General Accounting Office,
Washington, D.C.: Barriers and obstacles to vaccination.
SESSION 5: Introductions of New Vaccines
Chairperson: R.G. Douglas, Merck & Co., Inc., Whitehouse Station, New Jersey
L.K. Gordon, OraVax Inc., Cambridge, Massachusetts: A
perspective from industry. Oral vaccines and mucosal
immunity products in development for respiratory syncy-
tial virus, Helicobacter pylori, and Clostridium difficile.
Colloquium Summary:
D.A. Henderson, Baltimore, Maryland
P. Freeman, University of Massachusetts, Boston
Human Molecular Genetics: A Hands-on Workshop
November 16-November 19
FUNDED BY
Ethical, Legal, and Social Issues Program and Department
of Energy's Human Genome Project
ARRANGED BY
M. Bloom, DNA Learning Center, Cold Spring Harbor Laboratory
D. Micklos, DNA Learning Center, Cold Spring Harbor Laboratory
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory
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SESSION 1
D. Mick los, DNA Learning Center, Cold Spring Harbor
Laboratory: Mendelian view of the gene: From peas to
eugenics.
J.A. Witkowski, Banbury Center, Cold Spring Harbor Labor-
SESSION 2
B. Ward, Integrated Genetics, Inc., Waltham, Massachusetts:
Cytogenetics in the age of DNA.
D. Mick los, DNA Learning Center, Cold Spring Harbor
Laboratory: Laboratory I: Using restriction enzymes to
SESSION 3
M. Bloom, DNA Learning Center, Cold Spring Harbor
Laboratory: Cloning human disease genes.
P. Ward, Institute of Molecular Genetics, Baylor College of
Medicine, Houston, Texas: DNA-based diagnosis for hu-
man genetic diseases.
SESSION 4
M. Bloom and D. Mick los, DNA Learning Center, Cold
Spring Harbor Laboratory: Laboratory: Fingerprinting
your own DNA by polymerase chain reaction.
SESSION 5
M. Bloom and D. Mick los, DNA Learning Center, Cold Spring
Harbor Laboratory: Laboratory results: Analyzing finger-
printing results,
T. Tully, Cold Spring Harbor Laboratory: Genetics and be-
havior.
M.G. McInnis, The Johns Hopkins University, Baltimore,
atory: Modern view of the gene.
J.A. Witkowski, Banbury Center, Cold Spring Harbor Labor-
atory: PCR, RFLPs, and (CA)n: What they are; what they
do.
construct chromosome maps.
D. Mick los, DNA Learning Center, Cold Spring Harbor
Laboratory: Laboratory II: Construction of chromosome
map.
J. Friedman, HHMI, The Rockefeller University, New York,
New York: The genetics of obesity.
W.T. Brown, New York State Institute for Basic Research,
Staten Island, New York: Molecular Genetics and biology
of the fragile-X syndrome.
Maryland: Genetics of psychiatric disorders.
K. Culver, OncorPharm, Inc., Gaithersburg, Maryland:
Human gene therapy trials.
P. Reilly, Shriver Center for Mental Retardation, Waltham,
Massachusetts: Future of genetic testing and screening.
Looking to the Next Generation of Genetic Analysis
November 28-December 1
FUNDED BY
The Charles A. Dana Foundation
ARRANGED BY
A. Chakravarti, Case Western Reserve University, Cleveland, Ohio
E.S. Lander, Whitehead Institute for Biomedical Research, Cambridge, Massachusetts
SESSION 1: "Real World" Experience
Chairperson: K. Morgan, Montreal General Hospital, Canada
N.B. Freimer, University of California, San Francisco: IBD
mapping of loci for human behavioral traits.
J.R. De Paulo and M.G. McInnis, The Johns Hopkins Hospital,
Baltimore, Maryland: Studies of manic-depressive illness.
L. Peltonen, National Public Health Institute, Helsinki, Fin-
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land: Lessons from disease gene search in genetic isola-
tes.
M.S. Georges, University of Liege, Belgium: The application
of IBD mapping to locate disease genes in livestock: The
example of syndactyly.
J.D. Terwilliger, L. Kruglyak, L.A. Sandkuijl
SESSION 2: Genomic Technologies
Chairperson: A. Chakravarti, Case Western Reserve University,
T.J. Hudson, Whitehead Institute, Cambridge, Massachu-
setts: Integrated genetic, physical, and transcript map de-
velopment of 2-allele polymorphisms.
M.T. Boyce-Jacino, Molecular Tool Inc., Baltimore, Mary-
land: Identification and genotyping of diallelic polymor-
phisms.
D.G. Wang, Whitehead Institute, Cambridge, Massachusetts
SESSION 3: IBD Mapping in Families
Chairperson: M.S. Georges, University of Liege, Belgium
L. Kruglyak, Whitehead Institute, Cambridge, Massachusetts:
A new multipoint method for nonparametric linkage analy-
sis of pedigree data based on identity by descent.
D.W. Fulker, Institute for Behavioral Genetics, University of
Colorado, Boulder: Simple strategies for increasing power
in sib-pair QTL studies.
Cleveland, Ohio
and Robert Lipshutz, Affymetrix, Santa Clara, California:
Automated comparative sequencing of PCR products for
large-scale screening of biallelic markers and genotyping
them on DNA chips.
M. Zabeau, Keygene N.V., Wageningen, The Netherlands:
AFLP: A robust high throughput diallelic marker system for
the next generation of genetic analysis.
J.M. Olson, Case Western Reserve University, Cleveland,
Ohio: Two-locus linkage models for complex diseases.
N. Schork, Case Western Reserve University, Cleveland,
Ohio: IBD sibship mapping with multiple phenotypes: De-
sign and power issues.
A. Chakravarti, M. Zabeau
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SESSION 4: Association Mapping
Chairperson: N. Schork, Case Western Reserve University,
L.A. Sandkuijl, Delft, The Netherlands: A search for shared
DNA segments is most efficient in patients from recent
founder populations.
J.D. Terwilliger, University of Oxford, United Kingdom: Be-
havior of true and false positive sib-pair statistics in
genome screens.
Cleveland, Ohio
A. Lynn, Case Western Reserve University, Cleveland, Ohio:
Linkage disequilibrium mapping under heterogeneity.
S.-W. Guo, University of Michigan, School of Public Health,
Ann Arbor: Linkage disequilibrium mapping: Problems and
prospects.
SESSION 5: Population Genetics
Chairperson: E.S Lander, Whitehead Institute for Biomedical Research, Cambridge, Mas-
sachusetts
E. Puffenberger, Case Western Reserve University, Cleve- R.R. Hudson, University of California at Irvine: Effects of
land, Ohio: Genetic variation in the Old Order Mennon- background deleterious mutations on linked neutral varia-
ites of Lancaster County, Pennsylvania. tion.
K. Morgan, Montreal General Hospital, Canada: Genetic dif- K. Weiss, Pennsylvania State University, University Park:
ferentiation of the French Canadian population of Quebec. Population history and human variation.
Finding Genes: Experimental and Computational Methods
December 3-December 6
FUNDED BY
Cold Spring Harbor Laboratory Corporate Sponsor Program
ARRANGED BY
T.G. Marr, Cold Spring Harbor Laboratory, New York
D.L. Nelson, Baylor College of Medicine, Houston, Texas
Introduction and perspective: D.L. Nelson, Baylor College of Medicine, Houston, Texas,
and T.G. Marr, Cold Spring Harbor Laboratory
SESSION 1: Experimental Methods and Applications I: cDNA Selection
Chairperson: A.P. Monaco, Wellcome Trust Centre for Human Genetics, Oxford, United
Kingdom
S. Weissman, Yale University School of Medicine, New R. Anand, Zeneca Pharmaceuticals, Cheshire, United King-
Haven, Connecticut: cDNA detection and display. dom: Evaluation and optimization of preparative in situ
J. Rommens, The Hospital for Sick Children, Toronto, Cana- hybridization: A tool for gene hunting in the 5-10-Mb
da: Transcription maps. region.
SESSION 2: Experimental Methods and Applications II: Trapping Plus
Chairperson: L.-C. Tsui, The Hospital for Sick Children, Toronto, Canada
A. Buckler, Massachusetts General Hospital, Charlestown: cDNAs with ESTs: Efficiency, comprehensiveness, or
Exon amplification. ease?
A.P. Monaco, Wellcome Trust Centre for Human Genetics, J.W. Foster, University of Cambridge, United Kingdom:
Oxford, United Kingdom: Hybridization of PAC inserts to Radiation hybrid mapping.
cDNA libraries and exon trapping of PACs. C.C. Lee, Baylor College of Medicine, Houston, Texas:
G. Lennon, Lawrence Livermore National Laboratory, Califor- Reciprocal probing for cDNAs and cosmids.
nia: Comparing exon trapping and hybrid selection of
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SESSION 3: Experimental Methods and Applications III: Use and Mutation
Chairperson: D.L. Nelson, Baylor College of Medicine, Houston, Texas
G. Borsani, Telethon Institute for Genetics and Medicine
(TIGEM), Milan, Italy: Toward a transcription map of the
distal short arm of the human X chromosome.
N.C. Dracopoli, Sequana Therapeutics, Inc., La Jolla, Cali-
fornia: Finding genes for common disorders.
J. Liu, Merck Research Labs, West Point, Pennsylvania:
High-throughput mutation detection.
SESSION 4: Computational Applications I: Sequence Production/Analysis
Chairperson: A. Buckler, Massachusetts General Hospital, Charlestown, Massachusetts
L.-C. Tsui, The Hospital for Sick Children, Toronto, Canada:
Our experience of gene finding on chromosome 7.
D.L. Nelson, Baylor College of Medicine, Houston, Texas:
Sequence-based gene finding.
B.F. Koop, University of Victoria, Canada: Lessons from com-
parative sequencing.
E.C. Uberbacher, Oak Ridge National Laboratory, Tennes-
see: Discovering and characterizing genes using se-
quence analysis.
R.F. Smith, Baylor College of Medicine, Houston, Texas: Se-
quence analysis for function.
M.O. Zhang, Cold Spring Harbor Laboratory: What makes an
exon an exon?
SESSION 5: Computational Applications II: Sequence Analysis
Chairperson: R.F. Smith, Baylor College of Medicine, Houston, Texas
W.R. McCombie, Cold Spring Harbor Laboratory: Strategies
for sequence-based gene discovery.
J.-M. Claverie, CNRS, IBSM, Marseille, France: Progress in
large-scale sequence analysis.
T.G. Marr, Cold Spring Harbor Laboratory: Summary and dis-
cussion of computational applications: How good are they?
How can they be improved?
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Massa A.G. Hewitt, Laboratory Instructor
Diane S. Jedlicka, Laboratory Instructor
Diane Esposito, Laboratory Instructor
Flavio Della Seta, Laboratory Instructor
Einstein's comment to the effect "God is subtle but not malicious," applies equally
well to molecular genetics. On the face of it, this field must seem almost mali-
ciously abstract to even bright and motivated students. Doing experiments is
probably the only way to reduce this abstraction and give students a feeling for
the subtle beauty of molecular mechanics. For better or worse, bands on gels,
colonies on plates, and dots on filter paper are the major methods of inference in
molecular genetics-the ways of knowing molecules. Only when these methods
can be used to obtain predictable results, can students begin to believe that ex-
periments, indeed, offer a window on the unseen molecular world. Teachers
sometimes try to put the best spin on a failed experiment by saying that students
can learn as much from failure as success. In fact, in students' eyes, a failed ex-
periment can mean a failure of that mode of inference. A failed experiment throws
students back into the abstractive quandary in which they began. We believe that
experiments should work for students. Therefore, we have made it our raison
d'etre to adapt and refine molecular genetics laboratories to increase the prob-
ability of success in student hands.
The publication in November of Laboratory DNA Science: An Introduction to
Recombinant DNA Techniques and Methods of Genome Analysis marked anoth-
er high point in our effort to bring reproducible and high-level molecular genetics
laboratories into the biology classroom. The text incorporates the basic cloning
sequence (10 laboratories) from our original DNA Science course, plus 13 new
laboratories that cover gene library construction, hybridization, and polymerase
chain reaction (PCR). The author team, Mark Bloom, Dave Mick los, and Greg
Freyer (of Columbia University), believe these to be the most thoroughly tested
labs available today for teaching molecular genetics at the college level. Each
experiment incorporates insights from our own instruction of 2000 teaching facul-
ty at training workshops across the country and from the 30,000 students taught
in our Bio2000 Biochemistry Laboratory. The entire lab sequence is supported by
quality-assured reagents and kits available from the Carolina Biological Supply
Company.
Nothing has been left to chance. Greg even engineered the teaching plas-
mids, pAMP, pKAN, and pBLU, specifically for the course. These plasmids trans-
form well, give consistently high yields in plasmid preparations, simplify
colorimetric screening for recombinant plasmids, and yield restriction products
that are easily interpreted on agarose minigels. The laboratories also incorporate
insights drawn from extensive contacts within the biological research community.
Prescott Deininger and Mark Batzer, of the LSU Medical Center, introduced us to
the Alu insertion polymorphisms-which proved to be ideal for educational
demonstrations of human DNA typing. Collaborations with scientists at Cetus,
Perkin-Elmer, and Roche Molecular Systems were key to the development of the
LABORATORY DNA SCIENCE
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Dave Mick los, Mark Bloom, and
Greg Freyer on the release of
Laboratory DNA Science.
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PCR experiments, while scientists at Boehringer Mannheim aided with
colorimetric detection used in hybridization experiments.
We are all thankful to our editor, Cathy Pusateri, for keeping her promise to
produce Laboratory DNA Science in only 10 months! The 434-page book fea-
tures extensive prelab notes, flowchart diagrams, marginal notes, results and dis-
cussion, and for further research sections. Appendices include lists of needed
equipment, supplies, and reagents; recipes for media, stock solutions, and
reagents; restriction maps for plasmids; and complete sequence data for all
DNAs used in the course. A 99-page Instructor's Preparation Guide includes
hints on lab prep and answers to results and discussion questions. Laboratory
DNA Science has gotten off to a good start, selling 1000 copies in its first month.
Tracing the Rise of Precollege Laboratory Instruction in Molecular Genetics
We hope that Laboratory DNA Science will encourage college instructors to in-
creasingly bring molecular genetics labs into freshman biology and sophomore
electives. This echoes the DNALC's original effort to bring student laboratories on
molecular genetics into American high schools. In the summer of 1985, we were
among the very first academic groups to initiate teacher training in recombinant
DNA techniques. It is fair to say that prior to 1985, there was essentially no
precollege lab instruction in molecular genetics. Thus, taking the 1984-1985 aca-
demic year as the zero point-and using sales data for needed reagents and
teaching kits as an indicator of student exposures-one can trace the rise of an
entirely new era in science education. The notion that recombinant DNA tech-
niques are an important basis for student understanding was legitimized in 1989,
when the Educational Testing Service recommended two DNA-manipulation labs
for students who take its nationally administered Advanced Placement (AP) Biol-
ogy curriculum. As shown in the figure, the AP "mandate" helped to catalyze the
rapid adoption of several "core" techniques of recombinant DNA: bacterial trans-
Precollege Student Exposures to Four Molecular Genetics Laboratories
(extrapolated from sales of teaching kits and reagents by Carolina Biological Supply Company)
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formation, DNA restriction analysis, DNA recombination, and plasmid isolation.
Our studies of teacher innovation suggest that the estimated 3500 teachers
nationwide who have been trained using the DNA Science syllabus account for at
least half of 160,000 student exposures to molecular genetics laboratories in the
1994-1995 academic year. In addition to experimentation in the context of AP
courses, half- and full-year electives in molecular genetics/biotechnology are
being instituted in growing numbers of American high schools. In some schools,
it is filling the niche formerly occupied by anatomy and physiology or biology II; in
other schools, it is filling the new "tech-prep" niche. For example, 14 of 23
participants in the 1995 Leadership Institute are currently teaching molecular
genetics/biotechnology electives at their high schools.
Further Progress in Making PCR Widely Available to Biology Students
With support from the Howard Hughes Medical Institute and the National Science
Foundation (NSF), we continued our effort to make human DNA fingerprinting by
PCR practical for widespread use in biology classes. In December, Mark Bloom
and collaborator John Kruper taught the first of a series of NSF-supported work-
shops for college faculty, Human Genome Diversity-Student Allele Database.
Held at the Air Force Academy in Colorado Springs, the workshop drew together
24 college educators for in-depth training to implement experiments on DNA fin-
gerprinting in freshman and elective biology courses. The workshop revolves
around experiments from Laboratory DNA Science that allow students to use
PCR to analyze two types of human DNA polymorphisms-Alu insertions and vari-
able number tandem repeats (VNTRs). Alu is an example of a "jumping gene" that
has successfully reproduced and inserted about 500,000 copies of itself through-
out the human chromosomes. Some A /us inserted several million years ago,
when humans were radiating out of Africa to populate the globe. These Alu inser-
tions can be used as biological clocks to measure the genetic distance between
populations and to study how humans have evolved. VNTRs are chromosome
regions where a short DNA sequence is repeated numerous times. VNTRs are
highly variable from person to person, making them especially useful in human
identity. Several types of VNTR polymorphisms are used as evidence in rape,
murder, and paternity cases.
Mark Bloom worked for several years to simplify the biochemical procedures
for screening for Alu and VNTR polymorphisms. In collaboration with John
Kruper's bioscience computing group, at the University of Chicago, we also have
made significant progress in developing computer programs and instrumentation
to make the technology more accessible to students. During the year, the Chica-
go group developed a prototype Student Allele Database to run on their World
Wide Web server (http//:http.bsd.uchicago.edu/hgd-sad) and also reachable
through a link on the DNALC server (http//:darwin.cshl.org). The program allows
students to tabulate Alu insertion data, test Hardy-Weinberg equilibrium, and
compare two populations by contingency Chi-square and genetic distance. The
database is seeded with Alu data from a number of isolated populations from
around the world, which have been collected by researchers Prescott Deininger
and Mark Batzer, of LSU Medical School. Eventually, we hope the database will
also contain data submitted by thousands of students from around the United
States and Europe. In that way, students can participate in an evolving research
project on human diversity.
By year's end, we also had a stable, working prototype of a programmable
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thermal cycler to control the PCR. Commercial thermal cyclers cost several thou-
sand dollars and have put automated cycling out of reach of most educators. Our
Biogenerator, which will be available for about $700 in 1996, should remove a
major obstacle to the use of PCR in education. Water temperature in a Plexiglas
reaction vessel is raised by activating heater coils while temperature is lowered
by activating a valve that controls cold water flow into the vessel. Heating and
cooling are controlled by an analog-digital (A-D) interface that receives com-
mands from a personal computer and temperature information from a thermo-
couple. In addition to its low cost, Biogenerator has several advantages over
research-grade thermal cyclers that make it more suitable for the teaching
laboratory:
The simplicity of the apparatus helps students grasp the physical principles
of thermal cycling. The open design allows students to observe the mechan-
isms of heating and cooling, as well as feedback between the computer and
the thermocouple.
Animated screen icons provide quick references to the cycling state (activa-
tion of heater coils or cold water valve) and PCR state (DNA denaturing,
primer annealing, and primer extension).
A computer "strip chart" plots temperature change in real time, allowing stu-
dents to follow the course of the reaction, review the reaction profile, and cal-
culate temperature ramping.
Programs for Long Island Students Continue to Expand
The DNALC had its roots in the Cold Spring Harbor Curriculum Study, a teacher-
training program initiated in 1985 in cooperation with eight local school districts.
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Visitors and Program Participants, 1988-1995
Visitors and Participants 1988 1989 1990 1991 1992 1993 1994 1995
Student Labs (on-site) 2,031 3,753 3,758 4,248 4,624 3,422 3,961 4,682
Student Labs (off-site) 291 435 1,305 1,434 2,328
Teacher Labs 58 278 270 234 270 254 302 379
Student Workshops 32 13 24 176 234 351 361 503
Teacher Workshops 496 285 314 333 441 249 177 101
Lab Subtotal 2,617 4,329 4,366 5,282 6,004 5,581 6,235 7,993
Student Lecture Series 553 449 660 600 1,000 734 575 520
Exhibit Visitors 3,231 2,547 2,964 1,480 848 6,416 9,943 13,064
Total Visitors/Participants 6,401 7,325 7,990 7,362 7,852 12,731 16,753 21,577
The DNA Science curriculum that arose from this collaboration achieved national
prominence and was the basis for our nationwide teacher-training program. It
also provided the template for the development of Laboratory DNA Science and
its nationwide training program. Although our commitment to curriculum develop-
ment and dissemination continues, we devote increasing energy to developing
the DNALC facility as a resource for local students. In this sense, we are return-
ing to our roots in collaboration with Long Island and New York City schools.
The Curriculum Study continues as our major mechanism to work intensively
with local school systems. Over the years, it has grown from the original eight
members to 28 districts and private schools in 1995. As shown in the table
above, our visitation has nearly tripled since our opening in 1988. Cablevision's
Long Island Discovery drew 10,366 visitors in 1995, and the Story of a Gene Ex-
hibit drew 2698 visitors. Of special importance, lab participation has contributed
equally to our growth as exhibit visitation. Although it is hard for a science center
or museum to gauge the exposure received by an casual exhibit visitor, we know
that each lab participant has had a 1-3-hour, hands-on experience conducted
by a DNALC staff member, while workshop participants have had at least 20
hours of intensive instruction.
Over the past several years, we have devoted much effort to developing pro-
grams for middle-school students, including summer camps, academic-year lab
field trips, and in-school instruction. Under the direction of our trio of middle
school specialists, Jane Conigliaro, Diane Jedlicka, and Melissa Hewitt, these
programs became the major source of growth in 1995. Eight school districts were
members of the Genetics as a Model for Whole Learning Program-Half Hollow
Hills, Lawrence, Great Neck, Jericho, Locust Valley, Roslyn, South Huntington,
and Syosset-nearly doubling student participants to 2328. Although each pro-
gram is customized according to district needs, the typical program includes in-
school instruction and teacher mentoring by DNALC staff, as well as a field trip to
the DNALC for intensive use of the Story of a Gene Exhibit and experimentation in
the Bio2000 Laboratory. Science supervisors in these districts believe that they
are already beginning to see increased interest in science courses, as graduates
of our middle school programs move on to high school. Fortunately, these high
schools offer research and elective courses that will allow these gifted students
to follow up on their interest in biology.
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Student participation in lab field trips to the Bio2000 Laboratory increased
18% to 4682 students, thanks to excellent instruction offered by part-time in-
structors Flavio Della Seta, Diane Esposito, Diane Jedlicka, and Malissa Hewitt.
High school students (2894) performed labs on bacterial transformation, DNA
restriction analysis, and human DNA fingerprinting, and middle school students
(1788) performed experiments on Mendelian genetics, cell study, and DNA ex-
traction. The Great Moments in DNA Science Honors Student Seminar Series,
now in its 11th year, continued as a popular element of our annual calendar of
events, drawing the attendance of 520 local students and teachers. Speakers
and topics were:
Syd Mandelbaum, Imagen Instrumentation. Historical DNA Cases: The Solv-
ing of the Anastasia Mystery.
Dr. Michael Hengartner, CSHL. Apoptosis: Why and How Cells Commit
Suicide.
David Mick los, DNALC. DNA and OJ.
Student participation in summer workshops increased dramatically from 361
in 1994 to 558 in 1995, due to collaborations that enabled us to hold additional
workshops at four other sites in the New York metropolitan area. We continued
our collaboration with Port ledge School (Nassau County) to serve the great
demand for middle school workshops on the North Shore of Long Island. Central
Islip School District (Suffolk County), Roslyn Middle School (Nassau County), and
the American Museum of Natural History (AMNH, New York City) were sites for
middle school and high school workshops targeting primarily minority students.
We were especially pleased with a new collaboration that was made possible
through the support of AMNH President Ellen Futter and Chairman Anne
Sidamon-Eristoff, and a 2-year grant from the Barker Welfare Foundation. Eleven
sessions of Fun With DNA (grades 5-6) served a total of 315 participants, includ-
ing 202 minority students. Three sessions of the workshop, World of Enzymes
(grades 7-8), attracted 77 participants, including 26 minority students. Four ses-
sions of DNA Science (grades 10-12) drew 131 participants, including 83 minori-
ty students. New for 1995 were two sessions of Advanced DNA Science (grade
12) held at Central Islip High School and the Beckman Neuroscience Center that
served 35 participants, including 25 minority students.
DNA Boot Camp participants after a discussion led by Dr. Watson.
Training Workshops Reach Faculty and Opinion Leaders Nationwide
This year marked the ninth summer of NSF funding for our DNA Science Workshop.
In keeping with our commitment to bring high-level training to teachers from rural
and nonurban areas, workshops were held in Lawrence, Kansas, and Lewiston,
Maine, drawing the participation of 55 high school faculty. An additional 23 faculty,
representing 17 states and Puerto Rico, attended the month-long Leadership In-
stitute in Human and Molecular Genetics, held at the DNALC and Cold Spring Har-
bor Laboratory. Also known as "DNA Boot Camp," this intensive experience includes
practical laboratory and computer work, as well as an array of seminars presented
by CSHL scientists and visiting faculty:
Karen Buchavich, CSHL: Telomeres, Cancer, and Aging.
Xiaodong Cheng, CSHL: X-ray Structures Solved at CSHL.
Rob De Salle, American Museum of Natural History: Ancient DNA and Com-
parative Biology.
Mike DeStio, Half Hollow Hills School District: Sequenced Genetics Instruc-
tion-A District Perspective.
Anil Dhundale, Oncogene Science: Expression Screening for Drug Discovery.
Bruce Futcher, CSHL: Cell Cycle Control.
Fred Gil lam, Sachem North High School: Molecular Genetics Electives at the
High School Level.
Marvin Grubman, Plum Island Animal Disease Center: Molecular Approaches
to a Foot and Mouth Vaccine.
Mike Hengartner, CSHL: Apoptosis and Cell Suicide.
Gerry Latter, CSHL: 2-Dimensional Electrophoresis.
Rob Martienssen, CSHL: Transposon Tagging in Arabidopsis.
Dick McCombie, CSHL: Sequencing Genomes.
Bruce Stillman, CSHL: Research Highlights at CSHL.
Tim Tully, CSHL: CREB, Memory and Intelligence.
James Watson, CSHL: Perspectives on the Gene Revolution.
Jan Witkowski, CSHL: Human Genetics.
With funding from the Department of Energy, we continued our collaboration
with Banbury Center to increase knowledge of advances in human genetics
among influential "opinion leaders" in various fields. Continuing a shift in empha-
sis begun last year, the 1995 workshop drew 17 medical education directors
representing hospitals in 10 states, with the expectation that they can help hospi-
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tals better appreciate how the molecular genetics perspective is changing mod-
ern medicine. In addition to hands-on experiments on gene mapping and DNA
diagnosis, participants heard high-level seminars about topics on the interface of
molecular genetics, medicine, and society:
Ted Brown, NY State Institute for Basic Research: Molecular Genetics and
Biology of Fragile-X Syndrome.
Jeffrey Friedman, The Rockefeller University: Genetics of Obesity.
Ken Culver, OncorPharm: Human Gene Therapy Trials.
Melvin McInnis, Johns Hopkins University: Genetics of Psychiatric Disorders.
Philip Reilly, Shriver Center for Mental Retardation: Future of Genetic Testing
and Screening.
Tim Tully, CSHL: Genetics and Behavior.
Brian Ward, Integrated Genetics: Cytogenetics in the Age of DNA.
Patricia Ward, Baylor College of Medicine: DNA-based Diagnosis for Human
Genetic Diseases.
We Open Our First In-house Exhibit on Human Growth Hormone
In 1987, when the decision was made to begin development of our facility, the
Cold Spring Harbor Laboratory Trustees were adamant that we emphasize the
active process of acquiring knowledge. Then and now, our primary mission is to
develop and disseminate novel methods for students to actively experience the
world of molecular genetics. Thus, museum exhibits have always been consid-
ered ancillary to the hands-on experience students receive in our Bio2000
Biochemistry Laboratory and BioMedia Computer Laboratory.
For our opening in 1988, we were lucky enough to obtain loan of the Smith-
sonian Institution exhibit, The Search For Life, which allowed us effectively to
dodge exhibit development during our first 4 years. Prior to dismantling the
Smithsonian exhibit, in preparation for building renovations in 1993, we had
made ambitious plans to develop our first in-house exhibit on the technology of
gene hunting used in the Human Genome Project. However, by the time we were
ready to begin exhibit development in 1994, we were forced to reconsider our
310
Top right: middle-school students transform
the giant E. coli in the Plasmid Toss; Top left:
visitors take the Walk of Life, and Nicole Costa
(bottom left), who receives HGH therapy,
stands by her likeness.
plans. Two new programs in 1993-Cablevision's Long Island Discovery and
Genetics as a Model for Whole Learning-had significantly changed our predomi-
nantly high school clientele to include large numbers of elementary students. It
had become clear that our original exhibit concept was far too technical for
younger students; we had to scrap our previous plan and find a friendlier ap-
proach to a difficult subject matter.
The solution we came upon was, simply, to tell the Story of a Gene, i.e., to
organize the entire exhibit around a single gene. This case study approach al-
lowed us to cut a cross-section through modern biological research, touching
upon the hard science topics of molecular genetics, cell biology, and physiology,
as well as medical, personal, and social issues. This approach compelled us to
tell the story of human growth hormone (HGH), which is produced by the pituitary
gland within the brain. This is the best single example of a gene affecting a
visible human trait; HGH is largely responsible for a person's height. Problems
with this gene most commonly cause short stature, which is not life-threatening
and is treatable. The HGH gene was one of the first human genes isolated using
modern gene-hunting technology, and HGH was among the first recombinant
DNA therapeutics approved for use in humans. At the same time, there is con-
tinuing controversy over the use of recombinant HGH for nonclinical purposes
and to increase milk production in dairy cows. The exhibit blends art and science
and juxtaposes both micro- and macroscopic perspectives. A hand-painted
mural covering the walls and ceiling of the main gallery creates the environment
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within a single pituitary cell. The Cellarium mural is the backdrop for sculptured
molecular models, video displays, full-size human sculptures, and interactive
games.
At the microscale, visitors can follow the flow of genetic information from DNA
to RNA to protein through which HGH is manufactured within a pituitary cell. In
"The Walk of Life," visitors play the role of a cellular structure, the ribosome, with
each step along a walkway activating computer-controlled lights to illustrate the
translation of the genetic code into the HGH protein. On the macroscopic level,
visitors are asked to consider their own stature by comparing themselves to life-
size portraits of famous people, by placing themselves on a life-size growth
chart, and by visualizing themselves taller/shorter using a video morph. The
secretion of HGH by the pituitary and its stimulation of bone growth are traced by
a digital circuit of light-emitting diodes within a see-through human model. Our
long-time friends, Greg and Edna McLaughlin, of CBS News, produced an
engaging, "MTV-like" video following a day in the life of Nicole Costa, a local
elementary student being treated with HGH. A 'ring-toss" game allows visitors to
toss the HGH gene into a giant bacterium, illustrating the modern method for
making HGH.
Leaving the main gallery, and its macro/micro worlds of the present, the
visitor enters a small gallery with four scenes representing past and future issues
of HGH. "Gruesome Treatment" is a horror-story parody about extracting HGH
from cadaver brains, the medical source of HGH prior to recombinant methods.
"The Kuru Connection" shows how a deadly brain disease, first discovered
among cannibals in New Guinea, could contaminate HGH extract prepared from
human brain tissue. "Who Should Take Growth Hormone" takes place in a family
room, where a television shows news videos that explore the growing use of HGH
to increase athletic ability and counteract the aging process. "Milk and More Milk"
allows one to eavesdrop on four cows as they discuss the pros and cons of using
HGH in the dairy industry.
The development timeline for Story of a Gene was condensed to only 8
months-from storyline brainstorming in September, 1994, to opening in May,
1995. At the same time, we are very proud that essentially all exhibit elements, in-
cluding three-dimensional models, digital control circuitry, video morphs, and
casework, were developed in-house by DNALC staff and the CSHL carpentry
shop. Creative Director Sue Lauter worked tirelessly designing graphical and
computer components, developing technical specifications, interfacing with sub-
contractors, and supervising staff and art interns. Her effort is all the more ex-
traordinary in light of the fact that it occurred during her first year of motherhood.
Our team of elementary educators, Jane Conigliaro, Diane Jedlicka, and Malissa
Hewitt, carefully streamlined the narrative to improve readability for younger stu-
dents. They also developed curriculum guides, including vocabulary, ques-
tions/answers, and suggested readings, to help students get the most out of their
visit. The exhibit articulates seamlessly with our extensive program of hands-on
laboratories and computer experiences for 5th to 12th grade students. Develop-
ment of Story of a Gene was supported by major grants from the Weezie Founda-
tion and Genentech, Inc.
We Renovate the Last Available Space in Our 1925 School Building
In the fall, we completed renovation of 500 square feet of space in the east base-
ment to create a computer/design office, intern work area, and storage closets.
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The computer/design Office provides a focus for our growing effort to develop j j
-1111ft,-"10-
and distribute multimedia programming in biology. The office is occupied by two ...Alt -
senior staff members (currently Sue Lauter and Dave Micklos) and has four work-
stations for Macintosh, IBM/PC, and Unix machines. The adjacent intern area has
three additional computer workstations. In combination with the BioMedia Corn-
puter Laboratory and the Multitorium, the computer/design office gives us almost g
unmatched facilities for testing innovative, interactive methods for introducing Alv
students to modern biology. Our aim is to add additional staff in the areas of
computation and video production that will increase our capability to integrate
many types of audio and visual information into a modern learning system.
Through renovation, we also gained office and laboratory storage rooms. The
lab storage space was critical, considering that we maintain the equivalent of
four classrooms worth of laboratory equipment, as well as supplies for providing
in-school instruction for approximately 5000 elementary students. The east base-
ment renovation also provided the impetus to renovate the west office, which had
grown very cramped and had suffered water damage on several occasions. New -
carpeting and a more open plan gave an entirely new look. By reducing the num- Before and after in the new east
ber of workstations, we also gained room for an attractive library/meeting area. basement office.
Staff and Interns
The DNALC continues to operate very cost-effectively. According to survey
statistics published by the Association of Science-Technology Centers, the cur-
rent DNALC staff of 8.5 full-time equivalents (FTEs) is well below an average staff
of 12-14 FTEs for science centers with similar budgets, square-footages, and
visitation.
In July, Susan Lauter was promoted to Creative Director in recognition of her
long-term service to CSHL, her leadership in all phases of project design, and
her managerial role in the daily operation of the DNALC. While still a student at
the Cooper Union, in 1985, Sue began work at CSHL as an intern in the Develop-
ment and Public Affairs Department. She became designer at the DNALC in
1989. Over a 10-year period, Sue has proven herself a brilliant and adaptable
"generalist" capable of doing whatever is required to get the job done. Beyond
her obvious artistic talent, Sue is also a capable manager who knows virtually
every aspect of day-to-day operation of the DNALC. Sue was assisted by Denise
Sauer, an art student who graduated from SUNY Farmingdale in May with a
Bachelor of Technology degree in Visual Arts. Denise is continuing her studies at
the C.W. Post campus of Long Island University, pursuing a graduate degree in
Art History.
Chris Como, a senior at Cold Spring Harbor High School and a veteran intern
of the DNALC, continued to assist us as a computer intern. Michael Bellino, a stu-
dent at the Rhode Island School of Design, interned at the DNALC during the
summer in a computational position. Newcomers Trevor Carlson of Central Islip
High School and Michael Romanelli of Cold Spring Harbor High School joined the
DNALC staff late in 1995, filling the void left when Chris Como began his college
studies at Cornell University and Michael Bellino resumed his degree program at
the Rhode Island School of Design.
The laboratory instructional staff was ably assisted by high school interns Ken
Bassett (Massapequa), Jermel Watkins (Central Islip), Salley Ann Gibney (Cold
Spring Harbor), and Stacey Trotter (Walt Whitman). In the fall, we bid farewell to
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Ken, who began his freshman year at Drew College, while Jermel began a pre-
med course of study at the New York Institute of Technology, continuing to work
at the DNALC on a part-time basis. Newcomers SooJin Kim (Syosset), Chun-Der
Li (Half Hollow Hills), Rachael Neumann (Syosset), and Trevor Sammis (Hunting-
ton) joined the staff late in 1995. Assisting at Fun With DNA summer camps were
lab aides Aaron Bronfman (Long Island School for the Gifted), Brian Herz (Cornell
University), Todd Rebori (Walt Whitman High School), Matt Robbins (Jericho High
School), Paul Tanck (Massapequa High School), Stacey Trotter, Kristy Wagner
(Huntington High School), and Jermel Watkins.
Staff associates Twana Adams of Bronx Alternative School and Jerry Watkins
of Central Islip High School assumed lead teaching responsibilities at seven mi-
nority workshops hosted at the American Museum of Natural History in Manhat-
tan. A resident and community organizer in Harlem, Twana taught five Fun With
DNA Camps, with support from Kofi Brown of Farmingdale College, Shukrani
Tyehemba of Tuba City High School, and Sterling Brinson of Aviation High
School. In addition to instructing the workshop, Twana and her assistants han-
dled the complicated arrangements to chaperone and transport the young stu-
dents by public transport from Harlem. Jerry Watkins, father of DNALC intern
Jermel, is a graduate of our the DNA Science Workshop and the NSF Leadership
Institute. In addition to instructing two DNA Science Workshops at the Museum of
Natural History, Jerry also taught two student workshops in his home district,
where he is currently offering an elective course in molecular genetics.
Corporate Advisory Board
Although the DNALC's national curriculum efforts and programs for minority stu-
dents are funded by federal and private grants, activities for Long Island children
receive no foundation support. Tuition pays for the direct cost of lab field trips
and summer camps, but it is not enough to pay the true costs of maintaining a vi-
tal, innovative institution with an annual operating budget of approximately $1 mil-
lion. The Corporate Advisory Board was formed in 1992 to help close this funding
gap and provide a sustainable level of unrestricted annual giving. The Annual
Fund is essentially "think money," that pays for staff time needed to do the ad-
vance work on new curricula and programs. This flexibility allows us to move ag-
gressively into new areas-in advance of specific funding. Thus, we were over-
joyed to learn at year's end that the Annual Fund had met its $125,000 goal for
1995! This is incredible, considering that as few as 5 years ago we received vir-
tually no annual giving from Long Island companies.
The great cheer of meeting the 1995 goal was tempered by news that Corpo-
rate Advisory Board Chairman Rick Clark left New York at year's end to become
the chief financial officer of Insession, a computer software company based in
Boulder, Colorado. The loss was a double blow to Cold Spring Harbor
Laboratory, because we also lost the extremely capable services of Rick's wife
Jill, associate development director at the main campus. A partner at Price
Waterhouse, Rick was brought onto the Advisory Board by former Chairman
Doug Fox. As a new member to the Advisory Board in 1994, he organized the
first annual golf tournament at Piping Rock Club. This single event, which grew
dramatically in 1995, has been successful beyond our wildest expectations,
making up about half the Annual Fund. We will miss Rick and Jill tremendously.
The Corporate Advisory Board draws strength from Vice-Chairman Gary
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Frashier, President and CEO of Oncogene Science, who is our link to the growing
biotechnology industry on Long Island. Other members of the executive com-
mittee represent the gamut of Long Island businesses: Rocco Barrese, founding
partner at the patent law firm Dilworth and Barrese; Howard Blankman, founder of
the public relations firm Howard Blankman, Inc.; Tom Calabrese, managing
director at NYNEX; Bob Diller, Vice President of the scientific equipment firm
Brinkmann Instruments; Arthur Herman, chairman of A.D. Herman Construction;
Pat Peterson, President of the realty company Daniel Gale Agency; and Peter
Schiff, general partner of Northwood Ventures. A complete listing of Corporate
Advisory Board members and details on the Annual Fund are located in the
"Financial Support" Section.
Publications
Bloom, M., G. Freyer, and D. Mick los. 1995. Laboratory DNA Science: An Introduction to
Recombinant DNA Technology and Methods of Genome Analysis. Benjamin/Cum-
mings, Redwood, California.
1995 Workshops, Meetings, and Collaborations
January 10
January 13-14
January 18
January 19-20
January 20-21
January 26
January 26-28
January 28
February 2-4
February 13
February 22
March 11-12
March 17-18
March 23-25
March 25-26
March 30
April 8
April 12
April 19
April 20
April 25
April 26
April 28
May 2
May 6
May 10
May 11
May 17,19,21
Advisory Committee Meeting, National Marfan Association, Port Washington, New York
National Science Foundation Follow-up Workshop, DNA Science, University of Idaho, Moscow
Corporate Advisory Board Meeting, DNALC
Laboratories for Women in Science and Engineering Progi'am, SUNY Stony Brook, DNALC
National Science Foundation Follow-up Workshop, DNA Science, Colorado College, Colorado
Springs
Intensive Enrichment Planning Meeting, DNALC
National Science Foundation Grant Review, Washington, D.C.
Laboratory for 1 in 9 Breast Cancer Group, DNALC
National Science Foundation Grant Review, Washington, D.C.
Corporate Advisory Board Meeting, DNALC
Presentation to New Orleans Public Schools, John McDonogh High School, New Orleans,
Louisiana
National Science Foundation Follow-up Workshop, Advanced DNA Science, Trinity University, San
Antonio, Texas
National Science Foundation Grant Review, Washington D.C.
National Science Teachers Association Meeting, Philadelphia, Pennsylvania
National Science Foundation Follow-up Workshop, Advanced DNA Science, Boston University,
Massachusetts
Presentation to SEED Program, SUNY Westbury, DNALC
Laboratory for Corporate Advisory Board, DNALC
Great Moments In DNA Science Honors Student Seminar, DNALC
Corporate Advisory Board Meeting, DNALC
Introduction to Biotechnology Workshop, for Business Professionals, DNALC
Great Moments in DNA Science Honors Students Seminar, DNALC
Site visit by Captain Craig Maki, United States Air Force Academy, Colorado Springs, Colorado
Student Laboratory at A. Philip Randolph High School, Harlem, New York
Great Moments in DNA Science Honors Students Seminar, DNALC
Seminar for Harvard-Radcliffe Club, DNALC
Site visit by Claire Pillsbury and Adam Aaronsen, Tech Museum of Innovation, California
Long Island Business Association Meeting, DNALC
Story of a Gene Exhibit Openings, DNALC
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May 22 Television Program, New York State Courts in the Community, Bellport, New York
May 30 Site visit by Dr. Isadore Edelman, Columbia University, New York
May 31 Advisory Committee Meeting, American Association for the Advancement of Science,
Washington, D.C.
June 8 Seminar and Tour, Institute of Social Sciences, DNALC
June 12-16 DNA Science Workshop, Fiskbackskill and Jonkoping, Sweden
June 14 Award Presentation at BioPharm Conference, Boston, Massachusetts
June 26-30 Access Excellence Summit, San Francisco, California
DNA Science Workshop, DNALC
Computational Biology Workshop, DNALC
Howard Hughes/Barker Welfare Minority Workshop, DNA Science, American Museum of Natural
History, New York
July 3-28 National Science Foundation Leadership Institute, DNALC
July 6 Site visit by Dr. Susanna Benner, Museum of Technology and Work, Mannheim, Germany
July 10-14 Fun With DNA Workshop, Port ledge School, Locust Valley, New York
July 17-21 Fun With DNA Workshop, Port ledge School, Locust Valley, New York
Howard Hughes/Barker Welfare Minority Workshop, Fun With DNA, American Museum of Natural
History, New York
July 24-28 Fun With DNA Workshop, Port ledge School, Locust Valley, New York
Howard Hughes/Barker Welfare Minority Workshop, Fun With DNA, American Museum of Natural
History, New York
DNA Science Minority Workshop, Central Islip, New York
July 31-Aug 4 National Science Foundation Workshop, DNA Science, University of Kansas, Lawrence
World of Enzymes Workshop, DNALC
Howard Hughes/Barker Welfare Minority Workshop, Fun With DNA, American Museum of Natural
History, New York
August 7-11 National Science Foundation Workshop, DNA Science, Bates College, Lewiston, Maine
Fun With DNA Workshop, DNALC
Fun With DNA Minority Workshop, Central Islip, New York
Howard Hughes/Barker Welfare Minority Workshop, Fun With DNA, American Museum of Natural
History, New York
August 14-18 DNA Science Workshop, Frederick Cancer Research and Development Center, Maryland
Fun With DNA Minority Workshop, Central Islip, New York
Howard Hughes/Barker Welfare Minority Workshop, Fun With DNA, American Museum of Natural
History, New York
Computational Biology Workshop, DNALC
August 17-25 Advanced DNA Science Workshop, Beckman Neuroscience Center, CSHL
August 21-25 World of Enzymes Workshop, DNALC
Howard Hughes/Barker Welfare Minority Workshop, DNA Science, American Museum of Natural
History
August 28-Sept 1 DNA Science Workshop, DNALC
Fun With DNA Workshop, DNALC
September 6 Corporate Advisory Board Meeting, DNALC
September 11-13 Howard Hughes Precollege Director's Meeting, Chevy Chase, Maryland
September 26 Site visit by Bonnie Kaiser, Rockefeller University, New York, New York
September 27-29 Brinkmann Business Meeting, Denver Colorado
October 6 Filming at DNALC by Alligator Films, Bergen, Norway
October 10 Seminar for Kiwanis Club, Huntington
October 20 Queens Gateway Project Meeting, DNALC
October 25-28 National Association of Biology Teachers Convention, Phoenix, Arizona
October 28 Infectious Diseases: Ancient Plagues, New Epidemics Laboratory for Business Executives, DNALC
November 4 Benjamin/Cummings Strategies Workshop, Sacramento, California
November 7 Queens Gateway Project Meeting, DNALC
November 11 Benjamin/Cummings Strategies Workshop, DNALC
November 16-18 Department of Energy Human Genetics and Genome Analysis Workshop, DNALC and Banbury
Center
November 30 Cold Spring Harbor Laboratory Lecture, CSHL
December 2 Benjamin/Cummings Strategies Workshop, University of Cincinnati, Ohio
December 2-4 National Science Foundation Workshop Human Genome Diversity-Student Allele Database, United
States Air Force Academy, Colorado Springs, Colorado
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Sites of Major 3-10 Day Faculty Workshops 1985-1995
Key: High School
College
Middle School
ALABAMA University of Alabama, Tuscaloosa 1987, 1988,
1989, 1990
ARIZONA Tuba City High School 1988
ARKANSAS Henderson State University, Arkadelphia 1992
CALIFORNIA University of California, Davis 1986
San Francisco State University 1991
University of California, Northridge 1993
COLORADO Colorado College, Colorado Springs 1994
United States Air Force Academy, Colorado Springs 1995
CONNECTICUT Choate Rosemary Hall, Wallingford 1987
FLORIDA North Miami Beach Senior High School 1991
University of Western Florida, Pensacola 1991
Armwood Senior High School, Tampa 1991
GEORGIA Fernbank, Inc., Atlanta 1989
Morehouse College, Atlanta 1991
HAWAII Kamehameha Secondary School, Honolulu 1990
ILLINOIS Argonne National Laboratory 1986, 1987
University of Chicago 1992
INDIANA Butler University, Indianapolis 1987
IDAHO University of Idaho, Moscow 1994
IOWA Drake University, Des Moines 1987
KANSAS University of Kansas, Lawrence 1995
KENTUCKY Murray State University 1988
University of Kentucky, Lexington 1992
Western Kentucky University 1992
LOUISIANA Jefferson Parish Public Schools, Harvey 1990
John McDonogh High School, New Orleans 1993
MAINE Bates College, Lewiston 1995
MANITOBA Red River Community College, Winnipeg 1989
MARYLAND Annapolis Senior High School 1989
Frederick Cancer Research Center, Frederick 1995
McDonogh School, Baltimore 1988
Montgomery County Public Schools 1990-1992
St. John's College, Annapolis 1991
MASSACHUSETTS Beverly High School 1986
Dover-Sherborn High School, Dover 1989
Randolph High School 1988
Winsor School, Boston 1987
Boston University 1994
MICHIGAN Athens High School, Troy 1989
MISSISSIPPI Mississippi School for Math and Science, Columbus 1990-1991
MISSOURI Washington University, St. Louis 1989
NEW HAMPSHIRE St. Paul's School, Concord 1986, 1987
NEVADA University of Nevada, Reno 1992
NEW YORK Albany High School 1987
Bronx High School of Science 1987
Columbia University, New York 1993
Cold Spring Harbor High School 1985, 1987
DeWitt Middle School, Ithaca 1991, 1993
DNA Learning Center 1988-1995
DNA Learning Center 1990, 1992,
1995
DNA Learning Center 1990-1992
Fostertown School, Newburgh 1991
Huntington High School 1986
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Irvington High School 1986
Junior High School 263, Brooklyn 1991
Lindenhurst Junior High School 1991
Orchard Park Junior High School 1991
Plainview -Old Bethpage Middle School 1991
State University of New York, Purchase 1989
State University of New York, Stony Brook 1987, 1988,
1989, 1990
Titusville Middle School, Poughkeepsie 1991, 1993
Wheatley School, Old Westbury 1985
NORTH CAROLINA North Carolina School of Science, Durham 1987
OHIO Case Western Reserve University, Cleveland 1990
Cleveland Clinic 1987
North Westerville High School 1990
OKLAHOMA School of Science and Mathematics, Oklahoma City 1994
PANAMA University of Panama, Panama City 1994
PENNSYLVANIA Duquesne University, Pittsburgh-Germantown Academy 1988
PUERTO RICO University of Puerto Rico, Mayaguez 1992
University of Puerto Rico, Mayaguez 1992
University of Puerto Rico, Rio Piedras 1993
University of Puerto Rico, Rio Piedras 1994
SOUTH CAROLINA Medical University of South Carolina, Charleston 1988
University of South Carolina, Columbia 1988
TEXAS J.J. Pearce High School, Richardson 1990
Langham Creek High School, Houston 1991
Taft High School, San Antonio 1991
Trinity University, San Antonio 1994
UTAH University of Utah, Salt Lake City 1993
VERMONT University of Vermont, Burlington 1989
VIRGINIA Jefferson School of Science, Alexandria 1987
Mathematics and Science Center, Richmond 1990
WASHINGTON University of Washington, Seattle 1993
WASHINGTON, DC Howard University 1992
WEST VIRGINIA Bethany College 1989
WISCONSIN Marquette University, Milwaukee 1986, 1987
University of Wisconsin, Madison 1988, 1989
WYOMING University of Wyoming, Laramie 1991
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COLD SPRING HARBOR
LABORATORY PRESS
1995 PUBLICATIONS
General Books
Molecular Genetics of Cancer
Symposia on Quantitative Biology 59
Vaccines 95: Molecular Approaches to the Control
of Infectious Diseases
R.M. Chanock, F. Brown, H.S. Ginsberg, and E. Norrby
(eds.)
Archaea: A Laboratory Manual
F.T. Robb, A.R. Place, K.R. Sowers, H.J. Schreier,
S. DasSarma, and E.M. Fleischmann (eds.)
Archaea: Halophiles
S. DasSarma and E.M. Fleischmann (eds.)
Archaea: Methanogens
K.R. Sowers and H.J. Schreier (eds.)
Archaea: Thermophiles
F.T. Robb and A.R. Place (eds.)
Genetic Analysis of Pathogenic Bacteria: A Laboratory
Manual
S.R. Maloy, V.J. Stewart, and R.K. Taylor
Methods in Plant Molecular Biology A Laboratory
Course Manual
P. Maliga, D. Klessig, A. Cashmore, W. Gruissem, and
J. Varner
Methods in Yeast Genetics: A Laboratory Course
Manual, 1994 Edition
C. Kaiser, S. Michaelis, and A. Mitchell
PCR Primer: A Laboratory Manual
C.W. Dieffenbach and G.S. Dveksler (eds.)
Strategies for Protein Purification and Characterization:
A Laboratory Course Manual
D.R. Marshak, J.T. Kadonaga, R.R. Burgess, M.W. Knuth,
W.A. Brennan, Jr., and S.-H. Lin
The Cells of the Body: A History of Somatic Cell Genetics
H. Harris
The Statue Within
F. Jacob
Discovering Molecular Genetics: A Case Study Course with
Problems & Scenarios
J.H. Miller
CSHL Monograph Series
Translational Control
J.W.B. Hershey, M.B. Mathews, and N. Sonenberg (eds.)
Telomeres
E.H. Blackburn and C.W. Greider (eds.)
Cancer Surveys Series
Vol. 22: Molecular Mechanisms of the Immune Response
W.F. Bodmer and M.J. Owen (eds.)
Vol. 23: Preventing Prostate Cancer: Screening
versus Chemoprevention
R.T.D. Oliver, A. Belldegrun, and P.F.M. Wrigley (eds.)
Vol. 24: Cell Adhesion and Cancer
N. Hart and I. Hogg (eds.)
Vol. 25: Genetics and Cancer: A Second Look
B.A.J. Ponder, W.K. Cavenee, and E. Solomon (eds.)
Journals
Genes & Development (Volume 9, 24 issues)
T. Grodzicker and N. Hastie (eds.)
PCR Methods and Applications (Volume 4, 3 issues)
D. Bentley, E. Green, R. Gibbs, and R. Myers (eds.)
Genome Research (Volume 5, 5 issues)
A. Chakravarti, R. Gibbs, E. Green, R. Myers, and
M. Boguski (eds.)
Learning & Memory (Volume 2, 5 issues)
R. Davis, E. Kandel, R. Morris, C. Shatz, L. Squire, and
C. Stevens (eds.)
Videotapes
A Decade of PCR
Audiotape/CD
More Songs for a Cynical Scientist
R. Laskey
Other
The Lab Manual Source Book
A Crack in the Shield: Our Unvaccinated Children
Report prepared for the Sabin Foundation
CSHL Annual Report 1994
Banbury Center Annual Report 1994
Administration and Financial Annual Report 1994
Abstract/program books for 14 CSHL meetings
COLD SPRING HARBOR LABORATORY PRESS
The growth and expansion of our publishing program continued in 1995. Twenty books were pub-
lished, bringing the total in print to over 220. A new videotape series and a new audiotape/CD were
produced. The journals continued to expand in scope and frequency, as the PCR Methods and Ap-
plications journal was relaunched as a monthly research journal in genome science. The first issue
of an annual directory of laboratory products and their sources of supply was published, and a start
was made on the development of a searchable database of products and suppliers that could be
accessed via the World Wide Web. Program income rose by 14% to $5.12 million.
Book Publishing
For the past several years, the commissioning of new titles has focused primarily on laboratory
manuals, scholarly monographs, and books appropriate for graduate student teaching. Among the
1995 titles were eight manuals, two monographs, and an advanced textbook on molecular
genetics. The manuals on bacterial genetics, plant molecular biology, yeast genetics, and protein
purification each had roots in practical courses taught recently at the Laboratory, but there the
resemblance ended. Each book was individually crafted by its authors to reflect the needs of its
particular audience and required correspondingly painstaking in-house development. The most im-
mediately successful of the new crop of manuals was PCR Primer, edited by Carl Dieffenbach and
Gabriella Dveksler. This volume originated in a series of articles commissioned for our journal PCR
Methods and Applications, reviewing the use of the polymerase chain reaction from basics to ad-
vanced applications. The eventual reworking of this material into step-by-step protocols was ex-
plicit in the way the series was created. The result is an extremely useful book with a long life in
subsequent editions as variants on amplification technology continue to appear.
The book's appearance coincided with the tenth anniversary of the invention of PCR by Kary
Mullis, an event marked by a two-day meeting in September that was captured on videotape and
subsequently published. Mullis first described his discovery at the Laboratory's annual Symposium
in 1985. The extraordinary importance of PCR as a genetic technique is indicated by the fact that in
this institution alone, two books, two meetings, a journal, and a videotape series have been solely
devoted to it.
Two titles were added to the distinguished list in the CSHL Monograph series, thanks in large
measure to the dedication of senior Laboratory scientists. Michael Mathews and colleagues John
Hershey and Nahum Sonenberg edited a volume on the translation of RNA into protein that will
stand as this mature field's central reference for some years. The study of telomeres, on the other
hand, has recently entered a new and rapidly changing phase, and the decision to create a book
on the topic came from the recognition that the older information in the field was fragmented and
unfocused. Carol Greider and her mentor Elizabeth Blackburn assembled a volume that concisely
summarized what is known about these interesting chromosomal structures and the important fu-
ture directions that beckon from the fields of cancer biology and aging research.
Not every new title can be described in detail here (see opposite for a complete list), but three
deserve particular mention because of the very personal nature of their creation. Jeffrey Miller's
Discovering Molecular Genetics is an innovative textbook based on his much-praised graduate
course at the University of California, Los Angeles. The course is centered on Miller's unique selec-
tion and analysis of historically important papers. The book reprints the papers and captures the
imaginative exercises in thinking that Miller uses to illuminate the lessons they convey.
The author's personality also emerges strongly from The Cells of the Body, a history of somatic
cell genetics by one of its most distinguished scholars, Sir Henry Harris. Written for a broad sci-
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entific audience, the book begins with the discovery of cells and their origins and guides the reader
elegantly through the development of the concepts and techniques which made possible the pres-
ent era of molecular analysis.
One of the founding visionaries of that era, Francois Jacob, graciously agreed to the publication
of a special Cold Spring Harbor edition of his out-of-print autobiography The Statue Within. This
was accomplished in time for the meeting celebrating the fiftieth anniversary of the phage course in
August, and many of the participants were thrilled to be able to take home a copy of this unusually
personal and moving memoir signed by its legendary author.
Journal Publishing
As in each of the previous seven years, we entered 1995 bracing for further significant changes in
the journal program. The countdown began in June with the transformation of the successful, es-
tablished journal PCR Methods and Applications into the novel Genome Research. Planning for this
event had begun in mid 1994 with the conviction that basic PCR technology was becoming a
laboratory mainstay, no longer the engine of the many innovative variations and applications seen
four years earlier when the journal began. Our response was to reposition the journal as a place for
new and exciting original research in genome studies. Genome Research appeared first in August,
guided by an enthusiastic and influential editorial board led by the editors Aravinda Chakravarti,
Richard Gibbs, Eric Green, and Richard Myers (joined by Mark Boguski in December) and reviews
editor, Alison Stewart. After some anxieties concerning the printer's ability to maintain the new
monthly production schedule and an initially sluggish paper flow, the year finished strongly with is-
sues of high quality, fair size, and wide scope. Moreover, the journal's financial objectives were
met. This was no small achievement given the scale of the transformation undertaken-a simulta-
neous change of title, scope, audience, and renewal cycle. A further source of quiet satisfaction
was the use made of electronic to the print Each issue an article for
which additional information-video clips, large data sets, or software programs-were made avail-
able through the CSHL World Wide Web site. The article itself was available online, enhanced by
the provision of references hyperlinked to the corresponding abstracts in Med line. Genome Re-
search was the first major science journal to employ web technology in this way and its use taught
us much that was helpful.
A good deal of concern was also directed toward the development of our other fledgling journal
Learning & Memory. Launched in mid 1994, this journal serves a scientific community that is
producing some of the most fascinating results in current neuroscience, so competition from estab-
lished journals for good papers is fierce. Our journal is so far still a newcomer with promise, but
progress was made on the foundation created in 1994, and the journal's editors, Ron Davis, Eric
Kandel, Richard Morris, Larry Squire, Carla Schatz, and Chuck Stevens, resolutely maintained a
high standard of published papers. All concerned realized that starting this journal while the
molecular analysis of learning and memory is still in its infancy was a major challenge. Neverthe-
less, our commitment to success was renewed in 1995, and we were delighted when Jack Byrne
accepted the role of Editor from 1996 onward, building on the achievement of the founding editors.
The administrative and financial challenges presented by changes such as these can be taken
on only by a healthy journal publishing program. The essential foundation for that program is our
flagship journal Genes & Development, which had another year of widening scope, increased cir-
culation, and strong financial results. The editors Terri Grodzicker and Nick Hastie, leading a dis-
tinguished editorial board, continued to provide readers with papers describing first-class, reliable
science in some of the most innovative areas of molecular biology. More review articles were pub-
lished than ever before. The annual citation analysis conducted by the Institute for Scientific In-
formation on papers published in 1994 once again placed Genes & Development in the topmost
tier of biology journals.
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The Lab Manual Source Book
Our strong position in the publishing of laboratory manuals prompted us to embark in 1994 on a
new project, the creation of a comprehensive "Yellow Pages" of the products and services needed
by the users of laboratory manuals. Beginning early in 1995, more than 30,000 copies of The Lab
Manual Source Book were distributed free of charge to scientists worldwide. The goal was to
create a publication that would command the attention of both scientists and the companies that
supply them with products. The enthusiastic response from both camps indicated that a good start
had been made. Work began immediately on the preparation of the second annual edition, for pub-
lication in February 1996. Improvements were made in the product classification scheme, new
product categories were added, and the supplier list was expanded. Advertising sales efforts were
redoubled in order to fund greater circulation of the 1996 issue.
Alongside these activities, we initiated the creation of a dedicated World Wide Web site that
contained searchable versions of the product and supplier databases. Its title, BioSupplyNet, was
chosen to convey the concept of an extended network of information about laboratory materials
and their sources of supply that extended far beyond the information published in the Source Book.
Vendors were encouraged to make available through BioSupplyNet technical specifications, per-
formance data, and special pricing information-any kind of information valuable to end users that
would otherwise have to be conveyed statically and expensively in print. BioSupplyNet opened for
access in August and considerable efforts were made to promote awareness and use of it. It was
quickly recognized as the most advanced of several competing efforts to create a focus of product
information on the Web, and traffic to the site was heavy. We also became aware that the mainten-
ance of the online database, the enhancement of the site as Web technology evolved, and the full
exploitation of the site's capabilities for advanced marketing and online purchasing would require
investment on a larger scale than the Press could undertake unaided. As the year ended, discus-
sions were advancing with potential partners about the many exciting ways in which BioSupplyNet
could be developed to best advantage.
Marketing and Distribution
The year's direct mail marketing program centered on a widely dispatched Genetics and Cell Biol-
ogy catalog, a Plant Biology catalog, two issues of the Press newsletter announcing new titles, and
a variety of smaller brochures and flyers advertising specific titles.
The Press World Wide Web server also took its place as a valuable marketing tool this year, of-
fering a complete online catalog, announcements of new books on publication, and the opportunity
to place orders electronically. This initiative was extremely valuable not just for the income genera-
ted, which was surprisingly high, but because it offered the opportunity for direct interaction with
users of our publications, particularly overseas. Many valuable lessons were learned.
Another important marketing channel is the series of major scientific meetings attended each
year. Our exhibit stand is modestly sized, but still miraculously effective in displaying the ever-
increasing number and diversity of our publications. The conference landscape is changing as the
fortunes of the large scientific societies wax and wane. Two previously valuable meetings were dis-
appointing this year and will not be revisited, but new candidates were sampled and at least one
was found to fill the gap. However mixed the huge society meetings may be scientifically (and
several this year were excellent), the face-to-face encounter with tens of thousands of our
customers presents many valuable opportunities, not all quantifiable in dollars, and must not be
missed.
A smaller-scale but equally valuable interaction takes place each year with the 5000 attendees
at Laboratory meetings and courses, via the campus bookstore. A remarkable degree of com-
merce occurs in this small space, involving our publications, general science books, and items
visitors find useful. The bookstore had a successful year financially and after lobbying for relocation
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for some years, we were delighted with the November decision to move the bookstore into a three-
times larger space in the basement of Grace Auditorium. At the turn of the year, several options
were being considered on the best way to manage the much larger operation this new venue
would accommodate.
The compilation and analysis of sales data from the various marketing channels take place in
the computer system at our Plainview facility. First occupied by us five years ago, this building has
proved adaptable and adequate for our present and short-term future needs. A new lease was ne-
gotiated in February. Regrettably, the computer system itself has aged less well. Left behind by
seismic changes in computing environments, the system is based on software that runs only on
outmoded components for which maintenance contracts may soon be impossible. The search for
an alternative began early in 1995. Our objective is to find a cost-effective, flexible, low-mainten-
ance, publishing-specific system as compatible as possible with other databases operated in the
Laboratory that will allow effective management of records from over 50,000 accounts worldwide
and the simultaneous administration of both book purchases and journal subscriptions.
Despite its limitations, the computer system provided data for an increasing array of sales
reports and analyses necessary for informed decision making. This facility was particularly helpful
in a series of extended conversations in mid year on the nature and direction of our international
marketing program. Thirty percent of book sales already go overseas, but led by a consultant, we
assessed the extent of sales in each foreign country and targeted six in which special attention was
likely to increase sales cost-effectively. Contact with potential distributors in those countries was
made at the Frankfurt Book Fair and negotiations have ensued. We plan to develop significant busi-
ness for the first time in certain Pacific Rim and South American countries and increase our market
penetration in Europe.
In the meantime, we continued to supply books and journals direct to overseas customers. The
costs of international dispatch were continually reviewed, and in this ever-changing marketplace,
carriers were switched as necessary to ensure that the service provided to purchasers was both
economical and efficient.
Publishing is a team activity: Neither the most able author nor the most remarkable publication
can succeed without the ministrations of editors and typesetters, proofreaders and production staff,
marketers and order processors, and people who pick, pack, and post in the warehouse. The
Press is fortunate to have capable staff throughout the house who bring intelligence and care to
what they do. Their names are listed at the back of this volume: Here there is room only to acknowl-
edge their vital contribution to the program and to thank them for it. However, special mention must
go to Nancy Ford and Judy Cuddihy, Ingrid Benirschke, Nancy Hodson, Guy Keyes, and Joan
Boyce. These department heads provided the management skills and direction that got things
done and ensured the program's high quality of output and service.
New Products
During the year, agreements were reached with authors and editors of more than 20 new books. At
the same time, many other conversations were initiated about possible new publishing projects in a
variety of media, both print and electronic, in stand-alone and subscription formats. Such con-
versations, particularly with younger scientists, fuel the new publications necessary to sustain our
growth in the immediate future. We are also looking to the back list of distinguished books upon
which the current program is based, creating new editions as appropriate and employing new pub-
lishing technologies to adapt and reuse classic material from the past. Both the book and the jour-
nal programs are rising to more complex editorial and production challenges, and investment in
new, skilled staff is required. The book program, for example, urgently needs another developmen-
tal editor capable of managing a project all the way from conceptual discussions with potential au-
thors to the delivery of a bound book from the printer.
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Meanwhile, the wired world beckons insistently, promising radically to transform the means of
communication in science. Electronic mail is now ubiquitous, substituting for letters, faxes, and
phone calls. The communication of important science remains print-based . . . for now. We will con-
tinue to experiment with additional and alternative media, examining the potential of the latest tech-
nologies but conscious of the uncertainties that underlie the current business models for their ap-
plication. The promised transformation may be neither swift nor sudden, but we will be prepared.
John R. Inglis
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FINANCIAL STATEMENTS
STATEMENT OF FINANCIAL POSITION
December 31, 1995
Assets:
Cash and cash equivalents $ 13,459,548
Marketable securities 94,979,330
Accounts receivable 959,727
Grants receivable 3,028,747
Contributions receivable 500,000
Publications inventory 1,394,720
Prepaid expenses and other assets 2,078,234
Investment in employee residences 1,825,641
Land, buildings, and equipment:
Land and improvements 7,588,532
Buildings 59,706,386
Furniture, fixtures, and equipment 4,239,740
Laboratory equipment 10,554,994
Library books and periodicals 365,630
82,455,282
Less accumulated depreciation and amortization 24,634,265
Land, buildings, and equipment, net 57,821,017
Construction in progress 190,382
Total assets $ 176,237,346
Liabilities and Net Assets:
Accounts payable and accrued expenses $ 949,079
Notes payable 667,520
Bonds payable 30,000,000
Deferred revenue 5,351,669
Total liabilitieS 36,968,268
Net Assets:
Unrestricted
General operating 5,693,880
Designated:
For research program 1,150,000
Capital expenditures 34,010,961
Board designated endowment 49,544,118
Total unrestricted 90,398,959
Temporarily restricted 470,000
Permanently restricted 48,400,119
Total net assets 139,269,078
Total liabilities and net assets $ 176,237,346
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STATEMENT OF ACTIVITIES
Year Ended December 31, 1995
Unrestricted
Temporarily
Restricted
Permanently
Restricted Total
Support and revenue:
Public support $ 10,436,932 754,427 11,191,359
Government grant awards 12,105,851 12,105,851
Indirect cost allowances 9,007,870 - 9,007,870
Other revenue:
Program fees 1,773,800 - 1,773,800
Rental income 435,555 - - 435,555
Publications 5,119,484 - 5,119,484
Dining services 1,983,219 - 1,983,219
Rooms and apartments 1,664,609 - 1,664,609
Gain on sale of marketable securities 1,179,323 3,231,282 4,410,605
Investment income 6,903,504 6,903,504
Royalty & licensing fees 1,222,390 1,222,390
Recovery of valuation allowance 522,774 - 522,774
Miscellaneous 134,334 - 134,334
Total other revenue 20,938,992 3,231,282 24,170,274
Net assets released from restrictions:
Expiration of time restrictions 1,090,000 (1,090,000)
Total support and revenue 53,579,645 (1,090,000) 3,985,709 56,475,354
Expenses:
Program services:
Research 15,837,311 15,837,311
Summer programs 5,201,484 - 5,201,484
Publications 5,078,559 - 5,078,559
Banbury Center conferences 920,781 - 920,781
DNA Education Center programs 486,367 - 486,367
Total program services 27,524,502 - 27,524,502
Supporting services:
Direct research support 1,243,713 - 1,243,713
Library 591,520 591,520
Operation and maintenance of plant 5,514,513 5,514,513
General and administrative 4,655,785 - 4,655,785
Dining services 1,814,174 - 1,814,174
Interest 1,526,387 - - 1,526,387
Depreciation and amortization 2,820,555 - 2,820,555
Total supporting services 18,166,647 - - 18,166,647
Total expenses $ 45,691,149 45,691,149
Change in net assets before
cumulative effect of a change
in accounting principle $ 7,888,496 (1,090,000) 3,985,709 10,784,205
Cumulative effect in method of accounting
for contributions 1,560,000 1,560,000
Net assets at beginning of year 82,510,463 44,414,410 126,924,873
Net assets at end of year $ 90,398,959 470,000 48,400,119 139,269,078
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COMPARATIVE OPERATING HISTORY 1991-1995
(Dollars in Thousands)
1991 1992 1993 1994 1995
Income:
Main Lab:
Grants & contracts $ 15,172 16,800 18,136 19,293 19,653
Indirect cost reimbursement 7,170 8,388 8,383 8,460 8,881
Other 5,056 5,520 6,049 6,808 7,461
CSH Press 3,079 3,709 4,319 4,390 5,119
Banbury Center 1,090 1,104 1,281 1,569 1,732
DNA Learning Center 744 822 796 824 954
Total income 32,311 36,343 38,964 41,344 43,800
Expenses:
Main Lab:
Grants & contracts 15,172 16,800 18,136 19,293 19,653
Operation & maintenance of plant 3,904 4,241 4,777 5,141 5,266
General & administrative 2,468 2,634 2,785 2,909 3,329
Other 3,375 4,141 4,385 4,847 4,959
CSH Press 3,488 3,548 4,134 4,309 5,079
Banbury Center 1,063 1,070 1,226 1,498 1,643
DNA Learning Center 752 843 768 798 958
Total expenses 30,222 33,277 36,211 38,795 40,887
Excess before depreciation and
(designation) release of funds 2,089 3,066 2,753 2,549 2,913
Depreciation (1,898) (2,358) (2,522) (2,668) (2,821)
(Designation) release of funds (1) (100) (600) 0 200 0
Net operating excess $ 91 108 231 81 92
The above amounts are presented on a combined basis for all funds for which Cold Spring Harbor Laboratory prepares operating budgets.
(1) Funds designated to underwrite future direct and indirect expenses of the neuroscience and other research programs.
COLD SPRING HARBOR LABORATORY
SOURCES OF REVENUE
YEAR ENDED DECEMBER 31, 1995
Endowments and Board Designated Funds 11.3 %
Federal Grants 40.5 %
330
Foundation and Private
Contributions and Grants 13.8 %
Royalty and Licensing Fees 6.7 %
Interest and Miscellaneous 1.6 %
Corporate Contributions and Grants 5.3 °A
Auxiliary Activities 20.8 %
FINANCIAL SUPPORT OF THE LABORATORY
Cold Spring Harbor Laboratory, Banbury Center, and the DNA Learning Center receive a substan-
tial portion of their funding through grants from the Federal Government and through grants, capital
gifts, and annual contributions from private foundations, corporations, and individuals. The follow-
ing section summarizes funding that occurred during 1995.
GRANTS January 1, 1995-December 31, 1995
COLD SPRING HARBOR LABORATORY
Grantor Program/Principal Investigator Duration of Grant 1995 Funding'
FEDERAL GRANTS
NATIONAL INSTITUTES OF HEALTH
Program Projects Cancer Research Center, Dr. Herr
Cancer Center Support, Dr. Stillman
Research Support Dr. Arndt
Dr. Beach
Dr. Beach
Dr. Beach
Dr. Cheng
Dr. Cheng
1/92 -12/96
8/95 -7/00
1/95 -12/98
5/94 -4/96
4/93 -3/97
8/95 -5/00
4/93 -3/97
9/95 -8/97
$3,496,771
2,669,134 *
278,871 *
292,366
189,211
250,005 *
199,974
50,000 *
Dr. Cline 12/95 -11/98 265,296*
Dr. Enikolopov 9/94 -8/98 204,056
Dr. Futcher 4/93 -3/97 261,180
Dr. Futcher 1/91 -12/99 190,088
Dr. Greider 12/94 -11/98 271,168
Dr. Greider 8/91 -7/96 269,308
Dr. Helfman 4/94 -3/98 286,913
Dr. Helfman 8/93 -5/98 228,960
Dr. Hengartner 5/95 -4/00 213,983 *
Dr. Hernandez 7/92 -6/96 238,834
Dr. Hernandez 9/91 -8/96 239,433
Dr. Herr 3/92 -2/96 219,732
Dr. Krainer 7/94 -6/98 323,426
Dr. Lisitsyn 7/94 -6/99 203,495
Dr. Malinow 5/94 -4/97 118,534
Dr. Malinow 4/95 -2/98 247,205 *
Dr. Marr 6/95 -5/98 797,610*
Dr. Mathews 2/92 -1/97 291,477
Dr. Mathews 9/93 -8/98 317,582
Dr. Mathews 9/94 -9/97 33,845
Dr. McCombie 4/94 -3/97 432,959
Dr. Skowronski 12/93 -11/97 308,538
Dr. Spector 4/95 -3/99 338,536 *
Dr. Silva 7/95 -6/00 241,373 *
Dr. Stillman 7/91 -6/95 197,428
Dr. Tonks 8/91 -5/96 345,659
Dr. Tully 4/94 -3/97 327,494
Dr. Wig ler 7/95 -4/99 1,809,369
Fellowships Dr. Dai 8/94 -10/97 29,900
Dr. DeZazzo 1/95 -12/95 31,200 *
Dr. Edwards 9/95 -8/98 22,608 *
Dr. Mainen 10/95 -9/97 22,608 *
Dr. O'Gara 12/95 -12/96 23,700*
Dr. Zhang 9/92 -8/97 102,12
Training Support Training in Cancer Cell Biology
and Tumor Virology
7/94 -2/99 179,001
* New Grants Awarded in 1995
+ Includes direct and indirect cost
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Grantor Program/Principal Investigator Duration of Grant 1995 Funding+
Course Support Advanced Bacterial Genetics 5/93 -4/98 56,260
Cancer Research Center Workshops 4/92 -3/97 243,444
Neurobiology Short-term Training 5/82 -4/96 141,885
CSHL Analysis Large DNA Molecules 1991-1996 104,625
Essential Computational Genomics for 1991-1996 27,337
Molecular Biologists
Advanced In Situ Hybridization
and Immunocytochemistry
1992 -1997 50,759
Molecular Biology and Development
of Xenopus Laevis
4/93 -3/96 12,154
Automated Genome Sequencing 4/95 -3/98 71,250*
Meeting Support Genome Mapping and Sequencing 4/91 -3/96 32,394
Mechanisms of Eukaryotic 7/95 -6/96 3,000 *
Transcription
Programmed Cell Death 7/95 -6/96 8,000 *
Molecular Genetics and Phage 8/95 -7/96 2,000 *
Eukaryotic DNA Replication 9/95 -8/96 6,000 *
Neurobiology of Drosophila 9/95 -9/96 12,000 *
Tyrosine Phosphorylation and Cell 4/95 -3/96 7,000*
Signaling
Cell and Molecular Biology of Aplysia 4/95 -3/96 15,000 *
NATIONAL SCIENCE FOUNDATION
Research Support Dr. Cline 9/94 -8/96 79,373
Dr. Grotewold 11/94 -10/98 115,556
Dr. Ma 5/94 -4/97 134,500
Dr. Ma 8/94 -7/98 110,000
Dr. Martienssen 8/94 -7/98 150,000
Dr. Peunova 9/95 -8/98 90,000*
Fellowship Support Dr. Springer 12/93 -11/96 32,400
Training Support Undergraduate Research 6/91 -5/97 50,000
Program
Course Support Arabidopsis Molecular Genetics 6/95 -5/96 60,000 *
Molecular Biology and Development
of Xenopus laevis
4/93 -3/96 7,550
Macromolecular Crystallography 8/94 -7/97 15,000
Meeting Support Programmed Cell Death 8/95 -7/96 3,000 *
Tyrosine Phosphorylation and Cell 4/95 -3/96 6,000*
Signaling
Eukaryotic DNA Replication 6/95 -5/96 15,000 *
Signaling in Plant Development 7/95 -6/96 4,000*
Molecular Genetics of Phage 8/95 -7/96 5,000 *
Neurobiology of Drosophila 9/95 -8/96 10,000 *
Cell and Molecular Biology of Aplysia 4/95 -3/96 2,500 *
The Cytoskeleton and Cell Function 4/95 -3/96 4,000 *
DEPARTMENT OF ENERGY
Research Support Dr. Marr 7/94 -2/97 450,000
Meeting Support CSHL 60th Symposium: Protein Kinesis 1995 10,000 *
Molecular Genetics of Bacteria
and Phage
1995 11,800 *
Programmed Cell Death 1995 7,500 *
Signaling in Plant Development 1995 3,500 *
* New Grants Awarded in 1995
+ Includes direct and indirect cost
332
Grantor Program/Principal Investigator Duration of Grant 1995 Funding+
UNITED STATES DEPARTMENT OF AGRICULTURE
Research Support Dr. Ma 9/94 -9/96 69,322
Dr. Ma 9/95 -9/97 50,000 *
Dr. Martienssen 9/95 -9/97 63,444 *
Dr. Martienssen 3/95 -2/98 92,000 *
Dr. Sundaresan 8/94 -9/97 70,000
Dr. Sundaresan 9/94 -9/97 74,000
Meeting Support Signaling in Plant Development 8/95 -7/96 6,000 *
Molecular Markers for Plant Breeding
and Plant Genetics 11/95 -1/96 10,000*
UNITED STATES DEPARTMENT OF ARMY
Research Support Dr. Futcher/Dr. Marshak 6/94 -6/99 203,926
Dr. Wig ler/Dr. Lisitsyn 7/94 -8/98 200,000
UNITED STATES DEPARTMENT OF NAVY
Meeting Support The Cytoskeleton and Cell Function 4/95 -3/96 5,000 *
NONFEDERAL GRANTS
Research Support
American Cancer Society Dr. Enikolopov 7/95 -6/96 100,000 *
Dr. Ma 7/94 -6/97 28,500
Dr. Ma 1/95 -12/96 90,000 *
Dr. Marshak 7/93 -6/95 103,000
Dr. Wig ler, Professorship 1986 -2012 50,000
Dr. Wig ler, Supply Allowance 1995 10,000
American Heart Association Dr. Helfman 7/91 -6/96 35,000
Amp licon Corporation Dr. Wig ler 6/94 -5/97 596,000
Arnold & Mabel Beckman Dr. Silva 7/94 -6/96 100,000
Foundation
Sara Chait Foundation Dr. Marshak 12/91 -11/96 25,000
Council for Tobacco Research Dr. Arndt 8/95 -7/98 75,000 *
Dr. Helfman 7/91 -6/96 80,000
Dr. Tonks 1/95 -12/97 85,000 *
Geron Corporation Dr. Greider 2/94 -1/97 217,175
Irving Hansen Memorial Fund Dr. Tonks 8/95 -7/97 10,000 *
Johns Hopkins University/NIH Dr. Wig ler 7/95 -9/95 40,000 *
Esther A. & Joseph Klingenstein Dr. Cline 7/94 -6/96 33,333
Fund, Inc. Dr. Enkolopov 7/95 -6/98 40,000 *
Dr. Silva 7/93 -6/96 33,333
Long Island Breast Coalition Dr. Wig ler 11/94 -1/95 20,000
Robert Leet & Clara Guthrie Dr. Cline 7/94 -6/96 50,000 *
Patterson Trust
Mathers Charitable Foundation Dr. Malinow 8/91 -7/94 233,000
McKnight Endowment Fund Dr. Silva 7/95 -6/96 50,000 *
Memorial-Sloan Kettering/NIH Dr. Kobayashi 9/94 -7/97 175,000
Dr. Tonks 9/94 -7/97 185,944
Dr. Wig ler 9/95 -8/98 220,261 *
John Merck Fund Dr. Silva 5/95 -4/96 60,000 *
NYU Consortium/NIH Dr. Kobayashi 5/92 -4/97 74,643
Nanoprobes, Inc./NIH Dr. Spector 6/94 -5/96 29,087
National Down Syndrome Society Dr. Cline 7/95 -6/97 25,000 *
Lauri Strauss Leukemia Foundation Dr. Tonks 5/95 -4/96 15,000 *
Felix Schnyder Memorial Fund
St. Giles Foundation Dr. Beach/Dr. Wig ler 3/93 -2/96 50,000
Westvaco, Inc. Dr. Martienssen/Dr. McCombie 6/95 -5/96 290,000 *
Whitehall Foundation Dr. Silva 9/93 -8/96 45,000
Dr. Zhong 1/94 -12/96 40,000
* New Grants Awarded in 1995
+ Includes direct and indirect cost
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Grantor Program/Principal Investigator Duration of Grant 1995 Funding+
Equipment Support
Dextra Baldwin McGonagle Equipment 10/95 -9/96 10,000*
Foundation
Lorraine Grace Equipment 4/95 -3/96 15,000*
E.S. Moore Foundation Equipment 9/95 -12/95 10,000 "
Fellowships
Rita Allen Foundation Dr. Hengartner 9/94 -8/99 30,000
American Cancer Society Dr. Ellison 7/95 -6/98 24,000*
American Heart Association Dr. Temm-G rove 7/95 -6/97 21,650*
Austrian Science Foundation Dr. Gimona 4/94 -4/96 27,800
Swedish Cancer Society Dr. Berg 9/93 -9/95 25,000
Cancer Research Fund of the
Damon Runyon-Walter Winchell
Foundation Dr. Conklin 11/93 -10/96 32,500
Dr. Kim 1/95 -12/97 27,000*
Dr. Liang 9/94 -8/97 31,000
Dr. Weinreich 1/94 -12/96 31,000
CSHL Association Fellowship Support 4/95 -9/96 162,000 "
Jane Coffin Childs Dr. Mirzayan 7/93 -6/96 28,500
Dr. Verreault 10/94 -9/97 27,500
The Charles A. Dana Foundation Dr. Witkowski 1993 -1995 360,000
Demerec-Kaufmann Hollaender Dr. Grotewold 6/95 -5/96 5,000 *
Fellowship in Developmental
Genetics
Deutsche Forschungsge-
meinscaft
Dr. Giese 1994 -1996 34,000
Eton Student Internship Dr. Hoffman 8/95 -7/96 3,000 *
Fonds de la Recherche en
Sante du Quebec Dr. Autexier 5/92 -4/95 6,000
Foundation for Promotion
of Cancer Research, Japan
Dr. lizuka 1995 42,660 *
Glaxo Inc. Fellowship Support 1/95 -12/95 100,000*
Goldring International Group, Inc. Fellowship Support 7/94 -6/97 30,000
Human Frontier Science
Program Dr. Donovan 6/95 -5/96 35,400 *
Dr. Grossniklaus 11/94 -10/96 49,700
Dr. Hamaguchi 8/94 -7/96 43,700
Dr. Misteli 10/95 -9/96 35,400 *
Dr. Steiner 4/94 -3/96 30,400
Dr. Vignais 8/93 -7/95 40,500
Leukemia Society Dr. Autexier 7/95 -6/98 31,320*
Dr. Li 7/94 -6/97 33,480
Dr. Serrano 7/95 -6/99 31,320*
C.J. Martin Fellowship Dr. Tiganis 1995 24,000 "
(NHMRC, Australia)
Ministerio De Education Y Ciencia, Dr. Blasco 6/94 -6/95 16,000
Madrid Dr. Carnero 8/95 -7/96 19,000 "
Medical Research Council of Dr. Demetrick 11/91-11/95 43,260
Canada
Pew Scholars Program Dr. Krainer 7/92 -6/96 50,000
Dr. Lazebnik 7/95 -6/99 50,000 *
Dr. Zhong 7/94 -6/98 50,000
Andrew Seligson Memorial Fellowship Support 9/90 -5/96 75,000
Fellowship
Wellcome Trust Dr. Frenguelli 1995 12,403 *
Wendt Fellowships Neurobiology Fellowship Support 1/94 -12/96 50,000
Training Support
Burroughs Wellcome Foundation Summer Undergraduate Program 1995 40,260*
Jephson Educational Trust Summer Undergraduate Program 1995 7,500*
Howard Hughes Medical Institute Graduate Student Support 1995 26,000*
Phillips Petroleum Co. Summer Undergraduate Program 1995 1,000*
* New Grants Awarded in 1995
+ Includes direct and indirect cost
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Grantor Program/Principal Investigator Duration of Grant 1995 Funding+
Course Support
The Grass Foundation Scholarships 5/94 -4/96 18,240
Howard Hughes Medical Institute Advanced Neurobiology 1991-1999 285,063
Esther A. & Joseph Klingenstein Advanced Neurobiology 5/94 -4/97 60,000
Fund, Inc.
Monsanto Company Plant Breeding 3/95 -3/96 1,000 *
Pioneer Hi-Bred Plant Breeding 9/95 -8/96 9,000 *
Meeting Support
American Cyanamid Molecular Approach to the Control
of Infectious Diseases
10/95 -9/96 15,000*
Anheuser-Busch Companies Yeast Cell Biology 6/95 -5/96 500 *
CIBA-GEIGY Corporation Signaling in Plant Development 9/95 -8/96 500 *
DuPont Corporation Signaling in Plant Development 9/95 -8/96 500 *
Genetics Computer Group, Inc. Molecular Genetics and Phage 8/95 -7/96 1,000 *
Pharmacia Biotech Molecular Approaches to the Control
of Infectious Diseases
10/95 -9/96 12,000*
Pioneer Hi-Bred Signaling in Plant Development 9/95 -8/96 1,000 *
Promega Corporation Molecular Genetics and Sequencing 8/95 -7/96 1,000*
Quantum Soft General Atomics Genome Mapping and Sequencing 5/95 -4/96 500 *
The National Neurofibromatosis Neurofibromatosis 10/95 -9/96 20,000
Foundation, Inc.
University of Wisconsin/Madison RNA Process 5/95 -4/96 2,500*
(NSF Funds)
BANBURY CENTER
Grantor Program/Principal Investigator Duration of Grant 1995 Funding'
FEDERAL SUPPORT
NATIONAL INSTITUTES OF HEALTH
HIV and the Pathogenesis of AIDS 1995 25,000*
Lyme Disease Conference 1995 10,000 *
DEPARTMENT OF ENERGY
Human Genetics for Nonscientists: 1994 -1995 66,579
Practical Workshops for Policy Makers
and Opinion Leaders
NONFEDERAL SUPPORT
Meeting Support
Connaught Laboratories Lyme Disease Conference 1995 10,000 *
The Charles A. Dana Foundation Genetic Basis of Manic-Depressive Illness 1993 -1995 361,000
Finisterre Fund Imaging Meeting 1995 23,670 *
Fort Dodge Laboratories Lyme Disease Conference 1995 5,000 *
Medlmmune, Inc. Lyme Disease Conference 1995 2,000 *
Mothers' Voices, Inc. HIV and the Pathogenesis of AIDS 1995 5,000 *
OncorMed DNA Repair Meeting 1995 31,298 *
Pediatric AIDS Foundation HIV and the Pathogenesis of AIDS 1995 4,914 *
Private Contributions Neurofibromatosis Meeting 1995 15,000 *
Albert B. Sabin Vaccine HIV and the Pathogenesis of AIDS 1995 2,000 *
Foundation, Inc. Vaccine Development 1995 35,149
SmithKline Beecham Lyme Disease Conference 1995 5,000
Viaticus, Inc. HIV and the Pathogenesis of AIDS 1995 2,000 *
The William Stamps Farish Fund Molecular Genetics of Diabetes 1993 -1996 50,000
The Wilson Foundation Neurofibromatosis Meeting 1995 5,000 *
New Grants Awarded in 1995
+ Includes direct and indirect cost
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DNA LEARNING CENTER
Grantor Program/Principal Investigator Duration of Grant 1995 Funding+
FEDERAL GRANTS
NATIONAL SCIENCE FOUNDATION A Two-Part Program to Develop and Support 4/93 -3/96 242,193
Nationwide Corps of Human and Molecular
Genetics Resource Teachers at the
Secondary Level, David Mick los
Laboratory-based Instruction in Molecular
and Human Genetics for Teaching Faculty,
Mark Bloom
5/93 -4/95 35,835
A Novel Mechanism for Introducing 4/95 -4/98 33,395*
Human Genome Research in Freshman
Biology, Mark Bloom
NONFEDERAL GRANTS
Barker-Welfare Foundation MS Biology Camp/AMNH 6/95 -6/97 5,369 *
Genentech, Inc. Story of a Gene Exhibit 4/95 -4/96 32,747 *
Howard Hughes Medical Institute Precollege Science Education 7/94 -8/99 85,516
Initiative for Biomedical Research
Institutions
Stone Foundation Biomedia Teaching Laboratory 7/92 -6/96 61,360
Weezie Foundation Story of a Gene Exhibit 12/91 -12/95 15,940
The following schools each awarded a grant of $5,000 in 1995 for the Genetics as a Model for Whole Learning Program:
Locust Valley Central School District
Great Neck Public Schools
Jericho Union Free School District
The following schools awarded a grant for Curriculum Study in 1995
of $950:
Commack Union Free School District
East Meadow Union Free School District
East Williston Union Free School District
Garden City Union Free School District
Great Neck Public Schools
Half Hollow Hills Central School District
Harborfields Central School District
Herricks Union Free School District
Island Trees Union Free School District
Jericho Union Free School District
Lawrence Union Free School District
Locust Valley Central School District
of $1,500:
Ramaz School
of $2,000:
West Hempstead
* New Grants Awarded in 1995
+ Includes direct and indirect cost
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Manhasset Union Free School District
Massapequa Union Free School District
Northport-East Northport Union Free School District
North Shore Central School District
Oyster Bay-East Norwich Central School District
Plainedge Union Free School District
Port ledge School
Port Washington Union Free School District
Roslyn Public School
Sachem Central School District
South Huntington Union Free School District
Syosset Central School District
Cold Spring Harbor Laboratory is a nonprofit research and educational institution
chartered by the University of the State of New York. Less than half (44.1%) of
our annual support is derived from Federal grants and contracts, and thus we
rely heavily on support from the private sector: foundations, corporations, and in-
dividuals. Contributions from the private sector are tax exempt under the provi-
sions of Section 501(c)(3) of the Internal Revenue Code. In addition, the
Laboratory has been designated a "public charity" and therefore may receive
funds resulting from the termination of "private foundations."
METHODS OF CONTRIBUTING TO COLD SPRING HARBOR LABORATORY
Gifts of money can be made directly to Cold Spring Harbor Laboratory.
Securities: You can generally deduct the full amount of the gift on your income
tax return, and, of course, you need pay no capital gains tax on the stock's ap-
preciation.
We recommend any of the following methods:
(1) Have your broker sell the stock and remit the proceeds to Cold Spring Har-
bor Laboratory.
(2) Deliver the stock certificates to your broker with instructions to open an ac-
count for Cold Spring Harbor Laboratory and hold the securities in that ac-
count pending instructions from Cold Spring Harbor Laboratory.
(3) Send the unendorsed stock certificates directly to the Laboratory: Com-
ptroller, Cold Spring Harbor Laboratory, One Bungtown Road, Post Office
Box 100, Cold Spring Harbor, New York 11724. In a separate envelope,
send an executed stock power.
Pooled Income Funds: Combine gifts from a number of donors in a pool for at-
tractive investment and tax purposes.
Appreciated real estate or personal property: Sizable tax benefits can result
from such donations; the Laboratory can use some in its program and can sell
others.
Life insurance and charitable remainder trusts can be structured to suit the
donor's specific desires as to extent, timing, and tax needs.
Bequests: Most wills probably need to be updated. Designating Cold Spring
Harbor Laboratory as beneficiary ensures that a bequest will be utilized as
specified for continuing good.
Conversion of private foundation to "public" status on termination: This may
be done by creating a separate fund within Cold Spring Harbor Laboratory
whereby the assets of the private foundation are accounted for as a separate
fund and used for the purposes specified by the donor. Alternatively, the pri-
vate foundation can be established as a supporting organization of Cold Spring
Harbor Laboratory.
For additional information, please contact the Director of Development, Cold Spring Harbor
Laboratory, One Bungtown Road, Post Office Box 100, Cold Spring Harbor, NY 11724, or
call 516-367-8840.
CAPITAL AND PROGRAM CONTRIBUTIONS
January 1, 1995-December 31, 1995
Contributions of $5,000 and above, exclusive of Annual Fund
In 1995, the Laboratory received significant support in the form of capital and program contribu-
tions from individuals, foundations, and corporations.
Anonymous
Arrow Electronics, Inc.
Banbury Fund
Barker Welfare Foundation
Burroughs Wellcome Fund
John P. Cleary
D'Egville Foundation (Dr. Mark Ptashne)
Dextra Baldwin McGonagle Foundation
Dolan Family Foundation
William Stamps Farish Foundation
The Garfield Foundation
Garland Publishing (Elizabeth Borden)
Genentech
Dr. H. Bentley Glass
Glaxo Research Institute
Goldring Family Foundation
Mrs. Oliver R. Grace
Irving A. Hansen Memorial Fund
Estate of Maxine Harrison
Total $4,506,898
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Jephson Educational Trust
David L. Luke III
Edwin S. Marks
William and Marjorie Matheson
McKnight Endowment for Neuroscience
John Merck Fund
Edward S. Moore Foundation
1 in 9: Long Island Breast Cancer Coalition
William and Maude Pritchard Charitable Trust
Estate of Joan Read
John R. Reese
Thomas A. Saunders III
Alan and Edith Seligson
Frederica von Stade Benefit
Lauri Strauss Leukemia Foundation
Dr. and Mrs. James D. Watson
Westvaco Corporation
Robert Winthrop
ANNUAL CONTRIBUTIONS
Corporate Sponsor Program
The Corporate Sponsor Program continues to be a major source of support for the meetings held in
both Grace Auditorium on the main Laboratory campus and at Banbury Center. The Program
covers the cost of six meetings at Banbury Center and helps underwrite the costs of the meetings
in Grace Auditorium. The 1995 membership remained at the same level as in 1994, with 35 mem-
bers. It is clear that companies are rethinking their contributions to outside programs, but we have
been able to maintain the membership fee at the same level for four years and that fee, $20,500 in
1995, is a relatively small sum in the research budgets of the companies we approach. In addition,
substantial benefits return to member companies:
All on-site fees are waived for eight representatives of each company attending our meetings.
Three of these scientists may attend meetings at Banbury Center, where attendance is other-
wise only by invitation of the organizers.
Corporate Sponsors receive gratis copies of the Cold Spring Harbor Laboratory Press publica-
tions including the journals Genes & Development, Learning & Memory, and Genome Analysis.
Grace Auditorium is made available to Corporate Sponsor Program members for sponsorship
of scientific meetings on topics of their own choice.
Corporate Sponsors are acknowledged in all relevant publications, including the books of ab-
stracts given to every participant at meetings; the names of the sponsoring companies are
listed on the poster describing the meetings which is mailed to app i oximately 7,000 scientists
throughout the world.
On behalf of all the scientists that attend meetings at Cold Spring Harbor Laboratory, we thank the
Corporate Sponsors listed below and encourage other companies to help us promote research
through this Program.
American Cyanamid Company
Amgen Inc.
BASF Bioresearch Corporation
Beckman Instruments, Inc.
Becton Dickinson and Company
Bristol-Myers Squibb Company
Chugai Pharmaceutical Co., Ltd.
Chugai Research Institute for
Molecular Medicine, Inc.
Diagnostic Products Corporation
The Du Pont Merck
Pharmaceutical Company
Forest Laboratories, Inc.
Total $717,500
Genentech, Inc.
Glaxo
Hoffmann-La Roche Inc.
Human Genome Sciences, Inc.
Johnson & Johnson
Kyowa Hakko Kogyo Co., Ltd.
Life Technologies, Inc.
Marion Merrell Dow Inc.
Mitsubishi Kasei Institute of Life
Sciences
Monsanto Company
New England BioLabs, Inc.
Cncogene Science, Inc.
Pall Corporation
The Perkin-Elmer Corporation
Pfizer Inc.
Research Genetics, Inc.
Sandoz Research Institute
Schering-Plough Corporation
SmithKline Beecham Pharmaceuticals
Sumitomo Pharmaceuticals Co., Ltd.
The Upjohn Company
The Wellcome Research Laboratories,
Burroughs Wellcome Co.
Wyeth-Ayerst Research
Zeneca Group PLC
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Cold Spring Harbor Laboratory Association (CSHLA)
Officers
Mr. John P. Cleary, President
Mrs. James M. Large, Vice President
Mrs. Harry A. Brooks, Secretary/Treasurer
Directors
Mrs. Joseph S. Augusciak
Nicholas Bartilucci
Mrs. Harry G. Charlston
David C. Clark
David H. Deming
Mrs. John J. Genovese
John S. Grace
Mrs. Joyce Green
Mrs. Edward Greenberg
President's Report
Donald S. Kent, M.D.
Coe Kerr
Alan M. Kisner, M.D.
Mrs. George N. Lindsay
Robert L. Marcus
Edward F. McCann II
Mrs. Robert G. Merrill
Mrs. Vincent Nesi
Gerald D. Olin
Douglas E. Rogers
Philip M. Satow
Mrs. Thomas A. Saunders Ill
Mrs. Peter G. Schiff
James L. Spingarn
Bruce Stillman, Ph.D.
James D. Watson, Ph.D.
George W. Cutting, Honorary
Director
1995 was a year of consolidation and growth for the Cold Spring Harbor Laboratory Association.
Our mission in making new friends and maintaining old friends, in fund-raising for the support of
postdoctoral scientists, in providing support services for our scientific personnel, and in attempting
to maintain and improve community relations was conducted with enthusiasm and resolve. Mem-
bership in the Association now stands at 746. Moreover, efforts were made to diversify the con-
stituency of Laboratory support through mailings, personal contact, discussions with visitors, com-
munications with different school districts, and other community organizations.
Our year started out with our annual meeting held on February 5th. The experience was enrich-
ing in that our principal speaker was Dr. Rich Roberts, a 1993 Nobel Laureate who did the scientific
work resulting in his prize at Cold Spring Harbor Laboratory. His talk entitled "From Split Genes to
Stockholm" covered his research work leading up to the award and also provided us with vignettes
of the ceremony in Stockholm.
On March 25th, a fabulous evening was held at the Laboratory; we were entertained by Flicka
von Stade and three accompanists, Bruce Brubeck, Bill Crofut, and Joel Brown. The music was tru-
ly enchanting, with a medley of different musical work expressed through voice, piano, guitar, and
banjo. The proceeds from the evening went to the Undergraduate Research Program. With the help
and support from the Association, the performance was a unique and interesting musical experi-
ence.
In April, at the instigation of Jordan Saunders, a luncheon was held in New York with our Direc-
tor, Bruce Stillman, as the principal speaker. The meeting was a success, and kudos go as well to
Holly Brooks, Maureen Augusciak, and Mary Lindsay.
The Spring mailing for the Association Annual Fund began in May, and we thank each of our
solicitors for their ardent efforts in the fund-raising effort and also for the energy expended to ac-
quire new friends for the Laboratory.
On June 4th, during the annual Cold Spring Harbor Symposium, the Dorcas Cummings
Memorial Lecture was held, an annual event that is organized and sponsored by the Association.
Dr. Gunter Blobel, a member of the Board of Trustees and a research scientist at the Rockefeller In-
stitute, spoke on "How Proteins Find Their Addresses in the Cell." As is tradition, the lecture was fol-
lowed by special dinner parties hosted by members of the Association and friends of the
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Yuri Lazebnik (son of CSHL scientist Yuri Lazebnik) and Nobel prize winner Rich Roberts at the CSHL Associa-
tion Director's meeting.
Laboratory. Here, scientists who attended this important meeting met and mixed with our wonderful
friends. Special thanks go to each of our host and hostesses:
Mr. and Mrs. Henry Babcock, Jr.
Mr. and Mrs. John Cleary
Dr. and Mrs. Paul Cushman, Jr.
Mr. and Mrs. Norris Darrell, Jr.
Mr. and Mrs. Edward Fessenden
Mr. and Mrs. John J. Genovese
Mr. and Mrs. Edward Gerry
Mr. and Mrs. John Grace
Mr. and Mrs. Gordon Hargraves
Mr. and Mrs. Townsend Knight
Mr. and Mrs. Robert Lindsay
Mr. and Mrs. David Luke, III
Mr. and Mrs. Robert Merrill
Mr. and Mrs. Robert O'Connor
Mr. and Mrs. Gerald Olin
Mr. and Mrs. William F. Russell
Mr. and Mrs. James Spingarn
Mr. and Mrs. John Stevenson
Mr. and Mrs. Daniel Tenney, Jr.
With the fall came the introduction of a new lecture series called Next Generation Initiative,
which was held on four separate Thursday nights in October and November. The idea for this new
series was initiated by members of our community who felt that an approach should be developed
to introduce new and younger members of the community to the Laboratory. Each meeting was
preceded by a sandwich and salad buffet, which was followed by a lecture by members of the
scientific staff at the Laboratory. The talks were enriching. It is our hope that we can now improve
upon this good start. In addition, during the fall, through the efforts of Skip Hargraves, the Associa-
tion sponsored an estate-planning seminar conducted by Jennifer Jordan, a Trusts and Estates
partner at Cadwalader, Wickersham & Taft. Jennie was supported in this presentation by Townie
Knight, and for those who attended, it was certainly an informative experience. A significant new
event benefiting the Association and raising nearly $8,000, namely, the Tree Symposium, brought a
new constituency to the Laboratory. Carol Large, our Vice President and a Trustee of Old Westbury
Gardens, organized the event, which was a collaborative effort with Old Westbury Gardens and the
Cornell Cooperative Extension of Nassau County. It drew many new faces not only from Long Is-
land, but also from other parts of the northeast. More than 300 people attended this symposium.
In the fall, the efforts of our solicitors, and also an improved computer capability, allowed us to
solicit approximately three times as many friends as we have in the past. These new prospects
came to us from a variety of sources, including visits to the Laboratory, public inquiries, and sug-
gestions from members of people expressing interest in Laboratory activities. Prospecting is a
worthwhile exercise. We hope to continue to enlarge our membership base in the forthcoming year.
The final report reflects gifts by 162 major donors of $1,000 or more. The total number of donors in-
creased to 767 with total receipts in excess of $662,000, which exceeded last year's receipts by
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more than 9% and our goal of $600,000. All in all, it was a tremendous effort conducted by many
people including our directors.
On Sunday evening, October 22nd, John and Lola Grace gave an elegant buffet at their home
in Cove Neck to thank the Association's major donors. Guests included Laboratory scientists and
staff, and those in attendance were treated to a night of informal conversation and discussion. The
pleasure of the evening was enhanced by active participation of John and Lola's daughters, Lor-
raine and Victoria, and the introduction of John, Jr.
It is my privilege to acknowledge the significant effort given to the Laboratory and the Associa-
tion during the past six years by Jane Greenberg and Doug Rogers. In their different ways they
fostered considerable support and expended effort in furthering the interest of the Association and
the Laboratory for which we are very grateful. In addition, a special thank you to Dr. Donald Kent
for his service as a Director in 1995. A special thanks to Jean Schwind who completes her first year
as our staff director and to the other members of the Laboratory development organization who
have given of their time and effort to support the work of the Association.
February, 1996 John P. Cleary
Members of the Cold Spring Harbor Laboratory Association
BENEFACTORS
Mr. and Mrs. John P. Cleary
Mrs. John L. Davenport
The Dorothy Schiff Foundation
Mr. Robert B. Gardner, Jr.
The Garfield Foundation
Mrs. Oliver R. Grace
The Joyce Green Family Foundation
Mr. and Mrs. George N. Lindsay
Mr. and Mrs. David L. Luke III
Mr. Leonard Marx
Mr. and Mrs. Thomas J. McGrath
Dr. and Mrs. Walter C. Meier
Mr. AMU. C. Merrill
Mr. and Mrs. William R. Miller
Mr. and Mrs. Douglas P. Morris
The Olin Cohen Trust
Mr. and Mrs. Phillip M. Satow
PATRONS
The Ada Howe Kent Foundation
The Alex J. Weinstein Fdn, In
Mr. and Mrs. Roger Bahnik
Mr. Jeffrey I. Braverman
Mr. and Mrs. Rod Brayman
Mr. and Mrs. Harry A. Brooks
Mr. and Mrs. G. Morgan Browne
Mr. and Mrs. Peter B. Cannel!
Craigmyle Foundation
Mr. and Mrs. Norris Darrell, Jr.
Mr_ and Mrs. Edward H. Gerry
Mr. and Mrs. Thomas S. Gimbel
Mr. and Mrs. John S. Grace
Mrs. John W. Hadley
Mrs_ Dorothy H. Hirshon
Mr. and Mrs. Townsend J. Knight, Esq.
Dr. Laurie J. Landeau
Mr. and Mrs. James M. Large, Jr.
Mrs. Henry Lewis III
Mr. and Mrs. Robert V. Lindsay
Mrs. John H. Livingston
Mr. and Mrs. Robert L. Marcus
Mr. and Mrs. Robert R. Maxfield
Mr. and Mrs. Robert G. Merrill
Mr. and Mrs. Charles E. Murcott
Mr. Edward L. Palmer
Mr. and Mrs. John J. Phelan
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Jacquelin and Ronald Martel lo Mr. John G. Peterkin Mr. Wolfgang Schlaeger George M. Thomas
Ms. Pamela Mathews Harry and Marjorie Phillips Irving and Henrietta Schneider William J. Thompson
Mr. and Mrs. William B. Matteson Mr. and Mrs. Robert Pilkington William J. Scholan Shirley M. Tilghman
Joseph J. Matthews Mr. and Mrs. Graham L. Platt Dr. and Mrs. Seymour H. Schpoont Stanford W. Ting
Drs. Egon and Marcia Kramer Mayer The Honorable and Mrs. Thomas C. Platt Dr. and Mrs. Michael Schroder Mrs. Warren I. Titus
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Mrs. George C. Barclay Mr. Arnold E. Keppler Mr. and Mrs. Robert Mazlish Dr. A.R. and Mythily Srinivasan
Mr. Michael G.Berland Mrs. Leslie Learned Mr. and Mrs. Josef Mittlemann Dr. Garland Stern
Debra Errick and Michael J. Bode Mr. and Mrs. P.O'Donnell Lee Mr. and Mrs. David C. Noyes Sid and Carol Strickland
Ralph T. Brandifino Reverend and Mrs. T. Carleton Lee G.L. Redmond Dr. Janey Symington
Noreen and Anthony Cambria Dr. Monroe L. Levin Franz Schager Mr. and Mrs. R. Walker
Dr. Susan Friedlander Mr. Eugene J. Levitt, Esq. Mr. and Mrs. Tancred V. Schiavoni Mrs. Lorraine S. Wicks
Dr. and Mrs. Roy F. Gherardi Mr. and Mrs. John F. Mackay Mollie S. Shriftman Starr, Ph.D.
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CSHLA CORPORATE MATCHING AND FOUNDATION CONTRIBUTIONS AND OTHER DIRECT GIFTS
Arco Foundation
The Banbury Fund
BankAmerica Foundation
Banker's Trust
The Bado Foundation
Bristol-Myers Squibb Foundation, Inc.
Mr. John P. Campbell
Chemical Bank
Citibank
Citicorp
Computer Associates International,
Inc.
Corning Incorporated Foundation
Dean Witter Reynolds, Inc.
William H. Donner Foundation
The Equitable
Fluor Corporation
General Electric
Greenpoint Savings
Walter B. James Fund #2
CSHLA Annual Fund
The New York Community Trust
John A. Hartford Foundation
The Maxfield Foundation
Mr. and Mrs. Gerald M. Mayer, Jr.
J.P. Morgan and Company, Inc.
The General William Meyer Family
Foundation
The Miller Family Foundation
The Leo Model Foundation
MONY
The Nordemann Foundation
The Olian Foundation
Mr. and Mrs. George D. O'Neill
The Pechter Foundation
Penn Virginia Corporation
The Pentara Foundation, Inc.
The Charlotte Palmer Phillips
Foundation
Pfizer, Inc.
Phelps Dodge Foundation
CSHLA Membership (746) and Other Support
Benefactors, Patrons, Associates $567,842
Friends and Family 76,850
Benefits 8,308
Other 785
Total $ 653,785
Mr. and Mrs. Everett Post
The Reese Foundation
The Richard Foundation
The Russell Colgate Fund
Republic National Bank of NY
Reuters America
The J&H Rubin Foundation
Walter P. James Fund-Long Island
Community Fund
The David G. Salten Foundation
Mr. and Mrs. Henry Salzhauer
Mr. and Mrs. Peter G. Schiff
Scudder Charitable Trust
The Stebbins Fund
Union Pacific Corporation
The Whitehall Foundation
The Eugene F. Williams Charitable
Trust
James D. Wolfensohn, Inc.
Arthur Zankel
Undergraduate Research Program/Partners for the Future
The goal of the Laboratory's two student intern programs, the Undergraduate Research Program
for select college students and the Partners for the Future Program for top regional high school stu-
dents, is to produce future research scientists and to encourage awareness among young people
in general.
CONTRIBUTORS
H. Bentley Glass
Cornelius N. Bliss Memorial Fund
Burroughs Wellcome Fund
Garfield Fund
Jephson Educational Trust
Philips Petroleum Foundation
Estate of Joan Read
Frederica von Stade Fund
Total $ 363,374
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DNALC Corporate Advisory Board Annual Fund
An important objective of the Corporate Advisory Board of the DNA Learning Center is to provide a
sustainable level of annual funding for Learning Center programs. As a means of reaching this ob-
jective, the Board conducts an Annual Fund and an Annual Golf Tournament with the proceeds to
benefit the DNA Learning Center.
Richard M. Clark, Chairman
Gary E. Frashier, Vice Chairman
Michael Aboff
Andrew D. Ackerman
Rocco S. Barrese, Esq.
Howard M. Blankman
Thomas J. Calabrese
Robert E. Diller
Candido Fuentes, M.D.
Arthur D. Herman
ANNUAL FUND CONTRIBUTORS
CORPORATE BENEFACTOR "
Luitpold Pharmaceuticals
CORPORATE PATRONS **
ADEMCO
Laurie J. Landeau, V.M.D.
Newsday
NYNEX
Price Waterhouse
CORPORATE ASSOCIATES +
The Americana at Manhasset
Louis and Virginia Clemente
Foundation
Johnson & Higgins
KPMG Peat Marwick LLP
Meenan Oil Co., L.P.
Oncogene Science
Alberto I barguen
John Kean
John J. Lack
Laurie J. Landeau, V.M.D.
Ralf Lange
Jack Leahy
Lilo Leeds
Patricia Petersen
CORPORATE FRIENDS ++
Howard Blankman Inc.
Festo Corporation
Daniel Gale Real Estate
Companies
Harweb Foundation
A.D. Herman Construction
Company, Inc.
Lilo and Gerry Leeds
Ethel and Alexander Nichoson
Foundation
Official Offset Corporation
William D. Roche
The Schiff Foundation
Windemere/Friedlander
Development Corp.
William Roche
Wendy Vander Poel Russell
Horst Saalbach
Peter G. Schiff
Charles R. Schueler
Paul A. Vermylen, Jr.
Lawrence J. Waldman
Raymond A. Walters, Ph.D.
FRIENDS OF THE DNALC +++
Aboff's Inc.
Sharada Bhansali
Mr. and Mrs. George A. Bourne
Dino E. Carfora
Mr. Douglas B. Fox
Mr. and Mrs. Gerard DeGregoris, Jr.
Henry and Arlette Hoeppner
Charles H. Hoke, Jr., M.D.
Dominic J. Nardi, M.D.
Scott and Pamela Powell
Mr. John G. Roche
Michael and Roberta Schroder
Alexander J. Smith
Sabiha Haque-Soriano and Jerry A. Soriano
Stephanie and Jeff Stern
In-kind contributions were also received from Brinkmann Instruments and Leslie Supply Company.
A genetic education seminar was held in April 1995 for professionals who interface with genetic technology. Participants in-
cluded employees of Oncogene Science and other New York metropolitan area companies. The seminar raised $2,005 for the
Annual Fund.
Corporate Benefactors, $10,000 or more
- Corporate Patrons, $5,000 or more
+ Corporate Associates, $2,500 or more
++ Corporate Friends, $1,000 or more
+++ Friends of the DNALC, $10 or more
Total $ 65,815
GIFT IN HONOR CONTRIBUTOR TO DNALC
John G. Peterkin
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IN HONOR OF
Yi-Fu Sun
GOLF TOURNAMENT SPONSORS
A&B Graphics Inc. Mr. John P. Cleary The Inn on the Harbor Northwood Ventures
Aboff's, Inc. Mr. Peter C. Corio International Scientific NYNEX
American Airlines The Country Printer Communications O.C. Tanner
American Express Dilworth & Barrese ITT Hartford Official Offset Corp.
American Satellite Network, Inc. Dvirka & Bartilucci I. Janvey & Sons Oncogene Science
Mr. Charles L. Anderson Farrell, Fritz, Caemmerer, Cleary, Javelin Blue Oxford Health Plans
Angelina's Restaurant Barnosky & Armentano Kean Development Company Oyster Bay Frame Shop
The Lennard Axinn Company Festo Corporation Kean Landscapes Parker, Chapin, Flattau & Klimpl, LLP
The Badge Insurance Agency The First National Bank of KPMG Peat Marwick Mrs. Patricia Petersen
Barber-Colman, Aiello Co., Inc. Long Island Kraft Food Service Mr. John 0. Pickett III
Baxter Scientific Products Dr. Candido Fuentes L&L Camera Price Waterhouse
Beverly Books, Inc. Daniel Gale Agency Lawrence, Sappe & Lawrence Mr. R. John Punnett
Howard Blankman Incorporated Gale & Wentworth, Inc Mr. and Mrs. George N. Lindsay Mr. and Mrs. William D. Roche
Boehringer Mannheim Abel Grenier, Inc. Long Island Golfer Magazine Clare Rose, Nassau
Breakfast Productions A.D. Herman Construction Luitpold Pharmaceuticals Schneider Children's Hospital
Brinkmann Instruments Co., Inc. Mr. Peter A. Malito The Sheridan Press
Buckhurst Fish & Jacquemart Inc. Hickey's Carting, inc. Margolin, Winer & Evens Spinnaker Travel, Ltd.
Burt Building Materials Corp. Hilltop Computing Marotta Associates Stirling Creek Associates
Cablevision Hoffman & Baron Mr. Joseph Marotta Syosset Limousine Service
CCG Consulting Holmes Protection of Long J.P. Morgan & Co. Trattoria Grasso
Centerbrook Architects Island, Inc. Mr. Daniel L. Mosley U.S. Healthcare
Chase Manhattan Bank Huntington Business Products Mr. and Mrs. Vincent R. Nesi US Sprint
Chemical Bank Centre Mr. Joseph Nidzyn, Jr. US Trust Company
Mr. Robert J. Christopher, P.E., P.C. Huntington Hilton North Country Supply Winebow, Inc., Ltd.
Total $ 65,070
Total DNA Learning Center Annual Fund $ 130,985
MEMORIAL AND GIFT IN HONOR CONTRIBUTORS
ABB Combustion Engineering Systems
Mr. Esteban Araya
Mr. and Mrs. William Braden
Mr. and Mrs. James P. Cavanagh
Mr. and Mrs. Robert E. Cooper
Mr. and Mrs. Robert Davis
Dr. and Mrs. Robert R. Desnick
IN MEMORY OF
Mrs. Mildred Becker
Ms. Harriet Curtis
Mrs. Mary Love Glenn
Mrs. Mildred Goldammer-Birbach
Mrs. Lita Armenberg-Hazen
The Friends of Art & Preservation
in Embassies
Mr. and Mrs. Allen Goldring
Mr. Philip R. Herzig
Mrs. Janet H. Hutson
Mr. and Mrs. Richard Hyman
Mr. Ronald A. Krancer
Dr. and Mrs. Louis Lester
M.U.
Mr. Daniel Mahoney
Mr. Joseph Metzler
Mr. Dean Naven
Mr. David Oberon
Mr. William Osborne, Jr.
Mrs. Joan Read
Mr. Jack Salant
Mr. Michael Stewart
The Page and Otto Marx Foundation
Monica and Brent Mowery
Mr. and Mrs. Rushmore Patterson
Ms. Peggy Smith
Ms. Colette Tighe
Ms. Audrey B. Wall
Mr. and Mrs. Louis Wisnewski
IN HONOR OF
Mrs. Jane Spingarn
Annual Fund donations to "In Memory of" Oliver R. Grace by Helen Grace Spencer and Joyce Green.
Memorials and In Honor Totals $ 7,880
Total All Annual Funds $ 1,882,097
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LABORATORY STAFF
James D. Watson, President
Bruce W. Stillman, Director
Winship Herr, Asst. Director
G. Morgan Browne, Administrative Director
John P. Maroney, Asst. Administrative Director
William D. Keen, Comptroller
Terri I. Grodzicker, Asst. Director for Academic Affairs
Jan A. Witkowski, Director of Banbury Center
David A. Mick los, Director of DNA Learning Center
John R. Inglis, Executive Director of CSHL Press
Research Staff Gregory Hannon Kyoko Hidaka Cyril Sanders
Natalia Peunova Masumi Hidaka Brandt Schneider
Kim Arndt Rui-Ming Xu Craig Hinkley Juhan Sedman
Peter Barker Johannes Hofmann Manuel Serrano
David Beach " David Horowitz Gavin Sherlock
Xiaodong Cheng Genome Research John Horton Mona Spector
Holly Cline Associate Yan-Fen Hu Patricia Springer
Grigori Enikolopov Michael (Qiwei) Zhang Hai Huang Yuri Stasiv
Bruce Futcher Sui Huang Barbara Steiner
Carol Greider James Hudson Peiqing Sun*
Erich Grotewold Postdoctoral Research Masayoshi lizuka William Tansey
David Helfman Fellows Arthur Johnson Constance Temm
Michael Hengartner Chantal Autexier Christopher Jones Tony Tiganis
Nouria Hernandez* Anton Bennett Alyson Kass-Eisler Henry Tobin
Tatsuya Hirano Mikael Berg Paul Kaufman Alain Verreault
Leemor Joshua-Tor Maria Blasco Jeffrey Kogan Marie-Luce Vignais
Ryuji Kobayashi Gert Bolwig Thillai Koothan Jonathan Wallach
Adrian Krainer Stephen Brand Peter Krasnov Qizhi Wang
Yuri Lazebnik Karen Buchkovich Siyuan Le Yung-Chih (Judy) Wang
Hong Ma Mary Byrne Li Akiya Watakabe
Roberto Malinow Javier Caceres Chun Liang Michael Weinreich
Thomas Marr Hui-Zhi Cai Huey-Jane Liao Wei Wen
Akila Mayeda Maureen Caligiuri Athena Lin Angus Wilson
Robert Martienssen Douglas Conklin Fong Lin Mee-Wa Wong*
H. Peter Nest ler Gerhard Cullmann Mingsong Liu Scott Woody
Michael Mathews Kang Dai Ruiping Liu Nicholas Wright
W. Richard McCombie Robert Del Vecchio Yi Liu Gang-Yi Wu
Alcino Silva Flavio Della Seta Yu Liu Shaohui Zhang
Jacek Skowronski Serge Desnoyers Martin Lock Dong-Jing Zou
David Spector James Dezazzo Muhammed Lodhi
Arne Stenlund
Venkatesan Sundaresan
Dennis Dong
Joseph Donovan
Peter Lorenz
Scott Lowe Graduate Students
Masafumi Tanaka Joshua Dubnau Robert Lucito Robert Babb
Nicholas Tonks James Edwards May Luke Nicholas Carpino
Tim Tully Viola Ellison Zachary Mainen Kenneth Chang
Linda Van Aelst Hua-Ying Fan Salim Mamajiwalla Degui (Charlie) Chen
Shou Waga Howard Fearnhead Caroline Mirzayan Grace Chen
Michael Wig ler Nikolai Federov Thomas Misteli Jeffrey Christensen
Jerry Yin Catherine Flanagan Renu Mital Charles Di Como
Yi Zhong Andrew Flint Vivek Mittal* Andrea Doseff
Karl Giese Yukiko Mizukami Lavina Faleiro
Genetics Research Unit Mario Gimona Michael Murray Ethan Ford
Carnegie Institution Michael Greenberg Mariko Nakamura Richard Freiman
of Washington Ulrich Grossniklaus Margaret O'Gara Kimberly Gavin
Alfred D. Hershey Qing Gu Koji Okamoto Eric Gillitzer
Hui-Fu Guo Tsafrira Pe'ery Tina Gumienny
Staff Associates Michael GutchMasaaki Hamaguchi
Shannon Pendergrast*
Frank Pessler
Daniel Hoeppner
Chong (Chris) Huang
Joseph Colasanti Akemi Hanamura Y. Ramanathan John lafrate
Shobha Gunnery R. William Henry Michael Regulski Tracy Kuhlman
"Funding provided
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by Howard Hughes Medical Institute
Kenneth La Montagne
Benjamin Lee
Dezhi Liao
Qiong Liu
Michele Mc Donough
Paul Mintz
James Moore
Debra Morrison
Kathy O'Neill
Shirley Pinto
Julia Polyakova
Alex Rai
Hai Rao
Jose Rodriguez
Peter Rubinelli
Cynthia Sadowski*
Ahmed Samatar
Meenakshi Selvakumar
Setareh Sepehri
Andrew (Mark) Settles
Aneil Shirke
Michael Stebbins
Javor Stolarov
Deborah Taylor
Suzanne Tharin
Tzu-Ling Tseng
Hua Tu
Terrence Vale
Thomas Volpe
Herman Wijnen
Qiang Wu
Helena (Xiaohong) Yang
Qinghong Yang
Lee Zou
Visiting Scientists
Konstantin Galactionov
Boris Kuzin
Roberta Maestro
Mirjana Maletic-Savatic
Ronald Pruzan
Sanders Williams+
Howard Hughes Medical
Institute Employees
Support Staff
Susan Allan
Graceann Bartilucci
Xiao (Joan) Chen
Beicong Ma
Carol Sekunda
Judi Smith
Lin Ying Xie
Research Associates
Carmelita Bautista
Georgia Binns
On sabbatical at CSHL
Lisa Manche
Linda Rodgers
Lab Facility Management
Diane Esposito
Spencer Teplin
Laboratory Management
Linda Hiesiger
Technical Programming
Steven Cozza
David Cuddihy
Ryutaro Iwasaki
Moira Mallison
Edwin (Corp) Reed
Jacqueline Salit
Adam Tracy
Secretarial
Sadie Arana
Patricia Bird
Idee Mallardi
Carol Marcincuk
Jane Reader
Barbara Matusik
Madeline Wisnewski
Research Assistants
Thomas Connor
Catherine Hogel
Adriana Weissmann
Laboratory Technicians
Deborah Aufiero
Nick Bizios
Scott Bronson
Barry Burbach
Patricia Burfeind
Yow-Ning Chang
Jodi Coblentz
Martha Daddario
Nancy Dawkins
Xiaozhu Duan
Margaret Falkowski
Wendy Gagliano
Jill Grossman
Jill Hemish
Michiko Hirano
Jane Hoffman
Tamara Howard
Yi Hu
Santosh John
Jennifer Kahler
Nancy Kaplan
Paul Kearney
James Keller
Martine Lessard
Jianping Liu
Lin Luo
Thomas Malone
Jennifer Mc Cann
Karen Mc Cloy
Mila Mc Currach
Robert McGuirk
Irina Miloslayskaia
Elizabeth O'Connor
Nora Poppito
Michael Riggs
Simone Salghetti
Neena Sareen
Tiina Sedman
Rosemarie Sherlock
Stephanie Smith
Brian Svedberg
Sally Till
Jennifer Troge
Klara Velinzon
Miho Waga
Mary (Camille) Walker
Ikuko Watakabe
Patricia Wendel
Regina Whitaker
Jeanne Wiggins
Yifan Xu
Christina Yordan
Zhuang Yuan
Hong Zhou
Media Makers/
Laboratory Aides
Esteban Araya
June Blanchford
Patricia Brady
Jack Brodsky
Anthony Bug lino
Rodney Chisum
Janice Douglas
Corine Driessens
Stephen Gerold
Salvador Henriquez
Arina Kutuyeva
Steven Levine
Robert Lundsten
Zachary Marowitz
Vincent Meschan
John Newman
Margaret Wallace
Xiu-Xia Zhang
Art
Michael Ockler
James Duffy
Jessica Viccaro
Philip Renna
Information Services
Gerald Latter
Anthony Alicata
Jim Bense
Patrick Monardo
William Palafox
Robert Pace
Bobbie Peters
Lee Wilbur
CSHL Press
Acquisition
Laura Terwilliger
Editorial/Production Books
Nancy Ford
Janet Argentine
Patricia Barker
Dorothy Brown
Mary Cozza
Maryliz Dickerson
Joan Ebert
Elaine Gaveglia
Annette Kirk
Lee Martin
Eileen Paetz
Elizabeth Ritcey
Inez Sialiano
Editorial/Production
Journals
Judy Cuddihy
Nadine Dumser
Kristin Kraus
Doris Lawrence
Cynthia Schneider
Lab Manual Source Book
Joan Boyce
Rebecca Christensen
Penny Sheppard
Fulfillment/Distribution
Guy Keyes
Kathleen Cirone
Gabriella Horvath
Jacqueline Matura
Walter McKenna
Barbara Terry
Finance
Nancy Hodson
Marketing
Ingrid Benirschke
James Suddaby
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Advertising
Deborah Dufton
Bookstore
Connie Hallaran
Sharon Story
Public Affairs
Development/Library
Susan Cooper
Clare Bunce
Laura Hyman
Public Affairs
Margot Bennett
Edward Campodonico
Marlena Emmons
Wendy Goldstein
Lynn Hardin
Herb Parsons
Development
Jill Clark
Gordon Hargraves
Catherine Hills
Laura Hundt
Jean Schwind
Andrew Scott
Library
Margaret Henderson
Leigh Johnson
Joann Muscardin
Wanda Stolen
Claudia Zago
Accounting
Amy Anderson
Sharon Bense
Jennifer Blovsky
Guy Cozza
Karen Fabian
Mary Ellen Goldstein
Patricia Maroney
Alison McDermott
Carlos Mendez
Mary Ann Miceli
Patricia Urena
Noreen Vance
Barbara Wang
Grants
Susan Schultz
Maureen Davies
Kathleen Didie
Carol DuPree
Mary Horton
On sabbatical at CSHL
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Patricia Kurfess
William Mahoney
Dee McKeon
Personnel
Cheryl Sinclair
Marjorie Berko
Jan Eisenman
Kim Gronachan
Barbara Purcell
Merilyn Simkins
Rita Wienclaw
Food Service
James Hope
Keven Adler
Jaime Bonilla
Wagner Bonilla
Francis Bowdren
Guidetta Corino
Michael Corral
Joan Doxey
Julie Ehrlich
Karen Farrell
Alec Firestone
Katherine Hamas
Renee Le Strange
Guido Mosquera
Ronald Padden
Mauricio Rodriguez
Victoria Sharpe
William Suescun
Cathy Van Deurs
Leslie Wenzel
Keith Wieczorek
Meetings
David Stewart
Leslie Cook
James Koziol
Michela McBride
Andrew Mendelsohn
Margaret Stellabotte
Andrea Stephenson
Diane Tighe
Nancy Weeks
Purchasing
Philip Lembo
Carol Brower
Susan De Angelo
Bruce Fahlbusch
Heather Hess
Patricia Hinton
Edith Kappenberg
Susan Rose
Barbara Zane
Central Administration
Maureen Berejka
Barry Braunstein
Delia King
Roberta Salant
Banbury Center
Katya Davey
Eleanor Sidorenko
Beatrice Toliver
DNA Learning Center
Mark Bloom
Jane Conigliaro
Judy Cumella-Korabik
Flavio Della Seta
Diane Esposito
Malissa Hewitt
Diane Jedlicka
Susan Lauter
Facilities
Arthur Brings
Jack Richards
Peter Stahl
Margaret Chellis
Charles Schneider
Carpentry and Painting
Frank Russo
Michael Demers
John Meyer
Joseph Pirnak
Peter Rohde
Peter Schwind
Benjamin Veneable
Harry Wozniak
Electrical and Mechanical
Louis Jagoda
Russell Allen
Greg Beal
Robert Collins
Jeffrey Gold blum
Environmental Health
And Safety
Christopher Hubert
Randal Jones
John Pisciotta
Donald Rose, Jr.
Marlene Rubino
Equipment Design
Fabrication and Repair
Gus Dulis
Cliff Sutkevich
George Newell
Gary Montemurro
Grounds
Daniel Miller
William Bishop
Vincent Carey
Joseph Ellis
Lawrence Giordano
Edward Haab
William Kearney
Allen Lerch
Christopher McEvoy
Andrew Sauer
Eric Schlitter
Dariusz Slodkowski
Christopher Williams
Harris Research
Support Facility
Lisa Bianco
Charlene De Poto
Halina Swidzinski
Ryszard Swidzinski
Housekeeping
Steven Tang
Elizabeth Botti
Catherine Burke
Carol Caldarelli
Dessie Carter
Stephen Gay
Mary Genova
Daniel Jusino
Patricia Kazdal
George Leedham
Seth Manheim
Patricia Mc Adams
Susanne McPherson
Dora Merlino
Mary Muno
Wayne Pay
Ronald Romani
Claudia Schmid
Danuta Slodkowska
Jaroslaw Swidzinski
Yew Teo
Mario Testani
Jorge Valdes
Curtis Williams
Plumbing
Lane Smith
Keith Spooner
Security
Robert Gensel
Frank Carberry
Randy Wilfong
Shipping and Receiving
Scott Nitz
Christopher Oravitz
James Sabin
Uplands Sha Mi Sari Goren Visiting Scientists
Timothy Mulligan Ann Sutton Dorre Grueneberg Young-Seuk Bae
Stanley Schwarz Michael White Wei Guo Hiroyuki Nawa
Hao-Peng Xu Chang-Deok Han
Vincent Jung
Scientific Staff Tae-Kook Kim
De arturesp Postdoctoral Fellows Fong Lin Graduate Students
During 1995 Masahiro Akiyama Keiko Mizuno Maureen Barr
Zoltan Asztalos Piruz Nahreini David Casso
Research Staff Ariel Avilion Bradley Nefsky Nicholas Chester
Harriet Feilotter Susann Brady-Kalnay Charles Nicolette Patricia Elliott
James Garrels Yoon Cho Louis Pena Yuliang (Frank) Ma
Richard Roberts Kathleen Collins Henry Sadowski Robert Mihalek
Nickolai Lisitsyn Scott Davey Hong Sun Ann Ryan
Douglas Demetrick George Tokiwa Cynthia Sadowski
Staff Associates Cecilia Devlin Catherine Weiss Kenneth Simon
William Chang Bruno Frenguelli Christian van den Bos Sonia Witte
Eric Chang Doris Germain Hui Zhang Tao Zhong
On sabbatical at CSHL
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